

序号	专利号	链接	名称	发明人	提交	公开	授权
1	US9689018	http://59.45.142.240:8808/pdf/US9689018.pdf	Mixed cell diagnostic systems for detection of respiratory, herpes and	Diagnostic Hybrids, Inc.	24-Apr-98	4-Aug-14	27-Jun-17
2	US8828673	http://59.45.142.240:8808/pdf/US8828673.pdf	Mixed cell diagnostic systems for detection of respiratory, herpes and	Diagnostic Hybrids Inc	24-Apr-98	1-Mar-12	9-Sep-14
3	US7442508	http://59.45.142.240:8808/pdf/US7442508.pdf	Methods for detection and production of influenza viruses	Diagnostic Hybrids, Inc.	24-Apr-98	28-Apr-06	28-Oct-08
4	US6946291	http://59.45.142.240:8808/pdf/US6946291.pdf	Mixed cell diagnostic systems	Diagnostic Hybrids, Inc.	24-Apr-98	30-Mar-04	20-Sep-05
5	US20150031 016	http://59.45.142.240:8808/pdf/US20150031016A1.pdf	Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes	Diagnostic Hybrids Inc.	24-Apr-98	4-Aug-14	29-Jan-15
6	US20090286 222	http://59.45.142.240:8808/pdf/US20090286222A1.pdf	Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes	GOODRUM PATRICIA GAIL RAY	24-Apr-98	16-Oct-08	19-Nov-09
7	US20060286 667	http://59.45.142.240:8808/pdf/US20060286667A1.pdf	Methods for detection and production of influenza viruses	Diagnostic Hybrids, Inc.	24-Apr-98	28-Apr-06	21-Dec-06
8	US20060094 105	http://59.45.142.240:8808/pdf/US20060094105A1.pdf	Mixed cell diagnostic systems for detection of respiratory, herpes and	Diagnostic Hybrids, Inc.	24-Apr-98	20-Sep-05	4-May-06
9	US20070060 535	http://59.45.142.240:8808/pdf/US20070060535A1.pdf	Targeted delivery of antiviral compounds through hemoglobin	ADAMSON J G	30-Apr-98	13-Nov-06	15-Mar-07
10	US20050059 576	http://59.45.142.240:8808/pdf/US20050059576A1.pdf	Targeted delivery of antiviral compounds through hemoglobin	ADAMSON J. GORDON	30-Apr-98	17-May-04	17-Mar-05
11	US7604960	http://59.45.142.240:8808/pdf/US7604960.pdf	Transient protein expression methods	Crucell Holland B.V.	15-Apr-99	1-Jun-07	20-Oct-09
12	US20080199 495	http://59.45.142.240:8808/pdf/US20080199495A1.pdf	Stimulation of thymus for vaccination development	Monash University	15-Apr-99	24-May-07	21-Aug-08
13	US20080113 409	http://59.45.142.240:8808/pdf/US20080113409A1.pdf	Transient protein expression methods	HATEBOER GUUS	15-Apr-99	1-Jun-07	15-May-08
14	US20050020 524	http://59.45.142.240:8808/pdf/US20050020524A1.pdf	Hematopoietic stem cell gene therapy	Monash University	15-Apr-99	30-Dec-03	27-Jan-05
15	US20050002 913		Hematopoietic stem cell gene therapy	Monash University	15-Apr-99	18-Apr-03	6-Jan-05
16	US20040259 803	http://59.45.142.240:8808/pdf/US20040259803A1.pdf	Disease prevention by reactivation of the thymus	Monash University	15-Apr-99	30-Dec-03	23-Dec-04
17	US20040241 842	http://59.45.142.240:8808/pdf/US20040241842A1.pdf	Stimulation of thymus for vaccination development	Monash University	15-Apr-99	30-Dec-03	2-Dec-04
18	US20070031 832	http://59.45.142.240:8808/pdf/US20070031832A1.pdf	Methods of constructing biodiverse gene fragment libraries and	Phylogica Limited	5-May-99	20-Feb-04	8-Feb-07
19	US8815249	http://59.45.142.240:8808/pdf/US8815249.pdf	II-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	4-Sep-99	26-Jul-10	26-Aug-14
20	US9289487	http://59.45.142.240:8808/pdf/US9289487.pdf	II-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	14-Sep-99	11-Jan-05	22-Mar-16
21	US20100291 145	http://59.45.142.240:8808/pdf/US20100291145A1.pdf	II-KEY/ANTIGENIC EPIOTOPE HYBRID PEPTIDE VACCINES	ANTIGEN EXPRESS, INC.	14-Sep-99	26-Jul-10	18-Nov-10
22	US20060002 947	http://59.45.142.240:8808/pdf/US20060002947A1.pdf	II-key/antigenic epitope hybrid peptide vaccines	HUMPHREYS ROBERT	14-Sep-99	11-Jan-05	5-Jan-06
23	US7504384	http://59.45.142.240:8808/pdf/US7504384.pdf	Use of lipid conjugates in the treatment of infection	Yissum Research Development Company of the Hebrew University	10-Jan-00	8-Sep-05	17-Mar-09
24	US20060189 571	http://59.45.142.240:8808/pdf/US20060189571A1.pdf	Use of lipid conjugates in the treatment of infection	YEDGAR SAUL	10-Jan-00	8-Sep-05	24-Aug-06
25	US20060189 570	http://59.45.142.240:8808/pdf/US20060189570A1.pdf	Use of lipid conjugates in the treatment of infection	YEDGAR SAUL	10-Jan-00	8-Sep-05	24-Aug-06
26	US20060189 569	http://59.45.142.240:8808/pdf/US20060189569A1.pdf	Use of lipid conjugates in the treatment of infection	OJCIUS DAVID	10-Jan-00	8-Sep-05	24-Aug-06
27	US20060189 568	http://59.45.142.240:8808/pdf/US20060189568A1.pdf	Use of lipid conjugates in the treatment of infection	YEDGAR SAUL	10-Jan-00	8-Sep-05	24-Aug-06
28	US20060079 485	http://59.45.142.240:8808/pdf/US20060079485A1.pdf	Use of lipid conjugates in the treatment of infection	OJCIUS DAVID	10-Jan-00	8-Sep-05	13-Apr-06
29	US8735348	http://59.45.142.240:8808/pdf/US8735348.pdf	Casein derived peptides and uses thereof	Peptera Ltd.	1-Mar-00	5-Sep-12	27-May-14
30	US7666996	http://59.45.142.240:8808/pdf/US7666996.pdf	Casein derived peptides and uses thereof	Peptera Pharmaceuticals Ltd	1-Mar-00	1-Mar-04	23-Feb-10
31	US20130096 073	http://59.45.142.240:8808/pdf/US20130096073A1.pdf	Casein Derived Peptides And Uses Thereof	SIDELMAN ZVI	1-Mar-00	5-Sep-12	18-Apr-13
32	US20100317 601	http://59.45.142.240:8808/pdf/US20100317601A1.pdf	Casein Derived Peptides And Uses Thereof	SIDELMAN ZVI	1-Mar-00	28-Jul-10	16-Dec-10
33	US20090192 081	http://59.45.142.240:8808/pdf/US20090192081A1.pdf	Casein derived peptides and uses thereof	SIDELMAN ZVI	1-Mar-00	31-Oct-07	30-Jul-09
34	US20040167 073	http://59.45.142.240:8808/pdf/US20040167073A1.pdf	Casein derived peptides and uses thereof	Chay 13 Medical Research Group	1-Mar-00	1-Mar-04	26-Aug-04
35	US7820210	http://59.45.142.240:8808/pdf/US7820210.pdf	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy	Inhalation, Inc.	3-Apr-00	18-Mar-08	26-Oct-10
36	US7344740	http://59.45.142.240:8808/pdf/US7344740.pdf	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy	Inhalation, Inc.	3-Apr-00	27-Nov-04	18-Mar-08
37	US7048953	http://59.45.142.240:8808/pdf/US7048953.pdf	Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute	Inhalation, Inc.	3-Apr-00	2-May-03	23-May-06
38	US20080187 609	http://59.45.142.240:8808/pdf/US20080187609A1.pdf	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy	VAIL MARILYN L	3-Apr-00	18-Mar-08	7-Aug-08
39	US20070015 181	http://59.45.142.240:8808/pdf/US20070015181A1.pdf	System and methods for nucleic acid and polypeptide selection	WILLIAMS RICHARD R	19-May-00	2-May-06	18-Jan-07
40	US7439052	http://59.45.142.240:8808/pdf/US7439052.pdf	Method of making modified immunodeficiency virus particles	Lipid Sciences	29-Jun-00	10-Apr-06	21-Oct-08
41	US7407663	http://59.45.142.240:8808/pdf/US7407663.pdf	Modified immunodeficiency virus particles	Lipid Sciences, Inc.	29-Jun-00	20-Jun-03	5-Aug-08
42	US7407662	http://59.45.142.240:8808/pdf/US7407662.pdf	Modified viral particles with immunogenic properties and reduced lipid content	Lipid Sciences, Inc.	29-Jun-00	21-Jun-04	5-Aug-08
43	US20140050 763	http://59.45.142.240:8808/pdf/US20140050763A1.pdf	MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND PREVENTING	ELI LILLY & COMPANY	29-Jun-00	30-Oct-13	20-Feb-14
44	US20080267 997	http://59.45.142.240:8808/pdf/US20080267997A1.pdf	Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious	Lipid Sciences, Inc.	29-Jun-00	9-May-08	30-Oct-08

45	US20070031 923		Modified viral particles with immunogenic properties and reduced lipid content useful for treating and	CHAM BILL E	29-Jun-00	10-Apr-06	8-Feb-07
46	US20050032 222	http://59.45.142.240:8808/pdf/US20050032222A1.pdf	Modified viral particles with immunogenic properties and reduced lipid content useful for treating and	BELLOTTI MARC	29-Jun-00	21-Jun-04	10-Feb-05
47	US20040170 649	http://59.45.142.240:8808/pdf/US20040170649A1.pdf	Method of treating and preventing infectious diseases via creation of a modified viral particle with	CHAM BILL E.	29-Jun-00	20-Jun-03	2-Sep-04
48	US7592008	http://59.45.142.240:8808/pdf/US7592008.pdf	Membrane scaffold proteins	The Board of Trustees of the University of Illinois, a body corporate and politic of the	20-Nov-00	11-Jan-05	22-Sep-09
49	US20090257 950	http://59.45.142.240:8808/pdf/US20090257950A1.pdf	Membrane Scaffold Proteins	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF	20-Nov-00	10-Oct-07	15-Oct-09
50	US20060142 202	http://59.45.142.240:8808/pdf/US20060142202A1.pdf	Compositions and methods for targeted delivery of immune	3M INNOVATIVE PROPERTIES CO	8-Dec-00	23-Feb-06	29-Jun-06
51	US9944686	http://59.45.142.240:8808/pdf/US9944686.pdf	Treatment of tumors with recombinant interferon alpha	SUPERLAB FAR EAST LIMITED	28-Feb-01	5-Sep-13	17-Apr-18
52	US8551469	http://59.45.142.240:8808/pdf/US8551469.pdf	Treatment of tumors and viral diseases with recombinant interferon	Superlab Far East Limited	28-Feb-01	6-Oct-08	8-Oct-13
53	US20180258 151	http://59.45.142.240:8808/pdf/US20180258151A1.pdf	RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF	Not Available	28-Feb-01	2-Mar-18	13-Sep-18
54	US20140050 698	http://59.45.142.240:8808/pdf/US20140050698A1.pdf	RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF	Superlab Far East Limited	28-Feb-01	5-Sep-13	20-Feb-14
55	US20090123 417	http://59.45.142.240:8808/pdf/US20090123417A1.pdf	RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF	WEI GUANGWEN	28-Feb-01	6-Oct-08	14-May-09
56	US9428739	http://59.45.142.240:8808/pdf/US9428739.pdf	Norovirus and Sapovirus antigens	NOVARTIS VACCINES AND DIAGNOSTICS, INC	24-Mar-01	27-Nov-12	30-Aug-16
57	US20070026 009	http://59.45.142.240:8808/pdf/US20070026009A1.pdf	Systems and methods for identifying replikin scaffolds and uses of said	BOGOCH ELENORE S	27-Mar-01	16-Feb-06	1-Feb-07
58	US20040071 709	http://59.45.142.240:8808/pdf/US20040071709A1.pdf	Corona-virus-like particles comprising functionally deleted	BOSCH BEREND-JAN	17-May-01	14-Apr-03	15-Apr-04
59	US20060018 877	http://59.45.142.240:8808/pdf/US20060018877A1.pdf	Intradermal delivery of vaccines and therapeutic agents	ALARCON JASON B	29-Jun-01	29-Apr-05	26-Jan-06
60	US7405046	http://59.45.142.240:8808/pdf/US7405046.pdf	Compositions and methods for treatment of rhinovirus	The Quigley Corporation	6-Aug-01	27-Oct-06	29-Jul-08
61	US7166435	http://59.45.142.240:8808/pdf/US7166435.pdf	Compositions and methods for reducing the transmissivity of	The Quigley Corporation	6-Aug-01	14-Dec-04	23-Jan-07
62	US20070104 808	http://59.45.142.240:8808/pdf/US20070104808A1.pdf	COMPOSITIONS AND METHODS FOR TREATMENT OF RHINO VIRUS	THE QUIGLEY CORPORATION	6-Aug-01	27-Oct-06	10-May-07
63	US9677089	http://59.45.142.240:8808/pdf/US9677089.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	30-Mar-16	13-Jun-17
64	US9587250	http://59.45.142.240:8808/pdf/US9587250.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	Trustees of the University of	17-Dec-01	16-Jan-15	7-Mar-17
65	US9493788	http://59.45.142.240:8808/pdf/US9493788.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	16-Jan-15	15-Nov-16
66	US8962332	http://59.45.142.240:8808/pdf/US8962332.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	13-Sep-13	24-Feb-15
67	US8962330	http://59.45.142.240:8808/pdf/US8962330.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	31-Oct-07	24-Feb-15
68	US7790449	http://59.45.142.240:8808/pdf/US7790449.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses	The Trustees of the University of Pennsylvania	17-Dec-01	6-Sep-07	7-Sep-10
69	US7282199	http://59.45.142.240:8808/pdf/US7282199.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	25-Apr-03	16-Oct-07
70	US20190292 563	http://59.45.142.240:8808/pdf/US20190292563A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES	The Trustees of the University of Pennsylvania	17-Dec-01	8-Apr-19	26-Sep-19
71	US20190017 068	http://59.45.142.240:8808/pdf/US20190017068A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	17-Dec-01	26-Sep-18	17-Jan-19
72	US20170306 354	http://59.45.142.240:8808/pdf/US20170306354A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	17-Dec-01	1-May-17	26-Oct-17
73	US20170088 858	http://59.45.142.240:8808/pdf/US20170088858A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	17-Dec-01	20-Oct-16	30-Mar-17
74	US20160201 088	http://59.45.142.240:8808/pdf/US20160201088A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	17-Dec-01	30-Mar-16	14-Jul-16
75	US20150176 027	http://59.45.142.240:8808/pdf/US20150176027A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	17-Dec-01	16-Jan-15	25-Jun-15
76	US20140004 143	http://59.45.142.240:8808/pdf/US20140004143A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	17-Dec-01	13-Sep-13	2-Jan-14
77	US20090227 030	http://59.45.142.240:8808/pdf/US20090227030A1.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	31-Oct-07	10-Sep-09
78	US20080075 740	http://59.45.142.240:8808/pdf/US20080075740A1.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	31-Oct-07	27-Mar-08
79	US20080075 737	http://59.45.142.240:8808/pdf/US20080075737A1.pdf	Adeno-Associated Virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	6-Sep-07	27-Mar-08
80	US10590435	http://59.45.142.240:8808/pdf/US10590435.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	26-Sep-18	17-Mar-20

81	US10301650	http://59.45.142.240:8808/pdf/US10301650.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	1-May-17	28-May-19
82	US10266846	http://59.45.142.240:8808/pdf/US10266846.pdf	Adeno-associated virus (AAV) serotype 8 sequences, vectors	The Trustees of the University of	17-Dec-01	20-Oct-16	23-Apr-19
83	US20110002 888		Albumin Fusion Proteins	Human Gemone Sciences, Inc.	21-Dec-01	3-Jun-10	6-Jan-11
84	US20100291 033		Albumin Fusion Proteins	Human Genome Sciences, Inc.	21-Dec-01	3-Jun-10	18-Nov-10
85	US20090197 894	http://59.45.142.240:8808/pdf/US20090197894A1.pdf	NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS, INC.	21-Dec-01	14-Apr-09	6-Aug-09
86	US20080194 481		Albumin Fusion Proteins	Human Genome Sciences, Inc.	21-Dec-01	31-Oct-07	14-Aug-08
87	US20080004 206		Albumin fusion proteins	BELL ADAM	21-Dec-01	31-Jul-06	3-Jan-08
88	US20050119 251	http://59.45.142.240:8808/pdf/US20050119251A1.pdf	Nicotinamide derivatives and their use as therapeutic agents	FINE RICHARD M.	21-Dec-01	6-Jul-04	2-Jun-05
89	US8802647	http://59.45.142.240:8808/pdf/US8802647.pdf	Materials and methods for prevention and treatment of RNA	University of South Florida	30-Apr-02	17-Sep-12	12-Aug-14
90	US7354908	http://59.45.142.240:8808/pdf/US7354908.pdf	Materials and methods for prevention and treatment of RNA	University of South Florida	30-Apr-02	30-Apr-03	8-Apr-08
91	US20130129 702	http://59.45.142.240:8808/pdf/US20130129702A1.pdf	MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF	UNIVERSITY OF SOUTH FLORIDA	30-Apr-02	17-Sep-12	23-May-13
92	US20110052 558	http://59.45.142.240:8808/pdf/US20110052558A1.pdf	MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF	UNIVERSITY OF SOUTH FLORIDA	30-Apr-02	15-Dec-09	3-Mar-11
93	US20080175 832	http://59.45.142.240:8808/pdf/US20080175832A1.pdf	Materials and Methods for Prevention and Treatment of RNA Virus Diseases	BEHERA ARUNA K	30-Apr-02	17-Jan-08	24-Jul-08
94	US20050255 123	http://59.45.142.240:8808/pdf/US20050255123A1.pdf	Chimeric ebola virus envelopes and uses therefor	The Trustees of the University of	30-Apr-02	28-Apr-03	17-Nov-05
95	US7691599	http://59.45.142.240:8808/pdf/US7691599.pdf	Mammalian genes involved in viral infection and tumor suppression	Zirus, Inc.	2-May-02	2-May-03	6-Apr-10
96	US20070254 329	http://59.45.142.240:8808/pdf/US20070254329A1.pdf	Mammalian Genes Involved in Viral Infection and Tumor Suppression	RUBIN DONALD H	2-May-02	2-May-03	1-Nov-07
97	US20040142 852	http://59.45.142.240:8808/pdf/US20040142852A1.pdf	Composition and its therapeutic use	AL SARI AHMAD M. H	9-May-02	29-May-03	22-Jul-04
98	US7618788	http://59.45.142.240:8808/pdf/US7618788.pdf	Proteome epitope tags and methods of use thereof in protein modification	Millipore Corporation	10-May-02	5-Feb-04	17-Nov-09
99	US7460960	http://59.45.142.240:8808/pdf/US7460960.pdf	Proteome epitope tags and methods of use thereof in protein modification	Epitome Biosystems, Inc.	10-May-02	13-Nov-03	2-Dec-08
100	US20100184 613	http://59.45.142.240:8808/pdf/US20100184613A1.pdf	Proteome Epitope Tags and Methods of Use Thereof in Protein	Millipore Corporation	10-May-02	9-Oct-09	22-Jul-10
101	US20050069 911	http://59.45.142.240:8808/pdf/US20050069911A1.pdf	Proteome epitope tags and methods of use thereof in protein modification	engineOS, Inc.	10-May-02	5-Feb-04	31-Mar-05
102	US9957300	http://59.45.142.240:8808/pdf/US9957300.pdf	Virus-like particles, methods of preparation, and immunogenic	Emory University	17-May-02	4-May-15	1-May-18
103	US9045727	http://59.45.142.240:8808/pdf/US9045727.pdf	Virus-like particles, methods of preparation, and immunogenic	EMORY UNIVERSITY	17-May-02	4-Apr-06	2-Jun-15
104	US20150266 929	http://59.45.142.240:8808/pdf/US20150266929A1.pdf	VIRUS-LIKE PARTICLES, METHODS OF PREPARATION, AND	Not Available	17-May-02	4-May-15	24-Sep-15
105	US20060216 702	http://59.45.142.240:8808/pdf/US20060216702A1.pdf	Virus-like particles, methods of preparation, and immunogenic	COMPANS RICHARD W	17-May-02	4-Apr-06	28-Sep-06
106	US20060088 909	http://59.45.142.240:8808/pdf/US20060088909A1.pdf	Virus-like particles, methods of preparation, and immunogenic	COMPANS RICHARD W	17-May-02	19-May-03	27-Apr-06
107	US20050186 575	http://59.45.142.240:8808/pdf/US20050186575A1.pdf	Corona-virus-like particles comprising functionally deleted	BOSCH BEREND J.	17-May-02	30-Dec-03	25-Aug-05
108	US7115563	http://59.45.142.240:8808/pdf/US7115563.pdf	Composition and its therapeutic use	Insighion Holding Limited	29-May-02	29-May-03	3-Oct-06
109	US20090053 248	http://59.45.142.240:8808/pdf/US20090053248A1.pdf	Compositions and methods for transcellular molecular transport	Thomas Jefferson University	31-May-02	25-Mar-08	26-Feb-09
110	US7550140	http://59.45.142.240:8808/pdf/US7550140.pdf	Antibody to the human OX40 receptor	Crucell Holland B.V.	13-Jun-02	13-Jun-03	23-Jun-09
111	US20060281 072	http://59.45.142.240:8808/pdf/US20060281072A1.pdf	Agonistic Binding Molecules to the Human OX40 Receptor	BAKKER ALEXANDER	13-Jun-02	13-Jun-03	14-Dec-06
112	US7405207	http://59.45.142.240:8808/pdf/US7405207.pdf	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary	Epigenesis Pharmaceuticals, Inc.	17-Jun-02	17-Jun-03	29-Jul-08
113	US20050249 742	http://59.45.142.240:8808/pdf/US20050249742A1.pdf	Compositions and methods for modulating a cytotoxic T lymphocyte	Dana-Farber Cancer Institute, Inc.	27-Jun-02	22-Dec-04	10-Nov-05
114	US20070275 883	http://59.45.142.240:8808/pdf/US20070275883A1.pdf	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment	GOSSELIN GILLES	28-Jun-02	6-Sep-06	29-Nov-07
115	US7439349	http://59.45.142.240:8808/pdf/US7439349.pdf	Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary	Not Available	3-Jul-02	1-Jul-03	21-Oct-08
116	US8653034	http://59.45.142.240:8808/pdf/US8653034.pdf	Compositions and methods comprising phosphatidylethanolamine- binding	Board of Regents, The University of Texas System	15-Jul-02	8-May-08	18-Feb-14
117	US7790159	http://59.45.142.240:8808/pdf/US7790159.pdf	Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	7-Sep-10
118	US7714109	http://59.45.142.240:8808/pdf/US7714109.pdf	Combinations and kits for cancer treatment using selected antibodies	Board of Regents, The University of	15-Jul-02	15-Aug-03	11-May-10
119	US7678386	http://59.45.142.240:8808/pdf/US7678386.pdf	Liposomes coated with selected antibodies that bind to	Board of Regents the University of	15-Jul-02	15-Aug-03	16-Mar-10
120	US7625563	http://59.45.142.240:8808/pdf/US7625563.pdf	Cancer treatment methods using selected immunoconjugates for	Board of Regents, The University of	15-Jul-02	15-Aug-03	1-Dec-09
121	US7622118	http://59.45.142.240:8808/pdf/US7622118.pdf	Cancer treatment methods using selected antibodies to	Board of Regents, The University of	15-Jul-02	15-Aug-03	24-Nov-09
122	US7615223	http://59.45.142.240:8808/pdf/US7615223.pdf	Selected immunoconjugates for binding to aminophospholipids	Board of Regents, The University of	15-Jul-02	15-Aug-03	10-Nov-09

123	US7611704	http://59.45.142.240:8808/pdf/US7611704.pdf	Compositions and methods for treating viral infections using antibodies and immunoconjugates to	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	3-Nov-09
124	US7572448	http://59.45.142.240:8808/pdf/US7572448.pdf	Combined cancer treatment methods using selected antibodies to	Board of Regents, The University of	15-Jul-02	15-Aug-03	11-Aug-09
125	US7572442	http://59.45.142.240:8808/pdf/US7572442.pdf	Selected antibody compositions for binding to aminophospholipids	Board of Regents, The University of	15-Jul-02	15-Jul-03	11-Aug-09
126	US7511124	http://59.45.142.240:8808/pdf/US7511124.pdf	Compositions comprising phosphatidylethanolamine-binding	Board of Regents, The University of	15-Jul-02	15-Aug-03	31-Mar-09
127	US7455833	http://59.45.142.240:8808/pdf/US7455833.pdf	Methods and compositions for treating viral infections using antibodies and immunoconjugates to	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	25-Nov-08
128	US7384909	http://59.45.142.240:8808/pdf/US7384909.pdf	Anti-viral treatment methods using phosphatidylethanolamine- binding	Board of Regents, The University of	15-Jul-02	15-Aug-03	10-Jun-08
129	US7378386	http://59.45.142.240:8808/pdf/US7378386.pdf	Anti-viral treatment methods using phosphatidylethanolamine- binding	Board of Regents, The University of	15-Jul-02	15-Aug-03	27-May-08
130	US7247303	http://59.45.142.240:8808/pdf/US7247303.pdf	Selected antibody CDRs for binding to aminophospholipids	Board of Regents, The University of	15-Jul-02	15-Aug-03	24-Jul-07
131	US20160144 061	http://59.45.142.240:8808/pdf/US20160144061A1.pdf	Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding	Not Available	15-Jul-02	4-Feb-16	26-May-16
132	US20150132 220	http://59.45.142.240:8808/pdf/US20150132220A1.pdf	Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding	Not Available	15-Jul-02	8-Jan-15	14-May-15
133	US20140161 724	http://59.45.142.240:8808/pdf/US20140161724A1.pdf	Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding	Board of Regents, The University of Texas System	15-Jul-02	16-Dec-13	12-Jun-14
134	US20130243 756	http://59.45.142.240:8808/pdf/US20130243756A1.pdf	Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids	BOARD OF REGENTS, THE UNIVERSITY OF	15-Jul-02	19-Feb-13	19-Sep-13
135	US20110033 454	http://59.45.142.240:8808/pdf/US20110033454A1.pdf	Methods For Treating Diseases Using Antibodies to Aminophospholipids	Board of Regents, The University of	15-Jul-02	26-Aug-10	10-Feb-11
136	US20100310 638	http://59.45.142.240:8808/pdf/US20100310638A1.pdf	LIPOSOMES COMPRISING DURAMYCIN AND ANTI-VIRAL	Board of Regents, The University of	15-Jul-02	4-Mar-10	9-Dec-10
137	US20060257 866	http://59.45.142.240:8808/pdf/US20060257866A1.pdf	Methods for identifying small molecules that modulate premature translation termination and	ALMSTEAD NEIL G	24-Jul-02	24-Jul-03	16-Nov-06
138	US9139833	http://59.45.142.240:8808/pdf/US9139833.pdf	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	26-Jul-02	12-Mar-13	22-Sep-15
139	US20150361 432	http://59.45.142.240:8808/pdf/US20150361432A1.pdf	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	Not Available	26-Jul-02	6-Aug-15	17-Dec-15
140	US20140073 683	http://59.45.142.240:8808/pdf/US20140073683A1.pdf	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	Not Available	26-Jul-02	12-Mar-13	13-Mar-14
141	US20090186 056	http://59.45.142.240:8808/pdf/US20090186056A1.pdf	COMPOSITIONS AND METHODS FOR PREVENTING INFECTION	LA JOLLA BIOSCIENCES LLC	8-Aug-02	19-Mar-09	23-Jul-09
142	US20070021 326	http://59.45.142.240:8808/pdf/US20070021326A1.pdf	Composition and its Therapeutic Use	INSIGNION HOLDINGS LTD AND	9-Aug-02	25-Sep-06	25-Jan-07
143	US7482334	http://59.45.142.240:8808/pdf/US7482334.pdf	Therapeutic treatment methods	Hollis-Eden Pharmaceuticals,	28-Aug-02	12-Feb-07	27-Jan-09
144	US20150353 596	http://59.45.142.240:8808/pdf/US20150353596A1.pdf	17-Substituted Steroid Compounds	Not Available	28-Aug-02	24-Aug-15	10-Dec-15
145	US20080085 873		Disease treatment methods	Hollis-Eden Pharmaceuticals,	28-Aug-02	13-Oct-06	10-Apr-08
146	US20070275 938	http://59.45.142.240:8808/pdf/US20070275938A1.pdf	Therapeutic Treatment Methods	AHLEM CLARENCE N	28-Aug-02	12-Feb-07	29-Nov-07
147	US20070275 937	http://59.45.142.240:8808/pdf/US20070275937A1.pdf	Therapeutic Treatment Methods	AHLEM CLARENCE N	28-Aug-02	12-Feb-07	29-Nov-07
148	US20070265 236		Asthma Treatment Methods	AHLEM CLARENCE N	28-Aug-02	16-Oct-06	15-Nov-07
149	US20070213 309	http://59.45.142.240:8808/pdf/US20070213309A1.pdf	Sepsis Treatment Methods	AHLEM CLARENCE N	28-Aug-02	16-Oct-06	13-Sep-07
150	US20070203 107		Pharmaceutical compositions	Hollis-Eden Pharmaceuticals,	28-Aug-02	13-Oct-06	30-Aug-07
151	US20050101 581		Therapeutic treatment methods 2	AHLEM CLARENCE N	28-Aug-02	5-Dec-03	12-May-05
152	US20100233 146	http://59.45.142.240:8808/pdf/US20100233146A1.pdf	Coatings and Surface Treatments Having Active Enzymes and Peptides	REACTIVE SURFACES, LTD	9-Sep-02	29-May-09	16-Sep-10
153	US20100210 745	http://59.45.142.240:8808/pdf/US20100210745A1.pdf	Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active	REACTIVE SURFACES, LTD.	9-Sep-02	29-Jan-10	19-Aug-10
154	US8524488	http://59.45.142.240:8808/pdf/US8524488.pdf	Methods and devices for determining a cell characteristic, and applications	The Regents of the University of	10-Sep-02	9-Mar-05	3-Sep-13
155	US20050239 047	http://59.45.142.240:8808/pdf/US20050239047A1.pdf	Methods and devices for determining a cell characteristic, and applications	GIMZEWSKI JAMES K	10-Sep-02	9-Mar-05	27-Oct-05
156	US7358068	http://59.45.142.240:8808/pdf/US7358068.pdf	Antiviral oligonucleotides	Replicor, Inc.	13-Sep-02	12-Sep-03	15-Apr-08
157	US20100173 980	http://59.45.142.240:8808/pdf/US20100173980A1.pdf	ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV	JUTEAU JEAN-MARC	13-Sep-02	21-Dec-09	8-Jul-10
158	US20100172 965	http://59.45.142.240:8808/pdf/US20100172965A1.pdf	ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES	JUTEAU JEAN-MARC	13-Sep-02	21-Dec-09	8-Jul-10
159	US20090099 110	http://59.45.142.240:8808/pdf/US20090099110A1.pdf	Antiviral oligonucleotides	JUTEAU JEAN-MARC	13-Sep-02	28-Feb-08	16-Apr-09
160	US20090042 827	http://59.45.142.240:8808/pdf/US20090042827A1.pdf	ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV	JUTEAU JEAN-MARC	13-Sep-02	10-Jul-08	12-Feb-09
161	US20060135 458	http://59.45.142.240:8808/pdf/US20060135458A1.pdf	Antiviral oligonucleotides	JUTEAU JEAN-MARC	13-Sep-02	19-Oct-05	22-Jun-06
162	US7151091	http://59.45.142.240:8808/pdf/US7151091.pdf	Compositions and methods for preventing infection	La Jolla Biosciences LLC	20-Sep-02	22-Sep-03	19-Dec-06
163	US20070173 481	http://59.45.142.240:8808/pdf/US20070173481A1.pdf	Compositions and methods for preventing infection	JOLLA BIOSCIENCES LLC	20-Sep-02	11-Dec-06	26-Jul-07
164	US7504097	http://59.45.142.240:8808/pdf/US7504097.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	17-Mar-09
165	US7498152	http://59.45.142.240:8808/pdf/US7498152.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	3-Mar-09

166	US7488801	http://59.45.142.240:8808/pdf/US7488801.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	10-Feb-09
167	US7488589	http://59.45.142.240:8808/pdf/US7488589.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	10-Feb-09
168	US7488473	http://59.45.142.240:8808/pdf/US7488473.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	10-Feb-09
169	US7314613	http://59.45.142.240:8808/pdf/US7314613.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	19-May-04	1-Jan-08
170	US20090042 252	http://59.45.142.240:8808/pdf/US20090042252A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	Maxygen, Inc.	18-Nov-02	30-Oct-06	12-Feb-09
171	US20090011 465	http://59.45.142.240:8808/pdf/US20090011465A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MXYGEN, INC.	18-Nov-02	30-Oct-06	8-Jan-09
172	US20080227 149	http://59.45.142.240:8808/pdf/US20080227149A1.pdf	Interferon-Alpha Polypeptides and Conjugates	MXYGEN, INC.	18-Nov-02	25-Oct-07	18-Sep-08
173	US20070274 950	http://59.45.142.240:8808/pdf/US20070274950A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MXYGEN INC	18-Nov-02	19-May-04	29-Nov-07
174	US20070065 407	http://59.45.142.240:8808/pdf/US20070065407A1.pdf	Interferon-Alpha Polypeptides and Conjugates	MXYGEN INC	18-Nov-02	30-Oct-06	22-Mar-07
175	US20060257 925	http://59.45.142.240:8808/pdf/US20060257925A1.pdf	Method for isolating intracellular antibodies able to neutralize protein	LINE GENOMICS S.P.A.	21-Nov-02	21-Nov-03	16-Nov-06
176	US20070093 969	http://59.45.142.240:8808/pdf/US20070093969A1.pdf	Molecular nephrotoxicology modeling	CASTLE ARTHUR	22-Nov-02	24-Nov-03	26-Apr-07
177	US7777022	http://59.45.142.240:8808/pdf/US7777022.pdf	Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses	Rosetta Genomics, Ltd.	26-Nov-02	26-May-04	17-Aug-10
178	US7682688	http://59.45.142.240:8808/pdf/US7682688.pdf	Microporous materials, methods, and articles for localizing and quantifying	University of Utah Research	26-Nov-02	20-Nov-03	23-Mar-10
179	US7597936	http://59.45.142.240:8808/pdf/US7597936.pdf	Method of producing a pigmented composite microporous material	University of Utah Research	26-Nov-02	26-May-04	6-Oct-09
180	US20060134 397	http://59.45.142.240:8808/pdf/US20060134397A1.pdf	Microporous materials, methods, and articles for localizing and quantifying	SMITH ROGER E	26-Nov-02	20-Nov-03	22-Jun-06
181	US20060113 298	http://59.45.142.240:8808/pdf/US20060113298A1.pdf	Electromagnetic wave applicator	ZAIDAN HOJIN HANDOTAI KENKYU	27-Nov-02	27-Nov-03	1-Jun-06
182	US7148248	http://59.45.142.240:8808/pdf/US7148248.pdf	Method of treating or inhibiting the development of brain inflammation	NOZAKI MASAKO	29-Nov-02	26-Nov-03	12-Dec-06
183	US20180140 580	http://59.45.142.240:8808/pdf/US20180140580A1.pdf	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SPERM	Not Available	29-Nov-02	23-Oct-17	24-May-18
184	US20170007 577	http://59.45.142.240:8808/pdf/US20170007577A1.pdf	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SPERM	Not Available	29-Nov-02	19-Sep-16	12-Jan-17
185	US20070066 649	http://59.45.142.240:8808/pdf/US20070066649A1.pdf	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SPERM	Not Available	29-Nov-02	1-Nov-06	22-Mar-07
186	US20070066 648	http://59.45.142.240:8808/pdf/US20070066648A1.pdf	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SPERM	NOZAKI MASAKO	29-Nov-02	1-Nov-06	22-Mar-07
187	US20070060 611	http://59.45.142.240:8808/pdf/US20070060611A1.pdf	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SPERM	Not Available	29-Nov-02	1-Nov-06	15-Mar-07
188	US20070059 243	http://59.45.142.240:8808/pdf/US20070059243A1.pdf	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SPERM	Not Available	29-Nov-02	1-Nov-06	15-Mar-07
189	US20070054 937	http://59.45.142.240:8808/pdf/US20070054937A1.pdf	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SPERM	Not Available	29-Nov-02	1-Nov-06	8-Mar-07
190	US20050196 382	http://59.45.142.240:8808/pdf/US20050196382A1.pdf	Antiviral oligonucleotides targeting viral families		5-Dec-02	19-Oct-04	8-Sep-05
191	US20050176 661	http://59.45.142.240:8808/pdf/US20050176661A1.pdf	Antiviral oligonucleotides		5-Dec-02	12-Sep-03	11-Aug-05
192	US20050153 912	http://59.45.142.240:8808/pdf/US20050153912A1.pdf	Antiviral oligonucleotides targeting viral families		5-Dec-02	12-Sep-03	14-Jul-05
193	US8603469	http://59.45.142.240:8808/pdf/US8603469.pdf	Methods of treating cancer with human monoclonal antibodies	Genmab A/S	16-Dec-02	27-Dec-11	10-Dec-13
194	US7622559	http://59.45.142.240:8808/pdf/US7622559.pdf	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16-Dec-02	27-Jun-07	24-Nov-09
195	US7282568	http://59.45.142.240:8808/pdf/US7282568.pdf	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16-Dec-02	16-Dec-03	16-Oct-07
196	US20190248 883	http://59.45.142.240:8808/pdf/US20190248883A1.pdf	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	20-Feb-19	15-Aug-19
197	US20180251 540	http://59.45.142.240:8808/pdf/US20180251540A1.pdf	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	30-Apr-18	6-Sep-18
198	US20180134 783	http://59.45.142.240:8808/pdf/US20180134783A9.pdf	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	26-Apr-16	17-May-18
199	US20170334 984	http://59.45.142.240:8808/pdf/US20170334984A9.pdf	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	26-Apr-16	23-Nov-17
200	US20170190 770	http://59.45.142.240:8808/pdf/US20170190770A2.pdf	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	CORMORANT PHARMACEUTICALS	16-Dec-02	26-Apr-16	6-Jul-17
201	US20140170 156	http://59.45.142.240:8808/pdf/US20140170156A1.pdf	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	GENMAB A/S	16-Dec-02	7-Nov-13	19-Jun-14
202	US20100303 823	http://59.45.142.240:8808/pdf/US20100303823A1.pdf	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	GENMAB A/S	16-Dec-02	11-Nov-09	2-Dec-10
203	US20080118 517	http://59.45.142.240:8808/pdf/US20080118517A1.pdf	Human monoclonal antibodies against interleukin 8 (IL-8)	GENMAB A/S	16-Dec-02	27-Jun-07	22-May-08
204	US10253093	http://59.45.142.240:8808/pdf/US10253093.pdf	Human monoclonal antibodies against interleukin 8 (IL-8)	CORMORANT PHARMACEUTICALS	16-Dec-02	30-Apr-18	9-Apr-19
205	US10066012	http://59.45.142.240:8808/pdf/US10066012.pdf	Human monoclonal antibodies against interleukin 8 (IL-8)	CORMORANT PHARMACEUTICALS	16-Dec-02	26-Apr-16	4-Sep-18
206	US7598382	http://59.45.142.240:8808/pdf/US7598382.pdf	Aryl substituted imidazoquinolines	Coley Pharmaceutical	20-Dec-02	13-Jan-06	6-Oct-09
207	US7091214	http://59.45.142.240:8808/pdf/US7091214.pdf	Aryl substituted Imidazoquinolines	3M Innovative Properties Co	20-Dec-02	18-Dec-03	15-Aug-06
208	US20060111 387	http://59.45.142.240:8808/pdf/US20060111387A1.pdf	ARYL SUBSTITUTED IMIDAZOQUINOLINES	3M INNOVATIVE PROPERTIES CO	20-Dec-02	13-Jan-06	25-May-06
209	US20050069 555	http://59.45.142.240:8808/pdf/US20050069555A1.pdf	Thiosemicarbazones as anti-virals and immunopotentiators	BARSANTI PAUL A.	27-Dec-02	29-Dec-03	31-Mar-05
210	US9161976	http://59.45.142.240:8808/pdf/US9161976.pdf	Immunotherapy comprising TLR9 ligand and CD40 ligand	Trustees of Dartmouth College	30-Dec-02	22-Oct-12	20-Oct-15
211	US7387271	http://59.45.142.240:8808/pdf/US7387271.pdf	Immunostimulatory combinations	3M Innovative Properties Company	30-Dec-02	30-Dec-03	17-Jun-08
212	US20190083 592	http://59.45.142.240:8808/pdf/US20190083592A1.pdf	IMMUNOSTIMULATORY COMBINATIONS	Not Available	30-Dec-02	22-Oct-18	21-Mar-19
213	US20160129 095	http://59.45.142.240:8808/pdf/US20160129095A1.pdf	Immunostimulatory Combinations	Not Available	30-Dec-02	10-Sep-15	12-May-16

214	US20130115 228	http://59.45.142.240:8808/pdf/US20130115228A1.pdf	IMMUNOSTIMULATORY COMBINATIONS	TRUSTEES OF DARTMOUTH COLLEGE	30-Dec-02	22-Oct-12	9-May-13
215	US20110002 946	http://59.45.142.240:8808/pdf/US20110002946A1.pdf	Immunostimulatory Combinations	AHONEN CORY L	30-Dec-02	29-Jul-10	6-Jan-11
216	US20090123 460	http://59.45.142.240:8808/pdf/US20090123460A1.pdf	IMMUNOSTIMULATORY COMBINATIONS	3M Innovative Properties Company	30-Dec-02	17-Mar-08	14-May-09
217	US10105426	http://59.45.142.240:8808/pdf/US10105426.pdf	Immunostimulatory combinations	TRUSTEES OF DARTMOUTH COLLEGE	30-Dec-02	10-Sep-15	23-Oct-18
218	US20070042 381	http://59.45.142.240:8808/pdf/US20070042381A1.pdf	BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES	Rosetta Genomics	16-Jan-03	26-May-04	22-Feb-07
219	US7521424	http://59.45.142.240:8808/pdf/US7521424.pdf	Albumin fusion proteins	Human Genome Sciences, Inc.	22-Jan-03	7-Jul-05	21-Apr-09
220	US20100048 472	http://59.45.142.240:8808/pdf/US20100048472A1.pdf	Albumin Fusion Proteins	Human Genome Sciences, Inc.	22-Jan-03	20-Apr-09	25-Feb-10
221	US20070053 920	http://59.45.142.240:8808/pdf/US20070053920A1.pdf	Nematode polypeptide adjuvant	Not Available	22-Jan-03	21-Jan-04	8-Mar-07
222	US20060014 254	http://59.45.142.240:8808/pdf/US20060014254A1.pdf	Albumin fusion proteins	Human Genome Sciences, Inc.	22-Jan-03	7-Jul-05	19-Jan-06
223	US7625492	http://59.45.142.240:8808/pdf/US7625492.pdf	Charge-based water filtration systems	The University of Wyoming Research Center	28-Jan-03	28-Jan-04	1-Dec-09
224	US7625428	http://59.45.142.240:8808/pdf/US7625428.pdf	Bioagent air filtration systems	The University of Wyoming Research Center	28-Jan-03	28-Jan-04	1-Dec-09
225	US20060075 894	http://59.45.142.240:8808/pdf/US20060075894A1.pdf	Bioagent air filtration systems	University of Wyoming Research Corporation d/b/a Western Research Center	28-Jan-03	28-Jan-04	13-Apr-06
226	US20060070 952	http://59.45.142.240:8808/pdf/US20060070952A1.pdf	Charge-based water filtration systems	University of Wyoming Research Center	28-Jan-03	28-Jan-04	6-Apr-06
227	US7670565	http://59.45.142.240:8808/pdf/US7670565.pdf	Building decontamination with vaporous hydrogen peroxide	Steris Inc	31-Jan-03	3-Mar-08	2-Mar-10
228	US7361304	http://59.45.142.240:8808/pdf/US7361304.pdf	Building decontamination with vaporous hydrogen peroxide	Steris Inc.	31-Jan-03	29-Jan-04	22-Apr-08
229	US20050147 697	http://59.45.142.240:8808/pdf/US20050147697A1.pdf	Compositions and methods for reducing the transmissivity of influenza virus	ROSENBLOOM RICHARD A.	6-Feb-03	14-Dec-04	7-Jul-05
230	US7375180	http://59.45.142.240:8808/pdf/US7375180.pdf	Methods and compositions related to IRM compounds and Toll-like receptors	3M Innovative Properties Company	13-Feb-03	12-Feb-04	20-May-08
231	US20080182 900	http://59.45.142.240:8808/pdf/US20080182900A1.pdf	Method of treatment of virus infections using shikonic compounds	WANG FEIXIN	21-Feb-03	26-Sep-07	31-Jul-08
232	US20050222 258	http://59.45.142.240:8808/pdf/US20050222258A1.pdf	Pharmaceuticals comprising shikonic as active constituent	WANG FEIXIN	21-Feb-03	14-May-05	6-Oct-05
233	US9290786	http://59.45.142.240:8808/pdf/US9290786.pdf	Monoclonal antibody production by EBV transformation of B cells	Institute for Research in Biotechnology	26-Feb-03	25-Apr-13	22-Mar-16
234	US20180327 800	http://59.45.142.240:8808/pdf/US20180327800A1.pdf	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Not Available	26-Feb-03	21-May-18	15-Nov-18
235	US20160160 258	http://59.45.142.240:8808/pdf/US20160160258A1.pdf	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Not Available	26-Feb-03	8-Feb-16	9-Jun-16
236	US20140004 123	http://59.45.142.240:8808/pdf/US20140004123A1.pdf	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Institute For Research in Biotechnology	26-Feb-03	25-Apr-13	2-Jan-14
237	US20100021 470	http://59.45.142.240:8808/pdf/US20100021470A1.pdf	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	INSTITUTE FOR RESEARCH IN BIOTECHNOLOGY	26-Feb-03	26-Feb-04	28-Jan-10
238	US7485432	http://59.45.142.240:8808/pdf/US7485432.pdf	Selective modulation of TLR-mediated biological activity	3M Innovative Properties Company	27-Feb-03	27-Feb-04	3-Feb-09
239	US20060280 679	http://59.45.142.240:8808/pdf/US20060280679A1.pdf	Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing	BOWDISH KATHERINE S	4-Mar-03	17-Dec-04	14-Dec-06
240	US7163947	http://59.45.142.240:8808/pdf/US7163947.pdf	1-Amino 1H-imidazoquinolines	3M Innovative Properties Company	7-Mar-03	3-Sep-04	16-Jan-07
241	US9738894	http://59.45.142.240:8808/pdf/US9738894.pdf	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen AS	21-Mar-03	28-Mar-16	22-Aug-17
242	US9297010	http://59.45.142.240:8808/pdf/US9297010.pdf	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen AS	21-Mar-03	11-Feb-14	29-Mar-16
243	US8653252	http://59.45.142.240:8808/pdf/US8653252.pdf	Short interfering RNA (siRNA) analogues	Santaris Pharma AS	21-Mar-03	22-Mar-04	18-Feb-14
244	US20170009 237	http://59.45.142.240:8808/pdf/US20170009237A1.pdf	Short Interfering RNA (siRNA) Analogues	Not Available	21-Mar-03	28-Mar-16	12-Jan-17
245	US20140235 844	http://59.45.142.240:8808/pdf/US20140235844A1.pdf	Short Interfering RNA (siRNA) Analogues	Santaris Pharma AS	21-Mar-03	11-Feb-14	21-Aug-14
246	US20070191 294	http://59.45.142.240:8808/pdf/US20070191294A1.pdf	Short interfering rna (sirna) analogues	SANTARIS PHARMA AS	21-Mar-03	22-Mar-04	16-Aug-07
247	US7785775	http://59.45.142.240:8808/pdf/US7785775.pdf	Human virus causing severe acute respiratory syndrome (SARS) and its use	Versitech Limited	24-Mar-03	8-Jun-07	31-Aug-10
248	US7547512	http://59.45.142.240:8808/pdf/US7547512.pdf	High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24-Mar-03	24-Mar-04	16-Jun-09
249	US7375202	http://59.45.142.240:8808/pdf/US7375202.pdf	Human virus causing severe acute respiratory syndrome (SARS) and its use	The University of Hong Kong	24-Mar-03	24-Mar-04	20-May-08
250	US7267942	http://59.45.142.240:8808/pdf/US7267942B2.pdf	Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24-Mar-03	24-Mar-04	11-Sep-07
251	US20100285 457	http://59.45.142.240:8808/pdf/US20100285457A1.pdf	High-Throughput Diagnostic Assay For the Human Virus Causing Severe Acute Respiratory Syndrome (SARS)	CHAN KWOK HUNG	24-Mar-03	12-Jun-09	11-Nov-10
252	US20100184 019		Novel Human Virus Causing Severe Acute Respiratory Syndrome (SARS)	CHAN KWOK HUNG	24-Mar-03	10-Feb-10	22-Jul-10
253	US20050181 357	http://59.45.142.240:8808/pdf/US20050181357A1.pdf	High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	CHAN KWOK H.	24-Mar-03	24-Mar-04	18-Aug-05
254	US7691646	http://59.45.142.240:8808/pdf/US7691646.pdf	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and	Daikin Industries, Ltd.	28-Mar-03	21-Nov-08	6-Apr-10

255	US7470548	http://59.45.142.240:8808/pdf/US7470548.pdf	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and	Daikin Industries, Ltd.	28-Mar-03	26-Mar-04	30-Dec-08
256	US20090124 843	http://59.45.142.240:8808/pdf/US20090124843A1.pdf	HAZARDOUS SUBSTANCE REMOVING METHOD, HAZARDOUS SUBSTANCE REMOVING MATERIAL USED THEREIN SUCH AS AIR FILTER, MASK, WIPE SHEET, AND	Not Available	28-Mar-03	21-Nov-08	14-May-09
257	US20090078 263	http://59.45.142.240:8808/pdf/US20090078263A1.pdf	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and	ARAJ JUN-ICHIRO	28-Mar-03	21-Nov-08	26-Mar-09
258	US20060088 926	http://59.45.142.240:8808/pdf/US20060088926A1.pdf	Method of removing hazardous substance, and hazardous substance removing material using the same such as air cleaning filter, mask and wiping sheet, and method of storing	DAIKIN IND LTD	28-Mar-03	26-Mar-04	27-Apr-06
259	US20090068 142	http://59.45.142.240:8808/pdf/US20090068142A1.pdf	COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION	Three Rivers Pharmaceuticals LLC	1-Apr-03	29-Jul-08	12-Mar-09
260	US20080242 851	http://59.45.142.240:8808/pdf/US20080242851A1.pdf	MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET EFFECTS IN RNA INTERFERENCE	DHARMACON, INC.	2-Apr-03	19-Sep-07	2-Oct-08
261	US20060264 435		Novel compounds	BONNERT ROGER	7-Apr-03	6-Apr-04	23-Nov-06
262	US20060211 765		Novel compounds	ASTRAZENECA AB	7-Apr-03	6-Apr-04	21-Sep-06
263	US20070053 878		Sars	FOUCHIER RONALDUS A M	8-Apr-03	8-Apr-04	8-Mar-07
264	US7572621	http://59.45.142.240:8808/pdf/US7572621.pdf	Detection, characterization and treatment of viral infection and	Canadian Blood Services	9-Apr-03	11-Oct-05	11-Aug-09
265	US9801947	http://59.45.142.240:8808/pdf/US9801947.pdf	Methods and compositions for enhancing immune response	3M INNOVATIVE PROPERTIES COMPANY	10-Apr-03	6-Oct-14	31-Oct-17
266	US20170319 712	http://59.45.142.240:8808/pdf/US20170319712A1.pdf	METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE	3M INNOVATIVE PROPERTIES COMPANY	10-Apr-03	27-Jul-17	9-Nov-17
267	US20150044 279	http://59.45.142.240:8808/pdf/US20150044279A1.pdf	METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE	Not Available	10-Apr-03	6-Oct-14	12-Feb-15
268	US20060257 852		Severe acute respiratory syndrome coronavirus	Chiron Corporation	10-Apr-03	9-Apr-04	16-Nov-06
269	US20090298 914	http://59.45.142.240:8808/pdf/US20090298914A1.pdf	RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering	Sirna Therapeutics, Inc.	15-Apr-03	17-Nov-08	3-Dec-09
270	US20070270 360	http://59.45.142.240:8808/pdf/US20070270360A1.pdf	Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression	SIRNA THERAPEUTICS, INC.	15-Apr-03	13-Apr-04	22-Nov-07
271	US7582740	http://59.45.142.240:8808/pdf/US7582740.pdf	Methods and kits for detecting SARS-associated coronavirus	The Trustees of Columbia University In the City of New	17-Apr-03	23-Jan-04	1-Sep-09
272	US20100279 276	http://59.45.142.240:8808/pdf/US20100279276A1.pdf	METHODS FOR DETERMINING THE PRESENCE OF SARS CORONAVIRUS IN A SAMPLE	GEN-PROBE INCORPORATED	17-Apr-03	6-Jul-10	4-Nov-10
273	US20070026 014	http://59.45.142.240:8808/pdf/US20070026014A1.pdf	Interferon beta in severe acute respiratory syndrome (sars)	ARES TRADING S.A.	17-Apr-03	6-Apr-04	1-Feb-07
274	US20060135 422	http://59.45.142.240:8808/pdf/US20060135422A1.pdf	Use of angiotensin receptor blockers (ARBs) to treat diseases associated with ACE	MOSKOWITZ DAVID W	17-Apr-03	31-Mar-04	22-Jun-06
275	US20060134 609	http://59.45.142.240:8808/pdf/US20060134609A1.pdf	Compositions and methods for determining the presence of SARS	GETMAN DAMON K	17-Apr-03	16-Apr-04	22-Jun-06
276	US20080044 814		Reagents and Methods for Detecting Severe Acute Respiratory Syndrome	HIBBERD MARTIN L	21-Apr-03	21-Apr-04	21-Feb-08
277	US20070286 872	http://59.45.142.240:8808/pdf/US20070286872A1.pdf	Live Attenuated Nidovirus Vaccines	Vanderbilt University	22-Apr-03	22-Apr-04	13-Dec-07
278	US20100311 656	http://59.45.142.240:8808/pdf/US20100311656A1.pdf	TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS	SciClone Pharmaceuticals,	23-Apr-03	16-Jun-10	9-Dec-10
279	US20070036 744	http://59.45.142.240:8808/pdf/US20070036744A1.pdf	Treatment or prevention of respiratory viral infections with alpha	SciClone Pharmaceuticals,	23-Apr-03	23-Apr-04	15-Feb-07
280	US20030224 353	http://59.45.142.240:8808/pdf/US20030224353A1.pdf	Antisense antiviral agent and method for treating ssRNA viral	IVERSEN PATRICK L	24-Apr-03	24-Apr-03	4-Dec-03
281	US7776521	http://59.45.142.240:8808/pdf/US7776521.pdf	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers	25-Apr-03	14-May-07	17-Aug-10
282	US7220852	http://59.45.142.240:8808/pdf/US7220852.pdf	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers	25-Apr-03	12-Apr-04	22-May-07
283	US20070203 082	http://59.45.142.240:8808/pdf/US20070203082A1.pdf	RNAI Agents For Anti-SARS Coronavirus Therapy	Intradigm Corporation	25-Apr-03	26-Apr-04	30-Aug-07
284	US20050266 397	http://59.45.142.240:8808/pdf/US20050266397A1.pdf	Methods for identification of coronavirus	BLYN LAWRENCE B	26-Apr-03	22-Apr-04	1-Dec-05
285	US7339051	http://59.45.142.240:8808/pdf/US7339051.pdf	Compositions and methods for the treatment of severe acute coronavirus	Isis Pharmaceuticals,	28-Apr-03	26-Apr-04	4-Mar-08
286	US7151163	http://59.45.142.240:8808/pdf/US7151163.pdf	Antiviral agents for the treatment, control and prevention of infections	Sequoia Pharmaceuticals,	28-Apr-03	28-Apr-04	19-Dec-06
287	US20070258 999	http://59.45.142.240:8808/pdf/US20070258999A1.pdf	Sars Virus Nucleotide and Amino Acid Sequences and Uses Thereof	THE PUBLIC HEALTH AGENCY OF CANADA	28-Apr-03	28-Apr-04	8-Nov-07

288	US20070185 027	http://59.45.142.240:8808/pdf/US20070185027A1.pdf	ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY	SEQUOIA PHARMACEUTICALS, INC.	28-Apr-03	9-Nov-06	9-Aug-07
289	US20060258 577	http://59.45.142.240:8808/pdf/US20060258577A1.pdf	ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY	ERICKSON JOHN W	28-Apr-03	28-Apr-04	16-Nov-06
290	US20050100 885	http://59.45.142.240:8808/pdf/US20050100885A1.pdf	Compositions and methods for the treatment of severe acute	BAKER BRENDA F.	28-Apr-03	26-Apr-04	12-May-05
291	US9572899	http://59.45.142.240:8808/pdf/US9572899.pdf	Compositions for enhancing transport of molecules into cells	AVI BIOPHARMA, INC.	29-Apr-03	5-Nov-08	21-Feb-17
292	US7468418	http://59.45.142.240:8808/pdf/US7468418.pdf	Compositions for enhancing transport of molecules into cells	AVI BioPharma., Inc.	29-Apr-03	29-Apr-04	23-Dec-08
293	US20200016 280	http://59.45.142.240:8808/pdf/US20200016280A1.pdf	Compositions For Enhancing Transport Of Molecules Into Cells	Not Available	29-Apr-03	9-Apr-19	16-Jan-20
294	US20170368 203	http://59.45.142.240:8808/pdf/US20170368203A1.pdf	Compositions For Enhancing Transport Of Molecules Into Cells	Not Available	29-Apr-03	10-Jan-17	28-Dec-17
295	US20090082 547	http://59.45.142.240:8808/pdf/US20090082547A1.pdf	COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO CELLS	IVERSEN PATRICK L	29-Apr-03	5-Nov-08	26-Mar-09
296	US10300149	http://59.45.142.240:8808/pdf/US10300149.pdf	Compositions for enhancing transport of molecules into cells	SAREPTA THERAPEUTICS, INC.	29-Apr-03	10-Jan-17	28-May-19
297	US7374883	http://59.45.142.240:8808/pdf/US7374883.pdf	Method and kit for the detection of a novel coronavirus associated with the severe acute respiratory	QIAGEN Diagnostics GmbH	30-Apr-03	30-Apr-04	20-May-08
298	US20050142 536	http://59.45.142.240:8808/pdf/US20050142536A1.pdf	Method and kit for the detection of a novel coronavirus associated with the severe acute respiratory	LAUE THOMAS	30-Apr-03	30-Apr-04	30-Jun-05
299	US20040009 152	http://59.45.142.240:8808/pdf/US20040009152A1.pdf	Materials and methods for prevention and treatment of RNA	BEHERA ARUNA K.	30-Apr-03	30-Apr-03	15-Jan-04
300	US20080199 915	http://59.45.142.240:8808/pdf/US20080199915A1.pdf	Methods and Kits For Mass Production Of Derna	RNA-Line Oy	2-May-03	2-May-03	21-Aug-08
301	US20080090 224		Nucleic acid detection	HAI KANG LIFE CORPORATION LIMITED	2-May-03	30-Apr-04	17-Apr-08
302	US20070134 255	http://59.45.142.240:8808/pdf/US20070134255A1.pdf	Hmpv treatment with ribavirin and anti hmpv antibody	ViroNovative B.V.	2-May-03	3-May-04	14-Jun-07
303	US20040009 245	http://59.45.142.240:8808/pdf/US20040009245A1.pdf	Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute	VAIL MARILYN L.	2-May-03	2-May-03	15-Jan-04
304	US7604801	http://59.45.142.240:8808/pdf/US7604801.pdf	Methods for detecting parvovirus infections	The Research Foundation of State University of New	5-May-03	16-Oct-08	20-Oct-09
305	US7445889	http://59.45.142.240:8808/pdf/US7445889.pdf	Methods for detecting parvovirus infections	The Research Foundation of State University of New	5-May-03	5-May-04	4-Nov-08
306	US20090041 781	http://59.45.142.240:8808/pdf/US20090041781A1.pdf	METHODS FOR DETECTING PARVOVIRUS INFECTIONS	The Research Foundation of State University of New	5-May-03	16-Oct-08	12-Feb-09
307	US20070166 823	http://59.45.142.240:8808/pdf/US20070166823A1.pdf	Methods for detecting parvovirus infections	BLUTH MARTIN H	5-May-03	5-May-04	19-Jul-07
308	US7504382	http://59.45.142.240:8808/pdf/US7504382.pdf	Protease inhibitors for coronaviruses and SARS-CoV and the use thereof	Cytovia, Inc.	6-May-03	6-May-04	17-Mar-09
309	US20080300 191	http://59.45.142.240:8808/pdf/US20080300191A1.pdf	PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF	CAI SUI XIONG	6-May-03	6-May-04	4-Dec-08
310	US20070092 936		Severe acute respiratory syndrome	HAYNES BARTON F	8-May-03	10-May-04	26-Apr-07
311	US20070141 053	http://59.45.142.240:8808/pdf/US20070141053A1.pdf	Treatment of inflammatory respiratory diseases	Schering Aktiengesellschaft	9-May-03	7-May-04	21-Jun-07
312	US20070037 140	http://59.45.142.240:8808/pdf/US20070037140A1.pdf	Methods and compositions for detecting SARS virus	CAPITAL BIOCHIP COMPANY, LTD.	9-May-03	9-May-03	15-Feb-07
313	US20060263 765	http://59.45.142.240:8808/pdf/US20060263765A1.pdf	Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated	HOUDE MICHEL	9-May-03	5-May-04	23-Nov-06
314	US20040009 943	http://59.45.142.240:8808/pdf/US20040009943A1.pdf	Pathogen vaccines and methods for using the same	Inex Pharmaceuticals S.A.	12-May-03	12-May-03	15-Jan-04
315	US20040229 778	http://59.45.142.240:8808/pdf/US20040229778A1.pdf	Pharmaceutical compositions of antithrombin III for the treatment of	ELMALEH DAVID R.	13-May-03	13-May-03	18-Nov-04
316	US20070123 566		Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same	CHENGDU DIKANG PHARMACEUTICAL INSTITUTE	15-May-03	14-May-04	31-May-07
317	US7678774	http://59.45.142.240:8808/pdf/US7678774.pdf	Treating severe acute respiratory syndrome	Hemispherx Biopharma	16-May-03	26-Jan-07	16-Mar-10
318	US20090304 630	http://59.45.142.240:8808/pdf/US20090304630A1.pdf	Treating Severe and acute viral infections	HEMISPHERx BIOPHARMA	16-May-03	2-Aug-07	10-Dec-09
319	US20070141 080	http://59.45.142.240:8808/pdf/US20070141080A1.pdf	Treating severe acute respiratory syndrome	HEMISPHERx BIOPHARMA	16-May-03	26-Jan-07	21-Jun-07
320	US20070105 193	http://59.45.142.240:8808/pdf/US20070105193A1.pdf	Severe acute respiratory syndrome DNA vaccine compositions and	Vical Incorporated	16-May-03	12-May-04	10-May-07
321	US20060035 859	http://59.45.142.240:8808/pdf/US20060035859A1.pdf	Treating severe and acute viral infections	HEMISPHERx BIOPHARMA	16-May-03	6-Oct-05	16-Feb-06
322	US7429656	http://59.45.142.240:8808/pdf/US7429656.pdf	Inhibition of SARS-associated coronavirus (SCoV) infection and	The University of Hong Kong	19-May-03	14-Jun-06	30-Sep-08
323	US7129223	http://59.45.142.240:8808/pdf/US7129223.pdf	Inhibition of SARS-associated coronavirus (SCoV) infection and	The University of HongKong	19-May-03	19-May-04	31-Oct-06
324	US20060280 723	http://59.45.142.240:8808/pdf/US20060280723A1.pdf	Interferon for treating or preventing a coronavirus infection	Viragen, Inc	19-May-03	19-May-04	14-Dec-06
325	US20060258 611	http://59.45.142.240:8808/pdf/US20060258611A1.pdf	Inhibition of SARS-associated coronavirus (SCoV) infection and	UNIV HONG KONG	19-May-03	14-Jun-06	16-Nov-06
326	US7745119	http://59.45.142.240:8808/pdf/US7745119.pdf	System for detecting polynucleotides	Investigen, Inc.	20-May-03	21-Nov-05	29-Jun-10
327	US20110008 905	http://59.45.142.240:8808/pdf/US20110008905A1.pdf	SYSTEM FOR DETECTING POLYNUCLEOTIDES	INVESTIGEN	20-May-03	9-Jun-10	13-Jan-11
328	US20060263 847	http://59.45.142.240:8808/pdf/US20060263847A1.pdf	Compositions and methods for treatment of sever acute respiratory	SIBER GEORGE R	20-May-03	20-May-04	23-Nov-06
329	US20060147 958	http://59.45.142.240:8808/pdf/US20060147958A1.pdf	System for detecting polynucleotides	CHOI K Y	20-May-03	21-Nov-05	6-Jul-06

330	US20040235 047	http://59.45.142.240:8808/pdf/US20040235047A1.pdf	Compositions and methods for treatment of Severe Acute Respiratory Syndrome (SARS)	SIBER GEORGE R.	20-May-03	20-May-03	25-Nov-04
331	US20040167 161	http://59.45.142.240:8808/pdf/US20040167161A1.pdf	Method of treating or inhibiting the development of brain inflammation	NOZAKI MASAKO	20-May-03	26-Nov-03	26-Aug-04
332	US7361747	http://59.45.142.240:8808/pdf/US7361747.pdf	Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-	The University of Hong Kong	22-May-03	24-May-04	22-Apr-08
333	US20080069 839	http://59.45.142.240:8808/pdf/US20080069839A1.pdf	ISOLATION AND CHARACTERIZATION OF THE PRECURSOR VIRUS OF HUMAN SARS VIRUS: SARS-ASSOCIATED CORONA	GUAN YI	22-May-03	24-May-04	20-Mar-08
334	US7470666	http://59.45.142.240:8808/pdf/US7470666.pdf	Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory	Guangdong Techpool Biochem. Pharma. Co., Ltd.	26-May-03	25-May-04	30-Dec-08
335	US20070275 879	http://59.45.142.240:8808/pdf/US20070275879A1.pdf	Use of Ulinastatin and Its Pharmaceutical Composition for Treating Severe Acute Respiratory	GUANGDONG TECHPOOL BIOCHEM PHA	26-May-03	25-May-04	29-Nov-07
336	US7713515	http://59.45.142.240:8808/pdf/US7713515.pdf	Methods and compositions for use in diagnosing and characterizing diseases involving abnormal	R.E.D. Laboratories N.V.	27-May-03	26-May-04	11-May-10
337	US7687535	http://59.45.142.240:8808/pdf/US7687535.pdf	Substituted 3-sulfur indoles	AstraZeneca AB	27-May-03	25-May-04	30-Mar-10
338	US20090163 518	http://59.45.142.240:8808/pdf/US20090163518A1.pdf	Novel Compounds	BONNERT ROGER	27-May-03	4-Mar-09	25-Jun-09
339	US20080249 110	http://59.45.142.240:8808/pdf/US20080249110A1.pdf	Novel Substituted 3-Sulfur Indoles	BONNERT ROGER	27-May-03	25-May-04	9-Oct-08
340	US20050282 279	http://59.45.142.240:8808/pdf/US20050282279A1.pdf	Expression vector encoding coronavirus like particle	HWU PAUL L	29-May-03	28-May-04	22-Dec-05
341	US20160238 600	http://59.45.142.240:8808/pdf/US20160238600A1.pdf	METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF	Merus B.V.	30-May-03	27-Apr-16	18-Aug-16
342	US20040237 198	http://59.45.142.240:8808/pdf/US20040237198A1.pdf	Protecting shield for performing the insertion of a tube during emergency	YANG JUI KUANG	2-Jun-03	2-Jun-03	2-Dec-04
343	US7662860	http://59.45.142.240:8808/pdf/US7662860.pdf	3D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs	Shanghai Institute of Materia Medica, Chinese Academy of	4-Jun-03	2-Dec-05	16-Feb-10
344	US20060142 383	http://59.45.142.240:8808/pdf/US20060142383A1.pdf	3D-Structure model of SARS coronavirus 3CL protease and anti-	SHANGHAI LEAD DISCOVERY	4-Jun-03	2-Dec-05	29-Jun-06
345	US20060140 971	http://59.45.142.240:8808/pdf/US20060140971A1.pdf	Cell surface expression vector of sars virus antigen and	CHOI JAE C	4-Jun-03	4-Jun-04	29-Jun-06
346	US9388234	http://59.45.142.240:8808/pdf/US9388234.pdf	Systems and methods for identifying Replikin Scaffolds and uses of said	Not Available	6-Jun-03	19-Jun-13	12-Jul-16
347	US8494781	http://59.45.142.240:8808/pdf/US8494781.pdf	Systems and methods for identifying replikin scaffolds and uses of said	BOGOCH ELENORE S	6-Jun-03	10-Dec-10	23-Jul-13
348	US7442761	http://59.45.142.240:8808/pdf/US7442761.pdf	Replikin peptides and uses thereof	BOGOCH ELENORE S	6-Jun-03	4-Jun-04	28-Oct-08
349	US20140206 556	http://59.45.142.240:8808/pdf/US20140206556A1.pdf	Systems and Methods for Identifying Replikin Scaffolds and Uses of Said	Not Available	6-Jun-03	19-Jun-13	24-Jul-14
350	US20090053 257	http://59.45.142.240:8808/pdf/US20090053257A1.pdf	REPLIKIN PEPTIDES AND USES THEREOF	BOGOCH ELENORE S	6-Jun-03	10-Jul-08	26-Feb-09
351	US20070099 855	http://59.45.142.240:8808/pdf/US20070099855A1.pdf	Glycyrrhizin or derivatives thereof for for treating or preventing severe	Johann Wolfgang Goethe University	6-Jun-03	7-Jun-04	3-May-07
352	US20060257 976	http://59.45.142.240:8808/pdf/US20060257976A1.pdf	Methods and kits for propagating and evolving nucleic acids and proteins	RNA LINE OY	6-Jun-03	7-Jun-04	16-Nov-06
353	US7482149	http://59.45.142.240:8808/pdf/US7482149.pdf	Inhibition of SARS coronavirus infection with clinically approved	Genome Institute of Singapore	9-Jun-03	9-Jun-04	27-Jan-09
354	US20070003 565	http://59.45.142.240:8808/pdf/US20070003565A1.pdf	Use of hab18g/cd147 molecule as target for antiviral antagonists and	CHEN ZHINAN	9-Jun-03	9-Jun-03	4-Jan-07
355	US20060153 803	http://59.45.142.240:8808/pdf/US20060153803A1.pdf	Inhibition of sars coronavirus infection with clinically approved	STANTON LAWRENCE W	9-Jun-03	9-Jun-04	13-Jul-06
356	US20090226 885	http://59.45.142.240:8808/pdf/US20090226885A1.pdf	Nucleic Acid Sequences That Can Be Used As Primers And Probes In The Amplification And Detection Of Sars	OVERDIJK MARLIEKE	10-Jun-03	8-Mar-04	10-Sep-09
357	US20040071 757	http://59.45.142.240:8808/pdf/US20040071757A1.pdf	Inhalation antiviral patch	ROLF DAVID	10-Jun-03	10-Jun-03	15-Apr-04
358	US7786290	http://59.45.142.240:8808/pdf/US7786290.pdf	Double-stranded ribonucleic acid with increased effectiveness in an	Alnylam Pharmaceuticals,	13-Jun-03	14-Jun-04	31-Aug-10
359	US20100330 141	http://59.45.142.240:8808/pdf/US20100330141A1.pdf	PRODUCT FOR ABSORPTION PURPOSES	HJERTEN MARIE-CHRISTINE	13-Jun-03	13-Sep-10	30-Dec-10
360	US20100280 102	http://59.45.142.240:8808/pdf/US20100280102A1.pdf	DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ABSORPTION	Alnylam Pharmaceuticals	13-Jun-03	16-Jun-10	4-Nov-10
361	US20070275 465	http://59.45.142.240:8808/pdf/US20070275465A1.pdf	Double-Stranded Ribonucleic Acid with Increased Effectiveness in an	Alnylam Pharmaceuticals	13-Jun-03	14-Jun-04	29-Nov-07
362	US20070104 686	http://59.45.142.240:8808/pdf/US20070104686A1.pdf	Vaccines, immunotherapeutics and methods for using the same	CHATTERGOON MICHAEL A	13-Jun-03	14-Jun-04	10-May-07
363	US20070041 941	http://59.45.142.240:8808/pdf/US20070041941A1.pdf	Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for	BOYER JEAN D	13-Jun-03	14-Jun-04	22-Feb-07
364	US20060163 149	http://59.45.142.240:8808/pdf/US20060163149A1.pdf	Product for absorption purposes	HJERTEN MARIE-CHRISTINE	13-Jun-03	11-Jun-04	27-Jul-06
365	US20060110 803	http://59.45.142.240:8808/pdf/US20060110803A1.pdf	Antigenic peptides of SARS coronavirus and uses thereof	Crucell Holland B.V.	13-Jun-03	6-Dec-05	25-May-06
366	US20040253 328	http://59.45.142.240:8808/pdf/US20040253328A1.pdf	Anti-atypical pneumonia decoction	HU XIN YUAN	13-Jun-03	21-Jul-03	16-Dec-04
367	US7465836	http://59.45.142.240:8808/pdf/US7465836.pdf	Hydrolytically-resistant boron-containing therapeutics and methods	Anacor Pharmaceuticals,	16-Jun-03	15-Jun-04	16-Dec-08
368	US20090239 824	http://59.45.142.240:8808/pdf/US20090239824A1.pdf	HYDROLYTICALLY-RESISTANT BORON-CONTAINING	Anacor Pharmaceuticals,	16-Jun-03	13-Nov-08	24-Sep-09
369	US20080206 283		Vaccine Against Sars	DONG JOHN Y	17-Jun-03	17-Jun-04	28-Aug-08

370	US20040067 920	http://59.45.142.240:8808/pdf/US20040067920A1.pdf	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary	JOHNSON KEITH A.	17-Jun-03	17-Jun-03	8-Apr-04
371	US20050182 243	http://59.45.142.240:8808/pdf/US20050182243A1.pdf	Membrane scaffold proteins	BAYBURN TIMOTHY H.	18-Jun-03	11-Jan-05	18-Aug-05
372	US8541003	http://59.45.142.240:8808/pdf/US8541003.pdf	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof,	Protein Sciences Corporation	20-Jun-03	21-Jun-04	24-Sep-13
373	US7589092	http://59.45.142.240:8808/pdf/US7589092.pdf	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals,	20-Jun-03	27-Dec-06	15-Sep-09
374	US7491508	http://59.45.142.240:8808/pdf/US7491508.pdf	Methods of generating chimeric adenoviruses and uses for such	The Trustees of the University of	20-Jun-03	15-Jun-04	17-Feb-09
375	US7291498	http://59.45.142.240:8808/pdf/US7291498B2.pdf	Methods of generating chimeric adenoviruses and uses for such	The Trustees of the University of	20-Jun-03	20-Jun-03	6-Nov-07
376	US7244732	http://59.45.142.240:8808/pdf/US7244732.pdf	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals,	20-Jun-03	31-Mar-04	17-Jul-07
377	US20130216 566	http://59.45.142.240:8808/pdf/US20130216566A1.pdf	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof,	ADAMS DANIEL	20-Jun-03	21-Jun-04	22-Aug-13
378	US20090209 505	http://59.45.142.240:8808/pdf/US20090209505A1.pdf	PRODRUGS OF HETEROARYL COMPOUNDS	Koronis Pharmaceuticals,	20-Jun-03	7-Apr-09	20-Aug-09
379	US20090192 099	http://59.45.142.240:8808/pdf/US20090192099A1.pdf	PRODRUGS OF HETEROARYL COMPOUNDS	Koronis Pharmaceuticals,	20-Jun-03	30-Mar-09	30-Jul-09
380	US20080249 097	http://59.45.142.240:8808/pdf/US20080249097A1.pdf	PRODRUGS OF HETEROARYL COMPOUNDS	Koronis Pharmaceuticals,	20-Jun-03	27-Dec-06	9-Oct-08
381	US20070231 303	http://59.45.142.240:8808/pdf/US20070231303A1.pdf	METHODS OF GENERATING CHIMERIC ADENOVIRUSES AND USES FOR SUCH CHIMERIC	The Trustees of the University of Pennsylvania	20-Jun-03	20-Jun-03	4-Oct-07
382	US20070219 200	http://59.45.142.240:8808/pdf/US20070219200A1.pdf	PRODRUGS OF HETEROARYL COMPOUNDS	Koronis Pharmaceuticals,	20-Jun-03	15-May-07	20-Sep-07
383	US20060211 115	http://59.45.142.240:8808/pdf/US20060211115A1.pdf	Methods of generating chimeric adenoviruses and uses for such	The Trustees of the University of	20-Jun-03	15-Jun-04	21-Sep-06
384	US7635557	http://59.45.142.240:8808/pdf/US7635557.pdf	Enzymatic diagnostic test for SARS and other viral diseases	MND Diagnostic Ltd.	23-Jun-03	23-Jun-04	22-Dec-09
385	US20100143 888	http://59.45.142.240:8808/pdf/US20100143888A1.pdf	ENZYMATIC DIAGNOSTIC TEST FOR SARS AND OTHER VIRAL DISEASES	MND Diagnostic Ltd.	23-Jun-03	25-Nov-09	10-Jun-10
386	US20060178 341	http://59.45.142.240:8808/pdf/US20060178341A1.pdf	Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 inhibiting the swine influenza (SIV) and transmissible	CHUNG BONG H	23-Jun-03	23-Jun-04	10-Aug-06
387	US20080069 830	http://59.45.142.240:8808/pdf/US20080069830A1.pdf	Dna Sequences, Peptides, Antibodies and Vaccines for Prevention and	HOFFMAN STEPHEN L	24-Jun-03	24-Jun-04	20-Mar-08
388	US7479484	http://59.45.142.240:8808/pdf/US7479484.pdf	Peptides and peptidomimetics having immune-modulating, anti-	Takeda Pharmaceutical	25-Jun-03	25-Jun-04	20-Jan-09
389	US20090192 090	http://59.45.142.240:8808/pdf/US20090192090A1.pdf	PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-	TAKEDA PHARMACEUTICAL COMPANY LIMITED	25-Jun-03	31-Dec-08	30-Jul-09
390	US20060003 941	http://59.45.142.240:8808/pdf/US20060003941A1.pdf	Peptides and peptidomimetics having immune-modulating, anti-	KAWABE TAKUMI	25-Jun-03	25-Jun-04	5-Jan-06
391	US20190389 816	http://59.45.142.240:8808/pdf/US20190389816A1.pdf	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26-Jun-03	29-Aug-19	26-Dec-19
392	US20170260 147	http://59.45.142.240:8808/pdf/US20170260147A1.pdf	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26-Jun-03	23-May-17	14-Sep-17
393	US20150313 909	http://59.45.142.240:8808/pdf/US20150313909A1.pdf	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26-Jun-03	6-Feb-15	5-Nov-15
394	US20080166 370	http://59.45.142.240:8808/pdf/US20080166370A1.pdf	Immunogenic Compositions Comprising Multiple Gonococcal	CHIRON SRL	26-Jun-03	25-Jun-04	10-Jul-08
395	US20070274 994	http://59.45.142.240:8808/pdf/US20070274994A1.pdf	Virulence-Associated Adhesins	Novartis Vaccines and Diagnostics	26-Jun-03	25-Jun-04	29-Nov-07
396	US10472332	http://59.45.142.240:8808/pdf/US10472332.pdf	Antiviral compounds and methods	Biotron Limited	26-Jun-03	23-May-17	12-Nov-19
397	US7595381	http://59.45.142.240:8808/pdf/US7595381.pdf	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27-Jun-03	10-Jun-08	29-Sep-09
398	US7595163	http://59.45.142.240:8808/pdf/US7595163.pdf	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27-Jun-03	10-Jun-08	29-Sep-09
399	US7399588	http://59.45.142.240:8808/pdf/US7399588.pdf	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27-Jun-03	15-Jun-04	15-Jul-08
400	US20090117 537	http://59.45.142.240:8808/pdf/US20090117537A1.pdf	METHOD FOR DETECTING SARS CORONAVIRUS	EIKEN KAGAKU KABUSHIKI KAISHA	27-Jun-03	10-Jun-08	7-May-09
401	US20090092 962	http://59.45.142.240:8808/pdf/US20090092962A1.pdf	METHOD FOR DETECTING SARS CORONAVIRUS	EIKEN KAGAKU KABUSHIKI KAISHA	27-Jun-03	10-Jun-08	9-Apr-09
402	US20070099 178	http://59.45.142.240:8808/pdf/US20070099178A1.pdf	Method for detecting sars coronavirus	EIKEN KAGAKU KABUSHIKI KAISHA	27-Jun-03	15-Jun-04	3-May-07
403	US20050071 892	http://59.45.142.240:8808/pdf/US20050071892A1.pdf	Techniques and applications of establishment of SARS-CoV primate	GAO HONG	27-Jun-03	25-Jun-04	31-Mar-05
404	US20040077 587	http://59.45.142.240:8808/pdf/US20040077587A1.pdf	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment	LACOLLA PAOLA	27-Jun-03	27-Jun-03	22-Apr-04
405	US20050233 314	http://59.45.142.240:8808/pdf/US20050233314A1.pdf	Sensitive and quantitative detection of pathogens by real-time nested		30-Jun-03	30-Jun-04	20-Oct-05
406	US8592391	http://59.45.142.240:8808/pdf/US8592391.pdf	Method for therapeutic, clinical and veterinary use of poly-ICLC	SALAZAR ANDRES	1-Jul-03	17-Oct-08	26-Nov-13
407	US7393638	http://59.45.142.240:8808/pdf/US7393638.pdf	Assay system and methods for detecting SARS-CoV	AsiaGEN Corporation	1-Jul-03	1-Jul-03	1-Jul-08
408	US20050003 340	http://59.45.142.240:8808/pdf/US20050003340A1.pdf	Assay system and methods for detecting SARS-CoV	AsiaGEN Corporation	1-Jul-03	1-Jul-03	6-Jan-05
409	US20040005 998	http://59.45.142.240:8808/pdf/US20040005998A1.pdf	Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary	ONCOVIR, INC.	1-Jul-03	1-Jul-03	8-Jan-04

410	US7696406	http://59.45.142.240:8808/pdf/US7696406.pdf	Expression of a recombinant transgene	Board of Trustees Operating Michigan	3-Jul-03	2-Jul-04	13-Apr-10
411	US20150191 607	http://59.45.142.240:8808/pdf/US20150191607A1.pdf	Anti-fouling Paints and Coatings	REACTIVE SURFACES LTD	3-Jul-03	4-Dec-13	9-Jul-15
412	US20070136 890		Expression of a recombinant transgene	Board of Trustees Operating Michigan	3-Jul-03	2-Jul-04	14-Jun-07
413	US20080152 728	http://59.45.142.240:8808/pdf/US20080152728A1.pdf	Noble gas-chlorine mixture effective against microorganisms	GLOBUS ALFRED R	7-Jul-03	25-Apr-07	26-Jun-08
414	US20050008 535	http://59.45.142.240:8808/pdf/US20050008535A1.pdf	Noble gas-chlorine mixture effective against microorganisms	GLOBUS ALFRED R.	7-Jul-03	7-Jul-03	13-Jan-05
415	US20070172 817	http://59.45.142.240:8808/pdf/US20070172817A1.pdf	Methods of Producing Antibodies for Diagnostic and Therapeutic	CHANG XIAO-JIA	8-Jul-03	22-Nov-06	26-Jul-07
416	US20050009 110	http://59.45.142.240:8808/pdf/US20050009110A1.pdf	Methods of producing antibodies for diagnostic and therapeutic	CHANG XIAO-JIA	8-Jul-03	8-Jul-03	13-Jan-05
417	US9951317	http://59.45.142.240:8808/pdf/US9951317.pdf	Highly efficient influenza matrix (M1) proteins	NOVAVAX, INC.	11-Jul-03	6-Oct-16	24-Apr-18
418	US9464276	http://59.45.142.240:8808/pdf/US9464276.pdf	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11-Jul-03	23-Feb-15	11-Oct-16
419	US8992939	http://59.45.142.240:8808/pdf/US8992939.pdf	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11-Jul-03	24-Oct-11	31-Mar-15
420	US8551756	http://59.45.142.240:8808/pdf/US8551756.pdf	Avian influenza chimeric VLPs	Novavax, Inc.	11-Jul-03	19-Jan-10	8-Oct-13
421	US20190062 713	http://59.45.142.240:8808/pdf/US20190062713A1.pdf	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11-Jul-03	22-Mar-18	28-Feb-19
422	US20170253 861	http://59.45.142.240:8808/pdf/US20170253861A1.pdf	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11-Jul-03	6-Oct-16	7-Sep-17
423	US20150307 849	http://59.45.142.240:8808/pdf/US20150307849A1.pdf	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11-Jul-03	23-Feb-15	29-Oct-15
424	US20100184 192	http://59.45.142.240:8808/pdf/US20100184192A1.pdf	AVIAN INFLUENZA CHIMERIC VLPs	PUSHKO PETER	11-Jul-03	19-Jan-10	22-Jul-10
425	US10544399	http://59.45.142.240:8808/pdf/US10544399.pdf	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11-Jul-03	22-Mar-18	28-Jan-20
426	US20050107 324	http://59.45.142.240:8808/pdf/US20050107324A1.pdf	Modulation of CEACAM1 expression	BENNETT C. F.	12-Jul-03	12-Jul-04	19-May-05
427	US20050075 307	http://59.45.142.240:8808/pdf/US20050075307A1.pdf	Modulation of aminopeptidase N expression	BENNETT C. FRANK	12-Jul-03	12-Jul-04	7-Apr-05
428	US20070042 350	http://59.45.142.240:8808/pdf/US20070042350A1.pdf	Methods and compositions for detecting sars virus and other	CHENG JING	14-Jul-03	14-Jul-03	22-Feb-07
429	US7495011	http://59.45.142.240:8808/pdf/US7495011.pdf	Anti-coronavirus drug	aRigen Pharmaceuticals,	15-Jul-03	14-Jul-04	24-Feb-09
430	US20070092 938	http://59.45.142.240:8808/pdf/US20070092938A1.pdf	Diagnostics for sars virus	Temasek Life Sciences Laboratory	15-Jul-03	4-Feb-04	26-Apr-07
431	US20060223 847	http://59.45.142.240:8808/pdf/US20060223847A1.pdf	Anti-coronavirus drug	Arigen, Inc.	15-Jul-03	14-Jul-04	5-Oct-06
432	US20040175 378	http://59.45.142.240:8808/pdf/US20040175378A1.pdf	Selected antibody compositions and methods for binding to	Board of Regents, The University of	15-Jul-03	15-Jul-03	9-Sep-04
433	US20040170 620	http://59.45.142.240:8808/pdf/US20040170620A1.pdf	Selected antibody compositions for binding to aminoglycoside	RAN SOPHIA	15-Jul-03	15-Jul-03	2-Sep-04
434	US20050014 830	http://59.45.142.240:8808/pdf/US20050014830A1.pdf	Substances for breaking down conformation of microbes	CHU SHU FANG	17-Jul-03	4-Jun-04	20-Jan-05
435	US7618802	http://59.45.142.240:8808/pdf/US7618802.pdf	Compositions of coronaviruses with a recombination-resistant genome	The University of North Carolina at	21-Jul-03	19-Jan-06	17-Nov-09
436	US20060240 530	http://59.45.142.240:8808/pdf/US20060240530A1.pdf	Methods and compositions for infectious cDNA of SARS coronavirus	UNIV NORTH CAROLINA	21-Jul-03	19-Jan-06	26-Oct-06
437	US20060240 515	http://59.45.142.240:8808/pdf/US20060240515A1.pdf	Soluble fragments of the SARS-CoV spike glycoprotein	DIMITROV DIMITER S	21-Jul-03	19-Jan-06	26-Oct-06
438	US20060154 243		Antigenic peptides of SARS coronavirus and uses thereof	GOUDSMIT JAAP	21-Jul-03	20-Jan-06	13-Jul-06
439	US7696330	http://59.45.142.240:8808/pdf/US7696330.pdf	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22-Jul-03	20-Jan-06	13-Apr-10
440	US7332475	http://59.45.142.240:8808/pdf/US7332475.pdf	Preventive or therapeutic composition for viral infectious	Kyowa Hakko Kogyo Co., Ltd.	22-Jul-03	22-Jul-04	19-Feb-08
441	US20100172 917	http://59.45.142.240:8808/pdf/US20100172917A1.pdf	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22-Jul-03	16-Nov-09	8-Jul-10
442	US20060189 542	http://59.45.142.240:8808/pdf/US20060189542A1.pdf	Preventive or therapeutic composition for viral infectious	FURUKAWA SATORU	22-Jul-03	22-Jul-04	24-Aug-06
443	US20060121 580	http://59.45.142.240:8808/pdf/US20060121580A1.pdf	Binding molecules against SARS-coronavirus and uses thereof	CRUCCELL	22-Jul-03	20-Jan-06	8-Jun-06
444	US20040081 667	http://59.45.142.240:8808/pdf/US20040081667A1.pdf	Compositions and methods for treating and preventing infection	HILDRETH JAMES E.	22-Jul-03	22-Jul-03	29-Apr-04
445	US7491706	http://59.45.142.240:8808/pdf/US7491706.pdf	Artificial cpv single-stranded oligodeoxynucleotide and antiviral	Changchun Huapu Biotechnology Co.,	25-Jul-03	26-Jul-04	17-Feb-09
446	US20070155 683	http://59.45.142.240:8808/pdf/US20070155683A1.pdf	Artificial cpv single-stranded oligodeoxynucleotide and antiviral	WANG LIYING	25-Jul-03	26-Jul-04	5-Jul-07
447	US20060286 121	http://59.45.142.240:8808/pdf/US20060286121A1.pdf	Adenoviral vector-based vaccines	BROUGH DOUGLAS E.	25-Jul-03	23-Jan-06	21-Dec-06
448	US20050069 558	http://59.45.142.240:8808/pdf/US20050069558A1.pdf	Crystals and structures of SARS-CoV main protease	BONANNO JEFFREY B.	25-Jul-03	23-Jul-04	31-Mar-05
449	US20050058 982	http://59.45.142.240:8808/pdf/US20050058982A1.pdf	Modified small interfering RNA molecules and methods of use	Chiron Corporation	25-Jul-03	25-Jul-03	17-Mar-05
450	US7763618	http://59.45.142.240:8808/pdf/US7763618.pdf	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	29-Jul-03	29-Jul-04	27-Jul-10
451	US7371525	http://59.45.142.240:8808/pdf/US7371525.pdf	Compositions and methods for diagnosing and treating severe acute	The Chinese University of Hong	29-Jul-03	28-Jul-04	13-May-08
452	US20100305 138	http://59.45.142.240:8808/pdf/US20100305138A1.pdf	PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS	29-Jul-03	15-Jun-10	2-Dec-10
453	US20080286 756	http://59.45.142.240:8808/pdf/US20080286756A1.pdf	COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY	THE CHINESE UNIVERSITY OF HONG KONG	29-Jul-03	3-Apr-08	20-Nov-08
454	US20060293 308	http://59.45.142.240:8808/pdf/US20060293308A1.pdf	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	29-Jul-03	29-Jul-04	28-Dec-06
455	US20050095 618	http://59.45.142.240:8808/pdf/US20050095618A1.pdf	Compositions and methods for diagnosing and treating severe acute	The Chinese University of Hong	29-Jul-03	28-Jul-04	5-May-05
456	US9213027	http://59.45.142.240:8808/pdf/US9213027.pdf	Lipoparticles comprising proteins, methods of making, and using the	Integral Molecular, Inc.	30-Jul-03	1-Nov-13	15-Dec-15
457	US7754711	http://59.45.142.240:8808/pdf/US7754711.pdf	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	30-Jul-03	9-Feb-05	13-Jul-10
458	US7605161	http://59.45.142.240:8808/pdf/US7605161.pdf	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	30-Jul-03	29-Jul-04	20-Oct-09
459	US7514436	http://59.45.142.240:8808/pdf/US7514436.pdf	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	30-Jul-03	29-Jul-04	7-Apr-09

460	US7456180	http://59.45.142.240:8808/pdf/US7456180.pdf	Piperazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	30-Jul-03	29-Jul-04	25-Nov-08
461	US7335658	http://59.45.142.240:8808/pdf/US7335658.pdf	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	30-Jul-03	29-Jul-04	26-Feb-08
462	US20170079 253	http://59.45.142.240:8808/pdf/US20170079253A1.pdf	TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL	INSTITUT PASTEUR	30-Jul-03	17-Jul-12	23-Mar-17
463	US20140135 230	http://59.45.142.240:8808/pdf/US20140135230A1.pdf	Lipoparticles Comprising Proteins, Methods Of Making, And Using The	Integral Molecular, Inc.	30-Jul-03	1-Nov-13	15-May-14
464	US20110067 121	http://59.45.142.240:8808/pdf/US20110067121A1.pdf	Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses	INSTITUT PASTEUR	30-Jul-03	22-Dec-09	17-Mar-11
465	US20100048 584	http://59.45.142.240:8808/pdf/US20100048584A1.pdf	PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS	30-Jul-03	2-Sep-09	25-Feb-10
466	US20090197 890	http://59.45.142.240:8808/pdf/US20090197890A1.pdf	PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS	30-Jul-03	20-Feb-09	6-Aug-09
467	US20060252 767	http://59.45.142.240:8808/pdf/US20060252767A1.pdf	Piperazine derivatives and their use as therapeutic agents	XENON PHARMACEUTICALS	30-Jul-03	29-Jul-04	9-Nov-06
468	US20060199 802	http://59.45.142.240:8808/pdf/US20060199802A1.pdf	Pyridyl derivatives and their use as therapeutic agents	ABREO MELWYN	30-Jul-03	29-Jul-04	7-Sep-06
469	US20050123 563	http://59.45.142.240:8808/pdf/US20050123563A1.pdf	Lipoparticles comprising proteins, methods of making, and using the	DORANZ BENJAMIN J.	30-Jul-03	28-Jul-04	9-Jun-05
470	US20050114 910	http://59.45.142.240:8808/pdf/US20050114910A1.pdf	Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses	AURIAULT CLAUDE	30-Jul-03	2-Jul-04	26-May-05
471	US7635485	http://59.45.142.240:8808/pdf/US7635485.pdf	Method of accelerated vaccination against Ebola viruses	The United States of America as represented by the Department of Health and Human	1-Aug-03	17-Jan-06	22-Dec-09
472	US20060269 572		Accelerated vaccination	GEISBERT THOMAS W.	1-Aug-03	17-Jan-06	30-Nov-06
473	US7396914	http://59.45.142.240:8808/pdf/US7396914.pdf	SARS nucleic acids, proteins, antibodies, and uses thereof	University of Massachusetts	4-Aug-03	4-Aug-04	8-Jul-08
474	US20070270 361	http://59.45.142.240:8808/pdf/US20070270361A1.pdf	Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof	CHOU TE-HUI W	4-Aug-03	4-Aug-04	22-Nov-07
475	US20050069 869	http://59.45.142.240:8808/pdf/US20050069869A1.pdf	SARS nucleic acids, proteins, antibodies, and uses thereof	AMBROSINO DONNA	4-Aug-03	4-Aug-04	31-Mar-05
476	US20070178 533	http://59.45.142.240:8808/pdf/US20070178533A1.pdf	Method and diagnostic tests based on flow cytometric analysis of	AGRATI CHIARA	5-Aug-03	5-Aug-04	2-Aug-07
477	US20050070 460	http://59.45.142.240:8808/pdf/US20050070460A1.pdf	Infection prophylaxis using immune response modifier compounds	3M Innovative Properties Company	5-Aug-03	5-Aug-04	31-Mar-05
478	US20040204 420	http://59.45.142.240:8808/pdf/US20040204420A1.pdf	Compounds for modulating RNA interference	RANA TARIQ M.	5-Aug-03	5-Aug-03	14-Oct-04
479	US20050015 847	http://59.45.142.240:8808/pdf/US20050015847A1.pdf	Compositions and methods for preventing infection	HILDRETH JAMES E.	8-Aug-03	8-Aug-03	27-Jan-05
480	US20070219 149	http://59.45.142.240:8808/pdf/US20070219149A1.pdf	Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity	Japan as Represented by the Director-General of National Institute of	11-Aug-03	10-Aug-04	20-Sep-07
481	US8673932	http://59.45.142.240:8808/pdf/US8673932.pdf	Oxime substituted imidazo-containing compounds	3M Innovative Properties Company	12-Aug-03	12-Aug-04	18-Mar-14
482	US7648997	http://59.45.142.240:8808/pdf/US7648997.pdf	Hydroxylamine substituted imidazoquinolines	Coley Pharmaceutical	12-Aug-03	12-Aug-04	19-Jan-10
483	US20090041 818	http://59.45.142.240:8808/pdf/US20090041818A1.pdf	ANTIVIRAL AGENT, AND FABRIC AND ANTIVIRAL MEMBER SUPPORTING ANTIVIRAL AGENT	ITO HIROSHI	12-Aug-03	10-Aug-04	12-Feb-09
484	US20080114 019	http://59.45.142.240:8808/pdf/US20080114019A1.pdf	Hydroxylamine Substituted Imidazoquinolines	Coley Pharmaceutical	12-Aug-03	12-Aug-04	15-May-08
485	US20060229 356	http://59.45.142.240:8808/pdf/US20060229356A1.pdf	Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical	Universita' Degli Studi Di Roma "Tor Vergata"	12-Aug-03	11-Aug-04	12-Oct-06
486	US20070134 214	http://59.45.142.240:8808/pdf/US20070134214A1.pdf	Inactivated host cell delivery of polynucleotides encoding	XU FENG	13-Aug-03	12-Aug-04	14-Jun-07
487	US20060189 644	http://59.45.142.240:8808/pdf/US20060189644A1.pdf	Lipid-modified immune response modifiers	WIGHTMAN PAUL D	14-Aug-03	12-Aug-04	24-Aug-06
488	US20050037 338	http://59.45.142.240:8808/pdf/US20050037338A1.pdf	Method and means for detection of severe acute respiratory syndrome	TSENG KUO-TANG	14-Aug-03	14-Aug-03	17-Feb-05
489	US20050059 578	http://59.45.142.240:8808/pdf/US20050059578A1.pdf	Compositions comprising phosphatidylethanolamine-binding	HE JIN	15-Aug-03	15-Aug-03	17-Mar-05
490	US20050031 620	http://59.45.142.240:8808/pdf/US20050031620A1.pdf	Combined cancer treatment methods using selected antibodies to	HUANG XIANMING	15-Aug-03	15-Aug-03	10-Feb-05
491	US20050025 761	http://59.45.142.240:8808/pdf/US20050025761A1.pdf	Anti-viral treatment methods using phosphatidylethanolamine- binding	Board of Regents, The University of	15-Aug-03	15-Aug-03	3-Feb-05
492	US20050002 941	http://59.45.142.240:8808/pdf/US20050002941A1.pdf	Combinations and kits for cancer treatment using selected antibodies	Board of Regents, The University of	15-Aug-03	15-Aug-03	6-Jan-05
493	US20040265 367	http://59.45.142.240:8808/pdf/US20040265367A1.pdf	Liposomes coated with selected antibodies that bind to	HUANG XIANMING	15-Aug-03	15-Aug-03	30-Dec-04
494	US20040219 155	http://59.45.142.240:8808/pdf/US20040219155A1.pdf	Selected immunoconjugates for binding to aminophospholipids	RAN SOPHIA	15-Aug-03	15-Aug-03	4-Nov-04
495	US20040214 764	http://59.45.142.240:8808/pdf/US20040214764A1.pdf	Anti-viral treatment methods using phosphatidylethanolamine- binding	HE JIN	15-Aug-03	15-Aug-03	28-Oct-04
496	US20040213 779		Methods for treating viral infections using immunoconjugates to	RAN SOPHIA	15-Aug-03	15-Aug-03	28-Oct-04
497	US20040208 868	http://59.45.142.240:8808/pdf/US20040208868A1.pdf	Selected antibody CDRs for binding to aminophospholipids	Board of Regents, The University of	15-Aug-03	15-Aug-03	21-Oct-04
498	US20040147 440	http://59.45.142.240:8808/pdf/US20040147440A1.pdf	Compositions comprising cell-impermeant duramycin derivatives	Board of Regents, The University of	15-Aug-03	15-Aug-03	29-Jul-04
499	US20040131 622	http://59.45.142.240:8808/pdf/US20040131622A1.pdf	Combinations and kits for treating viral infections using immunoconjugates to	Board of Regents	15-Aug-03	15-Aug-03	8-Jul-04

500	US20040131 621		Combinations and kits for treating viral infections using antibodies to	RAN SOPHIA	15-Aug-03	15-Aug-03	8-Jul-04
501	US20040131 610	http://59.45.142.240:8808/pdf/US20040131610A1.pdf	Methods for treating viral infections using antibodies to	RAN SOPHIA	15-Aug-03	15-Aug-03	8-Jul-04
502	US9945856	http://59.45.142.240:8808/pdf/US9945856.pdf	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and	AMSTERDAM INSTITUTE OF VIRAL GENOMICS	18-Aug-03	13-Aug-14	17-Apr-18
503	US8835107	http://59.45.142.240:8808/pdf/US8835107.pdf	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and	Amsterdam Institute of Viral Genomics B.V.	18-Aug-03	26-Jul-10	16-Sep-14
504	US7803918	http://59.45.142.240:8808/pdf/US7803918.pdf	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and	Amsterdam Institute of Viral Genomics B.V.	18-Aug-03	18-Aug-04	28-Sep-10
505	US7709521	http://59.45.142.240:8808/pdf/US7709521.pdf	Substituted indole derivatives for pharmaceutical compositions for	AstraZeneca AB	18-Aug-03	16-Aug-04	4-May-10
506	US20150050 308	http://59.45.142.240:8808/pdf/US20150050308A1.pdf	CORONAVIRUS, NUCLEIC ACID, PROTEIN, AND METHODS FOR THE GENERATION OF VACCINE,	Not Available	18-Aug-03	13-Aug-14	19-Feb-15
507	US20110065 091	http://59.45.142.240:8808/pdf/US20110065091A1.pdf	Coronavirus, Nucleic Acid, Protein, and Methods for the Generation of Vaccine, Medicaments and	VAN DER HOEK CORNELIA MARIA	18-Aug-03	26-Jul-10	17-Mar-11
508	US20060264 444	http://59.45.142.240:8808/pdf/US20060264444A1.pdf	Substituted indole derivatives for pharmaceutical compositions for	BONNERT ROGER V	18-Aug-03	16-Aug-04	23-Nov-06
509	US7745442	http://59.45.142.240:8808/pdf/US7745442.pdf	Methods of reducing risk of infection from pathogens	Parion Sciences, Inc.	20-Aug-03	18-Aug-04	29-Jun-10
510	US7371850	http://59.45.142.240:8808/pdf/US7371850.pdf	Method and composition for reducing expression of ROCK II	Myriad Genetics, Inc.	20-Aug-03	20-Aug-04	13-May-08
511	US20090253 714	http://59.45.142.240:8808/pdf/US20090253714A1.pdf	Methods of reducing risk of infection from pathogens	Not Available	20-Aug-03	18-Aug-04	8-Oct-09
512	US20090062 229	http://59.45.142.240:8808/pdf/US20090062229A1.pdf	METHOD AND COMPOSITION FOR REDUCING THE EXPRESSION OF ROCK II	Myriad Genetics, Incorporated	20-Aug-03	6-May-08	5-Mar-09
513	US20050090 505	http://59.45.142.240:8808/pdf/US20050090505A1.pdf	Methods of reducing risk of infection from pathogens	HOPKINS SAMUEL E	20-Aug-03	18-Aug-04	28-Apr-05
514	US8394986	http://59.45.142.240:8808/pdf/US8394986.pdf	Phenoxyacetic acid derivatives	AstraZeneca AB	21-Aug-03	26-Jul-11	12-Mar-13
515	US20060293 352	http://59.45.142.240:8808/pdf/US20060293352A1.pdf	Phenoxyacetic acid derivatives	BONNERT ROGER V	21-Aug-03	18-Aug-04	28-Dec-06
516	US7709188	http://59.45.142.240:8808/pdf/US7709188.pdf	Multi-allelic detection of SARS-associated coronavirus	Birch Biomedical Research, LLC	22-Aug-03	13-Aug-04	4-May-10
517	US20070042 351	http://59.45.142.240:8808/pdf/US20070042351A1.pdf	Multi-allelic molecular detection of SARS-associated coronavirus	KOSTRIKIS LEONDIOS G	22-Aug-03	13-Aug-04	22-Feb-07
518	US20060003 340	http://59.45.142.240:8808/pdf/US20060003340A1.pdf	Multi-allelic molecular detection of SARS-associated coronavirus	Birch Biomedical Research, LLC	22-Aug-03	13-Aug-04	5-Jan-06
519	US20040229 211	http://59.45.142.240:8808/pdf/US20040229211A1.pdf	Sensitive diagnostic testing methodology using multiplex real time PCR with one dye (MOD) and its use as in severe acute respiratory	YEUNG WAH HIN ALEX	22-Aug-03	22-Aug-03	18-Nov-04
520	US8961477	http://59.45.142.240:8808/pdf/US8961477.pdf	Delivery of immune response modifier compounds	3M Innovative Properties Company	25-Aug-03	25-Aug-04	24-Feb-15
521	US20060195 067	http://59.45.142.240:8808/pdf/US20060195067A1.pdf	Delivery of immune response modifier compounds	KEDL ROSS M	25-Aug-03	25-Aug-04	31-Aug-06
522	US7629114	http://59.45.142.240:8808/pdf/US7629114.pdf	Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and	World Sense Technology Limited	26-Aug-03	20-Aug-04	8-Dec-09
523	US7585647	http://59.45.142.240:8808/pdf/US7585647.pdf	Nucleic acid encoding recombinant interferon	WEI GUANGWEN	28-Aug-03	26-Aug-04	8-Sep-09
524	US20150174 206	http://59.45.142.240:8808/pdf/US20150174206A1.pdf	USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE	Not Available	28-Aug-03	28-Jan-15	25-Jun-15
525	US20110027 228	http://59.45.142.240:8808/pdf/US20110027228A1.pdf	USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE	WEI GUANGWEN	28-Aug-03	15-Oct-10	3-Feb-11
526	US20100061 961	http://59.45.142.240:8808/pdf/US20100061961A1.pdf	RECOMBINANT SUPER-COMPOUND INTERFERON	WEI GUANGWEN	28-Aug-03	4-Sep-09	11-Mar-10
527	US20090220 456	http://59.45.142.240:8808/pdf/US20090220456A1.pdf	USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE	Not Available	28-Aug-03	11-Feb-09	3-Sep-09
528	US20050208 019	http://59.45.142.240:8808/pdf/US20050208019A1.pdf	Uses of interferons with altered spatial structure	WEI GUANGWEN	28-Aug-03	26-Aug-04	22-Sep-05
529	US20050169 885	http://59.45.142.240:8808/pdf/US20050169885A1.pdf	Recombinant super-compound interferon	WEI GUANGWEN	28-Aug-03	26-Aug-04	4-Aug-05
530	US20040138 187		Therapeutic treatment methods	AHLEM CLARENCE N	28-Aug-03	28-Aug-03	15-Jul-04
531	US20050250 677	http://59.45.142.240:8808/pdf/US20050250677A1.pdf	Glycopeptide antibiotic derivatives	BALZARINI JAN	1-Sep-03	1-Sep-03	10-Nov-05
532	US20050112 555	http://59.45.142.240:8808/pdf/US20050112555A1.pdf	Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of	DEWHURST STEPHEN	3-Sep-03	3-Sep-04	26-May-05
533	US7767817	http://59.45.142.240:8808/pdf/US7767817.pdf	Water soluble boronic acid fluorescent reporter compounds and	FANG HAO	5-Sep-03	7-Sep-04	3-Aug-10
534	US20070274 922	http://59.45.142.240:8808/pdf/US20070274922A1.pdf	Water Soluble Boronic Acid Fluorescent Reporter Compounds	FANG HAO	5-Sep-03	7-Sep-04	29-Nov-07
535	US7435538	http://59.45.142.240:8808/pdf/US7435538.pdf	High throughput screening method of drug for physiologically active	CellFree Sciences Co., Ltd.	8-Sep-03	8-Sep-04	14-Oct-08
536	US20060177 813		Novel high-throughput screening method of drug for bioactive protein	ENDO YAETA	8-Sep-03	8-Sep-04	10-Aug-06
537	US20050106 563	http://59.45.142.240:8808/pdf/US20050106563A1.pdf	Epitope profiles of SARS coronavirus		8-Sep-03	8-Sep-04	19-May-05
538	US20060281 128	http://59.45.142.240:8808/pdf/US20060281128A1.pdf	Compositions and methods using lentivirus-based vectors for	VIRXSYS CORPORATION	9-Sep-03	17-Aug-06	14-Dec-06
539	US20050196 381	http://59.45.142.240:8808/pdf/US20050196381A1.pdf	Lentivirus vector-based approaches for generating an immune response	DROPULIC BORO	9-Sep-03	9-Sep-04	8-Sep-05
540	US8546082	http://59.45.142.240:8808/pdf/US8546082.pdf	Methods for identification of sepsis-causing bacteria	Ibis Biosciences, Inc.	11-Sep-03	25-May-07	1-Oct-13
541	US8394945	http://59.45.142.240:8808/pdf/US8394945.pdf	Compositions for use in identification of bacteria	Ibis Biosciences, Inc.	11-Sep-03	7-Mar-07	12-Mar-13
542	US20100129 811	http://59.45.142.240:8808/pdf/US20100129811A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF PSEUDOMONAS AERUGINOSA	Ibis Biosciences, Inc.	11-Sep-03	2-Oct-09	27-May-10
543	US20100035 239	http://59.45.142.240:8808/pdf/US20100035239A1.pdf	Compositions for use in identification of bacteria	ISIS Pharmaceuticals, Inc.	11-Sep-03	17-Feb-05	11-Feb-10

544	US20090047 665	http://59.45.142.240:8808/pdf/US20090047665A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF	IBIS BIOSCIENCES, INC	11-Sep-03	16-Sep-08	19-Feb-09
545	US20080233 570	http://59.45.142.240:8808/pdf/US20080233570A1.pdf	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	25-Sep-08
546	US20080146 455	http://59.45.142.240:8808/pdf/US20080146455A1.pdf	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	19-Jun-08
547	US20080145 847	http://59.45.142.240:8808/pdf/US20080145847A1.pdf	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	19-Jun-08
548	US20080138 808	http://59.45.142.240:8808/pdf/US20080138808A1.pdf	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	12-Jun-08
549	US20070248 969	http://59.45.142.240:8808/pdf/US20070248969A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	25-Oct-07
550	US20070243 544	http://59.45.142.240:8808/pdf/US20070243544A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	18-Oct-07
551	US20070238 116	http://59.45.142.240:8808/pdf/US20070238116A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	11-Oct-07
552	US20070224 614	http://59.45.142.240:8808/pdf/US20070224614A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	7-Mar-07	27-Sep-07
553	US20070218 489	http://59.45.142.240:8808/pdf/US20070218489A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	20-Sep-07
554	US20060240 412	http://59.45.142.240:8808/pdf/US20060240412A1.pdf	Compositions for use in identification of adenoviruses	BLYN LAWRENCE	11-Sep-03	12-Apr-06	26-Oct-06
555	US20040170 959	http://59.45.142.240:8808/pdf/US20040170959A1.pdf	Methods for identifying antiviral oligonucleotides	Replicor, Inc.	11-Sep-03	12-Sep-03	2-Sep-04
556	US7723041	http://59.45.142.240:8808/pdf/US7723041B2.pdf	Assay for SARS coronavirus by amplification and detection of the	Becton, Dickinson and Company	12-Sep-03	3-Feb-09	25-May-10
557	US7521185	http://59.45.142.240:8808/pdf/US7521185.pdf	Assay for SARS coronavirus by amplification and detection of the	Becton, Dickinson and Company	12-Sep-03	13-Sep-04	21-Apr-09
558	US20090258 340	http://59.45.142.240:8808/pdf/US20090258340A1.pdf	Assay for SARS coronavirus by amplification and detection of the	Becton, Dickinson and Company	12-Sep-03	3-Feb-09	15-Oct-09
559	US20080044 816	http://59.45.142.240:8808/pdf/US20080044816A1.pdf	Assay for Sars Coronavirus by Amplification and Detection of the	BECTON, DICKINSON AND COMPANY	12-Sep-03	13-Sep-04	21-Feb-08
560	US20040229 828	http://59.45.142.240:8808/pdf/US20040229828A1.pdf	Antiviral oligonucleotides targeting RSV	Replicor, Inc.	12-Sep-03	12-Sep-03	18-Nov-04
561	US20040171 568	http://59.45.142.240:8808/pdf/US20040171568A1.pdf	Antiviral oligonucleotides targeting HIV	Replicor, Inc.	12-Sep-03	12-Sep-03	2-Sep-04
562	US20040162 254	http://59.45.142.240:8808/pdf/US20040162254A1.pdf	Antiviral oligonucleotides targeting HSV and CMV	Replicor, Inc.	12-Sep-03	12-Sep-03	19-Aug-04
563	US20040162 253	http://59.45.142.240:8808/pdf/US20040162253A1.pdf	Antiviral oligonucleotides targeting HBV	Replicor, Inc.	12-Sep-03	12-Sep-03	19-Aug-04
564	US20070166 784	http://59.45.142.240:8808/pdf/US20070166784A1.pdf	Combination approaches for generating immune responses	BARNETT SUSAN W	15-Sep-03	15-Sep-04	19-Jul-07
565	US20050113 298	http://59.45.142.240:8808/pdf/US20050113298A1.pdf	Receptor binding peptides derived from the SARS S protein		15-Sep-03	13-Sep-04	26-May-05
566	US20100279 279	http://59.45.142.240:8808/pdf/US20100279279A1.pdf	Compositions and methods for analysis of target analytes	DANIELZADEH ROBERT	17-Sep-03	30-Nov-07	4-Nov-10
567	US20100173 325	http://59.45.142.240:8808/pdf/US20100173325A1.pdf	Composition and Method for Analysis of Target Analytes	Millipore Corporation	17-Sep-03	4-Jul-09	8-Jul-10
568	US20070281 325	http://59.45.142.240:8808/pdf/US20070281325A1.pdf	COMPOSITIONS AND METHODS FOR ANALYSIS OF TARGET ANALYTES	DANIELZADEH ROBERT	17-Sep-03	20-Jul-06	6-Dec-07
569	US20040209 844	http://59.45.142.240:8808/pdf/US20040209844A1.pdf	Compositions and methods for preventing infection	HILDRETH JAMES E.	22-Sep-03	22-Sep-03	21-Oct-04
570	US20050112 558	http://59.45.142.240:8808/pdf/US20050112558A1.pdf	Prognostic PCR assay for severe acute respiratory syndrome (SARS)	The Chinese University of Hong	24-Sep-03	23-Sep-04	26-May-05
571	US20050112 559	http://59.45.142.240:8808/pdf/US20050112559A1.pdf	Compositions and methods for diagnosing and preventing severe		29-Sep-03	29-Sep-04	26-May-05
572	US9737618	http://59.45.142.240:8808/pdf/US9737618.pdf	Adeno-associated virus (AAV) glades, sequences, vectors	The Trustees of the University of	30-Sep-03	20-Jul-15	22-Aug-17
573	US20200155 704	http://59.45.142.240:8808/pdf/US20200155704A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	30-Sep-03	30-Jan-20	21-May-20
574	US20190054 188	http://59.45.142.240:8808/pdf/US20190054188A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	30-Sep-03	2-Oct-18	21-Feb-19
575	US20190022 249	http://59.45.142.240:8808/pdf/US20190022249A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	30-Sep-03	2-Oct-18	24-Jan-19
576	US20190015 527	http://59.45.142.240:8808/pdf/US20190015527A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	30-Sep-03	25-Jul-18	17-Jan-19
577	US20170159 027	http://59.45.142.240:8808/pdf/US20170159027A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	30-Sep-03	15-Feb-17	8-Jun-17
578	US20170028 082	http://59.45.142.240:8808/pdf/US20170028082A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	30-Sep-03	3-Aug-16	2-Feb-17
579	US20150315 612	http://59.45.142.240:8808/pdf/US20150315612A1.pdf	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES	Not Available	30-Sep-03	20-Jul-15	5-Nov-15
580	US20070036 760	http://59.45.142.240:8808/pdf/US20070036760A1.pdf	Adeno-associated virus (aav) clades, sequences, vectors containing same,	The Trutees of the University of	30-Sep-03	30-Sep-04	15-Feb-07
581	US20060115 875	http://59.45.142.240:8808/pdf/US20060115875A1.pdf	Detection, characterization and treatment of viral infection and	BROWN EARL	30-Sep-03	11-Oct-05	1-Jun-06
582	US20050119 284	http://59.45.142.240:8808/pdf/US20050119284A1.pdf	ANTIVIRAL AGENTS AND METHODS OF USE	Wisconsin Alumni Research	30-Sep-03	30-Sep-04	2-Jun-05
583	US10485883	http://59.45.142.240:8808/pdf/US10485883.pdf	Adeno-associated virus (AAV) clades, sequences, vectors containing same,	The Trustees of the University of	30-Sep-03	15-Feb-17	26-Nov-19
584	US10265417	http://59.45.142.240:8808/pdf/US10265417.pdf	Adeno-associated virus (AAV) clades, sequences, vectors containing same,	The Trustees of the University of	30-Sep-03	3-Aug-16	23-Apr-19
585	US9856254	http://59.45.142.240:8808/pdf/US9856254.pdf	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3-Oct-03	13-Jun-16	2-Jan-18
586	US9365567	http://59.45.142.240:8808/pdf/US9365567.pdf	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3-Oct-03	30-Sep-14	14-Jun-16
587	US9145410	http://59.45.142.240:8808/pdf/US9145410.pdf	Pyrazolopyridines and analogs thereof	3M Innovative Properties Company	3-Oct-03	26-Jan-12	29-Sep-15
588	US8871782	http://59.45.142.240:8808/pdf/US8871782.pdf	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3-Oct-03	1-Oct-04	28-Oct-14

589	US7544697	http://59.45.142.240:8808/pdf/US7544697.pdf	Pyrazolopyridines and analogs thereof	Coley Pharmaceutical	3-Oct-03	1-Apr-05	9-Jun-09
590	US20160280 707	http://59.45.142.240:8808/pdf/US20160280707A1.pdf	ALKOXY SUBSTITUTED IMIDAZOQUINOLINES	Not Available	3-Oct-03	13-Jun-16	29-Sep-16
591	US20150023 990	http://59.45.142.240:8808/pdf/US20150023990A1.pdf	ALKOXY SUBSTITUTED IMIDAZOQUINOLINES	3M INNOVATIVE PROPERTIES COMPANY	3-Oct-03	30-Sep-14	22-Jan-15
592	US20090318 435	http://59.45.142.240:8808/pdf/US20090318435A1.pdf	PYRAZOLOPYRIDINES AND ANALOGS THEREOF	BONK JASON D	3-Oct-03	8-Jun-09	24-Dec-09
593	US20090075 980	http://59.45.142.240:8808/pdf/US20090075980A1.pdf	Pyrazolopyridines and Analogs Thereof	Coley Pharmaceutical	3-Oct-03	31-Mar-06	19-Mar-09
594	US20070060 754	http://59.45.142.240:8808/pdf/US20070060754A1.pdf	Alkoxy substituted imidazoquinolines	HARALDSON CHAD A	3-Oct-03	1-Oct-04	15-Mar-07
595	US20060100 229	http://59.45.142.240:8808/pdf/US20060100229A1.pdf	Pyrazolopyridines and analogs thereof	BONK JASON D	3-Oct-03	1-Apr-05	11-May-06
596	US20050282 154	http://59.45.142.240:8808/pdf/US20050282154A1.pdf	Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus		6-Oct-03	5-Oct-04	22-Dec-05
597	US20050074 743	http://59.45.142.240:8808/pdf/US20050074743A1.pdf	Method and composition for treating a biological sample	CHAPMAN JOHN	6-Oct-03	6-Oct-03	7-Apr-05
598	US20050074 359	http://59.45.142.240:8808/pdf/US20050074359A1.pdf	Aircraft and passenger decontamination system	STERIS INC.	6-Oct-03	6-Oct-03	7-Apr-05
599	US20040142 322	http://59.45.142.240:8808/pdf/US20040142322A1.pdf	Continuous non-radioactive polymerase assay	Schering Corporation	7-Oct-03	7-Oct-03	22-Jul-04
600	US9290745	http://59.45.142.240:8808/pdf/US9290745.pdf	Luciferase biosensor	PROMEGA CORPORATION	10-Oct-03	14-Feb-14	22-Mar-16
601	US8673558	http://59.45.142.240:8808/pdf/US8673558.pdf	Luciferase biosensor	Promega Corporation	10-Oct-03	24-Apr-12	18-Mar-14
602	US20140273 156	http://59.45.142.240:8808/pdf/US20140273156A1.pdf	LUCIFERASE BIOSENSOR	PROMEGA CORPORATION	10-Oct-03	14-Feb-14	18-Sep-14
603	US20050153 310	http://59.45.142.240:8808/pdf/US20050153310A1.pdf	Luciferase biosensor	BUTLER BRAEDEN	10-Oct-03	1-Oct-04	14-Jul-05
604	US20070276 009	http://59.45.142.240:8808/pdf/US20070276009A1.pdf	Compositions and Methods for Viral Inhibition	CHANG BRYAN	15-Oct-03	15-Oct-04	29-Nov-07
605	US20070026 087	http://59.45.142.240:8808/pdf/US20070026087A1.pdf	Anti-coronavirus agent	Toagosei Co., Ltd.	16-Oct-03	31-Oct-03	1-Feb-07
606	US7223787	http://59.45.142.240:8808/pdf/US7223787.pdf	Prenylation inhibitors reduce host cell permissiveness to viral infection	Board of Regents, The University of Texas at Austin	21-Oct-03	21-Oct-03	29-May-07
607	US20050085 529	http://59.45.142.240:8808/pdf/US20050085529A1.pdf	Prenylation inhibitors reduce host cell permissiveness to viral infection		21-Oct-03	21-Oct-03	21-Apr-05
608	US8709447	http://59.45.142.240:8808/pdf/US8709447.pdf	Compositions and methods for activating innate and allergic responses	ID Biomedical Corporation of Ohio	22-Oct-03	26-Apr-12	29-Apr-14
609	US20090318 337	http://59.45.142.240:8808/pdf/US20090318337A1.pdf	Compositions and methods for activating innate and allergic responses	ID Biomedical Corporation of Ohio	22-Oct-03	22-Oct-04	24-Dec-09
610	US20070196 818	http://59.45.142.240:8808/pdf/US20070196818A1.pdf	Using Nucleic Acids for Clinical Microbiology Testing	O'HARA STEPHEN	22-Oct-03	22-Oct-04	23-Aug-07
611	US7799800	http://59.45.142.240:8808/pdf/US7799800.pdf	Lipid-modified immune response modifiers	3M Innovative Properties Company	30-Oct-03	12-Aug-04	21-Sep-10
612	US20080254 440	http://59.45.142.240:8808/pdf/US20080254440A1.pdf	Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and Immunoassay Reagent Using the	FUJII NOBUYUKI	31-Oct-03	29-Oct-04	16-Oct-08
613	US20050096 259	http://59.45.142.240:8808/pdf/US20050096259A1.pdf	Neutrophil activation by immune response modifier compounds		31-Oct-03	1-Nov-04	5-May-05
614	US7129042	http://59.45.142.240:8808/pdf/US7129042.pdf	Compositions and methods for detecting severe acute respiratory	Diagnostic Hybrids, Inc.	3-Nov-03	3-Nov-03	31-Oct-06
615	US20080076 115	http://59.45.142.240:8808/pdf/US20080076115A1.pdf	Compositions and Methods for Detecting Severe Acute Respiratory	GILLIM-ROSS LAURA	3-Nov-03	3-Nov-04	27-Mar-08
616	US20050095 582	http://59.45.142.240:8808/pdf/US20050095582A1.pdf	Compositions and methods for detecting severe acute respiratory	Diagnostic Hybrids, Inc.	3-Nov-03	3-Nov-03	5-May-05
617	US9725487	http://59.45.142.240:8808/pdf/US9725487.pdf	Compositions and methods for measles virus inhibition	Autoimmune Technologies, LLC	4-Nov-03	13-May-15	8-Aug-17
618	US9056900	http://59.45.142.240:8808/pdf/US9056900.pdf	Compositions and methods for coronavirus inhibition	Autoimmune Technologies, LLC	4-Nov-03	8-Aug-13	16-Jun-15
619	US8598116	http://59.45.142.240:8808/pdf/US8598116.pdf	Treatment of influenza virus infection	Educational Fund and Autoimmune Technologies, LLC	4-Nov-03	29-May-12	3-Dec-13
620	US7491793	http://59.45.142.240:8808/pdf/US7491793.pdf	Influenza virus inhibiting peptides	The Administrators of the Tulane Educational Fund	4-Nov-03	3-Nov-04	17-Feb-09
621	US20150239 940		COMPOSITIONS AND METHODS FOR VIRUS INHIBITION	AUTOIMMUNE TECHNOLOGIES, LLC	4-Nov-03	13-May-15	27-Aug-15
622	US20140045 743	http://59.45.142.240:8808/pdf/US20140045743A1.pdf	COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION	Autoimmune Technologies, LLC	4-Nov-03	8-Aug-13	13-Feb-14
623	US20090264 362	http://59.45.142.240:8808/pdf/US20090264362A1.pdf	Influenza virus inhibiting peptides	The Administrators of the Tulane Educational Fund	4-Nov-03	17-Feb-09	22-Oct-09
624	US20060280 754	http://59.45.142.240:8808/pdf/US20060280754A1.pdf	Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane	GARRY ROBERT F	4-Nov-03	3-Nov-04	14-Dec-06
625	US20040220 139		Inhibiting viral infections	SCEUSA NICHOLAS A	5-Nov-03	5-Nov-03	4-Nov-04
626	US20090232 748	http://59.45.142.240:8808/pdf/US20090232748A1.pdf	Virucidal activities of cetylpyridinium chloride	ViraTox, L.L.C.	7-Nov-03	18-Mar-09	17-Sep-09
627	US20050100 612	http://59.45.142.240:8808/pdf/US20050100612A1.pdf	Virucidal activities of cetylpyridinium chloride	ViraTox, L.L.C.	7-Nov-03	10-Sep-04	12-May-05
628	US7605135	http://59.45.142.240:8808/pdf/US7605135.pdf	Baicalin as a treatment for SARS infection	The University of Hong Kong	10-Nov-03	8-Nov-04	20-Oct-09
629	US20050215 494	http://59.45.142.240:8808/pdf/US20050215494A1.pdf	Baicalin and its derivatives as a treatment for SARS coronavirus infection	CHAN KWOK H	10-Nov-03	8-Nov-04	29-Sep-05
630	US20170039 316	http://59.45.142.240:8808/pdf/US20170039316A1.pdf	Compositions, processes and algorithms for microbial detection	Not Available	12-Nov-03	25-Oct-04	9-Feb-17
631	US20050214 748	http://59.45.142.240:8808/pdf/US20050214748A1.pdf	Peptide-based diagnostic reagents for SARS	CHANG TSENG Y	12-Nov-03	8-Nov-04	29-Sep-05
632	US20050208 020	http://59.45.142.240:8808/pdf/US20050208020A1.pdf	Enhancement of vaccine-induced immune responses and protection by heterologous boosting with	BRICE GARY T	12-Nov-03	10-Nov-04	22-Sep-05
633	US20050100 883	http://59.45.142.240:8808/pdf/US20050100883A1.pdf	Peptide-based diagnostic reagents for SARS	CHANG TSENG Y.	12-Nov-03	12-Nov-03	12-May-05
634	US20050031 592	http://59.45.142.240:8808/pdf/US20050031592A1.pdf	Methods and compositions for inducing immune responses and protective immunity by priming with	BRICE GARY L.	13-Nov-03	13-Nov-03	10-Feb-05

635	US20040180 380	http://59.45.142.240:8808/pdf/US20040180380A1.pdf	Proteome epitope tags and methods of use thereof in protein modification	engeneOS, Inc.	13-Nov-03	13-Nov-03	16-Sep-04
636	US8598192	http://59.45.142.240:8808/pdf/US8598192.pdf	Hydroxylamine substituted imidazoquinolines	3M Innovative Properties Company	14-Nov-03	12-Nov-04	3-Dec-13
637	US20090105 295	http://59.45.142.240:8808/pdf/US20090105295A1.pdf	HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES	Coley Pharmaceutical	14-Nov-03	12-Nov-04	23-Apr-09
638	US20090042 925	http://59.45.142.240:8808/pdf/US20090042925A1.pdf	OXIME SUBSTITUTED IMIDAZOQUINOLINES	Coley pharmaceutical	14-Nov-03	12-Nov-04	12-Feb-09
639	US20080050 718	http://59.45.142.240:8808/pdf/US20080050718A1.pdf	Methods, Articles, and Compositions for Identifying Oligonucleotides	ATKINS JOHN F	14-Nov-03	15-Nov-04	28-Feb-08
640	US7767658	http://59.45.142.240:8808/pdf/US7767658.pdf	Vaccine composition	Aventis Pasteur SA	17-Nov-03	9-Jan-08	3-Aug-10
641	US7344720	http://59.45.142.240:8808/pdf/US7344720.pdf	Vaccine composition	Sanofi Pasteur SA	17-Nov-03	15-Nov-04	18-Mar-08
642	US20080131 446	http://59.45.142.240:8808/pdf/US20080131446A1.pdf	Vaccine Composition	SANOFI PASTEUR SA	17-Nov-03	9-Jan-08	5-Jun-08
643	US20080044 426	http://59.45.142.240:8808/pdf/US20080044426A1.pdf	Novel Atypical Pneumonia-Causing Virus	BESTEBROER THEODORUS	18-Nov-03	18-Nov-04	21-Feb-08
644	US20090209 640	http://59.45.142.240:8808/pdf/US20090209640A1.pdf	Prevention of and countermeasures against viral infection	CHOKO CO., LTD.	20-Nov-03	15-Apr-09	20-Aug-09
645	US20050181 075	http://59.45.142.240:8808/pdf/US20050181075A1.pdf	Pharmacological enhancement and manufacturing method of antiviral	GONG JIAO	21-Nov-03	21-Nov-03	18-Aug-05
646	US9765071	http://59.45.142.240:8808/pdf/US9765071.pdf	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	14-Mar-16	19-Sep-17
647	US9328110	http://59.45.142.240:8808/pdf/US9328110.pdf	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	11-Mar-14	3-May-16
648	US8778963	http://59.45.142.240:8808/pdf/US8778963.pdf	Hydroxylamine and oxime substituted imidazoquinolines,	3M Innovative Properties Company	25-Nov-03	24-Nov-04	15-Jul-14
649	US8691837	http://59.45.142.240:8808/pdf/US8691837.pdf	Substituted imidazo ring systems and methods	3M Innovative Properties Company	25-Nov-03	24-Nov-04	8-Apr-14
650	US7750123	http://59.45.142.240:8808/pdf/US7750123.pdf	Antibodies against SARS-CoV and methods of use thereof	Dana Farber Cancer Institute, Inc	25-Nov-03	24-Nov-04	6-Jul-10
651	US20160194 322	http://59.45.142.240:8808/pdf/US20160194322A1.pdf	SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS	Not Available	25-Nov-03	14-Mar-16	7-Jul-16
652	US20140194 628	http://59.45.142.240:8808/pdf/US20140194628A1.pdf	SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	11-Mar-14	10-Jul-14
653	US20070099 901	http://59.45.142.240:8808/pdf/US20070099901A1.pdf	Hydroxylamine and oxime substituted imidazoquinolines,	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	24-Nov-04	3-May-07
654	US20070072 893	http://59.45.142.240:8808/pdf/US20070072893A1.pdf	Substituted imidazo ring systems and methods	AMOS DAVID T	25-Nov-03	24-Nov-04	29-Mar-07
655	US20050249 739	http://59.45.142.240:8808/pdf/US20050249739A1.pdf	Antibodies against SARS-CoV and methods of use thereof	MARASCO WAYNE	25-Nov-03	24-Nov-04	10-Nov-05
656	US20050208 066	http://59.45.142.240:8808/pdf/US20050208066A1.pdf	Recombinant baculovirus and virus-like particle	CHAO YU-CHAN	25-Nov-03	24-Nov-04	22-Sep-05
657	US20080027 092		1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory	BONNERT ROGER VICTOR	26-Nov-03	24-Nov-04	31-Jan-08
658	US20050287 118	http://59.45.142.240:8808/pdf/US20050287118A1.pdf	Bacterial plasmid with immunological adjuvant function and uses thereof		26-Nov-03	23-Nov-04	29-Dec-05
659	US20050214 890	http://59.45.142.240:8808/pdf/US20050214890A1.pdf	Novel "Cleave-N-Read" system for protease activity assay and methods	BAUDRY MICHEL	26-Nov-03	23-Nov-04	29-Sep-05
660	US7023593	http://59.45.142.240:8808/pdf/US7023593.pdf	Apparatus for forming nano-grating device	Industrial Technology	28-Nov-03	17-Mar-04	4-Apr-06
661	US7432045	http://59.45.142.240:8808/pdf/US7432045.pdf	Method of inhibiting influenza infection with antiviral peptides	Wisconsin Alumni Research	1-Dec-03	1-Dec-04	7-Oct-08
662	US20090041 803		Dioscorea Extracts	Academia Sinica	1-Dec-03	2-Sep-08	12-Feb-09
663	US20050203 024	http://59.45.142.240:8808/pdf/US20050203024A1.pdf	Peptides and methods for inducing cellular resistance to infection		1-Dec-03	1-Dec-04	15-Sep-05
664	US7736850	http://59.45.142.240:8808/pdf/US7736850.pdf	Strain of SARS-associated coronavirus and applications thereof	Centre National de la Recherche Scientifique	2-Dec-03	2-Dec-04	15-Jun-10
665	US20110065 089	http://59.45.142.240:8808/pdf/US20110065089A1.pdf	NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	2-Dec-03	6-Apr-10	17-Mar-11
666	US20070275 002	http://59.45.142.240:8808/pdf/US20070275002A1.pdf	Use Of Proteins And Peptides Encoded By The Genome Of A Novel Coronavirus	AZEBI SALIHA	2-Dec-03	2-Dec-04	29-Nov-07
667	US20070155 767	http://59.45.142.240:8808/pdf/US20070155767A1.pdf	Sulfone substituted imidazo ring ethers	DELLARIA JOSEPH F JR	4-Dec-03	3-Dec-04	5-Jul-07
668	US7622112	http://59.45.142.240:8808/pdf/US7622112.pdf	Anti-SARS monoclonal antibodies	Not Available	5-Dec-03	6-Dec-04	24-Nov-09
669	US20130236 884	http://59.45.142.240:8808/pdf/US20130236884A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF SARS CORONAVIRUS	IBIS BIOSCIENCES, INC.	5-Dec-03	7-May-13	12-Sep-13
670	US20080279 812	http://59.45.142.240:8808/pdf/US20080279812A1.pdf	Disease Prevention and Vaccination Prior to Thymic Reactivation	Monash University	5-Dec-03	19-Apr-04	13-Nov-08
671	US20080081 047	http://59.45.142.240:8808/pdf/US20080081047A1.pdf	Anti-Sars Monoclonal Antibodies	ANDONOV ANTON	5-Dec-03	6-Dec-04	3-Apr-08
672	US20060275 749	http://59.45.142.240:8808/pdf/US20060275749A1.pdf	Compositions for use in identification of orthopoxviruses	ISIS Pharmaceuticals,	5-Dec-03	24-Aug-05	7-Dec-06
673	US20060053 516	http://59.45.142.240:8808/pdf/US20060053516A1.pdf	Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization	The University of Hong Kong	5-Dec-03	3-Dec-04	9-Mar-06
674	US7829302	http://59.45.142.240:8808/pdf/US7829302.pdf	Method for detecting the specificity of activated lymphocyte	HU JUN	8-Dec-03	7-Dec-04	9-Nov-10
675	US20070172 448	http://59.45.142.240:8808/pdf/US20070172448A1.pdf	Method for detecting the specificity of activated lymphocyte	HU JUN	8-Dec-03	7-Dec-04	26-Jul-07
676	US20050158 411	http://59.45.142.240:8808/pdf/US20050158411A1.pdf	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy	VAIL MARILYN L.	8-Dec-03	27-Nov-04	21-Jul-05
677	US7598072	http://59.45.142.240:8808/pdf/US7598072.pdf	Assay to detect viral uncoating	Wisconsin Alumni Research	9-Dec-03	8-Dec-04	6-Oct-09
678	US20060099 606	http://59.45.142.240:8808/pdf/US20060099606A1.pdf	Assay to detect viral uncoating	NARAYAN SHAKTI	9-Dec-03	8-Dec-04	11-May-06
679	US8470346	http://59.45.142.240:8808/pdf/US8470346.pdf	Anti-viral pharmaceutical compositions	Mast Therapeutics, Inc	10-Dec-03	19-May-11	25-Jun-13
680	US20070298 415		Method of Amplifying Nucleic Acid	Takara Bio Inc.	10-Dec-03	6-Dec-04	27-Dec-07

681	US20070116 716	http://59.45.142.240:8808/pdf/US20070116716A1.pdf	Sars coronavirus s proteins and uses thereof	FIELDING BURTRAM C	10-Dec-03	10-Dec-04	24-May-07
682	US20050232 895	http://59.45.142.240:8808/pdf/US20050232895A1.pdf	Anti-viral pharmaceutical compositions	SD Pharmaceuticals, Inc	10-Dec-03	3-Dec-04	20-Oct-05
683	US7375210	http://59.45.142.240:8808/pdf/US7375210.pdf	PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using	Samsung Electronics Co., Ltd.	12-Dec-03	24-Nov-04	20-May-08
684	US20080194 422	http://59.45.142.240:8808/pdf/US20080194422A1.pdf	PCR PRIMER SET DETECTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR DETECTING SARS-CORONAVIRUS USING THE	SAMSUNG ELECTRONICS CO., LTD.	12-Dec-03	21-Apr-08	14-Aug-08
685	US20080096 186	http://59.45.142.240:8808/pdf/US20080096186A1.pdf	PCR PRIMER SET FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR DETECTING SARS-CORONAVIRUS USING THE	HWANG JUNG-JOO	12-Dec-03	24-Nov-04	24-Apr-08
686	US20040208 873	http://59.45.142.240:8808/pdf/US20040208873A1.pdf	Human monoclonal antibodies against interleukin-8 (IL-8)	GENMAB A/S	16-Dec-03	16-Dec-03	21-Oct-04
687	US20070248 949	http://59.45.142.240:8808/pdf/US20070248949A1.pdf	Sensitive and Specific Test to Detect Sars Coronavirus	AGENCY FOR SCIENCE, TECHNOLOGY AND	17-Dec-03	17-Dec-04	25-Oct-07
688	US20040147 543	http://59.45.142.240:8808/pdf/US20040147543A1.pdf	Aryl substituted imidazoquinolines	3M Innovative Properties Company	18-Dec-03	18-Dec-03	29-Jul-04
689	US20080033 172	http://59.45.142.240:8808/pdf/US20080033172A1.pdf	Mutagenic Heterocycles	Koronis Pharmaceuticals,	19-Dec-03	10-Dec-04	7-Feb-08
690	US20080009 496	http://59.45.142.240:8808/pdf/US20080009496A1.pdf	MUTAGENIC HETEROCYCLES	Koronis Pharmaceuticals,	19-Dec-03	27-Dec-06	10-Jan-08
691	US7700727	http://59.45.142.240:8808/pdf/US7700727.pdf	Compositions and kits for detecting pathogen infection	Biokit, S.A.	23-Dec-03	27-Apr-05	20-Apr-10
692	US20060286 119	http://59.45.142.240:8808/pdf/US20060286119A1.pdf	Compositions and methods for treatment of chronic and infectious	Biokit S.A.	23-Dec-03	6-Apr-06	21-Dec-06
693	US20060275 317	http://59.45.142.240:8808/pdf/US20060275317A1.pdf	Vaccine compositions for prevention of chronic and infectious diseases	Biokit S.A.	23-Dec-03	6-Apr-06	7-Dec-06
694	US20060270 835	http://59.45.142.240:8808/pdf/US20060270835A1.pdf	Diagnosis and treatment of Alzheimer disease	Biokit S.A.	23-Dec-03	6-Apr-06	30-Nov-06
695	US20060269 976	http://59.45.142.240:8808/pdf/US20060269976A1.pdf	METHOD FOR REDUCING LYSOZYME ENZYMATIC ACTIVITY	Biokit S.A.	23-Dec-03	5-Apr-06	30-Nov-06
696	US20060063 149	http://59.45.142.240:8808/pdf/US20060063149A1.pdf	Compositions and methods for detecting pathogen infection	BERTHET FRANCOIS Y	23-Dec-03	6-Sep-05	23-Mar-06
697	US20050202 415	http://59.45.142.240:8808/pdf/US20050202415A1.pdf	Replikin peptides and uses thereof	BOGOCH ELENORE S	23-Dec-03	4-Jun-04	15-Sep-05
698	US9364511	http://59.45.142.240:8808/pdf/US9364511.pdf	Antiviral preparations obtained from a natural cinnamon extract	RAMOT AT TEL-AVIV UNIVERSITY LTD	24-Dec-03	22-Jun-06	14-Jun-16
699	US8759307	http://59.45.142.240:8808/pdf/US8759307.pdf	Oligonucleotide compound and method for treating nidovirus infection	Sarepta Therapeutics, Inc.	24-Dec-03	25-Apr-08	24-Jun-14
700	US20150126 722	http://59.45.142.240:8808/pdf/US20150126722A1.pdf	OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING	Not Available	24-Dec-03	4-Jun-14	7-May-15
701	US20090012 280	http://59.45.142.240:8808/pdf/US20090012280A1.pdf	OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING	BESTWICK RICHARD K	24-Dec-03	25-Apr-08	8-Jan-09
702	US20070037 763	http://59.45.142.240:8808/pdf/US20070037763A1.pdf	Oligonucleotide compound and method for treating nidovirus	AVI BIOPHARMA INC	24-Dec-03	10-May-06	15-Feb-07
703	US20060275 515	http://59.45.142.240:8808/pdf/US20060275515A1.pdf	Antiviral preparations obtained from a natural cinnamon extract	OVADIA MICHAEL	24-Dec-03	22-Jun-06	7-Dec-06
704	US20050171 044	http://59.45.142.240:8808/pdf/US20050171044A1.pdf	Oligonucleotide compound and method for treating nidovirus	BESTWICK RICHARD K.	24-Dec-03	22-Dec-04	4-Aug-05
705	US8816089	http://59.45.142.240:8808/pdf/US8816089.pdf	Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise	Masatoshi Hagiwara	26-Dec-03	19-Nov-12	26-Aug-14
706	US7569536	http://59.45.142.240:8808/pdf/US7569536.pdf	Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise	Masatoshi Hagiwara	26-Dec-03	24-Dec-04	4-Aug-09
707	US20100016 359	http://59.45.142.240:8808/pdf/US20100016359A1.pdf	METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN	Masatoshi Hagiwara	26-Dec-03	29-Jun-09	21-Jan-10
708	US20070135 367	http://59.45.142.240:8808/pdf/US20070135367A1.pdf	Method for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise	FUKUHARA TAKESHI	26-Dec-03	24-Dec-04	14-Jun-07
709	US8802853	http://59.45.142.240:8808/pdf/US8802853.pdf	Arylalkenyl and arylalkynyl substituted imidazoquinolines	3M Innovative Properties Company	29-Dec-03	17-Dec-04	12-Aug-14
710	US20070167 476	http://59.45.142.240:8808/pdf/US20070167476A1.pdf	Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane	CELEBI AZIM A	29-Dec-03	22-Dec-04	19-Jul-07
711	US9642876	http://59.45.142.240:8808/pdf/US9642876.pdf	Method of preventing or treating sinusitis with oxidative reductive	SONOMA PHARMACEUTICALS, INC.	30-Dec-03	27-Oct-15	9-May-17
712	US9168318	http://59.45.142.240:8808/pdf/US9168318.pdf	Oxidative reductive potential water solution and methods of using the	Oculus Innovative Sciences, Inc.	30-Dec-03	11-Aug-04	27-Oct-15
713	US8735421	http://59.45.142.240:8808/pdf/US8735421.pdf	Imidazoquinolinyl sulfonamides	3M Innovative Properties Company	30-Dec-03	23-Dec-04	27-May-14
714	US20170239 291	http://59.45.142.240:8808/pdf/US20170239291A1.pdf	METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL	SONOMA PHARMACEUTICALS, INC.	30-Dec-03	9-May-17	24-Aug-17
715	US20160045 547	http://59.45.142.240:8808/pdf/US20160045547A1.pdf	METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL	OCULUS INNOVATIVE SCIENCES, INC.	30-Dec-03	27-Oct-15	18-Feb-16
716	US20090062 272	http://59.45.142.240:8808/pdf/US20090062272A1.pdf	IMIDAZOQUINOLINYL SULFONAMIDES	BONK JASON D	30-Dec-03	23-Dec-04	5-Mar-09
717	US20050239 735	http://59.45.142.240:8808/pdf/US20050239735A1.pdf	Enhancement of immune responses		30-Dec-03	30-Dec-04	27-Oct-05
718	US20050158 325	http://59.45.142.240:8808/pdf/US20050158325A1.pdf	Immunomodulatory combinations		30-Dec-03	30-Dec-04	21-Jul-05
719	US20050142 157	http://59.45.142.240:8808/pdf/US20050142157A1.pdf	Oxidative reductive potential water solution and methods of using the	Oculus Innovative Sciences, Inc.	30-Dec-03	11-Aug-04	30-Jun-05

720	US20050139 808	http://59.45.142.240:8808/pdf/US20050139808A1.pdf	Oxidative reductive potential water solution and process for producing	Oculus Innovative Sciences, Inc.	30-Dec-03	4-Jun-04	30-Jun-05
721	US20040141 950	http://59.45.142.240:8808/pdf/US20040141950A1.pdf	Immunostimulatory combinations	3M Innovative Properties Company	30-Dec-03	30-Dec-03	22-Jul-04
722	US10016455	http://59.45.142.240:8808/pdf/US10016455.pdf	Method of preventing or treating influenza with oxidative reductive	Sonoma Pharmaceuticals,	30-Dec-03	9-May-17	10-Jul-18
723	US20050266 425	http://59.45.142.240:8808/pdf/US20050266425A1.pdf	Methods for producing and identifying multispecific antibodies	Vaccinex, Inc.	31-Dec-03	29-Dec-04	1-Dec-05
724	US20070218 001	http://59.45.142.240:8808/pdf/US20070218001A1.pdf	Biotherapeutics, Diagnostics and Research Reagents	BIOTECH STUDIO, LLC	5-Jan-04	4-Jan-05	20-Sep-07
725	US20050148 658	http://59.45.142.240:8808/pdf/US20050148658A1.pdf	Method for preventing and treating severe acute respiratory syndrome	HENSLEY CHARLES	5-Jan-04	5-Jan-04	7-Jul-05
726	US8765138	http://59.45.142.240:8808/pdf/US8765138.pdf	Antiviral and antibacterial activity from medicinal mushrooms	Not Available	6-Jan-04	24-Sep-08	1-Jul-14
727	US20160000 754	http://59.45.142.240:8808/pdf/US20160000754A1.pdf	Antiviral Activity from Medicinal Mushrooms and their Active	Not Available	6-Jan-04	14-Sep-15	7-Jan-16
728	US20140105 928	http://59.45.142.240:8808/pdf/US20140105928A1.pdf	Antiviral and antibacterial activity from medicinal mushrooms	Not Available	6-Jan-04	20-Dec-13	17-Apr-14
729	US20110008 384	http://59.45.142.240:8808/pdf/US20110008384A1.pdf	Antiviral activity from medicinal mushrooms	STAMETS PAUL EDWARD	6-Jan-04	27-Mar-07	13-Jan-11
730	US20090130 138	http://59.45.142.240:8808/pdf/US20090130138A1.pdf	Antiviral and antibacterial activity from medicinal mushrooms	STAMETS PAUL EDWARD	6-Jan-04	24-Sep-08	21-May-09
731	US20060171 958	http://59.45.142.240:8808/pdf/US20060171958A1.pdf	Antiviral activity from medicinal mushrooms	STAMETS PAUL	6-Jan-04	22-Mar-06	3-Aug-06
732	US20050276 815	http://59.45.142.240:8808/pdf/US20050276815A1.pdf	Antiviral activity from medicinal mushrooms	STAMETS PAUL	6-Jan-04	6-Jan-05	15-Dec-05
733	US20050238 655	http://59.45.142.240:8808/pdf/US20050238655A1.pdf	Antiviral activity from medicinal mushrooms	STAMETS PAUL	6-Jan-04	4-Jan-05	27-Oct-05
734	US20060035 853	http://59.45.142.240:8808/pdf/US20060035853A1.pdf	Methods for tailoring the immune response to an antigen or	Biomedical Research Models, Inc.	7-Jan-04	7-Jan-05	16-Feb-06
735	US20060024 668	http://59.45.142.240:8808/pdf/US20060024668A1.pdf	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and	HOEK CORNELIA V D	7-Jan-04	18-Aug-04	2-Feb-06
736	US7491397	http://59.45.142.240:8808/pdf/US7491397.pdf	Receptor binding polypeptides	National Health Research Institutes	9-Jan-04	10-Jan-05	17-Feb-09
737	US20080213 284	http://59.45.142.240:8808/pdf/US20080213284A1.pdf	RECEPTOR BINDING POLYPEPTIDES	National Health Research Institutes, a Taiwanese	9-Jan-04	10-Jan-05	4-Sep-08
738	US20050036 951	http://59.45.142.240:8808/pdf/US20050036951A1.pdf	Methods of treating lung diseases	Arizeke Pharmaceuticals,	9-Jan-04	9-Jan-04	17-Feb-05
739	US20060024 271	http://59.45.142.240:8808/pdf/US20060024271A1.pdf	Treatments for viral infections using IFN cytokines and ribavirin, alone or	ALIBEK KEN	15-Jan-04	13-Jan-05	2-Feb-06
740	US20050214 747	http://59.45.142.240:8808/pdf/US20050214747A1.pdf	Compositions and methods for analysis of target analytes	DANIELZADEH ROBERT	16-Jan-04	17-Oct-04	29-Sep-05
741	US20090047 306		ADJUVANT COMPOSITIONS	M N L PHARMA LIMITED	21-Jan-04	21-Jan-05	19-Feb-09
742	US20040265 796	http://59.45.142.240:8808/pdf/US20040265796A1.pdf	Methods and kits for detecting SARS associated coronavirus	BRIESE THOMAS	23-Jan-04	23-Jan-04	30-Dec-04
743	US20050163 648	http://59.45.142.240:8808/pdf/US20050163648A1.pdf	METHOD AND APPARATUS FOR STERILIZING AIR IN LARGE VOLUMES BY RADIATION OF	LIANG MICHAEL Y.	26-Jan-04	26-Jan-04	28-Jul-05
744	US20050164 167	http://59.45.142.240:8808/pdf/US20050164167A1.pdf	Method of discovery and development of broad-spectrum	BUSCHER BENJAMIN A.	28-Jan-04	28-Jan-04	28-Jul-05
745	US20080152 544	http://59.45.142.240:8808/pdf/US20080152544A1.pdf	Building decontamination with hydrogen peroxide	STERIS INC.	29-Jan-04	3-Mar-08	26-Jun-08
746	US20040184 950	http://59.45.142.240:8808/pdf/US20040184950A1.pdf	Building decontamination with hydrogen peroxide	STERIS INC.	29-Jan-04	29-Jan-04	23-Sep-04
747	US20080249 039	http://59.45.142.240:8808/pdf/US20080249039A1.pdf	Modified Short Interfering Rna (Modified Signa)	SANTARIS PHARMA A/S	30-Jan-04	28-Jan-05	9-Oct-08
748	US20070059 686	http://59.45.142.240:8808/pdf/US20070059686A1.pdf	Materials and methods for the detection of severe acute respiratory	ERAGEN BIOSCIENCES INC	31-Jan-04	28-Jul-06	15-Mar-07
749	US20040234 457	http://59.45.142.240:8808/pdf/US20040234457A1.pdf	Methods of preventing and treating SARS using low pH respiratory tract	The Procter & Gamble Company	2-Feb-04	2-Feb-04	25-Nov-04
750	US20080004 236	http://59.45.142.240:8808/pdf/US20080004236A1.pdf	High Dose, Short Interval Use of Sulfated Polysaccharides for	COMPER WAYNE D	6-Feb-04	7-Feb-05	3-Jan-08
751	US7569384	http://59.45.142.240:8808/pdf/US7569384.pdf	Albumin fusion proteins	Human Genome Sciences, Inc.	9-Feb-04	8-Aug-06	4-Aug-09
752	US20100093 627	http://59.45.142.240:8808/pdf/US20100093627A1.pdf	ALBUMIN FUSION PROTEINS	Human Genome Sciences, Inc.	9-Feb-04	3-Aug-09	15-Apr-10
753	US20070048 282	http://59.45.142.240:8808/pdf/US20070048282A1.pdf	Albumin fusion proteins	Human Genome Sciences, Inc.	9-Feb-04	8-Aug-06	1-Mar-07
754	US20070027 306	http://59.45.142.240:8808/pdf/US20070027306A1.pdf	Albumin fusion proteins	HASELTINE WILLIAM A	9-Feb-04	8-Aug-06	1-Feb-07
755	US20080027 006		Compositions And Methods For Modification And Prevention Of Sars	The Regents of the University of California	12-Feb-04	14-Feb-05	31-Jan-08
756	US20040162 309	http://59.45.142.240:8808/pdf/US20040162309A1.pdf	Methods and compositions related to ORM compounds and toll-like	3M Innovative Properties Company	12-Feb-04	12-Feb-04	19-Aug-04
757	US8609370	http://59.45.142.240:8808/pdf/US8609370.pdf	Highly active glycoproteins-process conditions and an efficient method	Glycotope GmbH	13-Feb-04	14-Feb-05	17-Dec-13
758	US20080226 681	http://59.45.142.240:8808/pdf/US20080226681A1.pdf	Highly Active Glycoproteins-Process Conditions and an Efficient Method	Glycotope GmbH	13-Feb-04	14-Feb-05	18-Sep-08
759	US9447462	http://59.45.142.240:8808/pdf/US9447462.pdf	Methods for concurrent identification and quantification of an unknown	IBIS BIOSCIENCES, INC.	18-Feb-04	27-Jan-14	20-Sep-16
760	US7666592	http://59.45.142.240:8808/pdf/US7666592.pdf	Methods for concurrent identification and quantification of an unknown	Ibis Biosciences, Inc.	18-Feb-04	17-Feb-05	23-Feb-10
761	US20140141 502	http://59.45.142.240:8808/pdf/US20140141502A1.pdf	Methods For Concurrent Identification And Quantification Of	IBIS BIOSCIENCES, INC.	18-Feb-04	27-Jan-14	22-May-14
762	US20090004 643	http://59.45.142.240:8808/pdf/US20090004643A1.pdf	METHODS FOR CONCURRENT IDENTIFICATION AND QUANTIFICATION OF AN UNKNOWN	ISIS Pharmaceuticals, Inc.	18-Feb-04	17-Feb-05	1-Jan-09
763	US7803765	http://59.45.142.240:8808/pdf/US7803765.pdf	Methods of constructing biodiverse gene fragment libraries and	Phylogica Limited	20-Feb-04	20-Feb-04	28-Sep-10
764	US20100273 740	http://59.45.142.240:8808/pdf/US20100273740A1.pdf	Phospholipids for the Treatment of Infection by Togaviruses, Herpes	FLEMING RONALD A	20-Feb-04	23-Nov-09	28-Oct-10

765	US20050187 192	http://59.45.142.240:8808/pdf/US20050187192A1.pdf	Phospholipids for the treatment of infection by togaviruses, herpes		20-Feb-04	20-Feb-04	25-Aug-05
766	US20070082 971	http://59.45.142.240:8808/pdf/US20070082971A1.pdf	Use of a plastic composition and a product obtained thereby	POLYGIENE AB	23-Feb-04	27-Jan-05	12-Apr-07
767	US20070087 008	http://59.45.142.240:8808/pdf/US20070087008A1.pdf	Rab9a, rab11a, and modulators thereof related to infectious disease	UNIV VANDERBILT	24-Feb-04	24-Feb-05	19-Apr-07
768	US7781226	http://59.45.142.240:8808/pdf/US7781226.pdf	Particle on membrane assay system	The Board of Regents of the University of Texas	27-Feb-04	22-Dec-04	24-Aug-10
769	US20060257 993	http://59.45.142.240:8808/pdf/US20060257993A1.pdf	Integration of fluids and reagents into self-contained cartridges	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
770	US20060257 992	http://59.45.142.240:8808/pdf/US20060257992A1.pdf	Integration of fluids and reagents into self-contained cartridges containing sensor elements and	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
771	US20060257 991	http://59.45.142.240:8808/pdf/US20060257991A1.pdf	Integration of fluids and reagents into self-contained cartridges containing particle-based sensor	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
772	US20060257 941	http://59.45.142.240:8808/pdf/US20060257941A1.pdf	Integration of fluids and reagents into self-contained cartridges containing particle and membrane	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
773	US20060257 854	http://59.45.142.240:8808/pdf/US20060257854A1.pdf	Membrane assay system including preloaded particles	BALLARD KARRI L	27-Feb-04	22-Dec-04	16-Nov-06
774	US20050191 620	http://59.45.142.240:8808/pdf/US20050191620A1.pdf	Particle on membrane assay system	BALLARD KARRI L	27-Feb-04	22-Dec-04	1-Sep-05
775	US20040171 086	http://59.45.142.240:8808/pdf/US20040171086A1.pdf	Selective modulation of TLR-mediated biological activity	3M Innovative Properties Company	27-Feb-04	27-Feb-04	2-Sep-04
776	US20050281 828	http://59.45.142.240:8808/pdf/US20050281828A1.pdf	Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing	BOWDISH KATHERINE S	28-Feb-04	1-Apr-05	22-Dec-05
777	US20070203 060	http://59.45.142.240:8808/pdf/US20070203060A1.pdf	Casein Derived Peptides And Therapeutic Uses Thereof	SIDELMAN ZVI	1-Mar-04	1-Sep-06	30-Aug-07
778	US7691390	http://59.45.142.240:8808/pdf/US7691390.pdf	Viral protein	CHANG MING-FU	2-Mar-04	19-Sep-07	6-Apr-10
779	US20090068 636	http://59.45.142.240:8808/pdf/US20090068636A1.pdf	VIRAL PROTEIN	CHANG MING-FU	2-Mar-04	19-Sep-07	12-Mar-09
780	US20100035 227	http://59.45.142.240:8808/pdf/US20100035227A1.pdf	Compositions for use in identification of alphaviruses	ISIS Pharmaceuticals, Inc.	3-Mar-04	2-Mar-05	11-Feb-10
781	US20060259 249	http://59.45.142.240:8808/pdf/US20060259249A1.pdf	Rapid identification of microbial agents	ECKER DAVID J	3-Mar-04	3-Mar-05	16-Nov-06
782	US8420096	http://59.45.142.240:8808/pdf/US8420096.pdf	Cell-penetrating SOCS polypeptides that inhibit cytokine-induced	Vanderbilt University	4-Mar-04	4-Mar-05	16-Apr-13
783	US20090209 458	http://59.45.142.240:8808/pdf/US20090209458A1.pdf	Cell-penetrating socs polypeptides that inhibit cytokine-induced	VANDERBILT UNIVERSITY	4-Mar-04	4-Mar-05	20-Aug-09
784	US20040176 367	http://59.45.142.240:8808/pdf/US20040176367A1.pdf	1-Amino 1H-imidazoquinolines	3M Innovative Properties Company	5-Mar-04	5-Mar-04	9-Sep-04
785	US20160177 336	http://59.45.142.240:8808/pdf/US20160177336A1.pdf	Expression Tools for Multiprotein Applications	Not Available	9-Mar-04	11-Dec-15	23-Jun-16
786	US20080004 228	http://59.45.142.240:8808/pdf/US20080004228A1.pdf	New Expression Tools for Multiprotein Applications	BERGER IMRE	9-Mar-04	25-Nov-04	3-Jan-08
787	US20040214 785	http://59.45.142.240:8808/pdf/US20040214785A1.pdf	Surface sanitizing compositions with improved antimicrobial performance	Xantech Pharmaceuticals,	9-Mar-04	9-Mar-04	28-Oct-04
788	US7670807	http://59.45.142.240:8808/pdf/US7670807.pdf	RNA-dependent DNA polymerase from Geobacillus stearothermophilus	East Tennessee State Univ.	10-Mar-04	10-Mar-04	2-Mar-10
789	US20110020 897	http://59.45.142.240:8808/pdf/US20110020897A1.pdf	RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS STEAROTHERMOPHILUS	LAMPSON BERT C	10-Mar-04	1-Mar-10	27-Jan-11
790	US20100003 723	http://59.45.142.240:8808/pdf/US20100003723A1.pdf	RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS STEAROTHERMOPHILUS	LAMPSON BERT C	10-Mar-04	10-Mar-04	7-Jan-10
791	US20050203 038	http://59.45.142.240:8808/pdf/US20050203038A1.pdf	Modulation of ACE2 expression		10-Mar-04	10-Mar-04	15-Sep-05
792	US20050234 122	http://59.45.142.240:8808/pdf/US20050234122A1.pdf	Prevention of and countermeasures against viral infection	CHOKO CO., LTD.	11-Mar-04	11-Mar-04	20-Oct-05
793	US20070178 048	http://59.45.142.240:8808/pdf/US20070178048A1.pdf	Antiviral composition comprising p-menthane-3,8-diol	CLARKE PAUL D	12-Mar-04	2-Mar-05	2-Aug-07
794	US9326972	http://59.45.142.240:8808/pdf/US9326972.pdf	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor	Ohio University	16-Mar-04	9-Feb-12	3-May-16
795	US20160220 536	http://59.45.142.240:8808/pdf/US20160220536A1.pdf	USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND	Not Available	16-Mar-04	19-Feb-16	4-Aug-16
796	US20100004 304	http://59.45.142.240:8808/pdf/US20100004304A1.pdf	USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND	GIULLANT CESIDIO	16-Mar-04	1-Oct-08	7-Jan-10
797	US20060211 752	http://59.45.142.240:8808/pdf/US20060211752A1.pdf	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor	BENAVIDES-PERALTA URUGUAYSITO	16-Mar-04	17-May-05	21-Sep-06
798	US20060009 459	http://59.45.142.240:8808/pdf/US20060009459A1.pdf	Pyridazine derivatives and their use as therapeutic agents	ABREO MELWYN	16-Mar-04	9-Feb-05	12-Jan-06
799	US20050189 302	http://59.45.142.240:8808/pdf/US20050189302A1.pdf	Viral inactivation using ozone	KEYSER STEVEN A.	17-Mar-04	11-Oct-04	1-Sep-05
800	US20050117 187	http://59.45.142.240:8808/pdf/US20050117187A1.pdf	Apparatus for forming nano-grating device	CHEN YUNG-HSIN	17-Mar-04	17-Mar-04	2-Jun-05
801	US20080213 125	http://59.45.142.240:8808/pdf/US20080213125A1.pdf	Apparatus and Method for Using Ozone as a Disinfectant	Huawei Technologies Co., Ltd.	18-Mar-04	18-Mar-05	4-Sep-08
802	US7312036	http://59.45.142.240:8808/pdf/US7312036.pdf	Compositions for use in identification of viral hemorrhagic fever viruses	ISIS Pharmaceuticals, Inc.	22-Mar-04	21-Mar-05	25-Dec-07
803	US20060057 605	http://59.45.142.240:8808/pdf/US20060057605A1.pdf	Compositions for use in identification of viral hemorrhagic fever viruses	ISIS Pharmaceuticals, Inc.	22-Mar-04	21-Mar-05	16-Mar-06

804	US8697873	http://59.45.142.240:8808/pdf/US8697873.pdf	Amide substituted imidazopyridines, imidazoquinolines, and	3M Innovative Properties Company	24-Mar-04	24-Mar-05	15-Apr-14
805	US20080069 838		NOVEL HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES	CHAN KWOK HUNG	24-Mar-04	24-Mar-04	20-Mar-08
806	US20070219 196	http://59.45.142.240:8808/pdf/US20070219196A1.pdf	AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND	AMOS DAVID T	24-Mar-04	24-Mar-05	20-Sep-07
807	US20060099 573		Diagnostic assays	MIGUEZ MARIA-JOSE	24-Mar-04	24-Mar-05	11-May-06
808	US20050009 009	http://59.45.142.240:8808/pdf/US20050009009A1.pdf	Diagnostic assay for the human virus causing severe acute	CHAN KWOK HUNG	24-Mar-04	24-Mar-04	13-Jan-05
809	US20040191 833	http://59.45.142.240:8808/pdf/US20040191833A1.pdf	Selective activation of cellular activities mediated through a	3M Innovative Properties Company	24-Mar-04	24-Mar-04	30-Sep-04
810	US8969362	http://59.45.142.240:8808/pdf/US8969362.pdf	9-substituted 8-oxoadenine compound	AstraZeneca Aktiebolag	26-Mar-04	21-Oct-13	3-Mar-15
811	US20140045 837	http://59.45.142.240:8808/pdf/US20140045837A1.pdf	9-Substituted 8-Oxoadenine Compound	AstraZeneca Aktiebolag	26-Mar-04	21-Oct-13	13-Feb-14
812	US20070225 303	http://59.45.142.240:8808/pdf/US20070225303A1.pdf	8-Oxoadenine Compound	HASHIMOTO KAZUKI	26-Mar-04	25-Mar-05	27-Sep-07
813	US20070190 071	http://59.45.142.240:8808/pdf/US20070190071A1.pdf	9-Substituted 8-oxoadenine compound	AstraZeneca Aktiebolag	26-Mar-04	24-Mar-05	16-Aug-07
814	US20060292 151	http://59.45.142.240:8808/pdf/US20060292151A1.pdf	L-SIGN polymorphisms and methods involving use of same	GARDNER JASON P	26-Mar-04	28-Mar-05	28-Dec-06
815	US8529968	http://59.45.142.240:8808/pdf/US8529968.pdf	Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties,	Hightech Bio-Activities Holding GmbH	29-Mar-04	29-Mar-05	10-Sep-13
816	US20130338 224	http://59.45.142.240:8808/pdf/US20130338224A1.pdf	DECONTAMINATING COMPOSITION HAVING SIMULTANEOUSLY BACTERICIDAL, FUNGICIDAL AND VIROCIDAL PROPERTIES, METHODS FOR OBTAINING AND USING SAID	HIGHTECH BIO-ACTIVITIES HOLDING GMBH	29-Mar-04	7-Aug-13	19-Dec-13
817	US20070275 091	http://59.45.142.240:8808/pdf/US20070275091A1.pdf	Compositions And Methods For Improved Mucus Function	KING MALCOLM	30-Mar-04	30-Mar-05	29-Nov-07
818	US20050002 901	http://59.45.142.240:8808/pdf/US20050002901A1.pdf	Compositions and methods for treating coronavirus infection and	BLATT LAWRENCE M.	30-Mar-04	30-Mar-04	6-Jan-05
819	US20040170 965	http://59.45.142.240:8808/pdf/US20040170965A1.pdf	Mixed cell diagnostic systems	GOODRUM PATRICIA GAIL RAY	30-Mar-04	30-Mar-04	2-Sep-04
820	US20050220 816	http://59.45.142.240:8808/pdf/US20050220816A1.pdf	Mutant viral nucleic acids and vaccine containing same		31-Mar-04	31-Mar-04	6-Oct-05
821	US20050014 752	http://59.45.142.240:8808/pdf/US20050014752A1.pdf	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Inc.	31-Mar-04	31-Mar-04	20-Jan-05
822	US20050223 427	http://59.45.142.240:8808/pdf/US20050223427A1.pdf	Modified polynucleotides for reducing off-target effects in DNA interference	Dharmacon, Inc.	1-Apr-04	22-Dec-04	6-Oct-05
823	US8816053	http://59.45.142.240:8808/pdf/US8816053.pdf	Methods for treating viral infection using IL-28 and IL-29 cysteine	ZymoGenetics, Inc.	2-Apr-04	7-Sep-12	26-Aug-14
824	US20110008 280	http://59.45.142.240:8808/pdf/US20110008280A1.pdf	METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL- 29	ZymoGenetics, Inc.	2-Apr-04	20-May-10	13-Jan-11
825	US20090263 352	http://59.45.142.240:8808/pdf/US20090263352A1.pdf	METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL- 29	ZymoGenetics, LLC	2-Apr-04	21-May-09	22-Oct-09
826	US20080075 693	http://59.45.142.240:8808/pdf/US20080075693A1.pdf	METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL- 29	ZymoGenetics, Inc.	2-Apr-04	20-Sep-07	27-Mar-08
827	US20050244 423	http://59.45.142.240:8808/pdf/US20050244423A1.pdf	Methods for treating viral infection using IL-28 and IL-29 cysteine	HENDERSON KATHERINE E	2-Apr-04	4-Apr-05	3-Nov-05
828	US20080172 247	http://59.45.142.240:8808/pdf/US20080172247A1.pdf	Method to Decrease the Risk of a Vaccine-Induced Chronic Immune Mediated Disorder in Humans With a	CLASSEN IMMUNOTHERAPIES	6-Apr-04	6-Apr-05	17-Jul-08
829	US7745118	http://59.45.142.240:8808/pdf/US7745118.pdf	Comparative genomic resequencing	Roche Nimblegen, Inc.	8-Apr-04	8-Apr-05	29-Jun-10
830	US20050260 645	http://59.45.142.240:8808/pdf/US20050260645A1.pdf	Comparative genomic resequencing	ALBERT THOMAS	8-Apr-04	8-Apr-05	24-Nov-05
831	US7700273	http://59.45.142.240:8808/pdf/US7700273.pdf	Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor	The United States of America as represented by the Department of Health and Human	9-Apr-04	11-Apr-05	20-Apr-10
832	US20100266 598	http://59.45.142.240:8808/pdf/US20100266598A1.pdf	PEPTIDE THAT ELICITS NEUTRALIZING ANTIBODIES TARGETING THE HIV CO-RECEPTOR, CCR5	Government of the US, as Represented by the Secretary, Department of Health and Human	9-Apr-04	28-Dec-09	21-Oct-10
833	US20080160 010	http://59.45.142.240:8808/pdf/US20080160010A1.pdf	Peptide That Elicits Neutralizing Antibodies Targeting the Hiv Co-	The Government of the United States of	9-Apr-04	11-Apr-05	3-Jul-08
834	US20070192 906	http://59.45.142.240:8808/pdf/US20070192906A1.pdf	Rice plant having vaccine gene transferred thereto	EBINUMA HIROYASU	9-Apr-04	8-Apr-05	16-Aug-07
835	US20070166 384	http://59.45.142.240:8808/pdf/US20070166384A1.pdf	Methods , composition and preparations for delivery of immune	ZARRAGA ISIDRO ANGELO E	9-Apr-04	8-Apr-05	19-Jul-07
836	US20040265 351	http://59.45.142.240:8808/pdf/US20040265351A1.pdf	Methods and compositions for enhancing immune response	KEDL ROSS M.	9-Apr-04	9-Apr-04	30-Dec-04
837	US20040258 698	http://59.45.142.240:8808/pdf/US20040258698A1.pdf	Delivery of immune response modifier compounds	JING NAIYONG	9-Apr-04	9-Apr-04	23-Dec-04
838	US20040202 720	http://59.45.142.240:8808/pdf/US20040202720A1.pdf	Delivery of immune response modifier compounds using metal-containing particulate support	3M Innovative Properties Company	9-Apr-04	9-Apr-04	14-Oct-04
839	US9592277	http://59.45.142.240:8808/pdf/US9592277.pdf	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral	Avirid, Inc.	14-Apr-04	14-Apr-05	14-Mar-17
840	US20170209 376	http://59.45.142.240:8808/pdf/US20170209376A1.pdf	COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND	Not Available	14-Apr-04	10-Mar-17	27-Jul-17

841	US20090047 272	http://59.45.142.240:8808/pdf/US20090047272A1.pdf	Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for	APPELBAUM JACOB G	14-Apr-04	14-Apr-05	19-Feb-09
842	US20050004 144	http://59.45.142.240:8808/pdf/US20050004144A1.pdf	Combined use of IMPDH inhibitors with toll-like receptor agonists	REGENTS OF THE UNIVERSITY OF CALIFORNIA	14-Apr-04	14-Apr-04	6-Jan-05
843	US10335372	http://59.45.142.240:8808/pdf/US10335372.pdf	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral	Jacob G. Appelbaum	14-Apr-04	10-Mar-17	2-Jul-19
844	US20070202 492		Viral Assay	University Of Warwick	15-Apr-04	14-Apr-05	30-Aug-07
845	US20050004 071	http://59.45.142.240:8808/pdf/US20050004071A1.pdf	Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by	COMPER WAYNE D.	20-Apr-04	20-Apr-04	6-Jan-05
846	US20080171 057	http://59.45.142.240:8808/pdf/US20080171057A1.pdf	Reagents, Devices, and Methods For Proteomic Analysis With Applications Including Diagnostics, Vaccines,	NETWORK IMMUNOLOGY INC.	21-Apr-04	19-Apr-05	17-Jul-08
847	US20060190 189	http://59.45.142.240:8808/pdf/US20060190189A1.pdf	Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines,	HOFFMANN GEOFFREY W	21-Apr-04	16-Mar-06	24-Aug-06
848	US20050277 592		Beta-peptides	Yale University	21-Apr-04	21-Apr-05	15-Dec-05
849	US20050240 353	http://59.45.142.240:8808/pdf/US20050240353A1.pdf	Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines,		21-Apr-04	4-Feb-05	27-Oct-05
850	US20050271 711	http://59.45.142.240:8808/pdf/US20050271711A1.pdf	Therapeutic antimicrobial compositions and methods	The Procter & Gamble Company	26-Apr-04	25-Apr-05	8-Dec-05
851	US20050239 086	http://59.45.142.240:8808/pdf/US20050239086A1.pdf	Multiplex systems, methods, and kits for detecting and identifying nucleic	BRIESE THOMAS	27-Apr-04	27-Apr-04	27-Oct-05
852	US20040259 934	http://59.45.142.240:8808/pdf/US20040259934A1.pdf	Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with	CARROLL STEVEN S.	27-Apr-04	27-Apr-04	23-Dec-04
853	US20040235 952	http://59.45.142.240:8808/pdf/US20040235952A1.pdf	Inhibitors of severe acute respiratory syndrome (SARS) 3C-like	Agouron Pharmaceuticals,	27-Apr-04	27-Apr-04	25-Nov-04
854	US9592284	http://59.45.142.240:8808/pdf/US9592284.pdf	Immunization regimen with E4-deleted adenovirus prime and E1-	The Trustees of the University of	28-Apr-04	27-Apr-05	14-Mar-17
855	US9254315	http://59.45.142.240:8808/pdf/US9254315.pdf	Systems and methods for identifying replikin scaffolds and uses of said	Not Available	28-Apr-04	3-Feb-10	9-Feb-16
856	US8394386	http://59.45.142.240:8808/pdf/US8394386.pdf	Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated	The Trustees of the University of Pennsylvania	28-Apr-04	27-Apr-05	12-Mar-13
857	US20100247 550	http://59.45.142.240:8808/pdf/US20100247550A1.pdf	SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN	BOGOCH ELENORE S	28-Apr-04	3-Feb-10	30-Sep-10
858	US20080241 189	http://59.45.142.240:8808/pdf/US20080241189A1.pdf	Sequential Delivery Of Immunogenic Molecules Via Adenovirus And Adeno-Associated Virus-Mediated	The Trustees of the University of Pennsylvania	28-Apr-04	27-Apr-05	2-Oct-08
859	US20070231 347	http://59.45.142.240:8808/pdf/US20070231347A1.pdf	Immunization Regimen with E4-Deleted Adenovirus Prime and E1-	The Trustees of the University of	28-Apr-04	27-Apr-05	4-Oct-07
860	US20070218 536	http://59.45.142.240:8808/pdf/US20070218536A1.pdf	Polyvalent Viral Vectors and a System for Production Thereof	GAO GUANGPING	28-Apr-04	27-Apr-05	20-Sep-07
861	US20060051 374	http://59.45.142.240:8808/pdf/US20060051374A1.pdf	Compositions and methods for mucosal vaccination	3M Innovative Properties Company	28-Apr-04	28-Apr-05	9-Mar-06
862	US20060003 352	http://59.45.142.240:8808/pdf/US20060003352A1.pdf	Mass tag PCR for multiplex diagnostics	BRIESE THOMAS	29-Apr-04	28-Apr-05	5-Jan-06
863	US20040265 879	http://59.45.142.240:8808/pdf/US20040265879A1.pdf	Compositions for enhancing transport of molecules into cells	IVERSEN PATRICK J	29-Apr-04	29-Apr-04	30-Dec-04
864	US20040229 219	http://59.45.142.240:8808/pdf/US20040229219A1.pdf	Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute	GALLAHER WILLIAM R.	29-Apr-04	29-Apr-04	18-Nov-04
865	US7427479	http://59.45.142.240:8808/pdf/US7427479.pdf	Methods and kits for identifying target nucleotides in mixed	Applera Corporation	30-Apr-04	29-Apr-05	23-Sep-08
866	US20090068 665	http://59.45.142.240:8808/pdf/US20090068665A1.pdf	METHODS AND KITS FOR IDENTIFYING TARGET	APPLIED BIOSYSTEMS INC.	30-Apr-04	31-Jul-08	12-Mar-09
867	US20060003 351	http://59.45.142.240:8808/pdf/US20060003351A1.pdf	Methods and kits for identifying target nucleotides in mixed	Applera Corporation	30-Apr-04	29-Apr-05	5-Jan-06
868	US20050002 953	http://59.45.142.240:8808/pdf/US20050002953A1.pdf	SARS-coronavirus virus-like particles and methods of use	HEROLD JENS	4-May-04	4-May-04	6-Jan-05
869	US7622125	http://59.45.142.240:8808/pdf/US7622125.pdf	Polycistronic HIV vector constructs	Novartis Vaccines and Diagnostics	5-May-04	5-May-05	24-Nov-09
870	US20100040 676	http://59.45.142.240:8808/pdf/US20100040676A1.pdf	POLYCISTRONIC HIV VECTOR CONSTRUCTS	Novartis Vaccines and Diagnostics	5-May-04	22-Oct-09	18-Feb-10
871	US20050287 167	http://59.45.142.240:8808/pdf/US20050287167A1.pdf	Polycistronic HIV vector constructs		5-May-04	5-May-05	29-Dec-05
872	US20070231 295	http://59.45.142.240:8808/pdf/US20070231295A1.pdf	Antimicrobial Silicon Oxide Flakes	BUJARD PATRICE	12-May-04	2-May-05	4-Oct-07
873	US20070087 974	http://59.45.142.240:8808/pdf/US20070087974A1.pdf	TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS WITH IMMUNOMODULATOR	SCICLONE PHARMACEUTICALS, INC.	14-May-04	9-Nov-06	19-Apr-07
874	US7504205	http://59.45.142.240:8808/pdf/US7504205.pdf	Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for	The Burnham Institute	17-May-04	17-May-05	17-Mar-09
875	US20050276 818	http://59.45.142.240:8808/pdf/US20050276818A1.pdf	Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for	GODZIK ADAM	17-May-04	17-May-05	15-Dec-05
876	US9441247	http://59.45.142.240:8808/pdf/US9441247.pdf	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18-May-04	6-Jul-15	13-Sep-16
877	US9079943	http://59.45.142.240:8808/pdf/US9079943.pdf	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18-May-04	28-Mar-14	14-Jul-15
878	US8709441	http://59.45.142.240:8808/pdf/US8709441.pdf	TC-83-derived alphavirus vectors, particles and methods	Alphavax, Inc.	18-May-04	6-Jul-10	29-Apr-14

879	US20160348 132	http://59.45.142.240:8808/pdf/US20160348132A1.pdf	TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS	Not Available	18-May-04	11-Aug-16	1-Dec-16
880	US20150299 728	http://59.45.142.240:8808/pdf/US20150299728A1.pdf	TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS	Not Available	18-May-04	6-Jul-15	22-Oct-15
881	US20140205 629	http://59.45.142.240:8808/pdf/US20140205629A1.pdf	TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS	AlphaVax, Inc.	18-May-04	28-Mar-14	24-Jul-14
882	US20110027 306	http://59.45.142.240:8808/pdf/US20110027306A1.pdf	TC-83-Derived Alphavirus Vectors, Particles and Methods	AlphaVax, Inc.	18-May-04	6-Jul-10	3-Feb-11
883	US20050266 550	http://59.45.142.240:8808/pdf/US20050266550A1.pdf	TC-83-derived alphavirus vectors, particles and methods	Alphavax, Inc.	18-May-04	18-May-05	1-Dec-05
884	US10570416	http://59.45.142.240:8808/pdf/US10570416.pdf	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18-May-04	11-Aug-16	25-Feb-20
885	US7541436	http://59.45.142.240:8808/pdf/US7541436.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	4-May-07	2-Jun-09
886	US7541163	http://59.45.142.240:8808/pdf/US7541163.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	14-Aug-07	2-Jun-09
887	US7531630	http://59.45.142.240:8808/pdf/US7531630.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	13-Sep-06	12-May-09
888	US7531324	http://59.45.142.240:8808/pdf/US7531324.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	13-Sep-06	12-May-09
889	US7318918	http://59.45.142.240:8808/pdf/US7318918.pdf	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	18-May-05	15-Jan-08
890	US20080171 363	http://59.45.142.240:8808/pdf/US20080171363A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	14-Aug-07	17-Jul-08
891	US20080076 710	http://59.45.142.240:8808/pdf/US20080076710A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	4-May-07	27-Mar-08
892	US20080031 853	http://59.45.142.240:8808/pdf/US20080031853A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	ROCHE PALO ALTO LLC	19-May-04	15-Aug-07	7-Feb-08
893	US20070225 205	http://59.45.142.240:8808/pdf/US20070225205A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	14-Sep-06	27-Sep-07
894	US20070225 204	http://59.45.142.240:8808/pdf/US20070225204A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	14-Sep-06	27-Sep-07
895	US20070025 966	http://59.45.142.240:8808/pdf/US20070025966A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	13-Sep-06	1-Feb-07
896	US20070020 734	http://59.45.142.240:8808/pdf/US20070020734A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	13-Sep-06	25-Jan-07
897	US20070020 235	http://59.45.142.240:8808/pdf/US20070020235A1.pdf	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	13-Sep-06	25-Jan-07
898	US20050266 465	http://59.45.142.240:8808/pdf/US20050266465A1.pdf	Interferon-alpha polypeptides and conjugates		19-May-04	18-May-05	1-Dec-05
899	US20050004 063	http://59.45.142.240:8808/pdf/US20050004063A1.pdf	Inhibition of SARS-associated coronavirus (SCoV) infection and treatment of SARS	GUAN YI	19-May-04	19-May-04	6-Jan-05
900	US7722886	http://59.45.142.240:8808/pdf/US7722886B2.pdf	Compositions and methods for treatment of severe acute respiratory syndrome (SARS)	Wyeth	20-May-04	20-May-04	25-May-10
901	US9730997	http://59.45.142.240:8808/pdf/US9730997.pdf	Alphavirus vectors for respiratory pathogen vaccines	Novartis Vaccines and Diagnostics	21-May-04	20-Aug-14	15-Aug-17
902	US7452542	http://59.45.142.240:8808/pdf/US7452542.pdf	Live attenuated coronavirus vaccines	Vanderbilt University	21-May-04	23-May-05	18-Nov-08
903	US20150024 002	http://59.45.142.240:8808/pdf/US20150024002A1.pdf	ALPHAVIRUS VECTORS FOR RESPIRATORY PATHOGEN VACCINES	Not Available	21-May-04	20-Aug-14	22-Jan-15
904	US20110002 958	http://59.45.142.240:8808/pdf/US20110002958A1.pdf	Alphavirus Vectors for Respiratory Pathogen Vaccines	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	21-May-04	1-Jun-10	6-Jan-11
905	US20090104 226	http://59.45.142.240:8808/pdf/US20090104226A1.pdf	Alphavirus Vectors for Respiratory Pathogen Vaccines	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	21-May-04	20-May-05	23-Apr-09
906	US8716461	http://59.45.142.240:8808/pdf/US8716461.pdf	Human parvovirus	Blood Systems, Inc.	24-May-04	24-May-05	6-May-14
907	US20090162 831	http://59.45.142.240:8808/pdf/US20090162831A1.pdf	HUMAN PARVOVIRUS	DELWART ERIC L	24-May-04	24-May-05	25-Jun-09
908	US20040235 946	http://59.45.142.240:8808/pdf/US20040235946A1.pdf	Organosulphur prodrugs for the prevention and treatment of infectious diseases and pathogenic	OTT DAVID M.	24-May-04	24-May-04	25-Nov-04
909	US9024001	http://59.45.142.240:8808/pdf/US9024001.pdf	Alphavirus replicon packaging constructs	Novartis Vaccines and Diagnostics	25-May-04	20-May-05	5-May-15
910	US20080069 804	http://59.45.142.240:8808/pdf/US20080069804A1.pdf	Alphavirus Replicon Packaging Constructs	PERRI SILVIA	25-May-04	20-May-05	20-Mar-08
911	US20090011 403	http://59.45.142.240:8808/pdf/US20090011403A1.pdf	MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND ARTICLES THEREOF	UNIVERSITY OF UTAH RESEARCH FOUNDATION	26-May-04	17-May-05	8-Jan-09
912	US20050019 756	http://59.45.142.240:8808/pdf/US20050019756A1.pdf	Methods and compositions for use in diagnosing and characterizing diseases involving abnormal	DE MEIRLEIR KENNY	26-May-04	26-May-04	27-Jan-05
913	US20040253 624	http://59.45.142.240:8808/pdf/US20040253624A1.pdf	Microporous materials, methods of making, using, and articles thereof	DURTSCHI JACOB	26-May-04	26-May-04	16-Dec-04
914	US8703467	http://59.45.142.240:8808/pdf/US8703467.pdf	Inactivation of a pathogen in a sample by a treatment with formalin	Baxter Healthcare SA	27-May-04	26-May-05	22-Apr-14
915	US20060006 678	http://59.45.142.240:8808/pdf/US20060006678A1.pdf	Door handle cover	HERRON ROY H JR	27-May-04	26-May-05	12-Jan-06
916	US20050039 220	http://59.45.142.240:8808/pdf/US20050039220A1.pdf	Imageable animal model of SARS infection	XU MINGXU	27-May-04	27-May-04	17-Feb-05
917	US20080154 210	http://59.45.142.240:8808/pdf/US20080154210A1.pdf	Mixture for Transdermal Delivery of Low and High Molecular Weight	ORYXE	28-May-04	25-May-05	26-Jun-08
918	US7629443	http://59.45.142.240:8808/pdf/US7629443.pdf	Neutralizing monoclonal antibodies against severe acute respiratory	New York Blood Center, Inc.	2-Jun-04	8-Feb-06	8-Dec-09
919	US20060240 551	http://59.45.142.240:8808/pdf/US20060240551A1.pdf	Neutralizing monoclonal antibodies against severe acute respiratory	HE YUXIAN	2-Jun-04	8-Feb-06	26-Oct-06
920	US20080267 992	http://59.45.142.240:8808/pdf/US20080267992A1.pdf	Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S	Cancer Center, Sun Yat-Sun University	4-Jun-04	4-Jun-04	30-Oct-08
921	US20070244 133	http://59.45.142.240:8808/pdf/US20070244133A1.pdf	Thienopyrimidines and Thiazolopyrimidines for Use in	BOWER JUSTIN F	4-Jun-04	31-May-05	18-Oct-07
922	US20060002 932	http://59.45.142.240:8808/pdf/US20060002932A1.pdf	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell	Duke University	4-Jun-04	3-Jun-05	5-Jan-06
923	US20050025 788	http://59.45.142.240:8808/pdf/US20050025788A1.pdf	Systemic delivery of non-viral vector expressing SARS viral genomic	CHOU GEORGE CHIN-SHENG	4-Jun-04	4-Jun-04	3-Feb-05
924	US7393856	http://59.45.142.240:8808/pdf/US7393856.pdf	Anti-viral uses of borinic acid complexes	Anacor Pharmaceuticals,	14-Jun-04	14-Jun-05	1-Jul-08

925	US20080015 184	http://59.45.142.240:8808/pdf/US20080015184A1.pdf	Urea Substituted Imidazopyridines, Imidazoquinolines, and	3M INNOVATIVE PROPERTIES COMPANY	14-Jun-04	14-Jun-05	17-Jan-08
926	US20060188 519	http://59.45.142.240:8808/pdf/US20060188519A1.pdf	Peptides, antibodies, and methods for the diagnosis of SARS	AU MUN Y D	14-Jun-04	13-Jun-05	24-Aug-06
927	US20060019 927	http://59.45.142.240:8808/pdf/US20060019927A1.pdf	Anti-viral uses of borinic acid complexes	BELLINGER-KAWAHARA COMPANY	14-Jun-04	14-Jun-05	26-Jan-06
928	US9255140	http://59.45.142.240:8808/pdf/US9255140.pdf	Adjuvancy and immune potentiating properties of natural products of	NEW YORK BLOOD CENTER, INC.	15-Jun-04	23-Mar-09	9-Feb-16
929	US9017699	http://59.45.142.240:8808/pdf/US9017699.pdf	Adjuvancy and immune potentiating properties of natural products of	New York Blood Center, Inc.	15-Jun-04	18-Feb-10	28-Apr-15
930	US7700120	http://59.45.142.240:8808/pdf/US7700120.pdf	Adjuvancy and immune potentiating properties of natural products of	New York Blood Center	15-Jun-04	15-Jun-05	20-Apr-10
931	US20100266 634	http://59.45.142.240:8808/pdf/US20100266634A1.pdf	ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF NATURAL PRODUCTS OF	NEW YORK BLOOD CENTER, INC.	15-Jun-04	18-Feb-10	21-Oct-10
932	US20090191 229	http://59.45.142.240:8808/pdf/US20090191229A1.pdf	ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF NATURAL PRODUCTS OF	NEW YORK BLOOD CENTER	15-Jun-04	23-Mar-09	30-Jul-09
933	US20070213 356	http://59.45.142.240:8808/pdf/US20070213356A1.pdf	Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and	HARALDSON CHAD A	15-Jun-04	15-Jun-05	13-Sep-07
934	US20050054 644	http://59.45.142.240:8808/pdf/US20050054644A1.pdf	Hydrolytically-resistant boron-containing therapeutics and methods	AKAMA TSUTOMU	15-Jun-04	15-Jun-04	10-Mar-05
935	US9750797	http://59.45.142.240:8808/pdf/US9750797.pdf	Sustained release vaccine composition	VIRBAC CORPORATION	16-Jun-04	16-Jun-05	5-Sep-17
936	US20080199 491	http://59.45.142.240:8808/pdf/US20080199491A1.pdf	Sustained Release Vaccine Composition	BRANDON MALCOLM	16-Jun-04	16-Jun-05	21-Aug-08
937	US8623382	http://59.45.142.240:8808/pdf/US8623382.pdf	Immunogenic compositions for inducing an immune response to HIV	Wyeth LLC	17-Jun-04	18-Jan-11	7-Jan-14
938	US20080305 120	http://59.45.142.240:8808/pdf/US20080305120A1.pdf	Immunogenic Compositions Comprising Hsp60 Polypeptides	MEDIMMUNE, INC.	17-Jun-04	16-Jun-05	11-Dec-08
939	US20080269 115	http://59.45.142.240:8808/pdf/US20080269115A1.pdf	Immunogenic Sars Domain	BEADENKOPF ROBERT J	17-Jun-04	16-Jun-05	30-Oct-08
940	US20070190 031	http://59.45.142.240:8808/pdf/US20070190031A1.pdf	Plasmid having three complete transcriptional units and immunogenic compositions for	EGAN MICHAEL	17-Jun-04	15-Jun-05	16-Aug-07
941	US9938275	http://59.45.142.240:8808/pdf/US9938275.pdf	Substituted imidazoquinolines, imidazopyridines, and	3M Innovative Properties Company	18-Jun-04	23-Jan-17	10-Apr-18
942	US9550773	http://59.45.142.240:8808/pdf/US9550773.pdf	Substituted imidazoquinolines, imidazopyridines, and	3M Innovative Properties Company	18-Jun-04	13-Apr-15	24-Jan-17
943	US9006264	http://59.45.142.240:8808/pdf/US9006264.pdf	Substituted imidazoquinolines, imidazopyridines, and	3M Innovative Properties Company	18-Jun-04	9-Sep-13	14-Apr-15
944	US8541438	http://59.45.142.240:8808/pdf/US8541438.pdf	Substituted imidazoquinolines, imidazopyridines, and	3M Innovative Properties Company	18-Jun-04	21-Dec-10	24-Sep-13
945	US7636637	http://59.45.142.240:8808/pdf/US7636637.pdf	Variable length probe selection	Roche NimbleGen, Inc.	18-Jun-04	20-Jun-05	22-Dec-09
946	US20180222 906	http://59.45.142.240:8808/pdf/US20180222906A1.pdf	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND	3M Innovative Properties Company	18-Jun-04	9-Apr-18	9-Aug-18
947	US20170129 891	http://59.45.142.240:8808/pdf/US20170129891A1.pdf	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND	Not Available	18-Jun-04	23-Jan-17	11-May-17
948	US20150218 162	http://59.45.142.240:8808/pdf/US20150218162A1.pdf	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND	Not Available	18-Jun-04	13-Apr-15	6-Aug-15
949	US20140011 777	http://59.45.142.240:8808/pdf/US20140011777A1.pdf	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND	3M INNOVATIVE PROPERTIES COMPANY	18-Jun-04	9-Sep-13	9-Jan-14
950	US20070287 725		Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring	3M INNOVATIVE PROPERTIES COMPANY	18-Jun-04	17-Jun-05	13-Dec-07
951	US20070287 724		Substituted Imidazoquinolines, Imidazopyridines, and	3M INNOVATIVE PROPERTIES COMPANY	18-Jun-04	17-Jun-05	13-Dec-07
952	US20070259 907	http://59.45.142.240:8808/pdf/US20070259907A1.pdf	ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND	PRINCE RYAN B	18-Jun-04	17-Jun-05	8-Nov-07
953	US20070259 881	http://59.45.142.240:8808/pdf/US20070259881A1.pdf	Substituted Imidazo Ring Systems and Methods	CELEBI AZIM A	18-Jun-04	17-Jun-05	8-Nov-07
954	US20070219 228	http://59.45.142.240:8808/pdf/US20070219228A1.pdf	Aryl substituted imidazopyridines	AMOS DAVID T	18-Jun-04	17-Jun-05	20-Sep-07
955	US20070208 052	http://59.45.142.240:8808/pdf/US20070208052A1.pdf	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and	HEPPNER PHILIP D	18-Jun-04	17-Jun-05	6-Sep-07
956	US20050282 209	http://59.45.142.240:8808/pdf/US20050282209A1.pdf	Variable length probe selection	ALBERT THOMAS	18-Jun-04	20-Jun-05	22-Dec-05
957	US20090258 011	http://59.45.142.240:8808/pdf/US20090258011A1.pdf	Antibodies against west nile virus and therapeutic and prophylactic	Washington University	21-Jun-04	6-Apr-09	15-Oct-09
958	US20060067 940	http://59.45.142.240:8808/pdf/US20060067940A1.pdf	Antibodies against West Nile Virus and therapeutic and prophylactic	DIAMOND MICHAEL	21-Jun-04	21-Jun-05	30-Mar-06
959	US20100278 846	http://59.45.142.240:8808/pdf/US20100278846A1.pdf	NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALT-TARGETING AND PHAGOCYTIC POLYPEPTIDE TRANSPORT	FERGUSON IAN A	23-Jun-04	11-Dec-09	4-Nov-10
960	US20050048 473	http://59.45.142.240:8808/pdf/US20050048473A1.pdf	Enzymatic diagnostic test for SARS and other viral diseases	ARAD DORIT	23-Jun-04	23-Jun-04	3-Mar-05
961	US8889118	http://59.45.142.240:8808/pdf/US8889118.pdf	Anticancer agent containing dendritic cell having RNA virus transferred	DNA VEC Research Inc.	24-Jun-04	28-Apr-05	18-Nov-14
962	US20100226 931	http://59.45.142.240:8808/pdf/US20100226931A1.pdf	Compounds for immunopotentialiation	SILVER JOEL B	24-Jun-04	24-Jun-05	9-Sep-10
963	US20080021 038	http://59.45.142.240:8808/pdf/US20080021038A1.pdf	Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As	FAULL ALAN	24-Jun-04	20-Jun-05	24-Jan-08
964	US20080014 183	http://59.45.142.240:8808/pdf/US20080014183A1.pdf	Anticancer Agent Containing Dendritic Cell Having Rna Virus	DNAVEC RESEARCH INC.	24-Jun-04	28-Apr-05	17-Jan-08
965	US20070259 914	http://59.45.142.240:8808/pdf/US20070259914A1.pdf	Novel Piperidine Derivates as Modulators of Chemokine Receptor	TUCKER HOWARD	24-Jun-04	20-Jun-05	8-Nov-07

966	US20070099 968	http://59.45.142.240:8808/pdf/US20070099968A1.pdf	Antiviral compounds and methods	Biotron Limited	24-Jun-04	24-Jun-04	3-May-07
967	US20090297 555	http://59.45.142.240:8808/pdf/US20090297555A1.pdf	RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES COMPRISING HETEROLOGOUS	MEDIMMUNE, LLC	25-Jun-04	30-Jun-09	3-Dec-09
968	US20080044 384	http://59.45.142.240:8808/pdf/US20080044384A1.pdf	Recombinant Human Cytomegalovirus And Vaccines	MedImmune Vaccines, Inc.	25-Jun-04	24-Jun-05	21-Feb-08
969	US7629385	http://59.45.142.240:8808/pdf/US7629385.pdf	Sphingolipid-derived pharmaceutical compositions	Jado Technologies GmbH	29-Jun-04	29-Jun-05	8-Dec-09
970	US20100063 126	http://59.45.142.240:8808/pdf/US20100063126A1.pdf	Carbazole-Derived Pharmaceutical Compositions	JadoLabs GmbH	29-Jun-04	29-Jun-05	11-Mar-10
971	US20080255 076	http://59.45.142.240:8808/pdf/US20080255076A1.pdf	Steroid-Derived Pharmaceutical Compositions	JadoLabs GmbH	29-Jun-04	29-Jun-05	16-Oct-08
972	US20080090 913	http://59.45.142.240:8808/pdf/US20080090913A1.pdf	Sphingolipid-Derived Pharmaceutical Compositions	BRAXMEIER TOBIAS	29-Jun-04	29-Jun-05	17-Apr-08
973	US20060286 124	http://59.45.142.240:8808/pdf/US20060286124A1.pdf	Vaccine compositions and methods of treating coronavirus infection	ID Biomedical Corporation of	30-Jun-04	30-Jun-05	21-Dec-06
974	US20060051 744	http://59.45.142.240:8808/pdf/US20060051744A1.pdf	Feline infectious peritonitis (FIP) and systemic multi-organ coronavirus infection	AUSTIN KIMBERLY M	30-Jun-04	28-Jun-05	9-Mar-06
975	US9430610	http://59.45.142.240:8808/pdf/US9430610.pdf	Re-sequencing pathogen microarray	The United States of America, as represented by the Secretary of the	2-Jul-04	10-Apr-08	30-Aug-16
976	US7623997	http://59.45.142.240:8808/pdf/US7623997.pdf	Computer-implemented biological sequence identifier system and method	The United States of America as represented by the Secretary of the	2-Jul-04	6-Jun-06	24-Nov-09
977	US20100070 195	http://59.45.142.240:8808/pdf/US20100070195A1.pdf	COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER SYSTEM AND METHOD	The Government of the United States of America, as represented by the Secretary of the	2-Jul-04	12-Nov-09	18-Mar-10
978	US20090170 717	http://59.45.142.240:8808/pdf/US20090170717A1.pdf	RE-SEQUENCING PATHOGEN MICROARRAY	The Government of the United States of America, as represented by the Secretary of the Air	2-Jul-04	10-Apr-08	2-Jul-09
979	US20070253 978	http://59.45.142.240:8808/pdf/US20070253978A1.pdf	Copy choice recombination and uses thereof	NIMAN HENRY L	2-Jul-04	29-Dec-06	1-Nov-07
980	US20070059 728	http://59.45.142.240:8808/pdf/US20070059728A1.pdf	COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER SYSTEM AND METHOD	The Government of the US, as represented by the Secretary of the	2-Jul-04	6-Jun-06	15-Mar-07
981	US20060210 967	http://59.45.142.240:8808/pdf/US20060210967A1.pdf	Re-sequencing pathogen microarray	AGAN BRIAN K	2-Jul-04	2-Jul-05	21-Sep-06
982	US20090176 699	http://59.45.142.240:8808/pdf/US20090176699A1.pdf	Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial Adhesion	CHIRON SRL	6-Jul-04	6-Jul-05	9-Jul-09
983	US20080102 444	http://59.45.142.240:8808/pdf/US20080102444A1.pdf	METHODS AND COMPOSITIONS FOR DETECTING RHINOVIRUSES	Focus Technologies, Inc.	6-Jul-04	15-Oct-07	1-May-08
984	US20060008 810	http://59.45.142.240:8808/pdf/US20060008810A1.pdf	Methods and compositions for detecting rhinoviruses	Focus Technologies, Inc.	6-Jul-04	6-Jul-04	12-Jan-06
985	US8652533	http://59.45.142.240:8808/pdf/US8652533.pdf	Durable biocides and disinfectants	Mitsui Norin Co., Ltd.	7-Jul-04	5-Jul-05	18-Feb-14
986	US20080096 959	http://59.45.142.240:8808/pdf/US20080096959A1.pdf	Durable Biocides and Disinfectants	mitsui norin co., ltd.	7-Jul-04	5-Jul-05	24-Apr-08
987	US7354551	http://59.45.142.240:8808/pdf/US7354551.pdf	Room decontamination with hydrogen peroxide vapor	Steris Inc	8-Jul-04	8-Jul-04	8-Apr-08
988	US20080114 002	http://59.45.142.240:8808/pdf/US20080114002A1.pdf	Substituted Acids for the Treatment of Respiratory Diseases	ASTRAZENECA AB	8-Jul-04	6-Jul-05	15-May-08
989	US20060008 379	http://59.45.142.240:8808/pdf/US20060008379A1.pdf	Room decontamination with hydrogen peroxide vapor	STERIS INC.	8-Jul-04	8-Jul-04	12-Jan-06
990	US8821897	http://59.45.142.240:8808/pdf/US8821897.pdf	Viral adjuvants	The University of North Carolina at Chapel Hill	9-Jul-04	24-Nov-10	2-Sep-14
991	US7687475	http://59.45.142.240:8808/pdf/US7687475.pdf	RNA interference in respiratory epithelial cells	University of Iowa Research	9-Jul-04	16-Oct-07	30-Mar-10
992	US7320857	http://59.45.142.240:8808/pdf/US7320857.pdf	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus	Chinese National Human Genome Center at Shanghai	9-Jul-04	9-Jul-04	22-Jan-08
993	US7297786	http://59.45.142.240:8808/pdf/US7297786.pdf	RNA interference in respiratory epithelial cells	University of Iowa Research	9-Jul-04	11-Jul-05	20-Nov-07
994	US20110064 772	http://59.45.142.240:8808/pdf/US20110064772A1.pdf	VIRAL ADJUVANTS	University of North Carolina at Chapel Hill	9-Jul-04	24-Nov-10	17-Mar-11
995	US20080279 891	http://59.45.142.240:8808/pdf/US20080279891A1.pdf	Viral Adjuvants	JOHNSTON ROBERT E	9-Jul-04	8-Jul-05	13-Nov-08
996	US20080261 258	http://59.45.142.240:8808/pdf/US20080261258A1.pdf	Immune Cell Biosensors and Methods of Using Same	Amaox, Inc.	9-Jul-04	11-Jul-05	23-Oct-08
997	US20050112 554	http://59.45.142.240:8808/pdf/US20050112554A1.pdf	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus	HENG XU RUI	9-Jul-04	9-Jul-04	26-May-05
998	US20080096 928		Methods for treating Hepatitis C	AREFOLOV ALEXANDER	14-Jul-04	14-Jul-05	24-Apr-08
999	US20060223 863		Methods for treating Hepatitis C	AREFOLOV ALEXANDER	14-Jul-04	14-Jul-05	5-Oct-06
1000	US20060199 176		Coronavirus S peptides	CHONG PELE C S	15-Jul-04	14-Jul-05	7-Sep-06
1001	US20060287 263	http://59.45.142.240:8808/pdf/US20060287263A1.pdf	Methods and compositions for inducing antigen-specific immune	COLEY PHARMACEUTICAL GROUP LTD	18-Jul-04	18-Jul-05	21-Dec-06
1002	US20060019 923	http://59.45.142.240:8808/pdf/US20060019923A1.pdf	Methods and compositions for inducing innate immune responses	Coley Pharmaceutical Group Ltd	18-Jul-04	18-Jul-05	26-Jan-06
1003	US7424370	http://59.45.142.240:8808/pdf/US7424370.pdf	Computational method for identifying adhesin and adhesin-like proteins of bacterial pathogens	Council of Scientific and Industrial Research	20-Jul-04	7-Feb-05	9-Sep-08
1004	US20050288 866	http://59.45.142.240:8808/pdf/US20050288866A1.pdf	Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential	COUNCIL OF SCIENTIFIC AND INDUSTRIAL	20-Jul-04	7-Feb-05	29-Dec-05
1005	US7618635	http://59.45.142.240:8808/pdf/US7618635.pdf	Super-antigen fusion proteins and the use thereof	Healthbanks Biotech Co., Ltd.	21-Jul-04	19-Jul-05	17-Nov-09
1006	US7371837	http://59.45.142.240:8808/pdf/US7371837.pdf	Human virus causing respiratory tract infection and uses thereof	The University of Hong Kong	21-Jul-04	16-May-05	13-May-08

1007	US20090305 282	http://59.45.142.240:8808/pdf/US20090305282A1.pdf	NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF	CHAN KWOK HUNG	21-Jul-04	1-Jun-09	10-Dec-09
1008	US20080213 891	http://59.45.142.240:8808/pdf/US20080213891A1.pdf	RNAi Agents Comprising Universal Nucleobases	Alnylam Pharmaceuticals,	21-Jul-04	6-Aug-07	4-Sep-08
1009	US20070254 906	http://59.45.142.240:8808/pdf/US20070254906A1.pdf	Method of Administration of Denagins Receptor Antagonists	DarPharma, Inc.	21-Jul-04	21-Jul-05	1-Nov-07
1010	US20060134 753	http://59.45.142.240:8808/pdf/US20060134753A1.pdf	Super-antigen fusion proteins and the use thereof	Healthbanks Biotech Co., Ltd.	21-Jul-04	19-Jul-05	22-Jun-06
1011	US20060034 853		Novel human virus causing respiratory tract infection and uses thereof	CHAN KWOK H	21-Jul-04	16-May-05	16-Feb-06
1012	US20060019 967		SARS CoV main protease inhibitors	HSIEH HSING-PANG	21-Jul-04	20-Jul-05	26-Jan-06
1013	US20060018 923	http://59.45.142.240:8808/pdf/US20060018923A1.pdf	Novel human virus causing respiratory tract infection and uses thereof	CHAN KWOK H	21-Jul-04	21-Jul-04	26-Jan-06
1014	US7645881	http://59.45.142.240:8808/pdf/US7645881.pdf	Methods for treating hepatitis C	PTC Therapeutics, Inc.	22-Jul-04	14-Jul-05	12-Jan-10
1015	US20100099 672	http://59.45.142.240:8808/pdf/US20100099672A1.pdf	METHODS FOR TREATING HEPATITIS C	PTC THERAPEUTICS, INC.	22-Jul-04	23-Dec-09	22-Apr-10
1016	US20060019 976	http://59.45.142.240:8808/pdf/US20060019976A1.pdf	Methods for treating Hepatitis C	CHEN GUANGMING	22-Jul-04	14-Jul-05	26-Jan-06
1017	US20090131 328		FURIN INHIBITORS	SMITH JUDITH	23-Jul-04	22-Jul-05	21-May-09
1018	US20080260 769	http://59.45.142.240:8808/pdf/US20080260769A1.pdf	Polypeptides for Oligomeric Assembly of Antigen	CAPECCHI BARBARA	23-Jul-04	22-Jul-05	23-Oct-08
1019	US20090042 274	http://59.45.142.240:8808/pdf/US20090042274A1.pdf	Method of Purifying Virus Envelope	GENOMIDEA INC.	27-Jul-04	22-Jul-05	12-Feb-09
1020	US8778358		Immunogenic compositions for gram positive bacteria such as	Novartis Vaccines and Diagnostics,	29-Jul-04	18-Oct-10	15-Jul-14
1021	US20090304 681	http://59.45.142.240:8808/pdf/US20090304681A1.pdf	Methods for the treatment and prevention of infection using anti-	Not Available	29-Jul-04	27-Jul-05	10-Dec-09
1022	US20060205 713	http://59.45.142.240:8808/pdf/US20060205713A1.pdf	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	29-Jul-04	29-Jul-04	14-Sep-06
1023	US20060165 716		Immunogenic compositions for gram positive bacteria such as	BAROCCHI MICHELLE	29-Jul-04	29-Jul-05	27-Jul-06
1024	US20050065 143	http://59.45.142.240:8808/pdf/US20050065143A1.pdf	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	29-Jul-04	29-Jul-04	24-Mar-05
1025	US20100047 282	http://59.45.142.240:8808/pdf/US20100047282A1.pdf	METHOD OF ACCELERATED VACCINATION AGAINST EBOLA VIRUSES	The Government of the USA as represented by the Secretary of Health and Human	2-Aug-04	5-Nov-09	25-Feb-10
1026	US20050051 497		Viral inactivation using ozone	KEYSER STEVEN A.	2-Aug-04	2-Aug-04	10-Mar-05
1027	US20060292 178	http://59.45.142.240:8808/pdf/US20060292178A1.pdf	Proteins encoded by the severe acute respiratory syndrome (SARS)	Agency for Science, Technology and	4-Aug-04	4-Aug-05	28-Dec-06
1028	US20070066 639	http://59.45.142.240:8808/pdf/US20070066639A1.pdf	Oxime substituted imidazoquinolines	AMOS DAVID T	12-Aug-04	12-Aug-04	22-Mar-07
1029	US20060177 837	http://59.45.142.240:8808/pdf/US20060177837A1.pdf	Systems and methods for identifying diagnostic indicators	BOROZAN IVAN	13-Aug-04	15-Aug-05	10-Aug-06
1030	US20060035 926	http://59.45.142.240:8808/pdf/US20060035926A1.pdf	Benzothiazolium compounds	LEE SHIOW-JU	13-Aug-04	15-Aug-05	16-Feb-06
1031	US7332294	http://59.45.142.240:8808/pdf/US7332294.pdf	CXCL10-based diagnosis and treatment of respiratory illnesses	University Health Network	17-Aug-04	17-Aug-04	19-Feb-08
1032	US8470769	http://59.45.142.240:8808/pdf/US8470769.pdf	Method of treatment of bacterial infection by administration of poly-	Novabiotics, Ltd.	18-Aug-04	30-Nov-11	25-Jun-13
1033	US20110021 415		ANTIMICROBIAL PEPTIDES	NOVABIOTICS LIMITED	18-Aug-04	29-Sep-10	27-Jan-11
1034	US20070244 044		Antimicrobial Peptides	NOVABIOTICS LIMITED	18-Aug-04	18-Aug-05	18-Oct-07
1035	US20060143 719	http://59.45.142.240:8808/pdf/US20060143719A1.pdf	Use of golden hamster as infectivity model of SARS	CONTAMIN HUGUES	18-Aug-04	16-Aug-05	29-Jun-06
1036	US20050080 093	http://59.45.142.240:8808/pdf/US20050080093A1.pdf	Methods of reducing risk of infection from pathogenic	HOPKINS SAMUEL E.	18-Aug-04	18-Aug-04	14-Apr-05
1037	US20100029 552	http://59.45.142.240:8808/pdf/US20100029552A1.pdf	Peptide inhibitors of c-jun dimerization and uses thereof	Phylogica Limited	20-Aug-04	22-Aug-05	4-Feb-10
1038	US20060110 405	http://59.45.142.240:8808/pdf/US20060110405A1.pdf	Plasma or serum fraction for treatment and prevention of viral	BUCKHEIT ROBERT W JR	20-Aug-04	22-Aug-05	25-May-06
1039	US20050048 465	http://59.45.142.240:8808/pdf/US20050048465A1.pdf	Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and	World Sense Technology Limited	20-Aug-04	20-Aug-04	3-Mar-05
1040	US20070166 281	http://59.45.142.240:8808/pdf/US20070166281A1.pdf	Chloroquine coupled antibodies and other proteins with methods for their	KOSAK KENNETH M	21-Aug-04	22-Feb-07	19-Jul-07
1041	US9566291	http://59.45.142.240:8808/pdf/US9566291.pdf	Nutritional composition comprising indigestible oligosaccharides	N.V. Nutricia	24-Aug-04	24-Aug-05	14-Feb-17
1042	US8722741	http://59.45.142.240:8808/pdf/US8722741.pdf	Biphenyloxyacetic acid derivatives for the treatment of respiratory	AstraZeneca AB	24-Aug-04	6-Dec-11	13-May-14
1043	US7737135	http://59.45.142.240:8808/pdf/US7737135.pdf	Biphenyloxyacetic acid derivatives for the treatment of respiratory	AstraZeneca AB	24-Aug-04	22-Aug-05	15-Jun-10
1044	US20140296 179	http://59.45.142.240:8808/pdf/US20140296179A1.pdf	NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS AND Oligosaccharides	N.V. NUTRICIA	24-Aug-04	5-Mar-14	2-Oct-14
1045	US20130102 560	http://59.45.142.240:8808/pdf/US20130102560A1.pdf	NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS AND Oligosaccharides	N.V. NUTRICIA	24-Aug-04	14-Sep-12	25-Apr-13
1046	US20100160 285	http://59.45.142.240:8808/pdf/US20100160285A1.pdf	Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory	BIRKINSHAW TIMOTHY NICHOLAS	24-Aug-04	18-Dec-09	24-Jun-10
1047	US20080132 480	http://59.45.142.240:8808/pdf/US20080132480A1.pdf	Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory	AstraZeneca AB	24-Aug-04	22-Aug-05	5-Jun-08
1048	US20080124 323	http://59.45.142.240:8808/pdf/US20080124323A1.pdf	Nutritional Composition Comprising Indigestible Oligosaccharides	N.V. Nutricia	24-Aug-04	24-Aug-05	29-May-08
1049	US20070274 983	http://59.45.142.240:8808/pdf/US20070274983A1.pdf	Nutritional Composition Comprising Immunoglobulins and	NUTRICIA NV	24-Aug-04	24-Aug-05	29-Nov-07
1050	US20050048 072	http://59.45.142.240:8808/pdf/US20050048072A1.pdf	Immunostimulatory combinations and treatments	3M Innovative Properties Company	25-Aug-04	25-Aug-04	3-Mar-05
1051	US20060035 327	http://59.45.142.240:8808/pdf/US20060035327A1.pdf	Recombinant super-compound interferon and uses thereof	WEI GUANGWEN	26-Aug-04	10-Mar-05	16-Feb-06
1052	US20080153 850	http://59.45.142.240:8808/pdf/US20080153850A1.pdf	Adamantyl Derivates as P2x7 Receptor Antagonists	AstraZeneca AB	30-Aug-04	29-Aug-05	26-Jun-08

1053	US20050053 990		Cleavage of RNA by restriction endonucleases	ROBERTS RICHARD J	31-Aug-04	31-Aug-04	10-Mar-05
1054	US20080069 836	http://59.45.142.240:8808/pdf/US20080069836A1.pdf	METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED IMMUNOGENICITY	and Human Services	1-Sep-04	26-Feb-07	20-Mar-08
1055	US7579359	http://59.45.142.240:8808/pdf/US7579359.pdf	1-alkoxy 1H-imidazo ring systems and methods	3M Innovative Properties Company	2-Sep-04	1-Sep-05	25-Aug-09
1056	US20090270 443	http://59.45.142.240:8808/pdf/US20090270443A1.pdf	1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS	Not Available	2-Sep-04	2-Sep-05	29-Oct-09
1057	US20090005 376	http://59.45.142.240:8808/pdf/US20090005376A1.pdf	1-Alkoxy 1H-Imidazo Ring Systems and Methods	3M Innovative Properties Company	2-Sep-04	1-Sep-05	1-Jan-09
1058	US20080044 437	http://59.45.142.240:8808/pdf/US20080044437A1.pdf	Encapsulation System for Production of Recombinant Virus-Like Particles	CHEN QUN	2-Sep-04	1-Sep-05	21-Feb-08
1059	US20060171 962		SARS vaccine	Consejo Superior de Investigaciones Científicas	3-Sep-04	2-Sep-05	3-Aug-06
1060	US20060165 723	http://59.45.142.240:8808/pdf/US20060165723A1.pdf	Nucleic acid sequences encoding proteins capable of associating into a	Fort Dodge Veterinaria S.A.	3-Sep-04	2-Sep-05	27-Jul-06
1061	US20050054 640	http://59.45.142.240:8808/pdf/US20050054640A1.pdf	1-Amino 1H-imidazoquinolines	GRIESGRABER GEORGE W	3-Sep-04	3-Sep-04	10-Mar-05
1062	US9358280	http://59.45.142.240:8808/pdf/US9358280.pdf	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9-Sep-04	11-Jan-13	7-Jun-16
1063	US9220768	http://59.45.142.240:8808/pdf/US9220768.pdf	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9-Sep-04	14-Oct-11	29-Dec-15
1064	US8460914	http://59.45.142.240:8808/pdf/US8460914.pdf	Decreasing potential iatrogenic risks associated with vaccines and vaccine	Novartis AG	9-Sep-04	10-Jan-13	11-Jun-13
1065	US20190078 060	http://59.45.142.240:8808/pdf/US20190078060A1.pdf	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9-Sep-04	8-Nov-18	14-Mar-19
1066	US20160251 631	http://59.45.142.240:8808/pdf/US20160251631A1.pdf	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9-Sep-04	9-May-16	1-Sep-16
1067	US20130129 782	http://59.45.142.240:8808/pdf/US20130129782A1.pdf	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	NOVARTIS AG	9-Sep-04	11-Jan-13	23-May-13
1068	US20130122 487	http://59.45.142.240:8808/pdf/US20130122487A1.pdf	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9-Sep-04	10-Jan-13	16-May-13
1069	US20090081 252	http://59.45.142.240:8808/pdf/US20090081252A1.pdf	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	CHIRON BEHRING GMBH & CO.	9-Sep-04	9-Sep-05	26-Mar-09
1070	US10155932	http://59.45.142.240:8808/pdf/US10155932.pdf	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9-Sep-04	9-May-16	18-Dec-18
1071	US20130096 103	http://59.45.142.240:8808/pdf/US20130096103A1.pdf	IMIDAZOQUINOLINE COMPOUNDS	NOVARTIS VACCINES & DIAGNOSTICS, INC.	14-Sep-04	19-Jun-12	18-Apr-13
1072	US20080213 308	http://59.45.142.240:8808/pdf/US20080213308A1.pdf	Imidazoquinoline Compounds	CHU DANIEL	14-Sep-04	14-Sep-05	4-Sep-08
1073	US8906872	http://59.45.142.240:8808/pdf/US8906872.pdf	Antisense antiviral compound and method for treating ssRNA viral	Sarepta Therapeutics, Inc.	16-Sep-04	22-Dec-11	9-Dec-14
1074	US20150267 202	http://59.45.142.240:8808/pdf/US20150267202A1.pdf	ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING	Not Available	16-Sep-04	6-Nov-14	24-Sep-15
1075	US20060269 911	http://59.45.142.240:8808/pdf/US20060269911A1.pdf	Antisense antiviral compound and method for treating ssRNA viral	AVI BIOPHARMA INC	16-Sep-04	10-May-06	30-Nov-06
1076	US20060063 150	http://59.45.142.240:8808/pdf/US20060063150A1.pdf	Antisense antiviral compound and method for treating ssRNA viral	IVERSEN PATRICK L	16-Sep-04	14-Sep-05	23-Mar-06
1077	US20060057 161		Detection of coronavirus infection	CHOU CHIH-MING	16-Sep-04	16-Sep-04	16-Mar-06
1078	US10479996	http://59.45.142.240:8808/pdf/US10479996.pdf	Antisense antiviral compound and method for treating ss/RNA viral	Sarepta Therapeutics, Inc.	16-Sep-04	6-Nov-14	19-Nov-19
1079	US20050059 072	http://59.45.142.240:8808/pdf/US20050059072A1.pdf	Selective modulation of TLR gene expression	3M Innovative Properties Company	17-Sep-04	17-Sep-04	17-Mar-05
1080	US8617838	http://59.45.142.240:8808/pdf/US8617838.pdf	Fluorescent proteins and related methods and compounds	University of Massachusetts	20-Sep-04	20-Sep-05	31-Dec-13
1081	US7829712	http://59.45.142.240:8808/pdf/US7829712.pdf	Pyridazine derivatives for inhibiting human stearyl-CoA desaturase	Xenon Pharmaceuticals	20-Sep-04	20-Sep-05	9-Nov-10
1082	US7777036	http://59.45.142.240:8808/pdf/US7777036.pdf	Heterocyclic derivatives and their use as therapeutic agents	Xenon Pharmaceuticals	20-Sep-04	20-Sep-05	17-Aug-10
1083	US7767677	http://59.45.142.240:8808/pdf/US7767677.pdf	Heterocyclic derivatives and their use as stearyl-CoA desaturase	Xenon Pharmaceuticals	20-Sep-04	20-Sep-05	3-Aug-10
1084	US7592343	http://59.45.142.240:8808/pdf/US7592343.pdf	Pyridazine-piperazine compounds and their use as stearyl-CoA	Xenon Pharmaceuticals	20-Sep-04	20-Sep-05	22-Sep-09
1085	US7547698	http://59.45.142.240:8808/pdf/US7547698.pdf	Bicyclic heterocyclic derivatives and their use as inhibitors of stearyl-CoA desaturase	Xenon Pharmaceuticals	20-Sep-04	20-Sep-05	16-Jun-09
1086	US20110009 414	http://59.45.142.240:8808/pdf/US20110009414A9.pdf	HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC	Xenon Pharmaceuticals	20-Sep-04	6-May-09	13-Jan-11
1087	US20090306 090		HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA	Xenon Pharmaceuticals	20-Sep-04	13-Aug-09	10-Dec-09
1088	US20080261 257	http://59.45.142.240:8808/pdf/US20080261257A1.pdf	Fluorescent Proteins and Related Methods and Compounds	UNIVERSITY OF MASSACHUSETTS	20-Sep-04	20-Sep-05	23-Oct-08
1089	US20080207 587	http://59.45.142.240:8808/pdf/US20080207587A1.pdf	Pyridazine Derivatives for Inhibiting Human Stearyl-CoA- Desaturase	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	28-Aug-08
1090	US20080188 488	http://59.45.142.240:8808/pdf/US20080188488A1.pdf	Heterocyclic Derivatives and Their Use as Stearyl-CoA Desaturase	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	7-Aug-08
1091	US20080167 321	http://59.45.142.240:8808/pdf/US20080167321A1.pdf	Pyridine Derivatives For Inhibiting Human Stearyl-CoA-Desaturase	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	10-Jul-08
1092	US20080125 434		Heterocyclic Derivatives and Their Use as Stearyl-CoA Desaturase	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	29-May-08
1093	US20080108 629	http://59.45.142.240:8808/pdf/US20080108629A1.pdf	Heterocyclic Derivatives for the Treatment of Diseases Mediated by	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	8-May-08
1094	US20080096 895	http://59.45.142.240:8808/pdf/US20080096895A1.pdf	Heterocyclic Derivatives and Their Use as Stearyl-CoA Desaturase	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	24-Apr-08
1095	US20080015 230	http://59.45.142.240:8808/pdf/US20080015230A1.pdf	HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	17-Jan-08
1096	US20070299 081	http://59.45.142.240:8808/pdf/US20070299081A1.pdf	Heterocyclic Derivatives and Their Use as Mediators of Stearyl-CoA	XENON PHARMACEUTICALS INC	20-Sep-04	20-Sep-05	27-Dec-07

1097	US20070219 211	http://59.45.142.240:8808/pdf/US20070219211A1.pdf	Bicyclic Heterocyclic Derivatives and Their Use as Inhibitors of Stearoyl-CoA Desaturase	XENON PHARMACEUTICALS, INC.	20-Sep-04	20-Sep-05	20-Sep-07
1098	US7740858	http://59.45.142.240:8808/pdf/US7740858.pdf	SARS-CoV-specific B-cell epitope and applications thereof	National Taiwan University	21-Sep-04	21-Sep-04	22-Jun-10
1099	US20060062 804	http://59.45.142.240:8808/pdf/US20060062804A1.pdf	SARS-CoV-specific B-cell epitope and applications thereof	National Taiwan University	21-Sep-04	21-Sep-04	23-Mar-06
1100	US20050208 060		Vaccine composition	Aventis Pasteur S.A.	22-Sep-04	15-Nov-04	22-Sep-05
1101	US9198927	http://59.45.142.240:8808/pdf/US9198927.pdf	Targeting opposite strand replication intermediates of single- stranded DNA virus	ALNYLAM PHARMACEUTICALS, INC.	24-Sep-04	1-Mar-10	1-Dec-15
1102	US20100267 805	http://59.45.142.240:8808/pdf/US20100267805A1.pdf	TARGETING OPPOSITE STRAND REPLICATION INTERMEDIATES OF SINGLE-STRANDED VIRUSES BY	ALNYLAM PHARMACEUTICALS, INC.	24-Sep-04	1-Mar-10	21-Oct-10
1103	US20100041 617	http://59.45.142.240:8808/pdf/US20100041617A1.pdf	Modulating mxa expression	CHUNG EUN J	27-Sep-04	27-Sep-05	18-Feb-10
1104	US20080131 465	http://59.45.142.240:8808/pdf/US20080131465A1.pdf	Group A Streptococcus Crge Protein	MANETTI ANDREA	27-Sep-04	27-Sep-05	5-Jun-08
1105	US20070266 957	http://59.45.142.240:8808/pdf/US20070266957A1.pdf	Antipathogenic Domestic Livestock House, Disinfectants for Domestic Livestock House, Disinfectants for Living Organisms, Feedstuffs and	TAKAHASHI KAZUO	28-Sep-04	25-Aug-05	22-Nov-07
1106	US8586770	http://59.45.142.240:8808/pdf/US8586770.pdf	Unsaturated steroid compounds	Harbor Therapeutics, Inc.	29-Sep-04	18-Feb-11	19-Nov-13
1107	US20070077 201	http://59.45.142.240:8808/pdf/US20070077201A1.pdf	Stem cell expansion and uses	DOWDING CHARLES	29-Sep-04	25-Mar-06	5-Apr-07
1108	US20070014 719	http://59.45.142.240:8808/pdf/US20070014719A1.pdf	Steroid analogs and characterization and treatment methods	DOWDING CHARLES	29-Sep-04	29-Sep-05	18-Jan-07
1109	US20060093 616	http://59.45.142.240:8808/pdf/US20060093616A1.pdf	Process for vaccinating eucaryotic hosts and for protecting against	ALTMAYER RALF	29-Sep-04	28-Sep-05	4-May-06
1110	US9084808	http://59.45.142.240:8808/pdf/US9084808.pdf	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	1-Oct-04	9-May-14	21-Jul-15
1111	US20150148 402	http://59.45.142.240:8808/pdf/US20150148402A1.pdf	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	NOVARTIS AG	1-Oct-04	9-May-14	28-May-15
1112	US20080269 148		Modified Small Interfering Rna Molecules and Methods of Use	HAN JANG	1-Oct-04	30-Sep-05	30-Oct-08
1113	US20070249 686		Modulators of Crtn-2 Receptor Activity for the Treatment of	ASTRAZENECA AB	5-Oct-04	3-Oct-05	25-Oct-07
1114	US8846051	http://59.45.142.240:8808/pdf/US8846051.pdf	Modulation of replicative fitness by deoptimization of synonymous codons	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers	8-Oct-04	7-Oct-05	30-Sep-14
1115	US20180264 098	http://59.45.142.240:8808/pdf/US20180264098A1.pdf	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	The Government of the USA as represented by the Secretary of the Dept. of Health and	8-Oct-04	31-May-18	20-Sep-18
1116	US20170354 727	http://59.45.142.240:8808/pdf/US20170354727A1.pdf	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	Not Available	8-Oct-04	23-Aug-17	14-Dec-17
1117	US20140356 390	http://59.45.142.240:8808/pdf/US20140356390A1.pdf	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	The Government of the United States of America as represented by the Secretary of the	8-Oct-04	20-Aug-14	4-Dec-14
1118	US20090214 587		Recombinant virus and use thereof	Post Genome Institute Co., Ltd.	8-Oct-04	11-Oct-05	27-Aug-09
1119	US20090130 146		COMBINATION VACCINE	CHIRON BEHRING GMBH & CO. KG	8-Oct-04	7-Oct-05	21-May-09
1120	US20090117 113	http://59.45.142.240:8808/pdf/US20090117113A1.pdf	Immunogenic And Therapeutic Compositions For Streptococcus	Chiron Corporation	8-Oct-04	11-Oct-05	7-May-09
1121	US20080118 530	http://59.45.142.240:8808/pdf/US20080118530A1.pdf	Modulation of Replicative Fitness By Deoptimization of Synonymous	BURNS CARA C	8-Oct-04	7-Oct-05	22-May-08
1122	US7723570	http://59.45.142.240:8808/pdf/US7723570.pdf	Edible vaccines expressed in soybeans	SoyMeds, Inc.	12-Oct-04	12-Oct-05	25-May-10
1123	US20070192 905	http://59.45.142.240:8808/pdf/US20070192905A1.pdf	Edible vaccines expressed in soybeans	The University of North Carolina	12-Oct-04	12-Oct-05	16-Aug-07
1124	US10030250	http://59.45.142.240:8808/pdf/US10030250.pdf	Edible vaccines expressed in soybeans	Not Available	12-Oct-04	25-Jan-10	24-Jul-18
1125	US20080003 236	http://59.45.142.240:8808/pdf/US20080003236A1.pdf	ADENOVIRUS FIBER SHAFT COMPOSITION AND METHODS OF	GenVec, Inc.	18-Oct-04	13-Apr-07	3-Jan-08
1126	US20070253 860	http://59.45.142.240:8808/pdf/US20070253860A1.pdf	Process and device for sterilising ambient air	SCHRODER WERNER	18-Oct-04	18-Apr-07	1-Nov-07
1127	US8598134	http://59.45.142.240:8808/pdf/US8598134.pdf	RNAi modulation of RSV, PIV and other respiratory viruses and uses	South Alabama Medical Science Foundation	22-Oct-04	23-Jul-10	3-Dec-13
1128	US7790878	http://59.45.142.240:8808/pdf/US7790878.pdf	RNAi modulation of RSV, PIV and other respiratory viruses and uses	Alnylam Pharmaceuticals,	22-Oct-04	25-Jun-09	7-Sep-10
1129	US7592322	http://59.45.142.240:8808/pdf/US7592322.pdf	RNAi modulation of RSV, PIV and other respiratory viruses and uses	Alnylam Pharmaceuticals,	22-Oct-04	14-Jun-05	22-Sep-09
1130	US20110021 606	http://59.45.142.240:8808/pdf/US20110021606A1.pdf	RNAi Modulation of RSV, PIV and Other Respiratory Viruses and Uses	SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION	22-Oct-04	23-Jul-10	27-Jan-11
1131	US20100144 833	http://59.45.142.240:8808/pdf/US20100144833A1.pdf	RNAi Modulation Of RSV, PIV And Other Respiratory Viruses And Uses	BARIK SAILEN	22-Oct-04	25-Jun-09	10-Jun-10
1132	US20060089 324	http://59.45.142.240:8808/pdf/US20060089324A1.pdf	RNAi modulation of RSV, PIV and other respiratory viruses and uses	BARIK SAILEN	22-Oct-04	14-Jun-05	27-Apr-06
1133	US20060089 323	http://59.45.142.240:8808/pdf/US20060089323A1.pdf	RNAi modulation of RSV, PIV and other respiratory viruses and uses	BARIK SAILEN	22-Oct-04	14-Jun-05	27-Apr-06
1134	US20080118 495		Mammalian Genes Involved in Infection	RUBIN DONALD H	27-Oct-04	27-Oct-05	22-May-08
1135	US20060121 043	http://59.45.142.240:8808/pdf/US20060121043A1.pdf	Use of modulators of EphA2 and EphrinA1 for the treatment and	MEDIMMUNE, INC.	27-Oct-04	27-Oct-05	8-Jun-06
1136	US9809796	http://59.45.142.240:8808/pdf/US9809796.pdf	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	18-May-17	7-Nov-17

1137	US9714411	http://59.45.142.240:8808/pdf/US9714411.pdf	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	30-Nov-15	25-Jul-17
1138	US9222075	http://59.45.142.240:8808/pdf/US9222075.pdf	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	2-May-14	29-Dec-15
1139	US8748156	http://59.45.142.240:8808/pdf/US8748156.pdf	Animal protein-free media for cultivation of cells	Baxter Healthcare SA	29-Oct-04	16-Apr-13	10-Jun-14
1140	US8440408	http://59.45.142.240:8808/pdf/US8440408.pdf	Animal protein-free media for cultivation of cells	Baxter Healthcare SA	29-Oct-04	10-Dec-10	14-May-13
1141	US20190078 051	http://59.45.142.240:8808/pdf/US20190078051A1.pdf	Animal Protein-Free Media for Cultivation of Cells	Baxalta GmbH	29-Oct-04	29-Oct-18	14-Mar-19
1142	US20180023 048	http://59.45.142.240:8808/pdf/US20180023048A1.pdf	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Not Available	29-Oct-04	22-Sep-17	25-Jan-18
1143	US20170267 969	http://59.45.142.240:8808/pdf/US20170267969A1.pdf	Animal Protein-Free Media for Cultivation of Cells	Baxalta GmbH	29-Oct-04	18-May-17	21-Sep-17
1144	US20160083 689	http://59.45.142.240:8808/pdf/US20160083689A1.pdf	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Not Available	29-Oct-04	30-Nov-15	24-Mar-16
1145	US20150104 867	http://59.45.142.240:8808/pdf/US20150104867A1.pdf	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Baxter Healthcare SA	29-Oct-04	2-May-14	16-Apr-15
1146	US20130230 919	http://59.45.142.240:8808/pdf/US20130230919A1.pdf	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Baxter Healthcare SA	29-Oct-04	16-Apr-13	5-Sep-13
1147	US20080305 119	http://59.45.142.240:8808/pdf/US20080305119A1.pdf	Modified Bacteriophage Vectors and Uses Thereof	UNIVERSITY OF ROCHESTER	29-Oct-04	5-Oct-05	11-Dec-08
1148	US20080064 105	http://59.45.142.240:8808/pdf/US20080064105A1.pdf	Animal protein-free media for cultivation of cells	Baxter Healthcare Corporation	29-Oct-04	30-Oct-07	13-Mar-08
1149	US20080064 080	http://59.45.142.240:8808/pdf/US20080064080A1.pdf	Animal protein-free media for cultivation of cells	Baxter Healthcare Corporation	29-Oct-04	30-Oct-07	13-Mar-08
1150	US20080009 040	http://59.45.142.240:8808/pdf/US20080009040A1.pdf	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Baxter Healthcare Corporation	29-Oct-04	20-Sep-07	10-Jan-08
1151	US20060094 104	http://59.45.142.240:8808/pdf/US20060094104A1.pdf	Animal protein-free media for cultivation of cells	DORNER FRIEDRICH	29-Oct-04	29-Oct-04	4-May-06
1152	US10655099	http://59.45.142.240:8808/pdf/US10655099.pdf	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	29-Oct-18	19-May-20
1153	US10138461	http://59.45.142.240:8808/pdf/US10138461.pdf	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	22-Sep-17	27-Nov-18
1154	US20100015 211	http://59.45.142.240:8808/pdf/US20100015211A1.pdf	Combination Approaches For Generating Immune Responses	BARNETT SUSAN W	1-Nov-04	1-Nov-05	21-Jan-10
1155	US8691781	http://59.45.142.240:8808/pdf/US8691781.pdf	Compositions for treating respiratory viral infections and their use	Sirnaomics, Inc.	5-Nov-04	4-Nov-05	8-Apr-14
1156	US20080279 920	http://59.45.142.240:8808/pdf/US20080279920A1.pdf	Compositions For Treating Respiratory Viral Infections and	Intradigm Corporation	5-Nov-04	4-Nov-05	13-Nov-08
1157	US20080020 379	http://59.45.142.240:8808/pdf/US20080020379A1.pdf	Diagnosis and prognosis of infectious diseases clinical phenotypes and other physiologic states using host	AGAN BRIAN K	5-Nov-04	7-Nov-05	24-Jan-08
1158	US20080132 502	http://59.45.142.240:8808/pdf/US20080132502A1.pdf	5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors	ARNOULD JEAN-CLAUDE	9-Nov-04	7-Nov-05	5-Jun-08
1159	US7183300	http://59.45.142.240:8808/pdf/US7183300.pdf	Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl	AGARWAL ATUL	11-Nov-04	10-Nov-05	27-Feb-07
1160	US20080014 204	http://59.45.142.240:8808/pdf/US20080014204A1.pdf	Compositions Against Sars-Coronavirus and Uses Thereof	DE KRUIF CORNELIS A	11-Nov-04	10-Nov-05	17-Jan-08
1161	US20060100 232	http://59.45.142.240:8808/pdf/US20060100232A1.pdf	Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl	AGARWAL ATUL	11-Nov-04	10-Nov-05	11-May-06
1162	US20080113 337	http://59.45.142.240:8808/pdf/US20080113337A1.pdf	Method of Examining/Judging Presence of Virus Infection such as HIV or Presence of Prion Infection by Near-Infrared Spectroscopy and	OSAKA UNIVERSITY	12-Nov-04	10-Nov-05	15-May-08
1163	US20080227 219		Electrochemiluminescent assay	Not Available	17-Nov-04	16-Nov-05	18-Sep-08
1164	US9629907	http://59.45.142.240:8808/pdf/US9629907.pdf	Compositions for and methods of inducing mucosal immune responses	The Trustees of the University of	19-Nov-04	28-Oct-11	25-Apr-17
1165	US20080274 140	http://59.45.142.240:8808/pdf/US20080274140A1.pdf	Vaccines and Methods for Using the Same	KUTZLER MICHELE	19-Nov-04	18-Nov-05	6-Nov-08
1166	US7491489	http://59.45.142.240:8808/pdf/US7491489.pdf	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use	The University of Hong Knog	22-Nov-04	28-Oct-05	17-Feb-09
1167	US20070212 677	http://59.45.142.240:8808/pdf/US20070212677A1.pdf	Identifying off-target effects and hidden phenotypes of drugs in	Odyssey Thera, Inc.	22-Nov-04	31-Aug-06	13-Sep-07
1168	US20060160 109	http://59.45.142.240:8808/pdf/US20060160109A1.pdf	Harnessing network biology to improve drug discovery	Odyssey Thera, Inc.	22-Nov-04	21-Nov-05	20-Jul-06
1169	US20060110 758	http://59.45.142.240:8808/pdf/US20060110758A1.pdf	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use	UNIV HONG KONG	22-Nov-04	28-Oct-05	25-May-06
1170	US8524715	http://59.45.142.240:8808/pdf/US8524715.pdf	Phenoxyacetic acid derivatives useful for treating respiratory	Astrazeneca AB	23-Nov-04	22-Nov-05	3-Sep-13
1171	US20090149 448	http://59.45.142.240:8808/pdf/US20090149448A1.pdf	Phenoxyacetic Acid Derivatives Useful for Treating Respiratory	ASTRAZENECA AB	23-Nov-04	22-Nov-05	11-Jun-09
1172	US20080182 874		Novel Compounds	ASTRAZENECA AB	30-Nov-04	28-Nov-05	31-Jul-08
1173	US20060122 368		Antigen delivery platform	GOVERNMENT OF THE U.S.A. AS REP	3-Dec-04	2-Dec-05	8-Jun-06
1174	US9580429	http://59.45.142.240:8808/pdf/US9580429.pdf	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6-Dec-04	15-Sep-14	28-Feb-17
1175	US9115065	http://59.45.142.240:8808/pdf/US9115065.pdf	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with	Kineta, Inc.	6-Dec-04	26-Feb-13	25-Aug-15
1176	US9067873	http://59.45.142.240:8808/pdf/US9067873.pdf	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with	Kineta Four, LLC	6-Dec-04	19-Dec-13	30-Jun-15
1177	US8859568	http://59.45.142.240:8808/pdf/US8859568.pdf	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	Astrazeneca AB	6-Dec-04	3-Nov-10	14-Oct-14
1178	US8664274	http://59.45.142.240:8808/pdf/US8664274.pdf	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena	Siga Technologies, Inc.	6-Dec-04	6-Jul-11	4-Mar-14

1179	US8658697	http://59.45.142.240:8808/pdf/US8658697.pdf	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with	Siga Technologies, Inc.	6-Dec-04	26-Oct-10	25-Feb-14
1180	US8642596	http://59.45.142.240:8808/pdf/US8642596.pdf	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with	Siga Technologies, Inc.	6-Dec-04	6-Dec-05	4-Feb-14
1181	US8410149	http://59.45.142.240:8808/pdf/US8410149.pdf	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with	Siga Technologies Inc.	6-Dec-04	28-Oct-10	2-Apr-13
1182	US7829707	http://59.45.142.240:8808/pdf/US7829707.pdf	Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6-Dec-04	5-Dec-05	9-Nov-10
1183	US20150099 769	http://59.45.142.240:8808/pdf/US20150099769A1.pdf	PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN	Not Available	6-Dec-04	15-Sep-14	9-Apr-15
1184	US20140275 037	http://59.45.142.240:8808/pdf/US20140275037A1.pdf	SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS	Siga Technologies, Inc.	6-Dec-04	19-Dec-13	18-Sep-14
1185	US20130261 087	http://59.45.142.240:8808/pdf/US20130261087A1.pdf	SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS	SIGA TECHNOLOGIES INC.	6-Dec-04	6-Jul-11	3-Oct-13
1186	US20100256 096	http://59.45.142.240:8808/pdf/US20100256096A1.pdf	Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with	BAILEY THOMAS R	6-Dec-04	17-Jan-07	7-Oct-10
1187	US20090203 675	http://59.45.142.240:8808/pdf/US20090203675A1.pdf	Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with	SIGA TECHNOLOGIES, INC.	6-Dec-04	6-Dec-05	13-Aug-09
1188	US20060123 499	http://59.45.142.240:8808/pdf/US20060123499A1.pdf	Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and	CHEN JINDING	6-Dec-04	6-Dec-04	8-Jun-06
1189	US20110070 575	http://59.45.142.240:8808/pdf/US20110070575A1.pdf	Immunomodulatory Compositions, Combinations and Methods	Coley Pharmaceutical	8-Dec-04	8-Dec-05	24-Mar-11
1190	US20100113 565	http://59.45.142.240:8808/pdf/US20100113565A1.pdf	IMMUNOSTIMULATORY COMBINATIONS AND METHODS	Not Available	8-Dec-04	8-Dec-05	6-May-10
1191	US20100015 594	http://59.45.142.240:8808/pdf/US20100015594A1.pdf	HUMAN PAPILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL	GOULD TOBY	10-Dec-04	9-Dec-05	21-Jan-10
1192	US20080311 138	http://59.45.142.240:8808/pdf/US20080311138A1.pdf	Adjuvant Activity of Gastrointestinal Peptides	Not Available	13-Dec-04	13-Dec-05	18-Dec-08
1193	US20060270 041	http://59.45.142.240:8808/pdf/US20060270041A1.pdf	Cell lines for production of replication-defective adenovirus	HOWE JOHN A	13-Dec-04	12-Dec-05	30-Nov-06
1194	US20060128 628	http://59.45.142.240:8808/pdf/US20060128628A1.pdf	Human tissue antigen-binding peptides and their amino acid	CHEN SHOW-LI	15-Dec-04	15-Dec-04	15-Jun-06
1195	US20060275 841	http://59.45.142.240:8808/pdf/US20060275841A1.pdf	Assay method and apparatus with reduced sample matrix effects	BLANKFARD MARTIN	20-Dec-04	19-Dec-05	7-Dec-06
1196	US20060177 849	http://59.45.142.240:8808/pdf/US20060177849A1.pdf	Nucleic acid primer set, nucleic acid probe set and method for detecting respiratory disease virus using the	HUH NAM	23-Dec-04	23-Dec-05	10-Aug-06
1197	US20050277 181	http://59.45.142.240:8808/pdf/US20050277181A1.pdf	Compositions and methods for detecting pathogen infection	BERTHET FRANCOIS X	23-Dec-04	27-Apr-05	15-Dec-05
1198	US8710224	http://59.45.142.240:8808/pdf/US8710224.pdf	Heterocyclic compounds as CCR2B antagonists	AstraZeneca AB	24-Dec-04	13-Sep-13	29-Apr-14
1199	US20150165 019	http://59.45.142.240:8808/pdf/US20150165019A1.pdf	Saccharide Conjugate Vaccines	Not Available	24-Dec-04	5-Aug-14	18-Jun-15
1200	US20140038 978	http://59.45.142.240:8808/pdf/US20140038978A1.pdf	HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS	AstraZeneca AB	24-Dec-04	13-Sep-13	6-Feb-14
1201	US20090099 156	http://59.45.142.240:8808/pdf/US20090099156A1.pdf	Heterocyclic Compounds as Ccr2b antagonists	BOWER JUSTIN FAIRFIELD	24-Dec-04	19-Dec-05	16-Apr-09
1202	US20080260 773	http://59.45.142.240:8808/pdf/US20080260773A1.pdf	Saccharide Conjugate Vaccines	Not Available	24-Dec-04	23-Dec-05	23-Oct-08
1203	US8546383	http://59.45.142.240:8808/pdf/US8546383.pdf	Chiral fused [1,2]imidazo[4,5-c] ring compounds	3M Innovative Properties Company	30-Dec-04	25-May-12	1-Oct-13
1204	US20110021 554	http://59.45.142.240:8808/pdf/US20110021554A1.pdf	IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS	GUY CYNTHIA A	30-Dec-04	29-Sep-10	27-Jan-11
1205	US20100021 987		Compositions, Methods, and Kits for Enhancing Protein Expression	LIFESENSORS, INC.	30-Dec-04	30-Dec-05	28-Jan-10
1206	US20090124 652	http://59.45.142.240:8808/pdf/US20090124652A1.pdf	Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine	Takeda Pharmaceutical Company Limited	30-Dec-04	28-Dec-05	14-May-09
1207	US20080269 192	http://59.45.142.240:8808/pdf/US20080269192A1.pdf	Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds	Coley Pharmaceutical	30-Dec-04	29-Dec-05	30-Oct-08
1208	US20080207 674	http://59.45.142.240:8808/pdf/US20080207674A1.pdf	Immune Response Modifier Formulations And Methods	Coley Pharmaceutical	30-Dec-04	28-Dec-05	28-Aug-08
1209	US20080188 513	http://59.45.142.240:8808/pdf/US20080188513A1.pdf	1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine	taked Pharmaceutical Company Limited	30-Dec-04	28-Dec-05	7-Aug-08

1210	US20080085 895	http://59.45.142.240:8808/pdf/US20080085895A1.pdf	Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring	DANIELSON MICHAEL M	30-Dec-04	29-Dec-05	10-Apr-08
1211	US20130251 590	http://59.45.142.240:8808/pdf/US20130251590A1.pdf	Peracid/Peroxide Composition, Process for Accurately Making the Same, and Method for Use as an Evaporating Film Anti-Microbial	BioMed Protect ,LLC	11-Jan-05	21-Sep-09	26-Sep-13
1212	US20070066 552	http://59.45.142.240:8808/pdf/US20070066552A1.pdf	Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic	INTROGEN THERAPEUTICS INC	21-Jan-05	20-Jan-06	22-Mar-07
1213	US8956616	http://59.45.142.240:8808/pdf/US8956616.pdf	Constructs binding to phosphatidylserine and their use in	Board of Regents, The University of	24-Jan-05	24-Jan-06	17-Feb-15
1214	US20160311 886	http://59.45.142.240:8808/pdf/US20160311886A1.pdf	Constructs Binding to Phosphatidylserine and Their Use in	Not Available	24-Jan-05	12-Jul-16	27-Oct-16
1215	US20160015 826	http://59.45.142.240:8808/pdf/US20160015826A1.pdf	Constructs Binding to Phosphatidylserine and Their Use in	Not Available	24-Jan-05	2-Feb-15	21-Jan-16
1216	US20060228 299	http://59.45.142.240:8808/pdf/US20060228299A1.pdf	Constructs binding to phosphatidylserine and their use in	PEREGRINE PHARMACEUTICALS	24-Jan-05	24-Jan-06	12-Oct-06
1217	US20080146 612	http://59.45.142.240:8808/pdf/US20080146612A1.pdf	Novel Biomimetic Compounds, Inhibitors of the P2Y7 Receptor	ASTRAZENECA AB	27-Jan-05	25-Jan-06	19-Jun-08
1218	US8697140	http://59.45.142.240:8808/pdf/US8697140.pdf	Virucidal disinfectant	B. Braun Medical AG	28-Jan-05	28-May-09	15-Apr-14
1219	US20090252 775	http://59.45.142.240:8808/pdf/US20090252775A1.pdf	VIRUCIDAL DISINFECTANT	B. BRAUN MEDICAL AG	28-Jan-05	28-May-09	8-Oct-09
1220	US20090232 808	http://59.45.142.240:8808/pdf/US20090232808A1.pdf	MOLECULES AND CHIMERIC MOLECULES THEREOF	APOLLO LIFE SCIENCES LIMITED	28-Jan-05	27-Jan-06	17-Sep-09
1221	US20090035 861	http://59.45.142.240:8808/pdf/US20090035861A1.pdf	RNAi Medicine Having No Adverse Effects	GONDAI TAKUMA	28-Jan-05	27-Jan-06	5-Feb-09
1222	US20060193 745	http://59.45.142.240:8808/pdf/US20060193745A1.pdf	Virucidal disinfectant	ARNDT ANDREAS	28-Jan-05	27-Jan-06	31-Aug-06
1223	US20100221 349	http://59.45.142.240:8808/pdf/US20100221349A1.pdf	NUCLEIC ACID CONSTRUCTS	Powderject Vaccines, Inc	1-Feb-05	1-Feb-06	2-Sep-10
1224	US20080233 558	http://59.45.142.240:8808/pdf/US20080233558A1.pdf	Inhibitors of viral entry screening method	Medical Research Council	1-Feb-05	1-Aug-07	25-Sep-08
1225	US20180057 509	http://59.45.142.240:8808/pdf/US20180057509A1.pdf	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND	Not Available	9-Feb-05	2-Nov-17	1-Mar-18
1226	US20170088 559	http://59.45.142.240:8808/pdf/US20170088559A1.pdf	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND	Not Available	9-Feb-05	12-Dec-16	30-Mar-17
1227	US20150266 901	http://59.45.142.240:8808/pdf/US20150266901A1.pdf	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND	Not Available	9-Feb-05	8-Jun-15	24-Sep-15
1228	US20100240 693	http://59.45.142.240:8808/pdf/US20100240693A1.pdf	Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring	Coley Pharmaceutical	9-Feb-05	8-Feb-06	23-Sep-10
1229	US20080318 998	http://59.45.142.240:8808/pdf/US20080318998A1.pdf	Alkyloxy Substituted Thiazoloquinolines and	COLEY PHARMACEUTICAL	9-Feb-05	8-Feb-06	25-Dec-08
1230	US8658666	http://59.45.142.240:8808/pdf/US8658666.pdf	Substituted imidazoquinolines and imidazopyridines	3M Innovative Properties Company	11-Feb-05	10-Feb-06	25-Feb-14
1231	US20100069 427	http://59.45.142.240:8808/pdf/US20100069427A9.pdf	Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring	COLEY PHARMACEUTICAL	11-Feb-05	10-Feb-06	18-Mar-10
1232	US20090099 161	http://59.45.142.240:8808/pdf/US20090099161A1.pdf	Substituted Imidazoquinolines and Imidazopyridines	Coley Pharmaceutical Group, Inc	11-Feb-05	10-Feb-06	16-Apr-09
1233	US20090062 328	http://59.45.142.240:8808/pdf/US20090062328A1.pdf	Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring	COLEY PHARMACEUTICAL	11-Feb-05	10-Feb-06	5-Mar-09
1234	US20090005 371	http://59.45.142.240:8808/pdf/US20090005371A1.pdf	Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods	HEPPNER PHILIP D	11-Feb-05	10-Feb-06	1-Jan-09
1235	US7745147	http://59.45.142.240:8808/pdf/US7745147.pdf	Methods and uses of antibodies in the purification of interferon	ViraNative AB	12-Feb-05	13-Feb-06	29-Jun-10
1236	US20080319 170	http://59.45.142.240:8808/pdf/US20080319170A1.pdf	Methods and Uses of Antibodies in the Purification of Interferon	ViraNative AB	12-Feb-05	13-Feb-06	25-Dec-08
1237	US8486420	http://59.45.142.240:8808/pdf/US8486420.pdf	Live virus vaccines	Children's Hospital, Inc	15-Feb-05	15-Feb-06	16-Jul-13
1238	US20080260 775		New Live Virus Vaccines	JOHNSON PHILIP R	15-Feb-05	15-Feb-06	23-Oct-08
1239	US9572823	http://59.45.142.240:8808/pdf/US9572823.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	5-Apr-16	21-Feb-17
1240	US9566290	http://59.45.142.240:8808/pdf/US9566290.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	20-Apr-16	14-Feb-17
1241	US9566289	http://59.45.142.240:8808/pdf/US9566289.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	17-Feb-16	14-Feb-17
1242	US9549938	http://59.45.142.240:8808/pdf/US9549938.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	11-Mar-16	24-Jan-17
1243	US9353133	http://59.45.142.240:8808/pdf/US9353133.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	7-Mar-14	31-May-16
1244	US8889656	http://59.45.142.240:8808/pdf/US8889656.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	30-Apr-13	18-Nov-14
1245	US8722917	http://59.45.142.240:8808/pdf/US8722917.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	23-Jan-12	13-May-14
1246	US8440642	http://59.45.142.240:8808/pdf/US8440642.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	1-Sep-11	14-May-13
1247	US7767657	http://59.45.142.240:8808/pdf/US7767657.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	16-Aug-06	3-Aug-10
1248	US7582621	http://59.45.142.240:8808/pdf/US7582621.pdf	Boron-containing small molecules	Anacor Pharmaceuticals,	16-Feb-05	16-Feb-06	1-Sep-09
1249	US20190330 245	http://59.45.142.240:8808/pdf/US20190330245A1.pdf	Boron-Containing Small Molecules	Anacor Pharmaceuticals,	16-Feb-05	12-Jul-19	31-Oct-19
1250	US20190048 026	http://59.45.142.240:8808/pdf/US20190048026A1.pdf	Boron-Containing Small Molecules	Anacor Pharmaceuticals,	16-Feb-05	18-Oct-18	14-Feb-19
1251	US20170066 788	http://59.45.142.240:8808/pdf/US20170066788A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	18-Nov-16	9-Mar-17
1252	US20170066 787	http://59.45.142.240:8808/pdf/US20170066787A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	18-Nov-16	9-Mar-17
1253	US20160228 463	http://59.45.142.240:8808/pdf/US20160228463A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	20-Apr-16	11-Aug-16

1254	US20160206 638	http://59.45.142.240:8808/pdf/US20160206638A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	5-Apr-16	21-Jul-16
1255	US20160184 334	http://59.45.142.240:8808/pdf/US20160184334A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	11-Mar-16	30-Jun-16
1256	US20160151 399	http://59.45.142.240:8808/pdf/US20160151399A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	17-Feb-16	2-Jun-16
1257	US20160108 063	http://59.45.142.240:8808/pdf/US20160108063A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	21-Dec-15	21-Apr-16
1258	US20150119 364	http://59.45.142.240:8808/pdf/US20150119364A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	10-Nov-14	30-Apr-15
1259	US20150065 459	http://59.45.142.240:8808/pdf/US20150065459A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	10-Nov-14	5-Mar-15
1260	US20140142 064	http://59.45.142.240:8808/pdf/US20140142064A1.pdf	BORON-CONTAINING SMALL MOLECULES	ANACOR PHARMACEUTICALS, INC.	16-Feb-05	27-Jan-14	22-May-14
1261	US20130244 980	http://59.45.142.240:8808/pdf/US20130244980A1.pdf	BORON-CONTAINING SMALL MOLECULES	ANACOR PHARMACEUTICALS, INC.	16-Feb-05	30-Apr-13	19-Sep-13
1262	US20130210 770		PHARMACEUTICAL FORMULATIONS	Anacor Pharmaceuticals, Inc.	16-Feb-05	12-Apr-13	15-Aug-13
1263	US20130059 803	http://59.45.142.240:8808/pdf/US20130059803A1.pdf	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	7-Sep-12	7-Mar-13
1264	US20130059 802	http://59.45.142.240:8808/pdf/US20130059802A1.pdf	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	7-Sep-12	7-Mar-13
1265	US20100267 981	http://59.45.142.240:8808/pdf/US20100267981A1.pdf	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	2-Dec-09	21-Oct-10
1266	US20100190 748	http://59.45.142.240:8808/pdf/US20100190748A1.pdf	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	21-Jul-09	29-Jul-10
1267	US20060234 981	http://59.45.142.240:8808/pdf/US20060234981A1.pdf	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	16-Feb-06	19-Oct-06
1268	US20080171 066	http://59.45.142.240:8808/pdf/US20080171066A1.pdf	Listeriolysin-Containing Bacillus Spores as Antigen Delivery Agents	CUTTING SIMON	19-Feb-05	20-Feb-06	17-Jul-08
1269	US9435000	http://59.45.142.240:8808/pdf/US9435000.pdf	Primate T-lymphotropic viruses	Johns Hopkins University	21-Feb-05	20-Sep-13	6-Sep-16
1270	US8541221	http://59.45.142.240:8808/pdf/US8541221.pdf	Primate T-lymphotropic viruses	Johns Hopkins University	21-Feb-05	1-Jul-10	24-Sep-13
1271	US7794998	http://59.45.142.240:8808/pdf/US7794998.pdf	Primate T-lymphotropic viruses	Johns Hopkins University	21-Feb-05	24-Feb-07	14-Sep-10
1272	US20140080 121	http://59.45.142.240:8808/pdf/US20140080121A1.pdf	PRIMATE T-LYMPHOTROPIC VIRUSES	Johns Hopkins University	21-Feb-05	20-Sep-13	20-Mar-14
1273	US20100317 034	http://59.45.142.240:8808/pdf/US20100317034A1.pdf	PRIMATE T-LYMPHOTROPIC VIRUSES	and Johns Hopkins University	21-Feb-05	1-Jul-10	16-Dec-10
1274	US20100186 680	http://59.45.142.240:8808/pdf/US20100186680A1.pdf	LIVESTOCK STERILIZING METHOD, LIVESTOCK STERILIZING APPARATUS, AND LIVESTOCK OR	HAGIWARA NOBUKO	21-Feb-05	21-Feb-06	29-Jul-10
1275	US20080292 657		PRIMATE T-LYMPHOTROPIC VIRUSES	Centers for Disease Control and Prevention	21-Feb-05	24-Feb-07	27-Nov-08
1276	US8846710	http://59.45.142.240:8808/pdf/US8846710.pdf	Method of preferentially inducing the biogenesis of interferon	3M Innovative Properties Company	23-Feb-05	22-Feb-06	30-Sep-14
1277	US20090253 695	http://59.45.142.240:8808/pdf/US20090253695A1.pdf	Hydroxyalkyl Substituted Imidazonaphthyridines	Coley Pharmaceutical	23-Feb-05	22-Feb-06	8-Oct-09
1278	US20090069 314	http://59.45.142.240:8808/pdf/US20090069314A1.pdf	Hydroxyalkyl Substituted Imidazoquinoline Compounds and	Coley Pharmaceutical	23-Feb-05	22-Feb-06	12-Mar-09
1279	US8735410	http://59.45.142.240:8808/pdf/US8735410.pdf	Quinazoline derivatives as tyrosine kinase inhibitors	AstraZeneca AB	26-Feb-05	24-Feb-06	27-May-14
1280	US20130143 203	http://59.45.142.240:8808/pdf/US20130143203A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS VIRUSES	IBIS BIOSCIENCES, INC.	3-Mar-05	21-May-12	6-Jun-13
1281	US20090220 937	http://59.45.142.240:8808/pdf/US20090220937A1.pdf	Compositions for Use in Identification of Adventitious Viruses	IBIS BIOSCIENCES, INC.	3-Mar-05	3-Mar-06	3-Sep-09
1282	US20060205 040	http://59.45.142.240:8808/pdf/US20060205040A1.pdf	Compositions for use in identification of adventitious viruses	SAMPATH RANGAPATAN	3-Mar-05	3-Mar-06	14-Sep-06
1283	US20070185 044		Modulation of ace2 expression	BENNETT C F	8-Mar-05	8-Mar-05	9-Aug-07
1284	US20080124 302	http://59.45.142.240:8808/pdf/US20080124302A1.pdf	Uses of Recombinant Super-Compound Interferons	WEI GUANGWEN	9-Mar-05	9-Mar-06	29-May-08
1285	US9726607	http://59.45.142.240:8808/pdf/US9726607.pdf	Systems and methods for detecting multiple optical signals	GEN-PROBE INCORPORATED	10-Mar-05	3-Mar-14	8-Aug-17
1286	US9372156	http://59.45.142.240:8808/pdf/US9372156.pdf	System for processing contents of a receptacle to detect an optical signal	GEN-PROBE INCORPORATED	10-Mar-05	22-Feb-11	21-Jun-16
1287	US8663922	http://59.45.142.240:8808/pdf/US8663922.pdf	Systems and methods for detecting multiple optical signals	Gen-Probe Incorporated	10-Mar-05	1-Jun-10	4-Mar-14
1288	US8615368	http://59.45.142.240:8808/pdf/US8615368.pdf	Method for determining the amount of an analyte in a sample	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	24-Dec-13
1289	US8501461	http://59.45.142.240:8808/pdf/US8501461.pdf	System for performing multi-formatted assays	Gen-Probe Incorporated	10-Mar-05	3-Dec-09	6-Aug-13
1290	US7794659	http://59.45.142.240:8808/pdf/US7794659.pdf	Signal measuring system having a movable signal measuring device	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	14-Sep-10
1291	US7547516	http://59.45.142.240:8808/pdf/US7547516.pdf	Method for reducing the presence of amplification inhibitors in a reaction	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	16-Jun-09
1292	US20190049 378	http://59.45.142.240:8808/pdf/US20190049378A1.pdf	CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS	Not Available	10-Mar-05	21-Jun-18	14-Feb-19
1293	US20170261 431	http://59.45.142.240:8808/pdf/US20170261431A1.pdf	CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS	Not Available	10-Mar-05	19-May-17	14-Sep-17
1294	US20140178 977	http://59.45.142.240:8808/pdf/US20140178977A1.pdf	SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL SIGNALS	Gen-Probe Incorporated	10-Mar-05	3-Mar-14	26-Jun-14
1295	US20110053 169	http://59.45.142.240:8808/pdf/US20110053169A1.pdf	METHOD FOR CONTINUOUS MODE PROCESSING OF THE CONTENTS OF MULTIPLE REACTION RECEPTACLES IN A REAL-TIME AMPLIFICATION	GEN-PROBE INCORPORATED	10-Mar-05	4-Nov-10	3-Mar-11
1296	US20100240 063	http://59.45.142.240:8808/pdf/US20100240063A1.pdf	SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL SIGNALS	GEN-PROBE INCORPORATED	10-Mar-05	1-Jun-10	23-Sep-10
1297	US20070243 600	http://59.45.142.240:8808/pdf/US20070243600A1.pdf	System for performing multi-formatted assays	GEN-PROBE INCORPORATED	10-Mar-05	10-Mar-06	18-Oct-07
1298	US20070004 028	http://59.45.142.240:8808/pdf/US20070004028A1.pdf	Signal measuring system for conducting real-time amplification	GEN-PROBE INCORPORATED	10-Mar-05	10-Mar-06	4-Jan-07
1299	US20060276 972	http://59.45.142.240:8808/pdf/US20060276972A1.pdf	Method for determining the amount of an analyte in a sample	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	7-Dec-06

1300	US20060234 263	http://59.45.142.240:8808/pdf/US20060234263A1.pdf	Method for reducing the presence of amplification inhibitors in a reaction	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	19-Oct-06
1301	US20060211 130	http://59.45.142.240:8808/pdf/US20060211130A1.pdf	Method for continuous mode processing of multiple reaction receptacles in a real-time	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	21-Sep-06
1302	US20060210 433	http://59.45.142.240:8808/pdf/US20060210433A1.pdf	Signal measuring system having a movable signal measuring device	GEN-PROBE INCORPORATED	10-Mar-05	10-Mar-06	21-Sep-06
1303	US20060204 997	http://59.45.142.240:8808/pdf/US20060204997A1.pdf	Method for performing multi-formatted assays	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	14-Sep-06
1304	US10006862	http://59.45.142.240:8808/pdf/US10006862.pdf	Continuous process for performing multiple nucleic acid amplification	GEN-PROBE INCORPORATED	10-Mar-05	19-May-17	26-Jun-18
1305	US8840873	http://59.45.142.240:8808/pdf/US8840873.pdf	Method of treating second and third degree burns using oxidative	Oculus Innovative Sciences, Inc.	23-Mar-05	23-Mar-06	23-Sep-14
1306	US20060241 546	http://59.45.142.240:8808/pdf/US20060241546A1.pdf	Method of treating second and third degree burns using oxidative	Oculus Innovative Sciences, Inc.	23-Mar-05	23-Mar-06	26-Oct-06
1307	US20060235 350	http://59.45.142.240:8808/pdf/US20060235350A1.pdf	Method of treating skin ulcers using oxidative reductive potential water	Oculus Innovative Sciences, Inc.	23-Mar-05	23-Mar-06	19-Oct-06
1308	US7700728	http://59.45.142.240:8808/pdf/US7700728.pdf	Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell	Schering Corporation	24-Mar-05	24-Mar-06	20-Apr-10
1309	US7498409	http://59.45.142.240:8808/pdf/US7498409.pdf	Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists	Schering Corporation	24-Mar-05	23-Mar-06	3-Mar-09
1310	US20070072 202	http://59.45.142.240:8808/pdf/US20070072202A1.pdf	Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell	BATES ELIZABETH E M	24-Mar-05	24-Mar-06	29-Mar-07
1311	US20060269 936	http://59.45.142.240:8808/pdf/US20060269936A1.pdf	Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists	DOLLET SANDRA	24-Mar-05	23-Mar-06	30-Nov-06
1312	US9493572	http://59.45.142.240:8808/pdf/US9493572.pdf	GITR antibodies and methods of inducing or enhancing an immune	GITR, Inc.	25-Mar-05	23-Mar-15	15-Nov-16
1313	US9028823	http://59.45.142.240:8808/pdf/US9028823.pdf	Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding	GITR, Inc.	25-Mar-05	1-Mar-13	12-May-15
1314	US7812135	http://59.45.142.240:8808/pdf/US7812135.pdf	GITR-binding antibodies	TOLERRX, Inc.	25-Mar-05	27-Mar-06	12-Oct-10
1315	US20190023 799	http://59.45.142.240:8808/pdf/US20190023799A1.pdf	GITR Antibodies And Methods Of Inducing Or Enhancing An Immune	Not Available	25-Mar-05	28-Jun-18	24-Jan-19
1316	US20170137 527	http://59.45.142.240:8808/pdf/US20170137527A1.pdf	GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING AN	Not Available	25-Mar-05	7-Nov-16	18-May-17
1317	US20150259 427	http://59.45.142.240:8808/pdf/US20150259427A1.pdf	GITR BINDING MOLECULES AND USES THEREFOR	Not Available	25-Mar-05	23-Mar-15	17-Sep-15
1318	US20130183 321	http://59.45.142.240:8808/pdf/US20130183321A1.pdf	GITR BINDING MOLECULES AND USES THEREFOR	GITR, INC.	25-Mar-05	1-Mar-13	18-Jul-13
1319	US20070098 719	http://59.45.142.240:8808/pdf/US20070098719A1.pdf	GITR binding molecules and uses therefor	TolerRx, Inc.	25-Mar-05	27-Mar-06	3-May-07
1320	US10570209	http://59.45.142.240:8808/pdf/US10570209.pdf	Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-	GITR, Inc.	25-Mar-05	28-Jun-18	25-Feb-20
1321	US10030074	http://59.45.142.240:8808/pdf/US10030074.pdf	Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR	GITR, Inc.	25-Mar-05	7-Nov-16	24-Jul-18
1322	US20090163 533	http://59.45.142.240:8808/pdf/US20090163533A1.pdf	1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and	COLEY PHARMACEUTICAL GROUP, INC.	1-Apr-05	31-Mar-06	25-Jun-09
1323	US20090124 611	http://59.45.142.240:8808/pdf/US20090124611A1.pdf	Pyrazolopyridine-1,4-Diamines and Analogs Thereof	Coley Pharmaceutical	1-Apr-05	31-Mar-06	14-May-09
1324	US20060223 184	http://59.45.142.240:8808/pdf/US20060223184A1.pdf	Supports useful in incorporating biomolecules into cells and methods	FRUTOS ANTHONY G	5-Apr-05	5-Apr-05	5-Oct-06
1325	US20060223 074	http://59.45.142.240:8808/pdf/US20060223074A1.pdf	Spotting compositions and methods of use thereof	BUNCH THOMAS A	5-Apr-05	5-Apr-05	5-Oct-06
1326	US8999678	http://59.45.142.240:8808/pdf/US8999678.pdf	Method of increasing the function of an AAV vector	The Trustees of the University of	7-Apr-05	7-Apr-06	7-Apr-15
1327	US20180057 841	http://59.45.142.240:8808/pdf/US20180057841A1.pdf	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	Not Available	7-Apr-05	27-Oct-17	1-Mar-18
1328	US20170191 079	http://59.45.142.240:8808/pdf/US20170191079A1.pdf	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	Not Available	7-Apr-05	18-Jan-17	6-Jul-17
1329	US20150159 173	http://59.45.142.240:8808/pdf/US20150159173A1.pdf	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	The Trustees of the University of	7-Apr-05	18-Feb-15	11-Jun-15
1330	US20090197 338	http://59.45.142.240:8808/pdf/US20090197338A1.pdf	Method of Increasing the Function of an AAV Vector	The Trustees of teh University of	7-Apr-05	7-Apr-06	6-Aug-09
1331	US10626415	http://59.45.142.240:8808/pdf/US10626415.pdf	Method of increasing the function of an AAV vector	The Trustees of the University of	7-Apr-05	27-Oct-17	21-Apr-20
1332	US10301648	http://59.45.142.240:8808/pdf/US10301648.pdf	Method of increasing the function of an AAV vector	The Trustees of the University of	7-Apr-05	18-Feb-15	28-May-19
1333	US20070054 834	http://59.45.142.240:8808/pdf/US20070054834A1.pdf	Quaternary ammonium halides for treatment of infectious conditions	NANO BIO CORP	11-Apr-05	10-Apr-06	8-Mar-07
1334	US20070026 391	http://59.45.142.240:8808/pdf/US20070026391A1.pdf	Methods and compositions for identifying chemical or biological agents using multiplexed labeling	GHC TECHNOLOGIES INC	11-Apr-05	6-Apr-06	1-Feb-07
1335	US20070009 884	http://59.45.142.240:8808/pdf/US20070009884A1.pdf	Methods and apparatuses for detecting chemical or biological	GHC TECHNOLOGIES INC	11-Apr-05	6-Apr-06	11-Jan-07
1336	US20060293 267	http://59.45.142.240:8808/pdf/US20060293267A1.pdf	Dual functional oligonucleotides for use as antiviral agents	UNIVERSITY OF MASSACHUSETTS	13-Apr-05	13-Apr-06	28-Dec-06
1337	US7785612	http://59.45.142.240:8808/pdf/US7785612.pdf	Polyamino acid for use as adjuvant	Masanori Baba	20-Apr-05	19-Apr-06	31-Aug-10
1338	US20090285 901	http://59.45.142.240:8808/pdf/US20090285901A1.pdf	Polyamino acid for use as adjuvant	AKASHI MITSURU	20-Apr-05	27-Jul-09	19-Nov-09
1339	US20090092 633	http://59.45.142.240:8808/pdf/US20090092633A1.pdf	Polyamino acid for use as adjuvant	AKASHI MITSURU	20-Apr-05	19-Apr-06	9-Apr-09
1340	US20090042 942	http://59.45.142.240:8808/pdf/US20090042942A1.pdf	Muscarinic Receptor Antagonists	ASTRAZENECA AB	20-Apr-05	18-Apr-06	12-Feb-09

1341	US20060292 162	http://59.45.142.240:8808/pdf/US20060292162A1.pdf	Plasma or serum fraction for the treatment or prevention of bacterial	BUCKHEIT ROBERT W JR	22-Apr-05	24-Apr-06	28-Dec-06
1342	US20060280 748	http://59.45.142.240:8808/pdf/US20060280748A1.pdf	Plasma or serum fraction for treatment or prevention of abnormal	BUCKHEIT ROBERT W JR	22-Apr-05	24-Apr-06	14-Dec-06
1343	US20080193 474	http://59.45.142.240:8808/pdf/US20080193474A1.pdf	Immunostimulatory Compositions	GRAM CHRISTOPHER D	25-Apr-05	25-Apr-06	14-Aug-08
1344	US20070009 932	http://59.45.142.240:8808/pdf/US20070009932A1.pdf	Promoter engineering and genetic control	ALPER HAL S	27-Apr-05	26-Apr-06	11-Jan-07
1345	US8398992	http://59.45.142.240:8808/pdf/US8398992.pdf	Methods and compositions for polynucleotide vaccination	Polytopos LLC	29-Apr-05	22-Dec-11	19-Mar-13
1346	US20060246 081	http://59.45.142.240:8808/pdf/US20060246081A1.pdf	Methods and compositions for polynucleotide vaccination	DEEM MICHAEL W	29-Apr-05	29-Apr-05	2-Nov-06
1347	US9498548	http://59.45.142.240:8808/pdf/US9498548.pdf	Method of using oxidative reductive potential water solution in dental	Oculus Innovative Sciences, Inc.	2-May-05	2-May-06	22-Nov-16
1348	US7749445	http://59.45.142.240:8808/pdf/US7749445.pdf	Method and apparatus for analyzing bioprocess fluids	BioScale, Inc.	2-May-05	19-Dec-06	6-Jul-10
1349	US7648844	http://59.45.142.240:8808/pdf/US7648844.pdf	Method and apparatus for detection of analyte using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	19-Jan-10
1350	US7632638	http://59.45.142.240:8808/pdf/US7632638.pdf	Methods and apparatus for detecting viruses using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	15-Dec-09
1351	US7629137	http://59.45.142.240:8808/pdf/US7629137.pdf	Methods and apparatus for detecting bacteria using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	8-Dec-09
1352	US7615381	http://59.45.142.240:8808/pdf/US7615381.pdf	Method and apparatus for detecting estradiol and metabolites thereof	BioScale, Inc.	2-May-05	2-May-06	10-Nov-09
1353	US7611908	http://59.45.142.240:8808/pdf/US7611908.pdf	Method and apparatus for therapeutic drug monitoring using an	BioScale, Inc.	2-May-05	2-May-06	3-Nov-09
1354	US7598094	http://59.45.142.240:8808/pdf/US7598094.pdf	Methods and apparatus for detecting cardiac injury markers using an	BioScale, Inc.	2-May-05	2-May-06	6-Oct-09
1355	US20170071 980	http://59.45.142.240:8808/pdf/US20170071980A1.pdf	METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION IN DENTAL	OCULUS INNOVATIVE SCIENCES, INC.	2-May-05	22-Nov-16	16-Mar-17
1356	US20100233 031	http://59.45.142.240:8808/pdf/US20100233031A1.pdf	Method and Apparatus for Analyzing Bioprocess Fluids	BioScale, Inc.	2-May-05	25-May-10	16-Sep-10
1357	US20070224 700	http://59.45.142.240:8808/pdf/US20070224700A1.pdf	Method and apparatus for analyzing bioprocess fluids	BioScale, Inc.	2-May-05	19-Dec-06	27-Sep-07
1358	US20070042 441	http://59.45.142.240:8808/pdf/US20070042441A1.pdf	Method and apparatus for detecting estradiol and metabolites thereof	BioScale, Inc.	2-May-05	2-May-06	22-Feb-07
1359	US20070037 231	http://59.45.142.240:8808/pdf/US20070037231A1.pdf	Methods and apparatus for detecting bacteria using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	15-Feb-07
1360	US20070037 142	http://59.45.142.240:8808/pdf/US20070037142A1.pdf	Methods and apparatus for detecting viruses using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	15-Feb-07
1361	US20060257 945	http://59.45.142.240:8808/pdf/US20060257945A1.pdf	Methods and apparatus for detecting cardiac injury markers using an	BioScale, Inc.	2-May-05	2-May-06	16-Nov-06
1362	US20060253 060	http://59.45.142.240:8808/pdf/US20060253060A1.pdf	Method of using oxidative reductive potential water solution in dental	Oculus Innovative Sciences, Inc.	2-May-05	2-May-06	9-Nov-06
1363	US9163222	http://59.45.142.240:8808/pdf/US9163222.pdf	Mutations in OAS1 genes	Kineta Two, LLC	4-May-05	14-Nov-12	20-Oct-15
1364	US8951768	http://59.45.142.240:8808/pdf/US8951768.pdf	Mutations in OAS1 genes	Kineta Two, LLC	4-May-05	11-Jul-11	10-Feb-15
1365	US7642350	http://59.45.142.240:8808/pdf/US7642350.pdf	Purine derivatives	Pfizer Limited	4-May-05	3-May-06	5-Jan-10
1366	US20130142 773	http://59.45.142.240:8808/pdf/US20130142773A1.pdf	Mutations in OAS1 Genes	KINETA TWO, LLC	4-May-05	14-Nov-12	6-Jun-13
1367	US20060275 802	http://59.45.142.240:8808/pdf/US20060275802A1.pdf	Mutations in OAS1 genes	FELLIN P C	4-May-05	3-May-06	7-Dec-06
1368	US20060264 448	http://59.45.142.240:8808/pdf/US20060264448A1.pdf	Purine derivatives	PFIZER LTD	4-May-05	3-May-06	23-Nov-06
1369	US20090221 624	http://59.45.142.240:8808/pdf/US20090221624A1.pdf	4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS	BUSCHER BENJAMIN A	6-May-05	4-May-06	3-Sep-09
1370	US20060257 861	http://59.45.142.240:8808/pdf/US20060257861A1.pdf	Screening assay for inhibitors of severe acute respiratory syndrome (SARS) using SELDI-TOF Mass	Wright State University	12-May-05	12-May-06	16-Nov-06
1371	US20090214 537	http://59.45.142.240:8808/pdf/US20090214537A1.pdf	Serum Resistance Factors of Gram Positive Bacteria	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	13-May-05	12-May-06	27-Aug-09
1372	US7619067	http://59.45.142.240:8808/pdf/US7619067.pdf	Evolved interferon-alpha polypeptides	Maxygen, Inc.	18-May-05	17-May-06	17-Nov-09
1373	US20080226 597	http://59.45.142.240:8808/pdf/US20080226597A1.pdf	EVOLVED INTERFERON-ALPHA POLYPEPTIDES	MAXYGEN, INC.	18-May-05	17-May-06	18-Sep-08
1374	US7674795	http://59.45.142.240:8808/pdf/US7674795.pdf	Fluorene derivatives, composition containing said derivatives and the	Aventis Pharma SA	19-May-05	14-Nov-07	9-Mar-10
1375	US20080159 962	http://59.45.142.240:8808/pdf/US20080159962A1.pdf	Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries	IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE	19-May-05	19-May-06	3-Jul-08
1376	US20080153 837	http://59.45.142.240:8808/pdf/US20080153837A1.pdf	Novel Fluorene Derivatives, Composition Containing Said	AVENTIS PHARMA S.A.	19-May-05	14-Nov-07	26-Jun-08
1377	US20060270 614	http://59.45.142.240:8808/pdf/US20060270614A1.pdf	Use of chalcones for the treatment of viral disorders	BODDUPALLI SEKHAR	24-May-05	24-May-05	30-Nov-06
1378	US8481255	http://59.45.142.240:8808/pdf/US8481255.pdf	Scytovirin domain 1 related polypeptides	The United States of America, as represented by the Secretary, Department of Health and Human Services	25-May-05	30-Sep-11	9-Jul-13
1379	US20080311 125	http://59.45.142.240:8808/pdf/US20080311125A1.pdf	Scytovirin Domain 1 Related Polypeptides	Office of Technology Transfer	25-May-05	24-May-06	18-Dec-08
1380	US20080194 689	http://59.45.142.240:8808/pdf/US20080194689A1.pdf	Disinfectant and Germicidal Agent	REICHWAGEN SVEN	25-May-05	26-May-06	14-Aug-08
1381	US20060270 017	http://59.45.142.240:8808/pdf/US20060270017A1.pdf	Inactivation of a pathogen in a sample by a treatment with formalin	BARRETT NOEL	26-May-05	26-May-05	30-Nov-06
1382	US20080275 084	http://59.45.142.240:8808/pdf/US20080275084A1.pdf	Piperidines for the Treatment of Chemokine Mediated Diseases	ASTRAZENECA AB	27-May-05	24-May-06	6-Nov-08
1383	US20080200 505	http://59.45.142.240:8808/pdf/US20080200505A1.pdf	Piperidines for the Treatment of Chemokine Mediated Diseases	ASTRAZENECA AB	27-May-05	24-May-06	21-Aug-08
1384	US20060269 538	http://59.45.142.240:8808/pdf/US20060269538A1.pdf	Serine proteases with altered sensitivity to activity-modulating	COCO WAYNE M	27-May-05	26-May-06	30-Nov-06
1385	US20070015 172	http://59.45.142.240:8808/pdf/US20070015172A1.pdf	Expression profiles for microbial infection	Z-BioMed, Inc.	1-Jun-05	30-Nov-05	18-Jan-07

1386	US8840774	http://59.45.142.240:8808/pdf/US8840774.pdf	Electrochemistry and electrogenerated chemiluminescence	Board of Regents of the University of	3-Jun-05	28-Oct-13	23-Sep-14
1387	US8702958	http://59.45.142.240:8808/pdf/US8702958.pdf	Electrochemistry and electrogenerated chemiluminescence	Board of Regents of the University of	3-Jun-05	31-May-12	22-Apr-14
1388	US8541457	http://59.45.142.240:8808/pdf/US8541457.pdf	Aminothiazole derivatives as human stearyl-CoA desaturase inhibitors	Xenon Pharmaceuticals	3-Jun-05	5-Jun-06	24-Sep-13
1389	US20140116 887	http://59.45.142.240:8808/pdf/US20140116887A1.pdf	ELECTROCHEMISTRY AND ELECTROGENERATED CHEMILUMINESCENCE WITH A	Board of Regents of the University of Texas System	3-Jun-05	28-Oct-13	1-May-14
1390	US20130096 056	http://59.45.142.240:8808/pdf/US20130096056A1.pdf	AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA	XENON PHARMACEUTICALS	3-Jun-05	14-Sep-12	18-Apr-13
1391	US20100152 187	http://59.45.142.240:8808/pdf/US20100152187A1.pdf	AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA	XENON PHARMACEUTICALS	3-Jun-05	5-Jun-06	17-Jun-10
1392	US20070190 065	http://59.45.142.240:8808/pdf/US20070190065A1.pdf	Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS	ALTMAYER RALF	3-Jun-05	4-Dec-06	16-Aug-07
1393	US20070034 529	http://59.45.142.240:8808/pdf/US20070034529A1.pdf	Electrochemistry and electrogenerated chemiluminescence	BARD ALLEN J	3-Jun-05	2-Jun-06	15-Feb-07
1394	US20070014 778	http://59.45.142.240:8808/pdf/US20070014778A1.pdf	Endoribonuclease and uses thereof	LEE CHOW	6-Jun-05	5-Jun-06	18-Jan-07
1395	US20080031 868	http://59.45.142.240:8808/pdf/US20080031868A1.pdf	HUMAN LYSOZYME MEDICINE, ITS MANUFACTURING METHOD AND	AN MI	9-Jun-05	9-Jun-05	7-Feb-08
1396	US20070048 759	http://59.45.142.240:8808/pdf/US20070048759A1.pdf	DETECTION OF TARGET MOLECULES WITH LABELED NUCLEIC ACID	LI YOUNG	10-Jun-05	12-Jun-06	1-Mar-07
1397	US20090042 858	http://59.45.142.240:8808/pdf/US20090042858A1.pdf	LACTAM CONTAINING HCV INHIBITORS	BARSANTI PAUL	16-Jun-05	16-Jun-06	12-Feb-09
1398	US20100150 923	http://59.45.142.240:8808/pdf/US20100150923A1.pdf	FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR	Chinese Academy of Medical Sciences, Institute of Basic	20-Jun-05	13-Jun-06	17-Jun-10
1399	US20090149 429	http://59.45.142.240:8808/pdf/US20090149429A1.pdf	ANTIVIRAL COMPOUNDS	Myriad Genetics, Incorporated	22-Jun-05	22-Jun-06	11-Jun-09
1400	US20070203 073	http://59.45.142.240:8808/pdf/US20070203073A1.pdf	SARS and Ebola inhibitors and use thereof, and methods for their	BATES PAUL	22-Jun-05	21-Jun-06	30-Aug-07
1401	US20070116 600	http://59.45.142.240:8808/pdf/US20070116600A1.pdf	Detection device and methods associated therewith	COOK RICHARD A	23-Jun-05	23-Jun-06	24-May-07
1402	US20070031 283	http://59.45.142.240:8808/pdf/US20070031283A1.pdf	Assay cartridges and methods for point-of-care instruments	BLANKFARD MARTIN	23-Jun-05	23-Jun-06	8-Feb-07
1403	US20070003 577	http://59.45.142.240:8808/pdf/US20070003577A1.pdf	Purified trimeric S protein as vaccine against severe acute respiratory	CHU KID	28-Jun-05	27-Jun-06	4-Jan-07
1404	US20100105 873	http://59.45.142.240:8808/pdf/US20100105873A1.pdf	INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN	MEDIMMUNE, INC.	1-Jul-05	30-Jun-06	29-Apr-10
1405	US20080227 797	http://59.45.142.240:8808/pdf/US20080227797A1.pdf	Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of	ASTRAZENECA AB	4-Jul-05	3-Jul-06	18-Sep-08
1406	US20090232 843	http://59.45.142.240:8808/pdf/US20090232843A1.pdf	Identifying and predicting influenza variants and uses thereof	NIMAN HENRY L	8-Jul-05	4-Jan-08	17-Sep-09
1407	US20090214 590	http://59.45.142.240:8808/pdf/US20090214590A1.pdf	Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins	Wayne State University	8-Jul-05	10-Jul-06	27-Aug-09
1408	US20070053 933	http://59.45.142.240:8808/pdf/US20070053933A1.pdf	IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND	SHEPPARD PAUL O	20-Jul-05	20-Jul-06	8-Mar-07
1409	US8551738	http://59.45.142.240:8808/pdf/US8551738.pdf	Systems and methods for rapid identification of nucleic acid variants	Ibis Biosciences, Inc	21-Jul-05	11-Nov-09	8-Oct-13
1410	US20100070 194	http://59.45.142.240:8808/pdf/US20100070194A1.pdf	METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF NUCLEIC ACID	ECKER DAVID J	21-Jul-05	11-Nov-09	18-Mar-10
1411	US20090118 288	http://59.45.142.240:8808/pdf/US20090118288A1.pdf	N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine	ASTRAZENECA AB	21-Jul-05	19-Jul-06	7-May-09
1412	US20080207 688	http://59.45.142.240:8808/pdf/US20080207688A1.pdf	Novel Piperidine Derivatives	ASTRAZENECA AB	21-Jul-05	19-Jul-06	28-Aug-08
1413	US20070218 467	http://59.45.142.240:8808/pdf/US20070218467A1.pdf	Methods for rapid identification and quantitation of nucleic acid variants	ECKER DAVID J	21-Jul-05	21-Jul-06	20-Sep-07
1414	US20090098 530	http://59.45.142.240:8808/pdf/US20090098530A1.pdf	Cell Line For Producing Coronaviruses	CRUCCELL HOLLAND B.V.	22-Jul-05	21-Jul-06	16-Apr-09
1415	US8877187	http://59.45.142.240:8808/pdf/US8877187.pdf	Therapeutic antibodies for treatment and prophylaxis of transmittable	Avianax, LLC	25-Jul-05	23-Nov-10	4-Nov-14
1416	US20080166 701	http://59.45.142.240:8808/pdf/US20080166701A1.pdf	Immunoassay Method and Immunoassay Kit to Be Used Therein	ARKRAY, Inc.	25-Jul-05	24-Jul-06	10-Jul-08
1417	US20070021 439	http://59.45.142.240:8808/pdf/US20070021439A1.pdf	Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine	PARION SCIENCES INC	25-Jul-05	25-Jul-05	25-Jan-07
1418	US8652836	http://59.45.142.240:8808/pdf/US8652836.pdf	Defective ribosomal products in blebs (DRIBbles) and methods of use	Providence Health System	29-Jul-05	27-Jul-06	18-Feb-14
1419	US20170202 949	http://59.45.142.240:8808/pdf/US20170202949A1.pdf	DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE	Providence Health & Services - Oregon	29-Jul-05	29-Dec-16	20-Jul-17
1420	US20140186 292	http://59.45.142.240:8808/pdf/US20140186292A1.pdf	DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE	Providence Health & Services - Oregon	29-Jul-05	10-Feb-14	3-Jul-14
1421	US20090220 530	http://59.45.142.240:8808/pdf/US20090220530A1.pdf	DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE	HU HONG-MING	29-Jul-05	27-Jul-06	3-Sep-09
1422	US20080194 632	http://59.45.142.240:8808/pdf/US20080194632A1.pdf	Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of	ASTRAZENECA AB	1-Aug-05	31-Jul-06	14-Aug-08
1423	US20090220 547	http://59.45.142.240:8808/pdf/US20090220547A1.pdf	Reducing interference between oil-containing adjuvants and surfactant-	NOVARTIS VACCINES AND	2-Aug-05	2-Aug-06	3-Sep-09
1424	US20080280 951	http://59.45.142.240:8808/pdf/US20080280951A1.pdf	Salt II	ASTRAZENECA AB	2-Aug-05	31-Jul-06	13-Nov-08
1425	US20080227 817	http://59.45.142.240:8808/pdf/US20080227817A1.pdf	New Salt I	ASTRAZENECA AB	2-Aug-05	31-Jul-06	18-Sep-08
1426	US20080176 902	http://59.45.142.240:8808/pdf/US20080176902A1.pdf	Salt III	ASTRAZENECA AB	2-Aug-05	31-Jul-06	24-Jul-08

1427	US8648076	http://59.45.142.240:8808/pdf/US8648076.pdf	Cysteine protease inhibitors and their therapeutic applications	Hybrigenics SA	5-Aug-05	26-Jul-06	11-Feb-14
1428	US20090215 786		NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS	BOISSY GUILLAUME	5-Aug-05	26-Jul-06	27-Aug-09
1429	US20070032 499	http://59.45.142.240:8808/pdf/US20070032499A1.pdf	Novel cysteine protease inhibitors and their therapeutic applications	BOISSY GUILLAUME	5-Aug-05	5-Aug-05	8-Feb-07
1430	US7709511	http://59.45.142.240:8808/pdf/US7709511.pdf	Benzothiazolone derivatives	AstraZeneca AB	9-Aug-05	3-Aug-06	4-May-10
1431	US20100273 997	http://59.45.142.240:8808/pdf/US20100273997A1.pdf	Ribozyme to cleave coronavirus gene	FUKUDA NOBORU	9-Aug-05	9-Aug-06	28-Oct-10
1432	US20100210 688	http://59.45.142.240:8808/pdf/US20100210688A1.pdf	Novel Benzothiazolone Derivatives	BONNERT ROGER	9-Aug-05	27-Apr-10	19-Aug-10
1433	US20080300 275	http://59.45.142.240:8808/pdf/US20080300275A1.pdf	Novel Benzothiazolone Derivatives	ASTRAZENECA AB	9-Aug-05	3-Aug-06	4-Dec-08
1434	US20090053 708	http://59.45.142.240:8808/pdf/US20090053708A1.pdf	Method and/or Apparatus of Oligonucleotide Design and/or Nucleic Acid Detection	LEE CHARLIE	12-Aug-05	8-Aug-06	26-Feb-09
1435	US20070042 388	http://59.45.142.240:8808/pdf/US20070042388A1.pdf	Method of probe design and/or of nucleic acids detection	LEE CHARLIE	12-Aug-05	12-Aug-05	22-Feb-07
1436	US20070203 209	http://59.45.142.240:8808/pdf/US20070203209A1.pdf	Useful indole compounds	BARTOLINI WILMIN	18-Aug-05	18-Aug-06	30-Aug-07
1437	US9359360	http://59.45.142.240:8808/pdf/US9359360.pdf	TLR agonists	The Regents of The University of Calif.	22-Aug-05	20-Nov-12	7-Jun-16
1438	US20130165 455	http://59.45.142.240:8808/pdf/US20130165455A1.pdf	TLR AGONISTS	The Regents of The University of Calif.	22-Aug-05	20-Nov-12	27-Jun-13
1439	US20070111 231	http://59.45.142.240:8808/pdf/US20070111231A1.pdf	Detection of mutations in a gene associated with resistance to viral protein expression	Illumigen Biosciences, Inc.	23-Aug-05	23-Aug-06	17-May-07
1440	US20090202 995	http://59.45.142.240:8808/pdf/US20090202995A1.pdf	MOLECULAR CARDIOTOXICOLOGY MODELING	JOHNSON KORY R	26-Aug-05	28-Aug-06	13-Aug-09
1441	US8815244	http://59.45.142.240:8808/pdf/US8815244.pdf	Method for production of antibody using ostrich	Japan Science and Technology Agency	29-Aug-05	16-Aug-11	26-Aug-14
1442	US8765133	http://59.45.142.240:8808/pdf/US8765133.pdf	Method of producing anti-CD166 antibody in ostrich	Japan Science and Technology Agency	29-Aug-05	16-Aug-11	1-Jul-14
1443	US20090306 347	http://59.45.142.240:8808/pdf/US20090306347A1.pdf	ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF	JAPAN SCIENCE AND TECHNOLOGY AGENCY	29-Aug-05	29-Aug-06	10-Dec-09
1444	US20090221 653	http://59.45.142.240:8808/pdf/US20090221653A1.pdf	7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor	AstraZeneca AB	29-Aug-05	28-Aug-06	3-Sep-09
1445	US20090203 753	http://59.45.142.240:8808/pdf/US20090203753A1.pdf	7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor	AstraZeneca AB	29-Aug-05	28-Aug-06	13-Aug-09
1446	US9651543	http://59.45.142.240:8808/pdf/US9651543.pdf	Malaria antigen screening method	The United States of America as Represented by the Secretary of the	31-Aug-05	19-Apr-13	16-May-17
1447	US8765146	http://59.45.142.240:8808/pdf/US8765146.pdf	Adenoviral vector-based malaria vaccines	GenVec, Inc.	31-Aug-05	31-Aug-06	1-Jul-14
1448	US8450055	http://59.45.142.240:8808/pdf/US8450055.pdf	Malaria antigen screening method	The United States of America as Represented by the Secretary of the	31-Aug-05	25-Aug-06	28-May-13
1449	US20170219 560	http://59.45.142.240:8808/pdf/US20170219560A1.pdf	MALARIA ANTIGEN SCREENING METHOD	United States of America as Represented by the Secretary of the	31-Aug-05	10-Apr-17	3-Aug-17
1450	US20170082 607	http://59.45.142.240:8808/pdf/US20170082607A9.pdf	MALARIA ANTIGEN SCREENING METHOD	Not Available	31-Aug-05	19-Apr-13	23-Mar-17
1451	US20100222 234	http://59.45.142.240:8808/pdf/US20100222234A1.pdf	Malaria antigen screening method	AGUIR JOAO CARLOS	31-Aug-05	25-Aug-06	2-Sep-10
1452	US20070048 747	http://59.45.142.240:8808/pdf/US20070048747A1.pdf	Methods for assaying analytes	LESLIE THOMAS M	1-Sep-05	1-Sep-05	1-Mar-07
1453	US20100152 230	http://59.45.142.240:8808/pdf/US20100152230A1.pdf	HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS	Pfizer Inc.	2-Sep-05	1-Sep-06	17-Jun-10
1454	US20080194 922	http://59.45.142.240:8808/pdf/US20080194922A1.pdf	POTENTIATION FOR MEDICAL THERAPIES	HOLDEN JAMES F	7-Sep-05	28-Sep-07	14-Aug-08
1455	US20090281 042	http://59.45.142.240:8808/pdf/US20090281042A1.pdf	COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION OF VIRUSES	ARAD DORIT	8-Sep-05	10-Sep-06	12-Nov-09
1456	US8476292	http://59.45.142.240:8808/pdf/US8476292.pdf	Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-YI]-1,1-dimethylethyl}methanesulfonamide	3M Innovative Properties Company	9-Sep-05	8-Sep-06	2-Jul-13
1457	US20100317 684	http://59.45.142.240:8808/pdf/US20100317684A1.pdf	Amide and Carbamate Derivatives of N-{2-[4-Amino-2-(Ethoxymethyl)-1H-Imidazo[4,5-c] Quinolin-1-YI]-1,1-Dimethylethyl}	Coley Pharmaceutical Group, Inc.	9-Sep-05	8-Sep-06	16-Dec-10
1458	US20090176 821	http://59.45.142.240:8808/pdf/US20090176821A1.pdf	Amide and Carbamate Derivatives of Alkyl Substituted N-{4-(4- Amino-1H-Imidazo[4,5-C] Quinolin-1-YL)Butyl}Methanesulfonamides and	COLEY PHARMACEUTICAL GROUP, INC.	9-Sep-05	8-Sep-06	9-Jul-09
1459	EP2471551A 2	http://59.45.142.240:8808/pdf/EP2471551A2.pdf	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis Vaccines and Diagnostics	9-Sep-05	4-Jul-12	4-Jul-12
1460	US20100041 013	http://59.45.142.240:8808/pdf/US20100041013A1.pdf	ASSAY FOR A HEALTH STATE	HUMAN GENETIC SIGNATURES PTY LTD	14-Sep-05	14-Sep-06	18-Feb-10
1461	US20070060 499	http://59.45.142.240:8808/pdf/US20070060499A1.pdf	Chloroquine combination drugs and methods for their synthesis	KOSAK KENNETH M	15-Sep-05	22-Feb-06	15-Mar-07
1462	US7435588	http://59.45.142.240:8808/pdf/US7435588.pdf	Systems for detection and production of respiratory, herpes	Diagnostic Hybrids, Inc.	20-Sep-05	28-Apr-06	14-Oct-08
1463	US20100173 280	http://59.45.142.240:8808/pdf/US20100173280A1.pdf	Systems for Detection and Production of Respiratory, Herpes	Diagnostic Hybrids, Inc	20-Sep-05	19-Sep-06	8-Jul-10
1464	US20070065 939	http://59.45.142.240:8808/pdf/US20070065939A1.pdf	Systems for detection and production of respiratory, herpes	Diagnostic Hybrids, Inc.	20-Sep-05	28-Apr-06	22-Mar-07
1465	US20090192 153	http://59.45.142.240:8808/pdf/US20090192153A1.pdf	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag A corporation of	22-Sep-05	21-Sep-06	30-Jul-09
1466	US20090118 263	http://59.45.142.240:8808/pdf/US20090118263A1.pdf	Novel Adenine Compound	ASTRAZENECA AKTIEBOLAG	22-Sep-05	20-Sep-06	7-May-09

1467	US20090105 212	http://59.45.142.240:8808/pdf/US20090105212A1.pdf	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag a corporation of	22-Sep-05	22-Sep-06	23-Apr-09
1468	US20090099 216	http://59.45.142.240:8808/pdf/US20090099216A1.pdf	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag A corporation of	22-Sep-05	22-Sep-06	16-Apr-09
1469	US20090082 332	http://59.45.142.240:8808/pdf/US20090082332A1.pdf	PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS	ABBOT PHILIP	22-Sep-05	20-Sep-06	26-Mar-09
1470	US20080269 240	http://59.45.142.240:8808/pdf/US20080269240A1.pdf	Novel Adenine Compound	AstraZeneca Aktiebolag A Corporation of	22-Sep-05	21-Sep-06	30-Oct-08
1471	US20090205 116	http://59.45.142.240:8808/pdf/US20090205116A1.pdf	ARTICLE, LAMINATE AND ASSOCIATED METHODS	GENERAL ELECTRIC COMPANY	30-Sep-05	5-Dec-08	20-Aug-09
1472	US20100087 388	http://59.45.142.240:8808/pdf/US20100087388A1.pdf	ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS	Not Available	3-Oct-05	3-Oct-06	8-Apr-10
1473	US20090054 413	http://59.45.142.240:8808/pdf/US20090054413A1.pdf	Novel 5,6-Dihydropyrazolo[3,4-E][L,4]Diazepin-4 (1H) -One Derivatives for the Treatment of Asthma and Chronic Obstructive	AstraZeneca AB	3-Oct-05	2-Oct-06	26-Feb-09
1474	US20090203 112	http://59.45.142.240:8808/pdf/US20090203112A1.pdf	VERO CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION	Ricardo Kratje	4-Oct-05	3-Oct-06	13-Aug-09
1475	US20070111 309	http://59.45.142.240:8808/pdf/US20070111309A1.pdf	Vero cell line adapted to grow in suspension	DAELLI MARCELO G	4-Oct-05	29-Sep-06	17-May-07
1476	US8415394	http://59.45.142.240:8808/pdf/US8415394.pdf	Biphenyloxyacetic acid derivatives for the treatment of respiratory	Astrazeneca AB	6-Oct-05	21-Dec-11	9-Apr-13
1477	US20090192 163		Novel Compounds	ASTRAZENECA AB	6-Oct-05	5-Oct-06	30-Jul-09
1478	US20090036 535	http://59.45.142.240:8808/pdf/US20090036535A1.pdf	Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory	ASTRAZENECA AB	6-Oct-05	5-Oct-06	5-Feb-09
1479	US20090280 507	http://59.45.142.240:8808/pdf/US20090280507A1.pdf	METHOD FOR MEASUREMENT OF SARS VIRUS NUCLEOCAPSID PROTEIN, REAGENT KIT FOR THE MEASUREMENT, TEST DEVICE, MONOCLONAL ANTIBODY DIRECTED AGAINST SARS VIRUS NUCLEOCAPSID PROTEIN, AND HYBRIDOMA CAPABLE OF	SYSMEX CORPORATION	11-Oct-05	11-Oct-06	12-Nov-09
1480	US20100248 219	http://59.45.142.240:8808/pdf/US20100248219A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	30-Sep-10
1481	US20070184 434	http://59.45.142.240:8808/pdf/US20070184434A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	9-Aug-07
1482	US20070087 341	http://59.45.142.240:8808/pdf/US20070087341A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
1483	US20070087 340	http://59.45.142.240:8808/pdf/US20070087340A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
1484	US20070087 339	http://59.45.142.240:8808/pdf/US20070087339A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
1485	US20070087 338	http://59.45.142.240:8808/pdf/US20070087338A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
1486	US20070087 337	http://59.45.142.240:8808/pdf/US20070087337A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
1487	US20070087 336	http://59.45.142.240:8808/pdf/US20070087336A1.pdf	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
1488	US20070087 332	http://59.45.142.240:8808/pdf/US20070087332A1.pdf	Pulmonary stem cells, related methods and use of same	LING THAI-YEN	17-Oct-05	17-Oct-05	19-Apr-07
1489	US20090270 431	http://59.45.142.240:8808/pdf/US20090270431A1.pdf	Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating	THE UNIVERSITY OF GEORGIA RESEARCH	19-Oct-05	19-Oct-06	29-Oct-09
1490	US20070092 871	http://59.45.142.240:8808/pdf/US20070092871A1.pdf	Microarray for pathogen identification	COMBIMATRIX CORP	20-Oct-05	20-Oct-06	26-Apr-07
1491	US20070160 981		VIRAL PROTEASE	CHEN XIN	24-Oct-05	23-Oct-06	12-Jul-07
1492	US20100028 853	http://59.45.142.240:8808/pdf/US20100028853A1.pdf	OPTICAL DETERMINATION OF LIVING VS. NON-LIVING CELLS	Not Available	25-Oct-05	2-Nov-06	4-Feb-10
1493	US20090220 941	http://59.45.142.240:8808/pdf/US20090220941A1.pdf	COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND KITS AND METHODS USING SAME	MND DIAGNOSTIC LTD	25-Oct-05	25-Oct-06	3-Sep-09
1494	US20070141 597	http://59.45.142.240:8808/pdf/US20070141597A1.pdf	Biomimetic Biodeceptor of Toxins, Viruses, Bacteria, and Biological	HARMON H J	25-Oct-05	25-Oct-06	21-Jun-07
1495	US20070134 695	http://59.45.142.240:8808/pdf/US20070134695A1.pdf	Dengue virus detection measured by immunocytometry in a dendritic cell	BURGESS TIMOTHY	27-Oct-05	26-Oct-06	14-Jun-07
1496	US20070134 694	http://59.45.142.240:8808/pdf/US20070134694A1.pdf	Method for the measurement of dengue virus binding inhibition	BURGESS TIMOTHY	27-Oct-05	26-Oct-06	14-Jun-07
1497	US20190225 986	http://59.45.142.240:8808/pdf/US20190225986A1.pdf	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS	Not Available	28-Oct-05	30-Nov-18	25-Jul-19
1498	US20160281 109	http://59.45.142.240:8808/pdf/US20160281109A1.pdf	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS	Not Available	28-Oct-05	10-Jun-16	29-Sep-16
1499	US20150174 198	http://59.45.142.240:8808/pdf/US20150174198A1.pdf	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS	Not Available	28-Oct-05	17-Nov-14	25-Jun-15
1500	US20090162 320	http://59.45.142.240:8808/pdf/US20090162320A1.pdf	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS	DNAVEC Corporation	28-Oct-05	27-Oct-06	25-Jun-09
1501	US20070231 344	http://59.45.142.240:8808/pdf/US20070231344A1.pdf	Conjugate vaccines for non-proteinaceous antigens	The Brigham and Women's Hospital,	28-Oct-05	30-Oct-06	4-Oct-07
1502	US10017784	http://59.45.142.240:8808/pdf/US10017784.pdf	Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA	ID PHARMA CO., LTD.	28-Oct-05	17-Nov-14	10-Jul-18
1503	US20070098 735	http://59.45.142.240:8808/pdf/US20070098735A1.pdf	Methods for the Elimination of Pathogens and Other Particulate	CHANDAWARKAR RAJIV Y	29-Oct-05	30-Oct-06	3-May-07

1504	US20090304 729	http://59.45.142.240:8808/pdf/US20090304729A1.pdf	CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA	NOVARTIS VACCINES AND DIAGNOSTICS	1-Nov-05	1-Nov-06	10-Dec-09
1505	US10655108	http://59.45.142.240:8808/pdf/US10655108.pdf	Cell-derived viral vaccines with low levels of residual cell DNA	Seqirus UK Limited	1-Nov-05	1-Nov-06	19-May-20
1506	US8697087	http://59.45.142.240:8808/pdf/US8697087.pdf	Influenza vaccines including combinations of particulate	Novartis AG	4-Nov-05	6-Nov-06	15-Apr-14
1507	US20190167 786	http://59.45.142.240:8808/pdf/US20190167786A1.pdf	EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA	Not Available	4-Nov-05	9-Jul-18	6-Jun-19
1508	US20190134 186	http://59.45.142.240:8808/pdf/US20190134186A1.pdf	INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION	Not Available	4-Nov-05	10-Jul-18	9-May-19
1509	US20150246 110	http://59.45.142.240:8808/pdf/US20150246110A1.pdf	ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE- INDUCING	Novartis AG	4-Nov-05	14-May-15	3-Sep-15
1510	US20140248 312	http://59.45.142.240:8808/pdf/US20140248312A1.pdf	INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	28-Feb-14	4-Sep-14
1511	US20100158 943	http://59.45.142.240:8808/pdf/US20100158943A1.pdf	ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	24-Jun-10
1512	US20090304 742	http://59.45.142.240:8808/pdf/US20090304742A1.pdf	INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION	Novartis Vaccines and Diagnostics SRL	4-Nov-05	6-Nov-06	10-Dec-09
1513	US20090304 739	http://59.45.142.240:8808/pdf/US20090304739A1.pdf	INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	10-Dec-09
1514	US20090221 556		HYDROXY AND ALKOXY SUBSTITUTED 1H-	Pfizer Inc.	4-Nov-05	3-Nov-06	3-Sep-09
1515	US20090220 544	http://59.45.142.240:8808/pdf/US20090220544A1.pdf	ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	3-Sep-09
1516	US20090220 541	http://59.45.142.240:8808/pdf/US20090220541A1.pdf	EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	3-Sep-09
1517	US20090202 590	http://59.45.142.240:8808/pdf/US20090202590A1.pdf	INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	13-Aug-09
1518	US20090047 353	http://59.45.142.240:8808/pdf/US20090047353A1.pdf	CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	19-Feb-09
1519	US20080255 150		Novel Compounds	ASTRAZENECA AB	5-Nov-05	1-Nov-06	16-Oct-08
1520	US9512443	http://59.45.142.240:8808/pdf/US9512443.pdf	Recombinant expression of multiprotein complexes using	ETH ZURICH	8-Nov-05	6-Nov-06	6-Dec-16
1521	US20170037 090	http://59.45.142.240:8808/pdf/US20170037090A1.pdf	RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING	Not Available	8-Nov-05	26-Oct-16	9-Feb-17
1522	US20090222 936	http://59.45.142.240:8808/pdf/US20090222936A1.pdf	Recombinant Expression of Multiprotein Complexes Using	BERGER IMRE	8-Nov-05	6-Nov-06	3-Sep-09
1523	US20070149 487	http://59.45.142.240:8808/pdf/US20070149487A1.pdf	Antiviral Compositions and Methods	MAYO FOUNDATION FOR MEDICAL EDUCATION AND	8-Nov-05	7-Nov-06	28-Jun-07
1524	US9388429	http://59.45.142.240:8808/pdf/US9388429.pdf	Method for propagating adenoviral vectors encoding inhibitory gene	GenVec, Inc.	10-Nov-05	28-May-14	12-Jul-16
1525	US20180223 290	http://59.45.142.240:8808/pdf/US20180223290A1.pdf	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING	GenVec, Inc.	10-Nov-05	7-Sep-17	9-Aug-18
1526	US20160304 882	http://59.45.142.240:8808/pdf/US20160304882A1.pdf	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING	GenVec, Inc.	10-Nov-05	27-Jun-16	20-Oct-16
1527	US20140273 228	http://59.45.142.240:8808/pdf/US20140273228A1.pdf	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING	GenVec, Inc.	10-Nov-05	28-May-14	18-Sep-14
1528	US20090264 509	http://59.45.142.240:8808/pdf/US20090264509A1.pdf	Adenoviral vector-based foot-and-mouth disease vaccine	GENVEC, INC.	10-Nov-05	8-May-08	22-Oct-09
1529	US20090221 487	http://59.45.142.240:8808/pdf/US20090221487A1.pdf	POLYETHYLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1	Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A.	10-Nov-05	11-Nov-06	3-Sep-09
1530	US20080233 650	http://59.45.142.240:8808/pdf/US20080233650A1.pdf	Method for propagating adenoviral vectors encoding inhibitory gene	GENVEC, INC.	10-Nov-05	9-May-08	25-Sep-08
1531	US10640776	http://59.45.142.240:8808/pdf/US10640776.pdf	Method for propagating adenoviral vectors encoding inhibitory gene	GenVec, Inc.	10-Nov-05	7-Sep-17	5-May-20
1532	US9206396	http://59.45.142.240:8808/pdf/US9206396.pdf	Methods and devices for quantitative viral assay	Wisconsin Alumni Research	16-Nov-05	16-Nov-06	8-Dec-15
1533	US20070111 296	http://59.45.142.240:8808/pdf/US20070111296A1.pdf	Methods and Devices for Quantitative Viral Assay	SHU YING	16-Nov-05	16-Nov-06	17-May-07
1534	US20070116 785	http://59.45.142.240:8808/pdf/US20070116785A1.pdf	Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant	MILLER CHRISTOPHER C	18-Nov-05	20-Nov-06	24-May-07
1535	US20130095 552	http://59.45.142.240:8808/pdf/US20130095552A1.pdf	NOROVIRUS AND SAPOVIRUS ANTIGENS	Novartis Vaccines and Diagnostics	22-Nov-05	27-Nov-12	18-Apr-13
1536	US20100291 129	http://59.45.142.240:8808/pdf/US20100291129A1.pdf	Norovirus and sapovirus antigens	COIT DORIS	22-Nov-05	24-Mar-09	18-Nov-10
1537	US20070207 526	http://59.45.142.240:8808/pdf/US20070207526A1.pdf	Norovirus and sapovirus antigens	COIT DORIS	22-Nov-05	22-Nov-06	6-Sep-07
1538	US8883477	http://59.45.142.240:8808/pdf/US8883477.pdf	Oligoadenylylate synthetase (OAS)	Kineta Two, LLC	23-Nov-05	14-Jun-13	11-Nov-14
1539	US8859251	http://59.45.142.240:8808/pdf/US8859251.pdf	Oligoadenylylate synthetase (OAS)	Kineta Two, LLC	23-Nov-05	1-Jul-13	14-Oct-14
1540	US8486678	http://59.45.142.240:8808/pdf/US8486678.pdf	Pharmaceutical compositions for the treatment of virus infection	Kineta Two, LLC	23-Nov-05	1-Feb-12	16-Jul-13
1541	US7732177	http://59.45.142.240:8808/pdf/US7732177.pdf	Oligoadenylylate Synthetase (OAS)	Illumigen Biosciences, Inc	23-Nov-05	17-Nov-06	8-Jun-10
1542	US20140005 102	http://59.45.142.240:8808/pdf/US20140005102A1.pdf	Oligoadenylylate Synthetase (OAS)	Kineta Two LLC	23-Nov-05	1-Jul-13	2-Jan-14
1543	US20140005 101	http://59.45.142.240:8808/pdf/US20140005101A1.pdf	Oligoadenylylate Synthetase (OAS)	Kineta Two LLC	23-Nov-05	14-Jun-13	2-Jan-14
1544	US20100256 348	http://59.45.142.240:8808/pdf/US20100256348A1.pdf	Oligoadenylylate Synthetase (OAS)	ILLUMIGEN BIOSCIENCES, INC	23-Nov-05	30-Mar-10	7-Oct-10

1545	US20090111 828	http://59.45.142.240:8808/pdf/US20090111828A1.pdf	L-ALANINE DERIVATIVES	ASTRAZENECA AB	23-Nov-05	22-Nov-06	30-Apr-09
1546	US20080124 311	http://59.45.142.240:8808/pdf/US20080124311A1.pdf	Novel pharmaceutical compositions for the treatment of virus infection	Illumigen Biosciences, Inc.	23-Nov-05	17-Nov-06	29-May-08
1547	US20100119 550	http://59.45.142.240:8808/pdf/US20100119550A1.pdf	RECOMBINANT MULTIVALENT VACCINE	GOMI YASUYUKI	24-Nov-05	24-Nov-05	13-May-10
1548	EP2471938A 2		Recombinant polyvalent vaccine	National Institute of Biomedical	24-Nov-05	24-Nov-05	4-Jul-12
1549	EP2471937A 2		Recombinant polyvalent vaccine	National Institute of Biomedical	24-Nov-05	24-Nov-05	4-Jul-12
1550	EP2471936A 2		Recombinant polyvalent vaccine	National Institute of Biomedical	24-Nov-05	24-Nov-05	4-Jul-12
1551	US20080210 748	http://59.45.142.240:8808/pdf/US20080210748A1.pdf	Systems and methods for receiving pathogen related information and responding	Searete LLC, a limited liability corporation of the	30-Nov-05	11-Sep-07	4-Sep-08
1552	US20080193 919	http://59.45.142.240:8808/pdf/US20080193919A1.pdf	Systems and methods for receiving pathogen related information and responding	Searete LLC, a limited liability corporation of the	30-Nov-05	22-Jan-08	14-Aug-08
1553	US20080183 396	http://59.45.142.240:8808/pdf/US20080183396A1.pdf	Systems and methods for transmitting pathogen related information and responding	Searete LLC, a limited liability corporation of the	30-Nov-05	11-Sep-07	31-Jul-08
1554	US20080103 746	http://59.45.142.240:8808/pdf/US20080103746A1.pdf	Systems and methods for pathogen detection and response	Searete LLC, a limited liability	30-Nov-05	11-Sep-07	1-May-08
1555	US9574189	http://59.45.142.240:8808/pdf/US9574189.pdf	Enzymatic encoding methods for efficient synthesis of large libraries	Nuevolution A/S	1-Dec-05	1-Dec-06	21-Feb-17
1556	US20190330 618	http://59.45.142.240:8808/pdf/US20190330618A1.pdf	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF	Not Available	1-Dec-05	22-Jan-19	31-Oct-19
1557	US20170247 688	http://59.45.142.240:8808/pdf/US20170247688A1.pdf	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF	NUEVOLUTION A/S	1-Dec-05	12-Dec-16	31-Aug-17
1558	US20100221 242	http://59.45.142.240:8808/pdf/US20100221242A1.pdf	ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE	MCMAHON JAMES B	1-Dec-05	1-Dec-06	2-Sep-10
1559	US20090264 300	http://59.45.142.240:8808/pdf/US20090264300A1.pdf	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF	Nuevolution A/S	1-Dec-05	1-Dec-06	22-Oct-09
1560	US10287576	http://59.45.142.240:8808/pdf/US10287576B2.pdf	Enzymatic encoding methods for efficient synthesis of large libraries	NUEVOLUTION A/S	1-Dec-05	12-Dec-16	14-May-19
1561	US9676867	http://59.45.142.240:8808/pdf/US9676867.pdf	Chimeric T cell receptor comprising carbonic anhydrase IX (G250)	Dana-Farber Cancer Institute Inc.	2-Dec-05	8-May-13	13-Jun-17
1562	US9393215	http://59.45.142.240:8808/pdf/US9393215.pdf	Nanoparticles for use in immunogenic compositions	Novartis AG	2-Dec-05	1-Dec-06	19-Jul-16
1563	US9387242	http://59.45.142.240:8808/pdf/US9387242.pdf	Chimeric viruses presenting non-native surface proteins and uses thereof	Icahn School of Medicine at Mount	2-Dec-05	1-Dec-06	12-Jul-16
1564	US20200165 357	http://59.45.142.240:8808/pdf/US20200165357A1.pdf	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	Not Available	2-Dec-05	21-Oct-19	28-May-20
1565	US20180072 813	http://59.45.142.240:8808/pdf/US20180072813A1.pdf	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	Not Available	2-Dec-05	9-May-17	15-Mar-18
1566	US20170037 379	http://59.45.142.240:8808/pdf/US20170037379A1.pdf	CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS	Icahn School of Medicine at Mount	2-Dec-05	3-Mar-16	9-Feb-17
1567	US20130336 923	http://59.45.142.240:8808/pdf/US20130336923A1.pdf	Carbonic Anhydrase IX (G250) Antibodies and Methods of Use	DANA-FARBER CANCER INSTITUTE, THE	2-Dec-05	8-May-13	19-Dec-13
1568	US20100285 135	http://59.45.142.240:8808/pdf/US20100285135A1.pdf	Nanoparticles For Use In Immunogenic Compositions	NOVARTIS AG	2-Dec-05	1-Dec-06	11-Nov-10
1569	US20090068 095	http://59.45.142.240:8808/pdf/US20090068095A1.pdf	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	LO AGNES	2-Dec-05	4-Dec-06	12-Mar-09
1570	US10450383	http://59.45.142.240:8808/pdf/US10450383.pdf	Carbonic anhydrase IX (G250) antibodies and methods of use	DANA-FARBER CANCER INSTITUTE, THE	2-Dec-05	9-May-17	22-Oct-19
1571	US10308913	http://59.45.142.240:8808/pdf/US10308913.pdf	Chimeric viruses presenting non-native surface proteins and uses thereof	Icahn School of Medicine at Mount	2-Dec-05	3-Mar-16	4-Jun-19
1572	US20080311 042	http://59.45.142.240:8808/pdf/US20080311042A1.pdf	Loop-Variant PdZ Domains as Biotherapeutics, Diagnostics and Vaccines	DELAGRAVE SIMON	5-Dec-05	4-Dec-06	18-Dec-08
1573	US7462615	http://59.45.142.240:8808/pdf/US7462615.pdf	Inhibitors of cysteine proteases, the pharmaceutical compositions thereof	Hybrigenics SA	8-Dec-05	8-Dec-05	9-Dec-08
1574	US20090181 972	http://59.45.142.240:8808/pdf/US20090181972A1.pdf	Novel Inhibitors of Cysteine Proteases, The Pharmaceutical Compositions Thereof and their	BOISSY GUILLAUME	8-Dec-05	5-Dec-06	16-Jul-09
1575	US20070135 439		Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their	BOISSY GUILLAUME	8-Dec-05	8-Dec-05	14-Jun-07
1576	US9822339	http://59.45.142.240:8808/pdf/US9822339.pdf	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN	9-Dec-05	26-Aug-15	21-Nov-17
1577	US9127251	http://59.45.142.240:8808/pdf/US9127251.pdf	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN	9-Dec-05	8-Dec-06	8-Sep-15
1578	US9005974	http://59.45.142.240:8808/pdf/US9005974.pdf	Means and methods for influencing the stability of cells	Academisch Medisch Centrum Bij de Universiteit van	9-Dec-05	9-Dec-05	14-Apr-15
1579	US20170306 293	http://59.45.142.240:8808/pdf/US20170306293A1.pdf	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS	Not Available	9-Dec-05	2-Jun-17	26-Oct-17
1580	US20160060 598	http://59.45.142.240:8808/pdf/US20160060598A1.pdf	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF	Not Available	9-Dec-05	26-Aug-15	3-Mar-16
1581	US20100113 745	http://59.45.142.240:8808/pdf/US20100113745A1.pdf	Means and Methods for Influencing the Stability of Antibody Producing	Meibergdreef 9	9-Dec-05	8-Dec-06	6-May-10

1582	US20100093 038	http://59.45.142.240:8808/pdf/US20100093038A1.pdf	Means and Methods for Influencing the Stability of Cells	Academisch Medisch Centrum bij de Universiteit van	9-Dec-05	9-Dec-05	15-Apr-10
1583	US10273454	http://59.45.142.240:8808/pdf/US10273454.pdf	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN	9-Dec-05	2-Jun-17	30-Apr-19
1584	US20100144 759	http://59.45.142.240:8808/pdf/US20100144759A1.pdf	NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE	AstraZeneca AB	12-Dec-05	8-Dec-09	10-Jun-10
1585	US20080293 742	http://59.45.142.240:8808/pdf/US20080293742A1.pdf	Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of	CHESHIRE DAVID	12-Dec-05	11-Dec-06	27-Nov-08
1586	US20080124 303	http://59.45.142.240:8808/pdf/US20080124303A1.pdf	Methods and compositions for treatment of viral infections	Cavit Sciences, Inc	12-Dec-05	12-Jul-07	29-May-08
1587	US8734823	http://59.45.142.240:8808/pdf/US8734823.pdf	Device including altered microorganisms, and methods and	The Invention Science Fund I, LLC	14-Dec-05	28-May-10	27-May-14
1588	US8682619	http://59.45.142.240:8808/pdf/US8682619.pdf	Device including altered microorganisms, and methods and	The Invention Science Fund I, LLC	14-Dec-05	28-May-10	25-Mar-14
1589	US7767210	http://59.45.142.240:8808/pdf/US7767210.pdf	RNA virus vaccines and methods	The Board of Regents of the University of	14-Dec-05	14-Dec-06	3-Aug-10
1590	US20110045 024	http://59.45.142.240:8808/pdf/US20110045024A1.pdf	RNA VIRUS VACCINES AND METHODS	DITTMER DIRK P	14-Dec-05	2-Aug-10	24-Feb-11
1591	US20110028 945	http://59.45.142.240:8808/pdf/US20110028945A1.pdf	Device including altered microorganisms, and methods and	Searete LLC,	14-Dec-05	28-May-10	3-Feb-11
1592	US20110027 181	http://59.45.142.240:8808/pdf/US20110027181A1.pdf	Device including altered microorganisms, and methods and	Searete LLC	14-Dec-05	28-May-10	3-Feb-11
1593	US20070292 453	http://59.45.142.240:8808/pdf/US20070292453A1.pdf	RNA virus vaccines and methods	DITTMER DIRK P	14-Dec-05	14-Dec-06	20-Dec-07
1594	US8778845	http://59.45.142.240:8808/pdf/US8778845.pdf	Composition, device and associated method	Genral Electric Company	15-Dec-05	1-Mar-07	15-Jul-14
1595	US8741813	http://59.45.142.240:8808/pdf/US8741813.pdf	Composition, device and associated method	General Electric Company	15-Dec-05	28-Feb-07	3-Jun-14
1596	US20140072 956	http://59.45.142.240:8808/pdf/US20140072956A1.pdf	COMPOSITION, DEVICE AND ASSOCIATED METHOD	General Electric Company	15-Dec-05	28-Feb-07	13-Mar-14
1597	US20100129 321	http://59.45.142.240:8808/pdf/US20100129321A1.pdf	DIARYL UREA FOR TREATING VIRUS INFECTIONS	BAYER HEALTHCARE LLC	15-Dec-05	6-Dec-06	27-May-10
1598	US20090227 637	http://59.45.142.240:8808/pdf/US20090227637A1.pdf	DIARYL UREAS FOR TREATING VIRUS INFECTIONS	RIEDL BERND	15-Dec-05	6-Dec-06	10-Sep-09
1599	US20080293 775		Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for	ASTRAZENECA AB	15-Dec-05	12-Dec-06	27-Nov-08
1600	US20090264 653	http://59.45.142.240:8808/pdf/US20090264653A1.pdf	USEFUL INDOLE COMPOUNDS	BARDEN TIMOTHY	16-Dec-05	18-Dec-06	22-Oct-09
1601	US20070167 408	http://59.45.142.240:8808/pdf/US20070167408A1.pdf	NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED	ZENTARIS GmbH	19-Dec-05	19-Dec-06	19-Jul-07
1602	US20080287 453	http://59.45.142.240:8808/pdf/US20080287453A1.pdf	Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment	BOWER JUSTIN FAIRFIELD	21-Dec-05	18-Dec-06	20-Nov-08
1603	US9181303	http://59.45.142.240:8808/pdf/US9181303.pdf	Treatment of bacterial infections with cyclic antimicrobial peptides	NovaBiotics Limited	22-Dec-05	20-Jun-14	10-Nov-15
1604	US8785375	http://59.45.142.240:8808/pdf/US8785375.pdf	Cyclic antimicrobial peptides for treating bacterial infections	Novabiotics Ltd.	22-Dec-05	22-Aug-12	22-Jul-14
1605	US20140303 071		CYCLIC ANTIMICROBIAL PEPTIDES	Not Available	22-Dec-05	20-Jun-14	9-Oct-14
1606	US9890419	http://59.45.142.240:8808/pdf/US9890419.pdf	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc	23-Dec-05	20-May-16	13-Feb-18
1607	US9371563	http://59.45.142.240:8808/pdf/US9371563.pdf	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc	23-Dec-05	11-Mar-13	21-Jun-16
1608	US8986926	http://59.45.142.240:8808/pdf/US8986926.pdf	Compositions comprising oriented, immobilized macromolecules and	NanoString Technologies, Inc.	23-Dec-05	22-Dec-06	24-Mar-15
1609	US20180135 099	http://59.45.142.240:8808/pdf/US20180135099A1.pdf	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE	Not Available	23-Dec-05	2-Jan-18	17-May-18
1610	US20160265 025	http://59.45.142.240:8808/pdf/US20160265025A1.pdf	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE	Not Available	23-Dec-05	20-May-16	15-Sep-16
1611	US20130230 851	http://59.45.142.240:8808/pdf/US20130230851A1.pdf	Nanoreporters And Methods Of Manufacturing And Use Thereof	NANOSTRING TECHNOLOGIES, INC.	23-Dec-05	11-Mar-13	5-Sep-13
1612	US20100261 026	http://59.45.142.240:8808/pdf/US20100261026A1.pdf	Compositions comprising oriented, immobilized macromolecules and	NanoString Technologies, Inc.	23-Dec-05	22-Dec-06	14-Oct-10
1613	US20100015 607	http://59.45.142.240:8808/pdf/US20100015607A1.pdf	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE	INSTITUTE FOR SYSTEMS BIOLOGY	23-Dec-05	22-Dec-06	21-Jan-10
1614	US20070148 670	http://59.45.142.240:8808/pdf/US20070148670A1.pdf	Methods for detecting conformational changes in biopolymers	O'MALLEY SHAWN M	28-Dec-05	25-Oct-06	28-Jun-07
1615	US7781203	http://59.45.142.240:8808/pdf/US7781203.pdf	Supports for assaying analytes and methods of making and using	Corning Incorporated	29-Dec-05	7-Jun-06	24-Aug-10
1616	US20090182 133	http://59.45.142.240:8808/pdf/US20090182133A1.pdf	BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL AGENTS	Shanghai Institute of Materia Medica Chinese Academy of	29-Dec-05	15-Dec-06	16-Jul-09
1617	US20070154 348	http://59.45.142.240:8808/pdf/US20070154348A1.pdf	Supports for assaying analytes and methods of making and using	FRUTOS ANTHONY G	29-Dec-05	7-Jun-06	5-Jul-07
1618	US20070155 699	http://59.45.142.240:8808/pdf/US20070155699A1.pdf	Boron-containing small molecules	Anacor Pharmaceuticals	30-Dec-05	16-Aug-06	5-Jul-07
1619	US20070178 505	http://59.45.142.240:8808/pdf/US20070178505A1.pdf	Promoter engineering and genetic control	ALPER HAL S	3-Jan-06	3-Jan-07	2-Aug-07
1620	US9758568	http://59.45.142.240:8808/pdf/US9758568.pdf	Oligopeptide-free cell culture media	Baxalta GmbH	4-Jan-06	16-Nov-15	12-Sep-17
1621	US20170362 300	http://59.45.142.240:8808/pdf/US20170362300A1.pdf	OLIGOPEPTIDE-FREE CELL CULTURE MEDIA	Not Available	4-Jan-06	7-Aug-17	21-Dec-17
1622	US20070212 770	http://59.45.142.240:8808/pdf/US20070212770A1.pdf	Oligopeptide-free cell culture media	Baxter Healthcare, S.A.	4-Jan-06	3-Jan-07	13-Sep-07
1623	US8916340	http://59.45.142.240:8808/pdf/US8916340.pdf	Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding	The John Hopkins University	6-Jan-06	8-Jan-07	23-Dec-14
1624	US20170073 390	http://59.45.142.240:8808/pdf/US20170073390A1.pdf	Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II	Not Available	6-Jan-06	5-Dec-14	16-Mar-17
1625	US20090081 157	http://59.45.142.240:8808/pdf/US20090081157A1.pdf	Immunostimulatory Combinations for Vaccine Adjuvants	Not Available	9-Jan-06	9-Jan-07	26-Mar-09
1626	US20090083 865	http://59.45.142.240:8808/pdf/US20090083865A1.pdf	Transgenic Mouse Lines Expressing Human Acp2 and Usage Thereof	CHAN TEH-SHENG	11-Jan-06	11-Jan-07	26-Mar-09

1627	US8592567	http://59.45.142.240:8808/pdf/US8592567.pdf	Vaccines and immunotherapeutics using codon-optimized IL-15 and	The Trustees of the University of	13-Jan-06	3-May-12	26-Nov-13
1628	US20130115 244	http://59.45.142.240:8808/pdf/US20130115244A1.pdf	Immunogenic Substances Comprising a Polyinosinic Acid -	Yisheng Biopharma (Singapore) PTE.	13-Jan-06	1-Oct-12	9-May-13
1629	US20100003 277	http://59.45.142.240:8808/pdf/US20100003277A1.pdf	VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED IL-15 AND	KUTZLER MICHELE	13-Jan-06	12-Jan-07	7-Jan-10
1630	US20090311 334	http://59.45.142.240:8808/pdf/US20090311334A1.pdf	MUCOSAL IMMUNOGENIC SUBSTANCES COMPRISING A POLYINOSINIC ACID - POLYCYTIDILIC ACID BASED	LI LIE TAO VICTOR	13-Jan-06	27-Jun-06	17-Dec-09
1631	US20090264 307	http://59.45.142.240:8808/pdf/US20090264307A1.pdf	ARRAY-BASED POLYMORPHISM MAPPING AT SINGLE NUCLEOTIDE	The Trustees of Princeton University	13-Jan-06	12-Jan-07	22-Oct-09
1632	US20090220 514	http://59.45.142.240:8808/pdf/US20090220514A1.pdf	ADAM10 and its Uses Related to Infection	HODGE THOMAS	13-Jan-06	16-Jan-07	3-Sep-09
1633	US20090175 902		Immunogenic Substances Comprising A Polyinosinic Acid-	Not Available	13-Jan-06	27-Jun-06	9-Jul-09
1634	US20090317 421	http://59.45.142.240:8808/pdf/US20090317421A1.pdf	COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL	BURTS MONICA	18-Jan-06	18-Jan-07	24-Dec-09
1635	US20090124 512	http://59.45.142.240:8808/pdf/US20090124512A1.pdf	DNA ARRAY ANALYSIS AS A DIAGNOSTIC FOR CURRENT AND	REGENTS OF THE UNIVERSITY OF	18-Jan-06	18-Jan-07	14-May-09
1636	US9782434	http://59.45.142.240:8808/pdf/US9782434.pdf	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential	Sonoma Pharmaceuticals, Inc.	20-Jan-06	7-Jul-15	10-Oct-17
1637	US9072726	http://59.45.142.240:8808/pdf/US9072726.pdf	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential	Oculus Innovative Sciences, Inc.	20-Jan-06	21-Dec-09	7-Jul-15
1638	US8834445	http://59.45.142.240:8808/pdf/US8834445.pdf	Methods of treating or preventing peritonitis with oxidative reductive	Oculus Innovative Sciences, Inc.	20-Jan-06	30-Mar-12	16-Sep-14
1639	US20180028 562	http://59.45.142.240:8808/pdf/US20180028562A1.pdf	METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL	SONOMA PHARMACEUTICALS, INC.	20-Jan-06	10-Oct-17	1-Feb-18
1640	US20150306 137	http://59.45.142.240:8808/pdf/US20150306137A1.pdf	METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL	OCULUS INNOVATIVE SCIENCES, INC.	20-Jan-06	7-Jul-15	29-Oct-15
1641	US20100266 620	http://59.45.142.240:8808/pdf/US20100266620A1.pdf	Immunoconjugates for treatment of	SUN LE	20-Jan-06	19-Jan-07	21-Oct-10
1642	US20100092 399	http://59.45.142.240:8808/pdf/US20100092399A1.pdf	METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL	Oculus Innovative Sciences, Inc.	20-Jan-06	21-Dec-09	15-Apr-10
1643	US20070196 434	http://59.45.142.240:8808/pdf/US20070196434A1.pdf	Methods of preventing or treating sinusitis with oxidative reductive	Oculus Innovative Sciences, Inc.	20-Jan-06	22-Jan-07	23-Aug-07
1644	US20070196 357	http://59.45.142.240:8808/pdf/US20070196357A1.pdf	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential	Oculus Innovative Sciences, Inc.	20-Jan-06	22-Jan-07	23-Aug-07
1645	US20070196 274	http://59.45.142.240:8808/pdf/US20070196274A1.pdf	Immunoconjugates with improved efficacy for the treatment of	SUN LE	20-Jan-06	19-Jan-07	23-Aug-07
1646	US20070173 755	http://59.45.142.240:8808/pdf/US20070173755A1.pdf	Methods of treating or preventing peritonitis with oxidative reductive	Oculus Innovative Sciences, Inc.	20-Jan-06	22-Jan-07	26-Jul-07
1647	US20080015 194	http://59.45.142.240:8808/pdf/US20080015194A1.pdf	METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT	Joseph Errico	23-Jan-06	23-Jan-07	17-Jan-08
1648	US8623419	http://59.45.142.240:8808/pdf/US8623419.pdf	Technology for preparation of macromolecular microspheres	Ansun Biopharma, Inc.	24-Jan-06	4-Nov-11	7-Jan-14
1649	US20180071 219	http://59.45.142.240:8808/pdf/US20180071219A1.pdf	Technology for Preparation of Macromolecular Microspheres	Not Available	24-Jan-06	25-Sep-17	15-Mar-18
1650	US20150290 134	http://59.45.142.240:8808/pdf/US20150290134A1.pdf	TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES	Not Available	24-Jan-06	21-Apr-15	15-Oct-15
1651	US20140134 150	http://59.45.142.240:8808/pdf/US20140134150A1.pdf	TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES	Ansun Biopharma, Inc.	24-Jan-06	6-Jan-14	15-May-14
1652	US20100166 874	http://59.45.142.240:8808/pdf/US20100166874A1.pdf	Technology for Preparation of Macromolecular Microspheres	FANG FANG	24-Jan-06	8-Dec-09	1-Jul-10
1653	US20100129 386	http://59.45.142.240:8808/pdf/US20100129386A1.pdf	Composotions And Methods For The Identification And Treatment Of Immune-Mediated Inflammatory	CONG YINGZI	24-Jan-06	24-Jan-07	27-May-10
1654	US20070190 163	http://59.45.142.240:8808/pdf/US20070190163A1.pdf	Technology for preparation of macromolecular microspheres	FANG FANG	24-Jan-06	24-Jan-07	16-Aug-07
1655	US10583086	http://59.45.142.240:8808/pdf/US10583086.pdf	Technology for preparation of macromolecular microspheres	Ansun Biopharma, Inc.	24-Jan-06	25-Sep-17	10-Mar-20
1656	US20160158 340	http://59.45.142.240:8808/pdf/US20160158340A1.pdf	INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX	Not Available	27-Jan-06	4-Dec-15	9-Jun-16
1657	US20110027 314	http://59.45.142.240:8808/pdf/US20110027314A1.pdf	Influenza Vaccines Containing Hemagglutinin and Matrix Proteins	NOVARTIS VACCINES AND DIAGNOSTICS	27-Jan-06	26-Jan-07	3-Feb-11
1658	US20100254 985	http://59.45.142.240:8808/pdf/US20100254985A1.pdf	Protein Formulations	MEDIMMUNE, LLC	3-Feb-06	6-May-10	7-Oct-10
1659	US20080071 063	http://59.45.142.240:8808/pdf/US20080071063A1.pdf	Protein Formulations	MedImmune, Inc.	3-Feb-06	2-Feb-07	20-Mar-08
1660	US9422367	http://59.45.142.240:8808/pdf/US9422367.pdf	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	7-Feb-06	26-Nov-13	23-Aug-16
1661	US8623364	http://59.45.142.240:8808/pdf/US8623364.pdf	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8-Feb-06	24-Oct-12	7-Jan-14
1662	US7741450	http://59.45.142.240:8808/pdf/US7741450.pdf	Antibodies to GM-CSF	Morphotek Inc.	8-Feb-06	8-Feb-07	22-Jun-10
1663	US20160333 089	http://59.45.142.240:8808/pdf/US20160333089A1.pdf	Antigenic GM-CSF Peptides and Antibodies to GM-CSF	Not Available	8-Feb-06	18-Jul-16	17-Nov-16
1664	US20140086 928	http://59.45.142.240:8808/pdf/US20140086928A1.pdf	Antigenic GM-CSF Peptides and Antibodies to GM-CSF	MORPHOTEK, INC.	8-Feb-06	26-Nov-13	27-Mar-14
1665	US20130058 945	http://59.45.142.240:8808/pdf/US20130058945A1.pdf	Antigenic GM-CSF Peptides and Antibodies to GM-CSF	CHAO QIMIN	8-Feb-06	24-Oct-12	7-Mar-13
1666	US20100272 730	http://59.45.142.240:8808/pdf/US20100272730A1.pdf	Antigenic GM-CSF Peptides And Antibodies To GM-CSF	MORPHOTEK, INC.	8-Feb-06	16-Apr-10	28-Oct-10
1667	US20090300 778	http://59.45.142.240:8808/pdf/US20090300778A1.pdf	Neutral Sphingomyelinase-E and Its Use	HOPPE UTA	8-Feb-06	8-Feb-07	3-Dec-09

1668	US20080292 641	http://59.45.142.240:8808/pdf/US20080292641A1.pdf	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8-Feb-06	8-Feb-07	27-Nov-08
1669	US10023632	http://59.45.142.240:8808/pdf/US10023632.pdf	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8-Feb-06	18-Jul-16	17-Jul-18
1670	US20140221 631		BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals,	16-Feb-06	7-Mar-14	7-Aug-14
1671	US20130091 611	http://59.45.142.240:8808/pdf/US20130091611A1.pdf	Anti-viral Formulations Nanomaterials And Nanoparticles	LAMBKIN-WILLIAMS ROBERT	16-Feb-06	30-Nov-12	18-Apr-13
1672	US20100040 655	http://59.45.142.240:8808/pdf/US20100040655A1.pdf	Anti-viral Formulations Nanomaterials And Nanoparticles	INTRINSIQ MATERIALS	16-Feb-06	16-Feb-07	18-Feb-10
1673	US20090208 531	http://59.45.142.240:8808/pdf/US20090208531A1.pdf	ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA	National Institutes of Health Office of	16-Feb-06	16-Feb-07	20-Aug-09
1674	US7691877	http://59.45.142.240:8808/pdf/US7691877.pdf	Pharmaceuticals	Pfizer Inc.	17-Feb-06	16-Feb-07	6-Apr-10
1675	US20080031 877	http://59.45.142.240:8808/pdf/US20080031877A1.pdf	Purification of bacterial antigens	COVACCI ANTONELLO	17-Feb-06	16-Feb-07	7-Feb-08
1676	US20070197 478	http://59.45.142.240:8808/pdf/US20070197478A1.pdf	NOVEL PHARMACEUTICALS	PFIZER LTD	17-Feb-06	16-Feb-07	23-Aug-07
1677	US9920314	http://59.45.142.240:8808/pdf/US9920314.pdf	Compositions for and methods of identifying antigens	President and Fellows of Harvard	21-Feb-06	6-May-15	20-Mar-18
1678	US9051564	http://59.45.142.240:8808/pdf/US9051564.pdf	Compositions for and methods of identifying antigens	President and Fellows of Harvard	21-Feb-06	21-Feb-07	9-Jun-15
1679	US20190032 041	http://59.45.142.240:8808/pdf/US20190032041A1.pdf	COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS	Not Available	21-Feb-06	12-Feb-18	31-Jan-19
1680	US20160090 589	http://59.45.142.240:8808/pdf/US20160090589A1.pdf	COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS	Not Available	21-Feb-06	6-May-15	31-Mar-16
1681	US20090214 510	http://59.45.142.240:8808/pdf/US20090214510A1.pdf	Broad Spectrum Antiviral Compositions	Government of the US as represented by the Secretary, Department of Health and Human	21-Feb-06	21-Feb-07	27-Aug-09
1682	US20070197 646	http://59.45.142.240:8808/pdf/US20070197646A1.pdf	SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS	ACHILLION PHARMACEUTICALS, INC.	21-Feb-06	20-Feb-07	23-Aug-07
1683	US10662423	http://59.45.142.240:8808/pdf/US10662423.pdf	Compositions for and methods of identifying antigens	President and Fellows of Harvard	21-Feb-06	12-Feb-18	26-May-20
1684	US8951528	http://59.45.142.240:8808/pdf/US8951528.pdf	Immune response modifier conjugates	3M Innovative Properties Company	22-Feb-06	21-Feb-07	10-Feb-15
1685	US20150141 625	http://59.45.142.240:8808/pdf/US20150141625A1.pdf	IMMUNE RESPONSE MODIFIER CONJUGATES	Not Available	22-Feb-06	20-Jan-15	21-May-15
1686	US20090035 323	http://59.45.142.240:8808/pdf/US20090035323A1.pdf	IMMUNE RESPONSE MODIFIER CONJUGATES	Not Available	22-Feb-06	21-Feb-07	5-Feb-09
1687	US10472420	http://59.45.142.240:8808/pdf/US10472420.pdf	Immune response modifier conjugates	3M Innovative Properties Company	22-Feb-06	20-Jan-15	12-Nov-19
1688	US20070196 333	http://59.45.142.240:8808/pdf/US20070196333A1.pdf	Composition comprising mixtures of IEM alpha subtypes	HUANG SHIR-LY	23-Feb-06	23-Feb-06	23-Aug-07
1689	US9518093	http://59.45.142.240:8808/pdf/US9518093.pdf	Topical formulation of arginine-rich cyclic antimicrobial peptides	NOVABIOTICS LIMITED	24-Feb-06	9-Nov-15	13-Dec-16
1690	US8431160	http://59.45.142.240:8808/pdf/US8431160.pdf	Microparticles containing biodegradable polymer and cationic polysaccharide for use in	Novartis AG	24-Feb-06	24-Feb-07	30-Apr-13
1691	US20160168 203		Cyclic Antimicrobial Peptides	NOVABIOTICS LIMITED	24-Feb-06	9-Nov-15	16-Jun-16
1692	US20090169 636	http://59.45.142.240:8808/pdf/US20090169636A1.pdf	Microparticles containing biodegradable polymer and cationic polysaccharide for use in	Not Available	24-Feb-06	24-Feb-07	2-Jul-09
1693	US20090197 914	http://59.45.142.240:8808/pdf/US20090197914A1.pdf	Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions	CAGE PETER	7-Mar-06	6-Mar-07	6-Aug-09
1694	US20090012 125	http://59.45.142.240:8808/pdf/US20090012125A1.pdf	Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions	CAGE PETER	7-Mar-06	6-Mar-07	8-Jan-09
1695	US20090286 726	http://59.45.142.240:8808/pdf/US20090286726A1.pdf	USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR TREATMENT OF VIRAL DISEASES	TECNOGEN S.P.A.	10-Mar-06	28-Feb-07	19-Nov-09
1696	US20090062 259	http://59.45.142.240:8808/pdf/US20090062259A1.pdf	Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists	ASTRAZENECA AB	14-Mar-06	12-Mar-07	5-Mar-09
1697	US20140308 313	http://59.45.142.240:8808/pdf/US20140308313A1.pdf	COMPOSITIONS AND METHODS FOR IMMUNISATION USING CD1D	Not Available	15-Mar-06	26-Jun-14	16-Oct-14
1698	US20090304 743	http://59.45.142.240:8808/pdf/US20090304743A1.pdf	Composition and Methods for Immunisation Using CD1D Ligands	GALLI GRAZIA	15-Mar-06	15-Mar-07	10-Dec-09
1699	US20090298 821	http://59.45.142.240:8808/pdf/US20090298821A1.pdf	HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND	Pfizer Inc.	15-Mar-06	14-Mar-07	3-Dec-09
1700	US20090221 551	http://59.45.142.240:8808/pdf/US20090221551A1.pdf	SUBSTITUTED FUSED[1,2]IMIDAZO[4,5C] RING COMPOUNDS AND METHODS	Pfizer Inc.	15-Mar-06	14-Mar-07	3-Sep-09
1701	US20100143 302	http://59.45.142.240:8808/pdf/US20100143302A1.pdf	Recombinant Adenoviruses Based on Serotype 26 and 48, and Use	Beth Israel Deaconess Medical	16-Mar-06	15-Mar-07	10-Jun-10
1702	US20090221 640	http://59.45.142.240:8808/pdf/US20090221640A1.pdf	Novel Crystal Modifications	ASTRAZENECA AB	16-Mar-06	15-Mar-07	3-Sep-09
1703	US20080044 438	http://59.45.142.240:8808/pdf/US20080044438A1.pdf	Yeast Cell Particles As Oral Delivery Vehicles For Antigens	OSTROFF GARY R	17-Mar-06	16-Mar-07	21-Feb-08
1704	US20090233 907	http://59.45.142.240:8808/pdf/US20090233907A1.pdf	Pyridopyrimidine Derivatives and Their Use as BDE4 Inhibitors	ASTRAZENECA AB	22-Mar-06	20-Mar-07	17-Sep-09
1705	US20090186 025	http://59.45.142.240:8808/pdf/US20090186025A1.pdf	Fusion Protein Comprising an Fc Receptor Binding Polypeptide and an Antigenic Polypeptide for Mediating	ImmunoBiology Limited	22-Mar-06	22-Mar-07	23-Jul-09
1706	US20130101 622	http://59.45.142.240:8808/pdf/US20130101622A1.pdf	IMIDAZOQUINOXALINE COMPOUNDS AS	Novartis AG	23-Mar-06	7-May-12	25-Apr-13
1707	US20100010 217	http://59.45.142.240:8808/pdf/US20100010217A1.pdf	METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING COMPOUNDS	LAN JIONG	23-Mar-06	23-Mar-07	14-Jan-10
1708	US20090311 288	http://59.45.142.240:8808/pdf/US20090311288A1.pdf	IMIDAZOQUINOXALINE COMPOUNDS AS	Novartis AG	23-Mar-06	23-Mar-07	17-Dec-09
1709	US20090232 844	http://59.45.142.240:8808/pdf/US20090232844A1.pdf	IMMUNOPOTENTIATING COMPOUNDS	SUTTON JAMES	23-Mar-06	23-Mar-07	17-Sep-09
1710	US20100068 223	http://59.45.142.240:8808/pdf/US20100068223A1.pdf	Storage of Influenza Vaccines Without Refrigeration	SCHIEFFCZIK HANNO	24-Mar-06	23-Mar-07	18-Mar-10

1711	US20090061 027	http://59.45.142.240:8808/pdf/US20090061027A1.pdf	Composition For The Prevention and Treatment Of Common Cold	PANDALIS GEORGIOS	24-Mar-06	2-Mar-07	5-Mar-09
1712	US8871503	http://59.45.142.240:8808/pdf/US8871503.pdf	Construct	Isis Innovation Limited	28-Mar-06	28-Mar-07	28-Oct-14
1713	US20150232 878	http://59.45.142.240:8808/pdf/US20150232878A1.pdf	Construct	Not Available	28-Mar-06	20-Oct-14	20-Aug-15
1714	US20100292 307	http://59.45.142.240:8808/pdf/US20100292307A1.pdf	Construct	ISIS INNOVATION LIMITED	28-Mar-06	28-Mar-07	18-Nov-10
1715	US20090311 683	http://59.45.142.240:8808/pdf/US20090311683A1.pdf	COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FLUENT	IBIS BIOSCIENCES, INC.	6-Apr-06	6-Apr-07	17-Dec-09
1716	US7261867	http://59.45.142.240:8808/pdf/US7261867B1.pdf	Production of silver sulfate grains using organo-sulfate or organo-	Eastman Kodak Company	7-Apr-06	7-Apr-06	28-Aug-07
1717	US20100055 116	http://59.45.142.240:8808/pdf/US20100055116A1.pdf	Methods and Compositions for Targeting c-Ret	CHENG SHUHUA	13-Apr-06	13-Apr-07	4-Mar-10
1718	US20090286 813	http://59.45.142.240:8808/pdf/US20090286813A1.pdf	Thioxanthine Derivatives and Their Use as Inhibitors of MPO	ASTRAZENECA AB	13-Apr-06	12-Apr-07	19-Nov-09
1719	US20090149 475	http://59.45.142.240:8808/pdf/US20090149475A1.pdf	Thioxanthine Derivatives and Their Use as Inhibitors of MPO	ASTRAZENECA AB	13-Apr-06	12-Apr-07	11-Jun-09
1720	US20090036 653	http://59.45.142.240:8808/pdf/US20090036653A1.pdf	Methods for the directed expansion of epitopes for use as antibody	Peptimmune, Inc.	13-Apr-06	7-May-08	5-Feb-09
1721	US20070243 263	http://59.45.142.240:8808/pdf/US20070243263A1.pdf	Antiviral Methods	AgION Technologies, Inc.	14-Apr-06	21-Mar-07	18-Oct-07
1722	US9849143	http://59.45.142.240:8808/pdf/US9849143.pdf	Broad spectrum antiviral and methods of use	The Burlington HC Research Group,	17-Apr-06	16-Feb-17	26-Dec-17
1723	US9585849	http://59.45.142.240:8808/pdf/US9585849.pdf	Broad spectrum antiviral and methods of use	The Burlington HC Research Group,	17-Apr-06	17-Apr-07	7-Mar-17
1724	US20200093 841	http://59.45.142.240:8808/pdf/US20200093841A1.pdf	Broad Spectrum Antiviral and Methods of Use	Not Available	17-Apr-06	30-Apr-19	26-Mar-20
1725	US20180344 751	http://59.45.142.240:8808/pdf/US20180344751A1.pdf	Broad Spectrum Antiviral and Methods of Use	Not Available	17-Apr-06	26-Dec-17	6-Dec-18
1726	US20170157 151	http://59.45.142.240:8808/pdf/US20170157151A1.pdf	Broad Spectrum Antiviral and Methods of Use	Not Available	17-Apr-06	16-Feb-17	8-Jun-17
1727	US20110053 894	http://59.45.142.240:8808/pdf/US20110053894A1.pdf	Broad Spectrum Antiviral and Methods of Use	LOVELACE RESPIRATORY RESEARCH	17-Apr-06	17-Apr-07	3-Mar-11
1728	US20090233 965	http://59.45.142.240:8808/pdf/US20090233965A1.pdf	Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive	ASTRAZENECA AB	24-Apr-06	23-Apr-07	17-Sep-09
1729	US20170096 646	http://59.45.142.240:8808/pdf/US20170096646A1.pdf	Modified Adenovirus Hexon Protein and Uses Thereof	Not Available	28-Apr-06	20-Dec-16	6-Apr-17
1730	US20160102 295	http://59.45.142.240:8808/pdf/US20160102295A1.pdf	MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOF	Not Available	28-Apr-06	22-May-15	14-Apr-16
1731	US20090317 417	http://59.45.142.240:8808/pdf/US20090317417A1.pdf	Modified AAV Vectors Having Reduced Capsid Immunogenicity and	The Trustees of the University of	28-Apr-06	27-Apr-07	24-Dec-09
1732	US20090074 810	http://59.45.142.240:8808/pdf/US20090074810A1.pdf	Modified Adenovirus Hexon Protein and Uses Thereof	The Trustees of the University of	28-Apr-06	27-Apr-07	19-Mar-09
1733	US20090275 508	http://59.45.142.240:8808/pdf/US20090275508A1.pdf	USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT	SIGMA-TAU INDUSTRIE FARMACEUTICHE	2-May-06	12-Apr-07	5-Nov-09
1734	US20070265 226	http://59.45.142.240:8808/pdf/US20070265226A1.pdf	Hydrolytically-Resistant Boron-Containing Therapeutics And	Anacor Pharmaceuticals	2-May-06	2-May-07	15-Nov-07
1735	US8410114	http://59.45.142.240:8808/pdf/US8410114.pdf	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil	AstraZeneca AB	8-May-06	6-Jan-12	2-Apr-13
1736	US20110003 315	http://59.45.142.240:8808/pdf/US20110003315A1.pdf	CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME	INSTITUT DE RECHERCHES CLINIQUES DE	8-May-06	8-May-07	6-Jan-11
1737	US20090209 555	http://59.45.142.240:8808/pdf/US20090209555A1.pdf	2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE	HANSEN PETER	8-May-06	7-May-07	20-Aug-09
1738	US20090131 486	http://59.45.142.240:8808/pdf/US20090131486A1.pdf	2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE	HANSEN PETER	8-May-06	7-May-07	21-May-09
1739	US20130273 080	http://59.45.142.240:8808/pdf/US20130273080A1.pdf	SIALOADHESIN-RELATED COMPOSITIONS AND METHODS	DELPUTTE PETER	11-May-06	15-Mar-13	17-Oct-13
1740	US20090104 147	http://59.45.142.240:8808/pdf/US20090104147A1.pdf	Sialoadhesin-Related Compositions and Methods	DELPUTTE PETER	11-May-06	11-May-07	23-Apr-09
1741	US20080044 378	http://59.45.142.240:8808/pdf/US20080044378A1.pdf	Methods and Compositions for Protein Production Using Adenoviral	INTROGEN THERAPEUTICS, INC.	15-May-06	15-May-07	21-Feb-08
1742	US20090275 666	http://59.45.142.240:8808/pdf/US20090275666A1.pdf	CONDENSATION PRODUCTS, METHOD FOR THEIR PRODUCTION AND USE THEREOF IN MEDICAMENTS, AS DISINFECTANTS	BASF SE	17-May-06	28-Feb-07	5-Nov-09
1743	US20090258 074	http://59.45.142.240:8808/pdf/US20090258074A1.pdf	MIXTURES OF TANNINS, THEIR PRODUCTION AND USE IN MEDICAMENTS OR AS	BASF SE	17-May-06	28-Feb-07	15-Oct-09
1744	US9526700	http://59.45.142.240:8808/pdf/US9526700.pdf	Composition for inactivating an enveloped virus	VIROBLOCK SA	19-May-06	17-Nov-14	27-Dec-16
1745	US8889398	http://59.45.142.240:8808/pdf/US8889398.pdf	Composition for inactivating an enveloped virus	Viroblock SA	19-May-06	18-May-07	18-Nov-14
1746	US7728110	http://59.45.142.240:8808/pdf/US7728110.pdf	Antibodies to SARS coronavirus	Amgen, Inc.	19-May-06	21-May-07	1-Jun-10
1747	US20150065 458	http://59.45.142.240:8808/pdf/US20150065458A1.pdf	Composition for Inactivating an Enveloped Virus	Not Available	19-May-06	17-Nov-14	5-Mar-15
1748	US20080248 043		Antibodies to SARS coronavirus	Amgen Inc.	19-May-06	21-May-07	9-Oct-08
1749	US9757470	http://59.45.142.240:8808/pdf/US9757470.pdf	Peptides for assisting delivery across the blood brain barrier	Children's Medical Center Corporation	22-May-06	30-Apr-14	12-Sep-17
1750	US8748567	http://59.45.142.240:8808/pdf/US8748567.pdf	Method for delivery across the blood brain barrier	Children's Medical Center Corporation	22-May-06	22-May-07	10-Jun-14
1751	US20180028 677	http://59.45.142.240:8808/pdf/US20180028677A1.pdf	Peptides for Assisting Delivery Across the Blood Brain Barrier	Children's Medical Center Corporation	22-May-06	30-Jun-17	1-Feb-18
1752	US20140294 727	http://59.45.142.240:8808/pdf/US20140294727A1.pdf	PEPTIDES FOR ASSISTING DELIVERY ACROSS THE BLOOD	Children's Medical Center Corporation	22-May-06	30-Apr-14	2-Oct-14

1753	US20100262 374	http://59.45.142.240:8808/pdf/US20100262374A1.pdf	Systems and methods for analyzing	HWANG JENQ-NENG	22-May-06	21-May-07	14-Oct-10
1754	US20100233 084	http://59.45.142.240:8808/pdf/US20100233084A1.pdf	Method for Delivery Across the Blood Brain Barrier	IMMUNE DISEASE INSTITUTE INC	22-May-06	22-May-07	16-Sep-10
1755	US7741360	http://59.45.142.240:8808/pdf/US7741360.pdf	Bi-aryl or aryl-heteroaryl substituted indoles	AstraZeneca AB	26-May-06	25-May-07	22-Jun-10
1756	US20100311 797		Novel Compounds	BONNERT ROGER VICTOR	26-May-06	2-Jun-10	9-Dec-10
1757	US20080260 764		REPLIKIN PEPTIDES AND USES THEREOF	BOGOCH ELENORE S	30-May-06	30-May-07	23-Oct-08
1758	US8846697	http://59.45.142.240:8808/pdf/US8846697.pdf	Purine analogs	The Regents of the University of California	31-May-06	23-Apr-07	30-Sep-14
1759	US20130190 494		PURINE ANALOGS	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	31-May-06	8-Mar-13	25-Jul-13
1760	US8501746	http://59.45.142.240:8808/pdf/US8501746.pdf	Organic compounds	Novartis AG	5-Jun-06	4-Jun-07	6-Aug-13
1761	US20140024 583		ORGANIC COMPOUNDS	Not Available	5-Jun-06	15-Jul-13	23-Jan-14
1762	US20100035 761	http://59.45.142.240:8808/pdf/US20100035761A1.pdf	High-throughput rna structure analysis	GIDDINGS MORGAN C	5-Jun-06	5-Jun-07	11-Feb-10
1763	US20090131 459	http://59.45.142.240:8808/pdf/US20090131459A1.pdf	2-Thioxanthine Derivatives Acting as MPO Inhibitors	ASTRAZENECA AB	5-Jun-06	4-Jun-07	21-May-09
1764	US20090124 640	http://59.45.142.240:8808/pdf/US20090124640A1.pdf	Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor	ASTRAZENECA AB	5-Jun-06	4-Jun-07	14-May-09
1765	US20080051 297	http://59.45.142.240:8808/pdf/US20080051297A1.pdf	Method for determining antigen-specific T cell response in high throughput format	Centro di Biotecnologie Avanzate and	12-Jun-06	11-Jun-07	28-Feb-08
1766	US20070286 822	http://59.45.142.240:8808/pdf/US20070286822A1.pdf	Compounds for the Treatment of Periodontal Disease	ANACOR PHARMACEUTICALS	12-Jun-06	12-Jun-07	13-Dec-07
1767	US8673904	http://59.45.142.240:8808/pdf/US8673904.pdf	Epoxide inhibitors of cysteine proteases	The Board of Trustees of the Leland Stanford	13-Jun-06	13-Jun-07	18-Mar-14
1768	US20080176 841	http://59.45.142.240:8808/pdf/US20080176841A1.pdf	EPOXIDE INHIBITORS OF CYSTEINE PROTEASES	THE BOARD OF TRUSTEES OF THE LELAND STANFORD	13-Jun-06	13-Jun-07	24-Jul-08
1769	US8808686	http://59.45.142.240:8808/pdf/US8808686.pdf	Adjuvant-sparing multi-dose influenza vaccination regimen	Novartis AG	15-Jun-06	19-Sep-11	19-Aug-14
1770	US20090220 545	http://59.45.142.240:8808/pdf/US20090220545A1.pdf	Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen	NOVARTIS AG	15-Jun-06	15-Jun-07	3-Sep-09
1771	US20100209 451	http://59.45.142.240:8808/pdf/US20100209451A1.pdf	Compositions and Methods Related to Adenovirus Based Delivery of	INTROGEN THERAPEUTICS, INC.	16-Jun-06	18-Jun-07	19-Aug-10
1772	US20100234 355	http://59.45.142.240:8808/pdf/US20100234355A1.pdf	ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF ENZYME-MEDIATED PROCESSES	MARTIN BARRIE	19-Jun-06	18-Jun-07	16-Sep-10
1773	US20100028 381	http://59.45.142.240:8808/pdf/US20100028381A1.pdf	FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS	3M INNOVATIVE PROPERTIES COMPANY	19-Jun-06	18-Jun-07	4-Feb-10
1774	US20080207 596	http://59.45.142.240:8808/pdf/US20080207596A1.pdf	Novel compounds 329	MARTIN BARRIE	19-Jun-06	19-Jun-07	28-Aug-08
1775	US9085641	http://59.45.142.240:8808/pdf/US9085641.pdf	Peptides regulating the surface expression of the T cell receptor	Max-Delbruck-Centrum Fur Molekulare Medizin	23-Jun-06	23-Jun-07	21-Jul-15
1776	US8865166	http://59.45.142.240:8808/pdf/US8865166.pdf	Antibodies to IL-17A and uses thereof	MedImmune Limited	23-Jun-06	22-Jun-07	21-Oct-14
1777	US20100291 120	http://59.45.142.240:8808/pdf/US20100291120A1.pdf	PEPTIDES REGULATING THE SURFACE EXPRESSION OF THE T CELL RECEPTOR	MAX-DELBRUCK-CENTRUM FUR MOLEKULARE	23-Jun-06	23-Jun-07	18-Nov-10
1778	US20080044 423		COMPOUNDS	COCHRANE DUNCAN	23-Jun-06	22-Jun-07	21-Feb-08
1779	US20100015 283	http://59.45.142.240:8808/pdf/US20100015283A1.pdf	Method of Preparing Powder Kimchi and Kimchi Composition Using the	Not Available	26-Jun-06	26-Jun-07	21-Jan-10
1780	US20100143 406	http://59.45.142.240:8808/pdf/US20100143406A1.pdf	METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS LIKE PARTICLES	PUSHKO PETER	30-Jun-06	27-Jun-07	10-Jun-10
1781	US20100240 623	http://59.45.142.240:8808/pdf/US20100240623A1.pdf	8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR2	COOK ANTHONY	5-Jul-06	3-Jul-07	23-Sep-10
1782	US20100003 269	http://59.45.142.240:8808/pdf/US20100003269A1.pdf	METHODS AND USES OF CAULIFLOWER AND COLLARD FOR RECOMBINANT PROTEIN	THOMAS JEFFERSON UNIVERSITY	11-Jul-06	28-Jun-07	7-Jan-10
1783	US20100021 895	http://59.45.142.240:8808/pdf/US20100021895A1.pdf	Vectors for Inducing Homozygous Mutations and Methods of Using	RULEY H EARL	12-Jul-06	12-Jul-07	28-Jan-10
1784	US20080070 907	http://59.45.142.240:8808/pdf/US20080070907A1.pdf	Substituted chiral fused [1,2]imidazo [4,5-C] ring compounds and	Coley Pharmaceutical	12-Jul-06	12-Jul-07	20-Mar-08
1785	US9649324	http://59.45.142.240:8808/pdf/US9649324.pdf	Use of tylvalosin as antiviral agent	CAMBRIDGE UNIVERSITY TECHNICAL	13-Jul-06	8-Jun-15	16-May-17
1786	US9066964	http://59.45.142.240:8808/pdf/US9066964.pdf	Use of tylvalosin as antiviral agent	Cambridge University Technical	13-Jul-06	13-Jul-07	30-Jun-15
1787	US20150313 929	http://59.45.142.240:8808/pdf/US20150313929A1.pdf	USE OF TYLVALOSIN AS ANTIVIRAL AGENT	CAMBRIDGE UNIVERSITY TECHNICAL	13-Jul-06	8-Jun-15	5-Nov-15
1788	US20100047 277	http://59.45.142.240:8808/pdf/US20100047277A1.pdf	VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS	COMPANS RICHARD W	13-Jul-06	12-Jul-07	25-Feb-10
1789	US20100010 080	http://59.45.142.240:8808/pdf/US20100010080A1.pdf	USE OF TYLVALOSIN AS ANTIVIRAL AGENT	CAMBRIDGE UNIVERSITY TECHNICAL	13-Jul-06	13-Jul-07	14-Jan-10
1790	US8440704	http://59.45.142.240:8808/pdf/US8440704.pdf	Quercetin-containing compositions	Quercetin Pharmaceuticals LLC	17-Jul-06	16-Dec-09	14-May-13
1791	US7745486	http://59.45.142.240:8808/pdf/US7745486.pdf	Quercetin-containing compositions	Quercetin Pharma LLC	17-Jul-06	16-Jul-07	29-Jun-10
1792	US20100160 245	http://59.45.142.240:8808/pdf/US20100160245A1.pdf	Quercetin-Containing Compositions	Quercetin Pharma LLC	17-Jul-06	16-Dec-09	24-Jun-10
1793	US20100035 973	http://59.45.142.240:8808/pdf/US20100035973A1.pdf	DISRUPTION OF PROGRAMMED DEATH 1 (PD-1) LIGAND TO ADJUVANT ADENO-ASSOCIATED	Nationwide Children's Hospital, Inc.	17-Jul-06	13-Jul-07	11-Feb-10
1794	US20080015 247	http://59.45.142.240:8808/pdf/US20080015247A1.pdf	QUERCETIN-CONTAINING COMPOSITIONS	LINES THOMAS C	17-Jul-06	16-Jul-07	17-Jan-08

1795	US20100092 401	http://59.45.142.240:8808/pdf/US20100092401A1.pdf	IMMUNE RESPONSE MODIFIER FORMULATIONS	Graceway Pharmaceuticals, LLC	18-Jul-06	12-Jul-07	15-Apr-10
1796	US20090299 250	http://59.45.142.240:8808/pdf/US20090299250A1.pdf	ANTIVIRAL FILTER AND ITS USE IN AN AIR PURIFIER, AIR	Universite De Rouen	19-Jul-06	19-Jul-07	3-Dec-09
1797	US20090176 815	http://59.45.142.240:8808/pdf/US20090176815A1.pdf	Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of	ERIKSSON TOMAS	19-Jul-06	16-Jan-09	9-Jul-09
1798	US20080167 332	http://59.45.142.240:8808/pdf/US20080167332A1.pdf	Novel Compounds 243	ELKINS BARRY	19-Jul-06	18-Jul-07	10-Jul-08
1799	US8993295	http://59.45.142.240:8808/pdf/US8993295.pdf	Methods, compositions, and kits for the selective activation of protoxins	The General Hospital Corporation	20-Jul-06	20-Jul-07	31-Mar-15
1800	US20100055 761	http://59.45.142.240:8808/pdf/US20100055761A1.pdf	METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL	THE GENERAL HOSPITAL CORPORATION	20-Jul-06	20-Jul-07	4-Mar-10
1801	US20090285 854	http://59.45.142.240:8808/pdf/US20090285854A1.pdf	FROZEN STOCKPILING OF INFLUENZA VACCINES	Novartis AG	20-Jul-06	20-Jul-07	19-Nov-09
1802	US20100150 943		IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA	NOVARTIS AG	26-Jul-06	26-Jul-07	17-Jun-10
1803	US20080058 309	http://59.45.142.240:8808/pdf/US20080058309A1.pdf	Novel Compounds 171	ASTRAZENECA AB	27-Jul-06	26-Jul-07	6-Mar-08
1804	US20080170 996	http://59.45.142.240:8808/pdf/US20080170996A1.pdf	Compositions and Methods for Stimulation of Lung Innate Immunity	The Board of Regents of the University of Texas	28-Jul-06	30-Jul-07	17-Jul-08
1805	US20080031 770	http://59.45.142.240:8808/pdf/US20080031770A1.pdf	Apparatus and method for using ozone as a disinfectant	BOAST NIGEL	2-Aug-06	29-Nov-06	7-Feb-08
1806	US20080031 979	http://59.45.142.240:8808/pdf/US20080031979A1.pdf	USE OF EXTRACTS FOR THE TREATMENT OF VIRAL DISORDERS	BODDUPALLI SEKHAR	4-Aug-06	4-Aug-06	7-Feb-08
1807	US8884020	http://59.45.142.240:8808/pdf/US8884020.pdf	Indole compounds	Ironwood Pharmaceuticals, Inc.	7-Aug-06	7-Aug-07	11-Nov-14
1808	US20100197 708		INDOLE COMPOUNDS	BARDEN TIMOTHY	7-Aug-06	7-Aug-07	5-Aug-10
1809	US20100233 116		ORGANIC COMPOUNDS	DALES NATALIE	15-Aug-06	13-Aug-07	16-Sep-10
1810	US20150030 627	http://59.45.142.240:8808/pdf/US20150030627A1.pdf	Trans-complementing, replication deficient lentiviral vectors and methods for their use	VIRxSYS.CON390	17-Aug-06	8-Oct-14	29-Jan-15
1811	US20090214 533	http://59.45.142.240:8808/pdf/US20090214533A1.pdf	METHODS FOR CONVERTING OR INDUCING PROTECTIVE IMMUNITY	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE	17-Aug-06	17-Feb-09	27-Aug-09
1812	US20100273 670	http://59.45.142.240:8808/pdf/US20100273670A1.pdf	DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING DNA MICROARRAY	DAWSON ERICA	21-Aug-06	21-Aug-07	28-Oct-10
1813	US20100239 520		ORGANIC COMPOUNDS	DALES NATALIE	24-Aug-06	22-Aug-07	23-Sep-10
1814	US9145585	http://59.45.142.240:8808/pdf/US9145585.pdf	Method for using permuted nucleic acid probes	Ventana Medical Systems, Inc.	1-Sep-06	5-Aug-14	29-Sep-15
1815	US8828659	http://59.45.142.240:8808/pdf/US8828659.pdf	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1-Sep-06	11-Mar-13	9-Sep-14
1816	US8420798	http://59.45.142.240:8808/pdf/US8420798.pdf	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1-Sep-06	31-Aug-07	16-Apr-13
1817	US20140342 941	http://59.45.142.240:8808/pdf/US20140342941A1.pdf	METHOD FOR USING PERMUTED NUCLEIC ACID PROBES	Ventana Medical Systems, Inc.	1-Sep-06	5-Aug-14	20-Nov-14
1818	US20130183 670	http://59.45.142.240:8808/pdf/US20130183670A1.pdf	METHOD FOR PRODUCING NUCLEIC ACID PROBES	Ventana Medical Systems, Inc.	1-Sep-06	11-Mar-13	18-Jul-13
1819	US20100151 490	http://59.45.142.240:8808/pdf/US20100151490A1.pdf	Antigenic Protein Conjugates and Process for Preparing Same	ABBOTT LABORATORIES	1-Sep-06	25-Feb-10	17-Jun-10
1820	US20080057 513	http://59.45.142.240:8808/pdf/US20080057513A1.pdf	METHOD FOR PRODUCING NUCLEIC ACID PROBES	Ventana Medical Systems, Inc.	1-Sep-06	31-Aug-07	6-Mar-08
1821	US9795666	http://59.45.142.240:8808/pdf/US9795666.pdf	High-yield transgenic mammalian expression system for generating	Academia Sinica	5-Sep-06	11-Feb-15	24-Oct-17
1822	US8980281	http://59.45.142.240:8808/pdf/US8980281.pdf	High-yield transgenic mammalian expression system for generating	Academia Sinica	5-Sep-06	12-Feb-10	17-Mar-15
1823	US20150265 697	http://59.45.142.240:8808/pdf/US20150265697A1.pdf	HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR GENERATING VIRUS-LIKE	Academia Sinica	5-Sep-06	11-Feb-15	24-Sep-15
1824	US20100166 769	http://59.45.142.240:8808/pdf/US20100166769A1.pdf	High-yield Transgenic Mammalian Expression System for Generating	Academia Sinica	5-Sep-06	12-Feb-10	1-Jul-10
1825	US20100086 950	http://59.45.142.240:8808/pdf/US20100086950A1.pdf	IP-10 BASED IMMUNOLOGICAL MONITORING	Hvidovre Hospital	5-Sep-06	5-Sep-07	8-Apr-10
1826	US20080063 664	http://59.45.142.240:8808/pdf/US20080063664A1.pdf	High-yield transgenic mammalian expression system for generating	Academia Sinica	5-Sep-06	5-Sep-06	13-Mar-08
1827	US20100173 906	http://59.45.142.240:8808/pdf/US20100173906A1.pdf	Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-Tetraazacyclopenta[cd]Phenalenes	GRIESGRABER GEORGE W	6-Sep-06	6-Sep-07	8-Jul-10
1828	US20090082 287	http://59.45.142.240:8808/pdf/US20090082287A1.pdf	METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND	PARION SCIENCES, INC.	7-Sep-06	7-Sep-07	26-Mar-09
1829	US20080090 841	http://59.45.142.240:8808/pdf/US20080090841A1.pdf	METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND	PARION SCIENCES, Inc.	7-Sep-06	7-Sep-07	17-Apr-08
1830	US20080234 345	http://59.45.142.240:8808/pdf/US20080234345A1.pdf	METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE PROTECTIVE TRACT	Gene Logic Inc.	8-Sep-06	7-Sep-07	25-Sep-08
1831	US20080107 650	http://59.45.142.240:8808/pdf/US20080107650A1.pdf	METHOD FOR TREATING INFLAMMATORY DISEASES OF THE PROTECTIVE TRACT	Gene Logic Inc.	8-Sep-06	7-Sep-07	8-May-08
1832	US20160193 321	http://59.45.142.240:8808/pdf/US20160193321A1.pdf	MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS	Novartis AG	11-Sep-06	5-Nov-15	7-Jul-16
1833	US20100010 199	http://59.45.142.240:8808/pdf/US20100010199A1.pdf	MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS	NOVARTIS AG	11-Sep-06	11-Sep-07	14-Jan-10
1834	US9481912	http://59.45.142.240:8808/pdf/US9481912.pdf	Compositions and methods for detecting and identifying nucleic acid	Longhorn Vaccines and Diagnostics, LLC	12-Sep-06	8-Oct-13	1-Nov-16
1835	US9080204	http://59.45.142.240:8808/pdf/US9080204.pdf	Compositions and methods for rapid, real-time detection of influenza a	Longhorn Vaccines and Diagnostics, LLC	12-Sep-06	30-Dec-11	14-Jul-15

1836	US8652782	http://59.45.142.240:8808/pdf/US8652782.pdf	Compositions and methods for detecting, identifying and	Longhorn Vaccines & Diagnostics, LLC	12-Sep-06	26-Apr-11	18-Feb-14
1837	US20190323 068	http://59.45.142.240:8808/pdf/US20190323068A1.pdf	PCR Ready Compositions and Methods for Screening Biological	Longhorn Vaccines and Diagnostics, LLC	12-Sep-06	28-Jun-19	24-Oct-19
1838	US20140030 703	http://59.45.142.240:8808/pdf/US20140030703A1.pdf	Compositions and Methods for Detecting and Identifying Nucleic	LONGHORN VACCINES AND DIAGNOSTICS, LLC	12-Sep-06	8-Oct-13	30-Jan-14
1839	US20100009 343	http://59.45.142.240:8808/pdf/US20100009343A1.pdf	COMPOSITIONS AND METHOD FOR RAPID, REAL-TIME DETECTION OF INFLUENZA A VIRUS (H1N1) SWINE	Longhorn Vaccines & Diagnostics, LLC	12-Sep-06	28-Jul-09	14-Jan-10
1840	US9149473	http://59.45.142.240:8808/pdf/US9149473.pdf	Targeted whole genome amplification method for	IBIS BIOSCIENCES, INC.	14-Sep-06	14-Sep-07	6-Oct-15
1841	US20160108 461	http://59.45.142.240:8808/pdf/US20160108461A1.pdf	TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR IDENTIFICATION OF PATHOGENS	Not Available	14-Sep-06	5-Oct-15	21-Apr-16
1842	US20100254 944		Albumin Fusion Proteins	STUMP DAVID CARTER	14-Sep-06	13-Sep-07	7-Oct-10
1843	US20100035 232	http://59.45.142.240:8808/pdf/US20100035232A1.pdf	TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR IDENTIFICATION OF PATHOGENS	ECKER DAVID J	14-Sep-06	14-Sep-07	11-Feb-10
1844	US8828940	http://59.45.142.240:8808/pdf/US8828940.pdf	Method of treating an ischemia-reperfusion injury-related disorder	Compugen Ltd.	18-Sep-06	14-Dec-10	9-Sep-14
1845	US20150005 227	http://59.45.142.240:8808/pdf/US20150005227A1.pdf	METHOD OF TREATING AN ISCHEMIA-REPERFUSION INJURY-RELATED DISORDER BY	Not Available	18-Sep-06	7-Sep-14	1-Jan-15
1846	US20090054 342	http://59.45.142.240:8808/pdf/US20090054342A1.pdf	Bioactive peptides and method of using same	AYALON-SOFFER MICHAEL	18-Sep-06	18-Sep-07	26-Feb-09
1847	US20100150 960	http://59.45.142.240:8808/pdf/US20100150960A1.pdf	COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED IMMUNE RESPONSE	The United States of America, as represented by the Secretary, Department of Health and	22-Sep-06	21-Sep-07	17-Jun-10
1848	US20100029 718		ORGANIC COMPOUNDS	Novartis AG	22-Sep-06	19-Sep-07	4-Feb-10
1849	US20110034 438	http://59.45.142.240:8808/pdf/US20110034438A1.pdf	STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF	FORSCHUNGSVERBUND BERLIN E.V.	25-Sep-06	25-Sep-07	10-Feb-11
1850	US20090214 663	http://59.45.142.240:8808/pdf/US20090214663A1.pdf	Virus coated nanoparticles and uses thereof	ALBRECHT THOMAS B	26-Sep-06	26-Mar-09	27-Aug-09
1851	US9382545	http://59.45.142.240:8808/pdf/US9382545.pdf	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory	COLEY PHARMACEUTICAL GMBH	27-Sep-06	4-Oct-13	5-Jul-16
1852	US8580268	http://59.45.142.240:8808/pdf/US8580268.pdf	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory	Coley Pharmaceutical GmbH	27-Sep-06	27-Sep-07	12-Nov-13
1853	US20160348 115	http://59.45.142.240:8808/pdf/US20160348115A1.pdf	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory	Not Available	27-Sep-06	26-May-16	1-Dec-16
1854	US20140163 213	http://59.45.142.240:8808/pdf/US20140163213A1.pdf	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory	COLEY PHARMACEUTICAL GMBH	27-Sep-06	4-Oct-13	12-Jun-14
1855	US20100189 772	http://59.45.142.240:8808/pdf/US20100189772A1.pdf	Compositions of TLR ligands and antivirals	COLEY PHARMACEUTICAL GMBH	27-Sep-06	27-Sep-07	29-Jul-10
1856	US20100166 780	http://59.45.142.240:8808/pdf/US20100166780A1.pdf	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory	Pfizer Inc	27-Sep-06	27-Sep-07	1-Jul-10
1857	US10260071	http://59.45.142.240:8808/pdf/US10260071.pdf	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory	COLEY PHARMACEUTICAL GMBH	27-Sep-06	26-May-16	16-Apr-19
1858	US10106619	http://59.45.142.240:8808/pdf/US10106619.pdf	Virus vaccination and treatment methods with OX40 agonist	La Jolla Institute for Allergy and	4-Oct-06	4-Oct-07	23-Oct-18
1859	US8940864	http://59.45.142.240:8808/pdf/US8940864.pdf	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc	5-Oct-06	2-Oct-07	27-Jan-15
1860	US8937154	http://59.45.142.240:8808/pdf/US8937154.pdf	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc	5-Oct-06	2-Feb-12	20-Jan-15
1861	US20100130 430	http://59.45.142.240:8808/pdf/US20100130430A1.pdf	STABILIZED THERAPEUTIC SMALL HELICAL ANTIVIRAL PEPTIDES	New York Blood Center, Inc	5-Oct-06	2-Oct-07	27-May-10
1862	US20100086 571	http://59.45.142.240:8808/pdf/US20100086571A1.pdf	METHODS TO DECREASE THE RISK OF METABOLIC SYNDROME POST IMMUNIZATION	CLASSEN JOHN BARTHELOW	5-Oct-06	5-Oct-07	8-Apr-10
1863	US20180363 027	http://59.45.142.240:8808/pdf/US20180363027A1.pdf	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF ANTIGENS FROM	Not Available	6-Oct-06	15-May-18	20-Dec-18
1864	US20160340 713	http://59.45.142.240:8808/pdf/US20160340713A1.pdf	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF ANTIGENS FROM	Not Available	6-Oct-06	20-May-16	24-Nov-16
1865	US20100099 149	http://59.45.142.240:8808/pdf/US20100099149A1.pdf	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF ANTIGENS FROM	DNA GENOTEK INC.	6-Oct-06	5-Oct-07	22-Apr-10
1866	US20100286 251	http://59.45.142.240:8808/pdf/US20100286251A1.pdf	Mammalian Genes Involved In Viral Infection And Tumor Suppression	RUBIN DONALD H	11-Oct-06	5-Mar-10	11-Nov-10
1867	US9730912	http://59.45.142.240:8808/pdf/US9730912.pdf	Pharmaceutical compounds	ASTEX THERAPEUTICS LIMITED	12-Oct-06	12-Oct-07	15-Aug-17
1868	US9428439	http://59.45.142.240:8808/pdf/US9428439.pdf	Hydrobenzamide derivatives as inhibitors of Hsp90	ASTEX THERAPEUTICS LTD	12-Oct-06	7-Jan-14	30-Aug-16
1869	US8916552	http://59.45.142.240:8808/pdf/US8916552.pdf	Pharmaceutical combinations	Astex Therapeutics Limited	12-Oct-06	12-Oct-07	23-Dec-14
1870	US8883790	http://59.45.142.240:8808/pdf/US8883790.pdf	Pharmaceutical combinations	Astex Therapeutics Limited	12-Oct-06	12-Oct-07	11-Nov-14
1871	US8779132	http://59.45.142.240:8808/pdf/US8779132.pdf	Pharmaceutical compounds	Astex Therapeutics Limited	12-Oct-06	12-Oct-07	15-Jul-14
1872	US8653084	http://59.45.142.240:8808/pdf/US8653084.pdf	Hydrobenzamide derivatives as inhibitors of Hsp90	Astex Therapeutics Ltd	12-Oct-06	12-Oct-07	18-Feb-14
1873	US20140221 394	http://59.45.142.240:8808/pdf/US20140221394A1.pdf	HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90	Astex Therapeutic Ltd	12-Oct-06	7-Jan-14	7-Aug-14
1874	US20110046 155	http://59.45.142.240:8808/pdf/US20110046155A1.pdf	HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90	FREDERICKSON MARTYN	12-Oct-06	12-Oct-07	24-Feb-11
1875	US20100179 145		PHARMACEUTICAL COMBINATIONS	GALLAGHER NEIL JAMES	12-Oct-06	12-Oct-07	15-Jul-10
1876	US20100105 025	http://59.45.142.240:8808/pdf/US20100105025A1.pdf	DEVICES FOR GENERATING DETECTABLE POLYMERS	Not Available	12-Oct-06	12-Oct-07	29-Apr-10

1877	US20100092 474	http://59.45.142.240:8808/pdf/US20100092474A1.pdf	PHARMACEUTICAL COMBINATIONS	GALLAGHER NEIL JAMES	12-Oct-06	12-Oct-07	15-Apr-10
1878	US20080090 229	http://59.45.142.240:8808/pdf/US20080090229A1.pdf	Devices for generating detectable polymers	ENGELHARD ERIC K	12-Oct-06	12-Oct-06	17-Apr-08
1879	US20090275 583	http://59.45.142.240:8808/pdf/US20090275583A1.pdf	ANTIVIRAL COMPOUNDS AND USE THEREOF	Myriad Genetics, Incorporated, Hollis-Eden Pharmaceuticals,	13-Oct-06	13-Apr-09	5-Nov-09
1880	US20080090 791		Cystic fibrosis treatment methods	Myriad Genetics, Incorporated	13-Oct-06	13-Oct-06	17-Apr-08
1881	US20090105 203	http://59.45.142.240:8808/pdf/US20090105203A1.pdf	COMPOUNDS FOR TREATING VIRAL INFECTIONS	Myriad Genetics, Incorporated	16-Oct-06	16-Oct-07	23-Apr-09
1882	US20080207 573	http://59.45.142.240:8808/pdf/US20080207573A1.pdf	COMPOUNDS FOR TREATING VIRAL INFECTIONS	Myriad Genetics, Incorporated	16-Oct-06	7-May-08	28-Aug-08
1883	US20100184 190	http://59.45.142.240:8808/pdf/US20100184190A1.pdf	Influencing viral lipid constituents	MedImmune, LLC	17-Oct-06	9-Oct-07	22-Jul-10
1884	US20100099 745	http://59.45.142.240:8808/pdf/US20100099745A1.pdf	ENHANCING DISEASE RESISTANCE AGAINST RNA VIRAL INFECTIONS WITH INTRACYTOPLASMIC	GUO ZHA	18-Oct-06	16-Oct-07	22-Apr-10
1885	US20100130 503	http://59.45.142.240:8808/pdf/US20100130503A1.pdf	NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN	SANOFI-AVENTIS	24-Oct-06	24-Nov-09	27-May-10
1886	US20080176 217	http://59.45.142.240:8808/pdf/US20080176217A1.pdf	METHOD OF PREDICTING INFLUENZA OUTBREAKS BY CORRELATING AN INCREASE IN REPLIKIN COUNT IN SHRIMP WHITE SPOT SYNDROME VIRUS AND/OR	BOGOCH ELENORE S	24-Oct-06	24-Oct-07	24-Jul-08
1887	US9446062	http://59.45.142.240:8808/pdf/US9446062.pdf	Methods of treating ischemia-reperfusion injury with siRNAs	Quark Pharmaceuticals,	25-Oct-06	8-Jan-15	20-Sep-16
1888	US20150329 866	http://59.45.142.240:8808/pdf/US20150329866A1.pdf	NOVEL siRNAs AND METHODS OF USE THEREOF	Not Available	25-Oct-06	8-Jan-15	19-Nov-15
1889	US20090162 365	http://59.45.142.240:8808/pdf/US20090162365A1.pdf	Novel siRNAs and methods of use thereof	FEINSTEIN ELENA	25-Oct-06	25-Oct-07	25-Jun-09
1890	US20100144 846	http://59.45.142.240:8808/pdf/US20100144846A1.pdf	Oligoribonucleotides and uses thereof	COLEY PHARMACEUTICAL	26-Oct-06	26-Oct-07	10-Jun-10
1891	US20100047 179	http://59.45.142.240:8808/pdf/US20100047179A1.pdf	TARGETED SPLIT BIOMOLECULAR CONJUGATES FOR THE TREATMENT OF DISEASES, MALIGNANCIES AND DISORDERS, AND METHODS OF	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	27-Oct-06	26-Oct-07	25-Feb-10
1892	US20110038 879	http://59.45.142.240:8808/pdf/US20110038879A1.pdf	IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES	NOVARTIS AG	30-Oct-06	30-Oct-07	17-Feb-11
1893	US20100048 575	http://59.45.142.240:8808/pdf/US20100048575A1.pdf	NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC	COLLAND FREDERIC	30-Oct-06	25-Oct-07	25-Feb-10
1894	US20080103 149	http://59.45.142.240:8808/pdf/US20080103149A1.pdf	NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC	COLLAND FREDERIC	30-Oct-06	30-Oct-06	1-May-08
1895	US20080118 473	http://59.45.142.240:8808/pdf/US20080118473A1.pdf	Methods of treating a respiratory condition comprising probiotic	Alimentary Health Ltd.	1-Nov-06	31-Oct-07	22-May-08
1896	US20080233 128		Treatment of Viral Infections	KRAUSE WERNER	2-Nov-06	1-Nov-07	25-Sep-08
1897	US20070238 681		MODULATION OF ACE2 EXPRESSION	BENNETT C F	7-Nov-06	7-Dec-06	11-Oct-07
1898	US9744231	http://59.45.142.240:8808/pdf/US9744231.pdf	Quality control methods for oil-in-water emulsions containing squalene	NOVARTIS AG	8-Nov-06	27-Aug-13	29-Aug-17
1899	US8562943	http://59.45.142.240:8808/pdf/US8562943.pdf	Quality control methods for oil-in-water emulsions containing squalene	Novartis AG	8-Nov-06	6-Nov-07	22-Oct-13
1900	US20140178 428	http://59.45.142.240:8808/pdf/US20140178428A1.pdf	QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS	Novartis AG	8-Nov-06	27-Aug-13	26-Jun-14
1901	US20090117 115	http://59.45.142.240:8808/pdf/US20090117115A1.pdf	Binary epitope antibodies and B cell superantigen immune stimulants	NISHIYAMA YASUHIRO	9-Nov-06	9-Nov-07	7-May-09
1902	US20100029 713	http://59.45.142.240:8808/pdf/US20100029713A1.pdf	QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR	ASTRAZENECA AB	14-Nov-06	13-Nov-07	4-Feb-10
1903	US8895295	http://59.45.142.240:8808/pdf/US8895295.pdf	High density self-contained biological analysis	Biofire Diagnostics, LLC	15-Nov-06	14-Nov-07	25-Nov-14
1904	US8796423	http://59.45.142.240:8808/pdf/US8796423.pdf	Anti-TSG101 antibodies and their uses for treatment of viral infections	Eli Lilly and Company	15-Nov-06	18-Apr-08	5-Aug-14
1905	US20180216 164	http://59.45.142.240:8808/pdf/US20180216164A1.pdf	HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS	Not Available	15-Nov-06	19-Mar-18	2-Aug-18
1906	US20150322 491	http://59.45.142.240:8808/pdf/US20150322491A1.pdf	High density self-contained biological analysis	Not Available	15-Nov-06	16-Jul-15	12-Nov-15
1907	US20130280 298	http://59.45.142.240:8808/pdf/US20130280298A1.pdf	Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya	LECLERC DENIS	15-Nov-06	15-Mar-13	24-Oct-13
1908	US20100056 383	http://59.45.142.240:8808/pdf/US20100056383A1.pdf	HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS	JONES DAVID E	15-Nov-06	14-Nov-07	4-Mar-10
1909	US20100047 264	http://59.45.142.240:8808/pdf/US20100047264A1.pdf	Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya	FOLIA BIOTECH INC.	15-Nov-06	25-Oct-07	25-Feb-10
1910	US20090186 041	http://59.45.142.240:8808/pdf/US20090186041A1.pdf	ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS	Functional Genetics, Inc.	15-Nov-06	18-Apr-08	23-Jul-09
1911	US20080187 528	http://59.45.142.240:8808/pdf/US20080187528A1.pdf	ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS	Functional Genetics, Inc.	15-Nov-06	15-Nov-07	7-Aug-08
1912	US10053728	http://59.45.142.240:8808/pdf/US10053728.pdf	High density self-contained biological analysis	BioFire Diagnostics, LLC	15-Nov-06	16-Jul-15	21-Aug-18
1913	US20100152 184		PHARMACEUTICAL COMPOUNDS	ASTEX THERAPEUTICS	16-Nov-06	12-Oct-07	17-Jun-10
1914	US20080233 150	http://59.45.142.240:8808/pdf/US20080233150A1.pdf	RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPs)	MAHMOOD KUTUB	16-Nov-06	16-Nov-07	25-Sep-08
1915	US20100029 557	http://59.45.142.240:8808/pdf/US20100029557A1.pdf	ALPHA-LACTALBUMIN COMPOSITION	GULDMANN MARIANNE	17-Nov-06	15-Nov-07	4-Feb-10
1916	US8754015	http://59.45.142.240:8808/pdf/US8754015.pdf	Modified phase for displaying post-translationally modified proteins and	University of Rochester	21-Nov-06	20-Nov-07	17-Jun-14

1917	US20100284 967	http://59.45.142.240:8808/pdf/US20100284967A1.pdf	MODIFIED PHAGE FOR DISPLAYING POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services	21-Nov-06	20-Nov-07	11-Nov-10
1918	US20090105 092		VIRAL DATABASE METHODS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE	28-Nov-06	27-Nov-07	23-Apr-09
1919	US20080310 992	http://59.45.142.240:8808/pdf/US20080310992A1.pdf	APPARATUS AND METHOD FOR USING OZONE AS A DISINFECTANT	VIROFORCE SYSTEMS, INC.	29-Nov-06	17-Jun-08	18-Dec-08
1920	US8778846	http://59.45.142.240:8808/pdf/US8778846.pdf	Composition, device and associated method	General Electric Company	4-Dec-06	1-Mar-07	15-Jul-14
1921	US8765643	http://59.45.142.240:8808/pdf/US8765643.pdf	Composition, device and associated method	General Electric Company	4-Dec-06	1-Mar-07	1-Jul-14
1922	US20190314 483	http://59.45.142.240:8808/pdf/US20190314483A1.pdf	Vaccines Including Antigen From Four Strains of Influenza Virus	Not Available	6-Dec-06	30-Nov-18	17-Oct-19
1923	US20140178 429	http://59.45.142.240:8808/pdf/US20140178429A1.pdf	Vaccines Including Antigen From Four Strains of Influenza Virus	NOVARTIS AG	6-Dec-06	24-Sep-13	26-Jun-14
1924	US20110045 022	http://59.45.142.240:8808/pdf/US20110045022A1.pdf	VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF INFLUENZA VIRUS	TSAI THEODORE	6-Dec-06	5-Dec-07	24-Feb-11
1925	US20100093 862	http://59.45.142.240:8808/pdf/US20100093862A1.pdf	POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS.	Sapporo Medical University and Japan Science and	6-Dec-06	6-Dec-07	15-Apr-10
1926	US8450284	http://59.45.142.240:8808/pdf/US8450284.pdf	Coiled-coil lipopeptide helical bundles and synthetic virus-like particles	Universitaet Zuerich	9-Dec-06	6-Dec-07	28-May-13
1927	US20100015 173	http://59.45.142.240:8808/pdf/US20100015173A1.pdf	COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES	UNIVERSITÄT ZÜRICH PROREKTORAT	9-Dec-06	6-Dec-07	21-Jan-10
1928	US20080300 244		NOVEL COMPOUNDS	AstraZeneca AB	14-Dec-06	13-Dec-07	4-Dec-08
1929	US8758763	http://59.45.142.240:8808/pdf/US8758763.pdf	Archaeal polar lipid aggregates for administration to animals	National Research Council of Canada	15-Dec-06	23-Jan-13	24-Jun-14
1930	US20130195 932	http://59.45.142.240:8808/pdf/US20130195932A1.pdf	ARCHAEOAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO ANIMALS	NATIONAL RESEARCH COUNCIL OF	15-Dec-06	23-Jan-13	1-Aug-13
1931	US20100113 510	http://59.45.142.240:8808/pdf/US20100113510A1.pdf	QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	FORD RHONAN	19-Dec-06	17-Dec-07	6-May-10
1932	US20100249 200	http://59.45.142.240:8808/pdf/US20100249200A1.pdf	Novel Compounds 569	CONNOLLY STEPHEN	20-Dec-06	30-Mar-10	30-Sep-10
1933	US20100056 508	http://59.45.142.240:8808/pdf/US20100056508A1.pdf	AMINE DERIVATIVES AND THEIR USE IN BETA-2- ADRENORECEPTOR MEDIATED DISEASES	ASTRAZENECA AB	20-Dec-06	19-Dec-07	4-Mar-10
1934	US20100029 722		ORGANIC COMPOUNDS	DALES NATALIE	20-Dec-06	19-Dec-07	4-Feb-10
1935	US20100022 491	http://59.45.142.240:8808/pdf/US20100022491A1.pdf	4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHAZOL-7YL COMPOUNDS FOR MODULATION OF	ASTRAZENECA AB	20-Dec-06	19-Dec-07	28-Jan-10
1936	US20080207 698	http://59.45.142.240:8808/pdf/US20080207698A1.pdf	Novel Compounds 569	CONNOLLY STEPHEN	20-Dec-06	19-Dec-07	28-Aug-08
1937	US20080149 100	http://59.45.142.240:8808/pdf/US20080149100A1.pdf	Antiviral Heat Treatment	DE HAAN PETRUS THEODORUS	20-Dec-06	20-Dec-06	26-Jun-08
1938	US20110038 849	http://59.45.142.240:8808/pdf/US20110038849A1.pdf	INHIBITORY POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR PREVENTING CANCER	Intradigm Corporation	21-Dec-06	21-Dec-06	17-Feb-11
1939	US9499799	http://59.45.142.240:8808/pdf/US9499799.pdf	Cells and methodology to generate non-segmented negative-strand RNA	Centre National De La Recherche Scientifique	22-Dec-06	15-Oct-13	22-Nov-16
1940	US8586364	http://59.45.142.240:8808/pdf/US8586364.pdf	Cells and methodology to generate non-segmented negative-strand RNA	Institut Pasteur	22-Dec-06	21-Dec-07	19-Nov-13
1941	US7803796	http://59.45.142.240:8808/pdf/US7803796.pdf	Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus	Sungkyunkwan University Foundation For Corporate	22-Dec-06	20-Dec-07	28-Sep-10
1942	US7758868	http://59.45.142.240:8808/pdf/US7758868.pdf	Modified polymerases and attenuated viruses and methods of	The Penn State Research	22-Dec-06	24-Dec-07	20-Jul-10
1943	US20180305 357	http://59.45.142.240:8808/pdf/US20180305357A1.pdf	IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS	Not Available	22-Dec-06	25-Jun-18	25-Oct-18
1944	US20140051 148	http://59.45.142.240:8808/pdf/US20140051148A1.pdf	Cells and Methodology to Generate Non-Segmented Negative- Strand RNA	Centre National De La Recherche Scientifique	22-Dec-06	15-Oct-13	20-Feb-14
1945	US20100144 040	http://59.45.142.240:8808/pdf/US20100144040A1.pdf	CELLS AND METHODOLOGY TO GENERATE NON-SEGMENTED NEGATIVE STRAND RNA VIRUSES	CHARNEAU PIERRE	22-Dec-06	21-Dec-07	10-Jun-10
1946	US20100129 400	http://59.45.142.240:8808/pdf/US20100129400A1.pdf	ATTENUATED VIRUSES, VACCINES AND METHODS OF USE THEREOF	THE PENN STATE RESEARCH FOUNDATION	22-Dec-06	12-Jan-10	27-May-10
1947	US20080207 597	http://59.45.142.240:8808/pdf/US20080207597A1.pdf	HOMOPIPERAZINE COMPOUNDS THAT INHIBIT RIBOSOMAL FRAMESHIFTING BY BINDING TO RNA PSEUDOKNOT STRUCTURE OF	SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE	22-Dec-06	20-Dec-07	28-Aug-08
1948	US20080175 861	http://59.45.142.240:8808/pdf/US20080175861A1.pdf	MODIFIED POLYMERASES AND ATTENUATED VIRUSES AND METHODS OF USE THEREOF	THE PENN STATE RESEARCH FOUNDATION	22-Dec-06	24-Dec-07	24-Jul-08
1949	US10144735	http://59.45.142.240:8808/pdf/US10144735.pdf	Immune response modifier compositions and methods	3M Innovative Properties Company	22-Dec-06	25-Jun-18	4-Dec-18
1950	US10005772	http://59.45.142.240:8808/pdf/US10005772.pdf	Immune response modifier compositions and methods	3M Innovative Properties Company	22-Dec-06	20-Dec-07	26-Jun-18
1951	US20100158 928	http://59.45.142.240:8808/pdf/US20100158928A1.pdf	IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS	GRIESGRABER GEORGE W.	25-Dec-06	20-Dec-07	24-Jun-10
1952	US20080206 235	http://59.45.142.240:8808/pdf/US20080206235A1.pdf	COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE	Johns Hopkins University	27-Dec-06	27-Dec-07	28-Aug-08
1953	US20080156 743	http://59.45.142.240:8808/pdf/US20080156743A1.pdf	HAZARDOUS SUBSTANCE REMOVING MATERIAL, METHOD FOR REMOVING HAZARDOUS	FUJIFILM Corporation	27-Dec-06	27-Dec-07	3-Jul-08
1954	US20160068 587	http://59.45.142.240:8808/pdf/US20160068587A1.pdf	OLIGOPEPTIDE-FREE CELL CULTURE MEDIA	Not Available	3-Jan-07	16-Nov-15	10-Mar-16
1955	US20080167 198		Filter based detection system	COONEY CHRISTOPHER	4-Jan-07	4-Jan-07	10-Jul-08
1956	US20080166 793	http://59.45.142.240:8808/pdf/US20080166793A1.pdf	Sorting, amplification, detection, and identification of nucleic acid	The Regents of the University of	4-Jan-07	4-Jan-07	10-Jul-08
1957	US20090252 646	http://59.45.142.240:8808/pdf/US20090252646A1.pdf	STERILIZATION METHODS AND SYSTEMS FOR GAMING EQUIPMENT	Invention Factory, LLC	8-Jan-07	28-May-09	8-Oct-09

1958	US20100204 203	http://59.45.142.240:8808/pdf/US20100204203A1.pdf	Chemical Compounds 637: Pyridopyrimidinediones as PDE4	BONNERT ROGER VICTOR	11-Jan-07	10-Jan-08	12-Aug-10
1959	US20090124 596	http://59.45.142.240:8808/pdf/US20090124596A1.pdf	Chemical Compounds 637	BONNERT ROGER VICTOR	11-Jan-07	10-Jan-08	14-May-09
1960	US20080207 650	http://59.45.142.240:8808/pdf/US20080207650A1.pdf	Chemical Compounds 636	BONNERT ROGER VICTOR	11-Jan-07	10-Jan-08	28-Aug-08
1961	US20090304 683	http://59.45.142.240:8808/pdf/US20090304683A1.pdf	Soluble Fragments of The Sars-Cov Spike Glycoprotein	DIMITROV DIMITER S	19-Jan-07	19-Jan-07	10-Dec-09
1962	US20100034 852	http://59.45.142.240:8808/pdf/US20100034852A1.pdf	METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING DRUG RESISTANT STRAINS OF INFLUENZA	NIMAN HENRY L	25-Jan-07	24-Jan-08	11-Feb-10
1963	US9688982	http://59.45.142.240:8808/pdf/US9688982.pdf	Methods and compositions for the treatment of cancer or other	CITY OF HOPE	26-Jan-07	11-Oct-13	27-Jun-17
1964	US9200280	http://59.45.142.240:8808/pdf/US9200280.pdf	Methods and compositions for the treatment of cancer or other	CITY OF HOPE	26-Jan-07	9-Jun-14	1-Dec-15
1965	US9200279	http://59.45.142.240:8808/pdf/US9200279.pdf	Methods and compositions for the treatment of cancer or other	CITY OF HOPE	26-Jan-07	14-Jan-14	1-Dec-15
1966	US8772471	http://59.45.142.240:8808/pdf/US8772471.pdf	Targeted delivery of siRNA	Immune Disease Institute	26-Jan-07	25-Jan-08	8-Jul-14
1967	US8748405	http://59.45.142.240:8808/pdf/US8748405.pdf	Methods and compositions for the treatment of cancer or other	City of Hope	26-Jan-07	9-Sep-11	10-Jun-14
1968	US20200032 255	http://59.45.142.240:8808/pdf/US20200032255A1.pdf	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR	Not Available	26-Jan-07	6-Mar-19	30-Jan-20
1969	US20180142 239	http://59.45.142.240:8808/pdf/US20180142239A1.pdf	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR	Not Available	26-Jan-07	14-Jun-17	24-May-18
1970	US20140287 987	http://59.45.142.240:8808/pdf/US20140287987A1.pdf	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR	CITY OF HOPE	26-Jan-07	9-Jun-14	25-Sep-14
1971	US20140128 324	http://59.45.142.240:8808/pdf/US20140128324A1.pdf	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR	CITY OF HOPE	26-Jan-07	14-Jan-14	8-May-14
1972	US20140066 592	http://59.45.142.240:8808/pdf/US20140066592A1.pdf	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR	City of Hope	26-Jan-07	11-Oct-13	6-Mar-14
1973	US20100209 440	http://59.45.142.240:8808/pdf/US20100209440A1.pdf	Targeted Delivery of siRNA	Immune Disease Institute, Inc	26-Jan-07	25-Jan-08	19-Aug-10
1974	US10253318	http://59.45.142.240:8808/pdf/US10253318.pdf	Methods and compositions for the treatment of cancer or other	CITY OF HOPE	26-Jan-07	14-Jun-17	9-Apr-19
1975	US7579396	http://59.45.142.240:8808/pdf/US7579396.pdf	Polymer composite	Eastman Kodak Company	31-Jan-07	31-Jan-07	25-Aug-09
1976	US20080181 969	http://59.45.142.240:8808/pdf/US20080181969A1.pdf	POLYMER COMPOSITE	BARNES CRAIG L	31-Jan-07	31-Jan-07	31-Jul-08
1977	US9050376	http://59.45.142.240:8808/pdf/US9050376.pdf	Conjugates of synthetic TLR agonists and uses therefor	The Regents of the University of California	7-Feb-07	19-Jun-14	9-Jun-15
1978	US8790655	http://59.45.142.240:8808/pdf/US8790655.pdf	Conjugates of synthetic TLR agonists and uses therefor	The Regents of The University of California	7-Feb-07	8-Jan-13	29-Jul-14
1979	US20140302 120	http://59.45.142.240:8808/pdf/US20140302120A1.pdf	CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR	Not Available	7-Feb-07	19-Jun-14	9-Oct-14
1980	US20130156 807	http://59.45.142.240:8808/pdf/US20130156807A1.pdf	CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR	The Regents of The University of California	7-Feb-07	8-Jan-13	20-Jun-13
1981	US20100093 816		SALT	ARGENTA DISCOVERY LTD	7-Feb-07	6-Feb-08	15-Apr-10
1982	US9381226	http://59.45.142.240:8808/pdf/US9381226.pdf	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	8-Feb-07	8-Feb-08	5-Jul-16
1983	US20160354 428	http://59.45.142.240:8808/pdf/US20160354428A1.pdf	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	Not Available	8-Feb-07	2-Jun-16	8-Dec-16
1984	US20100184 663	http://59.45.142.240:8808/pdf/US20100184663A1.pdf	Methods and Compositions Related to Inhibition of Viral Entry	University of Utah Research	8-Feb-07	8-Feb-08	22-Jul-10
1985	US20100093 813	http://59.45.142.240:8808/pdf/US20100093813A1.pdf	Salts 668	ASTRAZENECA AB	8-Feb-07	6-Feb-08	15-Apr-10
1986	US20100029 732	http://59.45.142.240:8808/pdf/US20100029732A1.pdf	Combinations of Beta-2-Adrenoceptor Agonistic	ASTRAZENECA AB	8-Feb-07	6-Feb-08	4-Feb-10
1987	US20080249 145	http://59.45.142.240:8808/pdf/US20080249145A1.pdf	Salts 668	WHITTOCK ROBERT	8-Feb-07	7-Feb-08	9-Oct-08
1988	US20080242 649	http://59.45.142.240:8808/pdf/US20080242649A1.pdf	New Combination 665	CADOGAN ELAINE BRIDGET	8-Feb-07	7-Feb-08	2-Oct-08
1989	US10512665	http://59.45.142.240:8808/pdf/US10512665B2.pdf	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	8-Feb-07	2-Jun-16	24-Dec-19
1990	US20100178 299	http://59.45.142.240:8808/pdf/US20100178299A1.pdf	METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES	Northeastern University	13-Feb-07	13-Feb-08	15-Jul-10
1991	US8889117	http://59.45.142.240:8808/pdf/US8889117.pdf	Modular nanoparticles for adaptable vaccines	Yale University	15-Feb-07	15-Feb-08	18-Nov-14
1992	US20190117 793	http://59.45.142.240:8808/pdf/US20190117793A1.pdf	MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES	Not Available	15-Feb-07	1-Oct-18	25-Apr-19
1993	US20150125 384	http://59.45.142.240:8808/pdf/US20150125384A1.pdf	MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES	Not Available	15-Feb-07	10-Nov-14	7-May-15
1994	US20100104 503	http://59.45.142.240:8808/pdf/US20100104503A1.pdf	MODULAR NANOPARTICLES FOR ADAPTABLE VACCINES	CAPLAN MICHAEL J	15-Feb-07	15-Feb-08	29-Apr-10
1995	US10265407	http://59.45.142.240:8808/pdf/US10265407.pdf	Modular nanodevices for smart adaptable vaccines	Yale University	15-Feb-07	10-Nov-14	23-Apr-19
1996	US9957302	http://59.45.142.240:8808/pdf/US9957302.pdf	Treating cancer with viral nucleic acid	Mayo Foundation for Medical Education	20-Feb-07	6-Jul-15	1-May-18
1997	US20180215 794	http://59.45.142.240:8808/pdf/US20180215794A1.pdf	TREATING CANCER WITH VIRAL NUCLEIC ACID	Mayo Foundation for Medical Education	20-Feb-07	27-Mar-18	2-Aug-18
1998	US20150299 271	http://59.45.142.240:8808/pdf/US20150299271A1.pdf	TREATING CANCER WITH VIRAL NUCLEIC ACID	Not Available	20-Feb-07	6-Jul-15	22-Oct-15
1999	US20130345 414	http://59.45.142.240:8808/pdf/US20130345414A1.pdf	TREATING CANCER WITH VIRAL NUCLEIC ACID	Not Available	20-Feb-07	26-Jul-13	26-Dec-13
2000	US20100111 873	http://59.45.142.240:8808/pdf/US20100111873A1.pdf	TREATING CANCER WITH VIRAL NUCLEIC ACID	HADAC ELIZABETH M	20-Feb-07	20-Feb-08	6-May-10
2001	US20100247 574	http://59.45.142.240:8808/pdf/US20100247574A1.pdf	CHIMERIC NEWCASTLE DISEASE VIRUS VLPs	MAHMOOD KUTUB	21-Feb-07	21-Feb-08	30-Sep-10
2002	US20100086 942		COMPOUNDS	AstraZeneca AB	21-Feb-07	4-Dec-09	8-Apr-10
2003	US20080199 481		COMPOUNDS	ASTRAZENECA AB	21-Feb-07	19-Feb-08	21-Aug-08
2004	US20080269 156	http://59.45.142.240:8808/pdf/US20080269156A1.pdf	Inhibitors of RTP801 and their use in disease treatment	FEINSTEIN ELENA	26-Feb-07	26-Feb-08	30-Oct-08
2005	US8633308	http://59.45.142.240:8808/pdf/US8633308.pdf	Compounds for preventing or treating viral infections and methods	The Governors of The University of California	28-Feb-07	27-Feb-08	21-Jan-14
2006	US20100016 388	http://59.45.142.240:8808/pdf/US20100016388A1.pdf	Salts of a Selective Beta-2 Adrenoceptor Agonist	Not Available	1-Mar-07	29-Feb-08	21-Jan-10

2007	US20080299 182	http://59.45.142.240:8808/pdf/US20080299182A1.pdf	METHODS AND FORMULATIONS FOR TOPICAL GENE THERAPY	ONISHI ERIC	1-Mar-07	29-Feb-08	4-Dec-08
2008	US8497405	http://59.45.142.240:8808/pdf/US8497405.pdf	Process for dispersing vaporous hydrogen peroxide	STERIS Inc.	6-Mar-07	28-Feb-13	30-Jul-13
2009	US8460605	http://59.45.142.240:8808/pdf/US8460605.pdf	Decontaminant dispenser suitable for use as a projectile	STERIS Inc.	6-Mar-07	20-Feb-08	11-Jun-13
2010	US20130177 477	http://59.45.142.240:8808/pdf/US20130177477A1.pdf	DECONTAMINANT DISPENSER SUITABLE FOR USE AS A PROJECTILE	STERIS INC.	6-Mar-07	28-Feb-13	11-Jul-13
2011	US20080299 545	http://59.45.142.240:8808/pdf/US20080299545A1.pdf	CHROMATOGRAPHIC METHODS FOR ASSESSING ADENOVIRUS PURITY	CLARKE PETER	6-Mar-07	6-Mar-08	4-Dec-08
2012	US20080279 722	http://59.45.142.240:8808/pdf/US20080279722A1.pdf	TRANSPORTABLE DECONTAMINATION UNIT AND DECONTAMINATION PROCESS	BACIK MICHAEL A	6-Mar-07	20-Feb-08	13-Nov-08
2013	US20080279 721	http://59.45.142.240:8808/pdf/US20080279721A1.pdf	DECONTAMINATION UNIT AND DECONTAMINATION PROCESS	CENTANNI MICHAEL A	6-Mar-07	20-Feb-08	13-Nov-08
2014	US20080279 720	http://59.45.142.240:8808/pdf/US20080279720A1.pdf	DECONTAMINATION UNIT WITH COLLAPSIBLE DECONTAMINATION ENCLOSURE AND	CENTANNI MICHAEL A	6-Mar-07	20-Feb-08	13-Nov-08
2015	US20080267 819	http://59.45.142.240:8808/pdf/US20080267819A1.pdf	TRANSPORTABLE DECONTAMINATION UNIT AND DECONTAMINATION PROCESS	BACIK MICHAEL A	6-Mar-07	20-Feb-08	30-Oct-08
2016	US9486479	http://59.45.142.240:8808/pdf/US9486479.pdf	Antimicrobial solutions containing dichloride monoxide and methods of use thereof	Oculus Innovative Sciences, Inc.	13-Mar-07	21-Jul-14	8-Nov-16
2017	US8784900	http://59.45.142.240:8808/pdf/US8784900.pdf	Antimicrobial solutions containing dichlorine monoxide and methods of use thereof	Oculus Innovative Sciences, Inc.	13-Mar-07	13-Mar-08	22-Jul-14
2018	US8551968	http://59.45.142.240:8808/pdf/US8551968.pdf	Methods for generation of antibodies	National Jewish Health	13-Mar-07	13-Mar-08	8-Oct-13
2019	US8519106	http://59.45.142.240:8808/pdf/US8519106.pdf	Monoclonal human tumor-specific antibody	University of Zurich	13-Mar-07	13-Mar-08	27-Aug-13
2020	US20170049 813	http://59.45.142.240:8808/pdf/US20170049813A1.pdf	ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF	OCULUS INNOVATIVE SCIENCES, INC.	13-Mar-07	8-Nov-16	23-Feb-17
2021	US20140328 946	http://59.45.142.240:8808/pdf/US20140328946A1.pdf	ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORIDE MONOXIDE AND METHODS OF	Not Available	13-Mar-07	21-Jul-14	6-Nov-14
2022	US20140162 357	http://59.45.142.240:8808/pdf/US20140162357A1.pdf	METHODS FOR GENERATION OF ANTIBODIES	NATIONAL JEWISH HEALTH	13-Mar-07	4-Sep-13	12-Jun-14
2023	US20100330 075	http://59.45.142.240:8808/pdf/US20100330075A1.pdf	MONOCLONAL HUMAN TUMOR-SPECIFIC ANTIBODY	ABELA IRENE	13-Mar-07	13-Mar-08	30-Dec-10
2024	US20100279 351		Method for Generation of Antibodies	NATIONAL JEWISH MEDICAL AND RESEARCH CENTER	13-Mar-07	13-Mar-08	4-Nov-10
2025	US20100112 092	http://59.45.142.240:8808/pdf/US20100112092A1.pdf	ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF	Oculus Innovative Sciences, Inc.	13-Mar-07	13-Mar-08	6-May-10
2026	US20100062 441	http://59.45.142.240:8808/pdf/US20100062441A1.pdf	C-MET MUTATIONS AND USES THEREOF	SALGIA RAVI	15-Mar-07	14-Mar-08	11-Mar-10
2027	US20100130 491	http://59.45.142.240:8808/pdf/US20100130491A1.pdf	9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 1 MODULATORS	BONNERT ROGER VICTOR	19-Mar-07	19-Mar-08	27-May-10
2028	US20100087 443	http://59.45.142.240:8808/pdf/US20100087443A1.pdf	9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 1 MODULATORS	Not Available	19-Mar-07	19-Mar-08	8-Apr-10
2029	US20110028 715	http://59.45.142.240:8808/pdf/US20110028715A1.pdf	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag	20-Mar-07	14-Oct-10	3-Feb-11
2030	US20100099 870	http://59.45.142.240:8808/pdf/US20100099870A1.pdf	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag	20-Mar-07	19-Mar-08	22-Apr-10
2031	US20100093 998	http://59.45.142.240:8808/pdf/US20100093998A1.pdf	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag	20-Mar-07	19-Mar-08	15-Apr-10
2032	US20080234 319	http://59.45.142.240:8808/pdf/US20080234319A1.pdf	Novel Compounds 679	EBDEN MARK	22-Mar-07	21-Mar-08	25-Sep-08
2033	US8722725	http://59.45.142.240:8808/pdf/US8722725.pdf	Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition	Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical	23-Mar-07	21-Mar-08	13-May-14
2034	US20150290 234	http://59.45.142.240:8808/pdf/US20150290234A1.pdf	TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS	Not Available	23-Mar-07	21-Apr-15	15-Oct-15
2035	US20130216 612	http://59.45.142.240:8808/pdf/US20130216612A1.pdf	TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS	BBB HOLDING B V	23-Mar-07	2-May-13	22-Aug-13
2036	US20100204 266	http://59.45.142.240:8808/pdf/US20100204266A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED POPULATIONS OF BACILLI	Ibis Biosciences, INC	23-Mar-07	21-Mar-08	12-Aug-10
2037	US20100144 828	http://59.45.142.240:8808/pdf/US20100144828A1.pdf	CAFFEYOYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN, AND PREPARATION METHOD, PHARMACEUTICAL	ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICA	23-Mar-07	21-Mar-08	10-Jun-10
2038	US20100129 437	http://59.45.142.240:8808/pdf/US20100129437A1.pdf	TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS	BBB Holding B.V.	23-Mar-07	21-Mar-08	27-May-10
2039	US20090227 005	http://59.45.142.240:8808/pdf/US20090227005A1.pdf	Methods for pathogen detection	Searete LLC, a limited liability corporation of the	27-Mar-07	28-Sep-07	10-Sep-09
2040	US20080241 935		Methods for pathogen detection	Searete LLC, a limited liability corporation of the	27-Mar-07	27-Mar-07	2-Oct-08
2041	US20080241 910	http://59.45.142.240:8808/pdf/US20080241910A1.pdf	Devices for pathogen detection	Searete LLC, a limited liability corporation of the	27-Mar-07	27-Mar-07	2-Oct-08
2042	US20080241 909	http://59.45.142.240:8808/pdf/US20080241909A1.pdf	Microfluidic chips for pathogen detection	Searete LLC, a limited liability corporation of the	27-Mar-07	27-Mar-07	2-Oct-08
2043	US20080241 000	http://59.45.142.240:8808/pdf/US20080241000A1.pdf	Systems for pathogen detection	Searete LLC, a limited liability corporation of the	27-Mar-07	27-Mar-07	2-Oct-08
2044	US9476032	http://59.45.142.240:8808/pdf/US9476032.pdf	Attenuated viruses useful for vaccines	The Research Foundation for The State University of	30-Mar-07	31-Mar-08	25-Oct-16
2045	US20190010 469	http://59.45.142.240:8808/pdf/US20190010469A1.pdf	ATTENUATED VIRUSES USEFUL FOR VACCINES	Not Available	30-Mar-07	16-Jul-18	10-Jan-19
2046	US20170067 030	http://59.45.142.240:8808/pdf/US20170067030A1.pdf	ATTENUATED VIRUSES USEFUL FOR VACCINES	Not Available	30-Mar-07	7-Sep-16	9-Mar-17
2047	US20100209 454	http://59.45.142.240:8808/pdf/US20100209454A1.pdf	ATTENUATED VIRUSES USEFUL FOR VACCINES	CELLO JERONIMO	30-Mar-07	31-Mar-08	19-Aug-10

2048	US20080242 794	http://59.45.142.240:8808/pdf/US20080242794A1.pdf	COLOR STABILIZED ANTIMICROBIAL POLYMER COMPOSITES	BLANTON THOMAS N	30-Mar-07	30-Mar-07	2-Oct-08
2049	US20080241 511	http://59.45.142.240:8808/pdf/US20080241511A1.pdf	PRODUCTION OF SILVER SULFATE GRAINS USING INORGANIC ADDITIVES	BLANTON THOMAS N	30-Mar-07	30-Mar-07	2-Oct-08
2050	US10023845	http://59.45.142.240:8808/pdf/US10023845.pdf	Methods of making modified viral genomes	The Research Foundation for The State University of	30-Mar-07	7-Sep-16	17-Jul-18
2051	US9758820	http://59.45.142.240:8808/pdf/US9758820.pdf	Organism identification panel	BioFire Diagnostics, LLC	2-Apr-07	1-Apr-08	12-Sep-17
2052	US8560339	http://59.45.142.240:8808/pdf/US8560339.pdf	System and method to predict the global spread of infectious agents via	Kamran Khan	2-Apr-07	2-Apr-08	15-Oct-13
2053	US20180010 167	http://59.45.142.240:8808/pdf/US20180010167A1.pdf	ORGANISM IDENTIFICATION PANEL	Not Available	2-Apr-07	26-Jul-17	11-Jan-18
2054	US20140234 845	http://59.45.142.240:8808/pdf/US20140234845A1.pdf	ORGANISM IDENTIFICATION PANEL	Not Available	2-Apr-07	1-Apr-08	21-Aug-14
2055	US20100042 394	http://59.45.142.240:8808/pdf/US20100042394A1.pdf	System and Method to Predict the Global Spread of Infectious Agents	KHAN KAMRAN	2-Apr-07	2-Apr-08	18-Feb-10
2056	US8709730	http://59.45.142.240:8808/pdf/US8709730.pdf	Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-	Icahn School of Medicine at Mount Sinai	5-Apr-07	7-Apr-08	29-Apr-14
2057	US20130184 170	http://59.45.142.240:8808/pdf/US20130184170A1.pdf	OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING	GENERA BIOSYSTEMS LIMITED	5-Apr-07	4-Jun-12	18-Jul-13
2058	US20110033 498	http://59.45.142.240:8808/pdf/US20110033498A1.pdf	METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY INHIBITING THE DeISGLATION ACTIVITY OF OTU DOMAIN-	FRIAS-STACHEL NATALIA	5-Apr-07	7-Apr-08	10-Feb-11
2059	US20100279 888		COMPOSITIONS AND METHODS OF DETECTION	GENERA BIOSYSTEMS LIMITED	5-Apr-07	4-Apr-08	4-Nov-10
2060	US20200108 136	http://59.45.142.240:8808/pdf/US20200108136A1.pdf	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6-Apr-07	22-Nov-19	9-Apr-20
2061	US20170100 474	http://59.45.142.240:8808/pdf/US20170100474A1.pdf	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6-Apr-07	22-Jul-16	13-Apr-17
2062	US20140302 091	http://59.45.142.240:8808/pdf/US20140302091A1.pdf	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6-Apr-07	18-Nov-11	9-Oct-14
2063	US20080248 551	http://59.45.142.240:8808/pdf/US20080248551A1.pdf	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	OSORIO JORGE E	6-Apr-07	4-Apr-08	9-Oct-08
2064	US10525120	http://59.45.142.240:8808/pdf/US10525120.pdf	Methods and compositions for live attenuated viruses	TAKEDA VACCINES, INC.	6-Apr-07	22-Jul-16	7-Jan-20
2065	US9017696	http://59.45.142.240:8808/pdf/US9017696.pdf	Adenovirus vectors	Isis Innovation Limited	10-Apr-07	10-Apr-08	28-Apr-15
2066	US8415102	http://59.45.142.240:8808/pdf/US8415102.pdf	Methods and computer systems for identifying target-specific sequences	NanoString Technologies, Inc.	10-Apr-07	10-Apr-08	9-Apr-13
2067	US20150297 700		Novel Adenovirus Vectors	Not Available	10-Apr-07	27-Apr-15	22-Oct-15
2068	US20130178 372	http://59.45.142.240:8808/pdf/US20130178372A1.pdf	Methods And Computer Systems For Identifying Target-Specific	NANOSTRING TECHNOLOGIES, INC.	10-Apr-07	7-Mar-13	11-Jul-13
2069	US20100112 710	http://59.45.142.240:8808/pdf/US20100112710A1.pdf	METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN	NANOSTRING TECHNOLOGIES, INC.	10-Apr-07	10-Apr-08	6-May-10
2070	US10124048	http://59.45.142.240:8808/pdf/US10124048.pdf	Adenovirus vectors	Oxford University Innovation Limited	10-Apr-07	27-Apr-15	13-Nov-18
2071	US20090092 581	http://59.45.142.240:8808/pdf/US20090092581A1.pdf	Interferons of rhesus and cynomolgus origin and uses thereof	CLARK WILLIAM A	11-Apr-07	11-Apr-08	9-Apr-09
2072	US20140170 709		VECTOR FOR GENE THERAPY	TAKARA BIO INC.	20-Apr-07	31-Jan-14	19-Jun-14
2073	US9791437	http://59.45.142.240:8808/pdf/US9791437.pdf	Multianalyte assay	Nexus Dx, Inc.	30-Apr-07	15-Jun-15	17-Oct-17
2074	US20160011 183	http://59.45.142.240:8808/pdf/US20160011183A1.pdf	MULTIANALYTE ASSAY	Not Available	30-Apr-07	15-Jun-15	14-Jan-16
2075	US20100298 547	http://59.45.142.240:8808/pdf/US20100298547A1.pdf	METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE	BONNIN DUSTAN	7-May-07	7-May-08	25-Nov-10
2076	US8507545	http://59.45.142.240:8808/pdf/US8507545.pdf	Cytotoxic T cell activator comprising EP4 agonist	National University Corporation, Hamamatsu University School of	8-May-07	7-May-08	13-Aug-13
2077	US8436178	http://59.45.142.240:8808/pdf/US8436178.pdf	Imidazoquinolines with immuno-modulating properties	AstraZeneca AB	8-May-07	6-May-08	7-May-13
2078	US20130225 555	http://59.45.142.240:8808/pdf/US20130225555A1.pdf	Imidazoquinolines with Immuno-Modulating Properties	AstraZeneca AB	8-May-07	14-Mar-13	29-Aug-13
2079	US20100280 001	http://59.45.142.240:8808/pdf/US20100280001A1.pdf	IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES	BONNERT ROGER VICTOR	8-May-07	6-May-08	4-Nov-10
2080	US20100216 689	http://59.45.142.240:8808/pdf/US20100216689A1.pdf	CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST	National University Corporation, Hamamatsu University School of	8-May-07	7-May-08	26-Aug-10
2081	US20100286 238		SUPPRESSION OF VIRUSES INVOLVED IN RESPIRATORY	ARNDT GREGORY MARTIN	15-May-07	14-May-08	11-Nov-10
2082	US9200287	http://59.45.142.240:8808/pdf/US9200287.pdf	Phosphate-modified oligonucleotide analogs with enhanced	AduTide Pharmaceuticals	18-May-07	15-May-08	1-Dec-15
2083	US9381239	http://59.45.142.240:8808/pdf/US9381239.pdf	VLPs derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25-May-07	14-Apr-14	5-Jul-16
2084	US8697088	http://59.45.142.240:8808/pdf/US8697088.pdf	VLPs derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25-May-07	27-May-08	15-Apr-14
2085	US20140234 372	http://59.45.142.240:8808/pdf/US20140234372A1.pdf	NOVEL VLPs DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL	Not Available	25-May-07	14-Apr-14	21-Aug-14
2086	US20100291 544	http://59.45.142.240:8808/pdf/US20100291544A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF STRAINS OF	IBIS BIOSCIENCES, INC.	25-May-07	27-May-08	18-Nov-10
2087	US9832998	http://59.45.142.240:8808/pdf/US9832998.pdf	Antiviral compositions	Long Island University	30-May-07	19-Mar-15	5-Dec-17
2088	US8999316	http://59.45.142.240:8808/pdf/US8999316.pdf	Antiviral compounds	Long Island University	30-May-07	30-May-08	7-Apr-15
2089	US20150196 032		ANTIVIRAL COMPOSITIONS	Long Island University	30-May-07	19-Mar-15	16-Jul-15
2090	US20080299 070	http://59.45.142.240:8808/pdf/US20080299070A1.pdf	Antiviral Compounds	ENGEL ROBERT	30-May-07	30-May-08	4-Dec-08
2091	US9757407	http://59.45.142.240:8808/pdf/US9757407.pdf	Treatment of viral infections by modulation of host cell metabolic	The Trustees of Princeton University	1-Jun-07	21-Dec-15	12-Sep-17

2092	US9321831	http://59.45.142.240:8808/pdf/US9321831.pdf	RSV-specific binding molecules and means for producing them	MedImmune Limited	1-Jun-07	13-Sep-13	26-Apr-16
2093	US9029413	http://59.45.142.240:8808/pdf/US9029413.pdf	Treatment of viral infections by modulation of host cell metabolic	The Trustees of Princeton University	1-Jun-07	3-Apr-12	12-May-15
2094	US8562996	http://59.45.142.240:8808/pdf/US8562996.pdf	RSV-specific binding molecules and means for producing them	MedImmune Limited	1-Jun-07	30-May-08	22-Oct-13
2095	US20180327 484	http://59.45.142.240:8808/pdf/US20180327484A1.pdf	RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM	Not Available	1-Jun-07	23-Jul-18	15-Nov-18
2096	US20160346 309	http://59.45.142.240:8808/pdf/US20160346309A1.pdf	TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	Not Available	1-Jun-07	21-Dec-15	1-Dec-16
2097	US20150289 573	http://59.45.142.240:8808/pdf/US20150289573A1.pdf	SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE	Not Available	1-Jun-07	26-Jun-15	15-Oct-15
2098	US20140072 575	http://59.45.142.240:8808/pdf/US20140072575A1.pdf	RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM	MedImmune Limited	1-Jun-07	13-Sep-13	13-Mar-14
2099	US20100239 593	http://59.45.142.240:8808/pdf/US20100239593A1.pdf	RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM	MedImmune Limited	1-Jun-07	30-May-08	23-Sep-10
2100	US20090239 830	http://59.45.142.240:8808/pdf/US20090239830A1.pdf	Treatment of viral infections by modulation of host cell metabolic	BENNETT BRYSON	1-Jun-07	2-Jun-08	24-Sep-09
2101	US20080295 843	http://59.45.142.240:8808/pdf/US20080295843A1.pdf	SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE	HAAS MARCI B	1-Jun-07	1-Jun-07	4-Dec-08
2102	US20090076 076	http://59.45.142.240:8808/pdf/US20090076076A1.pdf	INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF	Baylor University	13-Jun-07	13-Jun-08	19-Mar-09
2103	US20110045 456	http://59.45.142.240:8808/pdf/US20110045456A1.pdf	COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS CONTAMINANT SPECIES	IBIS BIOSCIENCES, INC.	14-Jun-07	12-Jun-08	24-Feb-11
2104	US20130302 278	http://59.45.142.240:8808/pdf/US20130302278A1.pdf	USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST	IMMURX INC	15-Jun-07	16-Apr-13	14-Nov-13
2105	US20130267 578	http://59.45.142.240:8808/pdf/US20130267578A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE EXPRESSION	QUARK PHARMACEUTICALS, INC.	15-Jun-07	6-Jun-13	10-Oct-13
2106	US20100273 854	http://59.45.142.240:8808/pdf/US20100273854A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE EXPRESSION	FEINSTEIN ELENA	15-Jun-07	12-Jun-08	28-Oct-10
2107	US20100221 755	http://59.45.142.240:8808/pdf/US20100221755A1.pdf	USE OF ANTIBODY SECRETING CELL ELISPOT TO ASSESS ANTIBODY RESPONSES FOLLOWING ANTIGEN	University of Rochester	15-Jun-07	16-Jun-08	2-Sep-10
2108	US20100233 250		VACCINE	BARAS BENOIT	19-Jun-07	20-Jun-08	16-Sep-10
2109	US20080317 702	http://59.45.142.240:8808/pdf/US20080317702A1.pdf	METHOD FOR TREATING MICROORGANISMS AND/OR INFECTIOUS AGENTS	EDGINGTON GARRY	19-Jun-07	19-Jun-08	25-Dec-08
2110	US9796735	http://59.45.142.240:8808/pdf/US9796735.pdf	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	20-Jun-07	7-Nov-14	24-Oct-17
2111	US8895534	http://59.45.142.240:8808/pdf/US8895534.pdf	Boron containing small molecules	Anacor Pharmaceuticals, Inc.	20-Jun-07	30-Jul-10	25-Nov-14
2112	US8822409	http://59.45.142.240:8808/pdf/US8822409.pdf	Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with	Phylogica Limited	20-Jun-07	20-Jun-08	2-Sep-14
2113	US20180016 285	http://59.45.142.240:8808/pdf/US20180016285A1.pdf	Boron-Containing Small Molecules	Not Available	20-Jun-07	28-Sep-17	18-Jan-18
2114	US20150133 402	http://59.45.142.240:8808/pdf/US20150133402A1.pdf	BORON-CONTAINING SMALL MOLECULES	Not Available	20-Jun-07	7-Nov-14	14-May-15
2115	US20110053 831	http://59.45.142.240:8808/pdf/US20110053831A1.pdf	COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL	Phylogica Limited	20-Jun-07	20-Jun-08	3-Mar-11
2116	US20100292 504	http://59.45.142.240:8808/pdf/US20100292504A1.pdf	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	20-Jun-07	30-Jul-10	18-Nov-10
2117	US20090227 541	http://59.45.142.240:8808/pdf/US20090227541A1.pdf	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	20-Jun-07	19-Jun-08	10-Sep-09
2118	US20090118 503	http://59.45.142.240:8808/pdf/US20090118503A1.pdf	FAAH INHIBITORS	Not Available	20-Jun-07	20-Jun-08	7-May-09
2119	US10533021	http://59.45.142.240:8808/pdf/US10533021.pdf	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	20-Jun-07	28-Sep-17	14-Jan-20
2120	US20110046 134	http://59.45.142.240:8808/pdf/US20110046134A1.pdf	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL- CoA DESATURASE	BISCHOFF ALEXANDER	21-Jun-07	29-Oct-10	24-Feb-11
2121	US20090221 583	http://59.45.142.240:8808/pdf/US20090221583A1.pdf	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL- CoA DESATURASE	AURIGENE DISCOVERY TECHNOLOGIES	21-Jun-07	23-Jun-08	3-Sep-09
2122	US20100272 706		ANTIVIRALS	GREBER URS	22-Jun-07	20-Jun-08	28-Oct-10
2123	US8678002	http://59.45.142.240:8808/pdf/US8678002.pdf	Devices and methods for decreasing human pathogen transmission	Filligent Limited	26-Jun-07	25-Jun-08	25-Mar-14
2124	US20100330 140	http://59.45.142.240:8808/pdf/US20100330140A1.pdf	DEVICES AND METHODS FOR DECREASING HUMAN PATHOGEN TRANSMISSION	FILLIGENT LIMITED	26-Jun-07	25-Jun-08	30-Dec-10
2125	US8889692	http://59.45.142.240:8808/pdf/US8889692.pdf	Pyrazinone derivatives, pharmaceutically acceptance salts	AstraZeneca AB	27-Jun-07	14-Sep-12	18-Nov-14
2126	US8785408	http://59.45.142.240:8808/pdf/US8785408.pdf	Compositions and methods for reducing or protecting against human pathogen (HP) transmission	Quark Pharmaceuticals, Inc.	27-Jun-07	26-Jun-08	22-Jul-14
2127	US20190142 927	http://59.45.142.240:8808/pdf/US20190142927A1.pdf	LOW-ADDITIVE INFLUENZA VACCINES	Not Available	27-Jun-07	26-Jun-18	16-May-19
2128	US20170119 871	http://59.45.142.240:8808/pdf/US20170119871A1.pdf	LOW-ADDITIVE INFLUENZA VACCINES	Not Available	27-Jun-07	24-Jun-16	4-May-17
2129	US20150073 136		PYRAZINONE DERIVATIVES	Not Available	27-Jun-07	17-Nov-14	12-Mar-15
2130	US20100222 409	http://59.45.142.240:8808/pdf/US20100222409A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PRO-APOTOTIC GENES	FEINSTEIN ELENA	27-Jun-07	26-Jun-08	2-Sep-10
2131	US20100183 671	http://59.45.142.240:8808/pdf/US20100183671A1.pdf	LOW-ADDITIVE INFLUENZA VACCINES	Novartis Vaccines & Diagnostics GmbH & Co. KG	27-Jun-07	27-Jun-08	22-Jul-10
2132	US20170065 706	http://59.45.142.240:8808/pdf/US20170065706A1.pdf	METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE	Not Available	2-Jul-07	14-Sep-16	9-Mar-17

2133	US20170065 693	http://59.45.142.240:8808/pdf/US20170065693A1.pdf	Sequential administration of a replication defective adenovirus	Not Available	2-Jul-07	14-Sep-16	9-Mar-17
2134	US20130224 144	http://59.45.142.240:8808/pdf/US20130224144A1.pdf	SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN	Etubics Corporation	2-Jul-07	18-Sep-12	29-Aug-13
2135	US20100183 673	http://59.45.142.240:8808/pdf/US20100183673A1.pdf	METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE	ETUBICS CORPORATION	2-Jul-07	4-Jan-10	22-Jul-10
2136	US20100240 746	http://59.45.142.240:8808/pdf/US20100240746A1.pdf	STEREOISOMERS OF TRICYCLODECAN-9-YL- N-ACRYLATE	LUMAVITA AG	3-Jul-07	3-Jul-08	23-Sep-10
2137	US8507544	http://59.45.142.240:8808/pdf/US8507544.pdf	Bi-aryl amide compounds as CRTh2 receptor modulators	Astrazeneca AB	5-Jul-07	3-Jul-08	13-Aug-13
2138	US20090012 151	http://59.45.142.240:8808/pdf/US20090012151A1.pdf	Novel Compounds 951	BONNERT ROGER VICTOR	5-Jul-07	3-Jul-08	8-Jan-09
2139	US20110008 395	http://59.45.142.240:8808/pdf/US20110008395A1.pdf	MIXED MICELLES INCLUDING AMPHIPATHIC CONJUGATES OF RNA AGENTS AND LIPIDS	LEVCHENKO TATYANA S	6-Jul-07	7-Jul-08	13-Jan-11
2140	US20090053 299	http://59.45.142.240:8808/pdf/US20090053299A1.pdf	Methods for generating immune response using cationic-liposome-	Georgetown University	9-Jul-07	9-Jul-08	26-Feb-09
2141	US8987191	http://59.45.142.240:8808/pdf/US8987191.pdf	Bioactive peptides and methods of using same	Compugen Ltd.	12-Jul-07	21-Jun-13	24-Mar-15
2142	US8492329	http://59.45.142.240:8808/pdf/US8492329.pdf	Bioactive peptides and methods of using same	Compugen Ltd.	12-Jul-07	11-Jul-08	23-Jul-13
2143	US20150307 572	http://59.45.142.240:8808/pdf/US20150307572A1.pdf	BIOACTIVE PEPTIDES AND METHODS OF USING SAME	Not Available	12-Jul-07	23-Feb-15	29-Oct-15
2144	US20140005 097	http://59.45.142.240:8808/pdf/US20140005097A1.pdf	BIOACTIVE PEPTIDES AND METHODS OF USING SAME	Compugen Ltd.	12-Jul-07	21-Jun-13	2-Jan-14
2145	US9492528	http://59.45.142.240:8808/pdf/US9492528.pdf	Influenza virus-like particles (VLPs) comprising hemagglutinin	MEDICAGO INC.	13-Jul-07	2-Jul-09	15-Nov-16
2146	US9452210	http://59.45.142.240:8808/pdf/US9452210.pdf	Influenza virus-like particles (VLPs) comprising hemagglutinin produced	MEDICAGO INC.	13-Jul-07	4-Jan-13	27-Sep-16
2147	US8445447	http://59.45.142.240:8808/pdf/US8445447.pdf	B7-DC variants immunogenic compositions and methods of use	The Johns Hopkins University	13-Jul-07	7-Mar-12	21-May-13
2148	US20130183 341	http://59.45.142.240:8808/pdf/US20130183341A1.pdf	INFLUENZA VIRUS-LIKE PARTICLES (VLPs) COMPRISING HEMAGGLUTININ PRODUCED	MEDICAGO INC.	13-Jul-07	4-Jan-13	18-Jul-13
2149	US20100239 610	http://59.45.142.240:8808/pdf/US20100239610A1.pdf	INFLUENZA VIRUS-LIKE PARTICLES (VLPs) COMPRISING HEMAGGLUTININ PRODUCED	MEDICAGO INC.	13-Jul-07	11-Jul-08	23-Sep-10
2150	US20090042 292		B7-DC Variants	The Johns Hopkins University	13-Jul-07	11-Jul-08	12-Feb-09
2151	US20100279 273	http://59.45.142.240:8808/pdf/US20100279273A1.pdf	NUCLEIC ACID SEQUENCES FOR THE AMPLIFICATION AND DETECTION OF ORGANISMS	UNIVERSITE LAVAL	17-Jul-07	17-Jul-08	4-Nov-10
2152	US20100197 748		ANTI-MICROBIAL COMPOSITION	BYOTROL PLC	17-Jul-07	17-Jul-08	5-Aug-10
2153	US8728793	http://59.45.142.240:8808/pdf/US8728793.pdf	Amphipathic alpha-helical peptide compositions as antiviral agents	The Board of Trustees of the Leland Stanford	19-Jul-07	14-Jul-08	20-May-14
2154	US20110008 838	http://59.45.142.240:8808/pdf/US20110008838A1.pdf	CHIMERIC VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES	PUSHKO PETER	19-Jul-07	21-Jul-08	13-Jan-11
2155	US20100330 122	http://59.45.142.240:8808/pdf/US20100330122A1.pdf	VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND	PUSHKO PETER	19-Jul-07	21-Jul-08	30-Dec-10
2156	US20090105 151	http://59.45.142.240:8808/pdf/US20090105151A1.pdf	AMPHIPATHIC ALPHA-HELICAL PEPTIDE COMPOSITIONS AS ANTIVIRAL AGENTS	CHEONG KWANG HO	19-Jul-07	14-Jul-08	23-Apr-09
2157	US8524241	http://59.45.142.240:8808/pdf/US8524241.pdf	Fusion proteins comprising a fragment of Vibrio cholerae exotoxin	The General Hospital Corporation	20-Jul-07	18-Jul-08	3-Sep-13
2158	US8420094		Fusion proteins comprising a fragment of Vibrio cholerae exotoxin	The General Hospital Corporation	20-Jul-07	18-Jul-08	16-Apr-13
2159	US20100256 070	http://59.45.142.240:8808/pdf/US20100256070A1.pdf	RECOMBINANT VIBRIO CHOLERAEE EXOTOXINS	SEED BRIAN	20-Jul-07	18-Jul-08	7-Oct-10
2160	US9944928	http://59.45.142.240:8808/pdf/US9944928.pdf	Construction of pool of interfering nucleic acids covering entire RNA target sequence and related	York Yuan Yuan Zhu	23-Jul-07	2-Jul-15	17-Apr-18
2161	US20090099 043	http://59.45.142.240:8808/pdf/US20090099043A1.pdf	Construction of pool of interfering nucleic acids covering entire RNA target sequence and related	ZHU YORK YUAN YUAN	23-Jul-07	21-Nov-08	16-Apr-09
2162	US20190060 239	http://59.45.142.240:8808/pdf/US20190060239A1.pdf	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	17-Oct-18	28-Feb-19
2163	US20180028 449	http://59.45.142.240:8808/pdf/US20180028449A1.pdf	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	27-Jun-17	1-Feb-18
2164	US20170079 920	http://59.45.142.240:8808/pdf/US20170079920A1.pdf	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	5-Dec-16	23-Mar-17
2165	US20160235 675	http://59.45.142.240:8808/pdf/US20160235675A1.pdf	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	24-Mar-16	18-Aug-16
2166	US20150359 746	http://59.45.142.240:8808/pdf/US20150359746A1.pdf	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	17-Jun-15	17-Dec-15
2167	US20150050 713	http://59.45.142.240:8808/pdf/US20150050713A1.pdf	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	25-Jul-14	19-Feb-15
2168	US20140099 696	http://59.45.142.240:8808/pdf/US20140099696A1.pdf	Technology for the Preparation of Microparticles	Ansun Biopharma, Inc.	24-Jul-07	30-Apr-13	10-Apr-14
2169	US20090098 207	http://59.45.142.240:8808/pdf/US20090098207A1.pdf	Technology for the Preparation of Microparticles	NexBio, Inc.	24-Jul-07	24-Jul-08	16-Apr-09
2170	US20140023 592	http://59.45.142.240:8808/pdf/US20140023592A1.pdf	SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS	Fraunhofer-Gesellschaft zur Forderung der Angewandten	25-Jul-07	30-Sep-13	23-Jan-14
2171	US20100183 516	http://59.45.142.240:8808/pdf/US20100183516A1.pdf	SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS	BARTH STEFAN	25-Jul-07	25-Jul-08	22-Jul-10
2172	US9212205	http://59.45.142.240:8808/pdf/US9212205.pdf	Nucleic acid binding compounds and methods of use	University of Rochester	26-Jul-07	28-Jul-08	15-Dec-15
2173	US20100304 361	http://59.45.142.240:8808/pdf/US20100304361A1.pdf	METHOD AND DEVICE FOR MONITORING A THERAPEUTIC	DAS DEVELOPMENT PARTNERS	26-Jul-07	28-Jul-08	2-Dec-10
2174	US20100266 677	http://59.45.142.240:8808/pdf/US20100266677A1.pdf	NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE	UNIVERSITY OF ROCHESTER	26-Jul-07	28-Jul-08	21-Oct-10
2175	US20100227 767	http://59.45.142.240:8808/pdf/US20100227767A1.pdf	STOCHASTIC CONFINEMENT TO DETECT, MANIPULATE, AND UTILIZE MOLECULES AND ORGANISMS	BOEDICKER JAMES Q	26-Jul-07	28-Jul-08	9-Sep-10

2176	US20090123 494	http://59.45.142.240:8808/pdf/US20090123494A1.pdf	MOMLV-BASED PSEUDOVIRION PACKAGING CELL LINE	FLICK RAMON	31-Jul-07	31-Jul-08	14-May-09
2177	US20170362 170	http://59.45.142.240:8808/pdf/US20170362170A1.pdf	HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS	Not Available	3-Aug-07	29-Jun-17	21-Dec-17
2178	US20150023 921	http://59.45.142.240:8808/pdf/US20150023921A1.pdf	HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS	BIOTRON LIMITED	3-Aug-07	3-Apr-14	22-Jan-15
2179	US20110039 884	http://59.45.142.240:8808/pdf/US20110039884A1.pdf	Imidazopyridinones	Pfizer Limited	3-Aug-07	28-Oct-10	17-Feb-11
2180	US20100254 942	http://59.45.142.240:8808/pdf/US20100254942A1.pdf	HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS	BIOTRON LIMITED	3-Aug-07	4-Aug-08	7-Oct-10
2181	US20090221 631	http://59.45.142.240:8808/pdf/US20090221631A1.pdf	IMIDAZOPYRIDINONES	Not Available	3-Aug-07	15-May-09	3-Sep-09
2182	US20110008 283	http://59.45.142.240:8808/pdf/US20110008283A1.pdf	INTERFERON FUSION PROTEINS	ARTYMIUK PETER	8-Aug-07	5-Aug-08	13-Jan-11
2183	US8466124	http://59.45.142.240:8808/pdf/US8466124.pdf	RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory	Coley Pharmaceutical GmbH	13-Aug-07	12-Jun-12	18-Jun-13
2184	US20100272 785	http://59.45.142.240:8808/pdf/US20100272785A1.pdf	RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE	COLEY PHARMACEUTICAL GMBH	13-Aug-07	8-Aug-08	28-Oct-10
2185	US9434997	http://59.45.142.240:8808/pdf/US9434997.pdf	Methods, compounds and systems for detecting a microorganism in a	Lawrence Livermore National Security, US	24-Aug-07	21-Aug-08	6-Sep-16
2186	US20170044 595	http://59.45.142.240:8808/pdf/US20170044595A1.pdf	PCR Ready Compositions and Methods for Detecting and	Longhorn Vaccines and Diagnostics, LLC	24-Aug-07	26-Oct-16	16-Feb-17
2187	US20090081 675	http://59.45.142.240:8808/pdf/US20090081675A1.pdf	METHODS, COMPOUNDS AND SYSTEMS FOR DETECTING A	COLSTON JR BILL W	24-Aug-07	21-Aug-08	26-Mar-09
2188	US85557767	http://59.45.142.240:8808/pdf/US85557767.pdf	Synthetic apolipoprotein E mimicking polypeptides and methods of use	UAB Research Foundation	28-Aug-07	27-Aug-08	15-Oct-13
2189	US8497112	http://59.45.142.240:8808/pdf/US8497112.pdf	Method for producing viral vaccines	Baxter Healthcare SA	28-Aug-07	28-Aug-08	30-Jul-13
2190	US20130287 811	http://59.45.142.240:8808/pdf/US20130287811A1.pdf	Method for Producing Viral Vaccines	BAXTER HEALTHCARE SA	28-Aug-07	26-Jun-13	31-Oct-13
2191	US20100286 025	http://59.45.142.240:8808/pdf/US20100286025A1.pdf	SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND METHODS OF USE	ANANTHARAMAIAH GATTADAHALLI M	28-Aug-07	27-Aug-08	11-Nov-10
2192	US20090060 950	http://59.45.142.240:8808/pdf/US20090060950A1.pdf	Method for Producing Viral Vaccines	BAXTER HEALTHCARE	28-Aug-07	28-Aug-08	5-Mar-09
2193	US9271494	http://59.45.142.240:8808/pdf/US9271494.pdf	Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid	Ecolab USA, Inc.	30-Aug-07	30-Aug-07	1-Mar-16
2194	US8426565	http://59.45.142.240:8808/pdf/US8426565.pdf	Dendritic cell marker and uses thereof	Walter and Eliza Hall Institute of Medical	30-Aug-07	29-Aug-08	23-Apr-13
2195	US20160135 453	http://59.45.142.240:8808/pdf/US20160135453A1.pdf	SHELF STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID	Not Available	30-Aug-07	20-Jan-16	19-May-16
2196	US20130273 150	http://59.45.142.240:8808/pdf/US20130273150A1.pdf	Dendritic Cell Marker and Uses Thereof	CAMINSCHI IRINA	30-Aug-07	21-Mar-13	17-Oct-13
2197	US20090061 017	http://59.45.142.240:8808/pdf/US20090061017A1.pdf	SHELF STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID	BESSE MICHAEL	30-Aug-07	30-Aug-07	5-Mar-09
2198	US9370531	http://59.45.142.240:8808/pdf/US9370531.pdf	Method of providing patient specific immune response in amyloidoses	New York University	31-Aug-07	1-Sep-08	21-Jun-16
2199	US20180110 845	http://59.45.142.240:8808/pdf/US20180110845A1.pdf	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN	Not Available	31-Aug-07	18-Dec-17	26-Apr-18
2200	US20160354 451	http://59.45.142.240:8808/pdf/US20160354451A1.pdf	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN	Not Available	31-Aug-07	9-Jun-16	8-Dec-16
2201	US20100297 108	http://59.45.142.240:8808/pdf/US20100297108A1.pdf	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN	GRIMM JAN	31-Aug-07	1-Sep-08	25-Nov-10
2202	US20090126 514	http://59.45.142.240:8808/pdf/US20090126514A1.pdf	Devices for collection and preparation of biological agents	BELGRADER PHIL	5-Sep-07	5-Sep-07	21-May-09
2203	US20090068 759	http://59.45.142.240:8808/pdf/US20090068759A1.pdf	REUSABLE DETECTION SURFACES AND METHODS OF USING SAME	BioScale, Inc.	6-Sep-07	5-Sep-08	12-Mar-09
2204	US20110027 315	http://59.45.142.240:8808/pdf/US20110027315A1.pdf	PROTEIN CAGES AND THEIR USES	DOUGLAS TREVOR	7-Sep-07	5-Sep-08	3-Feb-11
2205	US9102741	http://59.45.142.240:8808/pdf/US9102741.pdf	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12-Sep-07	13-Oct-14	11-Aug-15
2206	US8858957	http://59.45.142.240:8808/pdf/US8858957.pdf	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12-Sep-07	14-Mar-13	14-Oct-14
2207	US8399651	http://59.45.142.240:8808/pdf/US8399651.pdf	Nucleic acids encoding GAS57 mutant antigens	Novartis AG	12-Sep-07	10-Sep-12	19-Mar-13
2208	US20160137 702	http://59.45.142.240:8808/pdf/US20160137702A1.pdf	GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES	Not Available	12-Sep-07	7-Aug-15	19-May-16
2209	US20150030 625	http://59.45.142.240:8808/pdf/US20150030625A1.pdf	GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES	Not Available	12-Sep-07	13-Oct-14	29-Jan-15
2210	US20130202 609	http://59.45.142.240:8808/pdf/US20130202609A1.pdf	GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES	GRANDI GUIDO	12-Sep-07	14-Mar-13	8-Aug-13
2211	US8598106	http://59.45.142.240:8808/pdf/US8598106.pdf	Anti-microbial composition exhibiting residual anti-microbial properties on	Byotrol PLC	17-Sep-07	5-Jul-11	3-Dec-13
2212	US20100279 906	http://59.45.142.240:8808/pdf/US20100279906A1.pdf	FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION	BYOTROL PLC	17-Sep-07	17-Sep-08	4-Nov-10
2213	US9056898	http://59.45.142.240:8808/pdf/US9056898.pdf	Attenuated RNA virus and applications thereof	Washington University	20-Sep-07	22-Sep-08	16-Jun-15
2214	US20100196 222	http://59.45.142.240:8808/pdf/US20100196222A1.pdf	AIR CLEANING APPARATUS	FUJIFILM CORPORATION	20-Sep-07	19-Sep-08	5-Aug-10
2215	US20090104 209	http://59.45.142.240:8808/pdf/US20090104209A1.pdf	METHODS OF REDUCING A VIRAL INFECTION AND KITS THEREFORE	LABONTE PATRICK	21-Sep-07	19-Sep-08	23-Apr-09
2216	US9421254	http://59.45.142.240:8808/pdf/US9421254.pdf	Immunostimulatory combinations of TLR ligands and methods of use	The United States of America, as represented by the Secretary, Department of Health and Human	24-Sep-07	24-Sep-08	23-Aug-16
2217	US8854617	http://59.45.142.240:8808/pdf/US8854617.pdf	Compounds and markers for surface-enhanced Raman scattering	Julius-Maximilians-Universitat	24-Sep-07	24-Sep-08	7-Oct-14
2218	US20100297 165	http://59.45.142.240:8808/pdf/US20100297165A1.pdf	IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USE	Office of Technology Transfer	24-Sep-07	24-Sep-08	25-Nov-10

2219	US20100284 917	http://59.45.142.240:8808/pdf/US20100284917A1.pdf	COMPOUNDS AND MARKERS FOR SURFACE-ENHANCED RAMAN SCATTERING	JULIUS-MAXIMILIANS-UNIVERSITÄT	24-Sep-07	24-Sep-08	11-Nov-10
2220	US8445650	http://59.45.142.240:8808/pdf/US8445650.pdf	Mutant botulinum neurotoxin serotype A polypeptide and uses	Thomas Jefferson University	25-Sep-07	25-Sep-08	21-May-13
2221	US20100247 560	http://59.45.142.240:8808/pdf/US20100247560A1.pdf	MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF	THOMAS JEFFERSON UNIVERSITY	25-Sep-07	25-Sep-08	30-Sep-10
2222	US20090235 625	http://59.45.142.240:8808/pdf/US20090235625A1.pdf	FILTER AND ASSOCIATED METHOD	GENERAL ELECTRIC COMPANY	28-Sep-07	28-Sep-07	24-Sep-09
2223	US20090155 564		ARTICLE AND ASSOCIATED METHOD	GENERAL ELECTRIC COMPANY	28-Sep-07	28-Sep-07	18-Jun-09
2224	US20090117 367		ARTICLE AND ASSOCIATED METHOD	GENERAL ELECTRIC COMPANY	28-Sep-07	28-Sep-07	7-May-09
2225	US9683256	http://59.45.142.240:8808/pdf/US9683256.pdf	Biological specimen collection and transport system	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	15-Dec-15	20-Jun-17
2226	US9416416	http://59.45.142.240:8808/pdf/US9416416.pdf	Biological specimen collection/transport compositions	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	16-Dec-11	16-Aug-16
2227	US9212399	http://59.45.142.240:8808/pdf/US9212399.pdf	Biological specimen collection and transport system and method of use	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	7-Jan-14	15-Dec-15
2228	US8669240	http://59.45.142.240:8808/pdf/US8669240.pdf	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1-Oct-07	19-Mar-13	11-Mar-14
2229	US8415330	http://59.45.142.240:8808/pdf/US8415330.pdf	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1-Oct-07	1-Oct-12	9-Apr-13
2230	US20190390 249	http://59.45.142.240:8808/pdf/US20190390249A1.pdf	BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	19-Jun-17	26-Dec-19
2231	US20170073 738	http://59.45.142.240:8808/pdf/US20170073738A1.pdf	Compositions and Methods for Detecting and Quantifying Nucleic	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	25-Nov-16	16-Mar-17
2232	US20160108 463	http://59.45.142.240:8808/pdf/US20160108463A1.pdf	Biological Specimen Collection and Transport System	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	15-Dec-15	21-Apr-16
2233	US20140193 804	http://59.45.142.240:8808/pdf/US20140193804A1.pdf	Biological Specimen Collection and Transport System and Method of Use	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	7-Jan-14	10-Jul-14
2234	US20140011 187	http://59.45.142.240:8808/pdf/US20140011187A1.pdf	Biological Specimen Collection and Transport System and Method of Use	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	19-Mar-13	9-Jan-14
2235	US20090312 285	http://59.45.142.240:8808/pdf/US20090312285A1.pdf	BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM AND METHODS OF USE	Longhorn Vaccines & Diagnostics, LLC	1-Oct-07	1-Oct-08	17-Dec-09
2236	US20090233 309	http://59.45.142.240:8808/pdf/US20090233309A1.pdf	BIOLOGICAL SPECIMEN COLLECTION/TRANSPORT COMPOSITIONS AND METHODS	LONGHORN VACCINES & DIAGNOSTICS, LLC	1-Oct-07	20-Apr-09	17-Sep-09
2237	US20190218 574	http://59.45.142.240:8808/pdf/US20190218574A1.pdf	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	The Trustees of the University of	2-Oct-07	28-Mar-19	18-Jul-19
2238	EP2517720A 1	http://59.45.142.240:8808/pdf/EP2517720A1.pdf	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	2-Oct-07	31-Oct-12	31-Oct-12
2239	US20090286 835		NOVEL COMPOUNDS	AstraZeneca AB	4-Oct-07	3-Oct-08	19-Nov-09
2240	US9186399	http://59.45.142.240:8808/pdf/US9186399.pdf	Immune stimulatory oligonucleotide analogs containing modified sugar	AdiutTide Pharmaceuticals	9-Oct-07	29-Sep-08	17-Nov-15
2241	US20090186 014	http://59.45.142.240:8808/pdf/US20090186014A1.pdf	METHOD FOR TREATMENT OF PANCREATITIS	Ore Pharmaceuticals Inc.	10-Oct-07	9-Oct-08	23-Jul-09
2242	US8697659	http://59.45.142.240:8808/pdf/US8697659.pdf	Analogues of glycolipids useful as immunoadjuvants	Luigi Panza	12-Oct-07	10-Oct-08	15-Apr-14
2243	US20110033 485	http://59.45.142.240:8808/pdf/US20110033485A1.pdf	ANALOGUES OF GLYCOLIPIDS USEFUL AS IMMUNOADJUVANTS	PANZA LUIGI	12-Oct-07	10-Oct-08	10-Feb-11
2244	US20100284 968	http://59.45.142.240:8808/pdf/US20100284968A1.pdf	Use of PS20/WFDC1 and Interferons to Diagnose, Monitor and Treat Viral	BAIG EHTESHAM	15-Oct-07	15-Oct-08	11-Nov-10
2245	US9533037	http://59.45.142.240:8808/pdf/US9533037.pdf	Methods for designing and preparing vaccines comprising directed sequence polymer compositions via	Declion Holdings LLC	16-Oct-07	16-Oct-08	3-Jan-17
2246	US8415118	http://59.45.142.240:8808/pdf/US8415118.pdf	Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof	Virginia Tech Intellectual	29-Oct-07	29-Oct-08	9-Apr-13
2247	US20100317 054	http://59.45.142.240:8808/pdf/US20100317054A1.pdf	PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF	VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.	29-Oct-07	29-Oct-08	16-Dec-10
2248	US20090111 091	http://59.45.142.240:8808/pdf/US20090111091A1.pdf	SPECIMEN PRETREATMENT LIQUID, KIT FOR MEASURING VIRUS, AND METHOD FOR DETECTING VIRUS	SYSMEX CORPORATION	31-Oct-07	31-Oct-08	30-Apr-09
2249	US9833492	http://59.45.142.240:8808/pdf/US9833492.pdf	Combinations of a caspase inhibitor and an antiviral agent	Centre National de la Recherche	2-Nov-07	15-May-15	5-Dec-17
2250	US9056071	http://59.45.142.240:8808/pdf/US9056071.pdf	Compounds and methods for preventing or treating a viral infection	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	2-Nov-07	19-Jun-13	16-Jun-15
2251	US20150246 091	http://59.45.142.240:8808/pdf/US20150246091A1.pdf	COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A VIRAL INFECTION	Not Available	2-Nov-07	15-May-15	3-Sep-15
2252	US20140031 276	http://59.45.142.240:8808/pdf/US20140031276A1.pdf	COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A VIRAL INFECTION	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	2-Nov-07	19-Jun-13	30-Jan-14
2253	US20100298 209	http://59.45.142.240:8808/pdf/US20100298209A1.pdf	COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION	ESTAQUIER JEROME	2-Nov-07	31-Oct-08	25-Nov-10
2254	US20090117 123	http://59.45.142.240:8808/pdf/US20090117123A1.pdf	IMMUNOPEPTIDES OF HPV E6 AND E7 PROTEINS	National Health Research Institutes	2-Nov-07	23-Sep-08	7-May-09
2255	US9347055	http://59.45.142.240:8808/pdf/US9347055.pdf	Method and kit for preparation of sample for use in nucleic acid	EIKEN KAGAKU KABUSHIKI KAISHA	5-Nov-07	5-Nov-08	24-May-16
2256	US8735567	http://59.45.142.240:8808/pdf/US8735567.pdf	Multi-targeted RNAi therapeutics for scarless wound healing of skin	Not Available	6-Nov-07	6-Nov-08	27-May-14
2257	US8466284	http://59.45.142.240:8808/pdf/US8466284.pdf	Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile	Astra Zeneca AB	6-Nov-07	5-Nov-08	18-Jun-13
2258	US20100319 074	http://59.45.142.240:8808/pdf/US20100319074A1.pdf	MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND HEALING OF SKIN	SIR NAOMICS, INC.	6-Nov-07	6-Nov-08	16-Dec-10
2259	US20100280 048	http://59.45.142.240:8808/pdf/US20100280048A1.pdf	Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile	ASTRAZENECA R&D	6-Nov-07	5-Nov-08	4-Nov-10
2260	USRE46873	http://59.45.142.240:8808/pdf/USRE46873.pdf	Multi-targeted RNAi therapeutics for scarless wound healing of skin	Sirnaomics, Inc.	6-Nov-07	26-May-16	29-May-18
2261	US20140161 906	http://59.45.142.240:8808/pdf/US20140161906A1.pdf	USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF	UNIVERSITY OF UTAH RESEARCH CORPORATION	8-Nov-07	12-Jun-13	12-Jun-14
2262	US20110003 890	http://59.45.142.240:8808/pdf/US20110003890A1.pdf	USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF	KENNEDY THOMAS P	8-Nov-07	10-Nov-08	6-Jan-11

2263	US8669263	http://59.45.142.240:8808/pdf/US8669263.pdf	Use of TAM receptor inhibitors as antimicrobials	Salk Institute for Biological Studies	9-Nov-07	8-Mar-13	11-Mar-14
2264	US8415361	http://59.45.142.240:8808/pdf/US8415361.pdf	Use of TAM receptor inhibitors as antimicrobials	The Salk Institute for Biological	9-Nov-07	7-Nov-08	9-Apr-13
2265	US20190134 193	http://59.45.142.240:8808/pdf/US20190134193A1.pdf	USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS	SALK INSTITUTE FOR BIOLOGICAL STUDIES	9-Nov-07	9-Aug-18	9-May-19
2266	US20130251 734	http://59.45.142.240:8808/pdf/US20130251734A1.pdf	USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS	The Salk Institute for Biological	9-Nov-07	8-Mar-13	26-Sep-13
2267	US20110027 267	http://59.45.142.240:8808/pdf/US20110027267A1.pdf	Fusion Proteins of Mannose Binding Lectins for Treatment of Disease	ANAPHORE, INC.	9-Nov-07	10-Nov-08	3-Feb-11
2268	US20100266 604	http://59.45.142.240:8808/pdf/US20100266604A1.pdf	USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS	The Salk Institute for Biological Studies	9-Nov-07	7-Nov-08	21-Oct-10
2269	US20100247 554	http://59.45.142.240:8808/pdf/US20100247554A1.pdf	USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS	BHATTACHARYYA SUCHITA	9-Nov-07	7-Nov-08	30-Sep-10
2270	US8945610	http://59.45.142.240:8808/pdf/US8945610.pdf	Condensation products based on bicyclic or polycyclic aromatics or	BASF SE	14-Nov-07	11-Nov-08	3-Feb-15
2271	US8470771	http://59.45.142.240:8808/pdf/US8470771.pdf	Method and medicament for inhibiting the infection of influenza virus	Institute of Microbiology, Chinese Academy of	14-Nov-07	18-Dec-07	25-Jun-13
2272	US20100316 695	http://59.45.142.240:8808/pdf/US20100316695A1.pdf	CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC AROMATICS OR HYDROXYAROMATICS	BASF SE	14-Nov-07	11-Nov-08	16-Dec-10
2273	US20100249 021	http://59.45.142.240:8808/pdf/US20100249021A1.pdf	METHOD AND MEDICAMENT FOR INHIBITING THE INFECTION OF INFLUENZA VIRUS	INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY	14-Nov-07	18-Dec-07	30-Sep-10
2274	US20110046 001	http://59.45.142.240:8808/pdf/US20110046001A1.pdf	Multiplex Assay for Respiratory Viruses	AUTOGENOMICS, INC	20-Nov-07	20-Nov-08	24-Feb-11
2275	US20100310 562	http://59.45.142.240:8808/pdf/US20100310562A1.pdf	SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES THEREOF	Bundesrepublik Deutschland letztvertreten durch das Robert Koch-Institut vertreten	20-Nov-07	19-Nov-08	9-Dec-10
2276	US8765939	http://59.45.142.240:8808/pdf/US8765939.pdf	Pyrimidine derivatives having immune modulating properties that act via TLR7 for the treatment of	AstraZeneca AB	22-Nov-07	16-Aug-12	1-Jul-14
2277	US20090209 524	http://59.45.142.240:8808/pdf/US20090209524A1.pdf	Novel Compounds	AstraZeneca AB	22-Nov-07	20-Nov-08	20-Aug-09
2278	US9669088	http://59.45.142.240:8808/pdf/US9669088.pdf	Vaccination with multiple clades of H5 influenza A virus	Seqirus UK Limited	26-Nov-07	25-Nov-08	6-Jun-17
2279	US20090175 948	http://59.45.142.240:8808/pdf/US20090175948A1.pdf	AEROSOL METHOD FOR NANO SILVER-SILICA COMPOSITE ANTI-MICROBIAL AGENT	BRINKER C JEFFREY	30-Nov-07	26-Nov-08	9-Jul-09
2280	US9867882	http://59.45.142.240:8808/pdf/US9867882.pdf	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4-Dec-07	25-Aug-15	16-Jan-18
2281	US9814777	http://59.45.142.240:8808/pdf/US9814777.pdf	Targeting lipids	Arbutus Biopharma Corporation	4-Dec-07	22-Oct-13	14-Nov-17
2282	US9370582	http://59.45.142.240:8808/pdf/US9370582.pdf	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	11-Jul-14	21-Jun-16
2283	US9370581	http://59.45.142.240:8808/pdf/US9370581.pdf	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	11-Jul-14	21-Jun-16
2284	US9352048	http://59.45.142.240:8808/pdf/US9352048.pdf	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	22-Jul-14	31-May-16
2285	US8828956	http://59.45.142.240:8808/pdf/US8828956.pdf	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4-Dec-07	4-Dec-12	9-Sep-14
2286	US8507455	http://59.45.142.240:8808/pdf/US8507455.pdf	Folate conjugates	Alnylam Pharmaceuticals, Inc.	4-Dec-07	4-Dec-08	13-Aug-13
2287	US8450467	http://59.45.142.240:8808/pdf/US8450467.pdf	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4-Dec-07	14-Dec-11	28-May-13
2288	US20190184 018	http://59.45.142.240:8808/pdf/US20190184018A1.pdf	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4-Dec-07	20-Nov-18	20-Jun-19
2289	US20190099 493	http://59.45.142.240:8808/pdf/US20190099493A1.pdf	Targeting Lipids	Arbutus Biopharma Corporation	4-Dec-07	10-Oct-17	4-Apr-19
2290	US20180326 070	http://59.45.142.240:8808/pdf/US20180326070A1.pdf	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4-Dec-07	20-Nov-17	15-Nov-18
2291	US20160375 137	http://59.45.142.240:8808/pdf/US20160375137A9.pdf	TARGETING LIPIDS	Tekmira Pharmaceuticals	4-Dec-07	22-Oct-13	29-Dec-16
2292	US20160051 691	http://59.45.142.240:8808/pdf/US20160051691A1.pdf	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4-Dec-07	25-Aug-15	25-Feb-16
2293	US20150119 445	http://59.45.142.240:8808/pdf/US20150119445A1.pdf	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	Not Available	4-Dec-07	22-Jul-14	30-Apr-15
2294	US20150119 444	http://59.45.142.240:8808/pdf/US20150119444A1.pdf	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	Not Available	4-Dec-07	11-Jul-14	30-Apr-15
2295	US20150011 615	http://59.45.142.240:8808/pdf/US20150011615A1.pdf	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	Not Available	4-Dec-07	11-Jul-14	8-Jan-15
2296	US20140045 919	http://59.45.142.240:8808/pdf/US20140045919A1.pdf	Folate Conjugates	Alnylam Pharmaceuticals, Inc.	4-Dec-07	8-Jul-13	13-Feb-14
2297	US20130178 512	http://59.45.142.240:8808/pdf/US20130178512A1.pdf	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	4-Dec-12	11-Jul-13
2298	US20090247 614	http://59.45.142.240:8808/pdf/US20090247614A1.pdf	Folate Conjugates	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	4-Dec-08	1-Oct-09
2299	US20090247 608	http://59.45.142.240:8808/pdf/US20090247608A1.pdf	Targeting Lipids	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	4-Dec-08	1-Oct-09
2300	US20090239 814	http://59.45.142.240:8808/pdf/US20090239814A1.pdf	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	4-Dec-08	24-Sep-09
2301	US20090192 505	http://59.45.142.240:8808/pdf/US20090192505A1.pdf	Method for cryospray ablation	Reset Medical, Inc.	5-Dec-07	5-Dec-08	30-Jul-09
2302	US9951122	http://59.45.142.240:8808/pdf/US9951122.pdf	Antibodies against influenza virus and methods of use thereof	BURNHAM INSTITUTE FOR MEDICAL	6-Dec-07	12-Aug-13	24-Apr-18
2303	US20180312 575	http://59.45.142.240:8808/pdf/US20180312575A1.pdf	ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE	Not Available	6-Dec-07	20-Mar-18	1-Nov-18

2304	US20140011 982	http://59.45.142.240:8808/pdf/US20140011982A1.pdf	Antibodies Against Influenza Virus and Methods of Use Thereof	BURNHAM INSTITUTE FOR MEDICAL RESEARCH	6-Dec-07	12-Aug-13	9-Jan-14
2305	US20110038 935	http://59.45.142.240:8808/pdf/US20110038935A1.pdf	ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE	LIDDINGTON ROBERT C	6-Dec-07	8-Dec-08	17-Feb-11
2306	EP2121732B 1	http://59.45.142.240:8808/pdf/EP2121732B1.pdf	COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES	Universitäts- und Landesbibliothek Bonn	6-Dec-07	4-Jul-12	4-Jul-12
2307	US20090306 042	http://59.45.142.240:8808/pdf/US20090306042A1.pdf	Novel Compounds 010	CAGE PETER ALAN	12-Dec-07	10-Dec-08	10-Dec-09
2308	US8673907	http://59.45.142.240:8808/pdf/US8673907.pdf	Pharmaceutically acceptable salts of methyl (3-{ [3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl)	AstraZeneca AB	17-Dec-07	16-Dec-08	18-Mar-14
2309	US20150183 837	http://59.45.142.240:8808/pdf/US20150183837A1.pdf	IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	17-Dec-07	13-Feb-15	2-Jul-15
2310	US20100330 190	http://59.45.142.240:8808/pdf/US20100330190A1.pdf	IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF	BOZIA JADRANKA	17-Dec-07	17-Dec-08	30-Dec-10
2311	US10030053	http://59.45.142.240:8808/pdf/US10030053.pdf	Immunogenic compositions and methods of use thereof	Emory University	17-Dec-07	13-Feb-15	24-Jul-18
2312	US9561263	http://59.45.142.240:8808/pdf/US9561263.pdf	Treatment of inflammatory illnesses with ACE2	Apeiron Biologics AG	18-Dec-07	18-Dec-08	7-Feb-17
2313	US20110020 315	http://59.45.142.240:8808/pdf/US20110020315A1.pdf	TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2	LOIBNER HANS	18-Dec-07	18-Dec-08	27-Jan-11
2314	US7700782	http://59.45.142.240:8808/pdf/US7700782.pdf	Compounds 569	AstraZeneca AB	19-Dec-07	19-Dec-07	20-Apr-10
2315	US8673983	http://59.45.142.240:8808/pdf/US8673983.pdf	Melanins synthesized chemically or via osmium catalysis	Loyola University Chicago	21-Dec-07	22-Dec-08	18-Mar-14
2316	US8409589	http://59.45.142.240:8808/pdf/US8409589.pdf	Mutant forms of streptolysin O	Novartis AG	21-Dec-07	14-Sep-11	2-Apr-13
2317	US7731978	http://59.45.142.240:8808/pdf/US7731978.pdf	Mutant forms of streptolysin O	Novartis AG	21-Dec-07	19-Dec-08	8-Jun-10
2318	US20100316 624	http://59.45.142.240:8808/pdf/US20100316624A1.pdf	TREATMENT OF FIBROSES AND LIVER DISORDERS	LOIBNER HANS	21-Dec-07	22-Dec-08	16-Dec-10
2319	US20100158 935	http://59.45.142.240:8808/pdf/US20100158935A1.pdf	MUTANT FORMS OF STREPTOLYSIN O	NOVARTIS AG	21-Dec-07	24-Feb-10	24-Jun-10
2320	US20090162 392	http://59.45.142.240:8808/pdf/US20090162392A1.pdf	MUTANT FORMS OF STREPTOLYSIN O	NOVARTIS AG	21-Dec-07	19-Dec-08	25-Jun-09
2321	US9370570	http://59.45.142.240:8808/pdf/US9370570.pdf	Polychlorinated biphenyls and squalene containing adjuvants	Novartis AG	28-Dec-07	10-Dec-13	21-Jun-16
2322	US8628786	http://59.45.142.240:8808/pdf/US8628786.pdf	Polychlorinated biphenyls and squalene containing adjuvants	Novartis AG	28-Dec-07	2-Dec-11	14-Jan-14
2323	US20140170 174	http://59.45.142.240:8808/pdf/US20140170174A1.pdf	POLYCHLORINATED BIPHENYLS AND SQUALENE CONTAINING	Novartis AG	28-Dec-07	10-Dec-13	19-Jun-14
2324	US20160074 481	http://59.45.142.240:8808/pdf/US20160074481A1.pdf	Clottable Concentrate Of Platelet Growth Factors And Preparation Method Thereof	Zheng Yang Biomedical Technology Co.,	7-Jan-08	30-Nov-15	17-Mar-16
2325	US20110027 257	http://59.45.142.240:8808/pdf/US20110027257A1.pdf	CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND PREPARATION METHOD THEREOF	GWO REI BIOMEDICAL TECHNOLOGY	7-Jan-08	7-Jan-09	3-Feb-11
2326	US9492413	http://59.45.142.240:8808/pdf/US9492413.pdf	Use of salt of an acetylsalicylic acid for the treatment of viral infections	Ventaleon GMBH	14-Jan-08	14-Jan-09	15-Nov-16
2327	US20100105 024	http://59.45.142.240:8808/pdf/US20100105024A1.pdf	RAPID TEST INCLUDING GENETIC SEQUENCE PROBE	Transgenex Nanobiotech, Inc	14-Jan-08	16-Apr-09	29-Apr-10
2328	US20090181 361	http://59.45.142.240:8808/pdf/US20090181361A1.pdf	Rapid test for detecting infection	KUMAR ARUN	14-Jan-08	14-Jan-08	16-Jul-09
2329	US8629098	http://59.45.142.240:8808/pdf/US8629098.pdf	Compositions and methods for adoptive and active immunotherapy	Yale University	15-Jan-08	14-Jan-09	14-Jan-14
2330	US20100284 965	http://59.45.142.240:8808/pdf/US20100284965A1.pdf	COMPOSITIONS AND METHODS FOR ADOPTIVE AND ACTIVE IMMUNOTHERAPY	Yale University	15-Jan-08	14-Jan-09	11-Nov-10
2331	US9458470	http://59.45.142.240:8808/pdf/US9458470.pdf	Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing	MEDICAGO INC.	21-Jan-08	23-Jan-13	4-Oct-16
2332	US20190177 739	http://59.45.142.240:8808/pdf/US20190177739A1.pdf	RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPs) PRODUCED IN TRANSGENIC PLANTS	Not Available	21-Jan-08	13-Dec-18	13-Jun-19
2333	US20170088 848	http://59.45.142.240:8808/pdf/US20170088848A1.pdf	Recombinant Influenza Virus-Like Particles (VLPs) Produced in Transgenic Plants Expressing	Medicago Inc.	21-Jan-08	2-Sep-16	30-Mar-17
2334	US20130142 826	http://59.45.142.240:8808/pdf/US20130142826A1.pdf	RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPs) PRODUCED IN TRANSGENIC PLANTS	MEDICAGO, INC.	21-Jan-08	23-Jan-13	6-Jun-13
2335	US20100310 604	http://59.45.142.240:8808/pdf/US20100310604A1.pdf	RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPs) PRODUCED IN TRANSGENIC PLANTS	MEDICAGO INC.	21-Jan-08	12-Jan-09	9-Dec-10
2336	US10190132	http://59.45.142.240:8808/pdf/US10190132.pdf	Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing	MEDICAGO INC.	21-Jan-08	2-Sep-16	29-Jan-19
2337	US9290545	http://59.45.142.240:8808/pdf/US9290545.pdf	Compositions and methods for the treatment of viral infections	Dana-Farber Cancer Institute, Inc	23-Jan-08	23-Jul-10	22-Mar-16
2338	US20160237 123	http://59.45.142.240:8808/pdf/US20160237123A1.pdf	COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS	Not Available	23-Jan-08	4-May-16	18-Aug-16
2339	US20160152 667	http://59.45.142.240:8808/pdf/US20160152667A1.pdf	COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS	Not Available	23-Jan-08	9-Feb-16	2-Jun-16
2340	US10259848	http://59.45.142.240:8808/pdf/US10259848.pdf	Compositions and methods comprising hydrocarbon-stapled truncated molecules	DANA-FARBER CANCER INSTITUTE, INC	23-Jan-08	4-May-16	16-Apr-19
2341	US20160199 407	http://59.45.142.240:8808/pdf/US20160199407A1.pdf	HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION	THE UNIVERSITY OF IOWA RESEARCH FOUNDATION	25-Jan-08	17-Dec-15	14-Jul-16
2342	US20100330 592	http://59.45.142.240:8808/pdf/US20100330592A1.pdf	METHOD FOR DETECTING TRUNCATED MOLECULES	KEY MARC E	29-Jan-08	29-Jan-09	30-Dec-10
2343	US9527903	http://59.45.142.240:8808/pdf/US9527903.pdf	Engineered antibody constant domain molecules	The United States of America, as represent by the Secretary, Department of Health and Human Services	31-Jan-08	1-Oct-13	27-Dec-16

2344	US8580927	http://59.45.142.240:8808/pdf/US8580927.pdf	Engineered antibody constant domain molecules	The United States of America, as represented by the Secretary, Department of Health and Human Services	31-Jan-08	30-Jan-09	12-Nov-13
2345	US20170081 393	http://59.45.142.240:8808/pdf/US20170081393A1.pdf	ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES	The U.S.A., as represented by the Secretary, Department of Health and Human Services	31-Jan-08	2-Dec-16	23-Mar-17
2346	US20140023 645	http://59.45.142.240:8808/pdf/US20140023645A1.pdf	ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES	The United States of America, as represented by the Secretary, Dept. of Health & Human Services	31-Jan-08	1-Oct-13	23-Jan-14
2347	US20100316 641	http://59.45.142.240:8808/pdf/US20100316641A1.pdf	ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES	DIMITROV DIMITRIS	31-Jan-08	30-Jan-09	16-Dec-10
2348	US10358481	http://59.45.142.240:8808/pdf/US10358481.pdf	Engineered antibody constant domain molecules	The United States of America, as represented by the Secretary, Department of Health and Human Services	31-Jan-08	2-Dec-16	23-Jul-19
2349	US8629271	http://59.45.142.240:8808/pdf/US8629271.pdf	Compounds	AstraZeneca AB	6-Feb-08	2-Apr-12	14-Jan-14
2350	US20090298 807		Compounds	ALCARAZ LILIAN	6-Feb-08	4-Feb-09	3-Dec-09
2351	US20090196 921	http://59.45.142.240:8808/pdf/US20090196921A1.pdf	Compositions Methods and Kits For Enhancing Immune Response To A Pathogen	The Procter & Gamble Company	6-Feb-08	6-Feb-09	6-Aug-09
2352	US8748464	http://59.45.142.240:8808/pdf/US8748464.pdf	Use of SIRT1 activators or inhibitors to modulate an immune response	The J. David Gladstone Institutes	7-Feb-08	16-Jul-10	10-Jun-14
2353	US20140030 295	http://59.45.142.240:8808/pdf/US20140030295A1.pdf	Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response	THE J. DAVID GLADSTONE INSTITUTES	7-Feb-08	17-Dec-12	30-Jan-14
2354	US20100330 114	http://59.45.142.240:8808/pdf/US20100330114A1.pdf	Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response	KWON HYE-SOOK	7-Feb-08	16-Jul-10	30-Dec-10
2355	EP2510946A 1	http://59.45.142.240:8808/pdf/EP2510946B1.pdf	Conjugates of synthetic tir agonists and uses therefor	The Regents of The University of California	7-Feb-08	17-Oct-12	17-Oct-12
2356	US20100329 971	http://59.45.142.240:8808/pdf/US20100329971A1.pdf	NOVEL HYDROXY RADICAL GENERATION METHOD, AND ANTI-VIRAL MATERIAL UTILIZING HYDROXYL RADICAL GENERATED BY	MOCHIGASE CO., LTD.	8-Feb-08	9-Feb-09	30-Dec-10
2357	US8461125	http://59.45.142.240:8808/pdf/US8461125.pdf	Compositions and methods to treat asthma	The Children's Hospital of Philadelphia	14-Feb-08	13-Aug-10	11-Jun-13
2358	US9416396	http://59.45.142.240:8808/pdf/US9416396.pdf	Covalently linked thermostable kinase for decontamination process	The Secretary of State for Health	20-Feb-08	18-Feb-09	16-Aug-16
2359	US20170052 190	http://59.45.142.240:8808/pdf/US20170052190A1.pdf	Covalently Linked Thermostable Kinase for Decontamination Process	Not Available	20-Feb-08	8-Jul-16	23-Feb-17
2360	US20100272 668	http://59.45.142.240:8808/pdf/US20100272668A1.pdf	ANTIVIRAL SUBSTANCE, ANTIVIRAL FIBER, AND ANTIVIRAL FIBER	Daiwabo Holdings Co., Ltd.	20-Feb-08	20-Feb-09	28-Oct-10
2361	US20100221 307	http://59.45.142.240:8808/pdf/US20100221307A1.pdf	ANTIVIRAL AGENTS, ANTIVIRAL FIBERS AND ANTIVIRAL FIBER	DAIWABO HOLDINGS CO., LTD.	20-Feb-08	20-Feb-09	2-Sep-10
2362	US20090264 444	http://59.45.142.240:8808/pdf/US20090264444A1.pdf	Organic compounds	CHOWDHURY SUJATAN	20-Feb-08	20-Feb-09	22-Oct-09
2363	US10466245	http://59.45.142.240:8808/pdf/US10466245.pdf	Covalently linked thermostable kinase for decontamination process	The Secretary of State for Health	20-Feb-08	8-Jul-16	5-Nov-19
2364	US9566326	http://59.45.142.240:8808/pdf/US9566326.pdf	Adjuvanted influenza vaccines for pediatric use	Seqirus UK Limited	22-Feb-08	21-Jun-13	14-Feb-17
2365	US8506966	http://59.45.142.240:8808/pdf/US8506966.pdf	Adjuvanted influenza vaccines for pediatric use	Novartis AG	22-Feb-08	20-Feb-09	13-Aug-13
2366	US20180207 258	http://59.45.142.240:8808/pdf/US20180207258A1.pdf	ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE	Not Available	22-Feb-08	5-Mar-18	26-Jul-18
2367	US20170202 955	http://59.45.142.240:8808/pdf/US20170202955A1.pdf	Adjuvanted Influenza Vaccines for Pediatric Use	Not Available	22-Feb-08	30-Dec-16	20-Jul-17
2368	US20130273 104	http://59.45.142.240:8808/pdf/US20130273104A1.pdf	Adjuvanted Influenza Vaccines for Pediatric Use	GROTH NICOLA	22-Feb-08	21-Jun-13	17-Oct-13
2369	US20090220 546	http://59.45.142.240:8808/pdf/US20090220546A1.pdf	Adjuvanted influenza vaccines for pediatric use	GROTH NICOLA	22-Feb-08	20-Feb-09	3-Sep-09
2370	US9746985	http://59.45.142.240:8808/pdf/US9746985.pdf	System and method for detecting, collecting, analyzing, and communicating event-related	Georgetown University	25-Feb-08	20-Apr-11	29-Aug-17
2371	US9529974	http://59.45.142.240:8808/pdf/US9529974.pdf	System and method for detecting, collecting, analyzing, and communicating event-related	Georgetown University	25-Feb-08	27-Jul-11	27-Dec-16
2372	US9489495	http://59.45.142.240:8808/pdf/US9489495.pdf	System and method for detecting, collecting, analyzing, and communicating event-related	GEORGETOWN UNIVERSITY	25-Feb-08	28-Aug-08	8-Nov-16
2373	US7725565	http://59.45.142.240:8808/pdf/US7725565.pdf	System and method for detecting, collecting, analyzing, and communicating event related	Georgetown University	25-Feb-08	19-Nov-08	25-May-10
2374	US20170322 682	http://59.45.142.240:8808/pdf/US20170322682A1.pdf	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING	Georgetown University	25-Feb-08	27-Jul-17	9-Nov-17
2375	US20170011 131	http://59.45.142.240:8808/pdf/US20170011131A1.pdf	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING	Georgetown University	25-Feb-08	23-Sep-16	12-Jan-17
2376	US20090216 860	http://59.45.142.240:8808/pdf/US20090216860A1.pdf	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING	Georgetown University	25-Feb-08	19-Nov-08	27-Aug-09
2377	US20090216 747	http://59.45.142.240:8808/pdf/US20090216747A1.pdf	System and method for detecting, collecting, analyzing, and communicating event-related	Georgetown University- OTC	25-Feb-08	28-Aug-08	27-Aug-09

2378	US10503347	http://59.45.142.240:8808/pdf/US10503347.pdf	System and method for detecting, collecting, analyzing, and communicating event-related	Georgetown University	25-Feb-08	27-Jul-17	10-Dec-19
2379	US10055502	http://59.45.142.240:8808/pdf/US10055502.pdf	System and method for detecting, collecting, analyzing, and communicating event related	Georgetown University	25-Feb-08	23-Sep-16	21-Aug-18
2380	US20140031 371	http://59.45.142.240:8808/pdf/US20140031371A1.pdf	POLY AROMATIC SODIUM CHANNEL BLOCKERS	PARION SCIENCES, Inc.	26-Feb-08	1-Oct-13	30-Jan-14
2381	US20090214 444	http://59.45.142.240:8808/pdf/US20090214444A1.pdf	POLY AROMATIC SODIUM CHANNEL BLOCKERS	PARION SCIENCES, Inc.	26-Feb-08	26-Feb-09	27-Aug-09
2382	US8765704	http://59.45.142.240:8808/pdf/US8765704.pdf	Modified small interfering RNA molecules and methods of use	Novartis AG	28-Feb-08	14-Dec-11	1-Jul-14
2383	US20150376 621	http://59.45.142.240:8808/pdf/US20150376621A1.pdf	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	ARROWHEAD RESEARCH CORPORATION	28-Feb-08	14-May-15	31-Dec-15
2384	US8895577	http://59.45.142.240:8808/pdf/US8895577.pdf	Compounds and compositions as TLR activity modulators	Not Available	3-Mar-08	22-Apr-13	25-Nov-14
2385	US8466167	http://59.45.142.240:8808/pdf/US8466167.pdf	Compounds and compositions as TLR activity modulators	IRM LLC	3-Mar-08	27-Feb-09	18-Jun-13
2386	US20130253 002	http://59.45.142.240:8808/pdf/US20130253002A1.pdf	COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS	CORTEZ ALEX	3-Mar-08	22-Apr-13	26-Sep-13
2387	US8679839	http://59.45.142.240:8808/pdf/US8679839.pdf	Cell line from roussetus as host cell for pathogen amplification	Probiogen AG	4-Mar-08	4-Mar-09	25-Mar-14
2388	US8629283	http://59.45.142.240:8808/pdf/US8629283.pdf	Compounds that modulate negative-sense, single-stranded RNA virus	Icahn School of Medicine at Mount Sinai	6-Mar-08	6-Mar-09	14-Jan-14
2389	US20100035 848	http://59.45.142.240:8808/pdf/US20100035848A1.pdf	THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT	BARNES THOMAS MICHAEL	10-Mar-08	10-Mar-09	11-Feb-10
2390	US9546371	http://59.45.142.240:8808/pdf/US9546371.pdf	Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	18-Mar-08	18-Mar-09	17-Jan-17
2391	US20160158 341	http://59.45.142.240:8808/pdf/US20160158341A1.pdf	PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS	Novartis AG	18-Mar-08	7-Dec-15	9-Jun-16
2392	US9737593	http://59.45.142.240:8808/pdf/US9737593.pdf	Carbon nanotube compositions and methods of use thereof	Yale University	19-Mar-08	15-Mar-13	22-Aug-17
2393	US8658178	http://59.45.142.240:8808/pdf/US8658178.pdf	Carbon nanotube compositions and methods of use thereof	Yale University	19-Mar-08	19-Mar-09	25-Feb-14
2394	US20170209 570	http://59.45.142.240:8808/pdf/US20170209570A1.pdf	Carbon Nanotube Compositions and Methods of Use Thereof	Not Available	19-Mar-08	17-Mar-17	27-Jul-17
2395	US20160213 761	http://59.45.142.240:8808/pdf/US20160213761A1.pdf	CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	19-Mar-08	5-Apr-16	28-Jul-16
2396	US20130216 581	http://59.45.142.240:8808/pdf/US20130216581A1.pdf	Carbon Nanotube Compositions and Methods of Use Thereof	UNIV YALE	19-Mar-08	15-Mar-13	22-Aug-13
2397	US10485856	http://59.45.142.240:8808/pdf/US10485856.pdf	Carbon nanotube compositions and methods of use thereof	Yale University	19-Mar-08	17-Mar-17	26-Nov-19
2398	US20110028 531	http://59.45.142.240:8808/pdf/US20110028531A1.pdf	NOVEL SIRNA COMPOUNDS FOR INHIBITING PTEN	FEINSTEIN ELENA	20-Mar-08	17-Mar-09	3-Feb-11
2399	US20090239 848	http://59.45.142.240:8808/pdf/US20090239848A1.pdf	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoAacyltransferase	FOREST LABORATORIES HOLDINGS LIMITED	20-Mar-08	20-Mar-09	24-Sep-09
2400	US20090239 810		NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoAacyltransferase	Forest Laboratories Holdings Limited	20-Mar-08	20-Mar-09	24-Sep-09
2401	US20110021 861	http://59.45.142.240:8808/pdf/US20110021861A1.pdf	HAZARDOUS SUBSTANCE-REMOVING MATERIAL	KOSUGI TAKUJI	25-Mar-08	23-Mar-09	27-Jan-11
2402	US9169318	http://59.45.142.240:8808/pdf/US9169318.pdf	Neutralizing molecules to viral antigens	Sea Lane Biotechnologies	28-Mar-08	18-Jul-11	27-Oct-15
2403	US20170136 118	http://59.45.142.240:8808/pdf/US20170136118A1.pdf	NEUTRALIZING MOLECULES TO VIRAL ANTIGENS	Not Available	28-Mar-08	8-Jun-16	18-May-17
2404	US20100040 635	http://59.45.142.240:8808/pdf/US20100040635A1.pdf	NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES	Sea Lane Biotechnologies	28-Mar-08	27-Mar-09	18-Feb-10
2405	US9744229	http://59.45.142.240:8808/pdf/US9744229.pdf	Vaccines and immunotherapeutics using IL-28 and compositions and methods of use thereof	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4-Apr-08	28-Apr-14	29-Aug-17
2406	US20190076 520	http://59.45.142.240:8808/pdf/US20190076520A1.pdf	VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND	Not Available	4-Apr-08	11-Sep-18	14-Mar-19
2407	US20140335 111	http://59.45.142.240:8808/pdf/US20140335111A1.pdf	VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND	The Trustees of the University of Pennsylvania	4-Apr-08	28-Apr-14	13-Nov-14
2408	US10646563	http://59.45.142.240:8808/pdf/US10646563.pdf	Vaccines and immunotherapeutics using IL-28 and compositions and methods of use thereof	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4-Apr-08	11-Sep-18	12-May-20
2409	US10071154	http://59.45.142.240:8808/pdf/US10071154.pdf	Vaccines and immunotherapeutics using IL-28 and compositions and methods of use thereof	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4-Apr-08	6-Apr-09	11-Sep-18
2410	US8815611	http://59.45.142.240:8808/pdf/US8815611.pdf	Surface for label independent detection and method thereof	Corning Incorporated	10-Apr-08	3-Apr-09	26-Aug-14
2411	US20090258 440	http://59.45.142.240:8808/pdf/US20090258440A1.pdf	SURFACE FOR LABEL INDEPENDENT DETECTION AND METHOD THEREOF	BUNCH THOMAS A	10-Apr-08	3-Apr-09	15-Oct-09
2412	US8664218	http://59.45.142.240:8808/pdf/US8664218.pdf	Pharmaceutical compounds	Astex Therapeutics Ltd.	11-Apr-08	30-Jan-13	4-Mar-14
2413	US20130210 820	http://59.45.142.240:8808/pdf/US20130210820A1.pdf	Pharmaceutical Compounds	ASTEX THERAPEUTICS	11-Apr-08	30-Jan-13	15-Aug-13
2414	US9498544	http://59.45.142.240:8808/pdf/US9498544.pdf	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of	Tissue Regeneration Therapeutics Inc.	21-Apr-08	13-Mar-15	22-Nov-16
2415	US9005599	http://59.45.142.240:8808/pdf/US9005599.pdf	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of	Tissue Regeneration Therapeutics Inc.	21-Apr-08	20-Apr-09	14-Apr-15
2416	US20150182 636	http://59.45.142.240:8808/pdf/US20150182636A1.pdf	GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL OR	Not Available	21-Apr-08	13-Mar-15	2-Jul-15
2417	US20100144 589	http://59.45.142.240:8808/pdf/US20100144589A1.pdf	METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN	BOGOCH ELENORE S	23-Apr-08	7-Aug-09	10-Jun-10
2418	US20090269 367	http://59.45.142.240:8808/pdf/US20090269367A1.pdf	METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC OUTBREAKS USING REPLIKIN	BOGOCH ELENORE S	23-Apr-08	23-Apr-09	29-Oct-09
2419	US9393295	http://59.45.142.240:8808/pdf/US9393295.pdf	Nanoparticles for use in pharmaceutical compositions	Novartis AG	28-Apr-08	28-Apr-09	19-Jul-16
2420	US20110038 900	http://59.45.142.240:8808/pdf/US20110038900A1.pdf	NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS	NOVARTIS AG	28-Apr-08	28-Apr-09	17-Feb-11

2421	US20110038 884	http://59.45.142.240:8808/pdf/US20110038884A1.pdf	IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST	NATIONAL UNIVERSITY CO., HAMAMATSU UNIVER. SCHOOL	28-Apr-08	27-Apr-09	17-Feb-11
2422	US9670507	http://59.45.142.240:8808/pdf/US9670507.pdf	Directed evolution and in vivo panning of virus vectors	The University of North Carolina at Chapel Hill	30-Apr-08	28-Jun-16	6-Jun-17
2423	US9402921	http://59.45.142.240:8808/pdf/US9402921.pdf	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30-Apr-08	22-Oct-14	2-Aug-16
2424	US9186419	http://59.45.142.240:8808/pdf/US9186419.pdf	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30-Apr-08	17-Jan-14	17-Nov-15
2425	US8632764	http://59.45.142.240:8808/pdf/US8632764.pdf	Directed evolution and in vivo panning of virus vectors	University of North Carolina at Chapel Hill	30-Apr-08	29-Apr-09	21-Jan-14
2426	US20160304 904	http://59.45.142.240:8808/pdf/US20160304904A1.pdf	Directed Evolution and In Vivo Panning of Virus Vectors	Not Available	30-Apr-08	28-Jun-16	20-Oct-16
2427	US20150118 201	http://59.45.142.240:8808/pdf/US20150118201A1.pdf	Directed Evolution and In Vitro Panning of Virus Vectors	Not Available	30-Apr-08	22-Oct-14	30-Apr-15
2428	US20140234 274	http://59.45.142.240:8808/pdf/US20140234274A1.pdf	Directed Evolution and In Vitro Panning of Virus Vectors	University of North Carolina at Chapel Hill	30-Apr-08	17-Jan-14	21-Aug-14
2429	US9217745	http://59.45.142.240:8808/pdf/US9217745.pdf	Arrayed detector system for measurement of influenza immune response	University of Rochester	2-May-08	11-Jul-13	22-Dec-15
2430	US8486619	http://59.45.142.240:8808/pdf/US8486619.pdf	Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral agents	University of Rochester	2-May-08	1-May-09	16-Jul-13
2431	US20160041 168	http://59.45.142.240:8808/pdf/US20160041168A1.pdf	ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA VIRUS RESPONSE	Not Available	2-May-08	23-Oct-15	11-Feb-16
2432	US20130288 922	http://59.45.142.240:8808/pdf/US20130288922A1.pdf	ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA VIRUS RESPONSE	UNIV ROCHESTER	2-May-08	11-Jul-13	31-Oct-13
2433	US20090275 016	http://59.45.142.240:8808/pdf/US20090275016A1.pdf	ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA VIRUS RESPONSE	UNIVERSITY OF ROCHESTER	2-May-08	1-May-09	5-Nov-09
2434	US8933019	http://59.45.142.240:8808/pdf/US8933019.pdf	Antiviral cell-penetrating peptides	New York Blood Center, Inc	6-May-08	31-Oct-12	13-Jan-15
2435	US20130059 776	http://59.45.142.240:8808/pdf/US20130059776A1.pdf	Antiviral Cell-Penetrating Peptides	CURRELLI FRANCESCA	6-May-08	31-Oct-12	7-Mar-13
2436	US20090281 041	http://59.45.142.240:8808/pdf/US20090281041A1.pdf	ANTIVIRAL CELL-PENETRATING PEPTIDES	CURRELLI FRANCESCA	6-May-08	5-May-09	12-Nov-09
2437	US20140335 104	http://59.45.142.240:8808/pdf/US20140335104A1.pdf	Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying	Not Available	13-May-08	14-Apr-14	13-Nov-14
2438	US20100261 779	http://59.45.142.240:8808/pdf/US20100261779A1.pdf	Phosphate-Modified Oligonucleotide Analogs with Enhanced Antiviral Activity	JURK MARION	15-May-08	15-May-08	14-Oct-10
2439	US9428571	http://59.45.142.240:8808/pdf/US9428571.pdf	Antibodies and processes for preparing the same	TAIGA BIOTECHNOLOGIES, INC.	16-May-08	18-Mar-15	30-Aug-16
2440	US8986702	http://59.45.142.240:8808/pdf/US8986702.pdf	Antibodies and processes for preparing the same	Taiga Biotechnologies, Inc.	16-May-08	18-May-09	24-Mar-15
2441	US20200148 749	http://59.45.142.240:8808/pdf/US20200148749A1.pdf	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16-May-08	10-Oct-19	14-May-20
2442	US20170348 369	http://59.45.142.240:8808/pdf/US20170348369A1.pdf	Plant Extract and Its Therapeutic Use	Not Available	16-May-08	18-Jul-17	7-Dec-17
2443	US20170044 237	http://59.45.142.240:8808/pdf/US20170044237A1.pdf	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16-May-08	23-Aug-16	16-Feb-17
2444	US20150259 399	http://59.45.142.240:8808/pdf/US20150259399A1.pdf	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16-May-08	18-Mar-15	17-Sep-15
2445	US20090285 921	http://59.45.142.240:8808/pdf/US20090285921A1.pdf	PLANT EXTRACT AND ITS THERAPEUTIC USE	Veritron Limited	16-May-08	1-Dec-08	19-Nov-09
2446	US10442853	http://59.45.142.240:8808/pdf/US10442853.pdf	Antibodies and processes for preparing the same	TAIGA BIOTECHNOLOGIES, INC.	16-May-08	23-Aug-16	15-Oct-19
2447	US9200329	http://59.45.142.240:8808/pdf/US9200329.pdf	Rapid epidemiologic typing of bacteria	BioFire Diagnostics, LLC	19-May-08	18-May-09	1-Dec-15
2448	US20160153 034	http://59.45.142.240:8808/pdf/US20160153034A1.pdf	Rapid Epidemiologic Typing of Bacteria	Not Available	19-May-08	11-Nov-15	2-Jun-16
2449	US20100035 234	http://59.45.142.240:8808/pdf/US20100035234A1.pdf	VACCINE ASSAYS	Novartis AG	19-May-08	19-May-09	11-Feb-10
2450	US10421991	http://59.45.142.240:8808/pdf/US10421991.pdf	Rapid epidemiologic typing of bacteria	BioFire Diagnostics, LLC	19-May-08	11-Nov-15	24-Sep-19
2451	US8541568	http://59.45.142.240:8808/pdf/US8541568.pdf	Compositions and methods using siRNA molecules for treatment of cancer	BIGNER DARELL D	24-May-08	26-May-09	24-Sep-13
2452	US8420784	http://59.45.142.240:8808/pdf/US8420784.pdf	Interleukin 10 receptor, (IL-10R) antibodies	Kyowa Hakko Kirin Co., Ltd.	27-May-08	27-May-09	16-Apr-13
2453	US20100143 411	http://59.45.142.240:8808/pdf/US20100143411A1.pdf	METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS	The Government of the U.S.A. as represented by the Secretary, Dept. of Health and Human Services	27-May-08	27-May-09	10-Jun-10
2454	US20100041 638	http://59.45.142.240:8808/pdf/US20100041638A1.pdf	Chemical Compounds 293	ANDREWS GLEN	27-May-08	26-May-09	18-Feb-10
2455	US8882484	http://59.45.142.240:8808/pdf/US8882484.pdf	Methods and compositions for production of recombinant protein in bacteria	Bayer HealthCare LLC	28-May-08	27-May-09	11-Nov-14
2456	US20150044 768	http://59.45.142.240:8808/pdf/US20150044768A1.pdf	METHODS AND COMPOSITIONS FOR PRODUCTION OF RECOMBINANT PROTEIN IN HBX-EXPRESSING CELLS	Not Available	28-May-08	24-Oct-14	12-Feb-15
2457	US9758553	http://59.45.142.240:8808/pdf/US9758553.pdf	Yeast strain for the production of proteins with terminal alpha-1,3-linked mannose	MERCK SHARP & DOHME CORP.	30-May-08	2-Jul-14	12-Sep-17
2458	US20140314 797	http://59.45.142.240:8808/pdf/US20140314797A1.pdf	YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH TERMINAL ALPHA-1,3-LINKED MANNOSE	Not Available	30-May-08	2-Jul-14	23-Oct-14
2459	US9834595	http://59.45.142.240:8808/pdf/US9834595.pdf	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral infection	Ablynx N.V.	5-Jun-08	29-Oct-15	5-Dec-17
2460	US9193780	http://59.45.142.240:8808/pdf/US9193780.pdf	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral infection	Ablynx N.V.	5-Jun-08	5-Jun-09	24-Nov-15

2461	US20200123 233	http://59.45.142.240:8808/pdf/US20200123233A1.pdf	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE	Ablynx N.V.	5-Jun-08	1-Aug-19	23-Apr-20
2462	US20190077 847	http://59.45.142.240:8808/pdf/US20190077847A1.pdf	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE	Ablynx N.V.	5-Jun-08	17-Oct-17	14-Mar-19
2463	US20160152 693	http://59.45.142.240:8808/pdf/US20160152693A1.pdf	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE	Ablynx N.V.	5-Jun-08	29-Oct-15	2-Jun-16
2464	US10550174		Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral	Ablynx N.V.	5-Jun-08	17-Oct-17	4-Feb-20
2465	US10407492		Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral	Ablynx N.V.	5-Jun-08	17-Oct-17	10-Sep-19
2466	US8470335	http://59.45.142.240:8808/pdf/US8470335.pdf	Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it	Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry AcademyCooperatio	13-Jun-08	13-Jun-08	25-Jun-13
2467	US9943614	http://59.45.142.240:8808/pdf/US9943614.pdf	Cationic steroid antimicrobial diagnostic, detection, screening and	BRIGHAM YOUNG UNIVERSITY	17-Jun-08	16-Jun-09	17-Apr-18
2468	US20100105 642		NOVEL COMPOUNDS 409	ASTRAZENECA AB	18-Jun-08	18-Jun-09	29-Apr-10
2469	US20100144 606	http://59.45.142.240:8808/pdf/US20100144606A1.pdf	COMBINATION 408	AstraZeneca AB	20-Jun-08	19-Jun-09	10-Jun-10
2470	US9951124	http://59.45.142.240:8808/pdf/US9951124.pdf	Antibody producing non-human	MERUS N.V.	27-Jun-08	25-Jan-13	24-Apr-18
2471	US9944695	http://59.45.142.240:8808/pdf/US9944695.pdf	Antibody producing non-human	Merus N.V.	27-Jun-08	30-Apr-14	17-Apr-18
2472	US9765133	http://59.45.142.240:8808/pdf/US9765133.pdf	Antibody producing non-human	Merus N.V.	27-Jun-08	29-Apr-14	19-Sep-17
2473	US9187426		Organic compounds	Novartis AG	27-Jun-08	25-Jun-09	17-Nov-15
2474	US20180142 006	http://59.45.142.240:8808/pdf/US20180142006A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Merus N.V.	27-Jun-08	12-Jan-18	24-May-18
2475	US20180142 005	http://59.45.142.240:8808/pdf/US20180142005A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Merus N.V.	27-Jun-08	12-Jan-18	24-May-18
2476	US20180142 004	http://59.45.142.240:8808/pdf/US20180142004A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Merus N.V.	27-Jun-08	11-Jan-18	24-May-18
2477	US20180142 003	http://59.45.142.240:8808/pdf/US20180142003A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Merus N.V.	27-Jun-08	9-Jan-18	24-May-18
2478	US20180142 002	http://59.45.142.240:8808/pdf/US20180142002A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Merus N.V.	27-Jun-08	5-Jan-18	24-May-18
2479	US20180134 770	http://59.45.142.240:8808/pdf/US20180134770A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Merus N.V.	27-Jun-08	12-Jan-18	17-May-18
2480	US20180031 555	http://59.45.142.240:8808/pdf/US20180031555A1.pdf	METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF	Merus N.V.	27-Jun-08	18-Jul-17	1-Feb-18
2481	US20160289 191		ORGANIC COMPOUNDS	NOVARTIS AG	27-Jun-08	9-Oct-15	6-Oct-16
2482	US20140317 766	http://59.45.142.240:8808/pdf/US20140317766A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Not Available	27-Jun-08	29-Apr-14	23-Oct-14
2483	US20140314 755	http://59.45.142.240:8808/pdf/US20140314755A1.pdf	ANTIBODY PRODUCING NON-HUMAN	Not Available	27-Jun-08	30-Apr-14	23-Oct-14
2484	US20130145 484	http://59.45.142.240:8808/pdf/US20130145484A1.pdf	ANTIBODY PRODUCING NON-HUMAN	MERUS B.V.	27-Jun-08	25-Jan-13	6-Jun-13
2485	US20100146 647	http://59.45.142.240:8808/pdf/US20100146647A1.pdf	Antibody producing non-human	Merus B. V.	27-Jun-08	19-Oct-09	10-Jun-10
2486	US20100069 614	http://59.45.142.240:8808/pdf/US20100069614A1.pdf	Antibody producing non-human	Merus B.V.	27-Jun-08	29-Jun-09	18-Mar-10
2487	US10605808		Antibody producing non-human	Merus N.V.	27-Jun-08	27-Apr-16	31-Mar-20
2488	US8506968	http://59.45.142.240:8808/pdf/US8506968.pdf	SARS vaccine compositions and methods of making and using them	Eli Lilly and Company	29-Jun-08	28-Dec-09	13-Aug-13
2489	US8501699	http://59.45.142.240:8808/pdf/US8501699.pdf	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Management Pty Ltd	3-Jul-08	7-Sep-12	6-Aug-13
2490	US20100035 836	http://59.45.142.240:8808/pdf/US20100035836A1.pdf	BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC	BETHELL RICHARD	3-Jul-08	1-Jul-09	11-Feb-10
2491	US20100021 907	http://59.45.142.240:8808/pdf/US20100021907A1.pdf	METHOD OF DETECTING A	KABUSHIKI KAISHA TOSHIBA	3-Jul-08	12-Jun-09	28-Jan-10
2492	US20150299 707	http://59.45.142.240:8808/pdf/US20150299707A1.pdf	CONSTRUCTION OF POOL OF INTERFERING NUCLEIC ACIDS COVERING ENTIRE RNA TARGET SEQUENCE AND RELATED	BIOMICS BIOTECHNOLOGIES CO., LTD.	7-Jul-08	2-Jul-15	22-Oct-15
2493	EP2167534B 1	http://59.45.142.240:8808/pdf/EP2167534B1.pdf	BIOACTIVE PEPTIDES AND METHOD OF USING SAME	Compugen Ltd.	11-Jul-08	4-Jul-12	4-Jul-12
2494	US9107970	http://59.45.142.240:8808/pdf/US9107970.pdf	Method and a filter for capturing	Not Available	15-Jul-08	13-Jul-09	18-Aug-15
2495	US9695445	http://59.45.142.240:8808/pdf/US9695445.pdf	Method for production of reprogrammed cell using chromosomally unintegrated virus	ID Pharma Co., Ltd.	16-Jul-08	29-Jul-15	4-Jul-17
2496	US9127256	http://59.45.142.240:8808/pdf/US9127256.pdf	Method for production of reprogrammed cell using chromosomally unintegrated virus	DNAVEC CORPORATION	16-Jul-08	16-Jul-09	8-Sep-15
2497	US20160177 337	http://59.45.142.240:8808/pdf/US20160177337A1.pdf	METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED	Not Available	16-Jul-08	8-Mar-16	23-Jun-16
2498	US20150337 334	http://59.45.142.240:8808/pdf/US20150337334A1.pdf	METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED	Not Available	16-Jul-08	29-Jul-15	26-Nov-15
2499	US20100015 633		METHODS AND KIT FOR ANALYTE DETECTION	GENERAL ELECTRIC COMPANY	18-Jul-08	18-Jul-08	21-Jan-10
2500	US20130259 829	http://59.45.142.240:8808/pdf/US20130259829A1.pdf	CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE FUNCTION	Viral Genetics, Inc.	25-Jul-08	6-Jun-13	3-Oct-13
2501	US20100166 782	http://59.45.142.240:8808/pdf/US20100166782A1.pdf	CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE FUNCTION	AGADJANYAN MICHAEL	25-Jul-08	23-Jul-09	1-Jul-10

2502	US20100028 369	http://59.45.142.240:8808/pdf/US20100028369A1.pdf	Hazardous substance removing material and method for removing	FUJIFILM Corporation	29-Jul-08	28-Jul-09	4-Feb-10
2503	US9101582	http://59.45.142.240:8808/pdf/US9101582.pdf	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease	31-Jul-08	27-Mar-13	11-Aug-15
2504	US8431134	http://59.45.142.240:8808/pdf/US8431134.pdf	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease	31-Jul-08	31-Jul-09	30-Apr-13
2505	US20130195 893	http://59.45.142.240:8808/pdf/US20130195893A1.pdf	USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN	The Government of the United States of America as represented by the Secretary of the	31-Jul-08	27-Mar-13	1-Aug-13
2506	US9216192	http://59.45.142.240:8808/pdf/US9216192.pdf	Toll-like receptor agonist formulations and their use	VentiRx Pharmaceuticals,	1-Aug-08	16-Jul-12	22-Dec-15
2507	US20160331 758	http://59.45.142.240:8808/pdf/US20160331758A1.pdf	TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE	Not Available	1-Aug-08	21-Dec-15	17-Nov-16
2508	US20100029 585	http://59.45.142.240:8808/pdf/US20100029585A1.pdf	TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE	DIETSCH GREGORY	1-Aug-08	31-Jul-09	4-Feb-10
2509	US20180085 432	http://59.45.142.240:8808/pdf/US20180085432A1.pdf	STING (Stimulator of Interferon Genes), A Regulator of Innate	Not Available	4-Aug-08	15-Sep-17	29-Mar-18
2510	US8840899	http://59.45.142.240:8808/pdf/US8840899.pdf	Use of mTOR inhibitors to enhance T cell immune responses	Emory University	5-Aug-08	5-Aug-09	23-Sep-14
2511	US20160324 834	http://59.45.142.240:8808/pdf/US20160324834A1.pdf	Use of mTOR Inhibitors to Enhance T Cell Immune Responses	Not Available	5-Aug-08	16-May-16	10-Nov-16
2512	US20150017 251	http://59.45.142.240:8808/pdf/US20150017251A1.pdf	MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS	NOVARTIS AG	6-Aug-08	18-Jul-14	15-Jan-15
2513	US9078885	http://59.45.142.240:8808/pdf/US9078885.pdf	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation)	7-Aug-08	7-Apr-14	14-Jul-15
2514	US8815837	http://59.45.142.240:8808/pdf/US8815837.pdf	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation)	7-Aug-08	29-Jun-12	26-Aug-14
2515	US20140248 357		Respiratory Disease Treatment	PULMAGEN THERAPEUTICS (INFLAMMATION)	7-Aug-08	7-Apr-14	4-Sep-14
2516	US20110053 986	http://59.45.142.240:8808/pdf/US20110053986A1.pdf	RESPIRATORY DISEASE TREATMENT	FINCH HARRY	7-Aug-08	4-Aug-10	3-Mar-11
2517	US20160267 244	http://59.45.142.240:8808/pdf/US20160267244A1.pdf	METHODS OF PREDICTING CANCER LETHALITY USING REPLICIN	Not Available	8-Aug-08	19-May-16	15-Sep-16
2518	US9546184	http://59.45.142.240:8808/pdf/US9546184.pdf	Alkyloxy substituted thiazoloquinolines and	3M INNOVATIVE PROPERTIES	13-Aug-08	8-Jun-15	17-Jan-17
2519	US20100040 703	http://59.45.142.240:8808/pdf/US20100040703A1.pdf	USE OF NITRIC OXIDE	MILLER CHRIS	13-Aug-08	12-Aug-09	18-Feb-10
2520	US8481270	http://59.45.142.240:8808/pdf/US8481270.pdf	Method for chromogenic detection of two or more target molecules in a	Ventana Medical Systems, Inc.	22-Aug-08	21-Aug-09	9-Jul-13
2521	US20130273 540	http://59.45.142.240:8808/pdf/US20130273540A1.pdf	METHOD FOR CHROMOGENIC DETECTION OF TWO OR MORE TARGET MOLECULES IN A SINGLE	BIENIARZ CHRISTOPHER A	22-Aug-08	7-Jun-13	17-Oct-13
2522	US20190062 408	http://59.45.142.240:8808/pdf/US20190062408A1.pdf	CONSERVED HEMAGGLUTININ EPIOTOPE, ANTIBODIES TO THE EPIOTOPE, AND METHODS OF USE	Not Available	25-Aug-08	20-Jun-18	28-Feb-19
2523	US20140227 262	http://59.45.142.240:8808/pdf/US20140227262A1.pdf	PD-1 Antagonists and Methods for Treating Infectious Disease	AMPLIMUNE, INC.	25-Aug-08	1-Nov-13	14-Aug-14
2524	US8881040	http://59.45.142.240:8808/pdf/US8881040.pdf	System and method for detecting, collecting, analyzing, and communicating event-related	Georgetown University	28-Aug-08	2-Dec-09	4-Nov-14
2525	US20100175 006	http://59.45.142.240:8808/pdf/US20100175006A1.pdf	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING	Georgetown University	28-Aug-08	2-Dec-09	8-Jul-10
2526	US10564160	http://59.45.142.240:8808/pdf/US10564160.pdf	Antibody-secreting cell assay	MABTECH AB	28-Aug-08	28-Aug-09	18-Feb-20
2527	US9828346	http://59.45.142.240:8808/pdf/US9828346.pdf	N-myristoyl transferase inhibitors	University of Dundee	2-Sep-08	31-Aug-15	28-Nov-17
2528	US9156811	http://59.45.142.240:8808/pdf/US9156811.pdf	N-myristoyl transferase inhibitors	University of Dundee	2-Sep-08	29-Aug-09	13-Oct-15
2529	US9063150	http://59.45.142.240:8808/pdf/US9063150.pdf	Method for detection of antigen-specific antibodies in biological samples	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers	2-Sep-08	25-Aug-09	23-Jun-15
2530	US20160060 224	http://59.45.142.240:8808/pdf/US20160060224A1.pdf	N-MYRISTOYL TRANSFERASE INHIBITORS	UNIVERSITY OF DUNDEE	2-Sep-08	31-Aug-15	3-Mar-16
2531	US9549949	http://59.45.142.240:8808/pdf/US9549949.pdf	Antiviral agent	NBC MESHTEC, INC.	3-Sep-08	31-Aug-09	24-Jan-17
2532	US20170086 463		ANTIVIRAL AGENT	Not Available	3-Sep-08	12-Dec-16	30-Mar-17
2533	US20100061 995	http://59.45.142.240:8808/pdf/US20100061995A1.pdf	Immunotherapy To Treat Or Prevent Viral Infection	CARRAGHER DAMIAN MICHAEL	8-Sep-08	8-Sep-08	11-Mar-10
2534	US20150132 337	http://59.45.142.240:8808/pdf/US20150132337A1.pdf	COMBINATION GAS VACCINES AND THERAPEUTICS	Not Available	17-Sep-08	13-Nov-14	14-May-15
2535	US20100092 470	http://59.45.142.240:8808/pdf/US20100092470A1.pdf	ANTIBODIES, ANALOGS AND USES THEREOF	ICB International, Inc.	22-Sep-08	21-Sep-09	15-Apr-10
2536	US8962580	http://59.45.142.240:8808/pdf/US8962580.pdf	Chemical modifications of monomers and oligonucleotides with	Alnylam Pharmaceuticals,	23-Sep-08	23-Sep-09	24-Feb-15

2537	US20190048 344	http://59.45.142.240:8808/pdf/US20190048344A1.pdf	CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH	Not Available	23-Sep-08	16-Aug-18	14-Feb-19
2538	US20150203 847	http://59.45.142.240:8808/pdf/US20150203847A1.pdf	CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH	Not Available	23-Sep-08	31-Dec-14	23-Jul-15
2539	US20100075 298	http://59.45.142.240:8808/pdf/US20100075298A1.pdf	Method for rapid identification and quantification of microorganisms	The Regents of the University of	23-Sep-08	23-Sep-08	25-Mar-10
2540	US20100099 079	http://59.45.142.240:8808/pdf/US20100099079A1.pdf	Non-dividing cell-based assay for high throughput antiviral compound	SAINZ JR BRUNO	26-Sep-08	24-Sep-09	22-Apr-10
2541	US20100099 665	http://59.45.142.240:8808/pdf/US20100099665A1.pdf	ISOQUINOLINONE DERIVATIVES	AstraZeneca AB	1-Oct-08	1-Oct-09	22-Apr-10
2542	US20190314 471	http://59.45.142.240:8808/pdf/US20190314471A1.pdf	MOLECULAR VACCINES FOR INFECTIOUS DISEASE	Not Available	2-Oct-08	27-Jun-19	17-Oct-19
2543	US10369204	http://59.45.142.240:8808/pdf/US10369204.pdf	Molecular vaccines for infectious disease	Dako Denmark A/S	2-Oct-08	2-Oct-09	6-Aug-19
2544	US9487837	http://59.45.142.240:8808/pdf/US9487837.pdf	Exosome-mediated diagnosis of hepatitis virus infections and	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	21-Jan-14	8-Nov-16
2545	US20200033 343	http://59.45.142.240:8808/pdf/US20200033343A1.pdf	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS	Not Available	6-Oct-08	14-Oct-19	30-Jan-20
2546	US20190346 443	http://59.45.142.240:8808/pdf/US20190346443A1.pdf	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS	Not Available	6-Oct-08	28-Jun-19	14-Nov-19
2547	US20170299 591	http://59.45.142.240:8808/pdf/US20170299591A2.pdf	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS	Not Available	6-Oct-08	13-Dec-16	19-Oct-17
2548	US20170168 052	http://59.45.142.240:8808/pdf/US20170168052A1.pdf	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS	Not Available	6-Oct-08	13-Dec-16	15-Jun-17
2549	US20170010 264	http://59.45.142.240:8808/pdf/US20170010264A1.pdf	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS	Not Available	6-Oct-08	20-Sep-16	12-Jan-17
2550	US20140134 606	http://59.45.142.240:8808/pdf/US20140134606A1.pdf	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	21-Jan-14	15-May-14
2551	US10495640	http://59.45.142.240:8808/pdf/US10495640.pdf	Exosome-mediated diagnosis of hepatitis virus infections and	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	13-Dec-16	3-Dec-19
2552	US10416161	http://59.45.142.240:8808/pdf/US10416161.pdf	Exosome-mediated diagnosis of hepatitis virus infections and	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	20-Sep-16	17-Sep-19
2553	US9963718	http://59.45.142.240:8808/pdf/US9963718.pdf	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of	VIRATHERAPEUTICS GMBH	8-Oct-08	7-Apr-17	8-May-18
2554	US9650649	http://59.45.142.240:8808/pdf/US9650649.pdf	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of	VIRATHERAPEUTICS GMBH	8-Oct-08	8-Oct-09	16-May-17
2555	US20150202 284	http://59.45.142.240:8808/pdf/US20150202284A1.pdf	METHOD OF MAKING A VACCINE	The United States of America, as represented by the Secretary, Dept. of Health & Human	11-Oct-08	20-Jan-15	23-Jul-15
2556	US20100093 851	http://59.45.142.240:8808/pdf/US20100093851A1.pdf	SILVER POLYAMIDE COMPOSITE	BISHOP KEVIN L	14-Oct-08	14-Oct-08	15-Apr-10
2557	US9408908	http://59.45.142.240:8808/pdf/US9408908.pdf	Combination adjuvant formulation	Not Available	16-Oct-08	15-Feb-13	9-Aug-16
2558	US9061001	http://59.45.142.240:8808/pdf/US9061001.pdf	Combination adjuvant formulation	Dalhousie University	16-Oct-08	15-Oct-09	23-Jun-15
2559	US20140248 313	http://59.45.142.240:8808/pdf/US20140248313A1.pdf	COMBINATION ADJUVANT FORMULATION	Dalhousie University	16-Oct-08	15-Feb-13	4-Sep-14
2560	US20100239 611	http://59.45.142.240:8808/pdf/US20100239611A1.pdf	Combination adjuvant formulation	BABIUK LORNE	16-Oct-08	15-Oct-09	23-Sep-10
2561	US8642260	http://59.45.142.240:8808/pdf/US8642260.pdf	Single quantum-dot based aptameric nanosensors	The Research Foundation of the City University of	21-Oct-08	21-Oct-09	4-Feb-14
2562	US20160278 349	http://59.45.142.240:8808/pdf/US20160278349A1.pdf	Immunocompromised Ungulates	Not Available	27-Oct-08	23-Mar-15	29-Sep-16
2563	US10149461	http://59.45.142.240:8808/pdf/US10149461.pdf	Immunocompromised ungulates	Revivicor, Inc.	27-Oct-08	23-Mar-15	11-Dec-18
2564	US8647676	http://59.45.142.240:8808/pdf/US8647676.pdf	Antimicrobial composition from	Nofima Ingrediens	28-Oct-08	28-Oct-09	11-Feb-14
2565	US8865865	http://59.45.142.240:8808/pdf/US8865865.pdf	N-terminally modified tetrapeptide derivatives having a C-terminal	Philipps-Universitat Marburg	29-Oct-08	29-Oct-09	21-Oct-14
2566	US8961983	http://59.45.142.240:8808/pdf/US8961983.pdf	Mucosal vaccine using cationic nanogel	National University Corporation Tokyo Medical and Dental	31-Oct-08	5-Sep-14	24-Feb-15
2567	US20100112 643	http://59.45.142.240:8808/pdf/US20100112643A1.pdf	METHOD FOR DIRECT CAPTURE OF RIBONUCLEIC ACID	The Government of the United States of America, as represented by the Secretary of the	4-Nov-08	4-Nov-08	6-May-10
2568	US9200074	http://59.45.142.240:8808/pdf/US9200074.pdf	Antibodies to IL-1 R1 and methods of making them	MEDIMMUNE LIMITED	7-Nov-08	16-Apr-14	1-Dec-15
2569	US8741604	http://59.45.142.240:8808/pdf/US8741604.pdf	Nucleic acid molecule encoding a specific IL-1R1 antibody	Medimmune Limited	7-Nov-08	14-Sep-12	3-Jun-14
2570	US20160096 895	http://59.45.142.240:8808/pdf/US20160096895A1.pdf	BINDING MEMBERS-513	Not Available	7-Nov-08	23-Oct-15	7-Apr-16
2571	US20140212 429	http://59.45.142.240:8808/pdf/US20140212429A1.pdf	BINDING MEMBERS-513	MEDIMMUNE LIMITED	7-Nov-08	16-Apr-14	31-Jul-14
2572	US20100221 257	http://59.45.142.240:8808/pdf/US20100221257A1.pdf	BINDING MEMBERS-513	MEDIMMUNE LIMITED	7-Nov-08	5-Nov-09	2-Sep-10
2573	US8840890	http://59.45.142.240:8808/pdf/US8840890.pdf	Rapid expression cloning of human monoclonal antibodies from memory	University of Maryland, Baltimore	12-Nov-08	12-Nov-09	23-Sep-14
2574	US20130178 383	http://59.45.142.240:8808/pdf/US20130178383A1.pdf	VESICLE ISOLATION METHODS	KLASS MICHAEL	12-Nov-08	29-Aug-12	11-Jul-13
2575	US8828929	http://59.45.142.240:8808/pdf/US8828929.pdf	Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof	Japan as Represented by Director-General of National Institute of	28-Nov-08	27-Nov-09	9-Sep-14
2576	US20130251 746	http://59.45.142.240:8808/pdf/US20130251746A1.pdf	Methods and Compositions for Bovine A25P Protein	East Carolina University	1-Dec-08	20-Dec-12	26-Sep-13

2577	US20140179 761	http://59.45.142.240:8808/pdf/US20140179761A1.pdf	TARGETING LIPIDS	Tekmira Pharmaceuticals	4-Dec-08	22-Oct-13	26-Jun-14
2578	US9890362	http://59.45.142.240:8808/pdf/US9890362.pdf	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5-Dec-08	19-Sep-14	13-Feb-18
2579	US9650685	http://59.45.142.240:8808/pdf/US9650685.pdf	Selective detection of human rhinovirus	The United States of America, as represented by the Secretary, Department of Health and Human Services,	5-Dec-08	15-Dec-14	16-May-17
2580	US8986933	http://59.45.142.240:8808/pdf/US8986933.pdf	Selective detection of human rhinovirus	The United States of America as represented by the Secretary of the Department of Health and Human Services,	5-Dec-08	5-Dec-08	24-Mar-15
2581	US8883500	http://59.45.142.240:8808/pdf/US8883500.pdf	Method of preparing adenosine-resistant anti-tumor T lymphocytes	Northeastern University	5-Dec-08	7-Dec-09	11-Nov-14
2582	US8871487	http://59.45.142.240:8808/pdf/US8871487.pdf	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5-Dec-08	4-Dec-09	28-Oct-14
2583	US20180251 737	http://59.45.142.240:8808/pdf/US20180251737A1.pdf	COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH	Not Available	5-Dec-08	28-Dec-17	6-Sep-18
2584	US20150099 263	http://59.45.142.240:8808/pdf/US20150099263A1.pdf	SELECTIVE DETECTION OF HUMAN RHINOVIRUS	Not Available	5-Dec-08	15-Dec-14	9-Apr-15
2585	US20150010 983	http://59.45.142.240:8808/pdf/US20150010983A1.pdf	COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH	Not Available	5-Dec-08	19-Sep-14	8-Jan-15
2586	US20100144 015	http://59.45.142.240:8808/pdf/US20100144015A1.pdf	COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH	KINNEY RICHARD	5-Dec-08	4-Dec-09	10-Jun-10
2587	US20100143 881	http://59.45.142.240:8808/pdf/US20100143881A1.pdf	Selective detection of human rhinovirus	and Human Services	5-Dec-08	5-Dec-08	10-Jun-10
2588	US20160039 867	http://59.45.142.240:8808/pdf/US20160039867A1.pdf	SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS	Complix NV	8-Dec-08	21-Aug-15	11-Feb-16
2589	US8828962	http://59.45.142.240:8808/pdf/US8828962.pdf	siRNA compositions and methods for potentially inhibiting viral infection	Xiangxue Group (Hong Kong)	11-Dec-08	12-Dec-11	9-Sep-14
2590	US8664188	http://59.45.142.240:8808/pdf/US8664188.pdf	siRNA compositions and methods for potentially inhibiting viral infection	Xiangxue Group (Hong Kong)	11-Dec-08	11-Dec-09	4-Mar-14
2591	US20130225 651	http://59.45.142.240:8808/pdf/US20130225651A1.pdf	siRNA Compositions and Methods for Potentially Inhibiting Viral Infection	The University of Hong Kong	11-Dec-08	12-Dec-11	29-Aug-13
2592	US20100166 661	http://59.45.142.240:8808/pdf/US20100166661A1.pdf	siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION	LIN YONGPING	11-Dec-08	11-Dec-09	1-Jul-10
2593	US20130289 043		(4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-oxides and derivatives	AstraZeneca AB	15-Dec-08	27-Jun-13	31-Oct-13
2594	US20100152 197	http://59.45.142.240:8808/pdf/US20100152197A1.pdf	(4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-oxides and derivatives	ASTRAZENECA AB	15-Dec-08	10-Dec-09	17-Jun-10
2595	US8969350	http://59.45.142.240:8808/pdf/US8969350.pdf	Pharmaceutical product comprising a p38 kinase inhibitor and a second	Astrazeneca AB	18-Dec-08	17-Dec-09	3-Mar-15
2596	US20150141 387	http://59.45.142.240:8808/pdf/US20150141387A1.pdf	PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE	Not Available	18-Dec-08	14-Jan-15	21-May-15
2597	US9006194	http://59.45.142.240:8808/pdf/US9006194.pdf	Compositions and methods for diminishing viral infection and inflammation associated with viral	Drexel University	19-Dec-08	17-Dec-09	14-Apr-15
2598	US20100160 486	http://59.45.142.240:8808/pdf/US20100160486A1.pdf	POLYOLEFIN ANTIMICROBIAL COMPOSITIONS AND MELT-PROCESSING METHODS	BISHOP KEVIN L	19-Dec-08	19-Dec-08	24-Jun-10
2599	US8741653	http://59.45.142.240:8808/pdf/US8741653.pdf	Single recombination system and methods of use	Emergent Product Development GmbH	22-Dec-08	16-Dec-09	3-Jun-14
2600	US20100160 323	http://59.45.142.240:8808/pdf/US20100160323A1.pdf	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA ACETYLTRANSFERASE	BISCHOFF ALEXANDER	23-Dec-08	22-Dec-09	24-Jun-10
2601	US9139647	http://59.45.142.240:8808/pdf/US9139647.pdf	Diagnosis and treatment of cancer using anti-TM4SF20 antibody	FORERUNNER PHARMA RESEARCH GERMANY	25-Dec-08	25-Dec-09	22-Sep-15
2602	US9045855	http://59.45.142.240:8808/pdf/US9045855.pdf	Anti-viral member	NBC Meshtec, Inc.	26-Dec-08	28-Dec-09	2-Jun-15
2603	US9012622	http://59.45.142.240:8808/pdf/US9012622.pdf	Compositions and methods using siRNA molecules and siRNA cocktails	Not Available	31-Dec-08	31-Dec-09	21-Apr-15
2604	US20100183 634	http://59.45.142.240:8808/pdf/US20100183634A1.pdf	MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES	Cornell University, a New York	1-Jan-09	31-Dec-09	22-Jul-10
2605	US9046523	http://59.45.142.240:8808/pdf/US9046523.pdf	Rapid bioluminescence detection system	THE SECRETARY OF STATE FOR HEALTH	7-Jan-09	2-Aug-13	2-Jun-15
2606	US20140030 740	http://59.45.142.240:8808/pdf/US20140030740A1.pdf	Rapid Bioluminescence Detection System	The Secretary of State for Health	7-Jan-09	2-Aug-13	30-Jan-14
2607	US20100196 285	http://59.45.142.240:8808/pdf/US20100196285A1.pdf	Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract	BAYERL THOMAS	7-Jan-09	6-Jan-10	5-Aug-10
2608	US9233148	http://59.45.142.240:8808/pdf/US9233148.pdf	Replikin-based compounds for prevention and treatment of influenza and methods of	Not Available	9-Jan-09	16-Oct-09	12-Jan-16
2609	US20100215 675	http://59.45.142.240:8808/pdf/US20100215675A1.pdf	REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND	BOGOCH ELENORE S	9-Jan-09	16-Oct-09	26-Aug-10
2610	US9102740	http://59.45.142.240:8808/pdf/US9102740.pdf	Cna-B domain antigens in vaccines against gram positive bacteria	NOVARTIS AG	12-Jan-09	7-Jun-13	11-Aug-15
2611	US8465751	http://59.45.142.240:8808/pdf/US8465751.pdf	CnaB domain antigens in vaccines against gram positive bacteria	Novartis AG	12-Jan-09	12-Jan-10	18-Jun-13
2612	US20140017 727	http://59.45.142.240:8808/pdf/US20140017727A1.pdf	Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE BACTERIA	Not Available	12-Jan-09	7-Jun-13	16-Jan-14
2613	US9175047	http://59.45.142.240:8808/pdf/US9175047.pdf	Peptidomimetic macrocycles	Aileron Therapeutics, Inc.	14-Jan-09	14-Jan-10	3-Nov-15
2614	US20180339 014	http://59.45.142.240:8808/pdf/US20180339014A1.pdf	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	7-Jun-18	29-Nov-18
2615	US20160251 399	http://59.45.142.240:8808/pdf/US20160251399A1.pdf	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	7-Apr-16	1-Sep-16

2616	US20160250 278	http://59.45.142.240:8808/pdf/US20160250278A1.pdf	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	7-Apr-16	1-Sep-16
2617	US20160068 573	http://59.45.142.240:8808/pdf/US20160068573A1.pdf	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	14-Sep-15	10-Mar-16
2618	US10022422	http://59.45.142.240:8808/pdf/US10022422.pdf	Peptidomimetic macrocycles	Alleron Therapeutics, Inc.	14-Jan-09	7-Apr-16	17-Jul-18
2619	US20100278 861	http://59.45.142.240:8808/pdf/US20100278861A1.pdf	METHODS AND COMPOSITIONS FOR PREDICTING EMERGENCE AND EXPANSION OF DRUG RESISTANT	NIMAN HENRY L	29-Jan-09	29-Jan-10	4-Nov-10
2620	US8940501	http://59.45.142.240:8808/pdf/US8940501.pdf	Methods for ligation and uses thereof	Whitehead Institute for Biomedical Research	30-Jan-09	1-Feb-10	27-Jan-15
2621	US20100278 829	http://59.45.142.240:8808/pdf/US20100278829A1.pdf	DUAL INHIBITION OF IMMUNOPHILIN/CYCLOPHILIN FAMILY MEMBERS AND EMMPRIN IMMUNOGLOBULIN RECEPTOR	EDWARDS III CARL KEITH	6-Feb-09	6-Feb-10	4-Nov-10
2622	US9278126	http://59.45.142.240:8808/pdf/US9278126.pdf	Influenza vaccines with reduced amounts of squalene	Seqirus UK Limited	10-Feb-09	10-Feb-10	8-Mar-16
2623	US20200155 664	http://59.45.142.240:8808/pdf/US20200155664A1.pdf	INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE	Not Available	10-Feb-09	26-Jun-19	21-May-20
2624	US20190142 929	http://59.45.142.240:8808/pdf/US20190142929A1.pdf	INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED	Not Available	10-Feb-09	15-Oct-18	16-May-19
2625	US20160235 835	http://59.45.142.240:8808/pdf/US20160235835A1.pdf	INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE	Seqirus UK Limited	10-Feb-09	27-Jan-16	18-Aug-16
2626	US10149901	http://59.45.142.240:8808/pdf/US10149901.pdf	Influenza vaccines with reduced amounts of squalene	Seqirus UK Limited	10-Feb-09	27-Jan-16	11-Dec-18
2627	US8703748	http://59.45.142.240:8808/pdf/US8703748.pdf	Cleaning composition for treating tissue for transplantation derived	CG BIO Co., Ltd.	11-Feb-09	10-Feb-10	22-Apr-14
2628	US20100204 286	http://59.45.142.240:8808/pdf/US20100204286A1.pdf	METHOD FOR REDUCING GASTROINTESTINAL ADVERSE	BYRNES JOHN J	12-Feb-09	11-Feb-10	12-Aug-10
2629	US20100203 582	http://59.45.142.240:8808/pdf/US20100203582A1.pdf	Protein Expression System Involving Mutated Severe Respiratory Syndrome-Associated Coronavirus	Academia Sinica	12-Feb-09	12-Feb-09	12-Aug-10
2630	US20100216 843	http://59.45.142.240:8808/pdf/US20100216843A1.pdf	NOVEL SALT 628	ASTRAZENECA R&D	20-Feb-09	16-Feb-10	26-Aug-10
2631	US20100215 683	http://59.45.142.240:8808/pdf/US20100215683A1.pdf	PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS HYPERVIRULENT	NOVARTIS AG	20-Feb-09	16-Feb-10	26-Aug-10
2632	US8440649	http://59.45.142.240:8808/pdf/US8440649.pdf	Phenanthroindolizidine analogues	National Health Research Institutes	24-Feb-09	11-Feb-10	14-May-13
2633	US20100216 773	http://59.45.142.240:8808/pdf/US20100216773A1.pdf	PHENANTHROINDOLIZIDINE ANALOGUES	National Health Research Institutes	24-Feb-09	11-Feb-10	26-Aug-10
2634	US9637524	http://59.45.142.240:8808/pdf/US9637524.pdf	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral	The Regents of the University of California	27-Feb-09	5-Nov-14	2-May-17
2635	US8906863	http://59.45.142.240:8808/pdf/US8906863.pdf	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral	The Regents of the University of California	27-Feb-09	1-Sep-11	9-Dec-14
2636	US8906862	http://59.45.142.240:8808/pdf/US8906862.pdf	Multiple antigen delivery system using hepatitis E virus like particle	National Institute of Infectious Disease	27-Feb-09	29-Aug-11	9-Dec-14
2637	US20150118 319	http://59.45.142.240:8808/pdf/US20150118319A1.pdf	PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E VIRUS AS AN ORAL DELIVERY VEHICLE	Not Available	27-Feb-09	5-Nov-14	30-Apr-15
2638	US9453043	http://59.45.142.240:8808/pdf/US9453043.pdf	Nucleic acid chemical modifications	ALNYLAM PHARMACEUTICALS, Inc.	2-Mar-09	22-Jan-15	27-Sep-16
2639	US8975389	http://59.45.142.240:8808/pdf/US8975389.pdf	Nucleic acid chemical modifications	Alnylam Pharmaceuticals, Inc.	2-Mar-09	2-Mar-10	10-Mar-15
2640	US20160348 110	http://59.45.142.240:8808/pdf/US20160348110A1.pdf	NUCLEIC ACID CHEMICAL MODIFICATIONS	Not Available	2-Mar-09	11-Aug-16	1-Dec-16
2641	US20150210 733	http://59.45.142.240:8808/pdf/US20150210733A1.pdf	NUCLEIC ACID CHEMICAL MODIFICATIONS	Not Available	2-Mar-09	22-Jan-15	30-Jul-15
2642	US20190040 105	http://59.45.142.240:8808/pdf/US20190040105A1.pdf	Method for Preventing and Treating Hyperpermeability	Not Available	5-Mar-09	19-Oct-18	7-Feb-19
2643	US20140364 358	http://59.45.142.240:8808/pdf/US20140364358A1.pdf	Method for Preventing and Treating Hyperpermeability	Apeptico Forschung UND Entwicklung GmbH	5-Mar-09	7-Mar-14	11-Dec-14
2644	US9719083	http://59.45.142.240:8808/pdf/US9719083.pdf	Bioagent detection methods	IBIS BIOSCIENCES, INC.	8-Mar-09	8-Mar-10	1-Aug-17
2645	US9403868	http://59.45.142.240:8808/pdf/US9403868.pdf	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	5-Mar-15	2-Aug-16
2646	US9381220	http://59.45.142.240:8808/pdf/US9381220.pdf	Sceletium extract and uses thereof	H. L. Hall & Sons Limited	20-Mar-09	15-Jul-14	5-Jul-16
2647	US9051353	http://59.45.142.240:8808/pdf/US9051353.pdf	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	24-Sep-13	9-Jun-15
2648	US8980338	http://59.45.142.240:8808/pdf/US8980338.pdf	Sceletium extract and uses thereof	H.L. Hall & Sons Limited	20-Mar-09	16-Mar-10	17-Mar-15
2649	US8822512	http://59.45.142.240:8808/pdf/US8822512.pdf	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	20-Sep-11	2-Sep-14
2650	US8604215	http://59.45.142.240:8808/pdf/US8604215.pdf	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	22-Mar-10	10-Dec-13
2651	US8552051	http://59.45.142.240:8808/pdf/US8552051.pdf	Use of pharmaceutical compositions containing macromembranes	H. L. Hall & Sons Limited	20-Mar-09	16-Mar-10	8-Oct-13
2652	US20150175 656	http://59.45.142.240:8808/pdf/US20150175656A1.pdf	CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS	Not Available	20-Mar-09	5-Mar-15	25-Jun-15
2653	US20150080 447	http://59.45.142.240:8808/pdf/US20150080447A1.pdf	Sceletium Extract and Uses Thereof	H. L. Hall & Sons Limited	20-Mar-09	15-Jul-14	19-Mar-15
2654	US20140024 804	http://59.45.142.240:8808/pdf/US20140024804A1.pdf	Crystalline Tripeptide Epoxy Ketone Protease Inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	24-Sep-13	23-Jan-14
2655	US20100240 903	http://59.45.142.240:8808/pdf/US20100240903A1.pdf	CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS	Onyx Therapeutics, Inc.	20-Mar-09	22-Mar-10	23-Sep-10
2656	US20150265 721	http://59.45.142.240:8808/pdf/US20150265721A1.pdf	Compounds and Methods for Modulating an Immune Response	Not Available	23-Mar-09	23-Dec-14	24-Sep-15
2657	US9415392	http://59.45.142.240:8808/pdf/US9415392.pdf	Slip chip device and methods	The University of Chicago	24-Mar-09	23-Mar-10	16-Aug-16
2658	US20160288 121	http://59.45.142.240:8808/pdf/US20160288121A1.pdf	Slip Chip Device and Methods	Not Available	24-Mar-09	25-May-16	6-Oct-16
2659	US20160256 870	http://59.45.142.240:8808/pdf/US20160256870A1.pdf	Slip Chip Device and Methods	Not Available	24-Mar-09	25-May-16	8-Sep-16
2660	US10543485	http://59.45.142.240:8808/pdf/US10543485.pdf	Slip chip device and methods	University of Chicago	24-Mar-09	25-May-16	28-Jan-20
2661	US8741311	http://59.45.142.240:8808/pdf/US8741311.pdf	Methods and compositions for immunization against virus	Academia Sinica	27-Mar-09	26-Mar-10	3-Jun-14
2662	US20200046 826	http://59.45.142.240:8808/pdf/US20200046826A1.pdf	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27-Mar-09	4-Jun-19	13-Feb-20
2663	US20150335 728	http://59.45.142.240:8808/pdf/US20150335728A1.pdf	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27-Mar-09	18-Feb-14	26-Nov-15
2664	US20100247 571	http://59.45.142.240:8808/pdf/US20100247571A1.pdf	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	ACADEMIA SINICA	27-Mar-09	26-Mar-10	30-Sep-10
2665	US10307475	http://59.45.142.240:8808/pdf/US10307475.pdf	Methods and compositions for immunization against virus	Academia Sinica	27-Mar-09	18-Feb-14	4-Jun-19

2666	US9393564	http://59.45.142.240:8808/pdf/US9393564.pdf	Bioagent detection systems, devices, and methods	IBIS BIOSCIENCES, INC	30-Mar-09	30-Mar-10	19-Jul-16
2667	US20160325 283	http://59.45.142.240:8808/pdf/US20160325283A1.pdf	BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODS	Not Available	30-Mar-09	18-Jul-16	10-Nov-16
2668	US9339525	http://59.45.142.240:8808/pdf/US9339525.pdf	Inhibition of biofilm organisms	Novabiotics Limited	31-Mar-09	31-Mar-10	17-May-16
2669	US20190175 528	http://59.45.142.240:8808/pdf/US20190175528A1.pdf	INHIBITION OF BIOFILM ORGANISMS	Not Available	31-Mar-09	13-Feb-19	13-Jun-19
2670	US20160206 575	http://59.45.142.240:8808/pdf/US20160206575A1.pdf	Inhibition of Biofilm Organisms	NOVABIOTICS LIMITED	31-Mar-09	28-Mar-16	21-Jul-16
2671	US20130237 507	http://59.45.142.240:8808/pdf/US20130237507A1.pdf	Novel Amide Compounds	BURKAMP FRANK	3-Apr-09	17-Apr-13	12-Sep-13
2672	US20100261 690	http://59.45.142.240:8808/pdf/US20100261690A1.pdf	NOVEL COMBINATIONS	ASTRAZENECA R&D	3-Apr-09	30-Mar-10	14-Oct-10
2673	US20100256 105	http://59.45.142.240:8808/pdf/US20100256105A1.pdf	NOVEL COMPOUNDS	AstraZeneca R&D	3-Apr-09	30-Mar-10	7-Oct-10
2674	US20100256 104	http://59.45.142.240:8808/pdf/US20100256104A1.pdf	NOVEL AMIDE COMPOUNDS	ASTRAZENECA R&D	3-Apr-09	30-Mar-10	7-Oct-10
2675	US20100256 103		NOVEL COMPOUNDS	ASTRAZENECA R&D	3-Apr-09	30-Mar-10	7-Oct-10
2676	US9168299	http://59.45.142.240:8808/pdf/US9168299.pdf	Methods for treating juvenile arthritis with anti-bile salt-stimulated	LIPUM AB	8-Apr-09	30-Oct-13	27-Oct-15
2677	US8597650	http://59.45.142.240:8808/pdf/US8597650.pdf	Methods for treating rheumatoid arthritis with anti-bile salt-	HERNELL OLLE	8-Apr-09	6-Apr-10	3-Dec-13
2678	US20160096 899	http://59.45.142.240:8808/pdf/US20160096899A1.pdf	METHODS FOR TREATING JUVENILE ARTHRITIS WITH ANTI-BILE SALT-STIMULATED LIPASE (BSSL)	Not Available	8-Apr-09	28-Sep-15	7-Apr-16
2679	US20140099 323	http://59.45.142.240:8808/pdf/US20140099323A1.pdf	METHODS FOR TREATMENT OF INFLAMMATORY DISEASES	Not Available	8-Apr-09	30-Oct-13	10-Apr-14
2680	US8609101	http://59.45.142.240:8808/pdf/US8609101.pdf	Granulocyte-macrophage colony-stimulating factor (GM-CSF)	Theraclone Sciences, Inc.	23-Apr-09	23-Apr-10	17-Dec-13
2681	US8551750	http://59.45.142.240:8808/pdf/US8551750.pdf	Device including bone cage and method for treatment of disease in a	The Invention Science Fund I, LLC	23-Apr-09	28-Jul-09	8-Oct-13
2682	US8551749	http://59.45.142.240:8808/pdf/US8551749.pdf	Device including bone cage and method for treatment of disease in a	The Invention Science Fund I, LLC	23-Apr-09	23-Apr-09	8-Oct-13
2683	US20160122 397	http://59.45.142.240:8808/pdf/US20160122397A1.pdf	REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND	Not Available	23-Apr-09	2-Dec-15	5-May-16
2684	US20100291 075	http://59.45.142.240:8808/pdf/US20100291075A1.pdf	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)	Theraclone Sciences, Inc.	23-Apr-09	23-Apr-10	18-Nov-10
2685	US20100272 776	http://59.45.142.240:8808/pdf/US20100272776A1.pdf	Device including bone cage and method for treatment of disease in a subject	Searete LLC, a limited liability corporation of the	23-Apr-09	28-Jul-09	28-Oct-10
2686	US20100272 771	http://59.45.142.240:8808/pdf/US20100272771A1.pdf	Device including bone cage and method for treatment of disease in a	HARLOW ED	23-Apr-09	23-Apr-09	28-Oct-10
2687	USH2284	http://59.45.142.240:8808/pdf/USH2284.pdf	Vaccines for protecting against influenza	Novartis AG	27-Apr-09	27-Apr-10	3-Sep-13
2688	USH2283	http://59.45.142.240:8808/pdf/USH2283.pdf	Vaccines for protecting against influenza	Novartis AG	27-Apr-09	27-Apr-10	3-Sep-13
2689	US20150174 257	http://59.45.142.240:8808/pdf/US20150174257A1.pdf	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE TRANSFER TO MONOCYTES AND	Not Available	29-Apr-09	3-Mar-15	25-Jun-15
2690	US20100280 067	http://59.45.142.240:8808/pdf/US20100280067A1.pdf	INHIBITORS OF ACETYL-COA CARBOXYLASE	ACHARYA VINOD PARAMESHWARAN	30-Apr-09	30-Apr-10	4-Nov-10
2691	US9797000	http://59.45.142.240:8808/pdf/US9797000.pdf	Non-target amplification method for detection of RNA splice-forms in a	QIAGEN GAITHERSBURG	1-May-09	30-Apr-10	24-Oct-17
2692	US20100311 039	http://59.45.142.240:8808/pdf/US20100311039A1.pdf	NON-TARGET AMPLIFICATION METHOD FOR DETECTION OF RNA SPLICED FORMS IN A SAMPLE	QIAGEN GAITHERSBURG	1-May-09	30-Apr-10	9-Dec-10
2693	US9810683	http://59.45.142.240:8808/pdf/US9810683.pdf	Use of live cell interferometry with reflective floor of observation chamber to determine changes in	The Regents of the University of California	6-May-09	25-Nov-13	7-Nov-17
2694	US8599383		Optical cytometry	The Regents of the University of	6-May-09	6-May-09	3-Dec-13
2695	US20140080 171	http://59.45.142.240:8808/pdf/US20140080171A1.pdf	OPTICAL CYTOMETRY	The Regents of the University of	6-May-09	25-Nov-13	20-Mar-14
2696	US20100284 016	http://59.45.142.240:8808/pdf/US20100284016A1.pdf	OPTICAL CYTOMETRY	THE REGENTS OF THE UNIVERSITY OF	6-May-09	6-May-09	11-Nov-10
2697	US9309325	http://59.45.142.240:8808/pdf/US9309325.pdf	Antibodies and methods of use thereof	The Regents of the University of	7-May-09	4-May-10	12-Apr-16
2698	US20100286 118	http://59.45.142.240:8808/pdf/US20100286118A1.pdf	SUBSTITUTED 1-CYANOETHYLHETEROCYCLIC CARBOX	FORD RHONAN	7-May-09	6-May-10	11-Nov-10
2699	US9102911	http://59.45.142.240:8808/pdf/US9102911.pdf	High density self-contained biological analysis	BioFire Diagnostics, LLC	15-May-09	28-Jan-13	11-Aug-15
2700	US20130137 172	http://59.45.142.240:8808/pdf/US20130137172A1.pdf	HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS	BioFire Diagnostics, Inc. f/k/a Idaho	15-May-09	28-Jan-13	30-May-13
2701	US9533978	http://59.45.142.240:8808/pdf/US9533978.pdf	Pyrimidine derivatives and their use in the treatment of cancer and	Sumitomo Dainippon Pharma	21-May-09	26-Aug-14	3-Jan-17
2702	US9504673	http://59.45.142.240:8808/pdf/US9504673.pdf	Agent for the prophylaxis and treatment of highly pathogenic	LTD ÆCeValenta-Intellecta	21-May-09	10-May-10	29-Nov-16
2703	US9072702	http://59.45.142.240:8808/pdf/US9072702.pdf	Reverse genetics using non-	Novartis AG	21-May-09	21-May-10	7-Jul-15
2704	US8476288	http://59.45.142.240:8808/pdf/US8476288.pdf	Salts 756	AstraZeneca AB	21-May-09	20-May-10	2-Jul-13
2705	US20190284 575	http://59.45.142.240:8808/pdf/US20190284575A1.pdf	REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS	Not Available	21-May-09	30-Jan-19	19-Sep-19
2706	US20160024 525	http://59.45.142.240:8808/pdf/US20160024525A1.pdf	REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS	NOVARTIS AG	21-May-09	7-May-15	28-Jan-16
2707	US20150080 396	http://59.45.142.240:8808/pdf/US20150080396A1.pdf	Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer	ASTRAZENECA AB	21-May-09	26-Aug-14	19-Mar-15
2708	US20140162 285	http://59.45.142.240:8808/pdf/US20140162285A1.pdf	Methods of Modulating Vesicular Trafficking	The General Hospital Corporation	21-May-09	2-Dec-13	12-Jun-14
2709	US20100298 364	http://59.45.142.240:8808/pdf/US20100298364A1.pdf	SALTS 756	AstraZeneca AB	21-May-09	20-May-10	25-Nov-10

2710	US20100297 651	http://59.45.142.240:8808/pdf/US20100297651A1.pdf	Methods of Modulating Vesicular Trafficking	THE GENERAL HOSPITAL CORPORATION	21-May-09	21-May-10	25-Nov-10
2711	US20100304 363	http://59.45.142.240:8808/pdf/US20100304363A1.pdf	PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION	ELECTRONICS AND TELECOMMUNICATIONS RESEARCH	27-May-09	26-May-10	2-Dec-10
2712	US9963611	http://59.45.142.240:8808/pdf/US9963611.pdf	Composition for use in decreasing the transmission of human	Innonix Technologies,	29-May-09	21-May-10	8-May-18
2713	US8815831	http://59.45.142.240:8808/pdf/US8815831.pdf	Treatment of Acinetobacter with alginate oligomers and antibiotics	Algipharma AS	3-Jun-09	3-Jun-10	26-Aug-14
2714	US9248178	http://59.45.142.240:8808/pdf/US9248178.pdf	Different serotypes of vesicular stomatitis virus as expression	Not Available	8-Jun-09	8-Jun-10	2-Feb-16
2715	US20130315 952	http://59.45.142.240:8808/pdf/US20130315952A1.pdf	ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC	Defyry, Inc.	9-Jun-09	13-Nov-12	28-Nov-13
2716	US20110000 480	http://59.45.142.240:8808/pdf/US20110000480A1.pdf	ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC	ENNIS JANE E	9-Jun-09	9-Jun-10	6-Jan-11
2717	US9517263	http://59.45.142.240:8808/pdf/US9517263.pdf	Benzonaphthylidine-containing vaccines	GlaxoSmithKline Biologicals SA	10-Jun-09	10-Jun-10	13-Dec-16
2718	US20110038 852	http://59.45.142.240:8808/pdf/US20110038852A1.pdf	ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND CHANNELS	3-V BIOSCIENCES, INC.	10-Jun-09	9-Jun-10	17-Feb-11
2719	US10342825	http://59.45.142.240:8808/pdf/US10342825.pdf	Solution containing hypochlorous acid and methods of using same	Sonoma Pharmaceuticals,	15-Jun-09	15-Jun-10	9-Jul-19
2720	US8444961	http://59.45.142.240:8808/pdf/US8444961.pdf	RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus	Sekisui Chemical Co., Ltd.	16-Jun-09	16-Jun-10	21-May-13
2721	US9822165	http://59.45.142.240:8808/pdf/US9822165.pdf	Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41	DANA-FARBER CANCER INSTITUTE, THE	18-Jun-09	18-Jun-10	21-Nov-17
2722	US20180037 636	http://59.45.142.240:8808/pdf/US20180037636A1.pdf	STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE	DANA-FARBER CANCER INSTITUTE, THE	18-Jun-09	21-Sep-17	8-Feb-18
2723	US10273290	http://59.45.142.240:8808/pdf/US10273290.pdf	Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat	DANA-FARBER CANCER INSTITUTE, THE	18-Jun-09	21-Sep-17	30-Apr-19
2724	US10040820	http://59.45.142.240:8808/pdf/US10040820.pdf	Method for the purification of protein complexes	Immunobiology Limited	19-Jun-09	21-Jun-10	7-Aug-18
2725	US8415309	http://59.45.142.240:8808/pdf/US8415309.pdf	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Management Pty Ltd	1-Jul-09	11-Jan-12	9-Apr-13
2726	US9744183	http://59.45.142.240:8808/pdf/US9744183.pdf	Nucleic acid prodrugs and methods of use thereof	WAVE LIFE SCIENCES LTD	6-Jul-09	6-Jul-10	29-Aug-17
2727	US20160347 784	http://59.45.142.240:8808/pdf/US20160347784A1.pdf	NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF	Not Available	6-Jul-09	27-May-16	1-Dec-16
2728	US10307434	http://59.45.142.240:8808/pdf/US10307434.pdf	Nucleic acid prodrugs and methods of use thereof	WAVE LIFE SCIENCES LTD	6-Jul-09	27-May-16	4-Jun-19
2729	US8828407	http://59.45.142.240:8808/pdf/US8828407.pdf	Chimaeric protein	The Pirbright Institute	7-Jul-09	5-Jul-10	9-Sep-14
2730	US20200172 600	http://59.45.142.240:8808/pdf/US20200172600A1.pdf	RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME	GLAXOSMITHKLINE BIOLOGICALS SA	15-Jul-09	16-Aug-17	4-Jun-20
2731	US20130323 835	http://59.45.142.240:8808/pdf/US20130323835A1.pdf	Mammalian Genes Involved in Infection	Zirus, Inc.	15-Jul-09	15-Jul-10	5-Dec-13
2732	US9310088	http://59.45.142.240:8808/pdf/US9310088.pdf	Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health	Technical University of Denmark	17-Jul-09	14-Jul-10	12-Apr-16
2733	US9125952	http://59.45.142.240:8808/pdf/US9125952.pdf	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym	17-Jul-09	13-Aug-14	8-Sep-15
2734	US8889181	http://59.45.142.240:8808/pdf/US8889181.pdf	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym	17-Jul-09	16-Jun-10	18-Nov-14
2735	US20140348 906	http://59.45.142.240:8808/pdf/US20140348906A1.pdf	IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOsome- ENCAPSULATED	Not Available	17-Jul-09	13-Aug-14	27-Nov-14
2736	US9187748	http://59.45.142.240:8808/pdf/US9187748.pdf	Compositions and methods for silencing ebola virus gene expression	Not Available	20-Jul-09	28-Mar-14	17-Nov-15
2737	US8716464	http://59.45.142.240:8808/pdf/US8716464.pdf	Compositions and methods for silencing Ebola virus gene	Not Available	20-Jul-09	20-Jul-10	6-May-14
2738	US20160264 971	http://59.45.142.240:8808/pdf/US20160264971A1.pdf	COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE	Not Available	20-Jul-09	9-Oct-15	15-Sep-16
2739	US20150111 945	http://59.45.142.240:8808/pdf/US20150111945A1.pdf	COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE	Not Available	20-Jul-09	28-Mar-14	23-Apr-15
2740	US9217157	http://59.45.142.240:8808/pdf/US9217157.pdf	Recombinant influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	27-Jul-09	27-Jul-10	22-Dec-15
2741	US9149445	http://59.45.142.240:8808/pdf/US9149445.pdf	Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of	THE TRUSTEES OF PRINCETON UNIVERSITY	27-Jul-09	27-Jul-10	6-Oct-15
2742	US8828406	http://59.45.142.240:8808/pdf/US8828406.pdf	Influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	30-Jul-09	29-Jul-10	9-Sep-14
2743	US9821052	http://59.45.142.240:8808/pdf/US9821052.pdf	Reverse genetics systems	Seqirus UK Limited	31-Jul-09	30-Jul-10	21-Nov-17
2744	US9416409	http://59.45.142.240:8808/pdf/US9416409.pdf	Capture primers and capture sequence linked solid supports for	IBIS BIOSCIENCES, INC.	31-Jul-09	30-Jul-10	16-Aug-16
2745	US8455483	http://59.45.142.240:8808/pdf/US8455483.pdf	Compoundsâ€801	AstraZeneca AB	31-Jul-09	30-Jul-10	4-Jun-13
2746	US20190119 744	http://59.45.142.240:8808/pdf/US20190119744A1.pdf	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR	Not Available	31-Jul-09	5-Nov-18	25-Apr-19
2747	US20180236 058	http://59.45.142.240:8808/pdf/US20180236058A1.pdf	REVERSE GENETICS SYSTEMS	Not Available	31-Jul-09	16-Oct-17	23-Aug-18
2748	US20170044 603	http://59.45.142.240:8808/pdf/US20170044603A1.pdf	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR	Not Available	31-Jul-09	15-Aug-16	16-Feb-17

2749	US20110053 909	http://59.45.142.240:8808/pdf/US20110053909A1.pdf	Compounds - 801	ALCARAZ LILIAN	31-Jul-09	30-Jul-10	3-Mar-11
2750	US20110028 334	http://59.45.142.240:8808/pdf/US20110028334A1.pdf	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR	IBIS BIOSCIENCES, INC.	31-Jul-09	30-Jul-10	3-Feb-11
2751	US10610584	http://59.45.142.240:8808/pdf/US10610584.pdf	Reverse genetics systems	Seqirus UK Limited	31-Jul-09	16-Oct-17	7-Apr-20
2752	US10119164	http://59.45.142.240:8808/pdf/US10119164.pdf	Capture primers and capture sequence linked solid supports for	IBIS BIOSCIENCES, INC.	31-Jul-09	15-Aug-16	6-Nov-18
2753	US9080209	http://59.45.142.240:8808/pdf/US9080209.pdf	Non-mass determined base compositions for nucleic acid	IBIS BIOSCIENCES, INC.	6-Aug-09	6-Aug-10	14-Jul-15
2754	US20150307 935	http://59.45.142.240:8808/pdf/US20150307935A1.pdf	NON-MASS DETERMINED BASE COMPOSITIONS FOR NUCLEIC ACID	Not Available	6-Aug-09	13-Jul-15	29-Oct-15
2755	US9320784	http://59.45.142.240:8808/pdf/US9320784.pdf	Peptides shared among lethal cancers and therapeutic	Not Available	7-Aug-09	19-Jul-12	26-Apr-16
2756	US20160193 315	http://59.45.142.240:8808/pdf/US20160193315A1.pdf	PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID	Not Available	7-Aug-09	17-Mar-16	7-Jul-16
2757	US20130084 303	http://59.45.142.240:8808/pdf/US20130084303A1.pdf	PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID	BOGOCH ELENORE S	7-Aug-09	19-Jul-12	4-Apr-13
2758	US8858958	http://59.45.142.240:8808/pdf/US8858958.pdf	Adjuvant comprising aluminum, oligonucleotide and polyclonal	Novartis AG	27-Aug-09	27-Aug-10	14-Oct-14
2759	US20110052 716	http://59.45.142.240:8808/pdf/US20110052716A1.pdf	Adjuvant Comprising Aluminum, Oligonucleotide and Polyclonal	O'HAGAN DEREK	27-Aug-09	27-Aug-10	3-Mar-11
2760	US20110065 111	http://59.45.142.240:8808/pdf/US20110065111A1.pdf	Compositions For Use In Genotyping Of <i>Klebsiella pneumoniae</i>	Ibis Biosciences, Inc.	31-Aug-09	27-Aug-10	17-Mar-11
2761	US9950062	http://59.45.142.240:8808/pdf/US9950062.pdf	Compounds and compositions as TLR activity modulators	GLAXOSMITHKLINE BIOLOGICALS SA	2-Sep-09	1-Sep-10	24-Apr-18
2762	US9045470	http://59.45.142.240:8808/pdf/US9045470.pdf	Compounds and compositions as TLR activity modulators	IRM LLC	2-Sep-09	1-Sep-10	2-Jun-15
2763	US20150225 432	http://59.45.142.240:8808/pdf/US20150225432A1.pdf	COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS	Novartis AG	2-Sep-09	24-Apr-15	13-Aug-15
2764	US20110053 893	http://59.45.142.240:8808/pdf/US20110053893A1.pdf	COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS	IRM LLC	2-Sep-09	1-Sep-10	3-Mar-11
2765	US9278128	http://59.45.142.240:8808/pdf/US9278128.pdf	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for	The Trustees of the University of Pennsylvania	14-Sep-09	6-Jan-14	8-Mar-16
2766	US8624011	http://59.45.142.240:8808/pdf/US8624011.pdf	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for	The Trustees of the University of Pennsylvania	14-Sep-09	14-Sep-10	7-Jan-14
2767	US20140193 439	http://59.45.142.240:8808/pdf/US20140193439A1.pdf	VACCINES AND IMMUNOTHERAPEUTICS COMPRISING IL-15 RECEPTOR ALPHA AND/OR NUCLEIC ACID MOLECULES ENCODING THE SAME, AND METHODS FOR USING THE	Not Available	14-Sep-09	6-Jan-14	10-Jul-14
2768	US9402812	http://59.45.142.240:8808/pdf/US9402812.pdf	Methods for the preparation of <i>lincomycin</i>	Indu Javeri	23-Sep-09	23-Sep-10	2-Aug-16
2769	US20160361 259	http://59.45.142.240:8808/pdf/US20160361259A1.pdf	Methods for the Preparation of <i>lincomycin</i>	Not Available	23-Sep-09	2-Aug-16	15-Dec-16
2770	US10143652	http://59.45.142.240:8808/pdf/US10143652.pdf	Methods for the preparation of <i>lincomycin</i>	CuriRx Inc.	23-Sep-09	2-Aug-16	4-Dec-18
2771	US9611481	http://59.45.142.240:8808/pdf/US9611481.pdf	Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and	UNIVERSITE DE MONTPELLIER	24-Sep-09	23-Sep-10	4-Apr-17
2772	US9238809	http://59.45.142.240:8808/pdf/US9238809.pdf	Compositions, methods, and kits for isolating and analyzing nucleic acids	QIAGEN GAITHERSBURG, MD	24-Sep-09	5-Aug-10	19-Jan-16
2773	US8993581	http://59.45.142.240:8808/pdf/US8993581.pdf	Methods for treating viral disorders	Trustees of Boston University	24-Sep-09	11-Jun-13	31-Mar-15
2774	US20200016 161	http://59.45.142.240:8808/pdf/US20200016161A1.pdf	METHODS FOR TREATING VIRAL DISORDERS	TRUSTEES OF BOSTON UNIVERSITY	24-Sep-09	22-Jul-19	16-Jan-20
2775	US20170027 944	http://59.45.142.240:8808/pdf/US20170027944A9.pdf	METHODS FOR TREATING VIRAL DISORDERS	Not Available	24-Sep-09	18-Feb-15	2-Feb-17
2776	US20150328 282	http://59.45.142.240:8808/pdf/US20150328282A1.pdf	METHODS FOR TREATING VIRAL DISORDERS	Not Available	24-Sep-09	5-Aug-15	19-Nov-15
2777	US20150157 636	http://59.45.142.240:8808/pdf/US20150157636A1.pdf	METHODS FOR TREATING VIRAL DISORDERS	Not Available	24-Sep-09	18-Feb-15	11-Jun-15
2778	US20140045 774	http://59.45.142.240:8808/pdf/US20140045774A1.pdf	METHODS FOR TREATING VIRAL DISORDERS	TRUSTEES OF BOSTON UNIVERSITY	24-Sep-09	11-Jun-13	13-Feb-14
2779	US20190241 618	http://59.45.142.240:8808/pdf/US20190241618A1.pdf	INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS	Not Available	30-Sep-09	22-Oct-18	8-Aug-19
2780	US10538558		Inhibition of TCR signaling with peptide variants	SIGNABLOK, INC	30-Sep-09	22-Oct-18	21-Jan-20
2781	US10138276	http://59.45.142.240:8808/pdf/US10138276.pdf	Inhibition of TCR signaling with peptide variants	SIGNABLOK, Inc.	30-Sep-09	30-Sep-10	27-Nov-18
2782	US9155309	http://59.45.142.240:8808/pdf/US9155309.pdf	Virus inactivating sheet	NBC MESHTEC, INC.	2-Oct-09	4-Oct-10	13-Oct-15
2783	US8436024	http://59.45.142.240:8808/pdf/US8436024.pdf	2-pyridone compounds	Astrazeneca AB	2-Oct-09	1-Oct-10	7-May-13
2784	US20150196 578	http://59.45.142.240:8808/pdf/US20150196578A1.pdf	COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS	Not Available	14-Oct-09	10-Dec-14	16-Jul-15
2785	US9890408	http://59.45.142.240:8808/pdf/US9890408.pdf	Multiple displacement amplification	IBIS BIOSCIENCES, INC.	15-Oct-09	15-Oct-10	13-Feb-18
2786	US9884129	http://59.45.142.240:8808/pdf/US9884129.pdf	Release of agents from cells	The Brigham and Women's Hospital,	15-Oct-09	5-Jan-15	6-Feb-18
2787	US8956863	http://59.45.142.240:8808/pdf/US8956863.pdf	Agents from cells	The Brigham and Women's Hospital,	15-Oct-09	15-Oct-10	17-Feb-15
2788	US20150125 540	http://59.45.142.240:8808/pdf/US20150125540A1.pdf	RELEASE OF AGENTS FROM CELLS	Not Available	15-Oct-09	5-Jan-15	7-May-15
2789	US8883481	http://59.45.142.240:8808/pdf/US8883481.pdf	Reverse genetics methods for virus rescue	Novartis AG	20-Oct-09	20-Oct-10	11-Nov-14
2790	US20150166 966	http://59.45.142.240:8808/pdf/US20150166966A1.pdf	REVERSE GENETICS METHODS FOR VIRUS RESCUE	Not Available	20-Oct-09	1-Oct-14	18-Jun-15
2791	US9518083	http://59.45.142.240:8808/pdf/US9518083.pdf	Gadd45beta targeting agents	Imperial Innovations Limited	22-Oct-09	10-Feb-15	13-Dec-16
2792	US8993717	http://59.45.142.240:8808/pdf/US8993717.pdf	Gadd45beta targeting agents	Imperial Innovations Limited	22-Oct-09	22-Oct-10	31-Mar-15

2793	US20150368 294	http://59.45.142.240:8808/pdf/US20150368294A1.pdf	GADD45BETA TARGETING AGENTS	Not Available	22-Oct-09	10-Feb-15	24-Dec-15
2794	US8633322	http://59.45.142.240:8808/pdf/US8633322.pdf	Alkynyl derivatives useful as DPP-1 inhibitors	Janssen Pharmaceuticals NV	29-Oct-09	28-Oct-10	21-Jan-14
2795	US9487749		Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30-Oct-09	12-Aug-14	8-Nov-16
2796	US9434769	http://59.45.142.240:8808/pdf/US9434769.pdf	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane	30-Oct-09	9-Jul-14	6-Sep-16
2797	US8841100	http://59.45.142.240:8808/pdf/US8841100.pdf	Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30-Oct-09	16-Feb-11	23-Sep-14
2798	US8802106	http://59.45.142.240:8808/pdf/US8802106.pdf	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane	30-Oct-09	29-Oct-10	12-Aug-14
2799	US20150119 318	http://59.45.142.240:8808/pdf/US20150119318A1.pdf	PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION	THE ADMINISTRATORS OF THE TULANE	30-Oct-09	9-Jul-14	30-Apr-15
2800	US20140349 375	http://59.45.142.240:8808/pdf/US20140349375A1.pdf	METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY	Biogenic Innovations, LLC	30-Oct-09	12-Aug-14	27-Nov-14
2801	US20130338 130	http://59.45.142.240:8808/pdf/US20130338130A1.pdf	METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT HERPESVIRUSES	Biogenic Innovations, LLC	30-Oct-09	19-Aug-13	19-Dec-13
2802	US9586998	http://59.45.142.240:8808/pdf/US9586998.pdf	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9-Nov-09	4-Aug-15	7-Mar-17
2803	US9133248	http://59.45.142.240:8808/pdf/US9133248.pdf	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9-Nov-09	9-Nov-10	15-Sep-15
2804	US20150329 834	http://59.45.142.240:8808/pdf/US20150329834A1.pdf	METHODS OF PROPAGATING MONKEY ADENOVIRAL VECTORS	GenVec, Inc.	9-Nov-09	4-Aug-15	19-Nov-15
2805	US20140227 704	http://59.45.142.240:8808/pdf/US20140227704A1.pdf	METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF NUCLEIC ACID	IBIS BIOSCIENCES, INC.	11-Nov-09	7-Oct-13	14-Aug-14
2806	US20140220 690		MAMMALIAN GENES INVOLVED IN INFECTION	VANDERBILT UNIVERSITY	11-Nov-09	28-Oct-10	7-Aug-14
2807	US20130178 466	http://59.45.142.240:8808/pdf/US20130178466A1.pdf	Treatment of Microbial Infections	BIOCOPEA LIMITED	11-Nov-09	9-Nov-10	11-Jul-13
2808	US9234175	http://59.45.142.240:8808/pdf/US9234175.pdf	Creating bioengineered lymph nodes	H. Lee Moffitt Cancer Center and Research Institute,	17-Nov-09	16-Nov-10	12-Jan-16
2809	US9816078	http://59.45.142.240:8808/pdf/US9816078.pdf	Compositions for increasing polypeptide stability and activity, and	SOLIS BIODYNE OÄœ	19-Nov-09	11-Mar-16	14-Nov-17
2810	US9321999	http://59.45.142.240:8808/pdf/US9321999.pdf	Compositions for increasing polypeptide stability and activity, and	SOLIS BIODYNE OÄœ	19-Nov-09	19-Nov-10	26-Apr-16
2811	US20200172 883	http://59.45.142.240:8808/pdf/US20200172883A1.pdf	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY AND RELATED METHODS	Not Available	19-Nov-09	13-Sep-19	4-Jun-20
2812	US20180245 056	http://59.45.142.240:8808/pdf/US20180245056A1.pdf	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY AND RELATED METHODS	Not Available	19-Nov-09	9-Oct-17	30-Aug-18
2813	US20160251 637	http://59.45.142.240:8808/pdf/US20160251637A1.pdf	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY AND RELATED METHODS	Not Available	19-Nov-09	11-Mar-16	1-Sep-16
2814	US9750690	http://59.45.142.240:8808/pdf/US9750690.pdf	Circulation of components during microfluidization and/or	NOVARTIS AG	3-Dec-09	5-Sep-14	5-Sep-17
2815	US9700616	http://59.45.142.240:8808/pdf/US9700616.pdf	Arranging interaction and back pressure chambers for	NOVARTIS AG	3-Dec-09	22-Mar-16	11-Jul-17
2816	US9463240	http://59.45.142.240:8808/pdf/US9463240.pdf	Arranging interaction and back pressure chambers for	NOVARTIS AG	3-Dec-09	11-Jul-14	11-Oct-16
2817	US8895629	http://59.45.142.240:8808/pdf/US8895629.pdf	Circulation of components during homogenization of emulsions	Novartis AG	3-Dec-09	3-Dec-10	25-Nov-14
2818	US8871816	http://59.45.142.240:8808/pdf/US8871816.pdf	Methods for producing vaccine adjuvants	Novartis AG	3-Dec-09	3-Dec-10	28-Oct-14
2819	US8778275	http://59.45.142.240:8808/pdf/US8778275.pdf	Methods for producing vaccine adjuvants	Novartis AG	3-Dec-09	3-Dec-10	15-Jul-14
2820	US8678184	http://59.45.142.240:8808/pdf/US8678184.pdf	Methods for producing vaccine adjuvants	Novartis AG	3-Dec-09	3-Dec-10	25-Mar-14
2821	US20190201 337	http://59.45.142.240:8808/pdf/US20190201337A1.pdf	HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS	Not Available	3-Dec-09	3-Jan-19	4-Jul-19
2822	US20180055 769	http://59.45.142.240:8808/pdf/US20180055769A1.pdf	CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF	Not Available	3-Dec-09	26-Jun-17	1-Mar-18
2823	US20160199 486	http://59.45.142.240:8808/pdf/US20160199486A1.pdf	ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION	Not Available	3-Dec-09	22-Mar-16	14-Jul-16
2824	US20160128 937	http://59.45.142.240:8808/pdf/US20160128937A1.pdf	CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF	Novartis AG	3-Dec-09	5-Sep-14	12-May-16
2825	US20160113 870	http://59.45.142.240:8808/pdf/US20160113870A1.pdf	CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF	Novartis AG	3-Dec-09	5-Sep-14	28-Apr-16
2826	US20150258 191	http://59.45.142.240:8808/pdf/US20150258191A1.pdf	ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION	Novartis AG	3-Dec-09	13-Mar-15	17-Sep-15
2827	US20130189 311	http://59.45.142.240:8808/pdf/US20130189311A1.pdf	ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION	Novartis AG	3-Dec-09	3-Dec-10	25-Jul-13
2828	US20130142 833	http://59.45.142.240:8808/pdf/US20130142833A1.pdf	CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF EMULSIONS	Novartis AG	3-Dec-09	3-Dec-10	6-Jun-13
2829	US20130129 786	http://59.45.142.240:8808/pdf/US20130129786A1.pdf	HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS	Novartis AG	3-Dec-09	3-Dec-10	23-May-13
2830	US10463615	http://59.45.142.240:8808/pdf/US10463615.pdf	Circulation of components during microfluidization and/or	NOVARTIS AG	3-Dec-09	26-Jun-17	5-Nov-19
2831	US10213383	http://59.45.142.240:8808/pdf/US10213383.pdf	Hydrophilic filtration during manufacture of vaccine adjuvants	NOVARTIS AG	3-Dec-09	3-Dec-10	26-Feb-19
2832	USRE46906	http://59.45.142.240:8808/pdf/USRE46906.pdf	Methods for producing vaccine adjuvants	NOVARTIS AG	3-Dec-09	13-Oct-15	26-Jun-18
2833	USRE46441	http://59.45.142.240:8808/pdf/USRE46441.pdf	Circulation of components during homogenization of emulsions	NOVARTIS AG	3-Dec-09	13-Oct-15	20-Jun-17
2834	US20180371 410	http://59.45.142.240:8808/pdf/US20180371410A1.pdf	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF	Not Available	4-Dec-09	28-Aug-18	27-Dec-18

2835	US20150203 816	http://59.45.142.240:8808/pdf/US20150203816A1.pdf	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF	Not Available	4-Dec-09	26-Mar-15	23-Jul-15
2836	US9758775	http://59.45.142.240:8808/pdf/US9758775.pdf	TAL effector-mediated DNA modification	Iowa State University Research	10-Dec-09	14-Apr-14	12-Sep-17
2837	US8697853	http://59.45.142.240:8808/pdf/US8697853.pdf	TAL effector-mediated DNA modification	Iowa State University Research	10-Dec-09	10-Jan-13	15-Apr-14
2838	US8586363	http://59.45.142.240:8808/pdf/US8586363.pdf	TAL effector-mediated DNA modification	Iowa State University Research	10-Dec-09	10-Dec-10	19-Nov-13
2839	US8450471	http://59.45.142.240:8808/pdf/US8450471.pdf	TAL effector-mediated DNA modification	Iowa State University Research	10-Dec-09	22-Mar-12	28-May-13
2840	US8440432	http://59.45.142.240:8808/pdf/US8440432.pdf	Tal effector-mediated DNA modification	Iowa State University Research	10-Dec-09	22-Mar-12	14-May-13
2841	US8440431	http://59.45.142.240:8808/pdf/US8440431.pdf	TAL effector-mediated DNA modification	Iowa State University Research	10-Dec-09	22-Mar-12	14-May-13
2842	US20200102 550	http://59.45.142.240:8808/pdf/US20200102550A1.pdf	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10-Dec-09	28-Aug-19	2-Apr-20
2843	US20180051 267	http://59.45.142.240:8808/pdf/US20180051267A1.pdf	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10-Dec-09	5-Oct-17	22-Feb-18
2844	US20180051 266	http://59.45.142.240:8808/pdf/US20180051266A1.pdf	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10-Dec-09	21-Aug-17	22-Feb-18
2845	US20140335 618	http://59.45.142.240:8808/pdf/US20140335618A1.pdf	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Iowa State University Research	10-Dec-09	14-Apr-14	13-Nov-14
2846	US20140335 592	http://59.45.142.240:8808/pdf/US20140335592A1.pdf	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Iowa State University Research	10-Dec-09	24-Feb-14	13-Nov-14
2847	US20130122 581	http://59.45.142.240:8808/pdf/US20130122581A1.pdf	TAL EFFECTOR-MEDIATED DNA MODIFICATION	IOWA STATE UNIVERSITY RESEARCH	10-Dec-09	10-Jan-13	16-May-13
2848	US10619153	http://59.45.142.240:8808/pdf/US10619153.pdf	TAL effector-mediated DNA modification	Iowa State University Research	10-Dec-09	5-Oct-17	14-Apr-20
2849	US10400225	http://59.45.142.240:8808/pdf/US10400225.pdf	TAL effector-mediated DNA modification	Iowa State University Research	10-Dec-09	21-Aug-17	3-Sep-19
2850	US9408907	http://59.45.142.240:8808/pdf/US9408907.pdf	Homogenous suspension of immunopotentiating compounds and	GlaxoSmithKline Biologicals SA	15-Dec-09	15-Dec-10	9-Aug-16
2851	US20160375 132	http://59.45.142.240:8808/pdf/US20160375132A1.pdf	HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING	Not Available	15-Dec-09	5-Jul-16	29-Dec-16
2852	US20130101 629	http://59.45.142.240:8808/pdf/US20130101629A1.pdf	HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING	NOVARTIS AG	15-Dec-09	15-Dec-10	25-Apr-13
2853	US10046048	http://59.45.142.240:8808/pdf/US10046048.pdf	Homogenous suspension of immunopotentiating compounds and	GLAXOSMITHKLINE BIOLOGICALS S.A.	15-Dec-09	5-Jul-16	14-Aug-18
2854	US9090897	http://59.45.142.240:8808/pdf/US9090897.pdf	Production of IFN-lambda by conventional dendritic cells	Bavarian Nordic A/S	18-Dec-09	17-Dec-10	28-Jul-15
2855	US8552032	http://59.45.142.240:8808/pdf/US8552032.pdf	Bicyclic derivatives useful as inhibitors of DRD-1	Janssen Pharmaceutica NV	18-Dec-09	16-Dec-10	8-Oct-13
2856	US8481547	http://59.45.142.240:8808/pdf/US8481547.pdf	Substituted benzothiazole and benzoxazole derivatives useful as	Janssen Pharmaceutica NV	18-Dec-09	16-Dec-10	9-Jul-13
2857	US20130267 429	http://59.45.142.240:8808/pdf/US20130267429A1.pdf	BIOLOGICAL SAMPLE TARGET CLASSIFICATION, DETECTION AND SELECTION METHODS, AND RELATED ARRAYS AND	GARDNER SHEA	21-Dec-09	2-May-13	10-Oct-13
2858	US9404160	http://59.45.142.240:8808/pdf/US9404160.pdf	Methods for the detection of microorganisms	Becton, Dickinson and Company	22-Dec-09	21-Dec-10	2-Aug-16
2859	US20140186 396	http://59.45.142.240:8808/pdf/US20140186396A1.pdf	METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED VIRUS-BASED VIRUS-LIKE	TAKEDA VACCINES, INC.	28-Dec-09	6-Mar-14	3-Jul-14
2860	US8709496	http://59.45.142.240:8808/pdf/US8709496.pdf	Use of deuterium oxide for the treatment of virus-based diseases of	D2 Bioscience Group Ltd.	6-Jan-10	23-May-12	29-Apr-14
2861	US9522171	http://59.45.142.240:8808/pdf/US9522171.pdf	EV576 for use in the treatment of viral infections of the respiratory	Volition Immuno Pharmaceuticals SA	8-Jan-10	2-Jan-15	20-Dec-16
2862	US20200155 646	http://59.45.142.240:8808/pdf/US20200155646A1.pdf	EV576 For Use in the Treatment of Viral Infections of the Respiratory	Volition Immuno Pharmaceuticals SA	8-Jan-10	7-Jun-19	21-May-20
2863	US20170065 677	http://59.45.142.240:8808/pdf/US20170065677A1.pdf	EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE	Volition Immuno Pharmaceuticals SA	8-Jan-10	22-Jul-16	9-Mar-17
2864	US20150196 619	http://59.45.142.240:8808/pdf/US20150196619A1.pdf	EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE	Not Available	8-Jan-10	2-Jan-15	16-Jul-15
2865	US8486959	http://59.45.142.240:8808/pdf/US8486959.pdf	Dibenzo[f,h]isoquinoline derivatives	National Health Research Institutes	14-Jan-10	14-Jan-11	16-Jul-13
2866	US9328093	http://59.45.142.240:8808/pdf/US9328093.pdf	Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof	HYBRIGENICS SA	15-Jan-10	17-Sep-14	3-May-16
2867	US9078868	http://59.45.142.240:8808/pdf/US9078868.pdf	Therapeutic agent for accelerating recovery of animal under medical	DAIICHI SANKYO COMPANY, LIMITED	15-Jan-10	14-Jan-11	14-Jul-15
2868	US20130157 283	http://59.45.142.240:8808/pdf/US20130157283A1.pdf	RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD	PRESIDENT AND FELLOWS OF	19-Jan-10	19-Jan-11	20-Jun-13
2869	US20130101 609	http://59.45.142.240:8808/pdf/US20130101609A1.pdf	IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES	NOVARTIS AG	24-Jan-10	24-Jan-11	25-Apr-13
2870	US10485761	http://59.45.142.240:8808/pdf/US10485761.pdf	Irradiated biodegradable polymer microparticles	GLAXOSMITHKLINE BIOLOGICALS S.A.	24-Jan-10	16-May-18	26-Nov-19
2871	US9895692	http://59.45.142.240:8808/pdf/US9895692.pdf	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29-Jan-10	5-Aug-15	20-Feb-18
2872	US9132423	http://59.45.142.240:8808/pdf/US9132423.pdf	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29-Jan-10	28-Jan-11	15-Sep-15
2873	US20160193 603	http://59.45.142.240:8808/pdf/US20160193603A1.pdf	SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE	Not Available	29-Jan-10	5-Aug-15	7-Jul-16
2874	US20130130 262	http://59.45.142.240:8808/pdf/US20130130262A1.pdf	SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE	BATTRELL C FREDERICK	29-Jan-10	28-Jan-11	23-May-13
2875	US20130196 380	http://59.45.142.240:8808/pdf/US20130196380A1.pdf	IN VITRO PROCESS FOR THE PREPARATION OF ANTIBODIES OF	JANSEN GABRIELE	5-Feb-10	4-Feb-11	1-Aug-13
2876	US20130178 448	http://59.45.142.240:8808/pdf/US20130178448A1.pdf	Treatment of Respiratory Disorders	BANNISTER ROBIN MARK	5-Feb-10	4-Feb-11	11-Jul-13

2877	US9034313	http://59.45.142.240:8808/pdf/US9034313.pdf	Nucleic acid molecules encoding rantes, and compositions comprising	Inovio Pharmaceuticals,	8-Feb-10	8-Feb-11	19-May-15
2878	US9572864	http://59.45.142.240:8808/pdf/US9572864.pdf	Compositions and uses of lectins	Emory University	12-Feb-10	11-Dec-15	21-Feb-17
2879	US20160175 394	http://59.45.142.240:8808/pdf/US20160175394A1.pdf	Compositions and Uses of Lectins	Emory University	12-Feb-10	11-Dec-15	23-Jun-16
2880	US20130203 655		METHODS FOR PREVENTING OR TREATING VIRAL INFECTION	KIELIAN MARGARET	12-Feb-10	9-Feb-11	8-Aug-13
2881	US20130189 247	http://59.45.142.240:8808/pdf/US20130189247A1.pdf	Multimeric Proteins Comprising Immunoglobulin Constant Domains	RESEARCH CORPORATION TECHNOLOGIES,	12-Feb-10	11-Feb-11	25-Jul-13
2882	US20150168 405	http://59.45.142.240:8808/pdf/US20150168405A1.pdf	OLIGONUCLEOTIDE BASED ANALYTE DETECTION METHOD	Not Available	16-Feb-10	24-Feb-15	18-Jun-15
2883	US9168269	http://59.45.142.240:8808/pdf/US9168269.pdf	Inhibitors of long and very long chain fatty acid metabolism as broad	THE TRUSTEES OF PRINCETON UNIVERSITY	18-Feb-10	18-Feb-11	27-Oct-15
2884	US20160271 137	http://59.45.142.240:8808/pdf/US20160271137A1.pdf	INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM	Not Available	18-Feb-10	27-Oct-15	22-Sep-16
2885	US20130190 381	http://59.45.142.240:8808/pdf/US20130190381A1.pdf	INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM	THE TRUSTEES OF PRINCETON UNIVERSITY	18-Feb-10	18-Feb-11	25-Jul-13
2886	US20170029 877	http://59.45.142.240:8808/pdf/US20170029877A1.pdf	POLYTAG PROBES	Not Available	26-Feb-10	31-Mar-16	2-Feb-17
2887	US9128101	http://59.45.142.240:8808/pdf/US9128101.pdf	Biomarkers for theranostics	Caris Life Sciences Switzerland	1-Mar-10	1-Mar-11	8-Sep-15
2888	US20130287 772	http://59.45.142.240:8808/pdf/US20130287772A1.pdf	BIOMARKERS FOR THERANOSTICS	Caris Life Sciences Luxembourg	1-Mar-10	1-Mar-11	31-Oct-13
2889	US9550757	http://59.45.142.240:8808/pdf/US9550757.pdf	Nuclear transport modulators and use thereof	Karyopharm Therapeutics Inc	5-Mar-10	28-Jun-13	24-Jan-17
2890	US20140155 370	http://59.45.142.240:8808/pdf/US20140155370A1.pdf	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	5-Mar-10	28-Jun-13	5-Jun-14
2891	US9494571	http://59.45.142.240:8808/pdf/US9494571.pdf	Methods of testing for intracellular pathogens	Novartis AG	8-Mar-10	7-Mar-11	15-Nov-16
2892	US20170022 577	http://59.45.142.240:8808/pdf/US20170022577A1.pdf	METHODS OF TESTING FOR INTRACELLULAR PATHOGENS	Novartis AG	8-Mar-10	23-Sep-16	26-Jan-17
2893	US8686152	http://59.45.142.240:8808/pdf/US8686152.pdf	4,4-disubstituted piperidine derivatives useful as inhibitors of	Janssen Pharmaceutica NV	10-Mar-10	9-Mar-11	1-Apr-14
2894	US20190091 221	http://59.45.142.240:8808/pdf/US20190091221A1.pdf	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	TRUSTEES OF BOSTON UNIVERSITY	11-Mar-10	23-Apr-18	28-Mar-19
2895	US20170042 898	http://59.45.142.240:8808/pdf/US20170042898A1.pdf	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	HEMAQUEST PHARMACEUTICALS, INC.	11-Mar-10	27-Oct-16	16-Feb-17
2896	US20160113 929	http://59.45.142.240:8808/pdf/US20160113929A1.pdf	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	Not Available	11-Mar-10	2-Jun-15	28-Apr-16
2897	US20130331 313	http://59.45.142.240:8808/pdf/US20130331313A1.pdf	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	HEMAQUEST PHARMACEUTICALS, INC.	11-Mar-10	7-Jun-13	12-Dec-13
2898	US9758840	http://59.45.142.240:8808/pdf/US9758840.pdf	Parasite detection via endosymbiont detection	IBIS BIOSCIENCES, INC.	14-Mar-10	11-Mar-11	12-Sep-17
2899	US9522962	http://59.45.142.240:8808/pdf/US9522962.pdf	Peptides, conjugates and method for increasing immunogenicity of a	Academisch Ziekenhuis Leiden	15-Mar-10	15-Mar-11	20-Dec-16
2900	US20130071 428	http://59.45.142.240:8808/pdf/US20130071428A1.pdf	PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A PEPTIDE	ACADEMISCH ZIEKENHUIS LEIDEN	15-Mar-10	15-Mar-11	21-Mar-13
2901	US9682133	http://59.45.142.240:8808/pdf/US9682133.pdf	Disrupted adenovirus-based vaccine against drug abuse	CORNELL UNIVERSITY	17-Mar-10	17-Mar-11	20-Jun-17
2902	US9365506	http://59.45.142.240:8808/pdf/US9365506.pdf	Compounds and compositions as TLR2 agonists	NOVARTIS AG	23-Mar-10	9-Jul-14	14-Jun-16
2903	US8808703	http://59.45.142.240:8808/pdf/US8808703.pdf	Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory	Not Available	23-Mar-10	23-Mar-11	19-Aug-14
2904	US20170039 314	http://59.45.142.240:8808/pdf/US20170039314A1.pdf	BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE	IOGENETICS, LLC	23-Mar-10	13-Sep-12	9-Feb-17
2905	US20140323 390	http://59.45.142.240:8808/pdf/US20140323390A1.pdf	COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS	IRM LLC	23-Mar-10	9-Jul-14	30-Oct-14
2906	US20130330 335		BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE	IOGENETICS, LLC	23-Mar-10	21-Mar-11	12-Dec-13
2907	US20130102 652	http://59.45.142.240:8808/pdf/US20130102652A1.pdf	METHODS AND COMPOSITIONS RELATED TO MODIFIED ADENOSINES FOR CONTROLLING	UNIVERSITY OF UTAH RESEARCH FOUNDATION	23-Mar-10	23-Mar-11	25-Apr-13
2908	US9459247	http://59.45.142.240:8808/pdf/US9459247.pdf	Quantitative measurement of nano/micro particle endocytosis with	Academia Sinica	29-Mar-10	29-Mar-11	4-Oct-16
2909	US8901071	http://59.45.142.240:8808/pdf/US8901071.pdf	Compounds and their use	Novabiotics Limited	31-Mar-10	30-Mar-11	2-Dec-14
2910	US20130102 524	http://59.45.142.240:8808/pdf/US20130102524A1.pdf	Compounds And Their Use	Novabiotics Limited	31-Mar-10	30-Mar-11	25-Apr-13
2911	US9717755	http://59.45.142.240:8808/pdf/US9717755.pdf	Method of treating inflammation	Cytosorbents Corporation	1-Apr-10	1-Apr-11	1-Aug-17
2912	US20190282 608	http://59.45.142.240:8808/pdf/US20190282608A1.pdf	Method Of Treating Inflammation	Not Available	1-Apr-10	29-May-19	19-Sep-19
2913	US20180311 273	http://59.45.142.240:8808/pdf/US20180311273A1.pdf	Method of Treating Inflammation	Not Available	1-Apr-10	26-Jun-18	1-Nov-18
2914	US20170296 574	http://59.45.142.240:8808/pdf/US20170296574A1.pdf	Method of Treating Inflammation	Not Available	1-Apr-10	28-Jun-17	19-Oct-17
2915	US20160279 163	http://59.45.142.240:8808/pdf/US20160279163A1.pdf	Method of Treating Inflammation	Not Available	1-Apr-10	3-Jun-16	29-Sep-16
2916	US20130203 836	http://59.45.142.240:8808/pdf/US20130203836A1.pdf	2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES	ALNYLAM PHARMACEUTICALS, INC.	1-Apr-10	31-Mar-11	8-Aug-13
2917	US20130195 792	http://59.45.142.240:8808/pdf/US20130195792A1.pdf	METHOD OF TREATING INFLAMMATION	CYTOSORBENTS CORPORATION	1-Apr-10	1-Apr-11	1-Aug-13
2918	US10034894	http://59.45.142.240:8808/pdf/US10034894.pdf	Method of treating inflammation	CYTOSORBENTS CORPORATION	1-Apr-10	28-Jun-17	31-Jul-18
2919	US9469876	http://59.45.142.240:8808/pdf/US9469876.pdf	Circulating biomarkers for metastatic prostate cancer	Caris Life Sciences Switzerland	6-Apr-10	6-Apr-11	18-Oct-16
2920	US20150301 055	http://59.45.142.240:8808/pdf/US20150301055A1.pdf	CIRCULATING BIOMARKERS FOR DISEASE	Not Available	6-Apr-10	1-Jul-15	22-Oct-15
2921	US20140162 888		CIRCULATING BIOMARKERS FOR DISEASE	Not Available	6-Apr-10	6-Apr-11	12-Jun-14

2922	US9249195	http://59.45.142.240:8808/pdf/US9249195.pdf	Reovirus vaccines and methods of use therefor	Vanderbilt University	7-Apr-10	4-Apr-11	2-Feb-16
2923	US20130259 887	http://59.45.142.240:8808/pdf/US20130259887A1.pdf	REOVIRUS VACCINES AND METHODS OF USE THEREFOR	BOEHME KARL W	7-Apr-10	4-Apr-11	3-Oct-13
2924	US9759723	http://59.45.142.240:8808/pdf/US9759723.pdf	B-cell antigen presenting cell assay	University of Pittsburghhac"Of the Commonwealth System of Higher	8-Apr-10	21-Mar-16	12-Sep-17
2925	US9746459	http://59.45.142.240:8808/pdf/US9746459.pdf	Antigen presenting cell assay	University of Pittsburghhac"Of the Commonwealth System of Higher	8-Apr-10	11-Oct-13	29-Aug-17
2926	US9322827	http://59.45.142.240:8808/pdf/US9322827.pdf	B-cell antigen presenting cell assay	University of Pittsburgh - Of the Commonwealth System of Higher	8-Apr-10	8-Apr-11	26-Apr-16
2927	US20190025 292		ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher	8-Apr-10	25-Sep-18	24-Jan-19
2928	US20170336 411	http://59.45.142.240:8808/pdf/US20170336411A1.pdf	B-CELL ANTIGEN PRESENTING CELL ASSAY	The University of Pittsburgh - Of the Commonwealth System of Higher	8-Apr-10	9-Aug-17	23-Nov-17
2929	US20170322 201		ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher	8-Apr-10	20-Jul-17	9-Nov-17
2930	US20160202 258	http://59.45.142.240:8808/pdf/US20160202258A1.pdf	B-CELL ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher	8-Apr-10	21-Mar-16	14-Jul-16
2931	US20140057 315		ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher	8-Apr-10	11-Oct-13	27-Feb-14
2932	US10222374	http://59.45.142.240:8808/pdf/US10222374.pdf	B-cell antigen presenting cell assay	Univeersity of Pittsburghhac"Of the Commonwealth System of Higher	8-Apr-10	9-Aug-17	5-Mar-19
2933	US10114011	http://59.45.142.240:8808/pdf/US10114011.pdf	Antigen presenting cell assay	University of Pittsburghhac"Of the Commonwealth System of Higher	8-Apr-10	20-Jul-17	30-Oct-18
2934	US20130195 914	http://59.45.142.240:8808/pdf/US20130195914A1.pdf	Expression Of Positive Sense Single Stranded RNA Virus And Uses	Viracine Therapeutics	12-Apr-10	8-Apr-11	1-Aug-13
2935	US9475832	http://59.45.142.240:8808/pdf/US9475832.pdf	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of	14-Apr-10	29-Sep-14	25-Oct-16
2936	US8846643	http://59.45.142.240:8808/pdf/US8846643.pdf	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of	14-Apr-10	11-Oct-12	30-Sep-14
2937	US20170096 441	http://59.45.142.240:8808/pdf/US20170096441A1.pdf	PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS	Not Available	14-Apr-10	9-Sep-16	6-Apr-17
2938	US20150080 344	http://59.45.142.240:8808/pdf/US20150080344A1.pdf	PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS	Not Available	14-Apr-10	29-Sep-14	19-Mar-15
2939	US9687536	http://59.45.142.240:8808/pdf/US9687536.pdf	Methods and compositions for intranasal delivery	SHIN NIPPON BIOMEDICAL LABORATORIES,	15-Apr-10	15-Apr-11	27-Jun-17
2940	US20130273 120	http://59.45.142.240:8808/pdf/US20130273120A1.pdf	METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY	HARUTA SHUNJI	15-Apr-10	14-Mar-13	17-Oct-13
2941	US20130129 781	http://59.45.142.240:8808/pdf/US20130129781A1.pdf	METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY	HARUTA SHUNJI	15-Apr-10	15-Apr-11	23-May-13
2942	US10463723	http://59.45.142.240:8808/pdf/US10463723.pdf	Methods and compositions for intranasal delivery	Shin Nippon Biomedical	15-Apr-10	14-Mar-13	5-Nov-19
2943	US20130281 324	http://59.45.142.240:8808/pdf/US20130281324A1.pdf	BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES	Nuevolution A/S	16-Apr-10	16-Apr-11	24-Oct-13
2944	US20130122 043	http://59.45.142.240:8808/pdf/US20130122043A1.pdf	MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF	WHITEHEAD INSTITUTE FOR BIOMEDICAL	20-Apr-10	20-Apr-11	16-May-13
2945	US20130165 417	http://59.45.142.240:8808/pdf/US20130165417A1.pdf	METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED PROTEIN	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION	23-Apr-10	23-Apr-11	27-Jun-13
2946	US20130203 151	http://59.45.142.240:8808/pdf/US20130203151A1.pdf	PRODUCTION OF ALPHAVIRUS REPLICON PARTICLES IN PERMISSIVE CELLS	BALSITIS SCOTT	26-Apr-10	26-Apr-11	8-Aug-13
2947	US9442107	http://59.45.142.240:8808/pdf/US9442107.pdf	Antibody-nanoparticle conjugates and methods for making and using	Ventana Medical Systems, Inc.	27-Apr-10	21-Apr-15	13-Sep-16
2948	US9040310	http://59.45.142.240:8808/pdf/US9040310.pdf	Antibody-nanoparticle conjugates and methods for making and using	Ventana Medical Systems, Inc.	27-Apr-10	27-Apr-11	26-May-15
2949	US20180372 733	http://59.45.142.240:8808/pdf/US20180372733A1.pdf	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH	Not Available	27-Apr-10	21-Jun-18	27-Dec-18
2950	US20170131 271	http://59.45.142.240:8808/pdf/US20170131271A1.pdf	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH	Not Available	27-Apr-10	12-Sep-16	11-May-17
2951	US20160116 462	http://59.45.142.240:8808/pdf/US20160116462A1.pdf	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH	Not Available	27-Apr-10	21-Apr-15	28-Apr-16
2952	US10031134	http://59.45.142.240:8808/pdf/US10031134.pdf	Antibody-nanoparticle conjugates and methods for making and using	Ventana Medical Systems, Inc.	27-Apr-10	12-Sep-16	24-Jul-18

2953	US20130236 396	http://59.45.142.240:8808/pdf/US20130236396A1.pdf	NANOPARTICLES PRODUCED FROM RECOMBINANT POLYMERS AND METHODS OF MAKING AND USING	UNIVERSITY OF UTAH RESEARCH FOUNDATION	3-May-10	3-May-11	12-Sep-13
2954	US9642873	http://59.45.142.240:8808/pdf/US9642873.pdf	Combinations of TGF β 2 and COX-2 inhibitors and methods for their	Sirnaomics, Inc.	4-May-10	4-May-11	9-May-17
2955	US20130225 655	http://59.45.142.240:8808/pdf/US20130225655A1.pdf	Combinations of TGF β 2 and COX-2 Inhibitors and Methods for Their	EVANS DAVID	4-May-10	4-May-11	29-Aug-13
2956	US9346769	http://59.45.142.240:8808/pdf/US9346769.pdf	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals,	5-May-10	23-Aug-13	24-May-16
2957	US8546432	http://59.45.142.240:8808/pdf/US8546432.pdf	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals,	5-May-10	5-May-11	1-Oct-13
2958	US8450350	http://59.45.142.240:8808/pdf/US8450350.pdf	Triazoles as inhibitors of fatty acid synthase	Infinity Pharmaceuticals,	5-May-10	5-May-11	28-May-13
2959	US20170119 734	http://59.45.142.240:8808/pdf/US20170119734A1.pdf	TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE	Not Available	5-May-10	22-Apr-16	4-May-17
2960	US20140079 667	http://59.45.142.240:8808/pdf/US20140079667A1.pdf	TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE	Infinity Pharmaceuticals,	5-May-10	23-Aug-13	20-Mar-14
2961	US20130243 727	http://59.45.142.240:8808/pdf/US20130243727A1.pdf	TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE	INFINITY PHARMACEUTICALS, INC.	5-May-10	29-Apr-13	19-Sep-13
2962	US9426989	http://59.45.142.240:8808/pdf/US9426989.pdf	Organic peroxide compounds for microorganism inactivation	NOVARTIS AG	6-May-10	6-May-11	30-Aug-16
2963	US20130149 194	http://59.45.142.240:8808/pdf/US20130149194A1.pdf	ORGANIC PEROXIDE COMPOUNDS FOR MICROORGANISM	GREGERSEN JENS PETER	6-May-10	6-May-11	13-Jun-13
2964	US9757478	http://59.45.142.240:8808/pdf/US9757478.pdf	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11-May-10	7-Jan-16	12-Sep-17
2965	US9339561	http://59.45.142.240:8808/pdf/US9339561.pdf	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11-May-10	5-May-14	17-May-16
2966	US9290794	http://59.45.142.240:8808/pdf/US9290794.pdf	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11-May-10	12-Nov-12	22-Mar-16
2967	US9248201	http://59.45.142.240:8808/pdf/US9248201.pdf	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11-May-10	5-May-14	2-Feb-16
2968	US8735559	http://59.45.142.240:8808/pdf/US8735559.pdf	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11-May-10	11-May-11	27-May-14
2969	US20160115 522	http://59.45.142.240:8808/pdf/US20160115522A1.pdf	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	Not Available	11-May-10	7-Jan-16	28-Apr-16
2970	US20140308 211	http://59.45.142.240:8808/pdf/US20140308211A1.pdf	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	Not Available	11-May-10	5-May-14	16-Oct-14
2971	US20140298 500	http://59.45.142.240:8808/pdf/US20140298500A1.pdf	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	Not Available	11-May-10	5-May-14	2-Oct-14
2972	US20140030 725	http://59.45.142.240:8808/pdf/US20140030725A1.pdf	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	PROMEGA CORPORATION	11-May-10	12-Nov-12	30-Jan-14
2973	US9867877	http://59.45.142.240:8808/pdf/US9867877.pdf	Methods for preparing squalene	NOVARTIS AG	12-May-10	22-Nov-16	16-Jan-18
2974	US9545440	http://59.45.142.240:8808/pdf/US9545440.pdf	Methods for preparing squalene	NOVARTIS AG	12-May-10	23-Oct-15	17-Jan-17
2975	US9199897	http://59.45.142.240:8808/pdf/US9199897.pdf	Methods for preparing squalene	NOVARTIS AG	12-May-10	12-May-11	1-Dec-15
2976	US20200061 187	http://59.45.142.240:8808/pdf/US20200061187A1.pdf	METHODS FOR PREPARING SQUALENE	Not Available	12-May-10	4-Nov-19	27-Feb-20
2977	US20170072 053	http://59.45.142.240:8808/pdf/US20170072053A1.pdf	METHODS FOR PREPARING SQUALENE	Not Available	12-May-10	22-Nov-16	16-Mar-17
2978	US20160051 670	http://59.45.142.240:8808/pdf/US20160051670A1.pdf	METHODS FOR PREPARING SQUALENE	Not Available	12-May-10	23-Oct-15	25-Feb-16
2979	US20130209 510	http://59.45.142.240:8808/pdf/US20130209510A1.pdf	METHODS FOR PREPARING SQUALENE	Novartis AG	12-May-10	12-May-11	15-Aug-13
2980	US10517947	http://59.45.142.240:8808/pdf/US10517947.pdf	Methods for preparing squalene	NOVARTIS AG	12-May-10	14-Dec-17	31-Dec-19
2981	US9982241	http://59.45.142.240:8808/pdf/US9982241.pdf	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14-May-10	1-Oct-15	29-May-18
2982	US9249427	http://59.45.142.240:8808/pdf/US9249427.pdf	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14-May-10	14-Nov-12	2-Feb-16
2983	US20190099 479	http://59.45.142.240:8808/pdf/US20190099479A1.pdf	RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF	Not Available	14-May-10	27-Apr-18	4-Apr-19
2984	US20160114 027	http://59.45.142.240:8808/pdf/US20160114027A1.pdf	RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF	Not Available	14-May-10	1-Oct-15	28-Apr-16
2985	US20130136 768	http://59.45.142.240:8808/pdf/US20130136768A1.pdf	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14-May-10	14-Nov-12	30-May-13
2986	US20130280 806	http://59.45.142.240:8808/pdf/US20130280806A1.pdf	MAMMALIAN GENES INVOLVED IN INFECTION	HODGE THOMAS	17-May-10	17-May-11	24-Oct-13
2987	US9574181	http://59.45.142.240:8808/pdf/US9574181.pdf	Influenza virus reassortment method	Seqirus UK Limited	21-May-10	24-Oct-14	21-Feb-17
2988	US8945904	http://59.45.142.240:8808/pdf/US8945904.pdf	Influenza virus reassortment	Novartis AG	21-May-10	20-May-11	3-Feb-15
2989	US20150118 746	http://59.45.142.240:8808/pdf/US20150118746A1.pdf	INFLUENZA VIRUS REASSORTMENT METHOD	Not Available	21-May-10	24-Oct-14	30-Apr-15
2990	US20130216 573	http://59.45.142.240:8808/pdf/US20130216573A1.pdf	INFLUENZA VIRUS REASSORTMENT	NOVARTIS AG	21-May-10	20-May-11	22-Aug-13
2991	US9034646	http://59.45.142.240:8808/pdf/US9034646.pdf	Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation	ZHENG YANG BIOMEDICAL TECHNOLOGY CO.,	25-May-10	26-Nov-12	19-May-15
2992	US20130143 810	http://59.45.142.240:8808/pdf/US20130143810A1.pdf	Virally-Inactivated Growth Factors-Containing Platelet Lysate Depleted of PDGF and VEGF and Preparation	BURNOUF THIERRY	25-May-10	26-Nov-12	6-Jun-13
2993	US8945943	http://59.45.142.240:8808/pdf/US8945943.pdf	Personal glucose meters for detection and quantification of a	The Board of Trustees of the	26-May-10	26-May-11	3-Feb-15
2994	US8581584	http://59.45.142.240:8808/pdf/US8581584.pdf	Membrane proteins, mechanisms of action and uses thereof	Florida State University Research	26-May-10	26-May-11	12-Nov-13
2995	US9096585	http://59.45.142.240:8808/pdf/US9096585.pdf	Antiviral compounds and uses thereof	Icahn School of Medicine at Mount	28-May-10	31-May-11	4-Aug-15
2996	US20130137 678	http://59.45.142.240:8808/pdf/US20130137678A1.pdf	Antiviral Compounds and Uses Thereof	MOUNT SINAI SCHOOL OF MEDICINE	28-May-10	31-May-11	30-May-13
2997	US20130243 841	http://59.45.142.240:8808/pdf/US20130243841A1.pdf	CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION	Novartis AG	1-Jun-10	1-Jun-11	19-Sep-13
2998	US20130224 245	http://59.45.142.240:8808/pdf/US20130224245A1.pdf	CONCENTRATION OF VACCINE ANTIGENS WITHOUT	Novartis AG	1-Jun-10	1-Jun-11	29-Aug-13
2999	US20180112 270	http://59.45.142.240:8808/pdf/US20180112270A1.pdf	C-CBL MUTATIONS AND USES THEREOF	Not Available	4-Jun-10	22-Mar-16	26-Apr-18

3000	US20130217 012	http://59.45.142.240:8808/pdf/US20130217012A1.pdf	C-CBL MUTATIONS AND USES THEREOF	The University of Chicago	4-Jun-10	3-Jun-11	22-Aug-13
3001	US20170321 192	http://59.45.142.240:8808/pdf/US20170321192A1.pdf	Recombinant RNA Viruses and Uses Thereof	Icahn School of Medicine at Mount Sinai	6-Jun-10	6-Apr-17	9-Nov-17
3002	US20130209 406	http://59.45.142.240:8808/pdf/US20130209406A1.pdf	RECOMBINANT RNA VIRUSES AND USES THEREOF	TENOEVER BENJAMIN P	6-Jun-10	6-Jun-11	15-Aug-13
3003	US20130261 196	http://59.45.142.240:8808/pdf/US20130261196A1.pdf	Nucleic Acids For Multiplex Organism Detection and Methods Of Use And Kits Thereof	DIAMOND LISA	11-Jun-10	10-Jun-11	3-Oct-13
3004	US20130137 140	http://59.45.142.240:8808/pdf/US20130137140A1.pdf	INCREASED PROTEIN EXPRESSION THROUGH INCREASED MEMBRANE COMPOSITION	UNIVERSITEIT GENT	17-Jun-10	15-Jun-11	30-May-13
3005	US20170000 878	http://59.45.142.240:8808/pdf/US20170000878A1.pdf	CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES	Not Available	23-Jun-10	9-Aug-16	5-Jan-17
3006	US20130171 129	http://59.45.142.240:8808/pdf/US20130171129A1.pdf	CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES	COULIBALY FASSELL JOSEPH	23-Jun-10	23-Jun-11	4-Jul-13
3007	US9895411	http://59.45.142.240:8808/pdf/US9895411.pdf	Analog of C5a and methods of using same	BOARD OF REGENTS OF THE UNIVERSITY OF MICHIGAN	29-Jun-10	29-Jun-11	20-Feb-18
3008	US20180140 659	http://59.45.142.240:8808/pdf/US20180140659A1.pdf	ANALOGS OF C5a AND METHODS OF USING SAME	Not Available	29-Jun-10	12-Jan-18	24-May-18
3009	US20150297 668	http://59.45.142.240:8808/pdf/US20150297668A1.pdf	ANALOGS OF C5a AND METHODS OF USING SAME	BOARD PF REGENTS OF THE UNIVERSITY OF MICHIGAN	29-Jun-10	29-Jun-11	22-Oct-15
3010	US10363282	http://59.45.142.240:8808/pdf/US10363282.pdf	Analog of C5a and methods of using same	Board of Regents of The University of Michigan	29-Jun-10	12-Jan-18	30-Jul-19
3011	US9512471	http://59.45.142.240:8808/pdf/US9512471.pdf	Methods and kits for detecting human papillomavirus	DIACARTA Inc	30-Jun-10	30-Jun-10	6-Dec-16
3012	US9291597	http://59.45.142.240:8808/pdf/US9291597.pdf	Detecting targets using mass tags and mass spectrometry	VENTANA MEDICAL SYSTEMS, INC	2-Jul-10	1-Jul-11	22-Mar-16
3013	US20190004 061	http://59.45.142.240:8808/pdf/US20190004061A1.pdf	DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY	Not Available	2-Jul-10	4-Aug-18	3-Jan-19
3014	US20160139 143	http://59.45.142.240:8808/pdf/US20160139143A1.pdf	DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY	Not Available	2-Jul-10	28-Dec-15	19-May-16
3015	US20130122 516	http://59.45.142.240:8808/pdf/US20130122516A1.pdf	DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY	BIENIARZ CHRISTOPHER	2-Jul-10	1-Jul-11	16-May-13
3016	US10078083	http://59.45.142.240:8808/pdf/US10078083.pdf	Detecting targets using mass tags and mass spectrometry	Ventana Medical Systems, Inc	2-Jul-10	28-Dec-15	18-Sep-18
3017	US9801897	http://59.45.142.240:8808/pdf/US9801897.pdf	Delivery of RNA to trigger multiple immune pathways	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	6-Jul-11	31-Oct-17
3018	US9795668	http://59.45.142.240:8808/pdf/US9795668.pdf	Delivery of self-replicating RNA using biodegradable polymer particles	GlaxoSmithKline Biologicals S.A.	6-Jul-10	23-Nov-15	24-Oct-17
3019	US9770463	http://59.45.142.240:8808/pdf/US9770463.pdf	Delivery of RNA to different cell types	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	7-Jun-11	26-Sep-17
3020	US9295646	http://59.45.142.240:8808/pdf/US9295646.pdf	Cationic oil-in-water emulsions	Novartis AG	6-Jul-10	18-Sep-11	29-Mar-16
3021	US9192661	http://59.45.142.240:8808/pdf/US9192661.pdf	Delivery of self-replicating RNA using biodegradable polymer particles	Novartis AG	6-Jul-10	7-Jun-11	24-Nov-15
3022	US20200048 636	http://59.45.142.240:8808/pdf/US20200048636A1.pdf	IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	18-Oct-19	13-Feb-20
3023	US20190343 862	http://59.45.142.240:8808/pdf/US20190343862A1.pdf	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	16-Jul-19	14-Nov-19
3024	US20180085 388	http://59.45.142.240:8808/pdf/US20180085388A1.pdf	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	5-Oct-17	29-Mar-18
3025	US20180050 059	http://59.45.142.240:8808/pdf/US20180050059A1.pdf	DELIVERY OF RNA TO DIFFERENT CELL TYPES	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	30-Aug-17	22-Feb-18
3026	US20160256 541	http://59.45.142.240:8808/pdf/US20160256541A1.pdf	Cationic Oil-In-Water Emulsions	Not Available	6-Jul-10	11-Mar-16	8-Sep-16
3027	US20160074 506	http://59.45.142.240:8808/pdf/US20160074506A1.pdf	DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES	Not Available	6-Jul-10	23-Nov-15	17-Mar-16
3028	US20130195 968	http://59.45.142.240:8808/pdf/US20130195968A1.pdf	VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA	Novartis AG	6-Jul-10	6-Jul-11	1-Aug-13
3029	US20130183 355	http://59.45.142.240:8808/pdf/US20130183355A1.pdf	DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES	NOVARTIS AG	6-Jul-10	7-Jun-11	18-Jul-13
3030	US20130177 640	http://59.45.142.240:8808/pdf/US20130177640A1.pdf	DELIVERY OF RNA TO DIFFERENT CELL TYPES	NOVARTIS AG	6-Jul-10	7-Jun-11	11-Jul-13
3031	US20130177 639	http://59.45.142.240:8808/pdf/US20130177639A1.pdf	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	NOVARTIS AG	6-Jul-10	6-Jul-11	11-Jul-13
3032	US20130171 241	http://59.45.142.240:8808/pdf/US20130171241A1.pdf	LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY	NOVARTIS AG	6-Jul-10	6-Jul-11	4-Jul-13
3033	US20130149 375	http://59.45.142.240:8808/pdf/US20130149375A1.pdf	IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF	GEALL ANDREW	6-Jul-10	6-Jul-11	13-Jun-13
3034	US10532067	http://59.45.142.240:8808/pdf/US10532067.pdf	Delivery of RNA to trigger multiple immune pathways	GlaxoSmithKline Biologicals S.A.	6-Jul-10	5-Oct-17	14-Jan-20
3035	US10487332	http://59.45.142.240:8808/pdf/US10487332.pdf	Immunisation of large mammals with low doses of RNA	GlaxoSmithKline Biologicals SA	6-Jul-10	6-Jul-11	26-Nov-19
3036	US10238733	http://59.45.142.240:8808/pdf/US10238733.pdf	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-10	11-Mar-16	26-Mar-19
3037	US20130095 135	http://59.45.142.240:8808/pdf/US20130095135A1.pdf	PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE PRODUCTION OF A VIRUS IN	GlaxoSmithKline Biologicals S.A.	8-Jul-10	6-Jul-11	18-Apr-13
3038	US9291628	http://59.45.142.240:8808/pdf/US9291628.pdf	Direct clone analysis and selection technology	Dublin City University	13-Jul-10	13-Jul-11	22-Mar-16
3039	US20160305 936	http://59.45.142.240:8808/pdf/US20160305936A1.pdf	DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGY	Not Available	13-Jul-10	18-Feb-16	20-Oct-16
3040	US20130190 206	http://59.45.142.240:8808/pdf/US20130190206A1.pdf	Direct Clone Analysis and Selection Technology	Dublin City University	13-Jul-10	13-Jul-11	25-Jul-13
3041	US20130115 215	http://59.45.142.240:8808/pdf/US20130115215A1.pdf	DOMAIN INSERTION IMMUNOCLOUTIN	ZHOU HONGXING	14-Jul-10	14-Jul-11	9-May-13
3042	US20130202 593	http://59.45.142.240:8808/pdf/US20130202593A1.pdf	INTRACELLULAR IMMUNITY	MEDICAL RESEARCH	23-Jul-10	23-Jan-13	8-Aug-13
3043	US9675550	http://59.45.142.240:8808/pdf/US9675550.pdf	Methods for inducing an immune response via buccal and/or sublingual administration of a	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	26-Jul-10	25-Jan-13	13-Jun-17
3044	US20180000 724	http://59.45.142.240:8808/pdf/US20180000724A1.pdf	METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL	Not Available	26-Jul-10	10-May-17	4-Jan-18
3045	US20140120 139	http://59.45.142.240:8808/pdf/US20140120139A1.pdf	METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL	Board of Regents, The University of Texas System	26-Jul-10	25-Jan-13	1-May-14
3046	US10646438		Methods for inducing an immune response via buccal and/or sublingual administration of a	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	26-Jul-10	10-May-17	12-May-20

3047	US9539321	http://59.45.142.240:8808/pdf/US9539321.pdf	HMGB1-derived peptides enhance immune response to antigens	The Regents of the University of California	27-Jul-10	9-Mar-15	10-Jan-17
3048	US8999349	http://59.45.142.240:8808/pdf/US8999349.pdf	HMGB1-derived peptides enhance immune response to antigens	The Regents of the University of California	27-Jul-10	27-Jul-11	7-Apr-15
3049	US20150306 213	http://59.45.142.240:8808/pdf/US20150306213A1.pdf	HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS	The Regents of the University of California	27-Jul-10	9-Mar-15	29-Oct-15
3050	US20130122 031	http://59.45.142.240:8808/pdf/US20130122031A1.pdf	HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS	MESSMER DAVORKA	27-Jul-10	27-Jul-11	16-May-13
3051	US9855287	http://59.45.142.240:8808/pdf/US9855287.pdf	Anti-viral azide containing compounds	LIFE TECHNOLOGIES	28-Jul-10	20-Aug-15	2-Jan-18
3052	US9144575	http://59.45.142.240:8808/pdf/US9144575.pdf	Anti-viral azide containing compounds	LIFE TECHNOLOGIES	28-Jul-10	28-Jul-11	29-Sep-15
3053	US20190105 334	http://59.45.142.240:8808/pdf/US20190105334A1.pdf	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	3-Dec-18	11-Apr-19
3054	US20180092 932	http://59.45.142.240:8808/pdf/US20180092932A1.pdf	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	7-Dec-17	5-Apr-18
3055	US20170333 457	http://59.45.142.240:8808/pdf/US20170333457A1.pdf	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	8-Aug-17	23-Nov-17
3056	US20150374 723	http://59.45.142.240:8808/pdf/US20150374723A1.pdf	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	20-Aug-15	31-Dec-15
3057	US20130209 550	http://59.45.142.240:8808/pdf/US20130209550A1.pdf	Anti-Viral Azide Containing Compounds	LIFE TECHNOLOGIES	28-Jul-10	28-Jul-11	15-Aug-13
3058	US20130209 364	http://59.45.142.240:8808/pdf/US20130209364A1.pdf	Anti-Viral Azide Containing Compounds	LIFE TECHNOLOGIES	28-Jul-10	28-Jul-11	15-Aug-13
3059	US10632133	http://59.45.142.240:8808/pdf/US10632133.pdf	Anti-viral azide containing compounds	LIFE TECHNOLOGIES	28-Jul-10	7-Dec-17	28-Apr-20
3060	US10179143	http://59.45.142.240:8808/pdf/US10179143.pdf	Anti-viral azide containing compounds	Life Technologies Corporation	28-Jul-10	8-Aug-17	15-Jan-19
3061	US9506063	http://59.45.142.240:8808/pdf/US9506063.pdf	siRNA compositions and methods for treatment of HPV and other	Sirnaomics, Inc.	29-Jul-10	29-Jan-13	29-Nov-16
3062	US20130345 284	http://59.45.142.240:8808/pdf/US20130345284A1.pdf	siRNA Compositions and Methods for Treatment of HPV and Other	Not Available	29-Jul-10	29-Jan-13	26-Dec-13
3063	US8476265	http://59.45.142.240:8808/pdf/US8476265.pdf	Compounds-801	AstraZeneca AB	30-Jul-10	14-Sep-12	2-Jul-13
3064	US8853382	http://59.45.142.240:8808/pdf/US8853382.pdf	Expression of antibody or a fragment thereof in Lactobacillus	Hera Pharmaceuticals,	5-Aug-10	4-Aug-11	7-Oct-14
3065	US20130323 819	http://59.45.142.240:8808/pdf/US20130323819A1.pdf	EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN LACTOBACILLUS	ALVAREZ MIGUEL ANGEL	5-Aug-10	4-Aug-11	5-Dec-13
3066	US9803236	http://59.45.142.240:8808/pdf/US9803236.pdf	Microarray-based assay integrated with particles for analyzing molecular	CapitalBio Corporation	6-Aug-10	6-Aug-10	31-Oct-17
3067	US20130217 584	http://59.45.142.240:8808/pdf/US20130217584A1.pdf	MICROARRAY-BASED ASSAY INTEGRATED WITH PARTICLES FOR ANALYZING MOLECULAR	CapitalBio Corporation	6-Aug-10	6-Aug-10	22-Aug-13
3068	US8557248	http://59.45.142.240:8808/pdf/US8557248.pdf	Methods and compositions for treating malaria	Cyvax, Inc.	9-Aug-10	9-Aug-11	15-Oct-13
3069	US20150104 500	http://59.45.142.240:8808/pdf/US20150104500A1.pdf	Methods and Compositions for Preventing a Condition	Not Available	9-Aug-10	28-Aug-14	16-Apr-15
3070	US20140010 837	http://59.45.142.240:8808/pdf/US20140010837A1.pdf	Methods and Compositions for Preventing a Condition	Cyvax, Inc.	9-Aug-10	11-Sep-13	9-Jan-14
3071	US20170165 359	http://59.45.142.240:8808/pdf/US20170165359A1.pdf	IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS	Not Available	11-Aug-10	23-Aug-16	15-Jun-17
3072	US20130196 903	http://59.45.142.240:8808/pdf/US20130196903A1.pdf	Multimeric Inhibitors of Viral Fusion and Use Thereof	JV BIO SRL	11-Aug-10	11-Aug-11	1-Aug-13
3073	US20150072 973	http://59.45.142.240:8808/pdf/US20150072973A1.pdf	NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND	Not Available	13-Aug-10	17-Sep-14	12-Mar-15
3074	US9127028	http://59.45.142.240:8808/pdf/US9127028.pdf	Substrates for chromogenic detection and methods of use in	Ventana Medical Systems, Inc.	16-Aug-10	12-Aug-11	8-Sep-15
3075	US20130115 593	http://59.45.142.240:8808/pdf/US20130115593A1.pdf	SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS	Ventana Medical Systems, Inc.	16-Aug-10	12-Aug-11	9-May-13
3076	US9795669	http://59.45.142.240:8808/pdf/US9795669.pdf	Lipidated immune response modifier compound compositions,	3M INNOVATIVE PROPERTIES COMPANY	17-Aug-10	15-Dec-15	24-Oct-17
3077	US9242980	http://59.45.142.240:8808/pdf/US9242980.pdf	Lipidated immune response modifier compound compositions,	3M Innovative Properties Company	17-Aug-10	16-Aug-11	26-Jan-16
3078	US20200030 441	http://59.45.142.240:8808/pdf/US20200030441A1.pdf	Lipidated Immune Response Modifier Compound Compositions,	Not Available	17-Aug-10	8-Jul-19	30-Jan-20
3079	US20180326 051	http://59.45.142.240:8808/pdf/US20180326051A1.pdf	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS,	Not Available	17-Aug-10	24-Jul-18	15-Nov-18
3080	US20180200 364	http://59.45.142.240:8808/pdf/US20180200364A1.pdf	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS,	3M Innovative Properties Company	17-Aug-10	27-Nov-17	19-Jul-18
3081	US20170189 521	http://59.45.142.240:8808/pdf/US20170189521A1.pdf	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS,	3M Innovative Properties Company	17-Aug-10	19-Aug-16	6-Jul-17
3082	US20160175 433	http://59.45.142.240:8808/pdf/US20160175433A1.pdf	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS,	Not Available	17-Aug-10	15-Dec-15	23-Jun-16
3083	US20130230 578	http://59.45.142.240:8808/pdf/US20130230578A1.pdf	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS,	3M INNOVATIVE PROPERTIES COMPANY	17-Aug-10	16-Aug-11	5-Sep-13
3084	US10383938	http://59.45.142.240:8808/pdf/US10383938.pdf	Lipidated immune response modifier compound compositions,	3M Innovative Properties Company	17-Aug-10	24-Jul-18	20-Aug-19
3085	US10052380	http://59.45.142.240:8808/pdf/US10052380.pdf	Lipidated immune response modifier compound compositions,	3M Innovative Properties Company	17-Aug-10	27-Nov-17	21-Aug-18
3086	US20140148 350	http://59.45.142.240:8808/pdf/US20140148350A1.pdf	CIRCULATING BIOMARKERS FOR DISEASE	Not Available	18-Aug-10	18-Aug-11	29-May-14
3087	US9801935	http://59.45.142.240:8808/pdf/US9801935.pdf	Soluble needle arrays for delivery of influenza vaccines	SEQIRUS UK LIMITED	20-Aug-10	11-Oct-16	31-Oct-17
3088	US9517205	http://59.45.142.240:8808/pdf/US9517205.pdf	Soluble needle arrays for delivery of influenza vaccines	Seqirus UK Limited	20-Aug-10	19-Aug-11	13-Dec-16
3089	US20180250 381	http://59.45.142.240:8808/pdf/US20180250381A1.pdf	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Not Available	20-Aug-10	12-Oct-17	6-Sep-18

3090	US20170119 872	http://59.45.142.240:8808/pdf/US20170119872A1.pdf	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Not Available	20-Aug-10	11-Oct-16	4-May-17
3091	US20130287 832	http://59.45.142.240:8808/pdf/US20130287832A1.pdf	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Novartis AG	20-Aug-10	19-Aug-11	31-Oct-13
3092	US20130157 876	http://59.45.142.240:8808/pdf/US20130157876A1.pdf	Systems and Methods for Detecting Antibiotic Resistance	TESSARAE, LLC	21-Aug-10	21-Feb-13	20-Jun-13
3093	US20130209 502	http://59.45.142.240:8808/pdf/US20130209502A1.pdf	ALUMINA NANOPARTICLE BIOCONJUGATES AND METHODS OF STIMULATING AN IMMUNE	HU HONG-MING	27-Aug-10	26-Aug-11	15-Aug-13
3094	US9254265	http://59.45.142.240:8808/pdf/US9254265.pdf	Small liposomes for delivery of immunogen encoding RNA	NOVARTIS AG	31-Aug-10	31-Aug-11	9-Feb-16
3095	US20130202 684	http://59.45.142.240:8808/pdf/US20130202684A1.pdf	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA	Lichtstrasse	31-Aug-10	31-Aug-11	8-Aug-13
3096	US20130195 969	http://59.45.142.240:8808/pdf/US20130195969A1.pdf	SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA	NOVARTIS AG	31-Aug-10	31-Aug-11	1-Aug-13
3097	US20130189 351	http://59.45.142.240:8808/pdf/US20130189351A1.pdf	LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA	NOVARTIS AG	31-Aug-10	31-Aug-11	25-Jul-13
3098	US9315530	http://59.45.142.240:8808/pdf/US9315530.pdf	Adsorption of immunopotentiators to insoluble metal salts	Novartis AG	1-Sep-10	1-Sep-11	19-Apr-16
3099	US20160213 776	http://59.45.142.240:8808/pdf/US20160213776A1.pdf	ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS	GlaxoSmithKline Biologicals SA	1-Sep-10	7-Apr-16	28-Jul-16
3100	US20130274 465	http://59.45.142.240:8808/pdf/US20130274465A1.pdf	ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS	IRM LLC	1-Sep-10	1-Sep-11	17-Oct-13
3101	US9580474	http://59.45.142.240:8808/pdf/US9580474.pdf	Polyionic papilloma virus-like particle (VLP) vaccines	THE JOHNS HOPKINS UNIVERSITY	8-Sep-10	8-Sep-11	28-Feb-17
3102	US20170327 543	http://59.45.142.240:8808/pdf/US20170327543A1.pdf	POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES	Not Available	8-Sep-10	31-Jan-17	16-Nov-17
3103	US20140050 753	http://59.45.142.240:8808/pdf/US20140050753A1.pdf	POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES	THE JOHNS HOPKINS UNIVERSITY	8-Sep-10	8-Sep-11	20-Feb-14
3104	US9565857	http://59.45.142.240:8808/pdf/US9565857.pdf	Antimicrobial solutions	Board of Regents, The University of	10-Sep-10	9-Sep-11	14-Feb-17
3105	US20130231 302	http://59.45.142.240:8808/pdf/US20130231302A1.pdf	ANTIMICROBIAL SOLUTIONS	BOARD OF REGENTS, THE UNIVERSITY OF	10-Sep-10	9-Sep-11	5-Sep-13
3106	US9290760	http://59.45.142.240:8808/pdf/US9290760.pdf	Modified iRNA agents	ALNYLAM PHARMACEUTICALS, INC.	15-Sep-10	14-Sep-11	22-Mar-16
3107	US20130317 080	http://59.45.142.240:8808/pdf/US20130317080A1.pdf	MODIFIED iRNA AGENTS	ALNYLAM PHARMACEUTICALS, INC.	15-Sep-10	14-Sep-11	28-Nov-13
3108	US9657278	http://59.45.142.240:8808/pdf/US9657278.pdf	Methods to produce bunyavirus replicon particles	Stichting Dienst Landbouwkundig Onderzoek	20-Sep-10	10-Jul-15	23-May-17
3109	US9321847	http://59.45.142.240:8808/pdf/US9321847.pdf	Activatable toxin complexes comprising a cleavable inhibitory	RAMOT at Tel Aviv University Ltd.	20-Sep-10	22-Aug-11	26-Apr-16
3110	US9109199	http://59.45.142.240:8808/pdf/US9109199.pdf	Methods to produce bunyavirus replicon particles	STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK	20-Sep-10	20-Sep-11	18-Aug-15
3111	US20160002 608	http://59.45.142.240:8808/pdf/US20160002608A1.pdf	METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES	Not Available	20-Sep-10	10-Jul-15	7-Jan-16
3112	US20130236 493	http://59.45.142.240:8808/pdf/US20130236493A1.pdf	METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES	STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK	20-Sep-10	20-Sep-11	12-Sep-13
3113	US20130210 894	http://59.45.142.240:8808/pdf/US20130210894A1.pdf	APPLICATION OF HIGHLY CONSERVED DOMAIN SEQUENCES FROM VIRAL GENOME AS TEMPLATE	CHEN LI	20-Sep-10	19-Sep-11	15-Aug-13
3114	US20130202 598	http://59.45.142.240:8808/pdf/US20130202598A1.pdf	ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY	RAMOT AT TEL-AVIV UNIVERSITY LTD.	20-Sep-10	22-Aug-11	8-Aug-13
3115	US9872895	http://59.45.142.240:8808/pdf/US9872895.pdf	TLR5 ligands, therapeutic methods, and compositions related thereto	Emory University	24-Sep-10	20-Sep-11	23-Jan-18
3116	US8809377	http://59.45.142.240:8808/pdf/US8809377.pdf	Deubiquitinase inhibitors and methods for use of the same	The Regents of the University of Michigan	24-Sep-10	23-Sep-11	19-Aug-14
3117	US20150165 009	http://59.45.142.240:8808/pdf/US20150165009A1.pdf	TLR5 LIGANDS, THERAPEUTIC METHODS, AND COMPOSITIONS RELATED THERETO	Emory University	24-Sep-10	20-Sep-11	18-Jun-15
3118	US20140357 673	http://59.45.142.240:8808/pdf/US20140357673A1.pdf	Deubiquitinase Inhibitors and Methods for Use of the Same	Not Available	24-Sep-10	31-Jul-14	4-Dec-14
3119	US20130291 134	http://59.45.142.240:8808/pdf/US20130291134A1.pdf	HUMANIZED TRANSGENIC MOUSE MODEL	BRUMEANU TEPDPR D	24-Sep-10	22-Aug-12	31-Oct-13
3120	US9138472	http://59.45.142.240:8808/pdf/US9138472.pdf	CD40L vaccines, compositions, and methods related thereto	EMORY UNIVERSITY	28-Sep-10	28-Sep-11	22-Sep-15
3121	US8758680	http://59.45.142.240:8808/pdf/US8758680.pdf	Method and device for cleaning air	Not Available	29-Sep-10	27-Sep-11	24-Jun-14
3122	US9382288	http://59.45.142.240:8808/pdf/US9382288.pdf	Derivatives of steroid benzylamines, having an antiparasitic antibacterial,	Justus-Liebig-Universitat Giessen	6-Oct-10	6-Oct-11	5-Jul-16
3123	US8933210	http://59.45.142.240:8808/pdf/US8933210.pdf	Label-free functional nucleic acid sensors for detecting target agents	The Board of Trustees of the Massachusetts Institute of Technology	6-Oct-10	6-Oct-11	13-Jan-15
3124	US20130266 645	http://59.45.142.240:8808/pdf/US20130266645A1.pdf	DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL	Justus-Liebig-Universitat Giessen	6-Oct-10	6-Oct-11	10-Oct-13
3125	US20140011 812	http://59.45.142.240:8808/pdf/US20140011812A1.pdf	Methods of Treating Inflammation	Massachusetts Institute of Technology	8-Oct-10	7-Oct-11	9-Jan-14
3126	US9701736	http://59.45.142.240:8808/pdf/US9701736.pdf	Influenza hemagglutinin-specific monoclonal antibodies for preventing	New York Blood Center, Inc.	20-Oct-10	9-Oct-14	11-Jul-17
3127	US8900585	http://59.45.142.240:8808/pdf/US8900585.pdf	Influenza hemagglutinin-specific monoclonal antibodies for preventing	New York Blood Center, Inc.	20-Oct-10	20-Oct-11	2-Dec-14
3128	US20150030 607	http://59.45.142.240:8808/pdf/US20150030607A1.pdf	INFLUENZA HEMAGGLUTININ-SPECIFIC MONOCLONAL ANTIBODIES FOR PREVENTING AND TREATING INFLUENZA VIRUS	Not Available	20-Oct-10	9-Oct-14	29-Jan-15
3129	US20130288 917	http://59.45.142.240:8808/pdf/US20130288917A1.pdf	Rapid High Resolution, High Throughput RNA Structure, RNA-Macromolecular Interaction, and RNA-Small Molecule Interaction	The Board of Trustees of the Leland Stanford Junior University	21-Oct-10	21-Oct-11	31-Oct-13

3130	US9310375	http://59.45.142.240:8808/pdf/US9310375.pdf	Luminophore-labeled molecules coupled with particles for	CapitalBio Corporation	27-Oct-10	27-Oct-10	12-Apr-16
3131	US20130267 436	http://59.45.142.240:8808/pdf/US20130267436A1.pdf	LUMINOPHORE-LABELED MOLECULES COUPLED WITH	CapitaBio Corporation	27-Oct-10	27-Oct-10	10-Oct-13
3132	US20130230 856	http://59.45.142.240:8808/pdf/US20130230856A1.pdf	CAPTURE OF TARGET DNA AND RNA BY PROBES COMPRISING	QUANTIBACT A/S	27-Oct-10	27-Oct-11	5-Sep-13
3133	US9821051	http://59.45.142.240:8808/pdf/US9821051.pdf	Reducing hospitalization in elderly influenza vaccine recipients	Seqirus UK Limited	28-Oct-10	21-Oct-11	21-Nov-17
3134	US9029315	http://59.45.142.240:8808/pdf/US9029315.pdf	Soluble PD-1 variants, fusion constructs, and uses thereof	The University of Hong Kong	11-Nov-10	11-Nov-11	12-May-15
3135	US20160317 496	http://59.45.142.240:8808/pdf/US20160317496A1.pdf	METHODS OF TREATING CANCER AND OTHER DISORDERS	Not Available	12-Nov-10	27-Jun-16	3-Nov-16
3136	US20130345 270	http://59.45.142.240:8808/pdf/US20130345270A1.pdf	METHODS OF TREATING CANCER AND OTHER DISORDERS	Waake Forest University Health	12-Nov-10	7-Nov-11	26-Dec-13
3137	US10071076	http://59.45.142.240:8808/pdf/US10071076.pdf	Methods of treating cancer and other disorders	Wake Forest University Health	12-Nov-10	27-Jun-16	11-Sep-18
3138	US8658767	http://59.45.142.240:8808/pdf/US8658767.pdf	Lipidated polypeptide vaccines	National Health Research Institutes	15-Nov-10	15-Nov-11	25-Feb-14
3139	US20130267 532	http://59.45.142.240:8808/pdf/US20130267532A1.pdf	CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF	HORI SEIJI	19-Nov-10	18-Nov-11	10-Oct-13
3140	US8877060	http://59.45.142.240:8808/pdf/US8877060.pdf	Methods for removing pathogens from a platelet preparation	Biovec Transfusion, LLC	23-Nov-10	31-Oct-11	4-Nov-14
3141	US20140087 363	http://59.45.142.240:8808/pdf/US20140087363A1.pdf	METHOD FOR GENERATING, STORING, TRANSPORTING, ELUTING AND DETECTING CLINICAL RELEVANT INFORMATION IN	HVIDOVRE HOSPITAL	9-Dec-10	9-Dec-11	27-Mar-14
3142	US20140242 692	http://59.45.142.240:8808/pdf/US20140242692A1.pdf	MAMMALIAN GENES INVOLVED IN TOXICITY AND INFECTION	Not Available	10-Dec-10	11-Dec-11	28-Aug-14
3143	US10202615	http://59.45.142.240:8808/pdf/US10202615.pdf	Mammalian genes involved in toxicity and infection	VANDERBILT UNIVERSITY	10-Dec-10	11-Dec-11	12-Feb-19
3144	US9618508	http://59.45.142.240:8808/pdf/US9618508.pdf	Flow cytometry analysis of materials adsorbed to metal cake	GlaxoSmithKline Biologicals SA	14-Dec-10	14-Dec-11	11-Apr-17
3145	US9376486	http://59.45.142.240:8808/pdf/US9376486.pdf	Human monoclonal antibody with specificity for Dengue virus serotype	DSO National Laboratories	14-Dec-10	14-Dec-11	28-Jun-16
3146	US20170029 489	http://59.45.142.240:8808/pdf/US20170029489A1.pdf	HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND	Not Available	14-Dec-10	1-Jun-16	2-Feb-17
3147	US20160058 012	http://59.45.142.240:8808/pdf/US20160058012A1.pdf	WEAR RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE	Not Available	14-Dec-10	24-Sep-15	3-Mar-16
3148	US20130330 840	http://59.45.142.240:8808/pdf/US20130330840A1.pdf	FLOW CYTOMETRY ANALYSIS OF MATERIALS ADSORBED TO METAL	NOVARTIS AG	14-Dec-10	14-Dec-11	12-Dec-13
3149	US20130259 871	http://59.45.142.240:8808/pdf/US20130259871A1.pdf	Human Monoclonal Antibody with Specificity for Dengue Virus	DSO NATIONAL LABORATORIES	14-Dec-10	14-Dec-11	3-Oct-13
3150	US10294293	http://59.45.142.240:8808/pdf/US10294293.pdf	Human monoclonal antibody with specificity for dengue virus serotype	DSO National Laboratories	14-Dec-10	1-Jun-16	21-May-19
3151	US9045472	http://59.45.142.240:8808/pdf/US9045472.pdf	Imidazoquinoline compounds	ASTRAZENECA AB	16-Dec-10	16-Dec-11	2-Jun-15
3152	US8895570	http://59.45.142.240:8808/pdf/US8895570.pdf	Purine derivatives	AstraZeneca AB	17-Dec-10	14-Dec-11	25-Nov-14
3153	US20130338 174	http://59.45.142.240:8808/pdf/US20130338174A1.pdf	PURINE DERIVATIVES	ABBOTT PHILLIP	17-Dec-10	14-Dec-11	19-Dec-13
3154	US9255144	http://59.45.142.240:8808/pdf/US9255144.pdf	Anti-IL-18 antibodies and their uses	MedImmune Limited	20-Dec-10	20-Dec-11	9-Feb-16
3155	US20140004 128	http://59.45.142.240:8808/pdf/US20140004128A1.pdf	ANTI-IL-18 ANTIBODIES AND THEIR USES	Medimmune Limited	20-Dec-10	20-Dec-11	2-Jan-14
3156	US20130344 100	http://59.45.142.240:8808/pdf/US20130344100A1.pdf	VIRUS LIKE PARTICLE PRODUCTION IN PLANTS	MEDICAGO INC.	22-Dec-10	22-Dec-11	26-Dec-13
3157	US9487838	http://59.45.142.240:8808/pdf/US9487838.pdf	Oligonucleotide probe for the detection of adenovirus	QIAGEN HAMBURG GMBH	28-Dec-10	28-Dec-10	8-Nov-16
3158	US20140106 335	http://59.45.142.240:8808/pdf/US20140106335A1.pdf	OLIGONUCLEOTIDE PROBE FOR THE DETECTION OF ADENOVIRUS	Qiagen Hamburg GMBH	28-Dec-10	28-Dec-10	17-Apr-14
3159	US20140050 778	http://59.45.142.240:8808/pdf/US20140050778A1.pdf	NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING AND USE THEREOF	UNIVERSITY OF ROCHESTER	28-Dec-10	28-Dec-11	20-Feb-14
3160	US9435795	http://59.45.142.240:8808/pdf/US9435795.pdf	Enhanced deposition of chromogens utilizing pyrimidine analogs	Ventana Medical Systems, Inc.	30-Dec-10	6-Oct-14	6-Sep-16
3161	US8871442	http://59.45.142.240:8808/pdf/US8871442.pdf	Enhanced deposition of chromogens	Ventana Medical Systems, Inc.	30-Dec-10	28-Dec-11	28-Oct-14
3162	US20150024 405	http://59.45.142.240:8808/pdf/US20150024405A1.pdf	ENHANCED DEPOSITION OF CHROMOGENS UTILIZING PYRIMIDINE ANALOGS	Ventana Medical Systems, Inc.	30-Dec-10	6-Oct-14	22-Jan-15
3163	US20140294 828	http://59.45.142.240:8808/pdf/US20140294828A1.pdf	ALPHABODIES SPECIFICALLY BINDING TO VIRAL PROTEINS AND METHODS FOR PRODUCING THE	COMPLIX SA	6-Jan-11	6-Jan-11	2-Oct-14
3164	US20130261 049	http://59.45.142.240:8808/pdf/US20130261049A1.pdf	ALPHABODIES SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION PROTEINS AND METHODS FOR	COMPLIX SA	6-Jan-11	2-Dec-11	3-Oct-13
3165	US9580468	http://59.45.142.240:8808/pdf/US9580468.pdf	Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	CENTRE DE INVESTIGACION BIOMEDICA EN REDBIOINGENIERIA BIOMATERIALES Y NANOMEDICINA	13-Jan-11	13-Jan-12	28-Feb-17
3166	US20190183 968	http://59.45.142.240:8808/pdf/US20190183968A1.pdf	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC	Not Available	13-Jan-11	27-Feb-19	20-Jun-19
3167	US20170209 590	http://59.45.142.240:8808/pdf/US20170209590A1.pdf	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC	Not Available	13-Jan-11	10-Jan-17	27-Jul-17
3168	US20140094 404	http://59.45.142.240:8808/pdf/US20140094404A1.pdf	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC	Not Available	13-Jan-11	13-Jan-12	3-Apr-14

3169	US10265371	http://59.45.142.240:8808/pdf/US10265371.pdf	Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA	13-Jan-11	10-Jan-17	23-Apr-19
3170	US9303000	http://59.45.142.240:8808/pdf/US9303000.pdf	Olefin containing nuclear transport modulators and uses thereof	KARYOPHARM THERAPEUTICS INC	17-Jan-11	16-Jan-12	5-Apr-16
3171	US20140154 282	http://59.45.142.240:8808/pdf/US20140154282A1.pdf	CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR STIMULATING IMMUNE RESPONSE	Not Available	26-Jan-11	26-Jan-12	5-Jun-14
3172	US8691777	http://59.45.142.240:8808/pdf/US8691777.pdf	Combination therapy	Emory University	27-Jan-11	25-Jan-12	8-Apr-14
3173	US20140017 279	http://59.45.142.240:8808/pdf/US20140017279A1.pdf	ADJUVANT NANOEMULSIONS WITH CRYSTALLISATION INHIBITORS	Novartis AG	27-Jan-11	27-Jan-12	16-Jan-14
3174	US10286056	http://59.45.142.240:8808/pdf/US10286056B2.pdf	Adjuvant nanoemulsions with crystallization inhibitors	GLAXOSMITHKLINE BIOLOGICALS S.A	27-Jan-11	27-Jan-12	14-May-19
3175	US9669092	http://59.45.142.240:8808/pdf/US9669092.pdf	Antagonism of the VIP signaling pathway	Emory University	2-Feb-11	31-Jan-12	6-Jun-17
3176	US20170258 904	http://59.45.142.240:8808/pdf/US20170258904A1.pdf	Antagonism of the VIP Signaling Pathway	Not Available	2-Feb-11	22-May-17	14-Sep-17
3177	US20130302 351	http://59.45.142.240:8808/pdf/US20130302351A1.pdf	ANTAGONISM OF THE VIP SIGNALING PATHWAY	EMORY UNIVERSITY	2-Feb-11	31-Jan-12	14-Nov-13
3178	US20140127 216	http://59.45.142.240:8808/pdf/US20140127216A1.pdf	NOVEL EXPRESSION CASSETTE FOR EFFICIENT SURFACE DISPLAY OF ANTIGENIC PROTEINS	Temasek Life Sciences Laboratory	8-Feb-11	8-Feb-12	8-May-14
3179	US10202617	http://59.45.142.240:8808/pdf/US10202617.pdf	Expression cassette for efficient surface display of antigenic proteins	Temasek Life Sciences Laboratory	8-Feb-11	8-Feb-12	12-Feb-19
3180	US20140199 347	http://59.45.142.240:8808/pdf/US20140199347A1.pdf	ADJUVANT COMPOSITIONS WITH 4-1BBL	UNIVERSITY OF LOUISVILLE RESEARCH	10-Feb-11	7-Feb-12	17-Jul-14
3181	US20140141 986	http://59.45.142.240:8808/pdf/US20140141986A1.pdf	CIRCULATING BIOMARKERS	Not Available	22-Feb-11	17-Feb-12	22-May-14
3182	US20140073 651	http://59.45.142.240:8808/pdf/US20140073651A1.pdf	BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	Actelion Pharmaceuticals Ltd	22-Feb-11	21-Feb-12	13-Mar-14
3183	US9915613	http://59.45.142.240:8808/pdf/US9915613.pdf	Systems and methods for distinguishing optical signals of different modulation frequencies in	GEN-PROBE INCORPORATED	24-Feb-11	21-Mar-14	13-Mar-18
3184	US9885092	http://59.45.142.240:8808/pdf/US9885092.pdf	Materials and methods for detection of HPV nucleic acids	QIAGEN GAITHERSBURG INC	24-Feb-11	23-Feb-12	6-Feb-18
3185	US8718948	http://59.45.142.240:8808/pdf/US8718948.pdf	Systems and methods for distinguishing optical signals of different modulation frequencies in	Gen-Probe Incorporated	24-Feb-11	24-Feb-12	6-May-14
3186	US20140203 192	http://59.45.142.240:8808/pdf/US20140203192A1.pdf	SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL	Gen-Probe Incorporated	24-Feb-11	21-Mar-14	24-Jul-14
3187	US20140203 189	http://59.45.142.240:8808/pdf/US20140203189A1.pdf	SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL	GEN-PROBE INCORPORATED	24-Feb-11	21-Mar-14	24-Jul-14
3188	US10641707	http://59.45.142.240:8808/pdf/US10641707.pdf	Systems and methods for distinguishing optical signals of different modulation frequencies in	Gen-Probe Incorporated	24-Feb-11	21-Mar-14	5-May-20
3189	US9458492	http://59.45.142.240:8808/pdf/US9458492.pdf	Methods and cells for identifying RIG-I pathway regulators	Kineta, Inc.	25-Feb-11	23-Feb-12	4-Oct-16
3190	US20130336 929	http://59.45.142.240:8808/pdf/US20130336929A1.pdf	METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS	KINETA, INC.	25-Feb-11	23-Feb-12	19-Dec-13
3191	US9796979	http://59.45.142.240:8808/pdf/US9796979.pdf	Oligonucleotide modulators of the toll-like receptor pathway	Quark Pharmaceuticals, Inc	3-Mar-11	28-Jul-16	24-Oct-17
3192	US9487778	http://59.45.142.240:8808/pdf/US9487778.pdf	Oligonucleotide modulators of the toll-like receptor pathway	QUARK PHARMACEUTICALS, INC	3-Mar-11	1-Mar-12	8-Nov-16
3193	US20160333 356	http://59.45.142.240:8808/pdf/US20160333356A1.pdf	OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY	Not Available	3-Mar-11	28-Jul-16	17-Nov-16
3194	US20140329 878	http://59.45.142.240:8808/pdf/US20140329878A1.pdf	OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY	Not Available	3-Mar-11	1-Mar-12	6-Nov-14
3195	US20200085 984	http://59.45.142.240:8808/pdf/US20200085984A1.pdf	APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE	7-Mar-11	25-Nov-19	19-Mar-20
3196	US20170234 781	http://59.45.142.240:8808/pdf/US20170234781A1.pdf	MEMBRANE-ASSISTED PURIFICATION	Accelerate Diagnostics, Inc	7-Mar-11	3-May-17	17-Aug-17
3197	US10254204	http://59.45.142.240:8808/pdf/US10254204.pdf	Membrane-assisted purification	Accelerate Diagnostics, Inc	7-Mar-11	3-May-17	9-Apr-19
3198	US9809591	http://59.45.142.240:8808/pdf/US9809591.pdf	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc	8-Mar-11	5-Oct-15	7-Nov-17
3199	US9624173	http://59.45.142.240:8808/pdf/US9624173.pdf	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc	8-Mar-11	19-Mar-15	18-Apr-17
3200	US8871790	http://59.45.142.240:8808/pdf/US8871790.pdf	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc	8-Mar-11	8-Mar-12	28-Oct-14
3201	US20190269 694	http://59.45.142.240:8808/pdf/US20190269694A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8-Mar-11	11-Oct-18	5-Sep-19
3202	US20170119 786	http://59.45.142.240:8808/pdf/US20170119786A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8-Mar-11	11-Nov-16	4-May-17
3203	US20160102 091	http://59.45.142.240:8808/pdf/US20160102091A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	3-V BIOSCIENCES, INC	8-Mar-11	5-Oct-15	14-Apr-16
3204	US20150259 292	http://59.45.142.240:8808/pdf/US20150259292A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8-Mar-11	19-Mar-15	17-Sep-15
3205	US20140322 355	http://59.45.142.240:8808/pdf/US20140322355A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	3-V BIOSCIENCES, INC	8-Mar-11	25-Jun-14	30-Oct-14
3206	US20140082 769	http://59.45.142.240:8808/pdf/US20140082769A1.pdf	MOLECULES AND METHODS FOR INHIBITION AND DETECTION OF PROTEIN	Not Available	11-Mar-11	12-Mar-12	20-Mar-14
3207	US20140004 146	http://59.45.142.240:8808/pdf/US20140004146A1.pdf	METHOD FOR PRODUCING VIRUS-LIKE PARTICLE BY USING DROSOPHILA CELL AND	INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY	17-Mar-11	19-Mar-12	2-Jan-14
3208	US9585953	http://59.45.142.240:8808/pdf/US9585953.pdf	Immunogenic compositions in particulate form and methods for	MUCOSIS B.V.	22-Mar-11	22-Mar-12	7-Mar-17
3209	US20140093 532	http://59.45.142.240:8808/pdf/US20140093532A1.pdf	Immunogenic Compositions In Particulate Form And Methods For	MUCOSIS B.V.	22-Mar-11	22-Mar-12	3-Apr-14

3210	US20140017 285	http://59.45.142.240:8808/pdf/US20140017285A1.pdf	ADJUVANT NANOEMULSIONS WITH PHOSPHOLIPIDS	NOVARTIS AG	24-Mar-11	23-Mar-12	16-Jan-14
3211	US10357568	http://59.45.142.240:8808/pdf/US10357568.pdf	Adjuvant nanoemulsions with phospholipids	GLAXOSMITHKLINE BIOLOGICALS S.A.	24-Mar-11	23-Mar-12	23-Jul-19
3212	US9914976	http://59.45.142.240:8808/pdf/US9914976.pdf	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL	25-Mar-11	27-May-16	13-Mar-18
3213	US9382590	http://59.45.142.240:8808/pdf/US9382590.pdf	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL	25-Mar-11	20-May-15	5-Jul-16
3214	US9051619	http://59.45.142.240:8808/pdf/US9051619.pdf	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL	25-Mar-11	23-Mar-12	9-Jun-15
3215	US20160326 598	http://59.45.142.240:8808/pdf/US20160326598A1.pdf	METHODS AND COMPOSITIONS FOR PROSTATE CANCER METASTASIS	Not Available	25-Mar-11	27-May-16	10-Nov-16
3216	US20150252 439	http://59.45.142.240:8808/pdf/US20150252439A1.pdf	Methods and Compositions for Prostate Cancer Metastasis	Not Available	25-Mar-11	20-May-15	10-Sep-15
3217	US20140248 620	http://59.45.142.240:8808/pdf/US20140248620A1.pdf	Methods and Compositions for Prostate Cancer Metastasis	Florida Agricultural and Mechanical	25-Mar-11	23-Mar-12	4-Sep-14
3218	US20170239 364	http://59.45.142.240:8808/pdf/US20170239364A1.pdf	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	Not Available	28-Mar-11	2-Mar-17	24-Aug-17
3219	US20140323 392	http://59.45.142.240:8808/pdf/US20140323392A1.pdf	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	UNIVERSITY OF UTAH RESEARCH FOUNDATION	28-Mar-11	28-Mar-12	30-Oct-14
3220	US10406229	http://59.45.142.240:8808/pdf/US10406229.pdf	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	28-Mar-11	2-Mar-17	10-Sep-19
3221	US9365523	http://59.45.142.240:8808/pdf/US9365523.pdf	Imidazolyl amide compounds and uses related thereto	Children's Healthcare of	31-Mar-11	28-Mar-12	14-Jun-16
3222	US9102938	http://59.45.142.240:8808/pdf/US9102938.pdf	2â€² and 5â€² modified monomers and oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	31-Mar-11	31-Mar-11	11-Aug-15
3223	US20140080 828	http://59.45.142.240:8808/pdf/US20140080828A1.pdf	IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO	CHILDREN'S HEALTHCARE OF ATLANTA, INC.	31-Mar-11	28-Mar-12	20-Mar-14
3224	US9895341	http://59.45.142.240:8808/pdf/US9895341.pdf	Inflammation and immunity treatments	Ocean Spray Cranberries, Inc.	1-Apr-11	30-Mar-12	20-Feb-18
3225	US20140134 206	http://59.45.142.240:8808/pdf/US20140134206A1.pdf	INFLAMMATION AND IMMUNITY TREATMENTS	OCEAN SPRAY CRANBERRIES, INC.	1-Apr-11	30-Mar-12	15-May-14
3226	US20140363 465	http://59.45.142.240:8808/pdf/US20140363465A1.pdf	MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE SAME	Beth Israel Deaconess Medical Center	4-Apr-11	4-Apr-12	11-Dec-14
3227	US20150139 949		ANTI-VIRAL COMBINATION THERAPY	Not Available	6-Apr-11	19-May-14	21-May-15
3228	US9044420	http://59.45.142.240:8808/pdf/US9044420.pdf	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular	IMMUNE DESIGN CORP.	8-Apr-11	6-Apr-12	2-Jun-15
3229	US20150335 733	http://59.45.142.240:8808/pdf/US20150335733A1.pdf	Immunogenic Composition and Methods of Using the Compositions for Inducing Humoral and Cellular	Not Available	8-Apr-11	27-Apr-15	26-Nov-15
3230	US9409987	http://59.45.142.240:8808/pdf/US9409987.pdf	Polypeptides and polynucleotides, and uses thereof for treatment of	COMPUGEN LTD	15-Apr-11	16-Apr-12	9-Aug-16
3231	US20180194 829	http://59.45.142.240:8808/pdf/US20180194829A1.pdf	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND	Not Available	15-Apr-11	13-Nov-17	12-Jul-18
3232	US20170304 354	http://59.45.142.240:8808/pdf/US20170304354A1.pdf	TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE	Marine Polymer Technologies, Inc.	15-Apr-11	13-Mar-17	26-Oct-17
3233	US20160347 816	http://59.45.142.240:8808/pdf/US20160347816A1.pdf	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND	Not Available	15-Apr-11	29-Feb-16	1-Dec-16
3234	US20140127 310	http://59.45.142.240:8808/pdf/US20140127310A1.pdf	TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE	Marine Polymer Technologies, Inc.	15-Apr-11	16-Apr-12	8-May-14
3235	US20140044 641	http://59.45.142.240:8808/pdf/US20140044641A1.pdf	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND	COMPUGEN LTD.	15-Apr-11	16-Apr-12	13-Feb-14
3236	US9132175	http://59.45.142.240:8808/pdf/US9132175.pdf	Bacillus based delivery system and methods of use	The Curators of the University of	18-Apr-11	18-Apr-11	15-Sep-15
3237	US20160053 222	http://59.45.142.240:8808/pdf/US20160053222A1.pdf	BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE	Not Available	18-Apr-11	9-Sep-15	25-Feb-16
3238	US20190216 841	http://59.45.142.240:8808/pdf/US20190216841A1.pdf	Regimens and Compositions for AAV-Mediated Passive Immunization of	Not Available	20-Apr-11	20-Mar-19	18-Jul-19
3239	US20140037 700	http://59.45.142.240:8808/pdf/US20140037700A1.pdf	Composition and Method for Enhancing an Immune Response	MICO BIO, INC.	20-Apr-11	19-Apr-12	6-Feb-14
3240	US20140031 418	http://59.45.142.240:8808/pdf/US20140031418A1.pdf	Regimens and Compositions for AAV-Mediated Passive Immunization of	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	20-Apr-11	20-Apr-12	30-Jan-14
3241	US9802937	http://59.45.142.240:8808/pdf/US9802937.pdf	Substituted pyrazolo[4,3- <i>b</i>]pyrimidines as kinase inhibitors	ORIGENIS GMBH	21-Apr-11	23-Apr-12	31-Oct-17
3242	US9499535	http://59.45.142.240:8808/pdf/US9499535.pdf	Kinase inhibitors	ORIGENIS GMBH	21-Apr-11	23-Apr-12	22-Nov-16
3243	US20140038 174	http://59.45.142.240:8808/pdf/US20140038174A1.pdf	Compositions and Methods for Detecting and Identifying Nucleic	LONGHORN VACCINES AND DIAGNOSTICS, LLC	26-Apr-11	8-Oct-13	6-Feb-14
3244	US8741564	http://59.45.142.240:8808/pdf/US8741564.pdf	Quantitative nuclease protection assay (QNPA) and sequencing	HTG Molecular Diagnostics, Inc.	4-May-11	26-Apr-12	3-Jun-14
3245	US20140235 460	http://59.45.142.240:8808/pdf/US20140235460A1.pdf	QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND SEQUENCING (QNPS)	HTG Molecular Diagnostics, Inc.	4-May-11	1-May-14	21-Aug-14
3246	US20140087 954	http://59.45.142.240:8808/pdf/US20140087954A1.pdf	QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND SEQUENCING (QNPS)	HTG Molecular Diagnostics, Inc.	4-May-11	26-Apr-12	27-Mar-14
3247	US9833504	http://59.45.142.240:8808/pdf/US9833504.pdf	Virus-like particles and process for preparing same	Folia Biotech Inc.	13-May-11	1-May-12	5-Dec-17
3248	US20140255 439	http://59.45.142.240:8808/pdf/US20140255439A1.pdf	VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME	FOLIA BIOTECH INC.	13-May-11	1-May-12	11-Sep-14

3249	US20140154 288	http://59.45.142.240:8808/pdf/US20140154288A1.pdf	PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE	FOLIA BIOTECH INC.	13-May-11	1-May-12	5-Jun-14
3250	US9880151	http://59.45.142.240:8808/pdf/US9880151.pdf	Method of determining, identifying or isolating cell-penetrating peptides	Phylogica Limited	23-May-11	23-May-12	30-Jan-18
3251	US20180209 960	http://59.45.142.240:8808/pdf/US20180209960A1.pdf	Method of Determining, Identifying or Isolating Cell-Penetrating Peptides	Not Available	23-May-11	11-Dec-17	26-Jul-18
3252	US20140141 452	http://59.45.142.240:8808/pdf/US20140141452A1.pdf	Method of Determining, Identifying or Isolating Cell-Penetrating Peptides	Phylogica Limited	23-May-11	23-May-12	22-May-14
3253	US10288601	http://59.45.142.240:8808/pdf/US10288601B2.pdf	Method of determining, identifying or isolating cell-penetrating peptides	Phylogica Limited	23-May-11	11-Dec-17	14-May-19
3254	US20160311 835		NOVEL ANTIBIOTICS	Not Available	26-May-11	30-Nov-15	27-Oct-16
3255	US9512181	http://59.45.142.240:8808/pdf/US9512181.pdf	Fusion proteins of ciliate granule lattice proteins, granular protein	Tetragenetics, Inc.	27-May-11	29-May-12	6-Dec-16
3256	US20150125 483	http://59.45.142.240:8808/pdf/US20150125483A1.pdf	FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS, GRANULAR PROTEIN PARTICLES	Tetragenetics, Inc.	27-May-11	29-May-12	7-May-15
3257	US9346866	http://59.45.142.240:8808/pdf/US9346866.pdf	Inhibition of tace activity with cyclic peptides	The Regents of the University of California	2-Jun-11	19-Sep-14	24-May-16
3258	US20160303 194	http://59.45.142.240:8808/pdf/US20160303194A1.pdf	Compositions And Method For Treatment Of Inflammatory Bowel	Not Available	2-Jun-11	21-Apr-16	20-Oct-16
3259	US20150080 319	http://59.45.142.240:8808/pdf/US20150080319A1.pdf	Inhibition Of Tace Activity With Cyclic Peptides	Not Available	2-Jun-11	19-Sep-14	19-Mar-15
3260	US20130157 964	http://59.45.142.240:8808/pdf/US20130157964A1.pdf	Blockade Of Inflammatory Proteases With Cyclic Peptides	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	2-Jun-11	1-Jun-12	20-Jun-13
3261	US10603356	http://59.45.142.240:8808/pdf/US10603356.pdf	Compositions and method for treatment of inflammatory bowel	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	2-Jun-11	21-Apr-16	31-Mar-20
3262	US10512669	http://59.45.142.240:8808/pdf/US10512669B2.pdf	Blockade of inflammatory proteases with cyclic peptides	The Regents of the University of California	2-Jun-11	1-Jun-12	24-Dec-19
3263	US9585968	http://59.45.142.240:8808/pdf/US9585968.pdf	Hydrazino 1H-imidazoquinolin-4- amines and conjugates made	3M Innovative Properties Company	3-Jun-11	14-Aug-15	7-Mar-17
3264	US9475804	http://59.45.142.240:8808/pdf/US9475804.pdf	Heterobifunctional linkers with polyethylene glycol segments and immune response modifier	3M Innovative Properties Company	3-Jun-11	1-Jun-12	25-Oct-16
3265	US9107958	http://59.45.142.240:8808/pdf/US9107958.pdf	Hydrazino 1H-imidazoquinolin-4- amines and conjugates made	3M Innovative Properties Company	3-Jun-11	1-Jun-12	18-Aug-15
3266	US20180186 792	http://59.45.142.240:8808/pdf/US20180186792A1.pdf	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE	3M Innovative Properties Company	3-Jun-11	26-Feb-18	5-Jul-18
3267	US20170173 164		HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE	Not Available	3-Jun-11	6-Mar-17	22-Jun-17
3268	US20170037 045	http://59.45.142.240:8808/pdf/US20170037045A1.pdf	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE	3M Innovative Properties Company	3-Jun-11	24-Oct-16	9-Feb-17
3269	US20150352 218	http://59.45.142.240:8808/pdf/US20150352218A1.pdf	HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE	3M INNOVATIVE PROPERTIES	3-Jun-11	14-Aug-15	10-Dec-15
3270	US20140286 988	http://59.45.142.240:8808/pdf/US20140286988A1.pdf	HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE	3M Innovative Properties Company	3-Jun-11	1-Jun-12	25-Sep-14
3271	US20140227 317	http://59.45.142.240:8808/pdf/US20140227317A1.pdf	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE	3M INNOVATIVE PROPERTIES COMPANY	3-Jun-11	1-Jun-12	14-Aug-14
3272	US10406142	http://59.45.142.240:8808/pdf/US10406142.pdf	Hydrazino 1H-imidazoquinolin-4- amines and conjugates made	3M Innovative Properties Company	3-Jun-11	6-Mar-17	10-Sep-19
3273	US9181290	http://59.45.142.240:8808/pdf/US9181290.pdf	Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D-	CHANG GUNG UNIVERSITY	17-Jun-11	19-Sep-11	10-Nov-15
3274	US20140314 739	http://59.45.142.240:8808/pdf/US20140314739A1.pdf	Vaccine adjuvant composition comprising inulin particles	Vaxine Pty Ltd.	18-Jun-11	19-Jun-12	23-Oct-14
3275	US9655896	http://59.45.142.240:8808/pdf/US9655896.pdf	Chemically and metabolically stable dipeptide possessing potent sodium	PARION SCIENCES, INC.	27-Jun-11	12-Jan-15	23-May-17
3276	US9586910	http://59.45.142.240:8808/pdf/US9586910.pdf	3,5-diamino-6-chloro-N-(N-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)p phenyl)butyl)carbamimidoyl)pyra	Parion Sciences, Inc.	27-Jun-11	18-Dec-13	7-Mar-17
3277	US9072738	http://59.45.142.240:8808/pdf/US9072738.pdf	Chemically and metabolically stable dipeptide possessing potent sodium	PARION SCIENCES, INC.	27-Jun-11	27-Jun-12	7-Jul-15
3278	US8669262	http://59.45.142.240:8808/pdf/US8669262.pdf	3,5-diamino-6-chloro-N-(N-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)p phenyl)butyl)carbamimidoyl)pyra	Parion Sciences, Inc.	27-Jun-11	26-Jun-12	11-Mar-14
3279	US20180104 241	http://59.45.142.240:8808/pdf/US20180104241A1.pdf	CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL	PARION SCIENCES, INC.	27-Jun-11	15-Dec-17	19-Apr-18
3280	US20170334 864	http://59.45.142.240:8808/pdf/US20170334864A1.pdf	3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-	Parion Sciences, Inc.	27-Jun-11	1-Mar-17	23-Nov-17
3281	US20150290 189	http://59.45.142.240:8808/pdf/US20150290189A1.pdf	CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL	PARION SCIENCES, INC.	27-Jun-11	12-Jan-15	15-Oct-15
3282	US20140142 118	http://59.45.142.240:8808/pdf/US20140142118A1.pdf	CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL	PARION SCIENCES, INC.	27-Jun-11	27-Jun-12	22-May-14

3283	US20140107 133	http://59.45.142.240:8808/pdf/US20140107133A1.pdf	3,5-DIAMINO-6-CHLORO-N-(N-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDE	Parion Sciences, Inc.	27-Jun-11	18-Dec-13	17-Apr-14
3284	US20130178 482	http://59.45.142.240:8808/pdf/US20130178482A1.pdf	3,5-DIAMINO-6-CHLORO-N-(N-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOPYRAZINE-2-	Parion Sciences, Inc.	27-Jun-11	26-Jun-12	11-Jul-13
3285	US10159672	http://59.45.142.240:8808/pdf/US10159672.pdf	Chemically and metabolically stable dipeptide possessing potent sodium channel blocking activity	PARION SCIENCES, INC.	27-Jun-11	15-Dec-17	25-Dec-18
3286	US20190112 394	http://59.45.142.240:8808/pdf/US20190112394A1.pdf	USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LABELING	Whitehead Institute for Biomedical Research	28-Jun-11	24-Sep-18	18-Apr-19
3287	US20140249 296	http://59.45.142.240:8808/pdf/US20140249296A1.pdf	USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LABELING	Whitehead Institute for Biomedical Research	28-Jun-11	28-Jun-12	4-Sep-14
3288	US20140134 699	http://59.45.142.240:8808/pdf/US20140134699A1.pdf	NOVEL STABILISATION METHOD FOR VIRUSES OR BACTERIA	Leukocare AG	28-Jun-11	28-Jun-12	15-May-14
3289	US20170211 096	http://59.45.142.240:8808/pdf/US20170211096A1.pdf	LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus-Producing Cells for the Therapy of	Not Available	29-Jun-11	7-Apr-17	27-Jul-17
3290	US9428574	http://59.45.142.240:8808/pdf/US9428574.pdf	Polypeptides and uses thereof for treatment of autoimmune disorders	COMPUGEN LTD.	30-Jun-11	1-Jul-12	30-Aug-16
3291	US20190248 866	http://59.45.142.240:8808/pdf/US20190248866A1.pdf	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES	Not Available	30-Jun-11	30-Apr-18	15-Aug-19
3292	US20160304 579	http://59.45.142.240:8808/pdf/US20160304579A1.pdf	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES	Not Available	30-Jun-11	29-Feb-16	20-Oct-16
3293	US20140255 349	http://59.45.142.240:8808/pdf/US20140255349A1.pdf	PEPTIDES WITH VIRAL INFECTION ENHANCING PROPERTIES AND METHODS OF USE	Centre National de la Recherche Scientifique	30-Jun-11	28-Jun-12	11-Sep-14
3294	US20140170 141	http://59.45.142.240:8808/pdf/US20140170141A1.pdf	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES AND INFECTION	COMPUGEN LTD.	30-Jun-11	1-Jul-12	19-Jun-14
3295	US10596264	http://59.45.142.240:8808/pdf/US10596264.pdf	Peptides with viral infection enhancing properties and their use	Centre National de la Recherche Scientifique	30-Jun-11	28-Jun-12	24-Mar-20
3296	US9655845	http://59.45.142.240:8808/pdf/US9655845.pdf	Oil-in-water emulsions that contain nucleic acids	GlaxoSmithKline Biologicals S.A.	6-Jul-11	6-Jul-12	23-May-17
3297	US9636410	http://59.45.142.240:8808/pdf/US9636410.pdf	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	6-Jul-12	2-May-17
3298	US9380785	http://59.45.142.240:8808/pdf/US9380785.pdf	Antiviral resin member	NBC MESHTEC, INC.	6-Jul-11	6-Jul-12	5-Jul-16
3299	US20200113 831	http://59.45.142.240:8808/pdf/US20200113831A1.pdf	LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	16-Dec-19	16-Apr-20
3300	US20190254 968	http://59.45.142.240:8808/pdf/US20190254968A1.pdf	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-11	2-May-19	22-Aug-19
3301	US20190091 329	http://59.45.142.240:8808/pdf/US20190091329A1.pdf	CATIONIC OIL-IN-WATER EMULSIONS	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	6-Dec-18	28-Mar-19
3302	US20170224 616	http://59.45.142.240:8808/pdf/US20170224616A1.pdf	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	24-Apr-17	10-Aug-17
3303	US20170202 960	http://59.45.142.240:8808/pdf/US20170202960A1.pdf	CATIONIC OIL-IN-WATER EMULSIONS	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	23-Mar-17	20-Jul-17
3304	US20140242 152	http://59.45.142.240:8808/pdf/US20140242152A1.pdf	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	6-Jul-11	6-Jul-12	28-Aug-14
3305	US20140227 346	http://59.45.142.240:8808/pdf/US20140227346A1.pdf	IMMUNOGENIC COMBINATION COMPOSITIONS AND USES THEREOF	Not Available	6-Jul-11	6-Jul-12	14-Aug-14
3306	US20140220 083	http://59.45.142.240:8808/pdf/US20140220083A1.pdf	CATIONIC OIL-IN-WATER EMULSIONS	Not Available	6-Jul-11	6-Jul-12	7-Aug-14
3307	US20140212 498	http://59.45.142.240:8808/pdf/US20140212498A1.pdf	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	Not Available	6-Jul-11	6-Jul-12	31-Jul-14
3308	US20140141 070	http://59.45.142.240:8808/pdf/US20140141070A1.pdf	LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES	Not Available	6-Jul-11	6-Jul-12	22-May-14
3309	US20140127 321	http://59.45.142.240:8808/pdf/US20140127321A1.pdf	ANTIVIRAL RESIN MEMBER	NBC MESHTEC, INC.	6-Jul-11	6-Jul-12	8-May-14
3310	US10307374	http://59.45.142.240:8808/pdf/US10307374.pdf	Oil-in-water emulsions that contain nucleic acids	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-11	24-Apr-17	4-Jun-19
3311	US10183074	http://59.45.142.240:8808/pdf/US10183074.pdf	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-11	23-Mar-17	22-Jan-19
3312	US9885082	http://59.45.142.240:8808/pdf/US9885082.pdf	Embodiments of a probe and method for targeting nucleic acids	University of Idaho	19-Jul-11	19-Jul-12	6-Feb-18
3313	US20140220 573	http://59.45.142.240:8808/pdf/US20140220573A1.pdf	EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING NUCLEIC ACIDS	University Of Idaho	19-Jul-11	19-Jul-12	7-Aug-14
3314	US9221832	http://59.45.142.240:8808/pdf/US9221832.pdf	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS	22-Jul-11	20-Jul-12	29-Dec-15
3315	US20170042 994	http://59.45.142.240:8808/pdf/US20170042994A1.pdf	COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTI-CD4 RECEPTOR GENE	ASSISTANCE PUBLIQUE - HOSPITAL DE MONTELIEN DE	22-Jul-11	29-Jul-16	16-Feb-17
3316	US20140199 379	http://59.45.142.240:8808/pdf/US20140199379A1.pdf	COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTI-CD4 RECEPTOR GENE	ASSISTANCE PUBLIQUE - HOSPITAL DE MONTELIEN DE	22-Jul-11	23-Jul-12	17-Jul-14
3317	US20140163 035	http://59.45.142.240:8808/pdf/US20140163035A1.pdf	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	ACTELION PHARMACEUTICALS	22-Jul-11	20-Jul-12	12-Jun-14
3318	US20140162 941		PROCESS FOR PREPARING BIOLOGICAL SAMPLES	BAYLOR COLLEGE OF MEDICINE	27-Jul-11	26-Jul-12	12-Jun-14
3319	US9714226	http://59.45.142.240:8808/pdf/US9714226.pdf	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	13-Nov-15	25-Jul-17
3320	US9428490	http://59.45.142.240:8808/pdf/US9428490.pdf	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	26-Jul-12	30-Aug-16
3321	US9206158	http://59.45.142.240:8808/pdf/US9206158.pdf	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	10-Jun-15	8-Dec-15
3322	US9079865	http://59.45.142.240:8808/pdf/US9079865.pdf	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	29-Jul-12	14-Jul-15
3323	US8999996	http://59.45.142.240:8808/pdf/US8999996.pdf	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	19-Mar-14	7-Apr-15
3324	US20200087 313	http://59.45.142.240:8808/pdf/US20200087313A1.pdf	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29-Jul-11	25-Apr-19	19-Mar-20
3325	US20190330 164	http://59.45.142.240:8808/pdf/US20190330164A1.pdf	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29-Jul-11	28-Nov-18	31-Oct-19

3326	US20180127 384	http://59.45.142.240:8808/pdf/US20180127384A1.pdf	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29-Jul-11	21-Jun-17	10-May-18
3327	US20170137 430	http://59.45.142.240:8808/pdf/US20170137430A1.pdf	Nuclear Transport Modulators And Uses Thereof	Not Available	29-Jul-11	22-Jul-16	18-May-17
3328	US20160304 472	http://59.45.142.240:8808/pdf/US20160304472A1.pdf	Hydrazide Containing Nuclear Transport Modulators and Uses	Not Available	29-Jul-11	13-Nov-15	20-Oct-16
3329	US20150274 698	http://59.45.142.240:8808/pdf/US20150274698A1.pdf	Hydrazide Containing Nuclear Transport Modulators And Uses	Not Available	29-Jul-11	10-Jun-15	1-Oct-15
3330	US20150018 332	http://59.45.142.240:8808/pdf/US20150018332A1.pdf	Nuclear Transport Modulators and Uses Thereof	KARYOPHARM THERAPEUTICS INC.	29-Jul-11	26-Jul-12	15-Jan-15
3331	US20140364 408	http://59.45.142.240:8808/pdf/US20140364408A1.pdf	Hydrazide Containing Nuclear Transport Modulators And Uses	KARYOPHARM THERAPEUTICS INC.	29-Jul-11	29-Jul-12	11-Dec-14
3332	US20140235 653	http://59.45.142.240:8808/pdf/US20140235653A1.pdf	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Karyopharm Therapeutics, Inc.	29-Jul-11	19-Mar-14	21-Aug-14
3333	US10544108	http://59.45.142.240:8808/pdf/US10544108.pdf	Hydrazide containing nuclear transport modulators and uses	Karyopharm Therapeutics Inc.	29-Jul-11	28-Nov-18	28-Jan-20
3334	US10173987	http://59.45.142.240:8808/pdf/US10173987.pdf	Hydrazide containing nuclear transport modulators and uses	Karyopharm Therapeutics Inc.	29-Jul-11	21-Jun-17	8-Jan-19
3335	US20200113 830	http://59.45.142.240:8808/pdf/US20200113830A1.pdf	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCAPSULATING BSA	GLAXOSMITHKLINE BIOLOGICALS S.A.	31-Aug-11	16-Dec-19	16-Apr-20
3336	US20140255 472	http://59.45.142.240:8808/pdf/US20140255472A1.pdf	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCAPSULATING BSA	Not Available	31-Aug-11	31-Aug-12	11-Sep-14
3337	US9199981	http://59.45.142.240:8808/pdf/US9199981.pdf	Compounds and compositions as c-kit kinase inhibitors	NOVARTIS AG	1-Sep-11	27-Aug-12	1-Dec-15
3338	US9023839	http://59.45.142.240:8808/pdf/US9023839.pdf	Compounds and compositions as c-kit kinase inhibitors	IRM LLC	1-Sep-11	22-Apr-14	5-May-15
3339	US8754071	http://59.45.142.240:8808/pdf/US8754071.pdf	Compounds and compositions as c-kit kinase inhibitors	Not Available	1-Sep-11	19-Sep-13	17-Jun-14
3340	US8569283	http://59.45.142.240:8808/pdf/US8569283.pdf	Compounds and compositions as c-kit kinase inhibitors	LIU XIAODONG	1-Sep-11	29-Aug-12	29-Oct-13
3341	US20150051 206		COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	29-Aug-12	19-Feb-15
3342	US20150011 508		COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	28-Aug-12	8-Jan-15
3343	US20140228 347	http://59.45.142.240:8808/pdf/US20140228347A1.pdf	COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	22-Apr-14	14-Aug-14
3344	US20140206 682		COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS	IRM LLC	1-Sep-11	31-Aug-12	24-Jul-14
3345	US20140031 333	http://59.45.142.240:8808/pdf/US20140031333A1.pdf	COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	19-Sep-13	30-Jan-14
3346	US20130059 846	http://59.45.142.240:8808/pdf/US20130059846A1.pdf	COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	27-Aug-12	7-Mar-13
3347	US20130059 832	http://59.45.142.240:8808/pdf/US20130059832A1.pdf	COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	29-Aug-12	7-Mar-13
3348	US9546150	http://59.45.142.240:8808/pdf/US9546150.pdf	Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease	HYBRIGENICS SA	2-Sep-11	29-Aug-12	17-Jan-17
3349	US20140302 077		LIVE ATTENUATED INFLUENZA VIRUS	Westfaelische Wilhelms-Universitaet	2-Sep-11	28-Aug-12	9-Oct-14
3350	US20150031 038		SAMPLE PREPARATION METHODS	Not Available	6-Sep-11	6-Sep-12	29-Jan-15
3351	US9345760	http://59.45.142.240:8808/pdf/US9345760.pdf	IPNV-ISAV bivalent vaccine using a virus-like particle-based platform	Advanced Bionutrition	9-Sep-11	7-Sep-12	24-May-16
3352	US20140348 791	http://59.45.142.240:8808/pdf/US20140348791A1.pdf	MODIFIED ADENOVRAL VECTORS AND METHODS OF TREATMENT	Beth Israel Deaconess Medical Center	9-Sep-11	7-Sep-12	27-Nov-14
3353	US20140314 858	http://59.45.142.240:8808/pdf/US20140314858A1.pdf	IPNV-ISAV BIVALENT VACCINE USING A VIRUS-LIKE PARTICLE-BASED PLATFORM AND METHODS	Advanced BioNutrition Corporation	9-Sep-11	7-Sep-12	23-Oct-14
3354	US9023855	http://59.45.142.240:8808/pdf/US9023855.pdf	Compounds	Chiesi Farmaceutici S.p.A.	14-Sep-11	11-Feb-14	5-May-15
3355	US8691826	http://59.45.142.240:8808/pdf/US8691826.pdf	Compounds	Chiesi Farmaceutici S.p.A.	14-Sep-11	13-Sep-12	8-Apr-14
3356	US20140315 215	http://59.45.142.240:8808/pdf/US20140315215A1.pdf	THERMOSTABLE ASSAY REAGENTS	The Secretary of State for Health	14-Sep-11	14-Sep-12	23-Oct-14
3357	US20140179 714		NOVEL COMPOUNDS	Chiesi Farmaceutici S.p.A.	14-Sep-11	11-Feb-14	26-Jun-14
3358	US20190262 448	http://59.45.142.240:8808/pdf/US20190262448A1.pdf	Cationic Oil-In-Water Emulsions	GLAXOSMITHKLINE BIOLOGICALS SA	18-Sep-11	7-Mar-19	29-Aug-19
3359	US9284560	http://59.45.142.240:8808/pdf/US9284560.pdf	Application of highly conserved domain sequences from viral genome as template to design	Biocross Institute of Molecular Medicine (Nantong) Co., Ltd.	19-Sep-11	19-Sep-11	15-Mar-16
3360	US8999975	http://59.45.142.240:8808/pdf/US8999975.pdf	Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of	Boehringer Ingelheim International GmbH	19-Sep-11	14-Sep-12	7-Apr-15
3361	US20130172 327	http://59.45.142.240:8808/pdf/US20130172327A1.pdf	SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE	BOEHRINGER INGELHEIM INTERNATIONAL	19-Sep-11	14-Sep-12	4-Jul-13
3362	US9801948	http://59.45.142.240:8808/pdf/US9801948.pdf	Antimicrobial compositions and methods of use thereof	Yale University	21-Sep-11	21-Sep-12	31-Oct-17
3363	US20140220 086	http://59.45.142.240:8808/pdf/US20140220086A1.pdf	Antimicrobial Compositions and Methods of Use Thereof	Not Available	21-Sep-11	21-Sep-12	7-Aug-14
3364	US9908946	http://59.45.142.240:8808/pdf/US9908946.pdf	Generation of binding molecules	Merus N.V.	26-Sep-11	16-Sep-15	6-Mar-18
3365	US9145588	http://59.45.142.240:8808/pdf/US9145588.pdf	Generation of binding molecules	MERUS BIOPHARMACEUTIC N.V.	26-Sep-11	26-Sep-12	29-Sep-15
3366	US20180179 300	http://59.45.142.240:8808/pdf/US20180179300A1.pdf	GENERATION OF BINDING MOLECULES	Merus N.V.	26-Sep-11	22-Nov-17	28-Jun-18
3367	US20160130 367	http://59.45.142.240:8808/pdf/US20160130367A1.pdf	GENERATION OF BINDING MOLECULES	Merus B.V.	26-Sep-11	16-Sep-15	12-May-16
3368	US20130096 020	http://59.45.142.240:8808/pdf/US20130096020A1.pdf	GENERATION OF BINDING MOLECULES	MERUS BIOPHARMACEUTIC N.V.	26-Sep-11	26-Sep-12	18-Apr-13
3369	US10647781	http://59.45.142.240:8808/pdf/US10647781.pdf	Generation of binding molecules	Merus N.V.	26-Sep-11	22-Nov-17	12-May-20
3370	US9474759	http://59.45.142.240:8808/pdf/US9474759.pdf	Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses,	Kansas State University Research Foundation	27-Sep-11	27-Sep-12	25-Oct-16

3371	US20140243 341	http://59.45.142.240:8808/pdf/US20140243341A1.pdf	BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER: PICORNAVIRUSES, CALICIVIRUSES AND	Not Available	27-Sep-11	27-Sep-12	28-Aug-14
3372	US20130085 095	http://59.45.142.240:8808/pdf/US20130085095A1.pdf	PROTEIN COMPLEMENTATION REGULATORS	Trustees of Boston University	29-Sep-11	28-Sep-12	4-Apr-13
3373	US20160362 454	http://59.45.142.240:8808/pdf/US20160362454A1.pdf	Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA	Not Available	7-Oct-11	10-Jun-16	15-Dec-16
3374	US20140335 117	http://59.45.142.240:8808/pdf/US20140335117A1.pdf	Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA	Not Available	7-Oct-11	5-Oct-12	13-Nov-14
3375	US8704169	http://59.45.142.240:8808/pdf/US8704169.pdf	Direct impact ionization (DII) mass spectrometry	The United States of America, as represented by the Secretary, Department of Health and Human Services	11-Oct-11	11-Oct-11	22-Apr-14
3376	US20170342 442	http://59.45.142.240:8808/pdf/US20170342442A1.pdf	RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES	GLAXOSMITHKLINE BIOLOGICALS, SA	11-Oct-11	15-Aug-17	30-Nov-17
3377	US20140271 829	http://59.45.142.240:8808/pdf/US20140271829A1.pdf	RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES	Not Available	11-Oct-11	11-Oct-12	18-Sep-14
3378	US20130087 700	http://59.45.142.240:8808/pdf/US20130087700A1.pdf	DIRECT IMPACT IONIZATION (DII) MASS SPECTROMETRY	Services, National Institutes of Health	11-Oct-11	11-Oct-11	11-Apr-13
3379	US9481630	http://59.45.142.240:8808/pdf/US9481630.pdf	Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND	19-Oct-11	28-Sep-12	1-Nov-16
3380	US20140328 874	http://59.45.142.240:8808/pdf/US20140328874A1.pdf	SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION	Not Available	19-Oct-11	19-Oct-12	6-Nov-14
3381	US20140302 124	http://59.45.142.240:8808/pdf/US20140302124A1.pdf	Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of	Immunotape, Inc.	19-Oct-11	18-Oct-12	9-Oct-14
3382	US20190247 489	http://59.45.142.240:8808/pdf/US20190247489A1.pdf	ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING	Not Available	20-Oct-11	16-Nov-18	15-Aug-19
3383	US20140248 320	http://59.45.142.240:8808/pdf/US20140248320A1.pdf	ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING	Not Available	20-Oct-11	19-Oct-12	4-Sep-14
3384	US9676727	http://59.45.142.240:8808/pdf/US9676727.pdf	Myxovirus therapeutics, compounds, and uses related thereto	Children's Healthcare of Atlanta	24-Oct-11	7-Jul-16	13-Jun-17
3385	US9499489	http://59.45.142.240:8808/pdf/US9499489.pdf	Myxovirus therapeutics, compounds, and uses related thereto	Children's Healthcare of Atlanta	24-Oct-11	24-Oct-12	22-Nov-16
3386	US20160310 511	http://59.45.142.240:8808/pdf/US20160310511A1.pdf	Myxovirus Therapeutics, Compounds, and Uses Related	Not Available	24-Oct-11	7-Jul-16	27-Oct-16
3387	US20140329 817	http://59.45.142.240:8808/pdf/US20140329817A1.pdf	MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED	CHILDREN'S HEALTHCARE OF ATLANTA	24-Oct-11	24-Oct-12	6-Nov-14
3388	US9174925	http://59.45.142.240:8808/pdf/US9174925.pdf	Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND	26-Oct-11	28-Sep-12	3-Nov-15
3389	US20140364 492	http://59.45.142.240:8808/pdf/US20140364492A1.pdf	PHORBOL TYPE DITERPENE COMPOUND, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF VIRAL INFECTIOUS	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	26-Oct-11	28-Sep-12	11-Dec-14
3390	US20140349 295		METHOD FOR DETECTING TARGET NUCLEIC ACID	Not Available	31-Oct-11	25-Oct-12	27-Nov-14
3391	US9593331	http://59.45.142.240:8808/pdf/US9593331.pdf	Double-stranded nucleic acid molecule for gene expression control	Osaka City University	2-Nov-11	1-Nov-12	14-Mar-17
3392	US20140315 982	http://59.45.142.240:8808/pdf/US20140315982A1.pdf	DOUBLE-STRANDED NUCLEIC ACID MOLECULE FOR GENE EXPRESSION CONTROL	Osaka City University	2-Nov-11	1-Nov-12	23-Oct-14
3393	US9783595	http://59.45.142.240:8808/pdf/US9783595.pdf	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7-Nov-11	2-Aug-16	10-Oct-17
3394	US9475862	http://59.45.142.240:8808/pdf/US9475862.pdf	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7-Nov-11	7-Nov-12	25-Oct-16
3395	US20180002 406	http://59.45.142.240:8808/pdf/US20180002406A1.pdf	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of	7-Nov-11	8-Sep-17	4-Jan-18
3396	US20160333 076	http://59.45.142.240:8808/pdf/US20160333076A1.pdf	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of Health and Human	7-Nov-11	2-Aug-16	17-Nov-16
3397	US20140348 785	http://59.45.142.240:8808/pdf/US20140348785A1.pdf	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	Not Available	7-Nov-11	7-Nov-12	27-Nov-14
3398	US20140342 407	http://59.45.142.240:8808/pdf/US20140342407A1.pdf	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of Health and Human	7-Nov-11	4-Aug-14	20-Nov-14
3399	US10047148	http://59.45.142.240:8808/pdf/US10047148.pdf	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human	7-Nov-11	8-Sep-17	14-Aug-18

3400	US10047147	http://59.45.142.240:8808/pdf/US10047147.pdf	Neutralizing GP41 antibodies and their use	The United States of American, as represented by the Secretary, Department of Health and Human Services	7-Nov-11	4-Aug-14	14-Aug-18
3401	US20150030 626	http://59.45.142.240:8808/pdf/US20150030626A1.pdf	IMMUNOMODULATORY CONJUGATES	Ascend Biopharmaceuticals LLC	9-Nov-11	9-Nov-12	29-Jan-15
3402	US10344261	http://59.45.142.240:8808/pdf/US10344261.pdf	Immunomodulatory conjugates	ASCEND BIOPHARMACEUTICALS LLC	9-Nov-11	9-Nov-12	9-Jul-19
3403	US20200016 589	http://59.45.142.240:8808/pdf/US20200016589A1.pdf	LOADING VIALS	Not Available	10-Nov-11	24-Sep-19	16-Jan-20
3404	US20180303 874		Compositions and Methods for the Prevention of Microbial Infections	Not Available	10-Nov-11	30-Nov-17	25-Oct-18
3405	US20140283 945	http://59.45.142.240:8808/pdf/US20140283945A1.pdf	LOADING VIALS	BioFire Diagnostics, LLC	10-Nov-11	9-Nov-12	25-Sep-14
3406	US10464060	http://59.45.142.240:8808/pdf/US10464060.pdf	Loading vials	BioFare Diagnostics, LLC	10-Nov-11	9-Nov-12	5-Nov-19
3407	US9375465	http://59.45.142.240:8808/pdf/US9375465.pdf	Conjugates of GM-CSF and IL-7, compositions and methods related thereto	Children's Healthcare of Atlanta	14-Nov-11	13-Nov-12	28-Jun-16
3408	US20160250 326	http://59.45.142.240:8808/pdf/US20160250326A1.pdf	Conjugates of GM-CSF and IL-7, and Compositions Thereof	Not Available	14-Nov-11	18-May-16	1-Sep-16
3409	US20130122 038	http://59.45.142.240:8808/pdf/US20130122038A1.pdf	HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES VIRUS-BASED VACCINES	Cruceff Holland B.V.	14-Nov-11	13-Nov-12	16-May-13
3410	US8673331	http://59.45.142.240:8808/pdf/US8673331.pdf	Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for	GP&E	18-Nov-11	18-Nov-11	18-Mar-14
3411	US20130129 805	http://59.45.142.240:8808/pdf/US20130129805A1.pdf	COMPOSITION WITH STERILIZING ACTIVITY AGAINST BACTERIA, FUNGUS AND VIRUSES, APPLICATION THEREOF AND METHOD FOR PREPARATION	GP&E	18-Nov-11	18-Nov-11	23-May-13
3412	US20140336 245	http://59.45.142.240:8808/pdf/US20140336245A1.pdf	VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENE DELIVERY	Not Available	22-Nov-11	21-Nov-12	13-Nov-14
3413	US10640785	http://59.45.142.240:8808/pdf/US10640785.pdf	Virus vectors for highly efficient transgene delivery	The Children's Hospital of Philadelphia	22-Nov-11	21-Nov-12	5-May-20
3414	US20190083 408	http://59.45.142.240:8808/pdf/US20190083408A1.pdf	CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF	Not Available	2-Dec-11	4-Dec-18	21-Mar-19
3415	US20140314 839	http://59.45.142.240:8808/pdf/US20140314839A1.pdf	CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF	Not Available	2-Dec-11	30-Nov-12	23-Oct-14
3416	US10220002	http://59.45.142.240:8808/pdf/US10220002.pdf	Controlled-release peptide compositions and uses thereof	BOARD OF REGENTS OF THE UNIVERSITY OF PENNSYLVANIA	2-Dec-11	30-Nov-12	5-Mar-19
3417	US20150099 261	http://59.45.142.240:8808/pdf/US20150099261A1.pdf	RESPIRATORY INFECTION ASSAY	Not Available	9-Dec-11	10-Dec-12	9-Apr-15
3418	US10294534	http://59.45.142.240:8808/pdf/US10294534.pdf	Respiratory infection assay	THE SECRETARY OF STATE FOR HEALTH	9-Dec-11	10-Dec-12	21-May-19
3419	US9981036	http://59.45.142.240:8808/pdf/US9981036.pdf	Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	12-Dec-11	26-Feb-16	29-May-18
3420	US9272024	http://59.45.142.240:8808/pdf/US9272024.pdf	Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and	The Trustees of the University of Pennsylvania	12-Dec-11	11-Dec-12	1-Mar-16
3421	US20200109 403	http://59.45.142.240:8808/pdf/US20200109403A1.pdf	IN VIVO DELIVERY OF OLIGONUCLEOTIDES	Not Available	12-Dec-11	18-Dec-19	9-Apr-20
3422	US20180333 485	http://59.45.142.240:8808/pdf/US20180333485A1.pdf	Compositions, Comprising Improved IL-12 Genetic Constructs And Vaccines, Immunotherapeutics And	Not Available	12-Dec-11	9-May-18	22-Nov-18
3423	US20160235 840	http://59.45.142.240:8808/pdf/US20160235840A1.pdf	Compositions, Comprising Improved IL-12 Genetic Constructs And Vaccines, Immunotherapeutics And	Not Available	12-Dec-11	26-Feb-16	18-Aug-16
3424	US20160040 161	http://59.45.142.240:8808/pdf/US20160040161A1.pdf	In Vivo Delivery of Oligonucleotides	OncoImmunin Inc.	12-Dec-11	12-Dec-12	11-Feb-16
3425	US20150004 188	http://59.45.142.240:8808/pdf/US20150004188A1.pdf	COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND	Not Available	12-Dec-11	11-Dec-12	1-Jan-15
3426	US10557136	http://59.45.142.240:8808/pdf/US10557136.pdf	In vivo delivery of oligonucleotides	OncoImmunin Inc.	12-Dec-11	12-Dec-12	11-Feb-20
3427	US9134247	http://59.45.142.240:8808/pdf/US9134247.pdf	Method and apparatus for two-step surface-enhanced raman	REAL-TIME ANALYZERS, INC.	16-Dec-11	16-Dec-11	15-Sep-15
3428	US20160003 747	http://59.45.142.240:8808/pdf/US20160003747A1.pdf	Apparatus for two-step surface-enhanced raman spectroscopy	REAL-TIME ANALYZERS, INC.	16-Dec-11	11-Sep-15	7-Jan-16
3429	US20130157 254	http://59.45.142.240:8808/pdf/US20130157254A1.pdf	Method and apparatus for two-step surface-enhanced raman	Real-Time Analyzers, Inc.	16-Dec-11	16-Dec-11	20-Jun-13
3430	US9481724	http://59.45.142.240:8808/pdf/US9481724.pdf	hDC-sign binding peptides	Sloan-Kettering Institute for Cancer Research	19-Dec-11	10-Dec-12	1-Nov-16
3431	US20150110 807	http://59.45.142.240:8808/pdf/US20150110807A1.pdf	HDC-SIGN BINDING PEPTIDES	Sloan-Kettering Institute for Cancer Research	19-Dec-11	10-Dec-12	23-Apr-15
3432	US9970061	http://59.45.142.240:8808/pdf/US9970061.pdf	Bioagent detection oligonucleotides	IBIS BIOSCIENCES, INC.	27-Dec-11	27-Dec-12	15-May-18
3433	US20180230 521	http://59.45.142.240:8808/pdf/US20180230521A1.pdf	BIOAGENT DETECTION OLIGONUCLEOTIDES	Not Available	27-Dec-11	13-Apr-18	16-Aug-18
3434	US20150184 231	http://59.45.142.240:8808/pdf/US20150184231A1.pdf	BIOAGENT DETECTION OLIGONUCLEOTIDES	Not Available	27-Dec-11	27-Dec-12	2-Jul-15
3435	US10662485	http://59.45.142.240:8808/pdf/US10662485.pdf	Bioagent detection oligonucleotides	IBIS BIOSCIENCES, INC.	27-Dec-11	13-Apr-18	26-May-20
3436	US9475872	http://59.45.142.240:8808/pdf/US9475872.pdf	Nucleic acid molecules encoding monoclonal antibodies specific for IL-12	ImmunoQure AG	28-Dec-11	2-Jan-13	25-Oct-16
3437	US20190023 779		METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES	Not Available	28-Dec-11	5-Oct-18	24-Jan-19
3438	US20170051 053		METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES	Not Available	28-Dec-11	7-Sep-16	23-Feb-17
3439	US20140363 422	http://59.45.142.240:8808/pdf/US20140363422A1.pdf	METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES	Not Available	28-Dec-11	2-Jan-13	11-Dec-14

3440	US10131709	http://59.45.142.240:8808/pdf/US10131709.pdf	Nucleic acid molecules encoding monoclonal antibodies specific for IL-23	ImmunoQure AG	28-Dec-11	7-Sep-16	20-Nov-18
3441	US20130217 071	http://59.45.142.240:8808/pdf/US20130217071A1.pdf	METHODS AND COMPOSITIONS FOR PERFORMING NUCLEIC ACID ANALYSES	MONTESCLAROS LUZ	30-Dec-11	21-Dec-12	22-Aug-13
3442	US20130197 296	http://59.45.142.240:8808/pdf/US20130197296A1.pdf	Removing Cells from an Organism	DAPPRICH JOHANNES	13-Jan-12	14-Jan-13	1-Aug-13
3443	US9409917	http://59.45.142.240:8808/pdf/US9409917.pdf	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD	20-Jan-12	18-Jan-13	9-Aug-16
3444	US9139620	http://59.45.142.240:8808/pdf/US9139620.pdf	Feline morbillivirus and uses thereof	THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA	20-Jan-12	22-Jan-13	22-Sep-15
3445	US20150025 075	http://59.45.142.240:8808/pdf/US20150025075A1.pdf	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	ACTELION PHARMACEUTICALS LTD	20-Jan-12	18-Jan-13	22-Jan-15
3446	US20130230 529	http://59.45.142.240:8808/pdf/US20130230529A1.pdf	NOVEL PARAMYXOVIRUS AND USES THEREOF	The University of Hong Kong	20-Jan-12	22-Jan-13	5-Sep-13
3447	US20130195 930	http://59.45.142.240:8808/pdf/US20130195930A1.pdf	Inulin and Inulin Acetate Formulations	SOUTH DAKOTA STATE UNIVERSITY	20-Jan-12	22-Jan-13	1-Aug-13
3448	US9618429	http://59.45.142.240:8808/pdf/US9618429.pdf	Polymer stabilization of chromogen solutions	Ventana Medical Systems, Inc	23-Jan-12	18-Jan-13	11-Apr-17
3449	US20170212 019	http://59.45.142.240:8808/pdf/US20170212019A1.pdf	POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS	Not Available	23-Jan-12	10-Apr-17	27-Jul-17
3450	US20130189 680	http://59.45.142.240:8808/pdf/US20130189680A1.pdf	POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS	VENTANA MEDICAL SYSTEMS, INC	23-Jan-12	18-Jan-13	25-Jul-13
3451	US9890361	http://59.45.142.240:8808/pdf/US9890361.pdf	Methods for increasing the infectivity of viruses utilizing alkyne- modified	LIFE TECHNOLOGIES CORPORATION	26-Jan-12	25-Jan-13	13-Feb-18
3452	US20180201 907		METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES	Not Available	26-Jan-12	13-Mar-18	19-Jul-18
3453	US20150037 288	http://59.45.142.240:8808/pdf/US20150037288A1.pdf	METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES	Not Available	26-Jan-12	25-Jan-13	5-Feb-15
3454	US20200085 943	http://59.45.142.240:8808/pdf/US20200085943A1.pdf	PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE	CureVac AG	31-Jan-12	29-Aug-19	19-Mar-20
3455	US20190008 954	http://59.45.142.240:8808/pdf/US20190008954A1.pdf	NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION	CureVac AG	31-Jan-12	11-Jun-18	10-Jan-19
3456	US20150118 264	http://59.45.142.240:8808/pdf/US20150118264A1.pdf	PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE	CureVac GMBH	31-Jan-12	31-Jan-13	30-Apr-15
3457	US20150118 183	http://59.45.142.240:8808/pdf/US20150118183A1.pdf	NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION	CUREVAC GMBH	31-Jan-12	31-Jan-13	30-Apr-15
3458	US9669089	http://59.45.142.240:8808/pdf/US9669089.pdf	Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an	CureVac AG	15-Feb-12	15-Feb-13	6-Jun-17
3459	US20180161 422	http://59.45.142.240:8808/pdf/US20180161422A1.pdf	NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF	CureVac AG	15-Feb-12	8-Feb-18	14-Jun-18
3460	US20150093 413	http://59.45.142.240:8808/pdf/US20150093413A1.pdf	NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF	CureVac GmbH	15-Feb-12	15-Feb-13	2-Apr-15
3461	US10166283	http://59.45.142.240:8808/pdf/US10166283.pdf	Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an	CureVac AG	15-Feb-12	21-Mar-17	1-Jan-19
3462	US20150024 415	http://59.45.142.240:8808/pdf/US20150024415A1.pdf	DETECTION AND QUANTIFICATION OF ANALYTES BASED ON SIGNAL INDUCED BY NUCLEIC ACID ANALYSES	The Board of Trustees of the University of California	16-Feb-12	19-Feb-13	22-Jan-15
3463	US20150111 955	http://59.45.142.240:8808/pdf/US20150111955A1.pdf	AAV VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER TO CELLS	Not Available	17-Feb-12	19-Feb-13	23-Apr-15
3464	US9828342	http://59.45.142.240:8808/pdf/US9828342.pdf	Isatin derivatives, pharmaceutical compositions thereof, and methods	CITY OF HOPE	24-Feb-12	25-Feb-13	28-Nov-17
3465	US20130225 637	http://59.45.142.240:8808/pdf/US20130225637A1.pdf	ISATIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE	HORNE DAVID A	24-Feb-12	25-Feb-13	29-Aug-13
3466	US20150037 281	http://59.45.142.240:8808/pdf/US20150037281A1.pdf	VARIANTS OF PROTHYMOSIN ALPHA AND METHODS OF USING SAME	Icahn School of Medicine at Mount Sinai	2-Mar-12	1-Mar-13	5-Feb-15
3467	US9725770	http://59.45.142.240:8808/pdf/US9725770.pdf	Methods and compositions for identification of source of microbial contamination	The Regents of the University of California	6-Mar-12	6-Mar-13	8-Aug-17
3468	US20170335 374	http://59.45.142.240:8808/pdf/US20170335374A1.pdf	METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE OF MICROBIAL CONTAMINATION IN A SAMPLE	Not Available	6-Mar-12	6-Jul-17	23-Nov-17
3469	US20140200 149	http://59.45.142.240:8808/pdf/US20140200149A1.pdf	Methods and compositions for identification of source of microbial contamination	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	6-Mar-12	6-Mar-13	17-Jul-14
3470	US9593334	http://59.45.142.240:8808/pdf/US9593334.pdf	Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting autophagy	University of Pittsburgh of the Commonwealth System of Higher Education	7-Mar-12	6-Mar-13	14-Mar-17
3471	US9320748	http://59.45.142.240:8808/pdf/US9320748.pdf	Immunologically useful arginine salts	Novartis AG	7-Mar-12	7-Mar-13	26-Apr-16
3472	US20180133 246	http://59.45.142.240:8808/pdf/US20180133246A1.pdf	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	1-Nov-17	17-May-18
3473	US20180125 883	http://59.45.142.240:8808/pdf/US20180125883A1.pdf	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	20-Sep-17	10-May-18

3474	US20170211 069	http://59.45.142.240:8808/pdf/US20170211069A1.pdf	USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE AND PROMOTING AUTOPHAGY	University of Pittsburgh - Of the Commonwealth System of Higher	7-Mar-12	27-Jan-17	27-Jul-17
3475	US20150272 988	http://59.45.142.240:8808/pdf/US20150272988A1.pdf	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Advanced Inhalation Therapies (AIT) Ltd	7-Mar-12	7-Mar-13	1-Oct-15
3476	US20150174 158	http://59.45.142.240:8808/pdf/US20150174158A1.pdf	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	7-Mar-13	25-Jun-15
3477	US20150132 339	http://59.45.142.240:8808/pdf/US20150132339A1.pdf	ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE VACCINES	Not Available	7-Mar-12	7-Mar-13	14-May-15
3478	US20150125 475	http://59.45.142.240:8808/pdf/US20150125475A1.pdf	IMMUNOLOGICALLY USEFUL ARGinine Salts	Not Available	7-Mar-12	7-Mar-13	7-May-15
3479	US20150045 412	http://59.45.142.240:8808/pdf/US20150045412A1.pdf	USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE	Not Available	7-Mar-12	6-Mar-13	12-Feb-15
3480	US20150044 305	http://59.45.142.240:8808/pdf/US20150044305A1.pdf	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	7-Mar-13	12-Feb-15
3481	US20150034 084	http://59.45.142.240:8808/pdf/US20150034084A1.pdf	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Advanced Inhalation Therapies (AIT) Ltd	7-Mar-12	7-Mar-13	5-Feb-15
3482	US9526803	http://59.45.142.240:8808/pdf/US9526803.pdf	Diagnostic chewing gum for pathogens	Julius-Maximilians-Universitaet	8-Mar-12	8-Mar-13	27-Dec-16
3483	US20150023 879	http://59.45.142.240:8808/pdf/US20150023879A1.pdf	DIAGNOSTIC CHEWING GUM FOR PATHOGENS	Julius-Maximilians-Universitaet	8-Mar-12	8-Mar-13	22-Jan-15
3484	US20150018 396	http://59.45.142.240:8808/pdf/US20150018396A1.pdf	PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA	Not Available	8-Mar-12	3-Mar-13	15-Jan-15
3485	US20150118 265	http://59.45.142.240:8808/pdf/US20150118265A1.pdf	MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES	Anthrogenesis Corporation	13-Mar-12	12-Mar-13	30-Apr-15
3486	US20150079 155	http://59.45.142.240:8808/pdf/US20150079155A1.pdf	Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole	Not Available	14-Mar-12	14-Mar-13	19-Mar-15
3487	US9676857	http://59.45.142.240:8808/pdf/US9676857.pdf	Soluble engineered monomeric Fc	The United States of America, as represented by the Secretary, Department of Health and Human	16-Mar-12	14-Mar-13	13-Jun-17
3488	US20170247 453	http://59.45.142.240:8808/pdf/US20170247453A1.pdf	SOLUBLE ENGINEERED MONOMERIC FC	The United States of America, as represented by the Secretary, Department of Health and Human	16-Mar-12	9-May-17	31-Aug-17
3489	US20150050 278	http://59.45.142.240:8808/pdf/US20150050278A1.pdf	SOLUBLE ENGINEERED MONOMERIC FC	Not Available	16-Mar-12	14-Mar-13	19-Feb-15
3490	US20130244 920	http://59.45.142.240:8808/pdf/US20130244920A1.pdf	WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND METHODS OF MAKING SAME	LEE DAVID M	16-Mar-12	16-Mar-12	19-Sep-13
3491	US10633447	http://59.45.142.240:8808/pdf/US10633447.pdf	Soluble engineered monomeric Fc	The United States of America, as represented by the Secretary, Department of Health and Human	16-Mar-12	9-May-17	28-Apr-20
3492	US9894888	http://59.45.142.240:8808/pdf/US9894888.pdf	Transgenic immunodeficient mouse expressing human S1PR1alpha	INSTITUT PASTEUR	26-Mar-12	26-Mar-13	20-Feb-18
3493	US20180160 662	http://59.45.142.240:8808/pdf/US20180160662A1.pdf	Transgenic Immunodeficient Mouse Expressing Human S1PR1alpha	Institut Pasteur	26-Mar-12	25-Jan-18	14-Jun-18
3494	US20150056 636	http://59.45.142.240:8808/pdf/US20150056636A1.pdf	Transgenic Immunodeficient Mouse Expressing Human S1PR1alpha	Not Available	26-Mar-12	26-Mar-13	26-Feb-15
3495	US9498527	http://59.45.142.240:8808/pdf/US9498527.pdf	Vaccine composition	NITTO DENKO CORPORATION	4-Apr-12	3-Apr-13	22-Nov-16
3496	US20190376 151	http://59.45.142.240:8808/pdf/US20190376151A1.pdf	MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING	Not Available	4-Apr-12	8-Feb-19	12-Dec-19
3497	US20190112 596	http://59.45.142.240:8808/pdf/US20190112596A1.pdf	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED	Not Available	4-Apr-12	12-Apr-18	18-Apr-19
3498	US20170028 054	http://59.45.142.240:8808/pdf/US20170028054A1.pdf	VACCINE COMPOSITION	NITTO DENKO CORPORATION	4-Apr-12	11-Oct-16	2-Feb-17
3499	US20160264 962	http://59.45.142.240:8808/pdf/US20160264962A1.pdf	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED	Not Available	4-Apr-12	28-Jul-15	15-Sep-16
3500	US20150232 957	http://59.45.142.240:8808/pdf/US20150232957A1.pdf	MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING	Not Available	4-Apr-12	4-Apr-13	20-Aug-15
3501	US20150150 878	http://59.45.142.240:8808/pdf/US20150150878A1.pdf	Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage	Not Available	4-Apr-12	4-Apr-13	4-Jun-15
3502	US20130274 129	http://59.45.142.240:8808/pdf/US20130274129A1.pdf	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED	ARNOLD MATTHIAS	4-Apr-12	4-Apr-13	17-Oct-13
3503	US20130266 612	http://59.45.142.240:8808/pdf/US20130266612A1.pdf	VACCINE COMPOSITION	NITTO DENKO CORPORATION	4-Apr-12	3-Apr-13	10-Oct-13
3504	US9107904	http://59.45.142.240:8808/pdf/US9107904.pdf	Immunostimulatory compositions and methods of use thereof	Massachusetts Institute of Technology	5-Apr-12	15-Mar-13	18-Aug-15
3505	US20190015 522	http://59.45.142.240:8808/pdf/US20190015522A1.pdf	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	5-Apr-12	19-Jul-18	17-Jan-19
3506	US20160095 936	http://59.45.142.240:8808/pdf/US20160095936A1.pdf	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	5-Apr-12	2-Jul-15	7-Apr-16
3507	US20130295 129	http://59.45.142.240:8808/pdf/US20130295129A1.pdf	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5-Apr-12	15-Mar-13	7-Nov-13
3508	US10029016	http://59.45.142.240:8808/pdf/US10029016.pdf	Immunostimulatory compositions and methods of use thereof	Massachusetts Insitute of Technology	5-Apr-12	2-Jul-15	24-Jul-18

3509	US20180346 522	http://59.45.142.240:8808/pdf/US20180346522A1.pdf	HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND	Not Available	10-Apr-12	6-Aug-18	6-Dec-18
3510	US20150079 121	http://59.45.142.240:8808/pdf/US20150079121A1.pdf	Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using	Not Available	10-Apr-12	10-Apr-13	19-Mar-15
3511	US10040828	http://59.45.142.240:8808/pdf/US10040828.pdf	Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	10-Apr-12	10-Apr-13	7-Aug-18
3512	US9879003	http://59.45.142.240:8808/pdf/US9879003.pdf	Host targeted inhibitors of dengue virus and other viruses	Dana-Farber Cancer Institute, Inc.	11-Apr-12	15-Mar-13	30-Jan-18
3513	US20190292 178	http://59.45.142.240:8808/pdf/US20190292178A9.pdf	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER	Dana-Farber Cancer Institute, Inc.	11-Apr-12	26-Jan-18	26-Sep-19
3514	US20180265 507	http://59.45.142.240:8808/pdf/US20180265507A1.pdf	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER	Dana-Farber Cancer Institute, Inc.	11-Apr-12	26-Jan-18	20-Sep-18
3515	US20150166 532	http://59.45.142.240:8808/pdf/US20150166532A1.pdf	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER	Not Available	11-Apr-12	15-Mar-13	18-Jun-15
3516	US20130273 113	http://59.45.142.240:8808/pdf/US20130273113A1.pdf	IMMUNOGENIC APOPTOSIS INDUCING COMPOSITIONS AND METHODS OF USE THEREOF	The Regents of the University of Michigan	12-Apr-12	15-Mar-13	17-Oct-13
3517	US9751945	http://59.45.142.240:8808/pdf/US9751945.pdf	Sortase-modified VHH domains and uses thereof	Whitehead Institute for Biomedical	13-Apr-12	15-Apr-13	5-Sep-17
3518	US20150086 576	http://59.45.142.240:8808/pdf/US20150086576A1.pdf	SORTASE-MODIFIED VHH DOMAINS AND USES THEREOF	Not Available	13-Apr-12	15-Apr-13	26-Mar-15
3519	US9908675	http://59.45.142.240:8808/pdf/US9908675.pdf	Powdered pouch and method of making same	MONOSOL, LLC	16-Apr-12	19-Jul-16	6-Mar-18
3520	US9394092	http://59.45.142.240:8808/pdf/US9394092.pdf	Powdered pouch and method of making same	MONOSOL, LLC	16-Apr-12	14-Mar-13	19-Jul-16
3521	US20180186 534	http://59.45.142.240:8808/pdf/US20180186534A1.pdf	Powdered Pouch And Method Of Making Same	MONOSOL, LLC	16-Apr-12	29-Dec-17	5-Jul-18
3522	US20160326 325	http://59.45.142.240:8808/pdf/US20160326325A1.pdf	POWDERED POUCH AND METHOD OF MAKING SAME	Not Available	16-Apr-12	19-Jul-16	10-Nov-16
3523	US20130273 277	http://59.45.142.240:8808/pdf/US20130273277A1.pdf	POWDERED POUCH AND METHOD OF MAKING SAME	Monosol, LLC.	16-Apr-12	14-Mar-13	17-Oct-13
3524	US20190316 109	http://59.45.142.240:8808/pdf/US20190316109A1.pdf	COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY DEPLETES P16 POSITIVE	Not Available	17-Apr-12	10-Jun-19	17-Oct-19
3525	US20190136 215	http://59.45.142.240:8808/pdf/US20190136215A1.pdf	Replication Conditional Virus that Specifically Kills Senescent Cells	Not Available	17-Apr-12	6-Jul-18	9-May-19
3526	US20150064 137	http://59.45.142.240:8808/pdf/US20150064137A1.pdf	USE OF ENGINEERED VIRUSES TO SPECIFICALLY KILL SENESCENT CELLS	Kythera Biopharmaceuticals, Inc.	17-Apr-12	16-Apr-13	5-Mar-15
3527	US10550378	http://59.45.142.240:8808/pdf/US10550378.pdf	Composition comprising a gene vector that selectively depletes P16	Kythera Biopharmaceuticals, Inc.	17-Apr-12	10-Jun-19	4-Feb-20
3528	US10378002	http://59.45.142.240:8808/pdf/US10378002.pdf	Replication conditional virus that specifically kills senescent cells	Kythera Biopharmaceuticals, Inc.	17-Apr-12	6-Jul-18	13-Aug-19
3529	US20200164 334	http://59.45.142.240:8808/pdf/US20200164334A1.pdf	MICROSPOTTING DEVICE	Not Available	18-Apr-12	11-Oct-19	28-May-20
3530	US20170209 844	http://59.45.142.240:8808/pdf/US20170209844A1.pdf	MICROSPOTTING DEVICE	Not Available	18-Apr-12	5-Jan-17	27-Jul-17
3531	US20150283 531	http://59.45.142.240:8808/pdf/US20150283531A1.pdf	Microspotting Device	Not Available	18-Apr-12	17-Apr-13	8-Oct-15
3532	US10471408	http://59.45.142.240:8808/pdf/US10471408.pdf	Microspotting device	BioFire Diagnostics, LLC	18-Apr-12	5-Jan-17	12-Nov-19
3533	US9872898	http://59.45.142.240:8808/pdf/US9872898.pdf	Compositions and methods for treating and preventing porcine reproductive and respiratory	Ohio State Innovation Foundation	24-Apr-12	3-Oct-16	23-Jan-18
3534	US9457074	http://59.45.142.240:8808/pdf/US9457074.pdf	Compositions and methods for treating and preventing porcine reproductive and respiratory	Ohio State Innovation Foundation	24-Apr-12	23-Feb-15	4-Oct-16
3535	US9005665	http://59.45.142.240:8808/pdf/US9005665.pdf	Compositions and methods for treating and preventing porcine reproductive and respiratory	Ohio State Innovation Foundation	24-Apr-12	24-Apr-13	14-Apr-15
3536	US20180185 469	http://59.45.142.240:8808/pdf/US20180185469A1.pdf	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND	Not Available	24-Apr-12	14-Dec-17	5-Jul-18
3537	US20170080 078	http://59.45.142.240:8808/pdf/US20170080078A1.pdf	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND	Not Available	24-Apr-12	3-Oct-16	23-Mar-17
3538	US20150265 696	http://59.45.142.240:8808/pdf/US20150265696A1.pdf	Compositions And Methods For Treating And Preventing Porcine Reproductive And Respiratory	Not Available	24-Apr-12	23-Feb-15	24-Sep-15
3539	US20140004 193	http://59.45.142.240:8808/pdf/US20140004193A1.pdf	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND	Not Available	24-Apr-12	24-Apr-13	2-Jan-14
3540	US10279028	http://59.45.142.240:8808/pdf/US10279028.pdf	Compositions and methods for treating and preventing porcine reproductive and respiratory	Ohio State Innovation Foundation	24-Apr-12	14-Dec-17	7-May-19
3541	US9433672	http://59.45.142.240:8808/pdf/US9433672.pdf	Compositions and methods for activating innate and allergic	ID Biomedical Corporation of Ohio	26-Apr-12	28-Apr-14	6-Sep-16
3542	US20140234 374	http://59.45.142.240:8808/pdf/US20140234374A1.pdf	COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND ALLERGIC	ID BIOMEDICAL CORPORATION OF OHIO	26-Apr-12	28-Apr-14	21-Aug-14
3543	US20150147 346	http://59.45.142.240:8808/pdf/US20150147346A1.pdf	REPLIKIN SEQUENCES AND THEIR ANTIBODIES FOR DIAGNOSTICS, THERAPEUTICS, AND VACCINES AGAINST PRION AND NEURODEGENERATIVE DISORDERS	Not Available	2-May-12	1-May-13	28-May-15
3544	US9452973	http://59.45.142.240:8808/pdf/US9452973.pdf	Modulators of the relaxin receptor 1	THE FLORIDA INTERNATIONAL UNIVERSITY BOARD	4-May-12	15-Mar-13	27-Sep-16
3545	US20170336 412	http://59.45.142.240:8808/pdf/US20170336412A1.pdf	Multiplex Immuno Screening Assay	Institut Pasteur	4-May-12	19-Jul-17	23-Nov-17

3546	US20170144 984	http://59.45.142.240:8808/pdf/US20170144984A1.pdf	MODULATORS OF THE RELAXIN RECEPTOR 1	Not Available	4-May-12	25-Aug-16	25-May-17
3547	US20150119 426	http://59.45.142.240:8808/pdf/US20150119426A1.pdf	MODULATORS OF THE RELAXIN RECEPTOR 1	Not Available	4-May-12	15-Mar-13	30-Apr-15
3548	US20150099 656	http://59.45.142.240:8808/pdf/US20150099656A1.pdf	Multiplex Immuno Screening Assay	Not Available	4-May-12	3-May-13	9-Apr-15
3549	US10209248	http://59.45.142.240:8808/pdf/US10209248.pdf	Multiplex immuno screening assay	Institut Pasteur	4-May-12	19-Jul-17	19-Feb-19
3550	US10125112	http://59.45.142.240:8808/pdf/US10125112.pdf	Modulators of the relaxin receptor 1	THE FLORIDA INTERNATIONAL UNIVERSITY BOARD	4-May-12	25-Aug-16	13-Nov-18
3551	US10119967	http://59.45.142.240:8808/pdf/US10119967.pdf	Multiplex immuno screening assay	Institut Pasteur	4-May-12	3-May-13	6-Nov-18
3552	US9861614	http://59.45.142.240:8808/pdf/US9861614.pdf	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc	9-May-12	23-Jun-15	9-Jan-18
3553	US9585874	http://59.45.142.240:8808/pdf/US9585874.pdf	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc	9-May-12	6-Jan-16	7-Mar-17
3554	US9266843	http://59.45.142.240:8808/pdf/US9266843.pdf	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc	9-May-12	9-May-13	23-Feb-16
3555	US9096543	http://59.45.142.240:8808/pdf/US9096543.pdf	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc	9-May-12	9-May-13	4-Aug-15
3556	US20200038 373	http://59.45.142.240:8808/pdf/US20200038373A1.pdf	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	16-May-19	6-Feb-20
3557	US20190008 833	http://59.45.142.240:8808/pdf/US20190008833A1.pdf	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	17-Jul-18	10-Jan-19
3558	US20170319 551	http://59.45.142.240:8808/pdf/US20170319551A1.pdf	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	24-Jan-17	9-Nov-17
3559	US20160354 347	http://59.45.142.240:8808/pdf/US20160354347A1.pdf	Nuclear Transport Modulators and Uses Thereof	Not Available	9-May-12	6-Jan-16	8-Dec-16
3560	US20160145 246	http://59.45.142.240:8808/pdf/US20160145246A1.pdf	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	23-Jun-15	26-May-16
3561	US20150111 893	http://59.45.142.240:8808/pdf/US20150111893A1.pdf	Nuclear Transport Modulators and Uses Thereof	Not Available	9-May-12	9-May-13	23-Apr-15
3562	US20130317 031	http://59.45.142.240:8808/pdf/US20130317031A1.pdf	Nuclear Transport Modulators And Uses Thereof	Karyopharm Therapeutics Inc	9-May-12	9-May-13	28-Nov-13
3563	US10617677	http://59.45.142.240:8808/pdf/US10617677.pdf	Nuclear transport modulators and uses thereof	Biogen MA Inc.	9-May-12	17-Jul-18	14-Apr-20
3564	US10335393	http://59.45.142.240:8808/pdf/US10335393.pdf	Nuclear transport modulators and uses thereof	Biogen MA Inc.	9-May-12	4-Dec-17	2-Jul-19
3565	US10058535	http://59.45.142.240:8808/pdf/US10058535.pdf	Nuclear transport modulators and uses thereof	Biogen MA Inc.	9-May-12	24-Jan-17	28-Aug-18
3566	US9556229	http://59.45.142.240:8808/pdf/US9556229.pdf	Modification of peptides using a bis(thioether)arylbridge approach	The Regents of the University of California	18-May-12	17-May-13	31-Jan-17
3567	US9376398	http://59.45.142.240:8808/pdf/US9376398.pdf	Carboxylic acid compounds	Astrazeneca Aktiebolag	18-May-12	17-May-13	28-Jun-16
3568	US20190119 220	http://59.45.142.240:8808/pdf/US20190119220A1.pdf	CARBOXYLIC ACID COMPOUNDS	Sumitomo Dainippon Pharma	18-May-12	23-Oct-18	25-Apr-19
3569	US20160251 319	http://59.45.142.240:8808/pdf/US20160251319A1.pdf	CARBOXYLIC ACID COMPOUNDS	Astrazeneca Aktiebolag	18-May-12	11-May-16	1-Sep-16
3570	US20150133 633	http://59.45.142.240:8808/pdf/US20150133633A1.pdf	MODIFICATION OF PEPTIDES USING A BIS(THIOETHER)ARYLBRIDGE APPROACH	Not Available	18-May-12	17-May-13	14-May-15
3571	US20150099 770	http://59.45.142.240:8808/pdf/US20150099770A1.pdf	CARBOXYLIC ACID COMPOUNDS	Not Available	18-May-12	17-May-13	9-Apr-15
3572	US10562861	http://59.45.142.240:8808/pdf/US10562861.pdf	Carboxylic acid compounds	Sumitomo Dainippon Pharma	18-May-12	23-Oct-18	18-Feb-20
3573	US10150743	http://59.45.142.240:8808/pdf/US10150743.pdf	Carboxylic acid compounds	Sumitomo Dainippon Pharma	18-May-12	11-May-16	11-Dec-18
3574	US9878988	http://59.45.142.240:8808/pdf/US9878988.pdf	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye	PARION SCIENCES, INC.	29-May-12	5-Jan-16	30-Jan-18
3575	US9260398	http://59.45.142.240:8808/pdf/US9260398.pdf	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye	PARION SCIENCES, INC.	29-May-12	9-Dec-14	16-Feb-16
3576	US8980898	http://59.45.142.240:8808/pdf/US8980898.pdf	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye	Parion Sciences, Inc.	29-May-12	29-May-13	17-Mar-15
3577	US20180111 907	http://59.45.142.240:8808/pdf/US20180111907A1.pdf	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND	Not Available	29-May-12	20-Dec-17	26-Apr-18
3578	US20160122 306	http://59.45.142.240:8808/pdf/US20160122306A1.pdf	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND	PARION SCIENCES, INC.	29-May-12	5-Jan-16	5-May-16
3579	US20150099 764	http://59.45.142.240:8808/pdf/US20150099764A1.pdf	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND	PARION SCIENCES, INC.	29-May-12	9-Dec-14	9-Apr-15
3580	US20130324 559	http://59.45.142.240:8808/pdf/US20130324559A1.pdf	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND	PARION SCIENCES, INC.	29-May-12	29-May-13	5-Dec-13
3581	US10526292	http://59.45.142.240:8808/pdf/US10526292.pdf	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye	Parion Sciences, Inc.	29-May-12	20-Dec-17	7-Jan-20
3582	US20150150 963	http://59.45.142.240:8808/pdf/US20150150963A1.pdf	VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS	THE AUSTRALIAN NATIONAL UNIVERSITY	5-Jun-12	5-Jun-13	4-Jun-15
3583	US9028837	http://59.45.142.240:8808/pdf/US9028837.pdf	Methods and compositions for poxvirus A252 protein	East Carolina University	7-Jun-12	20-Dec-12	12-May-15
3584	US20150140 121	http://59.45.142.240:8808/pdf/US20150140121A1.pdf	Compositions and Methods for Tight Junction Modulation	Not Available	8-Jun-12	10-Jun-13	21-May-15
3585	US9945780	http://59.45.142.240:8808/pdf/US9945780.pdf	Use of a fluorescent material to detect failure or deteriorated performance of a	GEN-PROBE INCORPORATED	14-Jun-12	7-Jun-13	17-Apr-18
3586	US20180180 544	http://59.45.142.240:8808/pdf/US20180180544A1.pdf	USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A	Not Available	14-Jun-12	22-Feb-18	28-Jun-18
3587	US20130344 613	http://59.45.142.240:8808/pdf/US20130344613A1.pdf	USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A	GEN-PROBE INCORPORATED	14-Jun-12	7-Jun-13	26-Dec-13
3588	US9458184	http://59.45.142.240:8808/pdf/US9458184.pdf	Compositions of TLR7 and/or TLR8 agonists conjugated to lipids	INVIVOGEN	15-Jun-12	15-Mar-13	4-Oct-16

3589	US9266844	http://59.45.142.240:8808/pdf/US9266844.pdf	Suppression of SARS replication by SARS helicase inhibitors	The Curators of the University of Missouri	15-Jun-12	17-Jun-13	23-Feb-16
3590	US20150283 233		Compositions and Methods for Enhancing Immune Responses	Not Available	15-Jun-12	17-Jun-13	8-Oct-15
3591	US20140005 241	http://59.45.142.240:8808/pdf/US20140005241A1.pdf	Suppression of Sars Replication by Sars Helicase Inhibitors	The Curators of the University of Missouri	15-Jun-12	17-Jun-13	2-Jan-14
3592	US20130336 996	http://59.45.142.240:8808/pdf/US20130336996A1.pdf	NOVEL COMPOSITIONS OF TLR7 AND/OR TLR8 AGONISTS	CAYLA	15-Jun-12	15-Mar-13	19-Dec-13
3593	US20150150 893	http://59.45.142.240:8808/pdf/US20150150893A1.pdf	ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION	Not Available	18-Jun-12	31-May-13	4-Jun-15
3594	US20140294 765	http://59.45.142.240:8808/pdf/US20140294765A1.pdf	LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER	COMPUGEN LTD.	21-Jun-12	19-Jun-13	2-Oct-14
3595	US9995706	http://59.45.142.240:8808/pdf/US9995706.pdf	Amperometric gas sensor	Steris Corporation	25-Jun-12	30-Sep-14	12-Jun-18
3596	US9995705	http://59.45.142.240:8808/pdf/US9995705.pdf	Amperometric gas sensor	Steris Corporation	25-Jun-12	30-Sep-14	12-Jun-18
3597	US9803197	http://59.45.142.240:8808/pdf/US9803197.pdf	Particle-nucleic acid conjugates and therapeutic uses related thereto	Emory University	25-Jun-12	27-Feb-13	31-Oct-17
3598	US9459233	http://59.45.142.240:8808/pdf/US9459233.pdf	Amperometric gas sensor	Steris Corporation	25-Jun-12	26-Feb-13	4-Oct-16
3599	US20180057 817	http://59.45.142.240:8808/pdf/US20180057817A1.pdf	Particle-Nucleic Acid Conjugates and Therapeutic Uses Related Thereto	Not Available	25-Jun-12	9-Oct-17	1-Mar-18
3600	US20160363 557	http://59.45.142.240:8808/pdf/US20160363557A1.pdf	AMPEROMETRIC GAS SENSOR	Not Available	25-Jun-12	25-Aug-16	15-Dec-16
3601	US20150166 989	http://59.45.142.240:8808/pdf/US20150166989A1.pdf	PARTICLE-NUCLEIC ACID CONJUGATES AND THERAPEUTIC USES RELATED THERETO	Not Available	25-Jun-12	27-Feb-13	18-Jun-15
3602	US20150021 204	http://59.45.142.240:8808/pdf/US20150021204A1.pdf	AMPEROMETRIC GAS SENSOR	Not Available	25-Jun-12	30-Sep-14	22-Jan-15
3603	US20150021 203	http://59.45.142.240:8808/pdf/US20150021203A1.pdf	AMPEROMETRIC GAS SENSOR	Not Available	25-Jun-12	30-Sep-14	22-Jan-15
3604	US20130341 206	http://59.45.142.240:8808/pdf/US20130341206A1.pdf	AMPEROMETRIC GAS SENSOR	STERIS CORPORATION	25-Jun-12	26-Feb-13	26-Dec-13
3605	US10155946	http://59.45.142.240:8808/pdf/US10155946.pdf	Particle-nucleic acid conjugates and therapeutic uses related thereto	Emory University	25-Jun-12	9-Oct-17	18-Dec-18
3606	US9868952	http://59.45.142.240:8808/pdf/US9868952.pdf	Compositions and methods for a€œresistance-proofa€ siRNA	Sirnaomics, Inc.	8-Jul-12	7-Jul-13	16-Jan-18
3607	US20160068 843	http://59.45.142.240:8808/pdf/US20160068843A1.pdf	Compositions and Methods for "Resistance-Proof" siRNA	Sirnaomics, Inc.	8-Jul-12	7-Jul-13	10-Mar-16
3608	US20200172 480		CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	5-Feb-20	4-Jun-20
3609	US20190367 453	http://59.45.142.240:8808/pdf/US20190367453A1.pdf	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	13-Aug-19	5-Dec-19
3610	US20190330 149	http://59.45.142.240:8808/pdf/US20190330149A1.pdf	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	9-May-19	31-Oct-19
3611	US20180021 448	http://59.45.142.240:8808/pdf/US20180021448A9.pdf	Conjugates of Cell Binding Molecules with Cytotoxic Agents	Hangzhou DAC Biotech Co., Ltd.	12-Jul-12	16-Apr-14	25-Jan-18
3612	US20170157 262	http://59.45.142.240:8808/pdf/US20170157262A1.pdf	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	Not Available	12-Jul-12	12-Jul-12	8-Jun-17
3613	US10501412	http://59.45.142.240:8808/pdf/US10501412B2.pdf	Conjugates of cell binding molecules with cytotoxic agents	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	12-Jul-12	10-Dec-19
3614	US10399941	http://59.45.142.240:8808/pdf/US10399941.pdf	Conjugates of cell binding molecules with cytotoxic agents	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	16-Apr-14	3-Sep-19
3615	US9982257	http://59.45.142.240:8808/pdf/US9982257.pdf	Chiral control	WAVE LIFE SCIENCES LTD.	13-Jul-12	12-Jul-13	29-May-18
3616	US9885037		Chiral control	WAVE LIFE SCIENCES LTD.	13-Jul-12	12-Jul-13	6-Feb-18
3617	US20170275 621	http://59.45.142.240:8808/pdf/US20170275621A1.pdf	CHIRAL CONTROL	Not Available	13-Jul-12	17-Mar-17	28-Sep-17
3618	US20150211 006	http://59.45.142.240:8808/pdf/US20150211006A1.pdf	CHIRAL CONTROL	Not Available	13-Jul-12	12-Jul-13	30-Jul-15
3619	US10590413	http://59.45.142.240:8808/pdf/US10590413.pdf	Chiral control	WAVE LIFE SCIENCES LTD.	13-Jul-12	17-Mar-17	17-Mar-20
3620	US9084758	http://59.45.142.240:8808/pdf/US9084758.pdf	Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof	The Catholic University of Korea Industry-Academic Cooperation	24-Jul-12	25-Aug-14	21-Jul-15
3621	US20140030 364	http://59.45.142.240:8808/pdf/US20140030364A1.pdf	ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF TETRACERA SCANDENS AND USE	Not Available	24-Jul-12	28-Mar-13	30-Jan-14
3622	US20170129 947	http://59.45.142.240:8808/pdf/US20170129947A1.pdf	REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED	Kolltan Pharmaceuticals, Inc.	25-Jul-12	20-Sep-16	11-May-17
3623	US20150164 800	http://59.45.142.240:8808/pdf/US20150164800A1.pdf	REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED	Salk Institute For Biological Studies	25-Jul-12	23-Jul-13	18-Jun-15
3624	US9588069	http://59.45.142.240:8808/pdf/US9588069.pdf	Methods for performing thermal melt analysis	GEN-PROBE INCORPORATED	31-Jul-12	31-Jul-13	7-Mar-17
3625	US20170160 218	http://59.45.142.240:8808/pdf/US20170160218A1.pdf	APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT ANALYSES AND COMPOSITIONS	Not Available	31-Jul-12	23-Feb-17	8-Jun-17
3626	US20140038 170	http://59.45.142.240:8808/pdf/US20140038170A1.pdf	APPARATUS, SYSTEMS, AND METHODS FOR PERFORMING THERMAL MELT ANALYSES AND	Not Available	31-Jul-12	31-Jul-13	6-Feb-14
3627	US10488353	http://59.45.142.240:8808/pdf/US10488353.pdf	Apparatus and system for performing thermal melt analyses	GEN-PROBE INCORPORATED	31-Jul-12	23-Feb-17	26-Nov-19
3628	US9504255	http://59.45.142.240:8808/pdf/US9504255.pdf	Physical antimicrobial method	NMS TECHNOLOGIES CO., LTD.	1-Aug-12	16-Jul-13	29-Nov-16
3629	US20150173 366	http://59.45.142.240:8808/pdf/US20150173366A1.pdf	PHYSICAL ANTIMICROBIAL METHOD	NMS TECHNOLOGIES CO., LTD.	1-Aug-12	16-Jul-13	25-Jun-15
3630	US9809845	http://59.45.142.240:8808/pdf/US9809845.pdf	Methods and reagents for amplifying nucleic acids	The United States of America, as represented by the Secretary, Department of Health and Human Services	6-Aug-12	6-Aug-12	7-Nov-17

3631	US20150159 205	http://59.45.142.240:8808/pdf/US20150159205A1.pdf	METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS	The United States of America, as represented by the Secretary, Department of	6-Aug-12	6-Aug-12	11-Jun-15
3632	US20150216 973		METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE	Not Available	8-Aug-12	8-Aug-13	6-Aug-15
3633	US20170368 167	http://59.45.142.240:8808/pdf/US20170368167A9.pdf	COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DYSREGULATIONS	Not Available	21-Aug-12	6-Jun-16	28-Dec-17
3634	US9346794	http://59.45.142.240:8808/pdf/US9346794.pdf	Substituted 4-pyridones and their use as inhibitors of neutrophil	Boehringer Ingelheim	23-Aug-12	29-Dec-15	24-May-16
3635	US9340507	http://59.45.142.240:8808/pdf/US9340507.pdf	Substituted 4-pyridones and their use as inhibitors of neutrophil	Boehringer Ingelheim	23-Aug-12	2-Sep-15	17-May-16
3636	US9102624	http://59.45.142.240:8808/pdf/US9102624.pdf	Substituted 4-pyridones and their use as inhibitors of neutrophil	Boehringer Ingelheim	23-Aug-12	20-Aug-13	11-Aug-15
3637	US20160130 265	http://59.45.142.240:8808/pdf/US20160130265A1.pdf	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	23-Aug-12	29-Dec-15	12-May-16
3638	US20150376 131	http://59.45.142.240:8808/pdf/US20150376131A1.pdf	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	23-Aug-12	2-Sep-15	31-Dec-15
3639	US20140057 926	http://59.45.142.240:8808/pdf/US20140057926A1.pdf	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	BOEHRINGER INGELHEIM INTERNATIONAL	23-Aug-12	20-Aug-13	27-Feb-14
3640	US20140057 920	http://59.45.142.240:8808/pdf/US20140057920A1.pdf	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	BOEHRINGER INGELHEIM INTERNATIONAL	23-Aug-12	20-Aug-13	27-Feb-14
3641	US20140057 916	http://59.45.142.240:8808/pdf/US20140057916A1.pdf	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	BOEHRINGER INGELHEIM INTERNATIONAL	23-Aug-12	20-Aug-13	27-Feb-14
3642	US20140056 929	http://59.45.142.240:8808/pdf/US20140056929A1.pdf	IMMUNOMODULATION BY CONTROLLING INTERFERON-GAMMA LEVELS WITH THE LONG NON-	The Board of Trustees of the Leland Stanford	23-Aug-12	23-Aug-13	27-Feb-14
3643	USRE46630	http://59.45.142.240:8808/pdf/USRE46630.pdf	Substituted 4-pyridones and their use as inhibitors of neutrophil	Boehringer Ingelheim	23-Aug-12	18-Sep-15	12-Dec-17
3644	US9661856	http://59.45.142.240:8808/pdf/US9661856.pdf	Synergy of plant antimicrobials with silver	The Arizona Board of Regents on Behalf of The	24-Aug-12	26-Aug-13	30-May-17
3645	US9605276	http://59.45.142.240:8808/pdf/US9605276.pdf	Replication defective adenovirus vector in vaccination	Etubics Corporation	24-Aug-12	15-Mar-13	28-Mar-17
3646	US20170165 341	http://59.45.142.240:8808/pdf/US20170165341A1.pdf	REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION	Not Available	24-Aug-12	15-Feb-17	15-Jun-17
3647	US20160076 053	http://59.45.142.240:8808/pdf/US20160076053A1.pdf	REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION	Not Available	24-Aug-12	15-Mar-13	17-Mar-16
3648	US10563224	http://59.45.142.240:8808/pdf/US10563224.pdf	Replication defective adenovirus vector in vaccination	Etubics Corporation	24-Aug-12	15-Feb-17	18-Feb-20
3649	US9511070	http://59.45.142.240:8808/pdf/US9511070.pdf	Heterocyclyl carboxamides for treating viral diseases	NovaDrug, LLC	31-Aug-12	30-Aug-13	6-Dec-16
3650	US20150307 530	http://59.45.142.240:8808/pdf/US20150307530A1.pdf	NOVEL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	31-Aug-12	30-Aug-13	29-Oct-15
3651	US20150238 489	http://59.45.142.240:8808/pdf/US20150238489A1.pdf	HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES	Not Available	31-Aug-12	30-Aug-13	27-Aug-15
3652	US9381244	http://59.45.142.240:8808/pdf/US9381244.pdf	VISTA modulators for diagnosis and treatment of cancer	KING'S COLLEGE LONDON	7-Sep-12	9-Sep-13	5-Jul-16
3653	US20200085 947	http://59.45.142.240:8808/pdf/US20200085947A1.pdf	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	Not Available	7-Sep-12	14-May-19	19-Mar-20
3654	US20190062 380	http://59.45.142.240:8808/pdf/US20190062380A1.pdf	FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND USE	Not Available	7-Sep-12	28-Aug-18	28-Feb-19
3655	US20170112 929	http://59.45.142.240:8808/pdf/US20170112929A1.pdf	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	Not Available	7-Sep-12	6-Jun-16	27-Apr-17
3656	US20150252 080	http://59.45.142.240:8808/pdf/US20150252080A1.pdf	FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND USE	Not Available	7-Sep-12	9-Sep-13	10-Sep-15
3657	US20140105 912	http://59.45.142.240:8808/pdf/US20140105912A1.pdf	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	THE TRUSTEES OF DARTMOUTH COLLEGE	7-Sep-12	9-Sep-13	17-Apr-14
3658	US10329329	http://59.45.142.240:8808/pdf/US10329329.pdf	Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of	UNIVERSITY OF MIAMI	7-Sep-12	28-Aug-18	25-Jun-19
3659	US9932323	http://59.45.142.240:8808/pdf/US9932323.pdf	Therapeutic hydroxypyridinones, hydroxypyrimidinones and	Rutgers, The State University of New	11-Sep-12	13-Jan-17	3-Apr-18
3660	US9573938	http://59.45.142.240:8808/pdf/US9573938.pdf	Therapeutic hydroxypyridinones, hydroxypyrimidinones and	Rutgers, The State University of New	11-Sep-12	11-Sep-13	21-Feb-17
3661	US20170204 083	http://59.45.142.240:8808/pdf/US20170204083A1.pdf	THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	11-Sep-12	13-Jan-17	20-Jul-17
3662	US20150232 454	http://59.45.142.240:8808/pdf/US20150232454A1.pdf	THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	11-Sep-12	11-Sep-13	20-Aug-15
3663	US9611474	http://59.45.142.240:8808/pdf/US9611474.pdf	Double-stranded oligonucleotide molecules to DDIT4 and methods of	QUARK PHARMACEUTICALS, INC.	12-Sep-12	12-Sep-13	4-Apr-17
3664	US20180010 125	http://59.45.142.240:8808/pdf/US20180010125A1.pdf	DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE	Quark Pharmaceuticals Inc.	12-Sep-12	15-Feb-17	11-Jan-18
3665	US20150267 194	http://59.45.142.240:8808/pdf/US20150267194A1.pdf	DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE	Quark Pharmaceutical, Inc.	12-Sep-12	12-Sep-13	24-Sep-15

3666	US10421962	http://59.45.142.240:8808/pdf/US10421962.pdf	Double-stranded oligonucleotide molecules to DDIT4 and methods of	Quark Pharmaceuticals,	12-Sep-12	15-Feb-17	24-Sep-19
3667	US9764027	http://59.45.142.240:8808/pdf/US9764027.pdf	Outer membrane vesicles	GLAXOSMITHKLINE BIOLOGICALS SA	18-Sep-12	18-Sep-13	19-Sep-17
3668	US20150231 232	http://59.45.142.240:8808/pdf/US20150231232A1.pdf	OUTER MEMBRANE VESICLES	Not Available	18-Sep-12	18-Sep-13	20-Aug-15
3669	US9873674	http://59.45.142.240:8808/pdf/US9873674.pdf	C-Rel inhibitors and uses thereof	CORNELL UNIVERSITY	21-Sep-12	19-Sep-13	23-Jan-18
3670	US20150218 109	http://59.45.142.240:8808/pdf/US20150218109A1.pdf	C-REL INHIBITORS AND USES THEREOF	Not Available	21-Sep-12	19-Sep-13	6-Aug-15
3671	US20150275 183	http://59.45.142.240:8808/pdf/US20150275183A1.pdf	Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus	Not Available	23-Sep-12	23-Sep-13	1-Oct-15
3672	US9636370	http://59.45.142.240:8808/pdf/US9636370.pdf	AAV vectors targeted to oligodendrocytes	The University of North Carolina at	28-Sep-12	27-Sep-13	2-May-17
3673	US20190328 804	http://59.45.142.240:8808/pdf/US20190328804A1.pdf	AAV Vectors Targeted to Oligodendrocytes	Not Available	28-Sep-12	15-Jul-19	31-Oct-19
3674	US20170274 024	http://59.45.142.240:8808/pdf/US20170274024A1.pdf	AAV Vectors Targeted to Oligodendrocytes	Not Available	28-Sep-12	17-Apr-17	28-Sep-17
3675	US20150238 550	http://59.45.142.240:8808/pdf/US20150238550A1.pdf	AAV Vectors Targeted to Oligodendrocytes	Not Available	28-Sep-12	27-Sep-13	27-Aug-15
3676	US9884032	http://59.45.142.240:8808/pdf/US9884032.pdf	Esters of short chains fatty acids for use in the treatment of immunogenic	PROPONENT BIOTECH GMBH	3-Oct-12	3-Mar-16	6-Feb-18
3677	US9415033	http://59.45.142.240:8808/pdf/US9415033.pdf	Esters of short chains fatty acids for use in the treatment of immunogenic	PROPONENT BIOTECH GMBH	3-Oct-12	3-Oct-13	16-Aug-16
3678	US20160250 168	http://59.45.142.240:8808/pdf/US20160250168A1.pdf	ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT	Not Available	3-Oct-12	3-Mar-16	1-Sep-16
3679	US20150246 015	http://59.45.142.240:8808/pdf/US20150246015A1.pdf	Esters of Short Chains Fatty Acids for Use in the Treatment of	Not Available	3-Oct-12	3-Oct-13	3-Sep-15
3680	US9907796	http://59.45.142.240:8808/pdf/US9907796.pdf	Methods of treating tumoral diseases, or bacterial or viral	INHIBIKASE THERAPEUTICS,	4-Oct-12	15-Sep-16	6-Mar-18
3681	US20150247 190	http://59.45.142.240:8808/pdf/US20150247190A1.pdf	METHODS AND SYSTEMS FOR MICROFLUIDICS IMAGING AND	Not Available	5-Oct-12	4-Oct-13	3-Sep-15
3682	US20200087 630		INFLUENZA VIRUS AND TYPE 1 DIABETES	Istituto Zooprofilattico Sperimentale delle	10-Oct-12	25-Jul-19	19-Mar-20
3683	US20150299 667		INFLUENZA VIRUS AND TYPE 1 DIABETES	ISTITUTO ZOOPROFILATTICO SPERIMENTALE	10-Oct-12	10-Oct-13	22-Oct-15
3684	US9717749	http://59.45.142.240:8808/pdf/US9717749.pdf	Production of stable non-polyadenylated RNAs	Massachusetts Institute of	16-Oct-12	16-Oct-13	1-Aug-17
3685	US20180140 625	http://59.45.142.240:8808/pdf/US20180140625A1.pdf	PRODUCTION OF STABLE NON-POLYADENYLATED RNAS	Massachusetts Institute of	16-Oct-12	31-Jul-17	24-May-18
3686	US20150315 574	http://59.45.142.240:8808/pdf/US20150315574A1.pdf	PRODUCTION OF STABLE NON-POLYADENYLATED RNAS	Massachusetts Institute of	16-Oct-12	16-Oct-13	5-Nov-15
3687	US9637491	http://59.45.142.240:8808/pdf/US9637491.pdf	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors	ORIGENIS GMBH	19-Oct-12	18-Oct-13	2-May-17
3688	US20180305 356		NOVEL KINASE INHIBITORS	Not Available	19-Oct-12	18-May-18	25-Oct-18
3689	US20150266 882	http://59.45.142.240:8808/pdf/US20150266882A1.pdf	PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS	Not Available	19-Oct-12	18-Oct-13	24-Sep-15
3690	US20150259 340		NOVEL KINASE INHIBITORS	Not Available	19-Oct-12	18-Oct-13	17-Sep-15
3691	US9657076	http://59.45.142.240:8808/pdf/US9657076.pdf	GM-CSF and IL-4 conjugates, compositions, and methods related	Children's Healthcare of	23-Oct-12	23-Oct-13	23-May-17
3692	US20190016 772	http://59.45.142.240:8808/pdf/US20190016772A1.pdf	GM-CSF and IL-4 Conjugates, Compositions, and Methods Related	Not Available	23-Oct-12	2-Oct-18	17-Jan-19
3693	US20170226 173	http://59.45.142.240:8808/pdf/US20170226173A1.pdf	GM-CSF and IL-4 Conjugates, Compositions, and Methods Related	Not Available	23-Oct-12	19-Apr-17	10-Aug-17
3694	US20160046 687	http://59.45.142.240:8808/pdf/US20160046687A1.pdf	GM-CSF AND IL-4 CONJUGATES, COMPOSITIONS, AND METHODS	Not Available	23-Oct-12	23-Oct-13	18-Feb-16
3695	US9295708	http://59.45.142.240:8808/pdf/US9295708.pdf	Modified release formulations for	Onyx Therapeutics, Inc.	24-Oct-12	24-Oct-13	29-Mar-16
3696	US20160213 610	http://59.45.142.240:8808/pdf/US20160213610A1.pdf	MODIFIED RELEASE FORMULATIONS FOR ORPAZOMIB	Not Available	24-Oct-12	28-Jan-16	28-Jul-16
3697	US20140113 855	http://59.45.142.240:8808/pdf/US20140113855A1.pdf	Modified Release Formulations for	Not Available	24-Oct-12	24-Oct-13	24-Apr-14
3698	US20190023 769	http://59.45.142.240:8808/pdf/US20190023769A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION	Not Available	29-Oct-12	21-Sep-18	24-Jan-19
3699	US20150284 451	http://59.45.142.240:8808/pdf/US20150284451A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION	Not Available	29-Oct-12	29-Oct-13	8-Oct-15
3700	US9701638	http://59.45.142.240:8808/pdf/US9701638.pdf	Therapeutic hydroxyquinolones	Rutgers, The State University of New	9-Nov-12	8-Nov-13	11-Jul-17
3701	US20150291 531	http://59.45.142.240:8808/pdf/US20150291531A1.pdf	THERAPEUTIC HYDROXYQUINOLONES	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	9-Nov-12	8-Nov-13	15-Oct-15
3702	US9567336	http://59.45.142.240:8808/pdf/US9567336.pdf	Conjugated TLR7 and/or TLR8 and TLR2 agonists	INVIVOGEN	19-Nov-12	15-Mar-13	14-Feb-17
3703	US20140141 033	http://59.45.142.240:8808/pdf/US20140141033A1.pdf	CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS	CAYLA	19-Nov-12	15-Mar-13	22-May-14
3704	US20140308 379	http://59.45.142.240:8808/pdf/US20140308379A1.pdf	USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISORDERS AND	The Trustees of the University of Pennsylvania	20-Nov-12	19-Nov-13	16-Oct-14
3705	US9822173	http://59.45.142.240:8808/pdf/US9822173.pdf	Heterodimeric immunoglobulins	AMGEN INC.	21-Nov-12	21-Nov-13	21-Nov-17
3706	US9562110	http://59.45.142.240:8808/pdf/US9562110.pdf	Bispecific antibody	Wuhan YZY Biopharma Co., Ltd.	21-Nov-12	21-Nov-12	7-Feb-17
3707	US9079965	http://59.45.142.240:8808/pdf/US9079965.pdf	Bispecific antibody	Wuhan YZY Biopharma Co., LTD.	21-Nov-12	13-Mar-14	14-Jul-15
3708	US20190153 086	http://59.45.142.240:8808/pdf/US20190153086A1.pdf	Heterodimeric Immunoglobulins	Not Available	21-Nov-12	5-Feb-19	23-May-19
3709	US20160046 705	http://59.45.142.240:8808/pdf/US20160046705A1.pdf	HETERODIMERIC IMMUNOGLOBULINS	Not Available	21-Nov-12	21-Nov-13	18-Feb-16
3710	US20150284 475	http://59.45.142.240:8808/pdf/US20150284475A1.pdf	BISPECIFIC ANTIBODY	Not Available	21-Nov-12	21-Nov-12	8-Oct-15

3711	US20140243 505	http://59.45.142.240:8808/pdf/US20140243505A1.pdf	BISPECIFIC ANTIBODY	WUHAN YZY BIOPHARMA CO.,	21-Nov-12	13-Mar-14	28-Aug-14
3712	US20140154 254	http://59.45.142.240:8808/pdf/US20140154254A1.pdf	HETERODIMERIC IMMUNOGLOBULINS	AMGEN INC.	21-Nov-12	21-Nov-13	5-Jun-14
3713	US10233237	http://59.45.142.240:8808/pdf/US10233237.pdf	Heterodimeric immunoglobulins	AMGEN INC.	21-Nov-12	21-Nov-13	19-Mar-19
3714	US9028841	http://59.45.142.240:8808/pdf/US9028841.pdf	Synergistic bacterial compositions and methods of production and use	Seres Health, Inc.	23-Nov-12	20-Mar-14	12-May-15
3715	US20150290 235	http://59.45.142.240:8808/pdf/US20150290235A1.pdf	USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES	Not Available	23-Nov-12	8-Nov-13	15-Oct-15
3716	US20140199 281	http://59.45.142.240:8808/pdf/US20140199281A1.pdf	SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF	Seres Health, Inc.	23-Nov-12	20-Mar-14	17-Jul-14
3717	US20150250 896	http://59.45.142.240:8808/pdf/US20150250896A1.pdf	HYDROPHILIC LINKERS AND THEIR USES FOR CONJUGATION OF DRUGS TO A CELL-BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd.	24-Nov-12	24-Nov-12	10-Sep-15
3718	US10131682	http://59.45.142.240:8808/pdf/US10131682.pdf	Hydrophilic linkers and their uses for conjugation of drugs to a cell binding	HANGZHOU DAC BIOTECH CO., LTD.	24-Nov-12	24-Nov-12	20-Nov-18
3719	US9938258	http://59.45.142.240:8808/pdf/US9938258.pdf	Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof	Karyopharm Therapeutics Inc	29-Nov-12	27-Nov-13	10-Apr-18
3720	US20160221 994	http://59.45.142.240:8808/pdf/US20160221994A1.pdf	Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof	Not Available	29-Nov-12	27-Nov-13	4-Aug-16
3721	US9789180	http://59.45.142.240:8808/pdf/US9789180.pdf	D-amino acid derivative-modified peptidoglycan and methods of use	The Regents of the University of	30-Nov-12	31-Mar-16	17-Oct-17
3722	US9303068	http://59.45.142.240:8808/pdf/US9303068.pdf	D-amino acid derivative-modified peptidoglycan and methods of use	The Regents of the University of	30-Nov-12	27-Nov-13	5-Apr-16
3723	US20180000 929	http://59.45.142.240:8808/pdf/US20180000929A1.pdf	D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF	Not Available	30-Nov-12	14-Sep-17	4-Jan-18
3724	US20170021 013	http://59.45.142.240:8808/pdf/US20170021013A1.pdf	D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF	Not Available	30-Nov-12	31-Mar-16	26-Jan-17
3725	US20140170 183	http://59.45.142.240:8808/pdf/US20140170183A1.pdf	D-Amino Acid Derivative-Modified Peptidoglycan and Methods of Use	The Regents of the University of	30-Nov-12	27-Nov-13	19-Jun-14
3726	US10016498	http://59.45.142.240:8808/pdf/US10016498.pdf	D-amino acid derivative-modified peptidoglycan and methods of use	The Regents of the University of	30-Nov-12	14-Sep-17	10-Jul-18
3727	US9402878	http://59.45.142.240:8808/pdf/US9402878.pdf	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals,	3-Dec-12	1-Jul-15	2-Aug-16
3728	US9163065	http://59.45.142.240:8808/pdf/US9163065.pdf	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals,	3-Dec-12	3-Dec-13	20-Oct-15
3729	US20200024 310	http://59.45.142.240:8808/pdf/US20200024310A1.pdf	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	1-Aug-19	23-Jan-20
3730	US20170121 372	http://59.45.142.240:8808/pdf/US20170121372A1.pdf	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	15-Jun-16	4-May-17
3731	US20150313 960	http://59.45.142.240:8808/pdf/US20150313960A1.pdf	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	1-Jul-15	5-Nov-15
3732	US20140194 345	http://59.45.142.240:8808/pdf/US20140194345A1.pdf	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	3-Dec-13	10-Jul-14
3733	US10414800	http://59.45.142.240:8808/pdf/US10414800.pdf	Methods for producing a depsipeptide	NovoBiotic Pharmaceuticals,	3-Dec-12	15-Jun-16	17-Sep-19
3734	US9556237	http://59.45.142.240:8808/pdf/US9556237.pdf	Antiviral rift valley fever virus peptides and methods of use	The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army MedicalResearch	6-Dec-12	4-Jun-15	31-Jan-17
3735	US20150337 015	http://59.45.142.240:8808/pdf/US20150337015A1.pdf	ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF USE	The United States of America, as represented by the Secretary of the Army, on behalf of	6-Dec-12	4-Jun-15	26-Nov-15
3736	US9718774	http://59.45.142.240:8808/pdf/US9718774.pdf	Indole carboxamide derivatives as P2X7 receptor antagonist	IDORSIA PHARMACEUTICALS	12-Dec-12	11-Dec-13	1-Aug-17
3737	US20150322 008	http://59.45.142.240:8808/pdf/US20150322008A1.pdf	INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR	ACTELION PHARMACEUTICALS	12-Dec-12	11-Dec-13	12-Nov-15
3738	US20150297 677	http://59.45.142.240:8808/pdf/US20150297677A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY	Children Medical Center Corporation	13-Dec-12	12-Dec-13	22-Oct-15
3739	US9700614	http://59.45.142.240:8808/pdf/US9700614.pdf	Intranasal vaccination dosage regimen	Eurocine Vaccines AB	17-Dec-12	17-Dec-13	11-Jul-17
3740	US9695134	http://59.45.142.240:8808/pdf/US9695134.pdf	3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-	Parion Sciences, Inc.	17-Dec-12	8-Jan-15	4-Jul-17
3741	US9593084	http://59.45.142.240:8808/pdf/US9593084.pdf	Chloro-pyrazine carboxamide derivatives with epithelial sodium	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	14-Mar-17
3742	US9029382	http://59.45.142.240:8808/pdf/US9029382.pdf	3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl)	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	12-May-15
3743	US20190308 943	http://59.45.142.240:8808/pdf/US20190308943A1.pdf	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE	Parion Sciences, Inc.	17-Dec-12	13-Mar-19	10-Oct-19
3744	US20190084 943	http://59.45.142.240:8808/pdf/US20190084943A1.pdf	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING	Parion Sciences, Inc.	17-Dec-12	23-Aug-18	21-Mar-19
3745	US20170362 187	http://59.45.142.240:8808/pdf/US20170362187A1.pdf	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE	Parion Sciences, Inc.	17-Dec-12	29-Jun-17	21-Dec-17
3746	US20170327 472	http://59.45.142.240:8808/pdf/US20170327472A1.pdf	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING	Parion Sciences, Inc.	17-Dec-12	7-Mar-17	16-Nov-17

3747	US20160184 424	http://59.45.142.240:8808/pdf/US20160184424A1.pdf	INTRANASAL VACCINATION DOSAGE REGIMEN	Not Available	17-Dec-12	17-Dec-13	30-Jun-16
3748	US20150306 205	http://59.45.142.240:8808/pdf/US20150306205A1.pdf	VACCINE COMPOSITION FOR NAIVE SUBJECTS	Not Available	17-Dec-12	17-Dec-13	29-Oct-15
3749	US20150299 142	http://59.45.142.240:8808/pdf/US20150299142A1.pdf	3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL PYRAZINE-2-CARBOXAMIDE	PARION SCIENCES, INC.	17-Dec-12	8-Jan-15	22-Oct-15
3750	US20140171 447	http://59.45.142.240:8808/pdf/US20140171447A1.pdf	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	19-Jun-14
3751	US20140170 244	http://59.45.142.240:8808/pdf/US20140170244A1.pdf	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	19-Jun-14
3752	US10246425	http://59.45.142.240:8808/pdf/US10246425.pdf	3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbaimidoyl)	Parion Sciences, Inc.	17-Dec-12	29-Jun-17	2-Apr-19
3753	US10071970	http://59.45.142.240:8808/pdf/US10071970.pdf	Chloro-pyrazine carboxamide derivatives with epithelial sodium	Parion Sciences, Inc.	17-Dec-12	7-Mar-17	11-Sep-18
3754	US9828382	http://59.45.142.240:8808/pdf/US9828382.pdf	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18-Dec-12	10-May-16	28-Nov-17
3755	US9556117	http://59.45.142.240:8808/pdf/US9556117.pdf	Indole carboxamide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	18-Dec-12	17-Dec-13	31-Jan-17
3756	US9365577	http://59.45.142.240:8808/pdf/US9365577.pdf	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18-Dec-12	17-Dec-13	14-Jun-16
3757	US20160251 362		NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	18-Dec-12	10-May-16	1-Sep-16
3758	US20150344 425	http://59.45.142.240:8808/pdf/US20150344425A1.pdf	INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	ACTELION PHARMACEUTICALS LTD.	18-Dec-12	17-Dec-13	3-Dec-15
3759	US20140171 414		NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	18-Dec-12	17-Dec-13	19-Jun-14
3760	US20140178 422	http://59.45.142.240:8808/pdf/US20140178422A1.pdf	PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM	The Administrators of the Tulane Educational Fund	21-Dec-12	15-Nov-13	26-Jun-14
3761	US10472647	http://59.45.142.240:8808/pdf/US10472647.pdf	Primary mesenchymal stem cells as a vaccine platform	The Administrators of the Tulane Educational Fund	21-Dec-12	15-Nov-13	12-Nov-19
3762	US9834812	http://59.45.142.240:8808/pdf/US9834812.pdf	Probe kit for detecting a single strand target nucleotide sequence	Fondazione Istituto Italiano Di Tecnologia	27-Dec-12	27-Dec-13	5-Dec-17
3763	US20160053 308	http://59.45.142.240:8808/pdf/US20160053308A1.pdf	PROBE KIT FOR DETECTING A SINGLE STRAND TARGET NUCLEOTIDE SEQUENCE	Fondzione Istituto Italiano Di Tecnolgia	27-Dec-12	27-Dec-13	25-Feb-16
3764	US20150320 842	http://59.45.142.240:8808/pdf/US20150320842A1.pdf	A COMPOSITION FOR PREVENTING OR TREATING AN RNA VIRAL INFECTION COMPRISING SAMHD1 OR A NUCLEIC ACID MOLECULE	SNU R&DB FOUNDATION	7-Jan-13	7-Jan-13	12-Nov-15
3765	US20190336 597	http://59.45.142.240:8808/pdf/US20190336597A1.pdf	METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES	Not Available	8-Jan-13	17-May-19	7-Nov-19
3766	US20160008 461	http://59.45.142.240:8808/pdf/US20160008461A1.pdf	METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES	Not Available	8-Jan-13	2-Aug-14	14-Jan-16
3767	US20140194 500	http://59.45.142.240:8808/pdf/US20140194500A1.pdf	Methods For Treating of SARS	Not Available	8-Jan-13	8-Jan-13	10-Jul-14
3768	US10335484	http://59.45.142.240:8808/pdf/US10335484.pdf	Methods of generating robust passive and active immune responses	HUMABS BIOMED SA	8-Jan-13	8-Jan-14	2-Jul-19
3769	US20150353 905	http://59.45.142.240:8808/pdf/US20150353905A1.pdf	CAS9-NUCLEIC ACID COMPLEXES AND USES RELATED THERETO	Not Available	16-Jan-13	15-Jan-14	10-Dec-15
3770	US10544405	http://59.45.142.240:8808/pdf/US10544405.pdf	Cas9-nucleic acid complexes and uses related thereto	Emory University	16-Jan-13	15-Jan-14	28-Jan-20
3771	US9388197	http://59.45.142.240:8808/pdf/US9388197.pdf	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	22-Jan-13	21-Jan-14	12-Jul-16
3772	US20150361 097	http://59.45.142.240:8808/pdf/US20150361097A1.pdf	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	Not Available	22-Jan-13	21-Jan-14	17-Dec-15
3773	US20150361 096	http://59.45.142.240:8808/pdf/US20150361096A1.pdf	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	Not Available	22-Jan-13	21-Jan-14	17-Dec-15
3774	US20150322 137	http://59.45.142.240:8808/pdf/US20150322137A1.pdf	HUMAN ANTIBODY SPECIFIC TO HUMAN METAPNEUMOVIRUS, OR ANTIGEN-BINDING FRAGMENT	Not Available	28-Jan-13	28-Jan-14	12-Nov-15
3775	US9993543	http://59.45.142.240:8808/pdf/US9993543.pdf	Immunogenic compositions comprising silicified virus and	Portland State University	31-Jan-13	31-Jan-14	12-Jun-18
3776	US20150359 871	http://59.45.142.240:8808/pdf/US20150359871A1.pdf	IMMUNOGENIC COMPOSITIONS COMPRISING SILICIFIED VIRUS AND METHODS OF USE	PORTLAND STATE UNIVERSITY	31-Jan-13	31-Jan-14	17-Dec-15
3777	US9827190	http://59.45.142.240:8808/pdf/US9827190.pdf	Intradermal delivery of immunological compositions comprising toll- like receptor 7	GLAXOSMITHKLINE BIOLOGICALS SA	1-Feb-13	30-Jan-14	28-Nov-17
3778	US20150366 796	http://59.45.142.240:8808/pdf/US20150366796A1.pdf	INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS COMPRISING TOLL-LIKE RECEPTOR	Not Available	1-Feb-13	30-Jan-14	24-Dec-15
3779	US20190192 581	http://59.45.142.240:8808/pdf/US20190192581A1.pdf	Methods of Populating a Gastrointestinal Tract	Not Available	4-Feb-13	1-Aug-18	27-Jun-19
3780	US20160158 294	http://59.45.142.240:8808/pdf/US20160158294A1.pdf	Methods of Populating a Gastrointestinal Tract	Not Available	4-Feb-13	4-Feb-14	9-Jun-16
3781	US10064900	http://59.45.142.240:8808/pdf/US10064900.pdf	Methods of populating a gastrointestinal tract	Seres Therapeutics, Inc.	4-Feb-13	4-Feb-14	4-Sep-18
3782	US20140220 063	http://59.45.142.240:8808/pdf/US20140220063A1.pdf	VACCINE COMPOSITION	Not Available	5-Feb-13	29-Jan-14	7-Aug-14
3783	US10076491	http://59.45.142.240:8808/pdf/US10076491.pdf	Vaccine composition	NITTO DENKO CORPORATION	5-Feb-13	29-Jan-14	18-Sep-18
3784	US9670166	http://59.45.142.240:8808/pdf/US9670166.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	6-Feb-13	5-Aug-16	6-Jun-17
3785	US9290459	http://59.45.142.240:8808/pdf/US9290459.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	6-Feb-13	9-Nov-15	22-Mar-16

3786	US20160340 319	http://59.45.142.240:8808/pdf/US20160340319A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	6-Feb-13	5-Aug-16	24-Nov-16
3787	US20160060 231	http://59.45.142.240:8808/pdf/US20160060231A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	6-Feb-13	9-Nov-15	3-Mar-16
3788	US20160060 230	http://59.45.142.240:8808/pdf/US20160060230A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	6-Feb-13	9-Nov-15	3-Mar-16
3789	US20140221 335	http://59.45.142.240:8808/pdf/US20140221335A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	BOEHRINGER INGELHEIM INTERNATIONAL	6-Feb-13	28-Jan-14	7-Aug-14
3790	US20150368 661	http://59.45.142.240:8808/pdf/US20150368661A1.pdf	METHODS FOR PRODUCING ANTIBODIES	Not Available	11-Feb-13	11-Feb-14	24-Dec-15
3791	US10066238	http://59.45.142.240:8808/pdf/US10066238.pdf	Methods for producing antibodies	UNIVERSITY OF LOUISVILLE RESEARCH	11-Feb-13	11-Feb-14	4-Sep-18
3792	US9913801	http://59.45.142.240:8808/pdf/US9913801.pdf	Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with	YOUR ENERGY SYSTEMS, LLC	15-Feb-13	15-Mar-13	13-Mar-18
3793	US20150374 626	http://59.45.142.240:8808/pdf/US20150374626A1.pdf	TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY	YOUR ENERGY SYSTEMS, LLC	15-Feb-13	15-Mar-13	31-Dec-15
3794	US9974845	http://59.45.142.240:8808/pdf/US9974845.pdf	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22-Feb-13	21-Feb-14	22-May-18
3795	US9295732	http://59.45.142.240:8808/pdf/US9295732.pdf	Conjugated TLR7 and/or TLR8 and TLR2 polyclonitic agonists	INVIVOGEN	22-Feb-13	22-Feb-13	29-Mar-16
3796	US20190381 155	http://59.45.142.240:8808/pdf/US20190381155A1.pdf	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	CureVac AG	22-Feb-13	29-Aug-19	19-Dec-19
3797	US20160206 719	http://59.45.142.240:8808/pdf/US20160206719A1.pdf	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	CureVac AG	22-Feb-13	5-Apr-16	21-Jul-16
3798	US20160130 345	http://59.45.142.240:8808/pdf/US20160130345A1.pdf	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	Not Available	22-Feb-13	21-Feb-14	12-May-16
3799	US20140242 108	http://59.45.142.240:8808/pdf/US20140242108A1.pdf	Conjugated TLR7 and/or TLR8 and TLR2 polyclonitic agonists	CAYLA	22-Feb-13	22-Feb-13	28-Aug-14
3800	US10434158	http://59.45.142.240:8808/pdf/US10434158.pdf	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22-Feb-13	7-Feb-18	8-Oct-19
3801	US10117920	http://59.45.142.240:8808/pdf/US10117920.pdf	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22-Feb-13	7-Feb-18	6-Nov-18
3802	US20160000 905	http://59.45.142.240:8808/pdf/US20160000905A1.pdf	Nanoparticle Delivery of TLR Agonists and Antigen	Not Available	25-Feb-13	24-Feb-14	7-Jan-16
3803	US20150377 887	http://59.45.142.240:8808/pdf/US20150377887A1.pdf	IN SITU AFFINITY MATURATION OF ANTIBODIES	Not Available	27-Feb-13	27-Feb-14	31-Dec-15
3804	US9889194	http://59.45.142.240:8808/pdf/US9889194.pdf	Immunogenic composition for MERS coronavirus infection	New York Blood Center, Inc	1-Mar-13	28-Feb-14	13-Feb-18
3805	US9696247	http://59.45.142.240:8808/pdf/US9696247.pdf	Sample fixation and stabilisation	RNASSIST LTD.	1-Mar-13	28-Feb-14	4-Jul-17
3806	US20180058 988	http://59.45.142.240:8808/pdf/US20180058988A1.pdf	SAMPLE FIXATION AND STABILISATION	Not Available	1-Mar-13	14-Aug-17	1-Mar-18
3807	US20170328 819	http://59.45.142.240:8808/pdf/US20170328819A1.pdf	SAMPLE FIXATION AND STABILISATION	Not Available	1-Mar-13	30-May-17	16-Nov-17
3808	US20160296 617	http://59.45.142.240:8808/pdf/US20160296617A1.pdf	Immunogenic Composition for MERS Coronavirus Infection	Not Available	1-Mar-13	28-Feb-14	13-Oct-16
3809	US20140295 404	http://59.45.142.240:8808/pdf/US20140295404A1.pdf	SAMPLE FIXATION AND STABILISATION	Not Available	1-Mar-13	28-Feb-14	2-Oct-14
3810	US10539488	http://59.45.142.240:8808/pdf/US10539488.pdf	Sample fixation and stabilisation	RNASSIST LTD.	1-Mar-13	14-Aug-17	21-Jan-20
3811	US10393633	http://59.45.142.240:8808/pdf/US10393633.pdf	Sample fixation and stabilisation	RNASSIST LTD.	1-Mar-13	30-May-17	27-Aug-19
3812	US9115093	http://59.45.142.240:8808/pdf/US9115093.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	4-Mar-13	20-Feb-14	25-Aug-15
3813	US20140249 129	http://59.45.142.240:8808/pdf/US20140249129A1.pdf	Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase	Boehringer Ingelheim International GmbH	4-Mar-13	20-Feb-14	4-Sep-14
3814	US9504747	http://59.45.142.240:8808/pdf/US9504747.pdf	Lipids and lipid compositions for the delivery of active agents	Novartis AG	8-Mar-13	7-Mar-14	29-Nov-16
3815	US20180369 386	http://59.45.142.240:8808/pdf/US20180369386A1.pdf	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Not Available	8-Mar-13	29-Aug-18	27-Dec-18
3816	US20170196 979	http://59.45.142.240:8808/pdf/US20170196979A1.pdf	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Novartis AG	8-Mar-13	27-Sep-16	13-Jul-17
3817	US20160106 842	http://59.45.142.240:8808/pdf/US20160106842A1.pdf	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Not Available	8-Mar-13	6-Mar-14	21-Apr-16
3818	US20140303 232	http://59.45.142.240:8808/pdf/US20140303232A1.pdf	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	NOVARTIS AG	8-Mar-13	7-Mar-14	9-Oct-14
3819	US10124065	http://59.45.142.240:8808/pdf/US10124065.pdf	Lipids and lipid compositions for the delivery of active agents	Novartis AG	8-Mar-13	6-Mar-14	13-Nov-18
3820	US20140255 426	http://59.45.142.240:8808/pdf/US20140255426A1.pdf	WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS	Children's Healthcare of Atlanta, Inc	11-Mar-13	10-Mar-14	11-Sep-14
3821	US9840731	http://59.45.142.240:8808/pdf/US9840731.pdf	Preservation of biological materials in non-aqueous fluid media	Gentegra, LLC	14-Mar-13	14-Mar-14	12-Dec-17
3822	US9713606	http://59.45.142.240:8808/pdf/US9713606.pdf	Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides	Boehringer Ingelheim International GmbH	14-Mar-13	1-Dec-15	25-Jul-17
3823	US9493518	http://59.45.142.240:8808/pdf/US9493518.pdf	Compositions and methods for treating clostridium difficile-	National Health Research Institutes	14-Mar-13	13-Mar-14	15-Nov-16
3824	US9101597	http://59.45.142.240:8808/pdf/US9101597.pdf	Immunoprotective primary mesenchymal stem cells and	Autoimmune Technologies, LLC	14-Mar-13	14-Mar-13	11-Aug-15
3825	US9073869	http://59.45.142.240:8808/pdf/US9073869.pdf	Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides	Boehringer Ingelheim International GmbH	14-Mar-13	11-Sep-14	7-Jul-15

3826	US8987249	http://59.45.142.240:8808/pdf/US8987249.pdf	Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides	Boehringer Ingelheim International GmbH	14-Mar-13	12-Mar-14	24-Mar-15
3827	US8889708	http://59.45.142.240:8808/pdf/US8889708.pdf	Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides	Boehringer Ingelheim	14-Mar-13	12-Mar-14	18-Nov-14
3828	US8877775	http://59.45.142.240:8808/pdf/US8877775.pdf	Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides	Boehringer Ingelheim International GmbH	14-Mar-13	12-Mar-14	4-Nov-14
3829	US8871783	http://59.45.142.240:8808/pdf/US8871783.pdf	Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides	Boehringer Ingelheim International GmbH	14-Mar-13	12-Mar-14	28-Oct-14
3830	US20200138 780	http://59.45.142.240:8808/pdf/US20200138780A1.pdf	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	Not Available	14-Mar-13	19-Dec-19	7-May-20
3831	US20190282 694	http://59.45.142.240:8808/pdf/US20190282694A1.pdf	IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS	AUTOIMMUNE TECHNOLOGIES, LLC	14-Mar-13	30-May-19	19-Sep-19
3832	US20190167 636	http://59.45.142.240:8808/pdf/US20190167636A1.pdf	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	Not Available	14-Mar-13	8-Feb-19	6-Jun-19
3833	US20170266 160	http://59.45.142.240:8808/pdf/US20170266160A1.pdf	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	Not Available	14-Mar-13	6-Jun-17	21-Sep-17
3834	US20160222 414	http://59.45.142.240:8808/pdf/US20160222414A1.pdf	CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA VIRAL VECTORS WITH BLUNTED INNATE	Not Available	14-Mar-13	15-Apr-16	4-Aug-16
3835	US20160129 110	http://59.45.142.240:8808/pdf/US20160129110A1.pdf	IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS	AUTOIMMUNE TECHNOLOGIES, LLC	14-Mar-13	17-Jul-15	12-May-16
3836	US20160081 982	http://59.45.142.240:8808/pdf/US20160081982A1.pdf	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	Not Available	14-Mar-13	1-Dec-15	24-Mar-16
3837	US20160030 443	http://59.45.142.240:8808/pdf/US20160030443A1.pdf	METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION	Not Available	14-Mar-13	14-Mar-14	4-Feb-16
3838	US20160008 451	http://59.45.142.240:8808/pdf/US20160008451A1.pdf	NANOPARTICLE-BASED COMPOSITIONS	Not Available	14-Mar-13	14-Mar-14	14-Jan-16
3839	US20150267 245	http://59.45.142.240:8808/pdf/US20150267245A1.pdf	PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS	GenTegra, LLC	14-Mar-13	14-Mar-14	24-Sep-15
3840	US20150105 375	http://59.45.142.240:8808/pdf/US20150105375A1.pdf	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	Not Available	14-Mar-13	18-Dec-14	16-Apr-15
3841	US20140275 159	http://59.45.142.240:8808/pdf/US20140275159A1.pdf	SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	14-Mar-13	12-Mar-14	18-Sep-14
3842	US20140275 155	http://59.45.142.240:8808/pdf/US20140275155A1.pdf	SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	BOEHRINGER INGELHEIM INTERNATIONAL	14-Mar-13	12-Mar-14	18-Sep-14
3843	US20140275 114	http://59.45.142.240:8808/pdf/US20140275114A1.pdf	SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (CYANO-METHYL)-AMIDES INHIBITORS OF	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	14-Mar-13	12-Mar-14	18-Sep-14
3844	US20140275 025	http://59.45.142.240:8808/pdf/US20140275025A1.pdf	SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	14-Mar-13	12-Mar-14	18-Sep-14
3845	US20140271 700	http://59.45.142.240:8808/pdf/US20140271700A1.pdf	COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DYSG	National Health Research Institutes	14-Mar-13	13-Mar-14	18-Sep-14
3846	US20140271 580	http://59.45.142.240:8808/pdf/US20140271580A1.pdf	IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS	THE ADMINISTRATORS OF THE TULANE	14-Mar-13	14-Mar-13	18-Sep-14
3847	US20140271 550	http://59.45.142.240:8808/pdf/US20140271550A1.pdf	Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune	The Trustees of the University of Pennsylvania	14-Mar-13	14-Mar-14	18-Sep-14
3848	US10485861	http://59.45.142.240:8808/pdf/US10485861.pdf	Nanoparticle-based compositions	Massachusetts Institute of Technology	14-Mar-13	14-Mar-14	26-Nov-19
3849	US10357562	http://59.45.142.240:8808/pdf/US10357562.pdf	Immunoprotective primary mesenchymal stem cells and methods	Autoimmune Technologies, LLC	14-Mar-13	17-Jul-15	23-Jul-19
3850	US10238633	http://59.45.142.240:8808/pdf/US10238633.pdf	Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-	Boehringer Ingelheim International GmbH	14-Mar-13	6-Jun-17	26-Mar-19
3851	US9786050	http://59.45.142.240:8808/pdf/US9786050.pdf	Stain-free histopathology by chemical imaging	The Board of Trustees of the University of	15-Mar-13	14-Mar-14	10-Oct-17

3852	US9745306	http://59.45.142.240:8808/pdf/US9745306.pdf	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase	Respivert Limited	15-Mar-13	14-Mar-14	29-Aug-17
3853	US9717732	http://59.45.142.240:8808/pdf/US9717732.pdf	Drug combination	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	1-Aug-17
3854	US9708375	http://59.45.142.240:8808/pdf/US9708375.pdf	Inhibitory polypeptides specific to WNT inhibitors	Amgen Inc.	15-Mar-13	14-Mar-14	18-Jul-17
3855	US9700558	http://59.45.142.240:8808/pdf/US9700558.pdf	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	11-Jul-17
3856	US9556184	http://59.45.142.240:8808/pdf/US9556184.pdf	Phosphoinositide 3-kinase inhibitors	Respivert, Ltd.	15-Mar-13	4-Dec-15	31-Jan-17
3857	US9227977	http://59.45.142.240:8808/pdf/US9227977.pdf	Phosphoinositide 3-kinase inhibitors	Respivert Ltd.	15-Mar-13	14-Mar-14	5-Jan-16
3858	US20190010 240	http://59.45.142.240:8808/pdf/US20190010240A1.pdf	COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND	Not Available	15-Mar-13	2-Aug-18	10-Jan-19
3859	US20170368 201	http://59.45.142.240:8808/pdf/US20170368201A1.pdf	SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE	The Children's Hospital of Philadelphia	15-Mar-13	8-Sep-17	28-Dec-17
3860	US20170358 082	http://59.45.142.240:8808/pdf/US20170358082A1.pdf	STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING	Not Available	15-Mar-13	2-Aug-17	14-Dec-17
3861	US20170334 919	http://59.45.142.240:8808/pdf/US20170334919A1.pdf	2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)METHYL)-3-(2-(TRIFLUORO-METHYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE	RESPIVERT LTD.	15-Mar-13	27-Jul-17	23-Nov-17
3862	US20170266 190		DRUG COMBINATION	Not Available	15-Mar-13	5-Jun-17	21-Sep-17
3863	US20160122 412	http://59.45.142.240:8808/pdf/US20160122412A1.pdf	COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND	Not Available	15-Mar-13	16-Mar-14	5-May-16
3864	US20160090 389		Phosphoinositide 3-Kinase Inhibitors	Respivert Ltd.	15-Mar-13	4-Dec-15	31-Mar-16
3865	US20160039 826	http://59.45.142.240:8808/pdf/US20160039826A1.pdf	2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS	Not Available	15-Mar-13	14-Mar-14	11-Feb-16
3866	US20160032 319	http://59.45.142.240:8808/pdf/US20160032319A1.pdf	VECTORS COMPRISING STUFFER/FILLER POLYNUCLEOTIDE SEQUENCES AND METHODS OF USE	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	15-Mar-13	14-Mar-14	4-Feb-16
3867	US20160024 158	http://59.45.142.240:8808/pdf/US20160024158A1.pdf	Inhibitory Polypeptides Specific to WNT Inhibitors	Not Available	15-Mar-13	14-Mar-14	28-Jan-16
3868	US20160022 801	http://59.45.142.240:8808/pdf/US20160022801A1.pdf	RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIER- SPECIFIC	Not Available	15-Mar-13	14-Mar-14	28-Jan-16
3869	US20160016 916	http://59.45.142.240:8808/pdf/US20160016916A1.pdf	Exo Olefin-Containing Nuclear Transport Modulators and Uses	Not Available	15-Mar-13	14-Mar-14	21-Jan-16
3870	US20160008 363		DRUG COMBINATION	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	14-Jan-16
3871	US20160000 790		DRUG COMBINATION	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	7-Jan-16
3872	US20140323 556	http://59.45.142.240:8808/pdf/US20140323556A1.pdf	SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE	Not Available	15-Mar-13	17-Mar-14	30-Oct-14
3873	US20140275 237	http://59.45.142.240:8808/pdf/US20140275237A1.pdf	BERAPROST ISOMER AS AN AGENT FOR THE TREATMENT OF VIRAL INFECTION	Gemmus Pharma Inc.	15-Mar-13	12-Mar-14	18-Sep-14
3874	US20140274 980		COMPOUND	RESPIVERT LTD.	15-Mar-13	14-Mar-14	18-Sep-14
3875	US20140270 457	http://59.45.142.240:8808/pdf/US20140270457A1.pdf	STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING	The Board of Trustees of the University of	15-Mar-13	14-Mar-14	18-Sep-14
3876	US10471063	http://59.45.142.240:8808/pdf/US10471063.pdf	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor	Verona Pharma PLC	15-Mar-13	5-Jun-17	12-Nov-19
3877	US10300124	http://59.45.142.240:8808/pdf/US10300124.pdf	Rodent hepadnavirus cores with reduced carrier-specific antigenicity	VLP BIOTECH, INC.	15-Mar-13	14-Mar-14	28-May-19
3878	US10072064	http://59.45.142.240:8808/pdf/US10072064.pdf	Composition comprised of antigen linked to a TNF superfamily ligand	Not Available	15-Mar-13	16-Mar-14	11-Sep-18
3879	US10013760	http://59.45.142.240:8808/pdf/US10013760.pdf	Stain-free histopathology by chemical imaging	BOARD OF TRUSTEES OF THE UNIVERSITY OF	15-Mar-13	2-Aug-17	3-Jul-18
3880	US20190060 262	http://59.45.142.240:8808/pdf/US20190060262A1.pdf	ENHANCED EXPRESSION OF RNA VECTORS	UNIVERSITY COURT OF THE UNIVERSITY OF CANTERBURY	25-Mar-13	5-Sep-18	28-Feb-19
3881	US9011767	http://59.45.142.240:8808/pdf/US9011767.pdf	Transportable vacuum assisted decontamination unit and	STERIS Inc.	1-Apr-13	31-Mar-14	21-Apr-15
3882	US20140294 670	http://59.45.142.240:8808/pdf/US20140294670A1.pdf	TRANSPORTABLE VACUUM ASSISTED DECONTAMINATION UNIT AND DECONTAMINATION PROCESS	STERIS Inc.	1-Apr-13	31-Mar-14	2-Oct-14
3883	US9539217	http://59.45.142.240:8808/pdf/US9539217.pdf	Nanoparticle compositions	Allertein Therapeutics, LLC	3-Apr-13	3-Apr-14	10-Jan-17
3884	US20170071 867	http://59.45.142.240:8808/pdf/US20170071867A1.pdf	NOVEL NANOPARTICLE COMPOSITIONS	Not Available	3-Apr-13	28-Nov-16	16-Mar-17
3885	US20160113 881	http://59.45.142.240:8808/pdf/US20160113881A1.pdf	NOVEL NANOPARTICLE COMPOSITIONS	Not Available	3-Apr-13	3-Apr-14	28-Apr-16
3886	US20160175 387	http://59.45.142.240:8808/pdf/US20160175387A1.pdf	Use of Immune Suppressive Domains as Medicaments	Not Available	10-Apr-13	10-Apr-14	23-Jun-16
3887	US20160166 676	http://59.45.142.240:8808/pdf/US20160166676A1.pdf	Use of Immune Suppressive Peptides as Adjuvants	Not Available	10-Apr-13	10-Apr-14	16-Jun-16
3888	US9447132	http://59.45.142.240:8808/pdf/US9447132.pdf	Highly active nucleoside derivative for the treatment of HCV	Achillion Pharmaceuticals,	12-Apr-13	14-Apr-14	20-Sep-16
3889	US20140309 189	http://59.45.142.240:8808/pdf/US20140309189A1.pdf	HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV	Achillion Pharmaceuticals,	12-Apr-13	14-Apr-14	16-Oct-14

3890	US20140309 164	http://59.45.142.240:8808/pdf/US20140309164A1.pdf	DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING	Achillion Pharmaceuticals,	12-Apr-13	14-Apr-14	16-Oct-14
3891	US20190336 969	http://59.45.142.240:8808/pdf/US20190336969A1.pdf	PARALLELIZED SAMPLE HANDLING	Not Available	19-Apr-13	27-Mar-19	7-Nov-19
3892	US20160114 322	http://59.45.142.240:8808/pdf/US20160114322A1.pdf	PARALLELIZED SAMPLE HANDLING	Not Available	19-Apr-13	18-Apr-14	28-Apr-16
3893	US20140314 809		MALARIA ANTIGEN SCREENING METHOD	Not Available	19-Apr-13	19-Apr-13	23-Oct-14
3894	US9719106	http://59.45.142.240:8808/pdf/US9719106.pdf	Tissue preferential codon modified expression cassettes, vectors	The Trustees of the University of	29-Apr-13	29-Apr-14	1-Aug-17
3895	US20170292 132	http://59.45.142.240:8808/pdf/US20170292132A1.pdf	TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING	Not Available	29-Apr-13	20-Jun-17	12-Oct-17
3896	US20160083 748	http://59.45.142.240:8808/pdf/US20160083748A1.pdf	TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING	Not Available	29-Apr-13	29-Apr-14	24-Mar-16
3897	US10647998	http://59.45.142.240:8808/pdf/US10647998.pdf	Tissue preferential codon modified expression cassettes, vectors	The Trustees of the University of	29-Apr-13	20-Jun-17	12-May-20
3898	US9770504	http://59.45.142.240:8808/pdf/US9770504.pdf	Generating peptoid vaccines	The Board of Regents of the University of Texas	3-May-13	2-May-14	26-Sep-17
3899	US20190292 216	http://59.45.142.240:8808/pdf/US20190292216A1.pdf	Cyclic Di-Nucleotide Induction of Type I Interferon	Not Available	3-May-13	19-Feb-19	26-Sep-19
3900	US20160067 333	http://59.45.142.240:8808/pdf/US20160067333A1.pdf	GENERATING PEPTOID VACCINES	The Board of Regents of the University of Texas	3-May-13	2-May-14	10-Mar-16
3901	US20140329 889	http://59.45.142.240:8808/pdf/US20140329889A1.pdf	CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON	Not Available	3-May-13	2-May-14	6-Nov-14
3902	US9822155	http://59.45.142.240:8808/pdf/US9822155.pdf	Method of preventively treating a subject at the risk of developing	Xiangxue Group (Hong Kong)	9-May-13	23-Aug-16	21-Nov-17
3903	US9464123	http://59.45.142.240:8808/pdf/US9464123.pdf	Peptides having activity of inhibiting infections of respiratory viruses and	XIANGXUE GROUP (HONG KONG)	9-May-13	21-Feb-14	11-Oct-16
3904	US20160368 956	http://59.45.142.240:8808/pdf/US20160368956A1.pdf	METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF DEVELOPING INFECTIONS OF A	Not Available	9-May-13	23-Aug-16	22-Dec-16
3905	US20150152 149	http://59.45.142.240:8808/pdf/US20150152149A1.pdf	Peptides Having Activity of Inhibiting Infections of Respiratory Viruses and	Not Available	9-May-13	21-Feb-14	4-Jun-15
3906	US20160146 806	http://59.45.142.240:8808/pdf/US20160146806A1.pdf	RECEPTORS FOR B7-H4	Not Available	17-May-13	19-May-14	26-May-16
3907	US9750798	http://59.45.142.240:8808/pdf/US9750798.pdf	Bunyaviruses with segmented glycoprotein precursor genes and	STICHTING WAGENINGEN RESEARCH	21-May-13	21-May-14	5-Sep-17
3908	US9476090	http://59.45.142.240:8808/pdf/US9476090.pdf	Signal propagation biomolecules, devices and methods	STC.UNM	21-May-13	21-May-14	25-Oct-16
3909	US20170333 553	http://59.45.142.240:8808/pdf/US20170333553A1.pdf	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS,	Not Available	21-May-13	1-Aug-17	23-Nov-17
3910	US20160271 241	http://59.45.142.240:8808/pdf/US20160271241A1.pdf	BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR GENES AND METHODS FOR GENERATING	Stichting Dienst Landbouwkundig Onderzoek	21-May-13	21-May-14	22-Sep-16
3911	US20140349 276	http://59.45.142.240:8808/pdf/US20140349276A1.pdf	SIGNAL PROPAGATION BIOMOLECULES, DEVICES AND METHODS	STC.UNM	21-May-13	21-May-14	27-Nov-14
3912	US10221446	http://59.45.142.240:8808/pdf/US10221446.pdf	Signal propagation biomolecules, devices and methods	STC.UNM	21-May-13	3-Oct-16	5-Mar-19
3913	US20140348 781	http://59.45.142.240:8808/pdf/US20140348781A1.pdf	CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS	CHILDREN'S HEALTHCARE OF ATLANTA, INC.	22-May-13	20-May-14	27-Nov-14
3914	US9982025	http://59.45.142.240:8808/pdf/US9982025.pdf	Monomeric griffithsin tandemers	The United States of America, as represented by the Secretary, Department of Health and Human	5-Jun-13	5-Jun-14	29-May-18
3915	US20190203 170	http://59.45.142.240:8808/pdf/US20190203170A1.pdf	Avian Cells for Improved Virus Production	Not Available	5-Jun-13	21-Dec-18	4-Jul-19
3916	US20160108 359	http://59.45.142.240:8808/pdf/US20160108359A1.pdf	AVIAN CELLS FOR IMPROVED VIRUS PRODUCTION	Not Available	5-Jun-13	3-Jun-14	21-Apr-16
3917	US20160108 097	http://59.45.142.240:8808/pdf/US20160108097A1.pdf	MONOMERIC GRIFFITHSIN TANDEMERS	The United States of America, as represented by the Secretary, Department of Health and Human	5-Jun-13	5-Jun-14	21-Apr-16
3918	US10202578	http://59.45.142.240:8808/pdf/US10202578.pdf	Chicken cells for improved virus production	THE PIRBRIGHT INSTITUTE	5-Jun-13	3-Jun-14	12-Feb-19
3919	US20190183 918	http://59.45.142.240:8808/pdf/US20190183918A1.pdf	SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES	Not Available	12-Jun-13	29-Oct-18	20-Jun-19
3920	US20160367 587	http://59.45.142.240:8808/pdf/US20160367587A1.pdf	Systemic In Vivo Delivery of Oligonucleotides	OncoImmunin, Inc.	12-Jun-13	12-Jun-14	22-Dec-16
3921	US9738624	http://59.45.142.240:8808/pdf/US9738624.pdf	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc	21-Jun-13	20-Jun-14	22-Aug-17
3922	US20160152 596	http://59.45.142.240:8808/pdf/US20160152596A1.pdf	Nuclear Transport Modulators and Uses Thereof	Karyopharm Therapeutics Inc	21-Jun-13	20-Jun-14	2-Jun-16
3923	US10407405	http://59.45.142.240:8808/pdf/US10407405.pdf	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc	21-Jun-13	17-Jul-17	10-Sep-19
3924	US20160146 786	http://59.45.142.240:8808/pdf/US20160146786A1.pdf	Method of monitoring cellular trafficking of peptides	Not Available	26-Jun-13	26-Jun-14	26-May-16
3925	US20160369 268	http://59.45.142.240:8808/pdf/US20160369268A1.pdf	TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES AND METHODS OF SYNTHESIS AND USE	The Board of Regents of the University of Texas	1-Jul-13	25-Jun-14	22-Dec-16
3926	US9856241	http://59.45.142.240:8808/pdf/US9856241.pdf	Substituted benzofuranyl and benzoxazolyl compounds and uses	Karyopharm Therapeutics Inc.	3-Jul-13	3-Jul-14	2-Jan-18
3927	US9828379	http://59.45.142.240:8808/pdf/US9828379.pdf	Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and	ABIDE THERAPEUTICS, INC.	3-Jul-13	1-Jul-14	28-Nov-17
3928	US20200102 292	http://59.45.142.240:8808/pdf/US20200102292A1.pdf	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND	Not Available	3-Jul-13	10-Jul-19	2-Apr-20

3929	US20180319 779	http://59.45.142.240:8808/pdf/US20180319779A1.pdf	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul-13	4-Dec-17	8-Nov-18
3930	US20160368 904	http://59.45.142.240:8808/pdf/US20160368904A1.pdf	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul-13	3-Jul-14	22-Dec-16
3931	US20160137 649	http://59.45.142.240:8808/pdf/US20160137649A1.pdf	PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL	Not Available	3-Jul-13	1-Jul-14	19-May-16
3932	US10399963	http://59.45.142.240:8808/pdf/US10399963.pdf	Substituted benzofuranyl and benzoxazolyl compounds and uses thereof	Karyopharm Therapeutics Inc.	3-Jul-13	4-Dec-17	3-Sep-19
3933	US20160122 312		ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	16-Jul-13	16-Jul-14	5-May-16
3934	US9840719	http://59.45.142.240:8808/pdf/US9840719.pdf	Variant AAV and compositions, methods and uses for gene transfer	The Children's Hospital of Philadelphia	22-Jul-13	22-Jul-14	12-Dec-17
3935	US20180187 213	http://59.45.142.240:8808/pdf/US20180187213A1.pdf	Variant AAV and Compositions, Methods and Uses for Gene Transfer	The Children's Hospital of Philadelphia	22-Jul-13	6-Dec-17	5-Jul-18
3936	US20150023 924	http://59.45.142.240:8808/pdf/US20150023924A1.pdf	VARIANT AAV AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS AND	Not Available	22-Jul-13	22-Jul-14	22-Jan-15
3937	US20150031 014	http://59.45.142.240:8808/pdf/US20150031014A1.pdf	DETECTING ANALYTES WITH A PH METER	The Board of Trustees of the University of Illinois	25-Jul-13	25-Jul-14	29-Jan-15
3938	US20180353 594	http://59.45.142.240:8808/pdf/US20180353594A1.pdf	METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS	Not Available	26-Jul-13	21-Aug-18	13-Dec-18
3939	US20160158 339	http://59.45.142.240:8808/pdf/US20160158339A1.pdf	METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS	Not Available	26-Jul-13	24-Jul-14	9-Jun-16
3940	US20160192 658	http://59.45.142.240:8808/pdf/US20160192658A1.pdf	HYDROGEN-CONTAINING ANTIMICROBIAL AGENT	Not Available	13-Aug-13	5-Aug-14	7-Jul-16
3941	US20190216 951	http://59.45.142.240:8808/pdf/US20190216951A1.pdf	METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS	CureVac AG	21-Aug-13	1-Apr-19	18-Jul-19
3942	US20160199 449	http://59.45.142.240:8808/pdf/US20160199449A1.pdf	METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING	Hemispherx Biopharma, Inc.	21-Aug-13	21-Aug-14	14-Jul-16
3943	US20160166 710	http://59.45.142.240:8808/pdf/US20160166710A1.pdf	METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS	CureVac AG	21-Aug-13	19-Feb-16	16-Jun-16
3944	US9963427	http://59.45.142.240:8808/pdf/US9963427.pdf	Dithiol mucolytic agents	PARION SCIENCES, INC.	23-Aug-13	11-Mar-16	8-May-18
3945	US9346753	http://59.45.142.240:8808/pdf/US9346753.pdf	Dithiol mucolytic agents	PARION SCIENCES, INC.	23-Aug-13	13-Aug-14	24-May-16
3946	US20160194 278	http://59.45.142.240:8808/pdf/US20160194278A1.pdf	DITHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	23-Aug-13	11-Mar-16	7-Jul-16
3947	US20150056 305	http://59.45.142.240:8808/pdf/US20150056305A1.pdf	DITHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	23-Aug-13	13-Aug-14	26-Feb-15
3948	US20160207 949	http://59.45.142.240:8808/pdf/US20160207949A1.pdf	NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd	2-Sep-13	2-Sep-13	21-Jul-16
3949	US20160207 980	http://59.45.142.240:8808/pdf/US20160207980A1.pdf	FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE, CONSISTENT, AND REPRODUCIBLE	AMGEN INC.	5-Sep-13	5-Sep-14	21-Jul-16
3950	US9856228	http://59.45.142.240:8808/pdf/US9856228.pdf	Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors	PROZYMEX A/S	9-Sep-13	8-Sep-14	2-Jan-18
3951	US20160207 900	http://59.45.142.240:8808/pdf/US20160207900A1.pdf	PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS	PROZYMEX A/S	9-Sep-13	8-Sep-14	21-Jul-16
3952	US20190298 750	http://59.45.142.240:8808/pdf/US20190298750A1.pdf	Nucleotide and Nucleoside Therapeutic Compositions and Uses	Not Available	11-Sep-13	21-Nov-18	3-Oct-19
3953	US20170143 758		INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Advanced Inhalation Therapies (AIT) Ltd	11-Sep-13	4-Jan-17	25-May-17
3954	US20160347 814	http://59.45.142.240:8808/pdf/US20160347814A1.pdf	VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND	Not Available	11-Sep-13	10-Mar-16	1-Dec-16
3955	US20160272 707	http://59.45.142.240:8808/pdf/US20160272707A1.pdf	VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES	Not Available	11-Sep-13	11-Sep-14	22-Sep-16
3956	US20160220 595	http://59.45.142.240:8808/pdf/US20160220595A1.pdf	NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THEREOF	Not Available	11-Sep-13	10-Sep-14	4-Aug-16
3957	US20150072 023		INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	11-Sep-13	11-Sep-14	12-Mar-15
3958	US10149859	http://59.45.142.240:8808/pdf/US10149859.pdf	Nucleotide and nucleoside therapeutic compositions and uses	Emory University	11-Sep-13	10-Sep-14	11-Dec-18
3959	US20160220 664	http://59.45.142.240:8808/pdf/US20160220664A1.pdf	ANTIGEN AND METHOD FOR PRODUCTION THEREOF	Not Available	13-Sep-13	12-Sep-14	4-Aug-16
3960	US10159729	http://59.45.142.240:8808/pdf/US10159729.pdf	Antigen and method for production thereof	Sallpro Biotech AB	13-Sep-13	12-Sep-14	25-Dec-18
3961	US20190352 608	http://59.45.142.240:8808/pdf/US20190352608A1.pdf	CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION	Not Available	16-Sep-13	30-Jan-19	21-Nov-19
3962	US20160215 262	http://59.45.142.240:8808/pdf/US20160215262A1.pdf	CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION	Not Available	16-Sep-13	16-Sep-14	28-Jul-16
3963	US10233425	http://59.45.142.240:8808/pdf/US10233425.pdf	CD137 enrichment for efficient tumor infiltrating lymphocyte	The Trustees of the University of Illinois	16-Sep-13	16-Sep-14	19-Mar-19
3964	US20160230 190	http://59.45.142.240:8808/pdf/US20160230190A1.pdf	Lentiviral Vectors Having a Mutated Integrase Protein and uses Thereof	Not Available	17-Sep-13	17-Sep-14	11-Aug-16
3965	US20160206 729	http://59.45.142.240:8808/pdf/US20160206729A1.pdf	IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV)	Not Available	19-Sep-13	19-Sep-14	21-Jul-16
3966	US9994558	http://59.45.142.240:8808/pdf/US9994558.pdf	Multicyclic compounds and methods of using same	Karyopharm Therapeutics Inc	20-Sep-13	19-Sep-14	12-Jun-18
3967	US20170096 417	http://59.45.142.240:8808/pdf/US20170096417A1.pdf	Multicyclic Compounds And Methods Of Using Same	Karyopharm Therapeutics Inc	20-Sep-13	19-Sep-14	6-Apr-17
3968	US20160228 533	http://59.45.142.240:8808/pdf/US20160228533A1.pdf	Use of EGFR Pathway Inhibitors to Increase Immune Responses to	Emory University	23-Sep-13	23-Sep-14	11-Aug-16
3969	US10034931	http://59.45.142.240:8808/pdf/US10034931.pdf	Use of EGFR pathway inhibitors to increase immune responses to	Emory University	23-Sep-13	23-Sep-14	31-Jul-18

3970	US20160237 455	http://59.45.142.240:8808/pdf/US20160237455A1.pdf	CRISPR-RELATED METHODS AND COMPOSITIONS	Editas Medicine, Inc.	27-Sep-13	26-Sep-14	18-Aug-16
3971	US20160287 697	http://59.45.142.240:8808/pdf/US20160287697A1.pdf	INJECTABLE VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	6-Oct-16
3972	US20160228 540	http://59.45.142.240:8808/pdf/US20160228540A1.pdf	NASAL MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	11-Aug-16
3973	US20160213 773	http://59.45.142.240:8808/pdf/US20160213773A1.pdf	MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	28-Jul-16
3974	US20160193 327	http://59.45.142.240:8808/pdf/US20160193327A1.pdf	MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	7-Jul-16
3975	US10391167	http://59.45.142.240:8808/pdf/US10391167.pdf	Mucosal vaccine composition	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	27-Aug-19
3976	US10071155	http://59.45.142.240:8808/pdf/US10071155.pdf	Nasal mucosal vaccine composition	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	11-Sep-18
3977	US20160258 949	http://59.45.142.240:8808/pdf/US20160258949A1.pdf	CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX PNEUMOCOCCUS SEROLOGY	Not Available	9-Oct-13	9-Oct-14	8-Sep-16
3978	US10209254	http://59.45.142.240:8808/pdf/US10209254.pdf	Chips, detection systems, and methods for multiplex pneumococcus	The UAB Research Foundation	9-Oct-13	9-Oct-14	19-Feb-19
3979	US9868736	http://59.45.142.240:8808/pdf/US9868736.pdf	Deubiquitinase inhibitors and methods for use of the same	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	10-Oct-13	10-Oct-14	16-Jan-18
3980	US20160237 082	http://59.45.142.240:8808/pdf/US20160237082A1.pdf	DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME	Not Available	10-Oct-13	10-Oct-14	18-Aug-16
3981	US20160238 601	http://59.45.142.240:8808/pdf/US20160238601A1.pdf	METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPIES	Not Available	14-Oct-13	14-Oct-14	18-Aug-16
3982	US9782470	http://59.45.142.240:8808/pdf/US9782470.pdf	Method of obtaining thermostable dried vaccine formulations	Merck Sharp & Dohme Corp.	16-Oct-13	13-Oct-14	10-Oct-17
3983	US20160235 837	http://59.45.142.240:8808/pdf/US20160235837A1.pdf	THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME	Not Available	16-Oct-13	16-Oct-14	18-Aug-16
3984	US20160228 532	http://59.45.142.240:8808/pdf/US20160228532A1.pdf	METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE FORMULATIONS	Merck Sharp & Dohme Corp.	16-Oct-13	13-Oct-14	11-Aug-16
3985	US20190358 304	http://59.45.142.240:8808/pdf/US20190358304A1.pdf	ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)- BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND	Not Available	18-Oct-13	29-May-19	28-Nov-19
3986	US20160331 816	http://59.45.142.240:8808/pdf/US20160331816A1.pdf	ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND	Not Available	18-Oct-13	18-Apr-16	17-Nov-16
3987	US10314893	http://59.45.142.240:8808/pdf/US10314893.pdf	Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced cardiac	The Trustees of the University of Pennsylvania	18-Oct-13	18-Apr-16	11-Jun-19
3988	US9809632	http://59.45.142.240:8808/pdf/US9809632.pdf	Universal protein tag for double stranded nucleic acid delivery	University of Washington Through its Center	23-Oct-13	22-Oct-14	7-Nov-17
3989	US20160222 072	http://59.45.142.240:8808/pdf/US20160222072A1.pdf	Universal Protein Tag for Double Stranded Nucleic Acid Delivery	Not Available	23-Oct-13	22-Oct-14	4-Aug-16
3990	US20160292 393	http://59.45.142.240:8808/pdf/US20160292393A1.pdf	SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND PROVIDING RESULTS THEREOF	Not Available	24-Oct-13	13-Apr-16	6-Oct-16
3991	US20150118 222	http://59.45.142.240:8808/pdf/US20150118222A1.pdf	TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY	Not Available	25-Oct-13	24-Oct-14	30-Apr-15
3992	US9884026	http://59.45.142.240:8808/pdf/US9884026.pdf	Modular particles for immunotherapy	YALE UNIVERSITY	1-Nov-13	31-Oct-14	6-Feb-18
3993	US20180200 196	http://59.45.142.240:8808/pdf/US20180200196A1.pdf	Modular Particulars for Immunotherapy	Not Available	1-Nov-13	3-Jan-18	19-Jul-18
3994	US20160303 052	http://59.45.142.240:8808/pdf/US20160303052A1.pdf	MODULAR PARTICLES FOR IMMUNOTHERAPY	Not Available	1-Nov-13	31-Oct-14	20-Oct-16
3995	US9655367	http://59.45.142.240:8808/pdf/US9655367.pdf	Disinfecting composition and wipes with reduced contact time	LONZA, INC.	6-Nov-13	4-Nov-14	23-May-17
3996	US20160279 193	http://59.45.142.240:8808/pdf/US20160279193A1.pdf	IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY	Not Available	6-Nov-13	6-Nov-14	29-Sep-16
3997	US20150125 502	http://59.45.142.240:8808/pdf/US20150125502A1.pdf	DISINFECTING COMPOSITION AND WIPES WITH REDUCED CONTACT TIME	Not Available	6-Nov-13	4-Nov-14	7-May-15
3998	US10517923	http://59.45.142.240:8808/pdf/US10517923.pdf	Immunosuppressive agents and their use in therapy	Norwegian University of Science and Technology	6-Nov-13	6-Nov-14	31-Dec-19
3999	US9834791	http://59.45.142.240:8808/pdf/US9834791.pdf	CRISPR-related methods and compositions with governing gRNAs	Editas Medicine, Inc.	7-Nov-13	7-Nov-14	5-Dec-17
4000	US20200017 926	http://59.45.142.240:8808/pdf/US20200017926A1.pdf	CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS	Not Available	7-Nov-13	28-Aug-19	16-Jan-20
4001	US20190169 639	http://59.45.142.240:8808/pdf/US20190169639A1.pdf	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAs	EDITAS MEDICINE, INC.	7-Nov-13	24-Jan-19	6-Jun-19
4002	US20180127 783	http://59.45.142.240:8808/pdf/US20180127783A1.pdf	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAs	EDITAS MEDICINE, INC.	7-Nov-13	29-Nov-17	10-May-18
4003	US20160263 156	http://59.45.142.240:8808/pdf/US20160263156A1.pdf	RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND THEIR USE FOR THE TREATMENT OF LUNG DISEASE	University of Pittsburgh - Of the Commonwealth System of Higher Education	7-Nov-13	6-Nov-14	15-Sep-16
4004	US20150232 881	http://59.45.142.240:8808/pdf/US20150232881A1.pdf	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAs	EDITAS MEDICINE, INC.	7-Nov-13	7-Nov-14	20-Aug-15
4005	US20150133 391	http://59.45.142.240:8808/pdf/US20150133391A1.pdf	CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS	Not Available	7-Nov-13	7-Nov-14	14-May-15

4006	US10640788	http://59.45.142.240:8808/pdf/US10640788.pdf	CRISPR-related methods and compositions with governing gRNAs	Editas Medicine, Inc.	7-Nov-13	24-Jan-19	5-May-20
4007	US10596197	http://59.45.142.240:8808/pdf/US10596197.pdf	Red blood cell membrane-derived microparticles and their use for the treatment of lung disease	University of Pittsburgh "Of the Commonwealth System of Higher	7-Nov-13	1-Jun-18	24-Mar-20
4008	US10450620	http://59.45.142.240:8808/pdf/US10450620.pdf	Cell-free nucleic acids for the analysis of the human microbiome and components thereof	The Board of Trustees of the Leland Stanford	7-Nov-13	7-Nov-14	22-Oct-19
4009	US10190137	http://59.45.142.240:8808/pdf/US10190137.pdf	CRISPR-related methods and compositions with governing gRNAs	Editas Medicine, Inc.	7-Nov-13	29-Nov-17	29-Jan-19
4010	US10004764	http://59.45.142.240:8808/pdf/US10004764.pdf	Red blood cell membrane-derived microparticles and their use for the treatment of lung disease	University of Pittsburgh "Of the Commonwealth System of Higher	7-Nov-13	6-Nov-14	26-Jun-18
4011	US20200056 221	http://59.45.142.240:8808/pdf/US20200056221A1.pdf	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADORPTION MEDIA	Not Available	8-Nov-13	25-Oct-19	20-Feb-20
4012	US20170073 727	http://59.45.142.240:8808/pdf/US20170073727A1.pdf	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADORPTION MEDIA	Not Available	8-Nov-13	2-Nov-16	16-Mar-17
4013	US20160084 835	http://59.45.142.240:8808/pdf/US20160084835A1.pdf	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADORPTION MEDIA	EXTERA MEDICAL CORPORATION	8-Nov-13	16-Oct-15	24-Mar-16
4014	US10487350	http://59.45.142.240:8808/pdf/US10487350.pdf	Methods for diagnosing infectious diseases using adorption media	ExThera Medical Corporation	8-Nov-13	16-Oct-15	26-Nov-19
4015	US10457974	http://59.45.142.240:8808/pdf/US10457974.pdf	Methods for diagnosing infectious diseases using adorption media	ExThera Medical Corporation	8-Nov-13	2-Nov-16	29-Oct-19
4016	US20160158 308	http://59.45.142.240:8808/pdf/US20160158308A1.pdf	TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED	CHILDREN'S HEALTHCARE OF ATLANTA, INC.	12-Nov-13	14-Aug-14	9-Jun-16
4017	US20170226 511	http://59.45.142.240:8808/pdf/US20170226511A1.pdf	APTAMERS FOR BINDING FLAVIVIRUS PROTEINS	National University of Singapore	13-Nov-13	13-Nov-14	10-Aug-17
4018	US9974848	http://59.45.142.240:8808/pdf/US9974848.pdf	Tetanus toxoid and CCL3 improve DC Vaccines	Duke University	14-Nov-13	14-Nov-14	22-May-18
4019	US20180236 054	http://59.45.142.240:8808/pdf/US20180236054A1.pdf	Tetanus Toxoid and CCL3 Improve DC Vaccines	Duke University	14-Nov-13	19-Apr-18	23-Aug-18
4020	US20160271 240	http://59.45.142.240:8808/pdf/US20160271240A1.pdf	Tetanus Toxoid and CCL3 Improve DC Vaccines	Duke University	14-Nov-13	14-Nov-15	22-Sep-16
4021	US20170037 376	http://59.45.142.240:8808/pdf/US20170037376A1.pdf	METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL, COMPOSITION USED IN METHOD, AND USES THEREOF	GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF	15-Nov-13	12-Nov-14	9-Feb-17
4022	US9644180	http://59.45.142.240:8808/pdf/US9644180.pdf	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	12-Jun-15	9-May-17
4023	US20200002 674	http://59.45.142.240:8808/pdf/US20200002674A1.pdf	ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE	Not Available	18-Nov-13	16-Sep-19	2-Jan-20
4024	US20190376 034	http://59.45.142.240:8808/pdf/US20190376034A1.pdf	PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF	Not Available	18-Nov-13	23-Aug-19	12-Dec-19
4025	US20190316 091	http://59.45.142.240:8808/pdf/US20190316091A1.pdf	ERYTHROID CELLS COMPRISING ARGINASE	Not Available	18-Nov-13	30-May-19	17-Oct-19
4026	US20190316 090	http://59.45.142.240:8808/pdf/US20190316090A1.pdf	ERYTHROID CELLS COMPRISING ARGININE DEIMINASE	RUBIUS THERAPEUTICS, INC.	18-Nov-13	30-May-19	17-Oct-19
4027	US20190316 089	http://59.45.142.240:8808/pdf/US20190316089A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	10-May-19	17-Oct-19
4028	US20190309 262	http://59.45.142.240:8808/pdf/US20190309262A1.pdf	ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE	Not Available	18-Nov-13	4-Jun-19	10-Oct-19
4029	US20190309 261	http://59.45.142.240:8808/pdf/US20190309261A1.pdf	ERYTHROID CELLS COMPRISING LYSINE OXIDASE	Not Available	18-Nov-13	4-Jun-19	10-Oct-19
4030	US20190264 177	http://59.45.142.240:8808/pdf/US20190264177A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	10-May-19	29-Aug-19
4031	US20190144 827	http://59.45.142.240:8808/pdf/US20190144827A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	RUBIUS THERAPEUTICS, INC.	18-Nov-13	19-Nov-18	16-May-19
4032	US20180265 847	http://59.45.142.240:8808/pdf/US20180265847A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	29-Mar-18	20-Sep-18
4033	US20180216 067	http://59.45.142.240:8808/pdf/US20180216067A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	29-Mar-18	2-Aug-18
4034	US20180208 897		SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	19-Mar-18	26-Jul-18
4035	US20180187 154	http://59.45.142.240:8808/pdf/US20180187154A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	20-Feb-18	5-Jul-18
4036	US20180187 153	http://59.45.142.240:8808/pdf/US20180187153A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	20-Feb-18	5-Jul-18
4037	US20180030 411	http://59.45.142.240:8808/pdf/US20180030411A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	13-Oct-17	1-Feb-18
4038	US20170369 843	http://59.45.142.240:8808/pdf/US20170369843A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	29-Mar-17	28-Dec-17
4039	US20160287 622	http://59.45.142.240:8808/pdf/US20160287622A1.pdf	COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING	Massachusetts Institute of Technology	18-Nov-13	7-Nov-14	6-Oct-16
4040	US20160257 932	http://59.45.142.240:8808/pdf/US20160257932A1.pdf	GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER	Not Available	18-Nov-13	17-May-16	8-Sep-16
4041	US20150306 212	http://59.45.142.240:8808/pdf/US20150306212A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	12-Jun-15	29-Oct-15
4042	US20150182 588	http://59.45.142.240:8808/pdf/US20150182588A1.pdf	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	23-Dec-14	2-Jul-15
4043	US10557119	http://59.45.142.240:8808/pdf/US10557119.pdf	Erythroid cells comprising phenylalanine ammonia lyase	RUBIUS THERAPEUTICS, INC.	18-Nov-13	10-May-19	11-Feb-20
4044	US10344263	http://59.45.142.240:8808/pdf/US10344263.pdf	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	29-Mar-17	9-Jul-19
4045	US10329531	http://59.45.142.240:8808/pdf/US10329531.pdf	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	13-Oct-17	25-Jun-19
4046	US10301594	http://59.45.142.240:8808/pdf/US10301594.pdf	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	19-Nov-18	28-May-19
4047	US10301593	http://59.45.142.240:8808/pdf/US10301593.pdf	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	19-Mar-18	28-May-19
4048	US10253296	http://59.45.142.240:8808/pdf/US10253296.pdf	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	28-Nov-17	9-Apr-19

4049	US20200071 421		BISPECIFIC ANTIBODY	Not Available	20-Nov-13	8-Apr-19	5-Mar-20
4050	US20170226 222		BISPECIFIC ANTIBODY	Not Available	20-Nov-13	18-Jan-17	10-Aug-17
4051	US20170151 291	http://59.45.142.240:8808/pdf/US20170151291A1.pdf	SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF	Not Available	25-Nov-13	25-Nov-14	1-Jun-17
4052	US10258655	http://59.45.142.240:8808/pdf/US10258655.pdf	Synergistic bacterial compositions and methods of production and use	Seres Therapeutics, Inc.	25-Nov-13	25-Nov-14	16-Apr-19
4053	US20160376 321	http://59.45.142.240:8808/pdf/US20160376321A1.pdf	A NOVEL SARS IMMUNOGENIC COMPOSITION	BAYLOR COLLEGE OF MEDICINE	26-Nov-13	21-Nov-14	29-Dec-16
4054	US20160376 596	http://59.45.142.240:8808/pdf/US20160376596A1.pdf	COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS	Bavarian Nordic A/S	28-Nov-13	25-Nov-14	29-Dec-16
4055	US20190022 213	http://59.45.142.240:8808/pdf/US20190022213A1.pdf	MERS-CoV Vaccine	Not Available	29-Nov-13	29-Jun-18	24-Jan-19
4056	US20170258 893	http://59.45.142.240:8808/pdf/US20170258893A1.pdf	MERS-CoV Vaccine	Not Available	29-Nov-13	26-Nov-14	14-Sep-17
4057	US10548971	http://59.45.142.240:8808/pdf/US10548971.pdf	MERS-CoV vaccine	INOVIO PHARMACEUTICALS, INC.	29-Nov-13	29-Jun-18	4-Feb-20
4058	US10016497	http://59.45.142.240:8808/pdf/US10016497.pdf	MERS-CoV vaccine	INOVIO PHARMACEUTICALS, INC.	29-Nov-13	26-Nov-14	10-Jul-18
4059	US20180360 736	http://59.45.142.240:8808/pdf/US20180360736A1.pdf	FILM DOSAGE FORM WITH EXTENDED RELEASE	Intelgenx Corp.	2-Dec-13	23-Aug-18	20-Dec-18
4060	US20190185 922	http://59.45.142.240:8808/pdf/US20190185922A1.pdf	LUMINOPHORE-LABELED MOLECULES COUPLED WITH	CapitalBio Corporation	5-Dec-13	20-Nov-18	20-Jun-19
4061	US20160304 586	http://59.45.142.240:8808/pdf/US20160304586A1.pdf	PROCESS FOR PREPARING INFLUENZA VACCINES	Crucell Holland B.V.	5-Dec-13	4-Dec-14	20-Oct-16
4062	US20160298 179	http://59.45.142.240:8808/pdf/US20160298179A1.pdf	LUMINOPHORE-LABELED MOLECULES COUPLED WITH	CapitalBio Corporation	5-Dec-13	2-Dec-14	13-Oct-16
4063	US10167499	http://59.45.142.240:8808/pdf/US10167499.pdf	Luminophore-labeled molecules coupled with particles for	CAPITALBIO TECHNOLOGY CORPORATION	5-Dec-13	2-Dec-14	1-Jan-19
4064	US20190144 930	http://59.45.142.240:8808/pdf/US20190144930A1.pdf	ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION	Not Available	6-Dec-13	9-Jan-19	16-May-19
4065	US20160304 942	http://59.45.142.240:8808/pdf/US20160304942A1.pdf	Enhanced Methods of Ribonucleic Acid Hybridization	Not Available	6-Dec-13	5-Dec-14	20-Oct-16
4066	US10253353	http://59.45.142.240:8808/pdf/US10253353.pdf	Enhanced methods of ribonucleic acid hybridization	The Broad Institute, Inc.	6-Dec-13	5-Dec-14	9-Apr-19
4067	US20200080 141	http://59.45.142.240:8808/pdf/US20200080141A1.pdf	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION	Not Available	11-Dec-13	19-Nov-19	12-Mar-20
4068	US20160304 954	http://59.45.142.240:8808/pdf/US20160304954A1.pdf	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE	Not Available	11-Dec-13	11-Dec-14	20-Oct-16
4069	US9957238	http://59.45.142.240:8808/pdf/US9957238.pdf	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel	Parion Sciences, Inc.	13-Dec-13	1-Mar-17	1-May-18
4070	US9586911	http://59.45.142.240:8808/pdf/US9586911.pdf	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel	Parion Sciences, Inc.	13-Dec-13	19-Dec-14	7-Mar-17
4071	US9102633	http://59.45.142.240:8808/pdf/US9102633.pdf	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel	Parion Sciences, Inc.	13-Dec-13	13-Dec-13	11-Aug-15
4072	US20190010 132	http://59.45.142.240:8808/pdf/US20190010132A1.pdf	ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM	Parion Sciences, Inc.	13-Dec-13	4-Apr-18	10-Jan-19
4073	US20170305 868	http://59.45.142.240:8808/pdf/US20170305868A1.pdf	ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM	Parion Sciences, Inc.	13-Dec-13	1-Mar-17	26-Oct-17
4074	US20150166 488	http://59.45.142.240:8808/pdf/US20150166488A1.pdf	ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM	PARION SCIENCES, INC.	13-Dec-13	19-Dec-14	18-Jun-15
4075	US20150166 487	http://59.45.142.240:8808/pdf/US20150166487A1.pdf	ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM	Parion Sciences, Inc.	13-Dec-13	13-Dec-13	18-Jun-15
4076	US10233158	http://59.45.142.240:8808/pdf/US10233158.pdf	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel	Parion Sciences, Inc.	13-Dec-13	4-Apr-18	19-Mar-19
4077	US9573955	http://59.45.142.240:8808/pdf/US9573955.pdf	Compounds	Chiese Farmaceutici S.p.A.	16-Dec-13	16-Dec-14	21-Feb-17
4078	US20150166 548		NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	16-Dec-13	16-Dec-14	18-Jun-15
4079	US20190358 170	http://59.45.142.240:8808/pdf/US20190358170A1.pdf	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19-Dec-13	12-Aug-19	28-Nov-19
4080	US20160317 458	http://59.45.142.240:8808/pdf/US20160317458A1.pdf	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19-Dec-13	17-Dec-14	3-Nov-16
4081	US20160311 759	http://59.45.142.240:8808/pdf/US20160311759A1.pdf	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19-Dec-13	17-Dec-14	27-Oct-16
4082	US10426737	http://59.45.142.240:8808/pdf/US10426737.pdf	Lipids and lipid compositions for the delivery of active agents	Novartis AG	19-Dec-13	17-Dec-14	1-Oct-19
4083	US10059655	http://59.45.142.240:8808/pdf/US10059655.pdf	Lipids and lipid compositions for the delivery of active agents	Novartis AG	19-Dec-13	17-Dec-14	28-Aug-18
4084	US20160338 998	http://59.45.142.240:8808/pdf/US20160338998A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND	3-V Biosciences, Inc.	20-Dec-13	19-Dec-14	24-Nov-16
4085	US10226449	http://59.45.142.240:8808/pdf/US10226449.pdf	Heterocyclic modulators of lipid synthesis and combinations thereof	3-V Biosciences, Inc.	20-Dec-13	19-Dec-14	12-Mar-19
4086	US20200102 544	http://59.45.142.240:8808/pdf/US20200102544A1.pdf	POXVIRUS-PLASMIDIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF,	Not Available	30-Dec-13	11-Sep-19	2-Apr-20
4087	US20190032 077	http://59.45.142.240:8808/pdf/US20190032077A1.pdf	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-13	9-Jul-18	31-Jan-19
4088	US20170029 847	http://59.45.142.240:8808/pdf/US20170029847A1.pdf	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-13	28-Jun-16	2-Feb-17
4089	US20160327 484	http://59.45.142.240:8808/pdf/US20160327484A1.pdf	A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF A PLANT OR YEAST HYDROLYSATE	Not Available	30-Dec-13	18-Dec-14	10-Nov-16
4090	US20160304 883	http://59.45.142.240:8808/pdf/US20160304883A1.pdf	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-13	28-Jun-16	20-Oct-16
4091	US20150191 704	http://59.45.142.240:8808/pdf/US20150191704A1.pdf	POXVIRUS-PLASMIDIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF,	Not Available	30-Dec-13	19-Dec-14	9-Jul-15

4092	US10527551	http://59.45.142.240:8808/pdf/US10527551.pdf	Method of predicting a performance characteristic of a plant or yeast	Baxalta GmbH	30-Dec-13	18-Dec-14	7-Jan-20
4093	US9994550	http://59.45.142.240:8808/pdf/US9994550.pdf	Heterocyclic modulators of lipid synthesis for use against cancer and	3-V Biosciences, Inc.	7-Jan-14	7-Jan-15	12-Jun-18
4094	US20200054 731	http://59.45.142.240:8808/pdf/US20200054731A1.pdf	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	7-Jan-14	15-Jul-19	20-Feb-20
4095	US20160326 141	http://59.45.142.240:8808/pdf/US20160326141A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND YEAST	Not Available	7-Jan-14	7-Jan-15	10-Nov-16
4096	US20160317 637	http://59.45.142.240:8808/pdf/US20160317637A1.pdf	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	7-Jan-14	7-Jan-15	3-Nov-16
4097	US10369205	http://59.45.142.240:8808/pdf/US10369205.pdf	Immunomodulatory compositions and methods of use thereof	Not Available	7-Jan-14	7-Jan-15	6-Aug-19
4098	US20160326 233	http://59.45.142.240:8808/pdf/US20160326233A1.pdf	NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS	Not Available	16-Jan-14	15-Jan-15	10-Nov-16
4099	US10167333	http://59.45.142.240:8808/pdf/US10167333.pdf	Neutralizing human monoclonal antibodies against hepatitis B virus	Not Available	16-Jan-14	15-Jan-15	1-Jan-19
4100	US9388198	http://59.45.142.240:8808/pdf/US9388198.pdf	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	21-Jan-14	21-Jan-14	12-Jul-16
4101	US9815805	http://59.45.142.240:8808/pdf/US9815805.pdf	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase	ASTRAZENECA AB	24-Jan-14	8-Nov-16	14-Nov-17
4102	US9522894	http://59.45.142.240:8808/pdf/US9522894.pdf	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase	AstraZeneca AB	24-Jan-14	21-Jan-15	20-Dec-16
4103	US20200017 455	http://59.45.142.240:8808/pdf/US20200017455A1.pdf	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL	Not Available	24-Jan-14	19-Mar-19	16-Jan-20
4104	US20180251 436	http://59.45.142.240:8808/pdf/US20180251436A1.pdf	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL	Not Available	24-Jan-14	19-Sep-17	6-Sep-18
4105	US20170057 938	http://59.45.142.240:8808/pdf/US20170057938A1.pdf	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL	Not Available	24-Jan-14	8-Nov-16	2-Mar-17
4106	US20150210 655	http://59.45.142.240:8808/pdf/US20150210655A1.pdf	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL	ASTRAZENECA AB	24-Jan-14	21-Jan-15	30-Jul-15
4107	US10669245	http://59.45.142.240:8808/pdf/US10669245.pdf	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1	ASTRAZENECA AB	24-Jan-14	19-Mar-19	2-Jun-20
4108	US10287258		Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase	ASTRAZENECA AB	24-Jan-14	19-Sep-17	14-May-19
4109	US20170212 116	http://59.45.142.240:8808/pdf/US20170212116A1.pdf	BIOSENSORS FOR THE DETECTION OF INFECTION AND ASSOCIATED	ULISSE BIOMED SRL	31-Jan-14	26-Jan-15	27-Jul-17
4110	US20170037 457	http://59.45.142.240:8808/pdf/US20170037457A1.pdf	NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING MASK OLIGONUCLEOTIDE, AND	Not Available	5-Feb-14	29-Jan-15	9-Feb-17
4111	US20190202 868	http://59.45.142.240:8808/pdf/US20190202868A1.pdf	CORONAVIRUS PROTEINS AND ANTIGENS	Phibro Animal Health Corporation	7-Feb-14	15-Mar-19	4-Jul-19
4112	US20160339 097	http://59.45.142.240:8808/pdf/US20160339097A1.pdf	CORONAVIRUS PROTEINS AND ANTIGENS	MJ Biologics, Inc.	7-Feb-14	4-Aug-16	24-Nov-16
4113	US10280199	http://59.45.142.240:8808/pdf/US10280199.pdf	Coronavirus proteins and antigens	Phibro Animal Health Corporation	7-Feb-14	4-Aug-16	7-May-19
4114	US20180250 602	http://59.45.142.240:8808/pdf/US20180250602A1.pdf	PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE	Not Available	11-Feb-14	1-May-18	6-Sep-18
4115	US20170035 878	http://59.45.142.240:8808/pdf/US20170035878A1.pdf	Multi-Functional Mucosal Vaccine Platform	Not Available	11-Feb-14	11-Feb-15	9-Feb-17
4116	US20170058 430	http://59.45.142.240:8808/pdf/US20170058430A1.pdf	BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS	Not Available	18-Feb-14	18-Feb-15	2-Mar-17
4117	USRE47493	http://59.45.142.240:8808/pdf/USRE47493.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	20-Feb-14	26-Mar-18	9-Jul-19
4118	US9221807	http://59.45.142.240:8808/pdf/US9221807.pdf	Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	21-Feb-14	12-Feb-15	29-Dec-15
4119	US20150239 875	http://59.45.142.240:8808/pdf/US20150239875A1.pdf	SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL	Not Available	21-Feb-14	12-Feb-15	27-Aug-15
4120	US20190128 893	http://59.45.142.240:8808/pdf/US20190128893A1.pdf	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24-Feb-14	7-Nov-18	2-May-19
4121	US20190127 405	http://59.45.142.240:8808/pdf/US20190127405A1.pdf	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24-Feb-14	7-Nov-18	2-May-19
4122	US20170089 911	http://59.45.142.240:8808/pdf/US20170089911A1.pdf	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24-Feb-14	24-Aug-16	30-Mar-17
4123	US10168336	http://59.45.142.240:8808/pdf/US10168336.pdf	Quinone methide analog signal amplification	Ventana Medical Systems, Inc.	24-Feb-14	24-Aug-16	1-Jan-19
4124	US20160362 730	http://59.45.142.240:8808/pdf/US20160362730A1.pdf	PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS	Not Available	26-Feb-14	26-Aug-16	15-Dec-16
4125	US20170152 274	http://59.45.142.240:8808/pdf/US20170152274A1.pdf	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	Hangzhou DAC Biotech Co., Ltd.	28-Feb-14	28-Feb-14	1-Jun-17
4126	US10464955	http://59.45.142.240:8808/pdf/US10464955.pdf	Charged linkers and their uses for conjugation	HANGZHOU DAC BIOTECH CO., LTD.	28-Feb-14	28-Feb-14	5-Nov-19
4127	US20170066 731	http://59.45.142.240:8808/pdf/US20170066731A1.pdf	SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS	Not Available	7-Mar-14	5-Mar-15	9-Mar-17
4128	US10071976	http://59.45.142.240:8808/pdf/US10071976.pdf	Small molecule fatty acid synthase inhibitors	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY	7-Mar-14	5-Mar-15	11-Sep-18
4129	US9415087	http://59.45.142.240:8808/pdf/US9415087.pdf	Compositions and methods for treating coronavirus infection	Ludwig-Maximilians-Universitaet	11-Mar-14	8-May-15	16-Aug-16

4130	US20160082 074	http://59.45.142.240:8808/pdf/US20160082074A1.pdf	COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION	LUDWIG-MAXIMILIANS-UNIVERSITAET	11-Mar-14	8-May-15	24-Mar-16
4131	US20170014 496	http://59.45.142.240:8808/pdf/US20170014496A1.pdf	COMBINATION OF VACCINATION AND OX40 AGONISTS	Not Available	12-Mar-14	12-Mar-14	19-Jan-17
4132	US10307472	http://59.45.142.240:8808/pdf/US10307472.pdf	Combination of vaccination and OX40 agonists	CureVac AG	12-Mar-14	12-Mar-14	4-Jun-19
4133	US20190247 485	http://59.45.142.240:8808/pdf/US20190247485A1.pdf	Dimethyl Fumarate and Vaccination Regimens	Biogen MA Inc.	14-Mar-14	23-Apr-19	15-Aug-19
4134	US20170000 873	http://59.45.142.240:8808/pdf/US20170000873A1.pdf	Dimethyl Fumarate and Vaccination Regimens	Not Available	14-Mar-14	13-Mar-15	5-Jan-17
4135	US10555993	http://59.45.142.240:8808/pdf/US10555993.pdf	Dimethyl fumarate and vaccination regimens	Biogen MA Inc.	14-Mar-14	23-Apr-19	11-Feb-20
4136	US10391160	http://59.45.142.240:8808/pdf/US10391160.pdf	Dimethyl fumarate and vaccination regimens	Biogen MA Inc.	14-Mar-14	13-Mar-15	27-Aug-19
4137	US9757446	http://59.45.142.240:8808/pdf/US9757446.pdf	Influenza virus vectors and uses therefor	FLUGEN, INC.	17-Mar-14	13-Mar-15	12-Sep-17
4138	US20180043 007	http://59.45.142.240:8808/pdf/US20180043007A1.pdf	INFLUENZA VIRUS VECTORS AND USES THEREFOR	Not Available	17-Mar-14	21-Aug-17	15-Feb-18
4139	US20170106 077	http://59.45.142.240:8808/pdf/US20170106077A1.pdf	INFLUENZA VIRUS VECTORS AND USES THEREFOR	Not Available	17-Mar-14	13-Mar-15	20-Apr-17
4140	US20170080 084	http://59.45.142.240:8808/pdf/US20170080084A1.pdf	OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION	Not Available	17-Mar-14	17-Mar-15	23-Mar-17
4141	US10500267	http://59.45.142.240:8808/pdf/US10500267.pdf	Influenza virus vectors and uses therefor	FluGen, Inc.	17-Mar-14	21-Aug-17	10-Dec-19
4142	US9873678	http://59.45.142.240:8808/pdf/US9873678.pdf	Chemical compounds	AstraZeneca AB	18-Mar-14	17-Mar-15	23-Jan-18
4143	US20190330 187	http://59.45.142.240:8808/pdf/US20190330187A1.pdf	Chemical Compounds	Not Available	18-Mar-14	10-May-19	31-Oct-19
4144	US20180162 838	http://59.45.142.240:8808/pdf/US20180162838A1.pdf	Chemical Compounds	Not Available	18-Mar-14	13-Dec-17	14-Jun-18
4145	US20170107 195	http://59.45.142.240:8808/pdf/US20170107195A1.pdf	Chemical Compounds	AstraZeneca AB	18-Mar-14	17-Mar-15	20-Apr-17
4146	US10336725	http://59.45.142.240:8808/pdf/US10336725.pdf	Chemical compounds	AstraZeneca AB	18-Mar-14	13-Dec-17	2-Jul-19
4147	US9884895	http://59.45.142.240:8808/pdf/US9884895.pdf	Methods and compositions for chimeric coronavirus spike proteins	The University of North Carolina at Chapel Hill	20-Mar-14	20-Mar-15	6-Feb-18
4148	US20170096 455	http://59.45.142.240:8808/pdf/US20170096455A1.pdf	METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS	The University of North Carolina at Chapel Hill	20-Mar-14	20-Mar-15	6-Apr-17
4149	US20170306 001	http://59.45.142.240:8808/pdf/US20170306001A1.pdf	CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS MULTIPLE INFLUENZA A VIRUSES	NATIONAL UNIVERSITY OF SINGAPORE	27-Mar-14	27-Mar-15	26-Oct-17
4150	US9919034	http://59.45.142.240:8808/pdf/US9919034.pdf	Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group	TAMIR BIOTECHNOLOGY, INC.	28-Mar-14	10-Jun-15	20-Mar-18
4151	US20150376 584	http://59.45.142.240:8808/pdf/US20150376584A1.pdf	METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY RABIES, MERS-COV, INFLUENZA, EBOLA, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITIS, CANINE PARVOVIRUS, ADENOVIRUS,	TAMIR BIOTECHNOLOGY, INC.	28-Mar-14	10-Jun-15	31-Dec-15
4152	US20170095 818	http://59.45.142.240:8808/pdf/US20170095818A1.pdf	INTEGRATED MICROFLUIDIC DEVICE FOR TARGET DELIVERY OF AN IMMUNOSTIMULATING AGENT	CapitalBio Corporation	31-Mar-14	31-Mar-15	6-Apr-17
4153	US20190388 473	http://59.45.142.240:8808/pdf/US20190388473A1.pdf	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1-Apr-14	30-Aug-19	26-Dec-19
4154	US20190314 496	http://59.45.142.240:8808/pdf/US20190314496A1.pdf	POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR	CureVac AG	1-Apr-14	18-Jun-19	17-Oct-19
4155	US20190247 440	http://59.45.142.240:8808/pdf/US20190247440A1.pdf	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1-Apr-14	12-Apr-19	15-Aug-19
4156	US20170252 430	http://59.45.142.240:8808/pdf/US20170252430A1.pdf	POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR	Not Available	1-Apr-14	1-Apr-15	7-Sep-17
4157	US20170020 926	http://59.45.142.240:8808/pdf/US20170020926A1.pdf	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1-Apr-14	13-Mar-15	26-Jan-17
4158	US10369216	http://59.45.142.240:8808/pdf/US10369216.pdf	Polymeric carrier cargo complex for use as an immunostimulating agent	CureVac AG	1-Apr-14	1-Apr-15	6-Aug-19
4159	US20170107 254		Modified Antimicrobial Peptides	Not Available	2-Apr-14	2-Apr-15	20-Apr-17
4160	US20190382 433	http://59.45.142.240:8808/pdf/US20190382433A1.pdf	GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY	THE UNIVERSITY OF NOTTINGHAM	4-Apr-14	25-Jul-19	19-Dec-19
4161	US20170275 323	http://59.45.142.240:8808/pdf/US20170275323A1.pdf	GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY	THE UNIVERSITY OF NOTTINGHAM	4-Apr-14	7-Apr-15	28-Sep-17
4162	US10428102	http://59.45.142.240:8808/pdf/US10428102.pdf	Glycolipids and pharmaceutical compositions thereof for use in	THE UNIVERSITY OF NOTTINGHAM	4-Apr-14	7-Apr-15	1-Oct-19
4163	US20170027 975	http://59.45.142.240:8808/pdf/US20170027975A1.pdf	Methods of Treating Coronavirus Infection	United States Government as represented by the Secretary, Department of Health and Human Services	7-Apr-14	7-Apr-15	2-Feb-17
4164	US20150283 221	http://59.45.142.240:8808/pdf/US20150283221A1.pdf	ATTENUATED LISTERIA MONOCYTOGENES MUTANT AS A VACCINE VECTOR FOR THE DELIVERY OF EXOGENEOUS	The Board of Trustees of the University of Illinois	7-Apr-14	7-Apr-15	8-Oct-15
4165	US10434116	http://59.45.142.240:8808/pdf/US10434116.pdf	Methods of treating coronavirus infection	United States Government as represented by the Secretary, Department of Health and Human Services	7-Apr-14	7-Apr-15	8-Oct-19
4166	US10293039	http://59.45.142.240:8808/pdf/US10293039.pdf	Attenuated Listeria monocytogenes mutant as a vaccine vector for the	Montana State University	7-Apr-14	7-Apr-15	21-May-19

4167	US20170165 230	http://59.45.142.240:8808/pdf/US20170165230A1.pdf	USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO	Not Available	9-Apr-14	9-Apr-15	15-Jun-17
4168	US9649309	http://59.45.142.240:8808/pdf/US9649309.pdf	Therapeutic uses of selected pyrimidine compounds with anti-Mer	The University of North Carolina at	11-Apr-14	3-Apr-15	16-May-17
4169	US9603850	http://59.45.142.240:8808/pdf/US9603850.pdf	MerTK-specific pyrazolopyrimidine compounds	The University of North Carolina at	11-Apr-14	3-Apr-15	28-Mar-17
4170	US9555031	http://59.45.142.240:8808/pdf/US9555031.pdf	Therapeutic uses of selected pyrrolopyrimidine compounds with	The University of North Carolina at	11-Apr-14	3-Apr-15	31-Jan-17
4171	US9555030	http://59.45.142.240:8808/pdf/US9555030.pdf	Therapeutic uses of selected pyrazolopyrimidine compounds with	The University of North Carolina at	11-Apr-14	3-Apr-15	31-Jan-17
4172	US20170136 043	http://59.45.142.240:8808/pdf/US20170136043A1.pdf	THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE	The University of North Carolina at Chapel Hill	11-Apr-14	30-Jan-17	18-May-17
4173	US20150291 609	http://59.45.142.240:8808/pdf/US20150291609A1.pdf	MERTK-SPECIFIC PYRIMIDINE COMPOUNDS	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
4174	US20150291 606	http://59.45.142.240:8808/pdf/US20150291606A1.pdf	MERTK-SPECIFIC PYRROLOPYRIMIDINE COMPOUNDS	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
4175	US20150291 605	http://59.45.142.240:8808/pdf/US20150291605A1.pdf	MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
4176	US20150290 212	http://59.45.142.240:8808/pdf/US20150290212A1.pdf	THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
4177	US20150290 197	http://59.45.142.240:8808/pdf/US20150290197A1.pdf	THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
4178	US20150290 194	http://59.45.142.240:8808/pdf/US20150290194A1.pdf	THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
4179	US10004755	http://59.45.142.240:8808/pdf/US10004755.pdf	Therapeutic uses of selected pyrrolopyrimidine compounds with	The University of North Carolina at	11-Apr-14	30-Jan-17	26-Jun-18
4180	US20170296 663	http://59.45.142.240:8808/pdf/US20170296663A1.pdf	Conjugates of Cell Binding Molecules with Cytotoxic Agents	Hangzhou DAC Biotech Co., Ltd.	16-Apr-14	16-Apr-14	19-Oct-17
4181	US9707278	http://59.45.142.240:8808/pdf/US9707278.pdf	Methods of modulating immune responses by modifying Akt3	Augusta University Research Institute,	17-Apr-14	17-Apr-15	18-Jul-17
4182	US20170022 242	http://59.45.142.240:8808/pdf/US20170022242A1.pdf	NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS	KATHOLIEKE UNIVERSITEIT LEUVEN, KU	17-Apr-14	17-Apr-15	26-Jan-17
4183	US20150343 028	http://59.45.142.240:8808/pdf/US20150343028A1.pdf	METHODS OF MODULATING IMMUNE RESPONSES BY MODIFYING AKT3	Not Available	17-Apr-14	17-Apr-15	3-Dec-15
4184	US9447097	http://59.45.142.240:8808/pdf/US9447097.pdf	4-amino-imidazoquinoline compounds	Hoffmann-La Roche Inc.	22-Apr-14	7-Apr-16	20-Sep-16
4185	US9334268	http://59.45.142.240:8808/pdf/US9334268.pdf	4-amino-imidazoquinoline compounds	HOFFMAN-LA ROCHE INC.	22-Apr-14	22-Apr-15	10-May-16
4186	US20160222 010	http://59.45.142.240:8808/pdf/US20160222010A1.pdf	4-AMINO-IMIDAZOQUINOLINE COMPOUNDS	Hoffmann-La Roche Inc.	22-Apr-14	7-Apr-16	4-Aug-16
4187	US20150299 194	http://59.45.142.240:8808/pdf/US20150299194A1.pdf	4-AMINO-IMIDAZOQUINOLINE COMPOUNDS	HOFFMANN-LA ROCHE INC.	22-Apr-14	22-Apr-15	22-Oct-15
4188	US9872900	http://59.45.142.240:8808/pdf/US9872900.pdf	Nucleic acid vaccines	ModernaTX, Inc.	23-Apr-14	5-Apr-16	23-Jan-18
4189	US20190015 501	http://59.45.142.240:8808/pdf/US20190015501A1.pdf	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23-Apr-14	27-Sep-18	17-Jan-19
4190	US20190008 948	http://59.45.142.240:8808/pdf/US20190008948A1.pdf	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23-Apr-14	16-Jul-18	10-Jan-19
4191	US20190000 959	http://59.45.142.240:8808/pdf/US20190000959A1.pdf	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23-Apr-14	27-Jul-18	3-Jan-19
4192	US20160331 828	http://59.45.142.240:8808/pdf/US20160331828A1.pdf	NUCLEIC ACID VACCINES	Moderna Therapeutics, Inc.	23-Apr-14	5-Apr-16	17-Nov-16
4193	US20160317 647	http://59.45.142.240:8808/pdf/US20160317647A1.pdf	NUCLEIC ACID VACCINES	Moderna Therapeutics, Inc.	23-Apr-14	1-Apr-16	3-Nov-16
4194	US10022435	http://59.45.142.240:8808/pdf/US10022435.pdf	Nucleic acid vaccines	ModernaTX, Inc.	23-Apr-14	1-Apr-16	17-Jul-18
4195	US20190194 299	http://59.45.142.240:8808/pdf/US20190194299A1.pdf	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND	Not Available	25-Apr-14	19-Nov-18	27-Jun-19
4196	US20170158 752	http://59.45.142.240:8808/pdf/US20170158752A1.pdf	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND	Not Available	25-Apr-14	27-Apr-15	8-Jun-17
4197	US10131704	http://59.45.142.240:8808/pdf/US10131704.pdf	Middle east respiratory syndrome coronavirus neutralizing antibodies	DANA-FARBER CANCER INSTITUTE, INC.	25-Apr-14	27-Apr-15	20-Nov-18
4198	US9765395	http://59.45.142.240:8808/pdf/US9765395.pdf	System and method for DNA sequencing and blood chemistry	Nanomedical Diagnostics, Inc.	28-Apr-14	10-Apr-15	19-Sep-17
4199	US9618476	http://59.45.142.240:8808/pdf/US9618476.pdf	System and method for electronic biological sample analysis	NANOMEDICAL DIAGNOSTICS, INC.	28-Apr-14	28-Apr-14	11-Apr-17
4200	US20180037 952	http://59.45.142.240:8808/pdf/US20180037952A1.pdf	SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS	Nanomedical Diagnostics, Inc.	28-Apr-14	21-Aug-17	8-Feb-18
4201	US20170307 562	http://59.45.142.240:8808/pdf/US20170307562A1.pdf	CHEMICALLY DIFFERENTIATED SENSOR ARRAY	Nanomedical Diagnostics, Inc.	28-Apr-14	8-May-17	26-Oct-17
4202	US20160054 312	http://59.45.142.240:8808/pdf/US20160054312A1.pdf	CHEMICALLY DIFFERENTIATED SENSOR ARRAY	Nanomedical Diagnostics, Inc.	28-Apr-14	15-Oct-15	25-Feb-16
4203	US20160025 675	http://59.45.142.240:8808/pdf/US20160025675A1.pdf	METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS	Nanomedical Diagnostics, Inc.	28-Apr-14	1-Oct-15	28-Jan-16
4204	US20150309 018	http://59.45.142.240:8808/pdf/US20150309018A1.pdf	SYSTEM AND METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS	NANOMEDICAL DIAGNOSTICS, INC.	28-Apr-14	28-Apr-14	29-Oct-15
4205	US20150307 936	http://59.45.142.240:8808/pdf/US20150307936A1.pdf	SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS	Nanomedical Diagnostics, Inc.	28-Apr-14	10-Apr-15	29-Oct-15
4206	US20170051 022	http://59.45.142.240:8808/pdf/US20170051022A1.pdf	ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY	Not Available	30-Apr-14	30-Apr-15	23-Feb-17
4207	US10604549	http://59.45.142.240:8808/pdf/US10604549.pdf	Adenovirus comprising an albumin-binding moiety	FUNDACIÀ INSTITUT D'INVESTIGACIÀ BIOMÀ DICA DE BELLVITGE	30-Apr-14	30-Apr-15	31-Mar-20
4208	US9944649	http://59.45.142.240:8808/pdf/US9944649.pdf	Compounds and compositions as toll-like receptor 7 agonists	Novartis Ag	1-May-14	29-Apr-15	17-Apr-18

4209	US20190345 166	http://59.45.142.240:8808/pdf/US20190345166A1.pdf	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7	Not Available	1-May-14	24-Jul-19	14-Nov-19
4210	US20180186 802	http://59.45.142.240:8808/pdf/US20180186802A1.pdf	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7	Not Available	1-May-14	27-Feb-18	5-Jul-18
4211	US20170057 968	http://59.45.142.240:8808/pdf/US20170057968A1.pdf	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7	NOVARTIS AG	1-May-14	29-Apr-15	2-Mar-17
4212	US20170044 168	http://59.45.142.240:8808/pdf/US20170044168A1.pdf	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7	NOVARTIS AG	1-May-14	29-Apr-15	16-Feb-17
4213	US10407431	http://59.45.142.240:8808/pdf/US10407431.pdf	Compounds and compositions as toll-like receptor 7 agonists	Novartis AG	1-May-14	27-Feb-18	10-Sep-19
4214	US20200072 836	http://59.45.142.240:8808/pdf/US20200072836A1.pdf	MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF	Not Available	5-May-14	2-Apr-19	5-Mar-20
4215	US20160077 094	http://59.45.142.240:8808/pdf/US20160077094A1.pdf	Media Elaborated with Newly Synthesized Antibodies (MENSA) and Uses Thereof	Not Available	5-May-14	5-May-15	17-Mar-16
4216	US20150335 657	http://59.45.142.240:8808/pdf/US20150335657A1.pdf	Methods for Modulating Sirtuin Enzymes	Not Available	5-May-14	4-May-15	26-Nov-15
4217	US10247729	http://59.45.142.240:8808/pdf/US10247729.pdf	Media elaborated with newly synthesized antibodies (MENSA) and Uses Thereof	MICROPLEX, INC.	5-May-14	5-May-15	2-Apr-19
4218	US20190117 702	http://59.45.142.240:8808/pdf/US20190117702A1.pdf	USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS	Indiana University Research and Technology	6-May-14	31-Oct-18	25-Apr-19
4219	US20150320 801	http://59.45.142.240:8808/pdf/US20150320801A1.pdf	USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS	Not Available	6-May-14	6-May-15	12-Nov-15
4220	US10143709	http://59.45.142.240:8808/pdf/US10143709.pdf	Use of ASC and ASC-CM to treat ARDS, SARS, and MERS	Indiana University Research and Technology	6-May-14	6-May-15	4-Dec-18
4221	US20150337 369	http://59.45.142.240:8808/pdf/US20150337369A1.pdf	SINGLE CELL ANALYSIS OF T CELLS USING HIGH-THROUGHPUT MULTIPLEX AMPLIFICATION AND	Not Available	7-May-14	30-Apr-15	26-Nov-15
4222	US10202640	http://59.45.142.240:8808/pdf/US10202640.pdf	Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing	The Board of Trustees of the Leland Stanford	7-May-14	30-Apr-15	12-Feb-19
4223	US9884876	http://59.45.142.240:8808/pdf/US9884876.pdf	Anti-viral compounds, pharmaceutical compositions, and methods of use thereof	Kineta, Inc.	9-May-14	8-May-15	6-Feb-18
4224	US20190002 477	http://59.45.142.240:8808/pdf/US20190002477A1.pdf	ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF	Kineta, Inc.	9-May-14	31-Jan-18	3-Jan-19
4225	US20170057 978	http://59.45.142.240:8808/pdf/US20170057978A1.pdf	ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF	Kineta, Inc.	9-May-14	8-May-15	2-Mar-17
4226	US9695135	http://59.45.142.240:8808/pdf/US9695135.pdf	Therapeutic catechols	Rutgers, The State University of New Jersey	12-May-14	11-May-15	4-Jul-17
4227	US20180207 145	http://59.45.142.240:8808/pdf/US20180207145A1.pdf	PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES	GlaxoSmithKline Intellectual Property	12-May-14	19-Mar-18	26-Jul-18
4228	US20170100 385	http://59.45.142.240:8808/pdf/US20170100385A1.pdf	PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2)	12-May-14	8-May-15	13-Apr-17
4229	US20150322 022	http://59.45.142.240:8808/pdf/US20150322022A1.pdf	THERAPEUTIC CATECHOLS	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	12-May-14	11-May-15	12-Nov-15
4230	US20190322 725	http://59.45.142.240:8808/pdf/US20190322725A1.pdf	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13-May-14	2-Jul-19	24-Oct-19
4231	US20190031 740	http://59.45.142.240:8808/pdf/US20190031740A1.pdf	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13-May-14	15-Oct-18	31-Jan-19
4232	US20170081 392	http://59.45.142.240:8808/pdf/US20170081392A1.pdf	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13-May-14	13-May-15	23-Mar-17
4233	US10647758	http://59.45.142.240:8808/pdf/US10647758.pdf	Compositions comprising AAV expressing dual antibody constructs	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	13-May-14	2-Jul-19	12-May-20
4234	US10385119	http://59.45.142.240:8808/pdf/US10385119.pdf	Compositions comprising AAV expressing dual antibody constructs	Trustees of the University of Pennsylvania	13-May-14	15-Oct-18	20-Aug-19
4235	US10138295	http://59.45.142.240:8808/pdf/US10138295.pdf	Compositions comprising AAV expressing dual antibody constructs	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	13-May-14	13-May-15	27-Nov-18
4236	US20190219 563	http://59.45.142.240:8808/pdf/US20190219563A1.pdf	Assay for Detecting TH1 and TH2 Cell Populations	Not Available	16-May-14	17-Dec-18	18-Jul-19
4237	US20170082 608	http://59.45.142.240:8808/pdf/US20170082608A1.pdf	Assay for Detecting TH1 and TH2 Cell Populations	Not Available	16-May-14	15-May-15	23-Mar-17
4238	US10156562	http://59.45.142.240:8808/pdf/US10156562.pdf	Assay for detecting Th1 and Th2 cell populations	AMGEN INC.	16-May-14	15-May-15	18-Dec-18
4239	US20170101 459	http://59.45.142.240:8808/pdf/US20170101459A1.pdf	CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING	Not Available	6-Jun-14	5-Jun-15	13-Apr-17
4240	US10400024	http://59.45.142.240:8808/pdf/US10400024.pdf	Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing	SANQUIN REAGENTS B.V.	6-Jun-14	5-Jun-15	3-Sep-19
4241	US9487528	http://59.45.142.240:8808/pdf/US9487528.pdf	Compounds	Chiesi Farmaceutici S.p.A.	9-Jun-14	5-Jun-15	8-Nov-16
4242	US20170168 044	http://59.45.142.240:8808/pdf/US20170168044A1.pdf	QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE MEASURING	XIAMEN UNIVERSITY	9-Jun-14	24-Sep-14	15-Jun-17
4243	US20150353 561		NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	9-Jun-14	5-Jun-15	10-Dec-15
4244	US9599606	http://59.45.142.240:8808/pdf/US9599606.pdf	ADP-ribose detection reagents	The Board of Regents of the University of Texas	10-Jun-14	9-Jun-15	21-Mar-17
4245	US20150355 172	http://59.45.142.240:8808/pdf/US20150355172A1.pdf	ADP-RIBOSE DETECTION REAGENTS	The Board of Regents of the University of Texas	10-Jun-14	9-Jun-15	10-Dec-15
4246	US9868740	http://59.45.142.240:8808/pdf/US9868740.pdf	Pyrimidinone compounds which are HNE inhibitors	CHIESI FARMACEUTICI S.p.A.	12-Jun-14	12-Jun-14	16-Jan-18

4247	US20170114 053	http://59.45.142.240:8808/pdf/US20170114053A1.pdf	HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF	The United States of America, as represented by the Secretary, Department of Health and Human Services	12-Jun-14	12-Jun-15	27-Apr-17
4248	US20170101 413		NOVEL COMPOUNDS	CHIESI FARMACEUTICI	12-Jun-14	12-Jun-14	13-Apr-17
4249	US10202367	http://59.45.142.240:8808/pdf/US10202367.pdf	Heterocyclic compounds and methods of use thereof	The United States of America, as represented by the Secretary, Department of Health and Human Services	12-Jun-14	12-Jun-15	12-Feb-19
4250	US20170143 820	http://59.45.142.240:8808/pdf/US20170143820A1.pdf	IMMUNOGENIC COMBINATIONS	GLAXOSMITHKLINE SA	13-Jun-14	12-Jun-15	25-May-17
4251	US20150369 806	http://59.45.142.240:8808/pdf/US20150369806A1.pdf	DETECTION OF VIRAL DISEASES USING A BIOCHIP THAT CONTAINS GOLD NANOPARTICLES	Not Available	19-Jun-14	17-Jun-15	24-Dec-15
4252	US9603864	http://59.45.142.240:8808/pdf/US9603864.pdf	Substituted nucleosides, nucleotides and analogs thereof	Alios BioPharma, Inc.	24-Jun-14	22-Jun-15	28-Mar-17
4253	US20170143 749	http://59.45.142.240:8808/pdf/US20170143749A1.pdf	SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS	Not Available	24-Jun-14	2-Feb-17	25-May-17
4254	US20150366 888	http://59.45.142.240:8808/pdf/US20150366888A1.pdf	SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS	Not Available	24-Jun-14	22-Jun-15	24-Dec-15
4255	US10307439	http://59.45.142.240:8808/pdf/US10307439.pdf	Substituted nucleosides, nucleotides and analogs thereof	Alios Biopharma, Inc.	24-Jun-14	2-Feb-17	4-Jun-19
4256	US9856224	http://59.45.142.240:8808/pdf/US9856224.pdf	Stable sodium channel blockers	PARION SCIENCES, INC.	30-Jun-14	30-Jan-17	2-Jan-18
4257	US20170267 649	http://59.45.142.240:8808/pdf/US20170267649A1.pdf	STABLE SODIUM CHANNEL BLOCKERS	PARION SCIENCES, INC.	30-Jun-14	30-Jan-17	21-Sep-17
4258	US20150376 145	http://59.45.142.240:8808/pdf/US20150376145A1.pdf	STABLE SODIUM CHANNEL BLOCKERS	PARION SCIENCES, INC.	30-Jun-14	30-Jun-15	31-Dec-15
4259	US20160008 809	http://59.45.142.240:8808/pdf/US20160008809A1.pdf	METHODS AND COMPOSITIONS FOR PAPER-BASED AND HYBRID MICROFLUIDIC DEVICES INTEGRATED WITH NUCLEIC ACID AMPLIFICATION FOR DISEASE	University of Texas at El Paso	10-Jul-14	10-Jul-15	14-Jan-16
4260	US20170173 585	http://59.45.142.240:8808/pdf/US20170173585A1.pdf	POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR DISEASE DETECTION	Not Available	11-Jul-14	10-Jul-15	22-Jun-17
4261	US9623040	http://59.45.142.240:8808/pdf/US9623040.pdf	Immunomodulation by controlling expression levels of microRNAs in dendritic cells	The Board of Trustees of the Leland Stanford	14-Jul-14	10-Jul-15	18-Apr-17
4262	US20160008 397	http://59.45.142.240:8808/pdf/US20160008397A1.pdf	IMMUNOMODULATION BY CONTROLLING EXPRESSION LEVELS OF MICRORNAs IN DENDRITIC	Not Available	14-Jul-14	10-Jul-15	14-Jan-16
4263	US20170196 954	http://59.45.142.240:8808/pdf/US20170196954A1.pdf	PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A	Not Available	15-Jul-14	14-Jul-15	13-Jul-17
4264	US9683017	http://59.45.142.240:8808/pdf/US9683017.pdf	Inhibitory peptides of viral infection	UNIVERSITY OF TENNESSEE RESEARCH	17-Jul-14	16-Jul-15	20-Jun-17
4265	US20170267 722	http://59.45.142.240:8808/pdf/US20170267722A1.pdf	INHIBITORY PEPTIDES OF VIRAL INFECTION	Not Available	17-Jul-14	25-May-17	21-Sep-17
4266	US20160016 999	http://59.45.142.240:8808/pdf/US20160016999A1.pdf	INHIBITORY PEPTIDES OF VIRAL INFECTION	Not Available	17-Jul-14	16-Jul-15	21-Jan-16
4267	US10308685	http://59.45.142.240:8808/pdf/US10308685.pdf	Inhibitory peptides of viral infection	UNIVERSITY OF TENNESSEE RESEARCH	17-Jul-14	25-May-17	4-Jun-19
4268	USRE47838	http://59.45.142.240:8808/pdf/USRE47838.pdf	Inhibitory peptides of viral infection	UNIVERSITY OF TENNESSEE RESEARCH	17-Jul-14	30-Jan-18	4-Feb-20
4269	US20160015 803	http://59.45.142.240:8808/pdf/US20160015803A1.pdf	IMMUNOSTIMULATORY COMBINATIONS AND USE THEREOF	Not Available	18-Jul-14	17-Jul-15	21-Jan-16
4270	US20170204 143	http://59.45.142.240:8808/pdf/US20170204143A1.pdf	Constrained proteins and uses thereof	Not Available	21-Jul-14	21-Jul-15	20-Jul-17
4271	US20160016 986	http://59.45.142.240:8808/pdf/US20160016986A1.pdf	STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT	Not Available	21-Jul-14	21-Jul-15	21-Jan-16
4272	US10294280	http://59.45.142.240:8808/pdf/US10294280.pdf	Constrained proteins and uses thereof	Monash University	21-Jul-14	21-Jul-15	21-May-19
4273	US20190310 168	http://59.45.142.240:8808/pdf/US20190310168A1.pdf	AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE	Not Available	22-Jul-14	4-Mar-19	10-Oct-19
4274	US20160025 603	http://59.45.142.240:8808/pdf/US20160025603A1.pdf	AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE	Not Available	22-Jul-14	21-Jul-15	28-Jan-16
4275	US9822127	http://59.45.142.240:8808/pdf/US9822127.pdf	GAK modulators as antivirals	The Board of Trustees of the Leland Stanford	23-Jul-14	23-Jul-15	21-Nov-17
4276	US20170216 427	http://59.45.142.240:8808/pdf/US20170216427A1.pdf	Coronavirus	Not Available	23-Jul-14	23-Jul-15	3-Aug-17
4277	US20170152 271	http://59.45.142.240:8808/pdf/US20170152271A1.pdf	GAK MODULATORS AS ANTIVIRALS	Katholieke Universiteit Leuven	23-Jul-14	23-Jul-15	1-Jun-17
4278	US10130701	http://59.45.142.240:8808/pdf/US10130701.pdf	Coronavirus	THE PIRBRIGHT INSTITUTE	23-Jul-14	23-Jul-15	20-Nov-18
4279	US20190328 865	http://59.45.142.240:8808/pdf/US20190328865A1.pdf	IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION	Not Available	28-Jul-14	17-Nov-17	31-Oct-19
4280	US9925215	http://59.45.142.240:8808/pdf/US9925215.pdf	Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for prophylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition	UNIWERSYTET JAGIELLONSKI	29-Jul-14	25-Oct-17	27-Mar-18

4281	US20180064 752	http://59.45.142.240:8808/pdf/US20180064752A1.pdf	ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL	Not Available	29-Jul-14	25-Oct-17	8-Mar-18
4282	US20170216 347	http://59.45.142.240:8808/pdf/US20170216347A1.pdf	ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL	UNIwersytet Jagiellonski	29-Jul-14	29-Jul-15	3-Aug-17
4283	US20170348 402		SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR	Not Available	30-Jul-14	30-Jul-15	7-Dec-17
4284	US9657015	http://59.45.142.240:8808/pdf/US9657015.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	23-May-17
4285	US9475779	http://59.45.142.240:8808/pdf/US9475779.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	25-Oct-16
4286	US9458113	http://59.45.142.240:8808/pdf/US9458113.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	4-Oct-16
4287	US9440930	http://59.45.142.240:8808/pdf/US9440930.pdf	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	13-Sep-16
4288	US9290457	http://59.45.142.240:8808/pdf/US9290457.pdf	Substituted dihydropyrimidinones and their use as inhibitors of	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	22-Mar-16
4289	US20160039 812	http://59.45.142.240:8808/pdf/US20160039812A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	31-Jul-14	27-Jul-15	11-Feb-16
4290	US20160031 831	http://59.45.142.240:8808/pdf/US20160031831A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
4291	US20160031 830	http://59.45.142.240:8808/pdf/US20160031830A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
4292	US20160031 829	http://59.45.142.240:8808/pdf/US20160031829A1.pdf	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
4293	US20160031 825	http://59.45.142.240:8808/pdf/US20160031825A1.pdf	SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
4294	US9440960	http://59.45.142.240:8808/pdf/US9440960.pdf	Substituted oxetanes and their use as inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	1-Aug-14	31-Jul-15	13-Sep-16
4295	US20160031 861	http://59.45.142.240:8808/pdf/US20160031861A1.pdf	SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF	Not Available	1-Aug-14	31-Jul-15	4-Feb-16
4296	US9657048	http://59.45.142.240:8808/pdf/US9657048.pdf	Enantiomers of the 1â€²,6â€²-isomer of neplanocin A	Auburn University	4-Aug-14	4-Aug-15	23-May-17
4297	US20190202 854	http://59.45.142.240:8808/pdf/US20190202854A1.pdf	ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A	Not Available	4-Aug-14	8-Mar-19	4-Jul-19
4298	US20170260 223	http://59.45.142.240:8808/pdf/US20170260223A1.pdf	ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A	Not Available	4-Aug-14	17-May-17	14-Sep-17
4299	US20170224 813	http://59.45.142.240:8808/pdf/US20170224813A1.pdf	VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	10-Aug-17
4300	US20170224 812	http://59.45.142.240:8808/pdf/US20170224812A1.pdf	LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	10-Aug-17
4301	US20170216 430	http://59.45.142.240:8808/pdf/US20170216430A1.pdf	IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	3-Aug-17
4302	US20170216 429	http://59.45.142.240:8808/pdf/US20170216429A1.pdf	COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	3-Aug-17
4303	US20160039 860	http://59.45.142.240:8808/pdf/US20160039860A1.pdf	ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A	Not Available	4-Aug-14	4-Aug-15	11-Feb-16
4304	US10471140	http://59.45.142.240:8808/pdf/US10471140.pdf	Composition for enhancing induction of humoral immunity, and vaccine	NITTO DENKO CORPORATION	4-Aug-14	18-Apr-19	12-Nov-19
4305	US10456464	http://59.45.142.240:8808/pdf/US10456464.pdf	Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	29-Oct-19
4306	US10369219	http://59.45.142.240:8808/pdf/US10369219.pdf	Composition for enhancing induction of humoral immunity, and vaccine	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	6-Aug-19
4307	US10286067		Composition for enhancing induction of humoral immunity, and vaccine	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	14-May-19

4308	US10227373	http://59.45.142.240:8808/pdf/US10227373.pdf	Enantiomers of the 1 α C ² ,6 α C ² -isomer of neplanocin A	Auburn University	4-Aug-14	17-May-17	12-Mar-19
4309	US20170211 058	http://59.45.142.240:8808/pdf/US20170211058A1.pdf	METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF POOLED SAMPLES	Not Available	6-Aug-14	5-Aug-15	27-Jul-17
4310	US10378008	http://59.45.142.240:8808/pdf/US10378008.pdf	Method and apparatus for automated processing of pooled samples	GFE BLUT MBH	6-Aug-14	5-Aug-15	13-Aug-19
4311	US20170216 348	http://59.45.142.240:8808/pdf/US20170216348A1.pdf	METAL NANOCLUSTERS AND USES THEREOF	Not Available	7-Aug-14	7-Aug-15	3-Aug-17
4312	US10357510	http://59.45.142.240:8808/pdf/US10357510.pdf	Metal nanoclusters and uses thereof	THE REGENTS OF THE UNIVERSITY OF ALABAMA	7-Aug-14	7-Aug-15	23-Jul-19
4313	US20170122 853	http://59.45.142.240:8808/pdf/US20170122853A1.pdf	PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF	8-Aug-14	7-Aug-15	4-May-17
4314	US20160051 669	http://59.45.142.240:8808/pdf/US20160051669A1.pdf	COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TRECS	Not Available	21-Aug-14	21-Aug-15	25-Feb-16
4315	US10293060	http://59.45.142.240:8808/pdf/US10293060.pdf	Method for increasing expression of RNA-encoded proteins	CureVac AG	21-Aug-14	19-Feb-16	21-May-19
4316	US20180037 617	http://59.45.142.240:8808/pdf/US20180037617A1.pdf	METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE	Institute of Biophysics, Chinese Academy of Sciences	22-Aug-14	21-Aug-15	8-Feb-18
4317	US20160052 959	http://59.45.142.240:8808/pdf/US20160052959A1.pdf	RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND DIAGNOSTIC	BRIGHAM YOUNG UNIVERSITY	22-Aug-14	19-Aug-15	25-Feb-16
4318	US10227376	http://59.45.142.240:8808/pdf/US10227376.pdf	Radiolabeled cationic steroid antimicrobials and diagnostic	BRIGHAM YOUNG UNIVERSITY	22-Aug-14	19-Aug-15	12-Mar-19
4319	US20160058 814	http://59.45.142.240:8808/pdf/US20160058814A1.pdf	PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND	Not Available	26-Aug-14	26-Aug-14	3-Mar-16
4320	US20180325 076	http://59.45.142.240:8808/pdf/US20180325076A1.pdf	ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM	OXISCIENCE, LLC	28-Aug-14	24-Jul-18	15-Nov-18
4321	US20160058 008	http://59.45.142.240:8808/pdf/US20160058008A1.pdf	ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM	Not Available	28-Aug-14	28-Aug-15	3-Mar-16
4322	US10028482	http://59.45.142.240:8808/pdf/US10028482.pdf	Disinfecting and deodorizing compositions and methods with	OxiScience LLC	28-Aug-14	28-Aug-15	24-Jul-18
4323	US20170360 908	http://59.45.142.240:8808/pdf/US20170360908A1.pdf	VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED IMMUNITY CONTAINING	NITTO DENKO CORPORATION	3-Sep-14	2-Sep-15	21-Dec-17
4324	US20170340 721		METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES	Not Available	3-Sep-14	3-Sep-15	30-Nov-17
4325	US20170281 759	http://59.45.142.240:8808/pdf/US20170281759A1.pdf	BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL	NITTO DENKO CORPORATION	3-Sep-14	2-Sep-15	5-Oct-17
4326	US10561722	http://59.45.142.240:8808/pdf/US10561722.pdf	Methods and compositions for enhancing immune responses	Bavarian Nordic A/S	3-Sep-14	3-Sep-15	18-Feb-20
4327	US10471141	http://59.45.142.240:8808/pdf/US10471141.pdf	Bisphosphonate-containing vaccine pharmaceutical composition for	NITTO DENKO CORPORATION	3-Sep-14	2-Sep-15	12-Nov-19
4328	US20190002 393	http://59.45.142.240:8808/pdf/US20190002393A1.pdf	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	5-Sep-14	19-Sep-18	3-Jan-19
4329	US20170275 243	http://59.45.142.240:8808/pdf/US20170275243A1.pdf	Lipids and Lipid Compositions for the Delivery of Active Agents	Novartis AG	5-Sep-14	4-Sep-15	28-Sep-17
4330	US20170274 064	http://59.45.142.240:8808/pdf/US20170274064A1.pdf	MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES	Not Available	5-Sep-14	4-Sep-15	28-Sep-17
4331	US10272149	http://59.45.142.240:8808/pdf/US10272149.pdf	Modified bat influenza viruses and their uses	J. CRAIG VENTER INSTITUTE	5-Sep-14	4-Sep-15	30-Apr-19
4332	US10125092	http://59.45.142.240:8808/pdf/US10125092.pdf	Lipids and lipid compositions for the delivery of active agents	Novartis AG	5-Sep-14	4-Sep-15	13-Nov-18
4333	US9909176	http://59.45.142.240:8808/pdf/US9909176.pdf	Efficient deep sequencing and rapid genomic speciation of RNA viruses	The Johns Hopkins University	8-Sep-14	1-Sep-15	6-Mar-18
4334	US20190151 474	http://59.45.142.240:8808/pdf/US20190151474A2.pdf	RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS, APTAMERS AND SMALL MOLECULES	Kyoto University	8-Sep-14	8-Sep-15	23-May-19
4335	US20160076 094	http://59.45.142.240:8808/pdf/US20160076094A1.pdf	Efficient Deep Sequencing and Rapid Genomic Speciation of RNA Viruses	Not Available	8-Sep-14	1-Sep-15	17-Mar-16
4336	US9879026	http://59.45.142.240:8808/pdf/US9879026.pdf	Substituted spirocycles	Boehringer Ingelheim	12-Sep-14	29-Nov-16	30-Jan-18
4337	US9540373	http://59.45.142.240:8808/pdf/US9540373.pdf	Substituted spirocycles	Boehringer Ingelheim	12-Sep-14	10-Sep-15	10-Jan-17
4338	US20170073 352	http://59.45.142.240:8808/pdf/US20170073352A1.pdf	NOVEL SUBSTITUTED SPIROCYCLES	Not Available	12-Sep-14	29-Nov-16	16-Mar-17
4339	US20160075 704	http://59.45.142.240:8808/pdf/US20160075704A1.pdf	NOVEL SUBSTITUTED SPIROCYCLES	Not Available	12-Sep-14	10-Sep-15	17-Mar-16
4340	USRE47636	http://59.45.142.240:8808/pdf/USRE47636.pdf	Substituted spirocycles	Boehringer Ingelheim	12-Sep-14	30-Nov-17	8-Oct-19
4341	US20160074 507	http://59.45.142.240:8808/pdf/US20160074507A1.pdf	METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING IMMUNE	Not Available	16-Sep-14	16-Sep-15	17-Mar-16
4342	US10010607	http://59.45.142.240:8808/pdf/US10010607.pdf	Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response	INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE	16-Sep-14	16-Sep-15	3-Jul-18
4343	US9845342	http://59.45.142.240:8808/pdf/US9845342.pdf	Fusion proteins, recombinant bacteria, and methods for using	Spogen Biotech Inc.	17-Sep-14	17-Sep-15	19-Dec-17
4344	US20180099 999	http://59.45.142.240:8808/pdf/US20180099999A1.pdf	FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA	Not Available	17-Sep-14	14-Dec-17	12-Apr-18
4345	US20170118 995	http://59.45.142.240:8808/pdf/US20170118995A1.pdf	MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE SAME, AND METHOD FOR CONTROLLING UNICELLULAR	Riken Techno System Co., Ltd.	17-Sep-14	6-Dec-16	4-May-17

4346	US20160108 096	http://59.45.142.240:8808/pdf/US20160108096A1.pdf	FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA	Not Available	17-Sep-14	17-Sep-15	21-Apr-16
4347	US10407472	http://59.45.142.240:8808/pdf/US10407472.pdf	Fusion proteins, recombinant bacteria, and methods for using	Spogen Biotech Inc.	17-Sep-14	14-Dec-17	10-Sep-19
4348	US20180368 417		ANTIMICROBIAL COMPOSITIONS AND METHODS	Not Available	23-Sep-14	19-Jun-18	27-Dec-18
4349	US20160081 346		ANTIMICROBIAL COMPOSITIONS AND METHODS	Not Available	23-Sep-14	22-Sep-15	24-Mar-16
4350	US20160101 145	http://59.45.142.240:8808/pdf/US20160101145A1.pdf	PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF	Not Available	24-Sep-14	24-Sep-15	14-Apr-16
4351	US20200147 203		VACCINATION OF IMMUNOCOMPROMISED SUBJECTS	Not Available	26-Sep-14	10-Jan-20	14-May-20
4352	US20170304 429		VACCINATION OF IMMUNOCOMPROMISED SUBJECTS	Not Available	26-Sep-14	25-Sep-15	26-Oct-17
4353	US20170290 909	http://59.45.142.240:8808/pdf/US20170290909A1.pdf	METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING	Bavarian Nordic A/S	26-Sep-14	25-Sep-15	12-Oct-17
4354	US10512684	http://59.45.142.240:8808/pdf/US10512684.pdf	Methods and compositions for intra-nasal immunization with	Bavarian Nordic A/S	26-Sep-14	25-Sep-15	24-Dec-19
4355	US20170298 100		ANTI-VIRAL PEPTIDES	Not Available	1-Oct-14	30-Sep-15	19-Oct-17
4356	US20170216 431	http://59.45.142.240:8808/pdf/US20170216431A1.pdf	VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION	NITTO DENKO CORPORATION	2-Oct-14	1-Oct-15	3-Aug-17
4357	US20170205 399	http://59.45.142.240:8808/pdf/US20170205399A1.pdf	POLYMERS AND CONJUGATES COMPRISING THE SAME	Not Available	2-Oct-14	31-Mar-17	20-Jul-17
4358	US10420837	http://59.45.142.240:8808/pdf/US10420837.pdf	Vaccine pharmaceutical composition for transdermal administration	NITTO DENKO CORPORATION	2-Oct-14	1-Oct-15	24-Sep-19
4359	US20170259 976	http://59.45.142.240:8808/pdf/US20170259976A1.pdf	DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME	MONOSOL, LLC	3-Oct-14	2-Oct-15	14-Sep-17
4360	US20170304 466		AAV-Based Gene Therapy	Not Available	6-Oct-14	6-Oct-15	26-Oct-17
4361	US20170304 459	http://59.45.142.240:8808/pdf/US20170304459A1.pdf	METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE	Not Available	10-Oct-14	7-Oct-15	26-Oct-17
4362	US20170304 420		POLYMER ADJUVANT	Oxford University Innovation Limited	10-Oct-14	9-Oct-15	26-Oct-17
4363	US20160114 022	http://59.45.142.240:8808/pdf/US20160114022A1.pdf	THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR FILOVIRUSES INCLUDING	Not Available	11-Oct-14	10-Oct-15	28-Apr-16
4364	US20170308 679	http://59.45.142.240:8808/pdf/US20170308679A1.pdf	BIOSECURITY SCREENING SYSTEM AND METHOD	Not Available	16-Oct-14	12-Oct-15	26-Oct-17
4365	US9474844	http://59.45.142.240:8808/pdf/US9474844.pdf	Methods for pathogen inactivation in blood using UV irradiation while	Hemalux LLC	22-Oct-14	29-Dec-15	25-Oct-16
4366	US9265876	http://59.45.142.240:8808/pdf/US9265876.pdf	Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat	Hemalux Technologies LLC	22-Oct-14	22-Oct-14	23-Feb-16
4367	US20200155 699	http://59.45.142.240:8808/pdf/US20200155699A1.pdf	MODIFIED VIRUS-LIKE PARTICLES OF CMV	Not Available	22-Oct-14	26-Nov-19	21-May-20
4368	US20170312 371	http://59.45.142.240:8808/pdf/US20170312371A1.pdf	MODIFIED VIRUS-LIKE PARTICLES OF CMV	SAIBA GMBH	22-Oct-14	20-Oct-15	2-Nov-17
4369	US10532107	http://59.45.142.240:8808/pdf/US10532107.pdf	Modified virus-like particles of CMV	SAIBA GMBH	22-Oct-14	20-Oct-15	14-Jan-20
4370	US20160113 920	http://59.45.142.240:8808/pdf/US20160113920A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL AND VIRAL ADHESION	Not Available	24-Oct-14	23-Oct-15	28-Apr-16
4371	US10039758	http://59.45.142.240:8808/pdf/US10039758.pdf	Compositions and methods for inhibiting bacterial and viral	Keck Graduate Institute of Applied Life Sciences	24-Oct-14	23-Oct-15	7-Aug-18
4372	US9969793	http://59.45.142.240:8808/pdf/US9969793.pdf	Compositions and methods for the treatment of immunodeficiency	ADMA Biologics, Inc.	28-Oct-14	13-Nov-17	15-May-18
4373	US9815886	http://59.45.142.240:8808/pdf/US9815886.pdf	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC	28-Oct-14	8-Jan-15	14-Nov-17
4374	US9714283	http://59.45.142.240:8808/pdf/US9714283.pdf	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC	28-Oct-14	2-Jul-15	25-Jul-17
4375	US9107906	http://59.45.142.240:8808/pdf/US9107906.pdf	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC	28-Oct-14	8-Jan-15	18-Aug-15
4376	US20180258 159	http://59.45.142.240:8808/pdf/US20180258159A1.pdf	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	14-May-18	13-Sep-18
4377	US20180086 818	http://59.45.142.240:8808/pdf/US20180086818A1.pdf	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	13-Nov-17	29-Mar-18
4378	US20170334 973	http://59.45.142.240:8808/pdf/US20170334973A1.pdf	NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE	Not Available	28-Oct-14	27-Oct-15	23-Nov-17
4379	US20160115 221	http://59.45.142.240:8808/pdf/US20160115221A1.pdf	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	2-Jul-15	28-Apr-16
4380	US20160114 037	http://59.45.142.240:8808/pdf/US20160114037A1.pdf	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	8-Jan-15	28-Apr-16
4381	US10611827	http://59.45.142.240:8808/pdf/US10611827.pdf	Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope	INTEGRATED BIOTHERAPEUTICS, INC.	28-Oct-14	27-Oct-15	7-Apr-20
4382	US20170313 765		DIRECT EXPRESSION OF ANTIBODIES	Not Available	29-Oct-14	28-Oct-15	2-Nov-17
4383	US20180142 198	http://59.45.142.240:8808/pdf/US20180142198A1.pdf	DELIVERY OF BIOMOLECULES TO IMMUNE CELLS	Not Available	31-Oct-14	30-Oct-15	24-May-18
4384	US20170334 941	http://59.45.142.240:8808/pdf/US20170334941A1.pdf	2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES	Not Available	31-Oct-14	30-Oct-15	23-Nov-17
4385	US9834757	http://59.45.142.240:8808/pdf/US9834757.pdf	Hand, foot, and mouth vaccines and methods of manufacture and use	Takeda Vaccines, Inc.	7-Nov-14	6-Nov-15	5-Dec-17
4386	US20190352 357	http://59.45.142.240:8808/pdf/US20190352357A1.pdf	HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS	Colorado State University Research Foundation	7-Nov-14	7-Aug-19	21-Nov-19
4387	US20180187 165	http://59.45.142.240:8808/pdf/US20180187165A1.pdf	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF	Takeda Vaccines, Inc.	7-Nov-14	27-Oct-17	5-Jul-18
4388	US20180125 965	http://59.45.142.240:8808/pdf/US20180125965A1.pdf	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF	Takeda Vaccines, Inc.	7-Nov-14	6-Nov-15	10-May-18

4389	US20160152 676	http://59.45.142.240:8808/pdf/US20160152676A1.pdf	HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS	COLORADO STATE UNIVERSITY RESEARCH	7-Nov-14	9-Nov-15	2-Jun-16
4390	US20160129 104	http://59.45.142.240:8808/pdf/US20160129104A1.pdf	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF	Not Available	7-Nov-14	6-Nov-15	12-May-16
4391	US10428128	http://59.45.142.240:8808/pdf/US10428128.pdf	Helix-grafted proteins as inhibitors of disease-relevant protein- protein	Colorado State University Research	7-Nov-14	9-Nov-15	1-Oct-19
4392	US10233429	http://59.45.142.240:8808/pdf/US10233429.pdf	Hand, foot, and mouth vaccines and methods of manufacture and use	Takeda Vaccines, Inc.	7-Nov-14	27-Oct-17	19-Mar-19
4393	US20170333 494		PROBIOTIC THERAPEUTIC APPLICATIONS	Not Available	10-Nov-14	9-Nov-15	23-Nov-17
4394	US20190380 891	http://59.45.142.240:8808/pdf/US20190380891A1.pdf	MOBILE CLINICS	Baylor College of Medicine	12-Nov-14	28-Aug-19	19-Dec-19
4395	US20170333 267	http://59.45.142.240:8808/pdf/US20170333267A1.pdf	MOBILE CLINICS	Baylor College of Medicine	12-Nov-14	11-Nov-15	23-Nov-17
4396	US10420685	http://59.45.142.240:8808/pdf/US10420685.pdf	Mobile clinics	Baylor College of Medicine	12-Nov-14	11-Nov-15	24-Sep-19
4397	US20170319 673	http://59.45.142.240:8808/pdf/US20170319673A1.pdf	TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS	Not Available	13-Nov-14	12-Nov-15	9-Nov-17
4398	US20190365 925	http://59.45.142.240:8808/pdf/US20190365925A1.pdf	AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM	Not Available	21-Nov-14	13-Jun-19	5-Dec-19
4399	US20170360 960	http://59.45.142.240:8808/pdf/US20170360960A1.pdf	AAV Vectors Targeted to the Central Nervous System	Not Available	21-Nov-14	20-Nov-15	21-Dec-17
4400	US10561743	http://59.45.142.240:8808/pdf/US10561743.pdf	AAV vectors targeted to the central nervous system	The University of North Carolina at Chapel Hill	21-Nov-14	13-Jun-19	18-Feb-20
4401	US10532110	http://59.45.142.240:8808/pdf/US10532110.pdf	AAV vectors targeted to the central nervous system	The University of North Carolina at Chapel Hill	21-Nov-14	20-Nov-15	14-Jan-20
4402	US9808490	http://59.45.142.240:8808/pdf/US9808490.pdf	Induced hepatocytes and uses thereof	ACCELERATED BIOSCIENCES CORP.	26-Nov-14	25-Nov-15	7-Nov-17
4403	US20180000 868	http://59.45.142.240:8808/pdf/US20180000868A1.pdf	Induced Hepatocytes and Uses Thereof	Not Available	26-Nov-14	15-Sep-17	4-Jan-18
4404	US20160199 416	http://59.45.142.240:8808/pdf/US20160199416A1.pdf	Induced Hepatocytes and Uses Thereof	Not Available	26-Nov-14	25-Nov-15	14-Jul-16
4405	US20170275 592		CULTURE MEDIUM	Koninklijke Nederlandse Akademie Van Wetenschappen	27-Nov-14	27-Nov-15	28-Sep-17
4406	US20190209 678	http://59.45.142.240:8808/pdf/US20190209678A1.pdf	MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS WITH ENHANCED STABILITY	Not Available	2-Dec-14	12-Mar-19	11-Jul-19
4407	US20180111 991	http://59.45.142.240:8808/pdf/US20180111991A1.pdf	MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T	Not Available	2-Dec-14	2-Jun-17	26-Apr-18
4408	US20170312 357	http://59.45.142.240:8808/pdf/US20170312357A1.pdf	MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS	Not Available	2-Dec-14	2-Dec-15	2-Nov-17
4409	US10500272	http://59.45.142.240:8808/pdf/US10500272.pdf	Manufacture of surfactant-containing compositions with enhanced stability	NOVARTIS AG	2-Dec-14	12-Mar-19	10-Dec-19
4410	US10238739	http://59.45.142.240:8808/pdf/US10238739.pdf	Manufacture of surfactant-containing compositions with enhanced stability	NOVARTIS AG	2-Dec-14	2-Dec-15	26-Mar-19
4411	US20170327 439	http://59.45.142.240:8808/pdf/US20170327439A1.pdf	DIHYDRONAPHTHALENE DERIVATIVE	ONO PHARMACEUTICAL CO., LTD.	3-Dec-14	3-Dec-14	16-Nov-17
4412	US20160159 927	http://59.45.142.240:8808/pdf/US20160159927A1.pdf	IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND	Not Available	5-Dec-14	7-Dec-15	9-Jun-16
4413	US20160158 154	http://59.45.142.240:8808/pdf/US20160158154A1.pdf	PROTEIN VESICLES AND METHODS OF MAKING AND USING THEREOF	Not Available	5-Dec-14	7-Dec-15	9-Jun-16
4414	US10370455	http://59.45.142.240:8808/pdf/US10370455.pdf	Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8	IMMUNEXT, INC.	5-Dec-14	7-Dec-15	6-Aug-19
4415	US20190001 010	http://59.45.142.240:8808/pdf/US20190001010A1.pdf	ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF	Not Available	8-Dec-14	13-Jul-18	3-Jan-19
4416	US20170333 586	http://59.45.142.240:8808/pdf/US20170333586A1.pdf	ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF	Not Available	8-Dec-14	23-May-15	23-Nov-17
4417	US10052398	http://59.45.142.240:8808/pdf/US10052398.pdf	Additive compositions for pigmented disinfection and methods thereof	Kinnos Inc.	8-Dec-14	23-May-15	21-Aug-18
4418	US20160160 178		IMMUNOTHERAPY USING STEM CELLS	Not Available	9-Dec-14	2-Dec-15	9-Jun-16
4419	US20180161 425	http://59.45.142.240:8808/pdf/US20180161425A1.pdf	NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY PRODUCTION IN IMMUNIZATION	Not Available	10-Dec-14	10-Dec-15	14-Jun-18
4420	US20180044 687	http://59.45.142.240:8808/pdf/US20180044687A1.pdf	ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION	Not Available	12-Dec-14	11-Dec-15	15-Feb-18
4421	US9409870	http://59.45.142.240:8808/pdf/US9409870.pdf	Compounds	CHIESI FARMACEUTICI	15-Dec-14	27-Nov-15	9-Aug-16
4422	US20160168 101		NOVEL COMPOUNDS	CHIESI FARMACEUTICI	15-Dec-14	27-Nov-15	16-Jun-16
4423	US20170369 470	http://59.45.142.240:8808/pdf/US20170369470A1.pdf	Cyclic Compounds and Uses Thereof	Not Available	16-Dec-14	16-Dec-15	28-Dec-17
4424	US20170275 253	http://59.45.142.240:8808/pdf/US20170275253A1.pdf	BENZAZEPINE SULFONAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	18-Dec-14	14-Jun-17	28-Sep-17
4425	US20170362 297	http://59.45.142.240:8808/pdf/US20170362297A1.pdf	CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF	Not Available	19-Dec-14	21-Dec-15	21-Dec-17
4426	US20170360 875	http://59.45.142.240:8808/pdf/US20170360875A1.pdf	METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS	MIDDLE TENNESSEE STATE UNIVERSITY	22-Dec-14	22-Dec-15	21-Dec-17
4427	US20160174 631	http://59.45.142.240:8808/pdf/US20160174631A1.pdf	PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER, FORMULATIONS FORMING THE SAME AND METHOD OF PRODUCING	Not Available	23-Dec-14	10-Dec-15	23-Jun-16
4428	US10201198	http://59.45.142.240:8808/pdf/US10201198.pdf	Protective masks with coating comprising different electrospun fibers interweaved with each other, formulations forming the same, and	Profit Royal Pharmaceutical Limited	23-Dec-14	10-Dec-15	12-Feb-19
4429	US20190022 116	http://59.45.142.240:8808/pdf/US20190022116A1.pdf	N4-Hydroxycytidine and Derivatives and Anti-Viral Use-Related Therapies	Not Available	26-Dec-14	16-Dec-15	24-Jan-19

4430	US20190367 525	http://59.45.142.240:8808/pdf/US20190367525A1.pdf	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	30-Dec-14	19-Jul-19	5-Dec-19
4431	US20190345 504		ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-14	26-Jul-19	14-Nov-19
4432	US20190308 980	http://59.45.142.240:8808/pdf/US20190308980A1.pdf	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	30-Dec-14	24-Jun-19	10-Oct-19
4433	US20180339 991	http://59.45.142.240:8808/pdf/US20180339991A1.pdf	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	30-Dec-14	24-May-18	29-Nov-18
4434	US20180339 988	http://59.45.142.240:8808/pdf/US20180339988A1.pdf	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	30-Dec-14	18-Jan-18	29-Nov-18
4435	US20180148 727		ARTIFICIAL NUCLEIC ACID MOLECULES	Not Available	30-Dec-14	29-Dec-15	31-May-18
4436	US20160185 786	http://59.45.142.240:8808/pdf/US20160185786A1.pdf	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	30-Dec-14	29-Dec-15	30-Jun-16
4437	US20160185 785	http://59.45.142.240:8808/pdf/US20160185785A1.pdf	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	30-Dec-14	29-Dec-15	30-Jun-16
4438	US10377760	http://59.45.142.240:8808/pdf/US10377760.pdf	Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7	FORMA Therapeutics, Inc.	30-Dec-14	18-Jan-18	13-Aug-19
4439	US10351571	http://59.45.142.240:8808/pdf/US10351571.pdf	Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7	FORMA Therapeutics, Inc.	30-Dec-14	24-May-18	16-Jul-19
4440	US10047375	http://59.45.142.240:8808/pdf/US10047375.pdf	Artificial nucleic acid molecules	CureVac AG	30-Dec-14	28-Jun-16	14-Aug-18
4441	US20180258 162	http://59.45.142.240:8808/pdf/US20180258162A1.pdf	Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections	Not Available	2-Jan-15	22-May-18	13-Sep-18
4442	US20160194 387	http://59.45.142.240:8808/pdf/US20160194387A1.pdf	Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections	Not Available	2-Jan-15	31-Dec-15	7-Jul-16
4443	US10005833	http://59.45.142.240:8808/pdf/US10005833.pdf	Methods of treating inflammation associated airway diseases and viral infections	THE BOARD OF REGENTS OF THE UNIVERSITY OF	2-Jan-15	31-Dec-15	26-Jun-18
4444	US20190211 355	http://59.45.142.240:8808/pdf/US20190211355A1.pdf	DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THEREOF	Not Available	5-Jan-15	4-Jan-16	11-Jul-19
4445	US20180187 211	http://59.45.142.240:8808/pdf/US20180187211A1.pdf	METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY	Not Available	9-Jan-15	7-Jan-16	5-Jul-18
4446	US20160201 110	http://59.45.142.240:8808/pdf/US20160201110A1.pdf	DIAGNOSIS AND TREATMENT OF INCIDENT DIABETES	Not Available	9-Jan-15	17-Nov-15	14-Jul-16
4447	US20180000 926		METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS	Not Available	15-Jan-15	15-Jan-16	4-Jan-18
4448	US20180312 544	http://59.45.142.240:8808/pdf/US20180312544A1.pdf	RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND USES THEREOF	The United States of America, as represented by the Secretary, Dept. of Health and Human Services	20-Jan-15	20-Jan-16	1-Nov-18
4449	US10654898	http://59.45.142.240:8808/pdf/US10654898.pdf	Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof	The United States of America, as represented by the Secretary, Department of Health and Human Services	20-Jan-15	20-Jan-16	19-May-20
4450	US20190247 367		TREATMENT OF INFECTIOUS DISEASES	CHILDREN'S MEDICAL CENTER CORPORATION	26-Jan-15	23-Apr-19	15-Aug-19
4451	US20180098 972		TREATMENT OF INFECTIOUS DISEASES	CHILDREN'S MEDICAL CENTER CORPORATION	26-Jan-15	26-Jan-16	12-Apr-18
4452	US9920128	http://59.45.142.240:8808/pdf/US9920128.pdf	Synthetic antiserum for rapid-turnaround therapies	The Johns Hopkins University	28-Jan-15	20-Jan-16	20-Mar-18
4453	US20180008 689	http://59.45.142.240:8808/pdf/US20180008689A1.pdf	RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL ROBUSTNESS AND SEQUENCE	Not Available	28-Jan-15	28-Jan-16	11-Jan-18
4454	US20160215 282	http://59.45.142.240:8808/pdf/US20160215282A1.pdf	SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIES	Not Available	28-Jan-15	20-Jan-16	28-Jul-16
4455	US20160213 647		COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION	Not Available	28-Jan-15	27-Jan-16	28-Jul-16
4456	US10206994	http://59.45.142.240:8808/pdf/US10206994.pdf	RNA virus attenuation by alteration of mutational robustness and	INSTITUT PASTEUR	28-Jan-15	28-Jan-16	19-Feb-19
4457	US20190309 039	http://59.45.142.240:8808/pdf/US20190309039A1.pdf	CRYPTIC POLYPEPTIDES AND USES THEREOF	Not Available	29-Jan-15	22-Apr-19	10-Oct-19
4458	US20180215 801	http://59.45.142.240:8808/pdf/US20180215801A1.pdf	CRYPTIC POLYPEPTIDES AND USES THEREOF	Not Available	29-Jan-15	29-Jan-16	2-Aug-18
4459	US10323074	http://59.45.142.240:8808/pdf/US10323074.pdf	Cryptic polypeptides and uses thereof	BOARD OF TRUSTEES OF MICHIGAN STATE	29-Jan-15	12-Dec-17	18-Jun-19
4460	US20190201 352	http://59.45.142.240:8808/pdf/US20190201352A1.pdf	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING	Not Available	30-Jan-15	12-Mar-19	4-Jul-19
4461	US20190031 679	http://59.45.142.240:8808/pdf/US20190031679A1.pdf	NOVEL MONOTHIOIOL MUCOLYTIC AGENTS	Not Available	30-Jan-15	5-Sep-18	31-Jan-19
4462	US20180303 768	http://59.45.142.240:8808/pdf/US20180303768A1.pdf	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING	Not Available	30-Jan-15	2-Jul-18	25-Oct-18
4463	US20180015 052	http://59.45.142.240:8808/pdf/US20180015052A1.pdf	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING	Not Available	30-Jan-15	28-Jan-16	18-Jan-18
4464	US20160222 023	http://59.45.142.240:8808/pdf/US20160222023A1.pdf	NOVEL MONOTHIOIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	30-Jan-15	29-Jan-16	4-Aug-16
4465	US10226434	http://59.45.142.240:8808/pdf/US10226434.pdf	Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity	Katholieke Universiteit Leuven/Lieden University Medical	30-Jan-15	2-Jul-18	12-Mar-19

4466	US10106551	http://59.45.142.240:8808/pdf/US10106551.pdf	Monothiol mucolytic agents	PARION SCIENCES, INC	30-Jan-15	29-Jan-16	23-Oct-18
4467	US10058516	http://59.45.142.240:8808/pdf/US10058516.pdf	Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus	Katholieke Universiteit Leuven	30-Jan-15	28-Jan-16	28-Aug-18
4468	US9938300	http://59.45.142.240:8808/pdf/US9938300.pdf	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-	Forma Therapeutics, Inc.	5-Feb-15	4-Feb-16	10-Apr-18
4469	US9932351	http://59.45.142.240:8808/pdf/US9932351.pdf	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5-Feb-15	4-Feb-16	3-Apr-18
4470	US9840491	http://59.45.142.240:8808/pdf/US9840491.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	4-Feb-16	12-Dec-17
4471	US20200087 280	http://59.45.142.240:8808/pdf/US20200087280A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	25-Nov-19	19-Mar-20
4472	US20190359 635	http://59.45.142.240:8808/pdf/US20190359635A1.pdf	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	5-Feb-15	18-Jul-19	28-Nov-19
4473	US20190359 629	http://59.45.142.240:8808/pdf/US20190359629A1.pdf	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	5-Feb-15	18-Jul-19	28-Nov-19
4474	US20190071 423	http://59.45.142.240:8808/pdf/US20190071423A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
4475	US20190071 422	http://59.45.142.240:8808/pdf/US20190071422A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
4476	US20190071 421	http://59.45.142.240:8808/pdf/US20190071421A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
4477	US20190071 420	http://59.45.142.240:8808/pdf/US20190071420A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
4478	US20190071 419	http://59.45.142.240:8808/pdf/US20190071419A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
4479	US20190071 418	http://59.45.142.240:8808/pdf/US20190071418A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
4480	US20180346 485	http://59.45.142.240:8808/pdf/US20180346485A1.pdf	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	5-Feb-15	27-Feb-18	6-Dec-18
4481	US20180346 480	http://59.45.142.240:8808/pdf/US20180346480A1.pdf	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	5-Feb-15	1-Mar-18	6-Dec-18
4482	US20180162 835	http://59.45.142.240:8808/pdf/US20180162835A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	11-Dec-17	14-Jun-18
4483	US20160229 872	http://59.45.142.240:8808/pdf/US20160229872A1.pdf	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	5-Feb-15	4-Feb-16	11-Aug-16
4484	US20160229 864	http://59.45.142.240:8808/pdf/US20160229864A1.pdf	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7	Not Available	5-Feb-15	4-Feb-16	11-Aug-16
4485	US20160229 833	http://59.45.142.240:8808/pdf/US20160229833A1.pdf	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7	Not Available	5-Feb-15	4-Feb-16	11-Aug-16
4486	US10519130	http://59.45.142.240:8808/pdf/US10519130.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
4487	US10519129	http://59.45.142.240:8808/pdf/US10519129.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
4488	US10519128	http://59.45.142.240:8808/pdf/US10519128.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
4489	US10519127	http://59.45.142.240:8808/pdf/US10519127.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
4490	US10513508	http://59.45.142.240:8808/pdf/US10513508.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	24-Dec-19
4491	US10513507	http://59.45.142.240:8808/pdf/US10513507.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	11-Dec-17	24-Dec-19
4492	US10508098	http://59.45.142.240:8808/pdf/US10508098B2.pdf	Quinazolinones and azaquinazolinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	17-Dec-19
4493	US10377773	http://59.45.142.240:8808/pdf/US10377773.pdf	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-	FORMA Therapeutics, Inc.	5-Feb-15	27-Feb-18	13-Aug-19
4494	US10377767	http://59.45.142.240:8808/pdf/US10377767.pdf	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	1-Mar-18	13-Aug-19
4495	US20190309 048	http://59.45.142.240:8808/pdf/US20190309048A1.pdf	Optimized Human Clotting Factor VIII Gene Expression Cassettes and	Not Available	6-Feb-15	20-May-19	10-Oct-19
4496	US20160229 904	http://59.45.142.240:8808/pdf/US20160229904A1.pdf	Optimized Human Clotting Factor VIII Gene Expression Cassettes and	Not Available	6-Feb-15	5-Feb-16	11-Aug-16
4497	US10308705	http://59.45.142.240:8808/pdf/US10308705.pdf	Optimized human clotting factor VIII gene expression cassettes and their	The University of North Carolina at	6-Feb-15	5-Feb-16	4-Jun-19
4498	US20200087 359	http://59.45.142.240:8808/pdf/US20200087359A1.pdf	GRIFFITHSIN MUTANTS	The United States of America,as represented by the Secretary,Department of Health and	10-Feb-15	27-Nov-19	19-Mar-20

4499	US20180016 307	http://59.45.142.240:8808/pdf/US20180016307A1.pdf	GRIFFITHSIN MUTANTS	The United States of America, as represented by the Secretary, Department of Health and Human Services	10-Feb-15	10-Feb-16	18-Jan-18
4500	US10501507	http://59.45.142.240:8808/pdf/US10501507B2.pdf	Griffithsin mutants	The United States of America, as represented by the Secretary, Department of Health and Human Services	10-Feb-15	10-Feb-16	10-Dec-19
4501	US20200140 398	http://59.45.142.240:8808/pdf/US20200140398A1.pdf	HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS	AZIENDA OSPEDALIERA UNIVERSITARIA	13-Feb-15	6-Jan-20	7-May-20
4502	US20190337 990	http://59.45.142.240:8808/pdf/US20190337990A1.pdf	POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY	Not Available	13-Feb-15	5-Jun-19	7-Nov-19
4503	US20180195 048	http://59.45.142.240:8808/pdf/US20180195048A1.pdf	METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION	Takeda Vaccines, Inc.	13-Feb-15	12-Feb-16	12-Jul-18
4504	US20180028 626	http://59.45.142.240:8808/pdf/US20180028626A1.pdf	IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION	Transgene SA	13-Feb-15	12-Feb-16	1-Feb-18
4505	US20180022 781	http://59.45.142.240:8808/pdf/US20180022781A1.pdf	POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	13-Feb-15	12-Feb-16	25-Jan-18
4506	US20180016 243	http://59.45.142.240:8808/pdf/US20180016243A1.pdf	HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS	Not Available	13-Feb-15	12-Feb-16	18-Jan-18
4507	US20170239 349	http://59.45.142.240:8808/pdf/US20170239349A1.pdf	COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL	Not Available	20-Feb-15	6-Jun-16	24-Aug-17
4508	US20180036 237	http://59.45.142.240:8808/pdf/US20180036237A1.pdf	OIL/SURFACTANT MIXTURES FOR SELF EMULSIFICATION	GLAXOSMITHKLINE BIOLOGICALS SA	23-Feb-15	23-Feb-16	8-Feb-18
4509	US20190256 579	http://59.45.142.240:8808/pdf/US20190256579A1.pdf	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The U.S.A., as represented by the Secretary, Department of Health and Human Services	24-Feb-15	3-May-19	22-Aug-19
4510	US20180244 756	http://59.45.142.240:8808/pdf/US20180244756A1.pdf	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The United States of America, as Represented by the Secretary, Dept. of Health and Human Services	24-Feb-15	24-Feb-16	30-Aug-18
4511	US10301377	http://59.45.142.240:8808/pdf/US10301377.pdf	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use	The United States of America, as Represented by the Secretary, Department of Health and Human Services	24-Feb-15	24-Feb-16	28-May-19
4512	US20180064 790	http://59.45.142.240:8808/pdf/US20180064790A1.pdf	Composition for Treatment or Prevention of Infectious Inflammatory Diseases, or Composition for Immune Enhancement, Comprising Tryptophanyl-tRNA Synthetase as an Adjuvant	Not Available	26-Feb-15	25-Aug-17	8-Mar-18
4513	US9727810	http://59.45.142.240:8808/pdf/US9727810.pdf	Spatially addressable molecular barcoding	Cellular Research, Inc.	27-Feb-15	26-Feb-16	8-Aug-17
4514	US20180036 398	http://59.45.142.240:8808/pdf/US20180036398A1.pdf	FLAVIVIRUS REPLICONS	Not Available	27-Feb-15	25-Feb-16	8-Feb-18
4515	US20180030 429	http://59.45.142.240:8808/pdf/US20180030429A1.pdf	Polypeptide Assemblies and Methods for the Production Thereof	Not Available	27-Feb-15	29-Feb-16	1-Feb-18
4516	US20170337 459	http://59.45.142.240:8808/pdf/US20170337459A1.pdf	SPATIALLY ADDRESSABLE MOLECULAR BARCODING	Not Available	27-Feb-15	2-Aug-17	23-Nov-17
4517	US20160253 584	http://59.45.142.240:8808/pdf/US20160253584A1.pdf	SPATIALLY ADDRESSABLE MOLECULAR BARCODING	Not Available	27-Feb-15	26-Feb-16	1-Sep-16
4518	US10501733	http://59.45.142.240:8808/pdf/US10501733B2.pdf	Polypeptide assemblies and methods for the production thereof	University of Utah Research	27-Feb-15	29-Feb-16	10-Dec-19
4519	US20180055 925	http://59.45.142.240:8808/pdf/US20180055925A1.pdf	DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS	The United States of America, as represented by the Secretary, Department of Health and Human Services	3-Mar-15	7-Aug-15	1-Mar-18
4520	US20180044 328	http://59.45.142.240:8808/pdf/US20180044328A1.pdf	PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Prozyme A/S	5-Mar-15	4-Mar-16	15-Feb-18
4521	US10479781	http://59.45.142.240:8808/pdf/US10479781.pdf	Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors	Neuprozyme Therapeutics APS	5-Mar-15	4-Mar-16	19-Nov-19
4522	US9822065	http://59.45.142.240:8808/pdf/US9822065.pdf	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6-Mar-15	14-Feb-17	21-Nov-17
4523	US9597333	http://59.45.142.240:8808/pdf/US9597333.pdf	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6-Mar-15	28-Sep-16	21-Mar-17
4524	US9475775	http://59.45.142.240:8808/pdf/US9475775.pdf	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6-Mar-15	4-Mar-16	25-Oct-16
4525	US20170014 423	http://59.45.142.240:8808/pdf/US20170014423A1.pdf	Benzazepine Dicarboxamide Compounds	Hoffmann-La Roche Inc.	6-Mar-15	28-Sep-16	19-Jan-17
4526	US20160257 653	http://59.45.142.240:8808/pdf/US20160257653A1.pdf	Benzazepine Dicarboxamide Compounds	Hoffmann-La Roche Inc.	6-Mar-15	4-Mar-16	8-Sep-16
4527	US20180237 502	http://59.45.142.240:8808/pdf/US20180237502A1.pdf	PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES, ANTIBODIES, AND ANTIBODY	Integrated BioTherapeutics, Inc.	11-Mar-15	11-Mar-16	23-Aug-18
4528	US20180073 073	http://59.45.142.240:8808/pdf/US20180073073A1.pdf	METHODS AND COMPOSITIONS FOR LABELING TARGETS AND LABELS FOR IMAGING	Not Available	18-Mar-15	16-Mar-16	15-Mar-18
4529	US20180079 746	http://59.45.142.240:8808/pdf/US20180079746A1.pdf	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	19-Mar-15	15-Mar-16	22-Mar-18
4530	US10189822	http://59.45.142.240:8808/pdf/US10189822.pdf	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	19-Mar-15	15-Mar-16	29-Jan-19
4531	US20190307 878	http://59.45.142.240:8808/pdf/US20190307878A1.pdf	IMMUNE COMPLEX	The Rockefeller University	20-Mar-15	10-May-19	10-Oct-19
4532	US10300127	http://59.45.142.240:8808/pdf/US10300127.pdf	Immune complex	The Rockefeller University	20-Mar-15	21-Mar-16	28-May-19
4533	US9636397	http://59.45.142.240:8808/pdf/US9636397.pdf	Adjuvant compositions and related methods	Vaxiant, LLC	24-Mar-15	24-Mar-16	2-May-17
4534	US20170202 959	http://59.45.142.240:8808/pdf/US20170202959A1.pdf	ADJUVANT COMPOSITIONS AND RELATED METHODS	Not Available	24-Mar-15	23-Mar-17	20-Jul-17
4535	US20160279 237	http://59.45.142.240:8808/pdf/US20160279237A1.pdf	ADJUVANT COMPOSITIONS AND RELATED METHODS	Not Available	24-Mar-15	24-Mar-16	29-Sep-16

4536	US20160279 165	http://59.45.142.240:8808/pdf/US20160279165A1.pdf	PULSE INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	24-Mar-15	24-Mar-16	29-Sep-16
4537	US10265395	http://59.45.142.240:8808/pdf/US10265395.pdf	Adjuvant compositions and related methods	Not Available	24-Mar-15	23-Mar-17	23-Apr-19
4538	US10039781	http://59.45.142.240:8808/pdf/US10039781.pdf	Pulse inhalation of nitric oxide for treating respiratory diseases	AIT THERAPEUTICS, INC	24-Mar-15	24-Mar-16	7-Aug-18
4539	US9974850	http://59.45.142.240:8808/pdf/US9974850.pdf	Immunogenic compositions and uses thereof	BOARD OF REGENTS, THE UNIVERSITY OF	25-Mar-15	25-Mar-16	22-May-18
4540	US20190314 480	http://59.45.142.240:8808/pdf/US20190314480A1.pdf	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	25-Mar-15	23-Apr-19	17-Oct-19
4541	US20180078 625	http://59.45.142.240:8808/pdf/US20180078625A1.pdf	COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE	Not Available	25-Mar-15	25-Mar-16	22-Mar-18
4542	US20160296 616	http://59.45.142.240:8808/pdf/US20160296616A1.pdf	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	25-Mar-15	25-Mar-16	13-Oct-16
4543	US10279029	http://59.45.142.240:8808/pdf/US10279029.pdf	Immunogenic compositions and uses thereof	BOARD OF REGENTS, THE UNIVERSITY OF	25-Mar-15	27-Feb-18	7-May-19
4544	US20180065 981	http://59.45.142.240:8808/pdf/US20180065981A1.pdf	HETEROCYCLYMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE A2B RECEPTOR	Not Available	26-Mar-15	21-Mar-16	8-Mar-18
4545	US10428083	http://59.45.142.240:8808/pdf/US10428083.pdf	Heterocyclmethyl-thienouracile as antagonists of the adenosine- A2B-	BAYER PHARMA AKTIENGESELLSCH	26-Mar-15	21-Mar-16	1-Oct-19
4546	US10077427	http://59.45.142.240:8808/pdf/US10077427.pdf	Means and methods for influencing the stability of cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN	26-Mar-15	26-Mar-15	18-Sep-18
4547	US20180072 752	http://59.45.142.240:8808/pdf/US20180072752A1.pdf	COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND	Not Available	30-Mar-15	2-Feb-16	15-Mar-18
4548	US20160289 740	http://59.45.142.240:8808/pdf/US20160289740A1.pdf	METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING	Not Available	30-Mar-15	29-Mar-16	6-Oct-16
4549	US9931316	http://59.45.142.240:8808/pdf/US9931316.pdf	Antiviral activity from medicinal mushrooms and their active	Not Available	31-Mar-15	14-Sep-15	3-Apr-18
4550	US20180200 224	http://59.45.142.240:8808/pdf/US20180200224A1.pdf	Antiviral Activity from Medicinal Mushrooms and Their Active	Not Available	31-Mar-15	12-Mar-18	19-Jul-18
4551	US9926340	http://59.45.142.240:8808/pdf/US9926340.pdf	NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants	Biolog Life Science Institute Forschungslabor und Biochemica-Vertrieb	8-Apr-15	1-Apr-16	27-Mar-18
4552	US20160299 141	http://59.45.142.240:8808/pdf/US20160299141A1.pdf	NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS	Biolog Life Science Institute Forschungslabor und Biochemica-	8-Apr-15	1-Apr-16	13-Oct-16
4553	US20160295 844	http://59.45.142.240:8808/pdf/US20160295844A1.pdf	GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF	Not Available	13-Apr-15	12-Apr-16	13-Oct-16
4554	US10561126	http://59.45.142.240:8808/pdf/US10561126.pdf	Genetically modified non-human animals and methods of use thereof	Institute for Research in	13-Apr-15	16-Apr-18	18-Feb-20
4555	US10123518	http://59.45.142.240:8808/pdf/US10123518.pdf	Genetically modified non-human animals and methods of use thereof	Institute For Research In	13-Apr-15	12-Apr-16	13-Nov-18
4556	US20180344 877	http://59.45.142.240:8808/pdf/US20180344877A1.pdf	RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE	Children's Healthcare of Atlanta, Inc.	16-Apr-15	8-Aug-18	6-Dec-18
4557	US20170326 256	http://59.45.142.240:8808/pdf/US20170326256A1.pdf	RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE	Children's Healthcare of Atlanta, Inc.	16-Apr-15	15-Apr-16	16-Nov-17
4558	US10058624	http://59.45.142.240:8808/pdf/US10058624.pdf	Recombinant promoters and vectors for protein expression in liver and	Children's Healthcare of	16-Apr-15	15-Apr-16	28-Aug-18
4559	US20180105 596	http://59.45.142.240:8808/pdf/US20180105596A1.pdf	ANTI-TYROS ANTIBODIES AND USES THEREOF	Not Available	17-Apr-15	15-Apr-16	19-Apr-18
4560	US20180100 181	http://59.45.142.240:8808/pdf/US20180100181A1.pdf	METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN	Not Available	17-Apr-15	15-Apr-16	12-Apr-18
4561	US20190056 122	http://59.45.142.240:8808/pdf/US20190056122A1.pdf	Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and	Synexis LLC	20-Apr-15	20-Apr-16	21-Feb-19
4562	US20180344 832	http://59.45.142.240:8808/pdf/US20180344832A1.pdf	METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY	Not Available	20-Apr-15	20-Apr-16	6-Dec-18
4563	US9828370	http://59.45.142.240:8808/pdf/US9828370.pdf	Compositions and methods for inhibiting kinases	INHIBIKASE THERAPEUTICS, INC	23-Apr-15	22-Apr-16	28-Nov-17
4564	US20200031 819	http://59.45.142.240:8808/pdf/US20200031819A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITTING KINASES	Not Available	23-Apr-15	26-Jun-19	30-Jan-20
4565	US20190119 266	http://59.45.142.240:8808/pdf/US20190119266A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITTING KINASES	Not Available	23-Apr-15	24-Oct-18	25-Apr-19
4566	US20190055 234	http://59.45.142.240:8808/pdf/US20190055234A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITTING KINASES	Not Available	23-Apr-15	24-Oct-18	21-Feb-19
4567	US20180057 488	http://59.45.142.240:8808/pdf/US20180057488A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITTING KINASES	Not Available	23-Apr-15	7-Nov-17	1-Mar-18
4568	US20160312 276	http://59.45.142.240:8808/pdf/US20160312276A1.pdf	METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION	Not Available	23-Apr-15	21-Apr-16	27-Oct-16
4569	US20160311 816	http://59.45.142.240:8808/pdf/US20160311816A1.pdf	COMPOSITIONS AND METHODS FOR INHIBITTING KINASES	Not Available	23-Apr-15	22-Apr-16	27-Oct-16
4570	US10344027	http://59.45.142.240:8808/pdf/US10344027.pdf	Compositions and methods for inhibiting kinases	Inhibikase Therapeutics, Inc	23-Apr-15	24-Oct-18	9-Jul-19
4571	US10316031	http://59.45.142.240:8808/pdf/US10316031.pdf	Compositions and methods for inhibiting kinases	Inhibikase Therapeutics, Inc	23-Apr-15	24-Oct-18	11-Jun-19
4572	US10118923	http://59.45.142.240:8808/pdf/US10118923.pdf	Compositions and methods for inhibiting kinases	Inhibikase Therapeutics, Inc	23-Apr-15	7-Nov-17	6-Nov-18
4573	US20180365 375	http://59.45.142.240:8808/pdf/US20180365375A1.pdf	METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC	Not Available	24-Apr-15	4-Oct-17	20-Dec-18
4574	US20160318 985	http://59.45.142.240:8808/pdf/US20160318985A1.pdf	Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored	Not Available	29-Apr-15	29-Apr-16	3-Nov-16

4575	US10072058	http://59.45.142.240:8808/pdf/US10072058.pdf	Chimeric virus-like particles incorporating fusion GPI anchored	Children's Healthcare of	29-Apr-15	29-Apr-16	11-Sep-18
4576	US20160318 861	http://59.45.142.240:8808/pdf/US20160318861A1.pdf	NOVEL PRODRUGS OF DITHIOL	PARION SCIENCES, INC	30-Apr-15	2-May-16	3-Nov-16
4577	US10526283	http://59.45.142.240:8808/pdf/US10526283.pdf	MUCOLYTIC AGENTS	PARION SCIENCES, INC	30-Apr-15	2-May-16	7-Jan-20
4578	US20190391 150	http://59.45.142.240:8808/pdf/US20190391150A1.pdf	Prodrugs of dithiol mucolytic agents	Not Available	1-May-15	10-Sep-19	26-Dec-19
4579	US20160320 390	http://59.45.142.240:8808/pdf/US20160320390A1.pdf	COMPOSITIONS AND METHODS FOR CAPTURING EVOSOMES	Not Available	1-May-15	1-May-15	3-Nov-16
4580	US20160327 506	http://59.45.142.240:8808/pdf/US20160327506A1.pdf	COMPOSITIONS AND METHODS FOR CAPTURING EVOSOMES	Not Available	1-May-15	1-May-15	3-Nov-16
4581	US10344320	http://59.45.142.240:8808/pdf/US10344320.pdf	CAPACITIVE LIQUID CRYSTAL BIOSENSORS	Not Available	6-May-15	5-May-16	10-Nov-16
4581	US10344320	http://59.45.142.240:8808/pdf/US10344320.pdf	Capacitive liquid crystal biosensors	The Johns Hopkins University	6-May-15	5-May-16	9-Jul-19
4582	US20180127 836	http://59.45.142.240:8808/pdf/US20180127836A1.pdf	IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF	Not Available	7-May-15	6-May-16	10-May-18
4583	US20200048 722	http://59.45.142.240:8808/pdf/US20200048722A1.pdf	METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND	Not Available	8-May-15	24-Aug-19	13-Feb-20
4584	US10072309	http://59.45.142.240:8808/pdf/US10072309.pdf	Methods for real-time multiplex isothermal detection and identification of bacterial, viral, and	Not Available	8-May-15	6-May-16	11-Sep-18
4585	US20180135 012	http://59.45.142.240:8808/pdf/US20180135012A1.pdf	MEMBRANE-RECEIVER COMPLEX	Not Available	13-May-15	13-May-16	17-May-18
4586	US20190284 531	http://59.45.142.240:8808/pdf/US20190284531A1.pdf	THERAPEUTICS	Not Available	15-May-15	24-May-19	19-Sep-19
4587	US20180194 850	http://59.45.142.240:8808/pdf/US20180194850A1.pdf	DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL	Not Available	15-May-15	13-May-16	12-Jul-18
4588	US20180125 952	http://59.45.142.240:8808/pdf/US20180125952A1.pdf	ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR	Not Available	15-May-15	13-May-16	10-May-18
4588	US20180125 952	http://59.45.142.240:8808/pdf/US20180125952A1.pdf	PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT	Not Available	15-May-15	13-May-16	10-May-18
4589	US20180066 228	http://59.45.142.240:8808/pdf/US20180066228A1.pdf	DETECTION OF T Cell Exhaustion or Lack of T Cell Costimulation and	Not Available	15-May-15	15-Nov-17	8-Mar-18
4590	US20170016 048	http://59.45.142.240:8808/pdf/US20170016048A1.pdf	COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF	Not Available	18-May-15	17-May-16	19-Jan-17
4591	US10614284	http://59.45.142.240:8808/pdf/US10614284.pdf	NUCLEIC ACIDS	Ventana Medical Systems, Inc.	26-May-15	21-Nov-17	7-Apr-20
4592	US20160348 153	http://59.45.142.240:8808/pdf/US20160348153A1.pdf	Descriptive measurements and quantification of staining artifacts for	THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of	29-May-15	31-May-16	1-Dec-16
4593	US20180371 536	http://59.45.142.240:8808/pdf/US20180371536A1.pdf	EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES FROM PATHOGENS	Not Available	1-Jun-15	26-May-16	27-Dec-18
4594	US20180149 659	http://59.45.142.240:8808/pdf/US20180149659A1.pdf	METHODS FOR RNA QUANTIFICATION	Not Available	4-Jun-15	3-Jun-16	31-May-18
4595	US20190256 585	http://59.45.142.240:8808/pdf/US20190256585A1.pdf	DIAGNOSIS AND TREATMENT OF	Not Available	10-Jun-15	10-Jun-16	22-Aug-19
4596	US20180163 182	http://59.45.142.240:8808/pdf/US20180163182A1.pdf	MEPS RELATED RENAL DISEASE	Not Available	10-Jun-15	10-Jun-16	14-Jun-18
4597	US20190083 569	http://59.45.142.240:8808/pdf/US20190083569A1.pdf	ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE DERIVED FROM VIMENTIN OR A FRAGMENT	Human Services	11-Jun-15	24-Jul-18	21-Mar-19
4598	US20180177 860	http://59.45.142.240:8808/pdf/US20180177860A1.pdf	PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-	Not Available	11-Jun-15	7-Jun-16	28-Jun-18
4599	US20160361 382	http://59.45.142.240:8808/pdf/US20160361382A1.pdf	CONJUGATING COMPOSITIONS	Not Available	11-Jun-15	13-Jun-16	15-Dec-16
4600	US20180318 366	http://59.45.142.240:8808/pdf/US20180318366A1.pdf	MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF	Not Available	15-Jun-15	15-Jun-16	8-Nov-18
4601	US20180187 131	http://59.45.142.240:8808/pdf/US20180187131A1.pdf	METHODS FOR TREATMENT OF	Not Available	16-Jun-15	15-Jun-16	5-Jul-18
4602	US20150284 416	http://59.45.142.240:8808/pdf/US20150284416A1.pdf	VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT, AND PREPARATION	COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES	16-Jun-15	16-Jun-15	8-Oct-15
4603	US10563154	http://59.45.142.240:8808/pdf/US10563154.pdf	MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF	SUZHOU M-CONJ BIOTECH CO., LTD	16-Jun-15	15-Jun-16	18-Feb-20
4604	US20160367 188	http://59.45.142.240:8808/pdf/US20160367188A1.pdf	METHOD OF TREATMENT USING	COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES	17-Jun-15	10-Sep-15	22-Dec-16
4605	US20180185 345	http://59.45.142.240:8808/pdf/US20180185345A1.pdf	ONCOLYTIC VIRUSES	Not Available	19-Jun-15	17-Jun-16	5-Jul-18
4606	US20180186 897	http://59.45.142.240:8808/pdf/US20180186897A1.pdf	DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME AND USE THEREOF	Not Available	26-Jun-15	24-Jun-16	5-Jul-18
4607	US20180179 274	http://59.45.142.240:8808/pdf/US20180179274A1.pdf	NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA	Not Available	26-Jun-15	24-Jun-16	28-Jun-18
4608	US20180177 862	http://59.45.142.240:8808/pdf/US20180177862A1.pdf	PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES	Not Available	26-Jun-15	24-Jun-16	28-Jun-18
4609	US20170002 042	http://59.45.142.240:8808/pdf/US20170002042A1.pdf	ANTIGENICALLY MATCHED	Not Available	1-Jul-15	1-Jul-16	5-Jan-17
4610	US10059741	http://59.45.142.240:8808/pdf/US10059741.pdf	INFLUENZA VACCINES	Aileron Therapeutics, Inc.	1-Jul-15	1-Jul-16	28-Aug-18
4611	US20180369 364	http://59.45.142.240:8808/pdf/US20180369364A1.pdf	PEPTIDOMIMETIC MACROCYCLES	Not Available	2-Jul-15	1-Jul-16	27-Dec-18
4612	US20170015 716	http://59.45.142.240:8808/pdf/US20170015716A1.pdf	RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE IMMUNODEFICIENCY VIRUS GAG	Not Available	2-Jul-15	1-Jul-16	19-Jan-17
4613	US10464975	http://59.45.142.240:8808/pdf/US10464975.pdf	STABILIZED ANTI-MICROBIAL	Dana-Farber Cancer Institute, Inc.	2-Jul-15	1-Jul-16	5-Nov-19
4614	US20180201 687	http://59.45.142.240:8808/pdf/US20180201687A1.pdf	PEPTIDES	Not Available	7-Jul-15	7-Jul-16	19-Jul-18
4614	US20180201 687	http://59.45.142.240:8808/pdf/US20180201687A1.pdf	Stabilized anti-microbial peptides	Not Available	7-Jul-15	7-Jul-16	19-Jul-18

4615	US20180196 061	http://59.45.142.240:8808/pdf/US20180196061A1.pdf	INFLUENZA POTENCY ASSAYS	Not Available	7-Jul-15	7-Jul-16	12-Jul-18
4616	US10416171	http://59.45.142.240:8808/pdf/US10416171.pdf	Influenza potency assays	Seqirus UK Limited	7-Jul-15	7-Jul-16	17-Sep-19
4617	US20180305 451	http://59.45.142.240:8808/pdf/US20180305451A1.pdf	HIDE1 COMPOSITIONS AND METHODS	Not Available	13-Jul-15	13-Jul-16	25-Oct-18
4618	US20200087 655	http://59.45.142.240:8808/pdf/US20200087655A1.pdf	PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES	Not Available	14-Jul-15	22-Nov-19	19-Mar-20
4619	US20190345 481	http://59.45.142.240:8808/pdf/US20190345481A1.pdf	PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM OXIDES	Not Available	14-Jul-15	5-Jul-19	14-Nov-19
4620	US20180201 998	http://59.45.142.240:8808/pdf/US20180201998A1.pdf	COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC DEAFNESS	CapitalBio Corporation	14-Jul-15	14-Jul-15	19-Jul-18
4621	US20170081 655	http://59.45.142.240:8808/pdf/US20170081655A1.pdf	PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES	Not Available	14-Jul-15	13-Jul-16	23-Mar-17
4622	US10526596	http://59.45.142.240:8808/pdf/US10526596.pdf	Purification of nucleic acids using metal titanium oxides	Abbott Molecular Inc	14-Jul-15	5-Jul-19	7-Jan-20
4623	US10392613	http://59.45.142.240:8808/pdf/US10392613.pdf	Purification of nucleic acids using copper titanium oxides	ABBOTT MOLECULAR INC	14-Jul-15	13-Jul-16	27-Aug-19
4624	US9839687	http://59.45.142.240:8808/pdf/US9839687.pdf	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	15-Jul-15	12-Dec-17
4625	US20180193 477	http://59.45.142.240:8808/pdf/US20180193477A1.pdf	DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS	Not Available	15-Jul-15	15-Jul-16	12-Jul-18
4626	US20170209 595	http://59.45.142.240:8808/pdf/US20170209595A1.pdf	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE	Suzhou M-Conj Biotech Co., Ltd.	15-Jul-15	5-Apr-17	27-Jul-17
4627	US20170202 975	http://59.45.142.240:8808/pdf/US20170202975A1.pdf	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE	Suzhou M-Conj Biotech Co., Ltd.	15-Jul-15	5-Apr-17	20-Jul-17
4628	US20170173 176	http://59.45.142.240:8808/pdf/US20170173176A1.pdf	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	22-Jun-17
4629	US20170173 168	http://59.45.142.240:8808/pdf/US20170173168A1.pdf	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	22-Jun-17
4630	US20170151 346	http://59.45.142.240:8808/pdf/US20170151346A1.pdf	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	13-Feb-17	1-Jun-17
4631	US20170143 845	http://59.45.142.240:8808/pdf/US20170143845A1.pdf	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING	SUZHOU M-CONJ BIOTECH CO., LTD	15-Jul-15	3-Feb-17	25-May-17
4632	US20150322 155	http://59.45.142.240:8808/pdf/US20150322155A1.pdf	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING	Robert Yongxin Zhao	15-Jul-15	15-Jul-15	12-Nov-15
4633	US20150314 017	http://59.45.142.240:8808/pdf/US20150314017A1.pdf	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE	Dr. Robert Yongxin Zhao	15-Jul-15	15-Jul-15	5-Nov-15
4634	US10328157	http://59.45.142.240:8808/pdf/US10328157.pdf	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	3-Feb-17	25-Jun-19
4635	US10322104	http://59.45.142.240:8808/pdf/US10322104.pdf	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD	15-Jul-15	5-Apr-17	18-Jun-19
4636	US10307391	http://59.45.142.240:8808/pdf/US10307391.pdf	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD	15-Jul-15	5-Apr-17	4-Jun-19
4637	US10293055	http://59.45.142.240:8808/pdf/US10293055.pdf	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	21-May-19
4638	US10292961	http://59.45.142.240:8808/pdf/US10292961.pdf	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD	15-Jul-15	15-Jul-15	21-May-19
4639	US10265291	http://59.45.142.240:8808/pdf/US10265291.pdf	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD	15-Jul-15	13-Feb-17	23-Apr-19
4640	US10232051	http://59.45.142.240:8808/pdf/US10232051.pdf	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	19-Mar-19
4641	US20180214 430	http://59.45.142.240:8808/pdf/US20180214430A1.pdf	Selective Inhibitors Of i-NOS For Use Against Viral Infection	UCL Business PLC	17-Jul-15	15-Jul-16	2-Aug-18
4642	US20180215 831	http://59.45.142.240:8808/pdf/US20180215831A1.pdf	Antibody Derivatives with Conditionally Enabled Effector Function	Not Available	27-Jul-15	27-Jul-16	2-Aug-18
4643	US20190060 364	http://59.45.142.240:8808/pdf/US20190060364A1.pdf	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	6-Nov-18	28-Feb-19
4644	US20190060 363	http://59.45.142.240:8808/pdf/US20190060363A1.pdf	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	6-Nov-18	28-Feb-19
4645	US20190054 122	http://59.45.142.240:8808/pdf/US20190054122A1.pdf	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	5-Nov-18	21-Feb-19
4646	US20180237 835	http://59.45.142.240:8808/pdf/US20180237835A1.pdf	METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS	American International Biotechnology LLC	31-Jul-15	29-Jul-16	23-Aug-18
4647	US20170130 200	http://59.45.142.240:8808/pdf/US20170130200A1.pdf	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	29-Jul-16	11-May-17
4648	US20170119 820	http://59.45.142.240:8808/pdf/US20170119820A1.pdf	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31-Jul-15	29-Jul-16	4-May-17
4649	US20170067 021	http://59.45.142.240:8808/pdf/US20170067021A1.pdf	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31-Jul-15	2-Sep-16	9-Mar-17
4650	US20170065 636	http://59.45.142.240:8808/pdf/US20170065636A1.pdf	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31-Jul-15	29-Aug-16	9-Mar-17
4651	US10662464	http://59.45.142.240:8808/pdf/US10662464.pdf	Methods of analyzing virus-derived therapeutics	American International Biotechnology LLC	31-Jul-15	29-Jul-16	26-May-20
4652	US10406177	http://59.45.142.240:8808/pdf/US10406177.pdf	Modified cells and methods of therapy	Intima Bioscience, Inc	31-Jul-15	29-Aug-16	10-Sep-19
4653	US10166255	http://59.45.142.240:8808/pdf/US10166255.pdf	Intracellular genomic transplant and methods of therapy	INTIMA BIOSCIENCE INC	31-Jul-15	29-Jul-16	1-Jan-19
4654	US9855284	http://59.45.142.240:8808/pdf/US9855284.pdf	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3-Aug-15	6-Dec-16	2-Jan-18
4655	US9598459	http://59.45.142.240:8808/pdf/US9598459.pdf	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3-Aug-15	28-Jul-16	21-Mar-17
4656	US20200101 087	http://59.45.142.240:8808/pdf/US20200101087A1.pdf	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3-Aug-15	21-Nov-19	2-Apr-20
4657	US20190134 062	http://59.45.142.240:8808/pdf/US20190134062A1.pdf	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3-Aug-15	8-Jan-19	9-May-19
4658	US20180221 464	http://59.45.142.240:8808/pdf/US20180221464A1.pdf	IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING	Not Available	3-Aug-15	3-Aug-16	9-Aug-18
4659	US20180185 392	http://59.45.142.240:8808/pdf/US20180185392A1.pdf	Pharmaceutical Compositions and Methods	Not Available	3-Aug-15	29-Nov-17	5-Jul-18

4660	US20170128 465	http://59.45.142.240:8808/pdf/US20170128465A1.pdf	Pharmaceutical Compositions and Methods	Not Available	3-Aug-15	6-Dec-16	11-May-17
4661	US20170051 007	http://59.45.142.240:8808/pdf/US20170051007A1.pdf	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3-Aug-15	28-Jul-16	23-Feb-17
4662	US10517881	http://59.45.142.240:8808/pdf/US10517881.pdf	Pharmaceutical compositions and methods	POP TEST ONCOLOGY LLC	3-Aug-15	8-Jan-19	31-Dec-19
4663	US10238666	http://59.45.142.240:8808/pdf/US10238666.pdf	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3-Aug-15	29-Nov-17	26-Mar-19
4664	US20200085 852	http://59.45.142.240:8808/pdf/US20200085852A1.pdf	EPIDERMAL MRNA VACCINE	Not Available	5-Aug-15	5-Aug-16	19-Mar-20
4665	US20190024 096	http://59.45.142.240:8808/pdf/US20190024096A1.pdf	PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL	Not Available	7-Aug-15	7-Aug-15	24-Jan-19
4666	US20170038 085	http://59.45.142.240:8808/pdf/US20170038085A1.pdf	AIR CURTAIN DEVICE	Not Available	7-Aug-15	19-Nov-15	9-Feb-17
4667	US20170035 845	http://59.45.142.240:8808/pdf/US20170035845A1.pdf	Compositions and Methods for Inhibiting Pro-Inflammatory Cytokines	Not Available	7-Aug-15	5-Aug-16	9-Feb-17
4668	US10018369	http://59.45.142.240:8808/pdf/US10018369.pdf	Air curtain device	KAWANO GIKEN CO., LTD.	7-Aug-15	19-Nov-15	10-Jul-18
4669	US20180237 788	http://59.45.142.240:8808/pdf/US20180237788A1.pdf	IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION	The Regents of the University of California	8-Aug-15	5-Aug-16	23-Aug-18
4670	US20190225 971	http://59.45.142.240:8808/pdf/US20190225971A1.pdf	METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE	Not Available	10-Aug-15	4-Aug-16	25-Jul-19
4671	US20180228 695	http://59.45.142.240:8808/pdf/US20180228695A1.pdf	DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN AS PRESCRIBED, AND TO AVOID	Not Available	11-Aug-15	11-Aug-16	16-Aug-18
4672	US10660824	http://59.45.142.240:8808/pdf/US10660824.pdf	Devices, system and method to control the delivery of oral medications to ensure they are efficacious , taken as prescribed, and	Not Available	11-Aug-15	11-Aug-16	26-May-20
4673	US20190218 207	http://59.45.142.240:8808/pdf/US20190218207A1.pdf	3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT	Not Available	17-Aug-15	17-Aug-16	18-Jul-19
4674	US20180244 660	http://59.45.142.240:8808/pdf/US20180244660A1.pdf	CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS	Not Available	17-Aug-15	17-Aug-16	30-Aug-18
4675	US20180235 948	http://59.45.142.240:8808/pdf/US20180235948A1.pdf	(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3-METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4-FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE	Not Available	18-Aug-15	18-Aug-16	23-Aug-18
4676	US10363247	http://59.45.142.240:8808/pdf/US10363247.pdf	(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3- methylpyrrolidine-1- carbonyl)phenyl)-7-(4- fluorophenyl)benzofuran- 2- yl)methyl)acrylamide for the	Karyopharm Therapeutics Inc.	18-Aug-15	18-Aug-16	30-Jul-19
4677	US20180244 759	http://59.45.142.240:8808/pdf/US20180244759A1.pdf	NOVEL METHODS OF GENERATING ANTIBODIES	Rutgers, The State University of New	19-Aug-15	18-Aug-16	30-Aug-18
4678	US9890206	http://59.45.142.240:8808/pdf/US9890206.pdf	H1N1 flu virus neutralizing antibodies	Medigen Biotechnology	20-Aug-15	20-Aug-15	13-Feb-18
4679	US20170051 046	http://59.45.142.240:8808/pdf/US20170051046A1.pdf	H1N1 FLU VIRUS NEUTRALIZING ANTIBODIES	MEDIGEN BIOTECHNOLOGY CORPORATION	20-Aug-15	20-Aug-15	23-Feb-17
4680	US20180243 347		IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	25-Aug-15	22-Aug-16	30-Aug-18
4681	US20190233 447	http://59.45.142.240:8808/pdf/US20190233447A1.pdf	PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED	Not Available	28-Aug-15	25-Feb-19	1-Aug-19
4682	US20180340 215	http://59.45.142.240:8808/pdf/US20180340215A1.pdf	SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET SEQUENCE	Not Available	28-Aug-15	26-Aug-16	29-Nov-18
4683	US20180237 786		ARTIFICIAL NUCLEIC ACID MOLECULES	CUREVAC AG	28-Aug-15	22-Aug-16	23-Aug-18
4684	US20180186 821	http://59.45.142.240:8808/pdf/US20180186821A1.pdf	PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN EMBEDDED TISSUE USING CAGED	Not Available	28-Aug-15	28-Feb-18	5-Jul-18
4685	US20190055 241	http://59.45.142.240:8808/pdf/US20190055241A1.pdf	GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS	Not Available	31-Aug-15	22-Oct-18	21-Feb-19
4686	US20180244 669	http://59.45.142.240:8808/pdf/US20180244669A1.pdf	IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED	Not Available	31-Aug-15	26-Aug-16	30-Aug-18
4687	US20180237 435	http://59.45.142.240:8808/pdf/US20180237435A1.pdf	GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS	Not Available	31-Aug-15	26-Aug-16	23-Aug-18
4688	US10487081	http://59.45.142.240:8808/pdf/US10487081.pdf	Guanidine substituted imidazo[4,5-c] ring compounds	3M Innovation Properties Company	31-Aug-15	22-Oct-18	26-Nov-19
4689	US10150768	http://59.45.142.240:8808/pdf/US10150768.pdf	Guanidine substituted imidazo[4,5-c] ring compounds	3M Innovative Properties Company	31-Aug-15	26-Aug-16	11-Dec-18
4690	US10118925	http://59.45.142.240:8808/pdf/US10118925.pdf	Imidazo[4,5-c] ring compounds containing substituted guanidine	3M Innovative Properties Company	31-Aug-15	26-Aug-16	6-Nov-18
4691	US20200166 505	http://59.45.142.240:8808/pdf/US20200166505A1.pdf	METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS	The U.S.A., as represented by the Secretary, Department of Health and Human	1-Sep-15	30-Jan-20	28-May-20
4692	US20180267 031	http://59.45.142.240:8808/pdf/US20180267031A1.pdf	METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS	The U.S.A., as represented by the Secretary, Department of Health and Human	1-Sep-15	8-Aug-16	20-Sep-18
4693	US20170058 365	http://59.45.142.240:8808/pdf/US20170058365A1.pdf	SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS	Not Available	1-Sep-15	3-Feb-16	2-Mar-17
4694	US10564152	http://59.45.142.240:8808/pdf/US10564152.pdf	Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium magnets	The United States of America, as represented by the Secretary, Department of Health and Human	1-Sep-15	8-Aug-16	18-Feb-20

4695	US20190030 187		siRNA nanoparticle Formulations for Treatment of Middle-East Respiratory	Sirnaomics, Inc.	8-Sep-15	7-Sep-16	31-Jan-19
4696	US20170073 730	http://59.45.142.240:8808/pdf/US20170073730A1.pdf	METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION	Not Available	11-Sep-15	8-Sep-16	16-Mar-17
4697	US10619186	http://59.45.142.240:8808/pdf/US10619186.pdf	Methods and compositions for library normalization	Cellular Research, Inc	11-Sep-15	8-Sep-16	14-Apr-20
4698	US20190255 085	http://59.45.142.240:8808/pdf/US20190255085A1.pdf	METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS	Not Available	16-Sep-15	1-Feb-19	22-Aug-19
4699	US20180326 039		VACCINE COMPOSITIONS	Not Available	16-Sep-15	16-Sep-16	15-Nov-18
4700	US20170071 964	http://59.45.142.240:8808/pdf/US20170071964A1.pdf	METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS	Not Available	16-Sep-15	16-Sep-16	16-Mar-17
4701	US10251904	http://59.45.142.240:8808/pdf/US10251904.pdf	Methods for treating arenaviridae and coronavirus virus infections	GILEAD SCIENCES, INC	16-Sep-15	16-Sep-16	9-Apr-19
4702	US20180334 480	http://59.45.142.240:8808/pdf/US20180334480A1.pdf	CORONAVIRUSES EPITOPE-BASED VACCINES	RAMOT AT TEL-AVIV UNIVERSITY LTD	17-Sep-15	15-Sep-16	22-Nov-18
4703	US20180194 735	http://59.45.142.240:8808/pdf/US20180194735A1.pdf	Sulfinylphenyl or Sulfonimidodiphenyl Benzazepines	Hoffmann La-Roche Inc	17-Sep-15	8-Mar-18	12-Jul-18
4704	US10428027	http://59.45.142.240:8808/pdf/US10428027.pdf	Sulfinylphenyl or sulfonimidodiphenyl benzazepines	Hoffmann La-Roche Inc	17-Sep-15	8-Mar-18	1-Oct-19
4705	US20200080 111	http://59.45.142.240:8808/pdf/US20200080111A1.pdf	Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and	Not Available	18-Sep-15	19-Sep-16	12-Mar-20
4706	US20200155 660	http://59.45.142.240:8808/pdf/US20200155660A1.pdf	COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER	Not Available	23-Sep-15	22-Nov-19	21-May-20
4707	US20180177 863	http://59.45.142.240:8808/pdf/US20180177863A1.pdf	METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES	Not Available	23-Sep-15	31-Oct-17	28-Jun-18
4708	US20170080 079	http://59.45.142.240:8808/pdf/US20170080079A1.pdf	METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES	Not Available	23-Sep-15	23-Sep-16	23-Mar-17
4709	US20170079 916	http://59.45.142.240:8808/pdf/US20170079916A1.pdf	COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER	Not Available	23-Sep-15	23-Sep-16	23-Mar-17
4710	US10383935	http://59.45.142.240:8808/pdf/US10383935.pdf	Methods of making and using live attenuated viruses	Regents of the University of	23-Sep-15	31-Oct-17	20-Aug-19
4711	US20180305 760	http://59.45.142.240:8808/pdf/US20180305760A1.pdf	Pathogen biomarkers and uses thereof	Not Available	30-Sep-15	30-Sep-16	25-Oct-18
4712	US20200101 158	http://59.45.142.240:8808/pdf/US20200101158A1.pdf	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE	Not Available	1-Oct-15	22-Oct-19	2-Apr-20
4713	US20190160 129	http://59.45.142.240:8808/pdf/US20190160129A1.pdf	Novel Polygonum Cupidatum Extracts and Their Use as	Not Available	1-Oct-15	1-Feb-19	30-May-19
4714	US20170340 735	http://59.45.142.240:8808/pdf/US20170340735A1.pdf	Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof	Not Available	1-Oct-15	19-Jun-17	30-Nov-17
4715	US20170165 366	http://59.45.142.240:8808/pdf/US20170165366A1.pdf	Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof	Not Available	1-Oct-15	13-Feb-17	15-Jun-17
4716	US20170095 521	http://59.45.142.240:8808/pdf/US20170095521A1.pdf	Novel Polygonum Cupidatum Extracts and Their Use as	Not Available	1-Oct-15	30-Sep-16	6-Apr-17
4717	US10507244	http://59.45.142.240:8808/pdf/US10507244.pdf	Anti-TIGIT antigen-binding proteins and methods of use thereof	Potenza Therapeutics, Inc	1-Oct-15	19-Jun-17	17-Dec-19
4718	US10350255	http://59.45.142.240:8808/pdf/US10350255.pdf	Polygonum cupidatum extracts	PhotoDynamic Inc.	1-Oct-15	30-Sep-16	16-Jul-19
4719	US20190216 915	http://59.45.142.240:8808/pdf/US20190216915A1.pdf	TRANSGENIC VERO-CD4/CCR5 CELL LINE	Not Available	2-Oct-15	15-Feb-19	18-Jul-19
4720	US20170266 272	http://59.45.142.240:8808/pdf/US20170266272A1.pdf	TRANSGENIC VERO-CD4/CCR5 CELL LINE	Not Available	2-Oct-15	6-Apr-17	21-Sep-17
4721	US10279027	http://59.45.142.240:8808/pdf/US10279027.pdf	Transgenic Vero-CD4/CCR5 cell line	INTERNATIONAL AIDS VACCINE INITIATIVE	2-Oct-15	6-Apr-17	7-May-19
4722	US20190016 785	http://59.45.142.240:8808/pdf/US20190016785A1.pdf	ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF	Not Available	7-Oct-15	7-Oct-16	17-Jan-19
4723	US20200010 883	http://59.45.142.240:8808/pdf/US20200010883A1.pdf	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS	Not Available	9-Oct-15	7-Jun-19	9-Jan-20
4724	US20180326 044	http://59.45.142.240:8808/pdf/US20180326044A1.pdf	NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL	Not Available	13-Oct-15	13-Oct-16	15-Nov-18
4725	US20190240 317	http://59.45.142.240:8808/pdf/US20190240317A1.pdf	HPV3 RNA VACCINES	ModernaTX, Inc.	22-Oct-15	28-Mar-19	8-Aug-19
4726	US20190216 917	http://59.45.142.240:8808/pdf/US20190216917A1.pdf	HMPV RNA VACCINES	ModernaTX, Inc.	22-Oct-15	28-Mar-19	18-Jul-19
4727	US20180326 045	http://59.45.142.240:8808/pdf/US20180326045A1.pdf	COMBINATION PIV3/HMPV RNA VACCINES	ModernaTX, Inc.	22-Oct-15	20-Jul-18	15-Nov-18
4728	US20170340 725	http://59.45.142.240:8808/pdf/US20170340725A1.pdf	COMBINATION PIV3/HMPV RNA VACCINES	ModernaTX, Inc.	22-Oct-15	11-Aug-17	30-Nov-17
4729	US10543269	http://59.45.142.240:8808/pdf/US10543269.pdf	hMPV RNA vaccines	ModernaTX, Inc.	22-Oct-15	28-Mar-19	28-Jan-20
4730	US10272150	http://59.45.142.240:8808/pdf/US10272150.pdf	Combination PIV3/hMPV RNA vaccines	ModernaTX, Inc.	22-Oct-15	20-Jul-18	30-Apr-19
4731	US10064934	http://59.45.142.240:8808/pdf/US10064934.pdf	Combination PIV3/hMPV RNA vaccines	ModernaTX, Inc.	22-Oct-15	11-Aug-17	4-Sep-18
4732	US20200115 434	http://59.45.142.240:8808/pdf/US20200115434A1.pdf	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES	Not Available	23-Oct-15	29-Oct-19	16-Apr-20
4733	US20190248 865		ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES	Not Available	23-Oct-15	21-Oct-16	15-Aug-19
4734	US20190022 216	http://59.45.142.240:8808/pdf/US20190022216A1.pdf	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES	Not Available	23-Oct-15	4-Sep-18	24-Jan-19
4735	US20180085 457	http://59.45.142.240:8808/pdf/US20180085457A1.pdf	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES	Not Available	23-Oct-15	1-Dec-17	29-Mar-18
4736	US10464988	http://59.45.142.240:8808/pdf/US10464988.pdf	Antibody/T-cell receptor chimeric constructs and uses thereof	EUREKA THERAPEUTICS, INC	23-Oct-15	4-Sep-18	5-Nov-19
4737	US20180319 811	http://59.45.142.240:8808/pdf/US20180319811A1.pdf	DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING	Not Available	30-Oct-15	28-Oct-16	8-Nov-18
4738	US20180303 090	http://59.45.142.240:8808/pdf/US20180303090A1.pdf	TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT	Not Available	30-Oct-15	17-Oct-16	25-Oct-18

4739	US10577375	http://59.45.142.240:8808/pdf/US10577375.pdf	Derivatives of porphyrins, their process of preparation and their use	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	30-Oct-15	28-Oct-16	3-Mar-20
4740	US20190184 067	http://59.45.142.240:8808/pdf/US20190184067A1.pdf	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND	Not Available	1-Nov-15	28-Feb-19	20-Jun-19
4741	US20190046 690		MATERIALS WITH IMPROVED PROPERTIES	Not Available	1-Nov-15	2-Nov-16	14-Feb-19
4742	US20170246 347		MATERIALS WITH IMPROVED PROPERTIES	Not Available	1-Nov-15	5-May-17	31-Aug-17
4743	US20170239 397	http://59.45.142.240:8808/pdf/US20170239397A1.pdf	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1-Nov-15	5-May-17	24-Aug-17
4744	US20170226 232	http://59.45.142.240:8808/pdf/US20170226232A1.pdf	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1-Nov-15	2-Nov-16	10-Aug-17
4745	US20180318 350	http://59.45.142.240:8808/pdf/US20180318350A1.pdf	Immune Cells with DNMT3A Gene Modifications and Methods Related	Not Available	4-Nov-15	4-Nov-16	8-Nov-18
4746	US20180321 242	http://59.45.142.240:8808/pdf/US20180321242A1.pdf	VIRAL BIOMARKERS AND USES THEREOF	Not Available	6-Nov-15	4-Nov-16	8-Nov-18
4747	US20180312 545		OPTIMIZED NUCLEIC ACID MOLECULES	Not Available	9-Nov-15	9-Nov-16	1-Nov-18
4748	US20180258 160	http://59.45.142.240:8808/pdf/US20180258160A1.pdf	Optimized Crosslinkers for Trapping a Target on a Substrate	Not Available	13-Nov-15	11-May-18	13-Sep-18
4749	US20180327 738	http://59.45.142.240:8808/pdf/US20180327738A1.pdf	STABILIZED REAGENTS FOR GENOME MODIFICATION	Not Available	20-Nov-15	18-Nov-16	15-Nov-18
4750	US20180372 747	http://59.45.142.240:8808/pdf/US20180372747A1.pdf	METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE TUMOR	Not Available	22-Nov-15	21-May-18	27-Dec-18
4751	US20190040 370	http://59.45.142.240:8808/pdf/US20190040370A1.pdf	TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR	Not Available	23-Nov-15	3-Aug-18	7-Feb-19
4752	US20170145 394	http://59.45.142.240:8808/pdf/US20170145394A1.pdf	TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR	Not Available	23-Nov-15	22-Nov-16	25-May-17
4753	US20190322 989	http://59.45.142.240:8808/pdf/US20190322989A1.pdf	PRODUCTION OF VIRUSES IN CELL CULTURE	Not Available	24-Nov-15	25-Jan-19	24-Oct-19
4754	US20190203 186		PRODUCTION OF VIRUSES IN AVIAN EGGS	Not Available	24-Nov-15	25-Jan-19	4-Jul-19
4755	US20180340 154		PRODUCTION OF VIRUSES IN AVIAN EGGS	Not Available	24-Nov-15	23-Nov-16	29-Nov-18
4756	US20180340 153	http://59.45.142.240:8808/pdf/US20180340153A1.pdf	PRODUCTION OF VIRUSES IN CELL CULTURE	Not Available	24-Nov-15	23-Nov-16	29-Nov-18
4757	US10626379	http://59.45.142.240:8808/pdf/US10626379.pdf	Production of viruses in cell culture	Commonwealth Scientific and Industrial Research	24-Nov-15	25-Jan-19	21-Apr-20
4758	US20180346 516	http://59.45.142.240:8808/pdf/US20180346516A1.pdf	PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS	Not Available	27-Nov-15	28-Nov-16	6-Dec-18
4759	US10538554	http://59.45.142.240:8808/pdf/US10538554.pdf	Peptides and uses thereof as antiviral agents	VIRAMATIX SDN BHD	27-Nov-15	28-Nov-16	21-Jan-20
4760	US20190292 561	http://59.45.142.240:8808/pdf/US20190292561A1.pdf	SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR	SPARK THERAPEUTICS, INC.	1-Dec-15	1-Dec-16	26-Sep-19
4761	US20190390 176	http://59.45.142.240:8808/pdf/US20190390176A1.pdf	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL	Not Available	2-Dec-15	3-Jul-19	26-Dec-19
4762	US20170159 026	http://59.45.142.240:8808/pdf/US20170159026A1.pdf	Novel Recombinant Adeno-Associated Virus Capsids with	Not Available	2-Dec-15	2-Dec-16	8-Jun-17
4763	US10385320	http://59.45.142.240:8808/pdf/US10385320.pdf	Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism	The Board of Trustees of the Leland Stanford	2-Dec-15	2-Dec-16	20-Aug-19
4764	US20180318 447	http://59.45.142.240:8808/pdf/US20180318447A1.pdf	COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY	Not Available	3-Dec-15	30-Nov-16	8-Nov-18
4765	US20180362 625		REGULATION OF CYTOKINE PRODUCTION	Not Available	4-Dec-15	2-Dec-16	20-Dec-18
4766	US20180360 877	http://59.45.142.240:8808/pdf/US20180360877A1.pdf	METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM	Not Available	8-Dec-15	8-Dec-16	20-Dec-18
4767	US20190062 326	http://59.45.142.240:8808/pdf/US20190062326A1.pdf	2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING	BAYER PHARMA AKTIENGESELLSCH AFT	10-Dec-15	7-Dec-16	28-Feb-19
4768	US20180371 461	http://59.45.142.240:8808/pdf/US20180371461A1.pdf	APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS VIRUSES AND TREATING	Not Available	10-Dec-15	1-Dec-16	27-Dec-18
4769	US9890169	http://59.45.142.240:8808/pdf/US9890169.pdf	Triazolinone compounds as HNE inhibitors	CHIESI FARMACEUTICI	14-Dec-15	12-Dec-16	13-Feb-18
4770	US20170166 574		NOVEL COMPOUNDS	CHIESI FARMACEUTICI	14-Dec-15	12-Dec-16	15-Jun-17
4771	US9890124	http://59.45.142.240:8808/pdf/US9890124.pdf	Benzazepine sulfonamide compounds	Hoffmann-La Roche Inc	15-Dec-15	14-Jun-17	13-Feb-18
4772	US20170175 140	http://59.45.142.240:8808/pdf/US20170175140A1.pdf	METHODS FOR USING A 5'-EXONUCLEASE TO INCREASE HOMOLOGOUS RECOMBINATION IN	Not Available	16-Dec-15	14-Dec-16	22-Jun-17
4773	US20190083 602	http://59.45.142.240:8808/pdf/US20190083602A1.pdf	METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS	Not Available	22-Dec-15	22-Dec-16	21-Mar-19
4774	US20190083 397	http://59.45.142.240:8808/pdf/US20190083397A1.pdf	OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID	NOVARTIS AG	23-Dec-15	21-Dec-16	21-Mar-19
4775	US20190160 063		NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	31-Dec-15	30-Dec-16	30-May-19
4776	US20190128 810	http://59.45.142.240:8808/pdf/US20190128810A1.pdf	SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR PERFORMANCE	Not Available	31-Dec-15	13-Dec-18	2-May-19
4777	US20190016 710	http://59.45.142.240:8808/pdf/US20190016710A1.pdf	MULTICYCLIC COMPOUNDS AND USES THEREOF	Not Available	31-Dec-15	29-Dec-16	17-Jan-19
4778	US20190016 690		NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	31-Dec-15	30-Dec-16	17-Jan-19

4779	US20190002 448		SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	31-Dec-15	29-Dec-16	3-Jan-19
4780	US20170191 933	http://59.45.142.240:8808/pdf/US20170191933A1.pdf	Systems and Methods for Analyzing a Sample and for Monitoring the Performance of an Optical Signal	Not Available	31-Dec-15	23-Dec-16	6-Jul-17
4781	US10526295	http://59.45.142.240:8808/pdf/US10526295.pdf	Nuclear transport modulators and use thereof	Karyopharm Therapeutics Inc.	31-Dec-15	30-Dec-16	7-Jan-20
4782	US10190984	http://59.45.142.240:8808/pdf/US10190984.pdf	Systems and methods for analyzing a sample and for monitoring the performance of an optical signal	GEN-PROBE INCORPORATED	31-Dec-15	23-Dec-16	29-Jan-19
4783	US20190040 451	http://59.45.142.240:8808/pdf/US20190040451A1.pdf	FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC NUCLEIC ACID SEQUENCES	Not Available	8-Jan-16	9-Jan-17	7-Feb-19
4784	US20180311 338	http://59.45.142.240:8808/pdf/US20180311338A1.pdf	MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME	Not Available	11-Jan-16	11-Jul-18	1-Nov-18
4785	US10363303	http://59.45.142.240:8808/pdf/US10363303.pdf	Microneedle compositions and methods of using same	VERNDARI, INC.	11-Jan-16	11-Jul-18	30-Jul-19
4786	US10022436	http://59.45.142.240:8808/pdf/US10022436.pdf	Microneedle compositions and methods of using same	VERNDARI, INC.	11-Jan-16	11-Jan-17	17-Jul-18
4787	US20200164 067	http://59.45.142.240:8808/pdf/US20200164067A1.pdf	Methods and Compositions for Inhibiting Akt3	Not Available	15-Jan-16	5-Feb-20	28-May-20
4788	US20200046 692	http://59.45.142.240:8808/pdf/US20200046692A1.pdf	SPECIFIC AKT3 INHIBITOR AND USES THEREOF	Not Available	15-Jan-16	2-Oct-19	13-Feb-20
4789	US20190269 672	http://59.45.142.240:8808/pdf/US20190269672A1.pdf	Specific Akt3 Inhibitor and Uses Thereof	Not Available	15-Jan-16	20-May-19	5-Sep-19
4790	US20190167 787	http://59.45.142.240:8808/pdf/US20190167787A1.pdf	Methods and Compositions for Inhibiting Akt3	Not Available	15-Jan-16	6-Feb-19	6-Jun-19
4791	US20170202 956	http://59.45.142.240:8808/pdf/US20170202956A1.pdf	Methods and Compositions for Inhibiting Akt3	Not Available	15-Jan-16	17-Jan-17	20-Jul-17
4792	US20170202 829	http://59.45.142.240:8808/pdf/US20170202829A1.pdf	Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications	Not Available	15-Jan-16	17-Jan-17	20-Jul-17
4793	US10588966	http://59.45.142.240:8808/pdf/US10588966.pdf	Methods and compositions for inhibiting Akt3	Augusta University Research Institute,	15-Jan-16	6-Feb-19	17-Mar-20
4794	US10525049	http://59.45.142.240:8808/pdf/US10525049.pdf	Specific Akt3 inhibitor and uses thereof	Augusta University Research Institute,	15-Jan-16	20-May-19	7-Jan-20
4795	US10342868	http://59.45.142.240:8808/pdf/US10342868.pdf	Methods and compositions for inhibiting Akt3	Augusta University Research Institute,	15-Jan-16	17-Jan-17	9-Jul-19
4796	US10292978	http://59.45.142.240:8808/pdf/US10292978.pdf	Specific Akt3 inhibitor and uses thereof	Augusta University Research Institute,	15-Jan-16	17-Jan-17	21-May-19
4797	US10159731	http://59.45.142.240:8808/pdf/US10159731.pdf	Methods and compositions for inhibiting Akt3	Augusta University Research Institute,	15-Jan-16	20-Feb-18	25-Dec-18
4798	US20190030 094	http://59.45.142.240:8808/pdf/US20190030094A1.pdf	BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR TREATING RESPIRATORY INFECTIONS	Not Available	27-Jan-16	27-Jan-17	31-Jan-19
4799	US20190022 214	http://59.45.142.240:8808/pdf/US20190022214A1.pdf	Attenuated Infectious Bronchitis Virus	Not Available	27-Jan-16	26-Jan-17	24-Jan-19
4800	US20190031 605	http://59.45.142.240:8808/pdf/US20190031605A1.pdf	TETRAHYDRONAPHTHALENE DERIVATIVE	ONO PHARMACEUTICAL Co., Ltd.	29-Jan-16	27-Jan-17	31-Jan-19
4801	US10597736	http://59.45.142.240:8808/pdf/US10597736.pdf	Compositions and methods for detecting viruses in a sample	Washington University	29-Jan-16	27-Jan-17	24-Mar-20
4802	US20190046 635	http://59.45.142.240:8808/pdf/US20190046635A1.pdf	COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND VACCINE PHARMACEUTICAL	NITTO DENKO CORPORATION	2-Feb-16	1-Feb-17	14-Feb-19
4803	US10266545	http://59.45.142.240:8808/pdf/US10266545.pdf	Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use	I-NOVA MEDICINSKA ISTRAZIVANJA	2-Feb-16	2-Feb-16	23-Apr-19
4804	US20190038 742	http://59.45.142.240:8808/pdf/US20190038742A1.pdf	MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME	Longeveron LLC	4-Feb-16	2-Feb-17	7-Feb-19
4805	US20200040 408	http://59.45.142.240:8808/pdf/US20200040408A1.pdf	HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION	Not Available	8-Feb-16	6-May-19	6-Feb-20
4806	US20170226 593	http://59.45.142.240:8808/pdf/US20170226593A1.pdf	HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION	Not Available	8-Feb-16	8-Feb-16	10-Aug-17
4807	US20190017 112	http://59.45.142.240:8808/pdf/US20190017112A1.pdf	METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE PROTECTION	HTG Molecular Diagnostics, Inc.	11-Feb-16	10-Feb-17	17-Jan-19
4808	US20170360 962	http://59.45.142.240:8808/pdf/US20170360962A1.pdf	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING	Not Available	16-Feb-16	18-Aug-17	21-Dec-17
4809	US20170348 433	http://59.45.142.240:8808/pdf/US20170348433A1.pdf	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING	The Board of Trustees of the Leland Stanford	16-Feb-16	16-Feb-17	7-Dec-17
4810	US10532111	http://59.45.142.240:8808/pdf/US10532111.pdf	Recombinant adeno-associated virus capsids resistant to pre- existing human neutralizing antibodies	The Board of Trustees of the Leland Stanford	16-Feb-16	18-Aug-17	14-Jan-20
4811	US10179176	http://59.45.142.240:8808/pdf/US10179176.pdf	Recombinant adeno-associated virus capsids resistant to pre- existing human neutralizing antibodies	The Board of Trustees of the Leland Stanford	16-Feb-16	16-Feb-17	15-Jan-19
4812	US20170241 998	http://59.45.142.240:8808/pdf/US20170241998A1.pdf	METHOD FOR THE IMMOBILIZATION OF BIOMOLECULES	Not Available	22-Feb-16	17-Feb-17	24-Aug-17
4813	US20170240 639	http://59.45.142.240:8808/pdf/US20170240639A1.pdf	ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY	Not Available	22-Feb-16	22-Feb-17	24-Aug-17
4814	US20190055 256		ANTI-VIRAL DRUG	DORING INTERNATIONAL CORP.	24-Feb-16	24-Feb-17	21-Feb-19
4815	US20190062 323	http://59.45.142.240:8808/pdf/US20190062323A1.pdf	PI-Kinase Inhibitors with Anti-Infective Activity	Not Available	26-Feb-16	24-Feb-17	28-Feb-19
4816	US20190060 435	http://59.45.142.240:8808/pdf/US20190060435A1.pdf	PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE	The United States of America, as represented by the Secretary, Dept of Health and Human	27-Feb-16	27-Feb-17	28-Feb-19
4817	US20170247 423	http://59.45.142.240:8808/pdf/US20170247423A1.pdf	STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL AGENTS FOR TREATING	Not Available	29-Feb-16	28-Feb-17	31-Aug-17
4818	US20190054 127	http://59.45.142.240:8808/pdf/US20190054127A1.pdf	ANTIVIRAL AGENT AND ANTIVIRAL FOOD	EDUCATIONAL CORPORATION	4-Mar-16	22-Nov-16	21-Feb-19

4819	US20190085 013	http://59.45.142.240:8808/pdf/US20190085013A1.pdf	NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THEREOF	Not Available	7-Mar-16	7-Mar-17	21-Mar-19
4820	US20170252 417	http://59.45.142.240:8808/pdf/US20170252417A1.pdf	PROTEIN-CHAPERONED T-CELL VACCINES	Not Available	7-Mar-16	7-Mar-17	7-Sep-17
4821	US20190083 520	http://59.45.142.240:8808/pdf/US20190083520A1.pdf	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto	Not Available	10-Mar-16	10-Mar-17	21-Mar-19
4822	US20170335 408	http://59.45.142.240:8808/pdf/US20170335408A1.pdf	Methods and Systems of Multi-Assay Processing and Analysis	Not Available	15-Mar-16	15-Mar-17	23-Nov-17
4823	US20190105 381	http://59.45.142.240:8808/pdf/US20190105381A1.pdf	METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID	Not Available	16-Mar-16	16-Mar-16	11-Apr-19
4824	US20190100 586	http://59.45.142.240:8808/pdf/US20190100586A1.pdf	Humanized Anti-Claudin-1 Antibodies and Uses Thereof	Chu Strasbourg, Les H ³ A ³ pitaux Universitaires de	22-Mar-16	21-Mar-17	4-Apr-19
4825	US20190381 162	http://59.45.142.240:8808/pdf/US20190381162A1.pdf	PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF	Not Available	28-Mar-16	27-Mar-17	19-Dec-19
4826	US20170281 966	http://59.45.142.240:8808/pdf/US20170281966A1.pdf	Device to Kill Micro-Organisms Inside the Respiratory Tract	Not Available	1-Apr-16	28-Mar-17	5-Oct-17
4827	US10010718	http://59.45.142.240:8808/pdf/US10010718.pdf	Device to kill micro-organisms inside the respiratory tract	Not Available	1-Apr-16	28-Mar-17	3-Jul-18
4828	US20190062 785	http://59.45.142.240:8808/pdf/US20190062785A1.pdf	MULTIVALENT VACCINES FOR RABIES VIRUS AND	Not Available	4-Apr-16	31-Mar-17	28-Feb-19
4829	US20190154 550	http://59.45.142.240:8808/pdf/US20190154550A1.pdf	BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE	Not Available	6-Apr-16	6-Apr-17	23-May-19
4830	US20190111 141	http://59.45.142.240:8808/pdf/US20190111141A1.pdf	A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE	Ewha University - Industry Collaboration	6-Apr-16	6-Apr-17	18-Apr-19
4831	US20180105 514	http://59.45.142.240:8808/pdf/US20180105514A1.pdf	HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS	Not Available	7-Apr-16	3-Jan-18	19-Apr-18
4832	US10189820	http://59.45.142.240:8808/pdf/US10189820.pdf	Heterocyclic amides useful as protein modulators	GlaxoSmithKline Intellectual Property Development	7-Apr-16	3-Jan-18	29-Jan-19
4833	US20190192 691	http://59.45.142.240:8808/pdf/US20190192691A1.pdf	REGULATED BIOCIRCUIT SYSTEMS	Not Available	11-Apr-16	11-Apr-17	27-Jun-19
4834	US20190094 224	http://59.45.142.240:8808/pdf/US20190094224A1.pdf	METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL	Not Available	11-Apr-16	6-Apr-17	28-Mar-19
4835	US20190390 179	http://59.45.142.240:8808/pdf/US20190390179A1.pdf	SYNTHETIC REVERSE TRANSCRIPTASES AND USES	Not Available	12-Apr-16	12-Apr-17	26-Dec-19
4836	US20190127 441	http://59.45.142.240:8808/pdf/US20190127441A1.pdf	METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY	University of Vermont and State	13-Apr-16	13-Apr-17	2-May-19
4837	US20190125 858	http://59.45.142.240:8808/pdf/US20190125858A1.pdf	COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE ATTENUATED VACCINE SUITABLE	Not Available	18-Apr-16	18-Apr-17	2-May-19
4838	US20200079 820	http://59.45.142.240:8808/pdf/US20200079820A1.pdf	DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL-BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd.	20-Apr-16	20-Apr-16	12-Mar-20
4839	US20190390 229	http://59.45.142.240:8808/pdf/US20190390229A1.pdf	GENE EDITING REAGENTS WITH REDUCED TOXICITY	Not Available	21-Apr-16	20-Apr-17	26-Dec-19
4840	US20170304 829	http://59.45.142.240:8808/pdf/US20170304829A1.pdf	PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION MODULE	Click Diagnostics, Inc.	22-Apr-16	21-Apr-17	26-Oct-17
4841	US9975885	http://59.45.142.240:8808/pdf/US9975885.pdf	Broad-spectrum non-covalent coronavirus protease inhibitors	PURDUE RESEARCH FOUNDATION	28-Apr-16	28-Apr-17	22-May-18
4842	US20190144 484		ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED	Not Available	28-Apr-16	28-Apr-17	16-May-19
4843	US20170313 685	http://59.45.142.240:8808/pdf/US20170313685A1.pdf	BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE	Purdue Research Foundation	28-Apr-16	28-Apr-17	2-Nov-17
4844	US20200165 630		COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29-Apr-16	28-Apr-17	28-May-20
4845	US20190224 339	http://59.45.142.240:8808/pdf/US20190224339A1.pdf	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29-Apr-16	28-Apr-17	25-Jul-19
4846	US20190153 471		COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29-Apr-16	28-Apr-17	23-May-19
4847	US20190298 824	http://59.45.142.240:8808/pdf/US20190298824A1.pdf	ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of	4-May-16	4-May-17	3-Oct-19
4848	US20190134 214	http://59.45.142.240:8808/pdf/US20190134214A1.pdf	GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and	Not Available	6-May-16	4-May-17	9-May-19
4849	US20190136 226	http://59.45.142.240:8808/pdf/US20190136226A1.pdf	DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION	Not Available	11-May-16	9-Nov-18	9-May-19
4850	US20170326 123	http://59.45.142.240:8808/pdf/US20170326123A1.pdf	Throat solution for treatment of cold, flu and sore throat	Not Available	12-May-16	12-May-16	16-Nov-17
4851	US20190144 556	http://59.45.142.240:8808/pdf/US20190144556A1.pdf	ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR	Not Available	13-May-16	12-May-17	16-May-19
4852	US20190135 875	http://59.45.142.240:8808/pdf/US20190135875A1.pdf	TRI-SEGMENTED PICHIIDE VECTORS AS VACCINE VECTORS	Not Available	18-May-16	17-May-17	9-May-19
4853	US20190077 764	http://59.45.142.240:8808/pdf/US20190077764A1.pdf	BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY	Hoffmann-La Roche Inc.	23-May-16	13-Nov-18	14-Mar-19
4854	US20190077 763	http://59.45.142.240:8808/pdf/US20190077763A1.pdf	BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY	Hoffmann-La Roche Inc.	23-May-16	13-Nov-18	14-Mar-19
4855	US10370338	http://59.45.142.240:8808/pdf/US10370338.pdf	Benzazepine dicarboxamide compounds with tertiary amide	Hoffmann-La Roche Inc.	23-May-16	13-Nov-18	6-Aug-19
4856	US20190285 632	http://59.45.142.240:8808/pdf/US20190285632A1.pdf	METABALOMICS AND VIRAL DIAGNOSTICS SUITE	Excision Biopharmaceutics, Inc.	24-May-16	24-May-17	19-Sep-19
4857	US9862706	http://59.45.142.240:8808/pdf/US9862706.pdf	Compounds	CHIESI FARMACEUTICI	31-May-16	26-May-17	9-Jan-18
4858	US9802919	http://59.45.142.240:8808/pdf/US9802919.pdf	Compounds	CHIESI FARMACEUTICI	31-May-16	26-May-17	31-Oct-17
4859	US20180009 787	http://59.45.142.240:8808/pdf/US20180009787A1.pdf	NOVEL COMPOUNDS	CHIESI FARMACEUTICI	31-May-16	22-Sep-17	11-Jan-18
4860	US20170342 405	http://59.45.142.240:8808/pdf/US20170342405A1.pdf	MOLECULAR INDEXING OF INTERNAL CHANNELS	Not Available	31-May-16	16-May-17	30-Nov-17

4861	US20170342 056		NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	31-May-16	26-May-17	30-Nov-17
4862	US20170340 611		NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	31-May-16	26-May-17	30-Nov-17
4863	US10640763	http://59.45.142.240:8808/pdf/US10640763.pdf	Molecular indexing of internal sequence	Cellular Research, Inc.	31-May-16	16-May-17	5-May-20
4864	US10172830	http://59.45.142.240:8808/pdf/US10172830.pdf	Pyrazolone compounds having human neutrophil elastase inhibitory activity	Chiesi Farmaceutici S.p.A.	31-May-16	26-May-17	8-Jan-19
4865	US10023558	http://59.45.142.240:8808/pdf/US10023558.pdf	Compounds	CHIESI FARMACEUTICI S.p.A.	31-May-16	22-Sep-17	17-Jul-18
4866	US20190380 995	http://59.45.142.240:8808/pdf/US20190380995A1.pdf	PREVENTION AND TREATMENT OF VIRAL INFECTIONS	Not Available	2-Jun-16	3-Jul-19	19-Dec-19
4867	US20190125 724	http://59.45.142.240:8808/pdf/US20190125724A1.pdf	PREVENTION AND TREATMENT OF VIRAL INFECTIONS	Not Available	2-Jun-16	27-Nov-18	2-May-19
4868	US10603299	http://59.45.142.240:8808/pdf/US10603299.pdf	Prevention and treatment of viral infections	Not Available	2-Jun-16	3-Jul-19	31-Mar-20
4869	US10383852	http://59.45.142.240:8808/pdf/US10383852.pdf	Prevention and treatment of viral infections	Not Available	2-Jun-16	27-Nov-18	20-Aug-19
4870	US20190209 604		OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF	WAVE LIFE SCIENCES LTD.	3-Jun-16	2-Jun-17	11-Jul-19
4871	US20190185 832	http://59.45.142.240:8808/pdf/US20190185832A1.pdf	DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING CAS9 NUCLEASE AND USES THEREOF	Not Available	3-Jun-16	2-Jun-17	20-Jun-19
4872	US20190187 151	http://59.45.142.240:8808/pdf/US20190187151A1.pdf	ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING STABLE ISOTOPIC STANDARDS	UVic Industry Partnerships Inc.	6-Jun-16	7-Apr-17	20-Jun-19
4873	US20190381 180	http://59.45.142.240:8808/pdf/US20190381180A1.pdf	HYBRID CARRIERS FOR NUCLEIC ACID CARGO	Not Available	9-Jun-16	9-Jun-17	19-Dec-19
4874	US20190336 611	http://59.45.142.240:8808/pdf/US20190336611A1.pdf	HYBRID CARRIERS FOR NUCLEIC ACID CARGO	CureVac AG	9-Jun-16	9-Jun-17	7-Nov-19
4875	US20190336 608	http://59.45.142.240:8808/pdf/US20190336608A1.pdf	CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY	CureVac AG	9-Jun-16	9-Jun-17	7-Nov-19
4876	US20200172 513	http://59.45.142.240:8808/pdf/US20200172513A1.pdf	DIHYDROPYRIMIDINYL BENZAZERINE CARBOXYAMIDE	Hoffmann-La Roche Inc.	12-Jun-16	5-Feb-20	4-Jun-20
4877	US20190135 788	http://59.45.142.240:8808/pdf/US20190135788A1.pdf	DIHYDROPYRIMIDINYL BENZAZERINE CARBOXYAMIDE	Hoffmann-La Roche Inc.	12-Jun-16	7-Dec-18	9-May-19
4878	US20190125 806	http://59.45.142.240:8808/pdf/US20190125806A1.pdf	Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for Producing	Murata Manufacturing Co., Ltd.	13-Jun-16	13-Dec-18	2-May-19
4879	US20180346 574	http://59.45.142.240:8808/pdf/US20180346574A1.pdf	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13-Jun-16	9-Aug-18	6-Dec-18
4880	US20180346 573	http://59.45.142.240:8808/pdf/US20180346573A1.pdf	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13-Jun-16	9-Aug-18	6-Dec-18
4881	US20180208 659	http://59.45.142.240:8808/pdf/US20180208659A1.pdf	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13-Jun-16	13-Jun-17	26-Jul-18
4882	US10059769	http://59.45.142.240:8808/pdf/US10059769.pdf	Anti-PD-L1 antibodies and uses thereof	I-MAB	13-Jun-16	13-Jun-17	28-Aug-18
4883	US20170360 881		PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF	Not Available	17-Jun-16	16-Jun-17	21-Dec-17
4884	US20180002 743	http://59.45.142.240:8808/pdf/US20180002743A1.pdf	FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE DETECTION OF RNA	Not Available	18-Jun-16	16-Jun-17	4-Jan-18
4885	US10400274	http://59.45.142.240:8808/pdf/US10400274.pdf	Fluorogenic probes and their use in quantitative detection of target RNA	Jan Biotech, Inc.	18-Jun-16	16-Jun-17	3-Sep-19
4886	US20190345 503	http://59.45.142.240:8808/pdf/US20190345503A1.pdf	CIRCULAR RNAs AND THEIR USE IN IMMUNOMODULATION	Not Available	20-Jun-16	15-Jun-17	14-Nov-19
4887	US20190175 716		Adenoviral Vector	Not Available	23-Jun-16	23-Jun-17	13-Jun-19
4888	US20190204 330	http://59.45.142.240:8808/pdf/US20190204330A1.pdf	APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND CELL SORTING	Not Available	28-Jun-16	19-Dec-18	4-Jul-19
4889	US20190187 130	http://59.45.142.240:8808/pdf/US20190187130A1.pdf	COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI-DYE QUINONE METHIDE AND	Not Available	28-Jun-16	19-Dec-18	20-Jun-19
4890	US20190151 844	http://59.45.142.240:8808/pdf/US20190151844A1.pdf	DEVICES AND METHODS FOR THE DETECTION OF MOLECULES USING A FLOW CELL	Click Diagnostics, Inc.	29-Jun-16	21-Dec-18	23-May-19
4891	US20200157 221	http://59.45.142.240:8808/pdf/US20200157221A1.pdf	ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30-Jun-16	28-Jan-20	21-May-20
4892	US20200086 324	http://59.45.142.240:8808/pdf/US20200086324A1.pdf	DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION	Not Available	30-Jun-16	27-Dec-18	19-Mar-20
4893	US20190048 082	http://59.45.142.240:8808/pdf/US20190048082A1.pdf	PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30-Jun-16	25-Oct-18	14-Feb-19
4894	US20180057 594	http://59.45.142.240:8808/pdf/US20180057594A1.pdf	PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30-Jun-16	29-Sep-17	1-Mar-18
4895	US10604574	http://59.45.142.240:8808/pdf/US10604574.pdf	Oncolytic viral delivery of therapeutic polypeptides	ONCORUS, INC.	30-Jun-16	25-Oct-18	31-Mar-20
4896	US20190194 150	http://59.45.142.240:8808/pdf/US20190194150A1.pdf	COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION	Arrakis Therapeutics, Inc.	1-Jul-16	30-Jun-17	27-Jun-19
4897	US20190223 445	http://59.45.142.240:8808/pdf/US20190223445A1.pdf	ANTIMICROBIAL GEOPOLYMER COMPOSITIONS	Not Available	14-Jul-16	13-Jul-17	25-Jul-19
4898	US20200000 931	http://59.45.142.240:8808/pdf/US20200000931A1.pdf	SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS	Not Available	15-Jul-16	10-Apr-19	2-Jan-20
4899	US20190336 456	http://59.45.142.240:8808/pdf/US20190336456A1.pdf	USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS	ABIOGEN PHARMA S.P.A.	15-Jul-16	13-Jul-17	7-Nov-19
4900	US20180015 174	http://59.45.142.240:8808/pdf/US20180015174A1.pdf	SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS	Not Available	15-Jul-16	14-Jul-17	18-Jan-18
4901	US10300145	http://59.45.142.240:8808/pdf/US10300145.pdf	Synthetic nanoparticles for delivery of immunomodulatory compounds	Massachusetts Institute of Technology	15-Jul-16	14-Jul-17	28-May-19
4902	US20190264 267		PHASING	Wave Life Sciences Ltd.	25-Jul-16	24-Jul-17	29-Aug-19
4903	US20190315 807	http://59.45.142.240:8808/pdf/US20190315807A1.pdf	VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCING THE EXPRESSION OF ANTIBODIES	Not Available	27-Jul-16	26-Jul-17	17-Oct-19
4904	US20190000 745	http://59.45.142.240:8808/pdf/US20190000745A1.pdf	POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF	eXion labs Inc.	28-Jul-16	4-Sep-18	3-Jan-19
4905	US20180028 431	http://59.45.142.240:8808/pdf/US20180028431A1.pdf	POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF	eXion labs Inc.	28-Jul-16	27-Jul-17	1-Feb-18
4906	US20190290 674	http://59.45.142.240:8808/pdf/US20190290674A1.pdf	Composition for Promoting Production of Immunostimulatory	Kyoto University	2-Aug-16	31-Jul-17	26-Sep-19

4907	US20180037 634	http://59.45.142.240:8808/pdf/US20180037634A1.pdf	ENGINEERED POLYPEPTIDES AND USES THEREOF	Not Available	2-Aug-16	2-Aug-17	8-Feb-18
4908	US20190194 322	http://59.45.142.240:8808/pdf/US20190194322A1.pdf	IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE CHECKPOINT AND USE THEREOF FOR	BIO-TECHNE CORPORATION	3-Aug-16	3-Aug-17	27-Jun-19
4909	US20180037 942	http://59.45.142.240:8808/pdf/US20180037942A1.pdf	ENZYME-INDEPENDENT MOLECULAR INDEXING	Not Available	3-Aug-16	1-Aug-17	8-Feb-18
4910	US20180037 871	http://59.45.142.240:8808/pdf/US20180037871A1.pdf	CANCER INITIATING CELL AND USE THEREOF	Not Available	8-Aug-16	8-Aug-16	8-Feb-18
4911	US20190292 236	http://59.45.142.240:8808/pdf/US20190292236A1.pdf	MODULATION OF IFI16 AND STING ACTIVITY	Not Available	9-Aug-16	9-Aug-17	26-Sep-19
4912	US20190127 401	http://59.45.142.240:8808/pdf/US20190127401A1.pdf	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12-Aug-16	20-Dec-18	2-May-19
4913	US20190127 400	http://59.45.142.240:8808/pdf/US20190127400A1.pdf	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12-Aug-16	20-Dec-18	2-May-19
4914	US20190127 399	http://59.45.142.240:8808/pdf/US20190127399A1.pdf	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12-Aug-16	20-Dec-18	2-May-19
4915	US20190119 743	http://59.45.142.240:8808/pdf/US20190119743A1.pdf	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	15-Aug-16	26-Oct-18	25-Apr-19
4916	US20180057 871	http://59.45.142.240:8808/pdf/US20180057871A1.pdf	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	15-Aug-16	1-Nov-17	1-Mar-18
4917	US10155980	http://59.45.142.240:8808/pdf/US10155980.pdf	Compositions and methods for detecting rare sequence variants	ACCURAGEN HOLDINGS LIMITED	15-Aug-16	1-Nov-17	18-Dec-18
4918	US20190211 024	http://59.45.142.240:8808/pdf/US20190211024A1.pdf	SMALL MOLECULES HAVING ANTIVIRAL PROPERTIES	General Research Laboratory	19-Aug-16	19-Aug-17	11-Jul-19
4919	US20190194 728	http://59.45.142.240:8808/pdf/US20190194728A1.pdf	Systemic inflammatory and pathogen biomarkers and uses	Not Available	24-Aug-16	24-Aug-17	27-Jun-19
4920	US20190194 226	http://59.45.142.240:8808/pdf/US20190194226A1.pdf	FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH	Not Available	26-Aug-16	1-Aug-17	27-Jun-19
4921	US10414779	http://59.45.142.240:8808/pdf/US10414779.pdf	Fused [1,2]imidazo[4,5-C] ring compounds substituted with	3M Innovative Properties Company	26-Aug-16	1-Aug-17	17-Sep-19
4922	US20190194 628	http://59.45.142.240:8808/pdf/US20190194628A1.pdf	METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION	Takeda Pharmaceutical Co., Ltd.	1-Sep-16	1-Sep-17	27-Jun-19
4923	US20190276 523	http://59.45.142.240:8808/pdf/US20190276523A1.pdf	COMPOSITION AND METHODS OF TREATING B CELL DISORDERS	Not Available	2-Sep-16	5-Sep-17	12-Sep-19
4924	US20190194 717	http://59.45.142.240:8808/pdf/US20190194717A1.pdf	METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM	JAPAN SCIENCE AND TECHNOLOGY AGENCY	5-Sep-16	4-Sep-17	27-Jun-19
4925	US20190201 433	http://59.45.142.240:8808/pdf/US20190201433A1.pdf	2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT	Atea Pharmaceuticals, Inc.	7-Sep-16	5-Mar-19	4-Jul-19
4926	US20180067 299	http://59.45.142.240:8808/pdf/US20180067299A1.pdf	ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION MONITORING	ELECTRONICS AND TELECOMMUNICATIONS RESEARCH	7-Sep-16	31-May-17	8-Mar-18
4927	US10591714	http://59.45.142.240:8808/pdf/US10591714.pdf	Endoscopic apparatus for thermal distribution monitoring	ELECTRONICS AND TELECOMMUNICATIONS RESEARCH	7-Sep-16	31-May-17	17-Mar-20
4928	US20200055 927	http://59.45.142.240:8808/pdf/US20200055927A1.pdf	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	25-Oct-19	20-Feb-20
4929	US20200055 926	http://59.45.142.240:8808/pdf/US20200055926A1.pdf	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	25-Oct-19	20-Feb-20
4930	US20190330 572	http://59.45.142.240:8808/pdf/US20190330572A1.pdf	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	21-Jun-19	31-Oct-19
4931	US20190085 057	http://59.45.142.240:8808/pdf/US20190085057A1.pdf	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	15-Nov-18	21-Mar-19
4932	US20190017 000	http://59.45.142.240:8808/pdf/US20190017000A1.pdf	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	19-Sep-18	17-Jan-19
4933	US20180327 697	http://59.45.142.240:8808/pdf/US20180327697A1.pdf	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	12-Jun-18	15-Nov-18
4934	US20180265 822	http://59.45.142.240:8808/pdf/US20180265822A1.pdf	LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	21-May-18	20-Sep-18
4935	US20180072 796	http://59.45.142.240:8808/pdf/US20180072796A1.pdf	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	17-Nov-17	15-Mar-18
4936	US20180066 216	http://59.45.142.240:8808/pdf/US20180066216A1.pdf	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	6-Sep-17	8-Mar-18
4937	US10604729	http://59.45.142.240:8808/pdf/US10604729.pdf	Liquid loading composition, method of making and use thereof	DEVMAR PRODUCTS, LLC	8-Sep-16	21-May-18	31-Mar-20
4938	US10501527	http://59.45.142.240:8808/pdf/US10501527.pdf	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Emergo Therapeutics, Inc.	8-Sep-16	7-Sep-17	10-Dec-19
4939	US10494420	http://59.45.142.240:8808/pdf/US10494420.pdf	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Emergo Therapeutics, Inc.	8-Sep-16	15-Nov-18	3-Dec-19
4940	US10457901	http://59.45.142.240:8808/pdf/US10457901.pdf	Cleaning composition, method of making and use thereof	DevMar Products, LLC	8-Sep-16	19-Sep-18	29-Oct-19
4941	US10370625	http://59.45.142.240:8808/pdf/US10370625.pdf	Cleaning composition, method of making and use thereof	DEVMAR PRODUCTS, LLC	8-Sep-16	6-Sep-17	6-Aug-19
4942	US10160796	http://59.45.142.240:8808/pdf/US10160796.pdf	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Emergo Therapeutics, Inc.	8-Sep-16	17-Nov-17	25-Dec-18
4943	US20200030 422	http://59.45.142.240:8808/pdf/US20200030422A1.pdf	COMBINATION OF VACCINATION AND DYAD ACQUISITION	CureVac AG	9-Sep-16	15-Apr-19	30-Jan-20
4944	US20190375 801	http://59.45.142.240:8808/pdf/US20190375801A1.pdf	HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR TREATMENT OF INFECTIOUS	Not Available	9-Sep-16	8-Sep-17	12-Dec-19
4945	US20190315 840	http://59.45.142.240:8808/pdf/US20190315840A1.pdf	ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND	Not Available	16-Sep-16	10-Jun-19	17-Oct-19
4946	US20190218 277	http://59.45.142.240:8808/pdf/US20190218277A1.pdf	ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND	Not Available	16-Sep-16	15-Sep-17	18-Jul-19
4947	US20180078 507	http://59.45.142.240:8808/pdf/US20180078507A1.pdf	BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL	Not Available	16-Sep-16	15-Sep-17	22-Mar-18
4948	US10604561	http://59.45.142.240:8808/pdf/US10604561.pdf	Anti-dengue virus antibodies, polypeptides containing variant Fc	Agency for Science, Technology and	16-Sep-16	15-Sep-17	31-Mar-20
4949	US20190293 656	http://59.45.142.240:8808/pdf/US20190293656A1.pdf	NON-RADIOACTIVE CYTOTOXICITY ASSAYS	Not Available	19-Sep-16	19-Sep-17	26-Sep-19

4950	US20190202 929	http://59.45.142.240:8808/pdf/US20190202929A1.pdf	COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS	Not Available	20-Sep-16	20-Sep-17	4-Jul-19
4951	US20180078 532	http://59.45.142.240:8808/pdf/US20180078532A1.pdf	IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB	AMGEN INC.	21-Sep-16	18-Sep-17	22-Mar-18
4952	US20190232 282	http://59.45.142.240:8808/pdf/US20190232282A1.pdf	METHODS AND COMPOSITIONS FOR DETECTING ANALYTES	Not Available	23-Sep-16	20-Sep-17	1-Aug-19
4953	US10548959	http://59.45.142.240:8808/pdf/US10548959.pdf	Compositions and methods for modified dendrimer nanoparticle	Massachusetts Institute of Technology	23-Sep-16	23-Sep-16	4-Feb-20
4954	US20180087 049	http://59.45.142.240:8808/pdf/US20180087049A1.pdf	MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN RAPID CLOT TUBES	Not Available	27-Sep-16	7-Sep-17	29-Mar-18
4955	US20190284 230	http://59.45.142.240:8808/pdf/US20190284230A1.pdf	ASSEMBLED GLYCOPROTEINS	Not Available	29-Sep-16	22-Sep-17	19-Sep-19
4956	US20190275 101	http://59.45.142.240:8808/pdf/US20190275101A1.pdf	STRUCTURE OF GII.4 NOROVIRUS PROTEASE - DESIGN OF BROAD-SPECTRUM PROTEASE INHIBITORS	Not Available	5-Oct-16	5-Oct-17	12-Sep-19
4957	US20190328 869	http://59.45.142.240:8808/pdf/US20190328869A1.pdf	IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR COMBINATION THERAPY	Transgene SA	10-Oct-16	10-Oct-17	31-Oct-19
4958	US20200017 588	http://59.45.142.240:8808/pdf/US20200017588A1.pdf	MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM	Not Available	14-Oct-16	16-Oct-17	16-Jan-20
4959	US20190231 004	http://59.45.142.240:8808/pdf/US20190231004A1.pdf	MASK	NBC MESHTEC INC.	17-Oct-16	13-Oct-17	1-Aug-19
4960	US20180105 815	http://59.45.142.240:8808/pdf/US20180105815A1.pdf	Bivalent siRNA Chimeras and Methods of Use Thereof	Not Available	18-Oct-16	6-Oct-17	19-Apr-18
4961	US20190262 371	http://59.45.142.240:8808/pdf/US20190262371A1.pdf	METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS	Not Available	20-Oct-16	20-Oct-17	29-Aug-19
4962	US20190250 153	http://59.45.142.240:8808/pdf/US20190250153A1.pdf	MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING	Board of Regents, The University of Texas at Austin	20-Oct-16	19-Oct-17	15-Aug-19
4963	US20190307 722	http://59.45.142.240:8808/pdf/US20190307722A1.pdf	ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CARBOHYDRATES	Not Available	21-Oct-16	20-Oct-17	10-Oct-19
4964	US20200061 185	http://59.45.142.240:8808/pdf/US20200061185A1.pdf	PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE	The Scripps Research Institute	25-Oct-16	25-Oct-17	27-Feb-20
4965	US20200163 878		LIPID NANOPARTICLE MRNA VACCINES	Not Available	26-Oct-16	26-Oct-17	28-May-20
4966	US20190382 799	http://59.45.142.240:8808/pdf/US20190382799A1.pdf	VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS	Not Available	27-Oct-16	19-Apr-19	19-Dec-19
4967	US20190374 576		VIRAL METHODS OF T CELL THERAPY	Not Available	27-Oct-16	19-Apr-19	12-Dec-19
4968	US20190275 519	http://59.45.142.240:8808/pdf/US20190275519A1.pdf	SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS	Not Available	8-Nov-16	8-Nov-17	12-Sep-19
4969	US20190321 481	http://59.45.142.240:8808/pdf/US20190321481A1.pdf	IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS	NantBio, Inc.	11-Nov-16	9-Nov-17	24-Oct-19
4970	US20190308 969		HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	11-Nov-16	13-Nov-17	10-Oct-19
4971	US20200062 764	http://59.45.142.240:8808/pdf/US20200062764A1.pdf	ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME	Not Available	17-Nov-16	17-Nov-17	27-Feb-20
4972	US20190314 482	http://59.45.142.240:8808/pdf/US20190314482A1.pdf	VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE	Medigen, Inc.	28-Nov-16	21-Nov-17	17-Oct-19
4973	US20190321 403	http://59.45.142.240:8808/pdf/US20190321403A1.pdf	ENGINEERED B CELLS AND RELATED COMPOSITIONS AND	Juno Therapeutics, Inc.	2-Dec-16	30-Nov-17	24-Oct-19
4974	US20190314 372	http://59.45.142.240:8808/pdf/US20190314372A1.pdf	PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS	Not Available	5-Dec-16	25-Mar-19	17-Oct-19
4975	US10287253	http://59.45.142.240:8808/pdf/US10287253B2.pdf	Substituted pyrimidines containing acidic groups as TLR7 modulators	APROS THERAPEUTICS, INC.	5-Dec-16	4-Dec-17	14-May-19
4976	US20200020 420	http://59.45.142.240:8808/pdf/US20200020420A1.pdf	Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of	Not Available	8-Dec-16	7-Dec-17	16-Jan-20
4977	US20200060 981	http://59.45.142.240:8808/pdf/US20200060981A1.pdf	CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES	Not Available	9-Dec-16	11-Dec-17	27-Feb-20
4978	US20200054 660	http://59.45.142.240:8808/pdf/US20200054660A1.pdf	DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY	St. Jude Children's Research Hospital	9-Dec-16	7-Dec-17	20-Feb-20
4979	US20190309 357	http://59.45.142.240:8808/pdf/US20190309357A1.pdf	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	25-Feb-19	10-Oct-19
4980	US20180340 219	http://59.45.142.240:8808/pdf/US20180340219A1.pdf	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	9-Mar-18	29-Nov-18
4981	US20180340 218	http://59.45.142.240:8808/pdf/US20180340218A1.pdf	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	9-Mar-18	29-Nov-18
4982	US10266887	http://59.45.142.240:8808/pdf/US10266887.pdf	CRISPR effector system based diagnostics	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	9-Mar-18	23-Apr-19
4983	US10266886	http://59.45.142.240:8808/pdf/US10266886.pdf	CRISPR effector system based diagnostics	MASSACHUSETTS INSTITUTED OF TECHNOLOGY	9-Dec-16	9-Mar-18	23-Apr-19
4984	US20180161 279	http://59.45.142.240:8808/pdf/US20180161279A1.pdf	GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO	Not Available	14-Dec-16	13-Dec-17	14-Jun-18
4985	US20190135 873	http://59.45.142.240:8808/pdf/US20190135873A1.pdf	COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOCYTOSE RELEASE	Not Available	19-Dec-16	19-Dec-18	9-May-19
4986	US20180305 412	http://59.45.142.240:8808/pdf/US20180305412A1.pdf	COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOCYTOSE RELEASE	Not Available	19-Dec-16	9-Jul-18	25-Oct-18
4987	US10544193	http://59.45.142.240:8808/pdf/US10544193.pdf	Compositions and methods for treating diseases by inhibiting	MOREHOUSE SCHOOL OF NESTLE	19-Dec-16	9-Jul-18	28-Jan-20
4988	US10040831	http://59.45.142.240:8808/pdf/US10040831.pdf	Compositions and methods for treating diseases by inhibiting	MOREHOUSE SCHOOL OF NESTLE	19-Dec-16	19-Dec-16	7-Aug-18
4989	US20190374 610	http://59.45.142.240:8808/pdf/US20190374610A1.pdf	MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF SUBSIDS	Not Available	20-Dec-16	20-Dec-17	12-Dec-19
4990	US20190352 615		METHOD FOR PURIFYING VIRUS	Not Available	22-Dec-16	21-Dec-17	21-Nov-19
4991	US20190358 335	http://59.45.142.240:8808/pdf/US20190358335A1.pdf	STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER	Not Available	12-Jan-17	12-Jan-18	28-Nov-19
4992	US20180200 365	http://59.45.142.240:8808/pdf/US20180200365A1.pdf	Methods and Compositions for Inhibiting Akt2	Not Available	17-Jan-17	20-Feb-18	19-Jul-18

4993	US20180208 653		METHODS FOR ENHANCING AN IMMUNE RESPONSE	Not Available	20-Jan-17	19-Jan-18	26-Jul-18
4994	US20180230 447	http://59.45.142.240:8808/pdf/US20180230447A1.pdf	ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)	Northwestern University	24-Jan-17	24-Jan-18	16-Aug-18
4995	US10443049	http://59.45.142.240:8808/pdf/US10443049.pdf	Active low molecular weight variants of angiotensin converting enzyme 2	Northwestern University	24-Jan-17	24-Jan-18	15-Oct-19
4996	US20190359 990	http://59.45.142.240:8808/pdf/US20190359990A1.pdf	VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF	Not Available	25-Jan-17	25-Jan-18	28-Nov-19
4997	US20190352 639	http://59.45.142.240:8808/pdf/US20190352639A1.pdf	GENOME EDITING REAGENTS AND THEIR USE	Not Available	10-Feb-17	12-Feb-18	21-Nov-19
4998	US9713641	http://59.45.142.240:8808/pdf/US9713641.pdf	Anti-TIGIT antigen-binding proteins and methods of use thereof	Potenza Therapeutics, Inc.	13-Feb-17	13-Feb-17	25-Jul-17
4999	US20190374 650	http://59.45.142.240:8808/pdf/US20190374650A1.pdf	COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER/BIOMACROMOLECULE	Not Available	22-Feb-17	21-Feb-18	12-Dec-19
5000	US20180245 053	http://59.45.142.240:8808/pdf/US20180245053A1.pdf	VIRAL VACCINES AND METHODS OF FORMING THE SAME	Not Available	27-Feb-17	27-Feb-18	30-Aug-18
5001	US20200056 159	http://59.45.142.240:8808/pdf/US20200056159A1.pdf	NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREOF	Not Available	28-Feb-17	27-Feb-18	20-Feb-20
5002	US20200087 298	http://59.45.142.240:8808/pdf/US20200087298A1.pdf	Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted	Not Available	1-Mar-17	27-Feb-18	19-Mar-20
5003	US20200172 879	http://59.45.142.240:8808/pdf/US20200172879A1.pdf	DHFR TUNABLE PROTEIN REGULATION	Not Available	3-Mar-17	2-Sep-19	4-Jun-20
5004	US20200010 519	http://59.45.142.240:8808/pdf/US20200010519A1.pdf	NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE	Not Available	10-Mar-17	9-Mar-18	9-Jan-20
5005	US20200048 649	http://59.45.142.240:8808/pdf/US20200048649A1.pdf	VIRUS-LIKE PARTICLES AND USES THEREOF	Not Available	13-Mar-17	13-Mar-18	13-Feb-20
5006	US20200131 518	http://59.45.142.240:8808/pdf/US20200131518A1.pdf	CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE	Not Available	14-Mar-17	14-Mar-18	30-Apr-20
5007	US20190241 646	http://59.45.142.240:8808/pdf/US20190241646A1.pdf	ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF	Not Available	15-Mar-17	15-Apr-19	8-Aug-19
5008	US20190144 929	http://59.45.142.240:8808/pdf/US20190144929A1.pdf	DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	Not Available	15-Mar-17	15-Mar-18	16-May-19
5009	US20180265 574	http://59.45.142.240:8808/pdf/US20180265574A1.pdf	Anti-pneumococcal hyperimmune globulin for the treatment and	Not Available	15-Mar-17	15-Mar-17	20-Sep-18
5010	US10259865	http://59.45.142.240:8808/pdf/US10259865.pdf	Anti-pneumococcal hyperimmune globulin for the treatment and	ADMA Biologics, Inc.	15-Mar-17	15-Mar-17	16-Apr-19
5011	US20200030 432	http://59.45.142.240:8808/pdf/US20200030432A1.pdf	ZOONOTIC DISEASE RNA VACCINES	ModernaTX, Inc.	17-Mar-17	16-Mar-18	30-Jan-20
5012	US20200017 554	http://59.45.142.240:8808/pdf/US20200017554A1.pdf	SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN GRY-UP-INDUCING PROTEIN	Not Available	23-Mar-17	22-Mar-18	16-Jan-20
5013	US20200173 925	http://59.45.142.240:8808/pdf/US20200173925A1.pdf	MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC BODY DETECTION	JAPAN SCIENCE AND TECHNOLOGY AGENCY	29-Mar-17	28-Mar-18	4-Jun-20
5014	US20200038 871	http://59.45.142.240:8808/pdf/US20200038871A1.pdf	DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING	Not Available	29-Mar-17	29-Mar-18	6-Feb-20
5015	US20200095 324	http://59.45.142.240:8808/pdf/US20200095324A1.pdf	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF	Not Available	30-Mar-17	30-Mar-18	26-Mar-20
5016	US20200040 042	http://59.45.142.240:8808/pdf/US20200040042A1.pdf	CHIMERIC MOLECULES AND USES THEREOF	Not Available	30-Mar-17	29-Mar-18	6-Feb-20
5017	US20200102 558	http://59.45.142.240:8808/pdf/US20200102558A1.pdf	TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY	Not Available	3-Apr-17	3-Oct-19	2-Apr-20
5018	US20200031 871	http://59.45.142.240:8808/pdf/US20200031871A1.pdf	NOVEL DEPSIPEPTIDES AND USES THEREOF	Not Available	4-Apr-17	30-Mar-18	30-Jan-20
5019	US20200017 832	http://59.45.142.240:8808/pdf/US20200017832A1.pdf	COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND	Not Available	5-Apr-17	5-Apr-18	16-Jan-20
5020	US20200102 362	http://59.45.142.240:8808/pdf/US20200102362A1.pdf	TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED	Not Available	6-Apr-17	5-Apr-18	2-Apr-20
5021	US20200101 153		MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME BOOST REGIMEN	Not Available	6-Apr-17	6-Apr-18	2-Apr-20
5022	US20200069 814		CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE	Hangzhou DAC Biotech Co., Ltd.	6-Apr-17	6-Apr-17	5-Mar-20
5023	US20200164 020	http://59.45.142.240:8808/pdf/US20200164020A1.pdf	PUM 1 PROTEIN AS TARGET FOR VIRAL INHIBITION	Not Available	12-Apr-17	12-Apr-17	28-May-20
5024	US20180305 773	http://59.45.142.240:8808/pdf/US20180305773A1.pdf	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA DETECTION	Not Available	12-Apr-17	12-Apr-18	25-Oct-18
5025	US20200124 599		ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING SELF-AMPLIFICATION	CELLEMEDY CO., LTD	13-Apr-17	13-Apr-18	23-Apr-20
5026	US20200093 909	http://59.45.142.240:8808/pdf/US20200093909A1.pdf	PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND	Not Available	19-Apr-17	19-Apr-18	26-Mar-20
5027	US20200085 872	http://59.45.142.240:8808/pdf/US20200085872A1.pdf	IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS	Not Available	19-Apr-17	19-Apr-18	19-Mar-20
5028	US20200115 448	http://59.45.142.240:8808/pdf/US20200115448A1.pdf	CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING	Not Available	26-Apr-17	22-Oct-19	16-Apr-20
5029	US20200078 335	http://59.45.142.240:8808/pdf/US20200078335A1.pdf	COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS	Not Available	1-May-17	1-May-18	12-Mar-20
5030	US20200171 085	http://59.45.142.240:8808/pdf/US20200171085A1.pdf	Method of Treating Respiratory Tract Infection	Not Available	19-May-17	18-May-18	4-Jun-20
5031	US10544102	http://59.45.142.240:8808/pdf/US10544102.pdf	Benzazepine dicarboxamide compounds with secondary amide	Hoffmann-La Roche Inc.	19-May-17	13-Nov-18	28-Jan-20

5032	US20200149 048	http://59.45.142.240:8808/pdf/US20200149048A1.pdf	Transbiotic Regulation of Bacterial Gene Expression	Not Available	22-May-17	22-May-18	14-May-20
5033	US20200155 662	http://59.45.142.240:8808/pdf/US20200155662A1.pdf	COMBINATION IMMUNOTHERAPIES COMPRISING IL-15	Not Available	26-May-17	25-May-18	21-May-20
5034	US20200140 547	http://59.45.142.240:8808/pdf/US20200140547A1.pdf	MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE	Not Available	26-May-17	25-May-18	7-May-20
5035	US20200113 967	http://59.45.142.240:8808/pdf/US20200113967A1.pdf	PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS	Not Available	26-May-17	26-May-17	16-Apr-20
5036	US20200100 480		TRAIT SELECTION IN AVIANS	Not Available	31-May-17	31-May-18	2-Apr-20
5037	US20200087 646	http://59.45.142.240:8808/pdf/US20200087646A1.pdf	OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE	Not Available	31-May-17	31-May-18	19-Mar-20
5038	US20200165 613		VIRUS LIKE PARTICLE	The University of Leeds	1-Jun-17	31-May-18	28-May-20
5039	US20200147 193	http://59.45.142.240:8808/pdf/US20200147193A1.pdf	COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER	Not Available	2-Jun-17	2-Jun-18	14-May-20
5040	US20200138 937	http://59.45.142.240:8808/pdf/US20200138937A1.pdf	Genetically Attenuated Nucleic Acid Vaccine	Not Available	2-Jun-17	1-Jun-18	7-May-20
5041	US20200138 936	http://59.45.142.240:8808/pdf/US20200138936A1.pdf	Phenotypically Wild-Type and Genetically Attenuated Viruses	Not Available	2-Jun-17	1-Jun-18	7-May-20
5042	US20200165 632	http://59.45.142.240:8808/pdf/US20200165632A1.pdf	ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR CELL-TO-CELL TRANSDUCTION	Spark Therapeutics, Inc.	7-Jun-17	6-Jun-18	28-May-20
5043	US20180355 017	http://59.45.142.240:8808/pdf/US20180355017A1.pdf	COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES	Not Available	7-Jun-17	6-Jun-18	13-Dec-18
5044	US10590112	http://59.45.142.240:8808/pdf/US10590112.pdf	Dihydropyrimidinyl benzazepine carbohydrate compounds	Hoffmann-La Roche Inc.	9-Jun-17	7-Dec-18	17-Mar-20
5045	US20200101 142	http://59.45.142.240:8808/pdf/US20200101142A1.pdf	PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY	Not Available	12-Jun-17	12-Jun-18	2-Apr-20
5046	US20200123 203		COMPOSITIONS COMPRISING CURONS AND USES THEREOF	FLAGSHIP PIONEERING INNOVATIONS V,	13-Jun-17	13-Jun-18	23-Apr-20
5047	US20190211 361	http://59.45.142.240:8808/pdf/US20190211361A1.pdf	COMPOSITIONS COMPRISING CURONS AND USES THEREOF	Not Available	13-Jun-17	27-Mar-19	11-Jul-19
5048	US20200113 996	http://59.45.142.240:8808/pdf/US20200113996A1.pdf	CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE	Not Available	23-Jun-17	21-Jun-18	16-Apr-20
5049	US20200129 487	http://59.45.142.240:8808/pdf/US20200129487A1.pdf	CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND	TAIHO PHARMACEUTICAL CO., LTD.	30-Jun-17	29-Jun-18	30-Apr-20
5050	US20190040 378		NOVEL NUCLEIC ACID MOLECULES	Not Available	4-Jul-17	3-Jul-18	7-Feb-19
5051	US20200165 594	http://59.45.142.240:8808/pdf/US20200165594A1.pdf	CRISPR SYSTEM BASED ANTIVIRAL THERAPY	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	7-Jul-17	6-Jul-18	28-May-20
5052	US20190083 525	http://59.45.142.240:8808/pdf/US20190083525A1.pdf	COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING	Not Available	11-Jul-17	10-Jul-18	21-Mar-19
5053	US20190015 432	http://59.45.142.240:8808/pdf/US20190015432A1.pdf	Lipid Disulfide Prodrugs and Uses Related Thereto	Not Available	13-Jul-17	13-Jul-18	17-Jan-19
5054	US20200149 062	http://59.45.142.240:8808/pdf/US20200149062A1.pdf	ENGINEERED TSC2	Not Available	14-Jul-17	13-Jul-18	14-May-20
5055	US20200176 079	http://59.45.142.240:8808/pdf/US20200176079A1.pdf	METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE	Not Available	19-Jul-17	18-Jul-18	4-Jun-20
5056	US20200165 585	http://59.45.142.240:8808/pdf/US20200165585A1.pdf	NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS	Not Available	27-Jul-17	27-Jul-18	28-May-20
5057	US20200155 667	http://59.45.142.240:8808/pdf/US20200155667A1.pdf	VACCINE COMPOSITIONS	Not Available	27-Jul-17	24-Jan-20	21-May-20
5058	US20200171 060	http://59.45.142.240:8808/pdf/US20200171060A1.pdf	FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST ENDOGENOUS AND EXOGENOUS	Not Available	31-Jul-17	26-Jan-18	4-Jun-20
5059	US20190314 455	http://59.45.142.240:8808/pdf/US20190314455A1.pdf	CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES	Not Available	3-Aug-17	7-Jun-19	17-Oct-19
5060	US10610571	http://59.45.142.240:8808/pdf/US10610571.pdf	Cytokine conjugates for the treatment of proliferative and infectious diseases	SYNTHORX, INC.	3-Aug-17	7-Jun-19	7-Apr-20
5061	US20190046 654	http://59.45.142.240:8808/pdf/US20190046654A1.pdf	ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREFOR	Not Available	9-Aug-17	9-Aug-18	14-Feb-19
5062	US20190048 049	http://59.45.142.240:8808/pdf/US20190048049A1.pdf	CARGOMERS	CERENIS THERAPEUTICS HOLDINGS CO.	10-Aug-17	10-Aug-18	14-Feb-19
5063	US20200127 954	http://59.45.142.240:8808/pdf/US20200127954A9.pdf	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	31-Dec-18	23-Apr-20
5064	US20190207 890	http://59.45.142.240:8808/pdf/US20190207890A1.pdf	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	31-Dec-18	4-Jul-19
5065	US20190169 595	http://59.45.142.240:8808/pdf/US20190169595A1.pdf	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	25-Jan-19	6-Jun-19
5066	US20190062 724	http://59.45.142.240:8808/pdf/US20190062724A1.pdf	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	27-Mar-18	28-Feb-19
5067	US10666592	http://59.45.142.240:8808/pdf/US10666592.pdf	RNA targeting methods and compositions	Salk Institute for Biological Studies	22-Aug-17	31-Dec-18	26-May-20
5068	US10476825	http://59.45.142.240:8808/pdf/US10476825.pdf	RNA targeting methods and compositions	Salk Institute for Biological Studies	22-Aug-17	27-Mar-18	12-Nov-19
5069	US20190119 701	http://59.45.142.240:8808/pdf/US20190119701A1.pdf	METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREFOR	Not Available	8-Sep-17	7-Sep-18	25-Apr-19
5070	US20200093 855	http://59.45.142.240:8808/pdf/US20200093855A1.pdf	ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC	Not Available	11-Sep-17	3-Jun-19	26-Mar-20
5071	US20190076 468	http://59.45.142.240:8808/pdf/US20190076468A1.pdf	ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC	Not Available	11-Sep-17	11-Sep-17	14-Mar-19
5072	US20190085 024	http://59.45.142.240:8808/pdf/US20190085024A1.pdf	Alpha-Ketoamide Inhibitors Of Cysteine Proteases	Not Available	15-Sep-17	17-Sep-18	21-Mar-19
5073	US20190105 653	http://59.45.142.240:8808/pdf/US20190105653A1.pdf	PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING WATERBORNE PATHOGENS	Not Available	5-Oct-17	5-Oct-18	11-Apr-19
5074	US20190367 553	http://59.45.142.240:8808/pdf/US20190367553A1.pdf	COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA	Not Available	27-Oct-17	26-Apr-19	5-Dec-19
5075	US20190169 677	http://59.45.142.240:8808/pdf/US20190169677A1.pdf	PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR DETECTION OF	Click Diagnostics, Inc.	9-Nov-17	9-Nov-18	6-Jun-19
5076	US20190154 687		DETECTION DEVICE AND DETECTION METHOD	Kabushiki Kaisha Toshiba	17-Nov-17	7-Mar-18	23-May-19

5077	US20190166 866	http://59.45.142.240:8808/pdf/US20190166866A1.pdf	METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX FROM A SUBSTANTIAL CATCH	Not Available	4-Dec-17	30-Nov-18	6-Jun-19
5078	US20190358 312	http://59.45.142.240:8808/pdf/US20190358312A1.pdf	ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE	Not Available	19-Dec-17	19-Dec-18	28-Nov-19
5079	US20190201 552	http://59.45.142.240:8808/pdf/US20190201552A1.pdf	Aptamer Compositions and Methods of Use Thereof	Not Available	28-Dec-17	28-Dec-18	4-Jul-19
5080	US20200046 865	http://59.45.142.240:8808/pdf/US20200046865A1.pdf	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29-Dec-17	22-Aug-19	13-Feb-20
5081	US20190247 529	http://59.45.142.240:8808/pdf/US20190247529A1.pdf	METHOD AND SYSTEM FOR DECONTAMINATING SMALL ENCLOSURES	Not Available	29-Dec-17	23-Apr-19	15-Aug-19
5082	US20190201 565	http://59.45.142.240:8808/pdf/US20190201565A1.pdf	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29-Dec-17	11-Sep-18	4-Jul-19
5083	US20190201 564	http://59.45.142.240:8808/pdf/US20190201564A1.pdf	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29-Dec-17	29-Dec-17	4-Jul-19
5084	US10398795	http://59.45.142.240:8808/pdf/US10398795.pdf	Decontamination device and method using ultrasonic cavitation	TOMI ENVIRONMENTAL SOLUTIONS, INC.	29-Dec-17	29-Dec-17	3-Sep-19
5085	US10391188	http://59.45.142.240:8808/pdf/US10391188.pdf	Decontamination device and method using ultrasonic cavitation	TOMI ENVIRONMENTAL SOLUTIONS, INC.	29-Dec-17	11-Sep-18	27-Aug-19
5086	US20190203 268	http://59.45.142.240:8808/pdf/US20190203268A1.pdf	LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED ASSAY FOR DETECTING MICROORGANISMS	Not Available	2-Jan-18	31-Dec-18	4-Jul-19
5087	US20190220 524	http://59.45.142.240:8808/pdf/US20190220524A1.pdf	DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN KNOWLEDGE GRAPHS	Not Available	16-Jan-18	29-Mar-18	18-Jul-19
5088	US20190263 934	http://59.45.142.240:8808/pdf/US20190263934A1.pdf	FC VARIANTS WITH ENHANCED BINDING TO FCRI AND PROLONGED	Not Available	26-Jan-18	25-Jan-19	29-Aug-19
5089	US20190292 580	http://59.45.142.240:8808/pdf/US20190292580A1.pdf	DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR MOLECULAR SENSING	Rutgers, The State University of New Jersey	23-Mar-18	22-Mar-19	26-Sep-19
5090	US20190298 752	http://59.45.142.240:8808/pdf/US20190298752A1.pdf	METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)	Invisra, Inc.	27-Mar-18	26-Mar-19	3-Oct-19
5091	US20200157 222		ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	29-Mar-18	29-Mar-19	21-May-20
5092	US20200024 616	http://59.45.142.240:8808/pdf/US20200024616A1.pdf	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC	Not Available	30-Mar-18	29-Mar-19	23-Jan-20
5093	US20190345 221	http://59.45.142.240:8808/pdf/US20190345221A1.pdf	BROAD SPECTRUM VACCINE, PREPARING METHOD AND APPLICATION THEREOF	Tianjin Dongya Biological Technology Co., Ltd.	9-May-18	9-May-18	14-Nov-19
5094	US20190370 834	http://59.45.142.240:8808/pdf/US20190370834A1.pdf	SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS PATHOGENS	Not Available	1-Jun-18	1-Jun-18	5-Dec-19
5095	US20190365 756	http://59.45.142.240:8808/pdf/US20190365756A1.pdf	PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS	Not Available	4-Jun-18	3-Jun-19	5-Dec-19
5096	US20200009 244	http://59.45.142.240:8808/pdf/US20200009244A1.pdf	NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS	Not Available	13-Jun-18	13-Jun-19	9-Jan-20
5097	US20200017 514	http://59.45.142.240:8808/pdf/US20200017514A1.pdf	ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION	Not Available	12-Jul-18	12-Jul-18	16-Jan-20
5098	US20200016 286	http://59.45.142.240:8808/pdf/US20200016286A1.pdf	Production of Immune-Response-Stimulating Aerosols By Non-Thermal Plasma Treatment Of	Not Available	13-Jul-18	12-Jul-19	16-Jan-20
5099	US20200054 259	http://59.45.142.240:8808/pdf/US20200054259A1.pdf	HIGH DENSITY ANALOG MULTITREXING	EnLiSense, LLC	17-Aug-18	16-Aug-19	20-Feb-20
5100	US20200071 723	http://59.45.142.240:8808/pdf/US20200071723A1.pdf	RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL	Not Available	30-Aug-18	29-Aug-19	5-Mar-20
5101	US20200079 781	http://59.45.142.240:8808/pdf/US20200079781A1.pdf	Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related	Not Available	5-Sep-18	1-Aug-19	12-Mar-20
5102	US20200085 756	http://59.45.142.240:8808/pdf/US20200085756A1.pdf	NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF	Not Available	14-Sep-18	12-Jul-19	19-Mar-20
5103	US20200147 171	http://59.45.142.240:8808/pdf/US20200147171A1.pdf	COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES	Not Available	18-Sep-18	18-Sep-19	14-May-20
5104	US20200093 919	http://59.45.142.240:8808/pdf/US20200093919A1.pdf	MODIFIED PEDV SPIKE PROTEIN	Not Available	20-Sep-18	18-Sep-19	26-Mar-20
5105	US20200101 119	http://59.45.142.240:8808/pdf/US20200101119A1.pdf	METHODS OF TREATMENT OF INFECTIONS USING BACTERIA	Not Available	27-Sep-18	26-Sep-19	2-Apr-20
5106	US20200123 205	http://59.45.142.240:8808/pdf/US20200123205A1.pdf	Inhibition Of TCR Signaling With Peptide Variants	Not Available	22-Oct-18	18-Dec-19	23-Apr-20
5107	US20200140 493	http://59.45.142.240:8808/pdf/US20200140493A1.pdf	Engineering Virus-like Nanocarriers for Biomolecule Delivery	Not Available	26-Oct-18	25-Oct-19	7-May-20
5108	US20200138 818	http://59.45.142.240:8808/pdf/US20200138818A1.pdf	METHODS OF TREATING PAIN AND/OR INFLAMMATORY RESPONSES USING COMPOSITIONS	Not Available	7-Nov-18	6-Nov-19	7-May-20
5109	US20200157 600	http://59.45.142.240:8808/pdf/US20200157600A1.pdf	METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME ANALYSIS	Not Available	19-Nov-18	19-Nov-18	21-May-20
5110	US20200164 058	http://59.45.142.240:8808/pdf/US20200164058A1.pdf	TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY	King Abdulaziz University	27-Nov-18	27-Nov-18	28-May-20
5111	US9962439	http://59.45.142.240:8808/pdf/US9962439.pdf	Injectable vaccine composition	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	8-May-18